Rank NCT Number Title Acronym Status Study Results Conditions Interventions Outcome Measures Sponsor/Collaborators Gender Age Phases Enrollment Funded Bys Study Type Study Designs Other IDs Start Date Primary Completion Date Completion Date First Posted Results First Posted Last Update Posted Locations Study Documents URL 1 NCT05890027 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation Not yet recruiting No Results Available Ptosis, Eyelid Drug: Phenylephrine Ophthalmic|Other: Eyelid Tape Change in ptosis as measured by the tangent screen visual field test|Change in ptosis as measured by the margin to reflex distance 1 (MRD1) University of Miami All 18 Years to 90 Years   (Adult, Older Adult) Phase 4 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 20230019 July 1, 2023 July 1, 2024 July 1, 2024 June 5, 2023 June 5, 2023 University of Miami Bascom Palmer Eye Institute, Miami, Florida, United States https://ClinicalTrials.gov/show/NCT05890027 2 NCT05890014 Effects of Diet on Perinatal Mood and Cognition Recruiting No Results Available Mood|Mothers|Healthy Dietary Supplement: Flavonoid-rich diet Mean depressive symptoms|Mean state anxiety|Mean postpartum-specific anxiety symptoms|Mean current affect|Mean partner depressive symptoms|Mean subjective memory scores|Mean subjective mood scores|Subjective sleep scores|Blood pressure|Verbal memory|Sustained attention and executive functioning|Visuospatial working memory University of Reading Female 18 Years and older   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science UReading mothers study March 14, 2023 March 2024 March 2024 June 5, 2023 June 5, 2023 University of Reading, Reading, Berkshire, United Kingdom https://ClinicalTrials.gov/show/NCT05890014 3 NCT05890001 A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease Enrolling by invitation No Results Available Non-erosive Reflux Disease|Erosive Esophagitis Drug: BLI5100 Frequency of treatment-emergent adverse events Braintree Laboratories All 18 Years to 85 Years   (Adult, Older Adult) Phase 3 400 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment BLI5100-303 April 5, 2023 March 31, 2024 September 30, 2024 June 5, 2023 June 5, 2023 Research Site 24, Huntsville, Alabama, United States|Research Site 62, Phoenix, Arizona, United States|Research Site 10, Huntington Park, California, United States|Research Site 13, Santa Ana, California, United States|Research Site 41, Santa Maria, California, United States|Research Site 91, Doral, Florida, United States|Research Site 42, Miami Lakes, Florida, United States|Research Site 43, Miami, Florida, United States|Research Site 17, New Port Richey, Florida, United States|Research Site 11, Sunrise, Florida, United States|Research Site 01, Gurnee, Illinois, United States|Research Site 02, Oak Lawn, Illinois, United States|Research Site 45, Houma, Louisiana, United States|Research Site 12, Marrero, Louisiana, United States|Research Site 48, Metairie, Louisiana, United States|Research Site 06, Las Vegas, Nevada, United States|Research Site 07, Great Neck, New York, United States|Research Site 40, Rochester, New York, United States|Research Site 20, Columbus, Ohio, United States|Research Site 60, Nashville, Tennessee, United States|Research Site 16, South Ogden, Utah, United States https://ClinicalTrials.gov/show/NCT05890001 4 NCT05889988 A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Not yet recruiting No Results Available Breast Neoplasm Change in chronic neuropathy symptoms Mayo Clinic All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Cohort|Time Perspective: Prospective MC220904 June 2023 June 2025 June 2025 June 5, 2023 June 5, 2023 Mayo Clinic Minnesota, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT05889988 5 NCT05889975 The Efficacy of Different Adjunctive Plaque Control Modalities in Orthodontic Patients Recruiting No Results Available Gingivitis Device: interdental brush|Device: single tufted brush|Device: water irrigator Change in BOP score|change in Gingival index|change in plaque index|Mean relative change in macrophage migration inhibition level in salivary Fluid University of Baghdad All 14 Years to 25 Years   (Child, Adult) Phase 3 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment 738622 May 9, 2023 June 2023 July 2023 June 5, 2023 June 5, 2023 Ola, Baghdad, Iraq https://ClinicalTrials.gov/show/NCT05889975 6 NCT05889962 Ultrasound-guided Pudendal Nerve Block for Pain After Hemorrhoidectomy Not yet recruiting No Results Available Hemorrhoids|Postoperative Pain Procedure: Pudendal nerve block|Procedure: Placebo block Pain score on the numeric rating scale (NRS) at baseline|Postoperative pain score on the numeric rating scale (NRS) at 6 hours|Postoperative pain score on the numeric rating scale (NRS) at 12 hours|Postoperative pain score on the numeric rating scale (NRS) at 24 hours|Postoperative pain score on the numeric rating scale (NRS) at 48 hours|Postoperative pain score on the numeric rating scale (NRS) at 7 days|Opioid consumption at 6 hours|Opioid consumption at 12 hours|Opioid consumption at 24 hours|Opioid consumption at 48 hours|Opioid consumption at 7 days|Quality of recovery at baseline|Quality of recovery at 24 hours|Quality of recovery at 48 hours|Quality of recovery at 7 days|Time to first rescue analgesics|Time to the first urination|Time to the first defecation|Patient satisfaction with pain control|Postoperative complications Taipei Medical University Hospital All 20 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment N202303039 July 2023 July 2024 September 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889962 7 NCT05889949 Microvascular Invasion for Guiding Treatment of BCLC Stage B HCC Active, not recruiting No Results Available Radiomics|Hepatocellular Carcinoma|TACE|Microvascular Invasion|Multi-kinase Inhibitors Drug: Sorafenib|Drug: Lenvatinib Overall Survival, OS|Progression-Free Survival, PFS|Tumor response|Adverse events Sun Yat-sen University All 18 Years to 75 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective HCC 007 June 1, 2019 May 31, 2023 May 31, 2023 June 5, 2023 June 5, 2023 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05889949 8 NCT05889936 A Transdiagnostic Intervention for Health-related Habits (LEV) Recruiting No Results Available Intervention|Life Style|Health-Related Behavior|Feasibility|Quality of Life|Disabilities Physical|Disability Physical|Mental Health Wellness Behavioral: Lev Study 1: Completion rate healthcare workers|Study 1: Completion rate participants|Study 1: Level of treatment credibility healthcare workers|Study 1: Level of treatment credibility participants|Study 1: Treatment satisfaction healthcare workers (individual sessions)|Study 1: Treatment satisfaction participants (individual sessions)|Study 1: Treatment satisfaction participants (the whole intervention)|Study 1: Open answer questions regarding Treatment satisfaction measured by The Evaluation Questionnaire|Study 1: Well-being before and after the intervention measures by The Evaluation Questionnaire|Study 1: Adverse events after the intervention|Study 2: What general themes underlying unhealthy and healthy habits can be found in individuals with disabilities?|Study 1: Quality of life measured with WHOQOL-BREF.|Study 1: Do Lev lead to healthier habits?|Study 1: To what extent were individual goals met?|Study 2: How do the themes (e.g., situation, context, behavior, short term gratification) behind unhealthy habits vary for specific living habits?|Study 2: How do the themes behind unhealthy habits vary for different disabilities?|Study 2: How do the themes behind unhealthy habits vary depending on sex? Region Stockholm|Karolinska Institutet All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment The LEV Project January 25, 2023 December 21, 2023 December 21, 2023 June 5, 2023 June 5, 2023 Region Stockholm, Habilitering & Hälsa, Stockholm, Sweden https://ClinicalTrials.gov/show/NCT05889936 9 NCT05889923 Training and Evaluation of Ultrasound-Guided Procedures Completed No Results Available Learning Anesthesia Procedures Device: With EDU Distance to target|number of redirects Clear Guide Medical|University of Miami All 22 Years to 60 Years   (Adult) Not Applicable 38 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other UMiami 2021 August 16, 2021 December 31, 2022 December 31, 2022 June 5, 2023 June 5, 2023 University of Miami, Miami, Florida, United States https://ClinicalTrials.gov/show/NCT05889923 10 NCT05889910 Effectiveness of the Implementation of a Standardized Care Plan to Improve Fear of Falling and Incidence of Falls FFC23 Active, not recruiting No Results Available Falls|Fear of Falling|Nursing Procedure: Health education workshop Short Falls Efficacy Scale-International adapted to Spanish.|Number of participants with post-intervention Falls. Gerencia de Atención Primaria, Madrid All 65 Years and older   (Older Adult) Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment FEARFALL_CARE February 13, 2023 May 3, 2023 May 3, 2024 June 5, 2023 June 5, 2023 Centro de Salud Sector III., Getafe, Madrid, Spain https://ClinicalTrials.gov/show/NCT05889910 11 NCT05889897 Prevalence, Risk Factors and Outcomes of Pediatric Vascular Thrombosis Not yet recruiting No Results Available Vascular Thrombosis Number of pediatrics with vascular thrombosis|Number of risk factors of pediatric vascular thrombosis Assiut University All 1 Day to 18 Years   (Child, Adult) 15 Other Observational Observational Model: Other|Time Perspective: Prospective pediatric vascular thrombosis July 1, 2023 April 1, 2024 July 1, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889897 12 NCT05889884 Eight Units Extended Maxillary Fixed Retainer Extended FR Completed No Results Available Orthodontic Retention Device: Extended maxillary fixed retainer Evaluation of dental changes|lateral cephalometric changes assessment|PDL response through probing depth assessment|Gingival bleeding assessment|Plaque assessment|Gingival assessment Alexandria University All 14 Years to 28 Years   (Child, Adult) Not Applicable 26 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other 0479-8/2022 August 28, 2022 February 28, 2023 February 28, 2023 June 5, 2023 June 5, 2023 Faculty of dentistry , Alexandria university, Alexandria, Egypt https://ClinicalTrials.gov/show/NCT05889884 13 NCT05889871 A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Not yet recruiting No Results Available HR+/HER2-breast Cancer Drug: Standard endocrine therapy plus Apatinib 3-year survival without invasive disease (iDFS)|3-year distant disease free survival (DDFS)|5-year overall survival (OS)|security|PRO (patient reported outcome) Fudan University Female 18 Years to 70 Years   (Adult, Older Adult) Phase 3 916 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SCHBCC-N050 June 1, 2023 June 1, 2026 June 1, 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889871 14 NCT05889858 Medical Follow-up of Medical Secretaries of General Practitioners Suivi-secret Not yet recruiting No Results Available Medical Follow-up of Medical Secretaries Other: Data collection type of attending physician Université de Reims Champagne-Ardenne All 18 Years and older   (Adult, Older Adult) 200 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional 2023_RIPH_002_Suivi-Secret June 1, 2023 August 1, 2023 January 1, 2024 June 5, 2023 June 5, 2023 Université de Reims Champagne Ardenne, Reims, France https://ClinicalTrials.gov/show/NCT05889858 15 NCT05889845 Candin for the Treatment of Common Warts Not yet recruiting No Results Available Common Warts (Verruca Vulgaris) Drug: Candin, Intradermal Solution|Drug: Placebo Number of participants with complete resolution of the treatment wart|Time to wart clearance|Number of participants with clinical clearance of at least 50% of all measured warts|Number of participants with clinical clearance of all measured warts|Time to clinical clearance of all measured warts Nielsen BioSciences, Inc. All 12 Years and older   (Child, Adult, Older Adult) Phase 3 330 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment CFW-3A June 2023 June 2025 June 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889845 16 NCT05889832 Contactless Measurement of Heart Rate, Heart Rate Variability and Breathing Rate Using Remote Photoplethysmography Recruiting No Results Available Heart Rate|Heart Rate Variability|Respiratory Rate Diagnostic Test: measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops) Accuracy of heart rate (HR) measurement with the software under test compared with the ECG-based measurement|Accuracy of heart rate variability index (SDNN) measurement with the software under test compared with the ECG-based measurement|Accuracy of breathing rate (BR) measurement with the software under test compared with the impedance pneumography-based measurement|Accuracy of instantaneous heart rate measurement with the software under test compared with the ECG-based measurement|Accuracy of measurement of heart rate (HR) with the software under test on a smartphone held by someone else (compared with reference measurements).|Accuracy of measurement of heart rate variability index (SDNN - the standard deviation of NN intervals) with the software under test on a smartphone held by someone else (compared with reference measurements).|Accuracy of measurement of breathing rate (BR) with the software under test on a smartphone held by someone else (compared with reference measurements).|Accuracy of measurement of heart rate (HR) with the software under test on a smartphone held in hand/s (compared with reference measurements).|Accuracy of measurement of heart rate variability index (SDNN - the standard deviation of NN intervals) with the software under test on a smartphone held in hand/s (compared with reference measurements).|Accuracy of measurement of breathing rate (BR) with the software under test on a smartphone held in hand/s (compared with reference measurements).|Accuracy of measurement of heart rate (HR) with the software under test in daylight conditions (compared with reference measurements).|Accuracy of measurement of heart rate variability index (SDNN - the standard deviation of NN intervals) with the software under test in daylight conditions (compared with reference measurements).|Accuracy of measurement of breathing rate (BR) with the software under test in daylight conditions (compared with reference measurements).|Accuracy of measurement of heart rate (HR) with the software under test in the supine position (compared with reference measurements).|Accuracy of measurement of heart rate variability index (SDNN - the standard deviation of NN intervals) with the software under test in the supine position (compared with reference measurements).|Accuracy of measurement breathing rate (BR) with the software under test in the supine position (compared with reference measurements).|Utility of the software under test for self-measurement of physiological parameters (assessed with a questionnaire).|Utility of the software under test for the measurement of someone's physiological parameters (assessed with a questionnaire). MX LABS spółka z ograniczoną odpowiedzialnością oddział w Polsce All 18 Years and older   (Adult, Older Adult) Not Applicable 130 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic MDF-01-008-01 April 26, 2023 October 2023 October 2023 June 5, 2023 June 5, 2023 Uniwersyteckie Centrum Wsparcia Badań Klinicznych we Wrocławiu, Wrocław, Dolnośląskie, Poland https://ClinicalTrials.gov/show/NCT05889832 17 NCT05889819 Orange Almond Potato Cookies Supplementation CS Completed No Results Available Nutritional Stunting Dietary Supplement: Almond orange potato cookies for stunted under-five children|Behavioral: Balanced nutrition education for stunted under-five children Mean change of weight|Mean change of height|Mean change of HZ score|Balanced nutrition of stunted under-five children knowledge Indonesia University All 12 Months to 59 Months   (Child) Not Applicable 42 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment IndonesiaUniversity January 5, 2023 February 15, 2023 February 20, 2023 June 5, 2023 June 5, 2023 Depok, Depok Jaya, Sawangan Sub-districts, Depok, West Java, Indonesia https://ClinicalTrials.gov/show/NCT05889819 18 NCT05889806 AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens) Enrolling by invitation No Results Available Oncology|Hematologic Malignancy|Gastro-Intestinal Disorder|Autoimmune Diseases|Pregnancy Related|Infectious Disease|Cardiovascular Diseases|Genitourinary Disease|Renal Disease Other: Observational Study Only. NO Intervention. Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations. Audubon Bioscience All 18 Years and older   (Adult, Older Adult) 10000 Industry Observational Observational Model: Cohort|Time Perspective: Prospective US005 May 10, 2023 May 10, 2043 June 10, 2043 June 5, 2023 June 5, 2023 AUD, New Orleans, Louisiana, United States https://ClinicalTrials.gov/show/NCT05889806 19 NCT05889793 Evaluating Emetine for Viral Outbreaks (EVOLVE) EVOLVE Not yet recruiting No Results Available COVID-19 Drug: Emetine Hydrochloride|Drug: Placebo Evaluate effectiveness of emetine in symptomatic Covid-19 patients|Evaluate safety of emetine in symptomatic Covid-19 patients|Virologic conversion as assessed by SARS-CoV-2 real time polymerase chain reaction (RT-PCR)|Anti-inflammatory effect of emetine Johns Hopkins University|Nepal Health Research Council|Bharatpur Hospital Chitwan|Stony Brook University|Rutgers University All 30 Years and older   (Adult, Older Adult) Phase 2|Phase 3 600 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment IRB00283778 July 15, 2023 June 14, 2025 June 14, 2025 June 5, 2023 June 5, 2023 Johns Hopkins University, The Center for TB and AIDS Research, Baltimore, Maryland, United States https://ClinicalTrials.gov/show/NCT05889793 20 NCT05889780 Screening for and Responding to Food Insecurity Among Infusion Patients Not yet recruiting No Results Available Cancer|Diet, Healthy|Nutrition, Healthy Other: Food pantry referrals|Other: No-prep, ready-to-eat meals|Other: Vouchers Food security|Patient satisfaction|Patient wellbeing University of Texas Southwestern Medical Center All 18 Years and older   (Adult, Older Adult) Not Applicable 45 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 48557 January 1, 2024 December 31, 2024 December 31, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889780 21 NCT05889767 Exercise-Induced Gut Permeability in Normal-weight Obesity Recruiting No Results Available Normal-weight Obesity|Obesity Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max) Serum concentrations of FABP2 following short, intense exercise|Serum concentrations of LBP following short, intense exercise|Serum concentrations of sCD14 following short, intense exercise|Serum concentrations of FABP2 following sustained, moderate exercise|Serum concentrations of IL-6 following sustained, moderate exercise|VO2 Max|Respiratory exchange ratio (RER) during VO2 max test|Maximum workload during exercise sessions|Heart rate dynamics during exercise sessions Oklahoma State University All 18 Years to 50 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention IRB-22-28-STW January 10, 2023 August 1, 2023 August 1, 2023 June 5, 2023 June 5, 2023 208 Nancy Randolph Davis, Oklahoma State University, Stillwater, Oklahoma, United States https://ClinicalTrials.gov/show/NCT05889767 22 NCT05889754 Reliability and Validity of the Turkish Version of the PedHAL Not yet recruiting No Results Available Hemophilia|Hemophilia A, Severe|Hemophilia B Paediatric Haemophilia Activities List|FISH Hasan Kalyoncu University Male 4 Years to 17 Years   (Child) 50 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023/53 May 30, 2023 August 30, 2023 December 30, 2023 June 5, 2023 June 5, 2023 Hasan Kalyoncu University, Gaziantep, Şahinbey, Turkey https://ClinicalTrials.gov/show/NCT05889754 23 NCT05889741 Combining Stellate Ganglion Block With Prolonged Exposure for PTSD Not yet recruiting No Results Available Stress Disorders, Post-Traumatic Drug: Ropivacaine injection|Drug: Normal saline Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)|Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)|Patient Health Questionnaire-9 items (PHQ-9)|General Anxiety Disorder Screener - 7 Items (GAD-7)|Posttraumatic Cognitions Inventory (PTCI)|Psychophysiological arousal - Galvanic Skin Response|Psychophysiological arousal - Skin Temperature|Psychophysiological arousal - Heart Rate|Psychophysiological arousal - Interbeat Interval|Psychophysiological arousal - Three-Dimensional Accelerometer Movement|Psychophysiological arousal - Electrodermal Activity|Psychophysiological arousal - Photoplethysmography The University of Texas Health Science Center at San Antonio|United States Department of Defense All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 140 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment HSC20230087H August 2023 March 2026 August 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889741 24 NCT05889728 Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer Recruiting No Results Available Breast Cancer Drug: [68Ga]GA-NeoB Assessment of Diagnostic Accuracy using a standard of truth (Biopsy, response to treatment RECIST and correlate images)|Comparison of SUVmax/mean|Quantitative Variation in Lesion measuring total tumor volume and lesional intensity|Comparison of variation in total tumour volume St Vincent's Hospital, Sydney|Novartis Female 18 Years and older   (Adult, Older Adult) Phase 2 20 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic Best TRial February 20, 2023 February 20, 2025 February 23, 2025 June 5, 2023 June 5, 2023 St Vincent's Hospital, Sydney, New South Wales, Australia https://ClinicalTrials.gov/show/NCT05889728 25 NCT05889715 Assessment of Plant-based Program Using Shared Medical Appointment Recruiting No Results Available Chronic Disease|Nutrition, Healthy Other: Green Wellness Program: Plants-2-Plate Total Cholesterol from blood chemistry panel|Low Density Lipoprotein (LDL) from blood chemistry panel|HDL-Cholesterol from blood chemistry panel|Triglycerides from blood chemistry panel|Tumor necrosis factor-alfa (TNF-α) from blood inflammatory biomarker|Interleukin (IL)-18 measurement from blood test|C-reactive protein (HsCRP) measurement from blood test|Soluble Intercellular Adhesion Molecule-1 (sICAM1) measurement from blood test|Adherence to WFPB measurement|Physical activity measurement|Systolic Blood pressure measurement|Diastolic Blood pressure measurement|Waist circumference measurement|Weight measurement The University of Texas Health Science Center at San Antonio|Louise L Morrison Trust All 18 Years and older   (Adult, Older Adult) Not Applicable 45 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other HSC20220903H July 2023 December 2023 May 2024 June 5, 2023 June 5, 2023 UT Health San Antonio, School of Nursing, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05889715 26 NCT05889702 Kentucky Access to Recovery Evaluation Not yet recruiting No Results Available Substance Use Disorders|Treatment Adherence and Compliance Behavioral: KATR Linkage Strategy Change in Recovery Capital per person|Change in number of drug overdoses per person|Change in number of days of illicit substance use per person Terry Bunn|University of Kentucky All 18 Years and older   (Adult, Older Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Prospective 81811|R01CE003513-01-00|R01CE003513-01 June 2023 December 2024 December 2024 June 5, 2023 June 5, 2023 FAHE, Berea, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States https://ClinicalTrials.gov/show/NCT05889702 27 NCT05889689 Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters Recruiting No Results Available Teen Pregnancy|Contraception Behavior|Sexually Transmitted Diseases|Reproductive Health|Sexual Risk Behavior Behavioral: Relationship Smarts Plus & Mind Matters|Behavioral: Relationship Smarts Plus alone|Behavioral: Preparing Adolescents for Young Adulthood (PAYA). Unprotected sex as measured by 4 items from the survey. The 4 items will be combined to create a binary variable as an indicator of either protected sex or unprotected sex.|Sexual intercourse as measured by a binary indicator asking participants if they ever engaged in sexual intercourse|Oral sex as measured by a single binary indicator asking participants if they ever engaged in oral sex|Sexual Initiation as measured by a 7- item 5 response ordinal scale categorical indicator of when individuals intent to start engaging in different sexual activities|Skills to negotiate abstinence & resist pressure to have sex measured by a 10-item scale on a 5-point scale showing how confident they are in answering each of the 10 items. A score will be calculated by averaging their responses.|Intent to use condoms as measured by a binary indicator that asks participants if they will use condoms and other contraceptives|Knowledge of HIV/STIs as measured by 8-item True/False/Unsure responses to survey items. Items will be scored as 1 if correct & 0 if incorrect. Composite scores of correct items will be calculated. Scores range from 0 to 8|Future-oriented goals as measured by a 10-item 6-point response scale, respondents will show how much they agree or disagree with each of the 10 statements. A score will be calculated for each of the respondents by averaging their responses.|Healthy life skills measured by a 12-item 6-point response scale, respondents will show how much they agree or disagree with each of the 12 items. A score will be calculated for each of the respondents by averaging their responses.|Awareness of healthy relationships as measured by a 10-item 6-point response scale, respondents will show how much they agree or disagree with each of the 10 statements. A score will be calculated for each of the respondents by averaging their responses.|General communication skills as measured by a 7-item scale on a 5-point scale, respondents will show how much they agree or disagree with each of the 7 statements. A score will be calculated for each of the respondents by averaging their responses.|Parent/guardian communication about sex measured by a 6-item scale on a 5-point scale, respondents will show how confident they are in answering each of the 6 items. A score will be calculated for each of the respondents by averaging their responses.|Conflict resolution skills as measured using 8 items on a 5-point scale, respondents will show how confident they are in answering each of the 8 statements. A score will be calculated for each of the respondents by averaging their responses.|Conflict resolution skills as measured using 8 items on a five-point response scale, respondents will show how confident they are in answering each of the 8 statements. A score will be calculated for each of the respondents by averaging their responses.|Resilience as measured by the Connor-Davidson Resilience Scale (CD-RISC). A 5 point rating of how participants have felt over the past month. Scores range from 0-4. An average score will be calculated. Trinity Church Inc.|AMTC & Associates|Department of Health and Human Services All Child, Adult, Older Adult Not Applicable 2250 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 90AP2700-01-00 June 2023 March 30, 2025 March 30, 2025 June 5, 2023 June 5, 2023 Trinity Church Inc, Miami Gardens, Florida, United States https://ClinicalTrials.gov/show/NCT05889689 28 NCT05889676 Validation of a Simultaneous Ocular/Cervical VEMP With Mastoid Vibration by B250 BCVEMP By B250 Recruiting No Results Available Vertigo Diagnostic Test: VEMP by bone conduction response rate Region Stockholm All Child, Adult, Older Adult 120 Other Observational Observational Model: Cohort|Time Perspective: Prospective K2023-3904 May 30, 2023 December 31, 2024 December 31, 2024 June 5, 2023 June 5, 2023 Karolinska University Hospital, Hearing and Balance Unit, Stockholm, Sweden https://ClinicalTrials.gov/show/NCT05889676 29 NCT05889663 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] CLN-IDN-0003 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889663 30 NCT05889650 External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial ELASTIC Not yet recruiting No Results Available Severe Traumatic Brain Injury|Intracranial Hypertension Procedure: External Lumbar drainage Safety of ELD in selected Severe TBI patients|Feasibility of ELD in selected Severe TBI patients|Reduction in ICP burden using ELD in selected severe TBI patients|Utility of non-invasive ICP based brain compliance to predict safety of ELD|Utility of automated pupillometry to predict safety of ELD Brain Trauma Foundation|Uniformed Services University of the Health Sciences|University of Kansas|The Cleveland Clinic|Weill Medical College of Cornell University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 23-17380 September 2023 May 2025 August 2025 June 5, 2023 June 5, 2023 Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05889650 31 NCT05889637 Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists Not yet recruiting No Results Available Pulmonary Aspiration Diagnostic Test: Gastric ultrasound Number of subjects that are at risk for aspiration|Number of subjects that are at low risk for aspiration|Age|Number of participants that are male as indicated in the medical records|Number of participants that are female as indicated in the medical records|Body mass Index (BMI)|Physical status as assessed by the American Society of Anesthesiologists (ASA) physical status classification system|Number of participants with diabetes|Number of participants with reported nothing by mouth (NPO) status|Pain severity as assessed by the numeric scale|Number of participants with Gastroesophageal reflux disease (GERD)|Number of participants that have use opioids preoperatively The University of Texas Health Science Center, Houston All 18 Years and older   (Adult, Older Adult) 124 Other Observational Observational Model: Cohort|Time Perspective: Prospective HSC-MS-23-0300 June 9, 2023 May 31, 2024 May 31, 2024 June 5, 2023 June 5, 2023 The University of Texas Health Science Center at Houston, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05889637 32 NCT05889624 Responding With Evidence and Access for Childhood Headaches Not yet recruiting No Results Available Headache|Headache Disorders|Headache, Migraine|Migraine|Migraine Disorders|Migraine With Aura|Migraine Without Aura|Chronic Migraine Behavioral: CBT|Drug: Amitriptyline Change in number of headache days|Reduction to a PedMIDAS score of 20 or less|Change in absolute headache disability score on PedMIDAS|Change in absolute headache days Children's Hospital Medical Center, Cincinnati|Patient-Centered Outcomes Research Institute All 10 Years to 17 Years   (Child) Not Applicable 400 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment REACH Study|MP-2021C3-24936 August 30, 2023 July 31, 2027 December 31, 2027 June 5, 2023 June 5, 2023 University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama, United States|Phoenix Children's Hospital - Barrow Neurological Institute, Phoenix, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado/Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Children's Health System, Wilmington, Delaware, United States|Clinical Integrative Research Center of Atlanta, Inc, Atlanta, Georgia, United States|University of Louisville Health/Norton, Louisville, Kentucky, United States|Louisiana State Univ/Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Dent Neurological Institute, Amherst, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Childrens, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Health Science Center/ LeBonheur Children's Hospital, Memphis, Tennessee, United States|Marshall Health, Huntington, West Virginia, United States https://ClinicalTrials.gov/show/NCT05889624 33 NCT05889611 Iterative Endotracheal Tube Cuff Pressure Monitoring SIPBIE Recruiting No Results Available Spine Disease Balloon pressure University Hospital, Strasbourg, France All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Case-Only|Time Perspective: Retrospective 8904 March 22, 2023 March 22, 2024 March 22, 2024 June 5, 2023 June 5, 2023 Service d'Anesthésiologie - Réanimation Chirurgicale - CHU de Strasbourg - France, Strasbourg, France https://ClinicalTrials.gov/show/NCT05889611 34 NCT05889598 Resistance Exercise Training to Improve Bone and Articular Cartilage Health in Women REPROOF Active, not recruiting No Results Available Osteoporosis|Osteoarthritis Other: Ballistic Resistance Lower Body Strength Training|Other: Conventional Resistance Lower Body Strength Training Change in Femoral neck bone mineral content from baseline|Change in Femoral neck bone mineral density from baseline|Bone Mineral Content (Femur)|Bone Mineral Density (Femur)|Bone Mineral Content (Spine)|Bone Mineral Density (Spine)|bone mineral content (Forearm)|bone mineral density (Forearm)|Bone mineral content (Lower leg)|bone mineral density (Lower Leg)|Bone mineral content (Total body)|bone mineral density (Total Body)|cortical bone subdensity (Forearm)|total bone density (Forearm)|trabecular bone density (Forearm)|bone total density (Forearm)|cortical bone density (Forearm)|total bone density (Lower leg)|trabecular bone density (Lower leg)|cortical bone subdensity (Lower leg)|bone total density (Lower leg)|cortical bone density (Lower leg)|total bone density (66% of Lower leg)|cortical density (Lower leg)|T2 relaxation time|cartilage thickness|Change in bone turnover biomarkers (CTX-1 and P1NP) in bodily samples|Lower limb power|Lower limb force|Lower limb velocity|Quadriceps cross-sectional area|Triceps surae cross-sectional area|Lower extremity functioning|Mobility/agility|Pain, symptoms, activities of daily living, sport and recreation function, and knee-related quality of life following knee injury|Pain, stiffness, and physical function of the hip and knee|Physical Activity Level|Physical activity and inactivity level|Daily calcium intake|Static postural sway|Static postural sway (elliptical area) Loughborough University|Versus Arthritis Female 50 Years to 70 Years   (Adult, Older Adult) Not Applicable 110 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 304156 March 1, 2022 July 31, 2023 December 2025 June 5, 2023 June 5, 2023 Loughborough University, Loughborough, Leicestershire, United Kingdom https://ClinicalTrials.gov/show/NCT05889598 35 NCT05889585 Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant HGT-QoL Recruiting No Results Available Germ Cell Tumor Compare the quality of life between the three groups measured with the EORTC-QLQ C-30 questionnaire.|Compare late side effects between the three groups.|Compare correlated morbidities between the three groups.|Compare fatigue measured by the MFI-20 scale between the three groups.|Compare symptoms of post-traumatic stress measured by the IES scale between the three groups.|Compare current social and professional situation between the three groups. Gustave Roussy, Cancer Campus, Grand Paris Male 18 Years and older   (Adult, Older Adult) 180 Other Observational Observational Model: Other|Time Perspective: Prospective 2021-A00855-36|2020/3139 May 31, 2023 May 2024 May 2024 June 5, 2023 June 5, 2023 Gustave Roussy, Villejuif, France https://ClinicalTrials.gov/show/NCT05889585 36 NCT05889572 Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis IASO Not yet recruiting No Results Available Amyotrophic Lateral Sclerosis Drug: MaaT033 Safety and tolerability: Incidence of Treatment Emergent Adverse Events (TEAE) grade >3, according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0|Changes in gut microbiota profile|Changes in levels of biomarkers in blood|Changes in levels of fecal calprotectin MaaT Pharma All 18 Years to 80 Years   (Adult, Older Adult) Phase 1 15 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MPNS01 June 2023 March 2024 June 2024 June 5, 2023 June 5, 2023 Centre Hospitalier Universitaire de Lille - CIC, Lille, France|Hôpital de la Pitié-Salpêtrière - CIC Neuroscience, Paris, France https://ClinicalTrials.gov/show/NCT05889572 37 NCT05889559 Evaluation of the Diagnostic and Therapeutic Value of Tissue Ultrafiltration in Patients at Risk of Acute Compartment Syndrome (ACS) Not yet recruiting No Results Available Acute Compartment Syndrome Device: Tissue Ultrafiltration Catheters To test whether there are differences in the incidence of ACS in patients with severe leg injuries treated with active TUF compared to the control group.|To test whether TUF reduces the incidence of fasciotomy compared to control patients.|To test whether TUF reduces Intramuscular Pressure (IMP) compared to control patients.|To test the impact of TUF on improving patient global health|To test the impact of TUF on improving patient physical function Major Extremity Trauma Research Consortium All 18 Years to 60 Years   (Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention IRB00268346 August 1, 2023 January 1, 2025 July 1, 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889559 38 NCT05889546 Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer Recruiting No Results Available Small Cell Lung Cancer Procedure: Biospecimen Collection Determining the Feasibility of the Creation of a Rapid Autopsy Program at IUSCCC for SCLC through enrollment and sample collections|Utilization of Tissue to Better Understand the Complex Biology of SCLC Indiana University All 18 Years and older   (Adult, Older Adult) 10 Other Observational Observational Model: Case-Only|Time Perspective: Prospective CTO-IUSCCC-0783 August 31, 2022 December 31, 2024 December 31, 2025 June 5, 2023 June 5, 2023 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States https://ClinicalTrials.gov/show/NCT05889546 39 NCT05889533 Eswatini Ring Study: Increasing PrEP Options for Women Recruiting No Results Available HIV Prevention|PrEP|AGYW|PrEP Ring Characterize implementation of the service delivery package for informed PrEP choice for women|Describe patterns of PrEP use in the context of informed PrEP choice FHI 360|United States Agency for International Development (USAID) Female 18 Years and older   (Adult, Older Adult) 1000 Other|U.S. Fed Observational Observational Model: Cohort|Time Perspective: Prospective FHI 360 May 9, 2023 December 31, 2024 December 31, 2024 June 5, 2023 June 5, 2023 Dvokolwako Health Centre, Dvokolwako, Swaziland|Manzini KP Community Centre, Manzini, Swaziland|Matsapha Mobile Clinic, Matsapha, Swaziland|Mbabane Key Population (KP) Community Centre, Mbabane, Swaziland|Mbabane Public Health Unit, Mbabane, Swaziland|Motshane Clinic, Mbabane, Swaziland|Siphofaneni Inkhundla (DREAMS Outreach), Siphofaneni, Swaziland|New Haven Clinic, Velebantfu, Swaziland https://ClinicalTrials.gov/show/NCT05889533 40 NCT05889520 The UFIM (Ultraprocessed Foods In Breast Milk) Project UFIM Recruiting No Results Available Child Malnutrition|Child Allergy|Maternal Exposure To evaluate the presence of the major UPFs-derived compounds AGEs in breast milk|Dietary intake of UPF in lactating women|Dietary intake of AGEs in lactating women|Skin AGEs accumulation levels in lactating women Federico II University Female 18 Years to 35 Years   (Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Prospective 163/2023 May 23, 2023 May 23, 2026 May 23, 2026 June 5, 2023 June 5, 2023 Department of Traslational Medical Science - University of Naples Federico II, Naples, Italy https://ClinicalTrials.gov/show/NCT05889520 41 NCT05889507 Cooling in Mild Encephalopathy Versus Targeted Normothermia COMET Not yet recruiting No Results Available Neonatal Encephalopathy|Newborn Asphyxia Procedure: Whole body hypothermia|Procedure: Targeted normothermia|Other: Supportive neonatal intensive care|Diagnostic Test: Follow up assessment at 2 years of age Mean Cognitive Composite Scale score from the Bayley IV examination|Neonatal seizures|Duration of intensive care.|Duration of hospital stay.|Duration of mechanical ventilation.|Duration of inotropic support.|Number of babies with bloodstream or cerebrospinal fluid positive infection.|Number of babies with thrombocytopenia or coagulopathy requiring transfusion of blood products.|Opioid use.|Number of babies exclusively breastfeeding at hospital discharge.|Brain injury scores on conventional magnetic resonance imaging|Survival without any neurological impairment.|Preschool Child Behaviour Checklist (CBCL 1½-5) Thayyil, Sudhin All 0 Hours to 6 Hours   (Child) Not Applicable 426 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment 326176 September 1, 2023 March 30, 2029 March 30, 2029 June 5, 2023 June 5, 2023 William Harvey Hospital, Ashford, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|St Michaels Hospital, Bristol, United Kingdom|Frimley Park Hospital, Camberley, United Kingdom|Ashford and St Peter's Hospital, Chertsey, United Kingdom|Darent Valley Hospital, Dartford, United Kingdom|Medway NHS Foundation Trust, Gillingham, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|East Sussex Hospital, Hastings, United Kingdom|Princess Royal Hospital, Haywards Heath, United Kingdom|Liverpool Womens NHS Foundation Trust, Liverpool, United Kingdom|Homerton University Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|Queen Elisabeth the Queen Mother Hospital, Margate, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|East Surrey Hospital, Redhill, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Turnbridge Wells Hospital, Tunbridge Wells, United Kingdom|Worthing Hospital, Worthing, United Kingdom https://ClinicalTrials.gov/show/NCT05889507 42 NCT05889494 Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients Not yet recruiting No Results Available Postoperative Hemorrhage|Postoperative Anemia|Postoperative Blood Loss Other: Autologous Whole Blood Management|Other: Standard Care involving allogenic and/or derivative transfusion. Adequacy of recruitment.|Number of allogenic units transfused.|Dose of prothrombin complex concentrates.|Dose of fibrinogen.|24-Hour chest tube output.|Time to extubation.|ICU length of stay.|Hospital length of stay.|Incidence of postoperative myocardial infarction (MI).|Incidence of infection.|Incidence of post-operative stroke.|Incidence of acute lung injury.|Incidence of acute kidney injury (AKI).|Incidence of new requirement renal replacement therapy.|Incidence of new onset atrial fibrillation.|Incidence of death within 30-days post-operatively. University of Alberta|University Hospital Foundation|Alberta Innovates Health Solutions|EPICORE Centre All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 64 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment Pro00110883 July 1, 2023 June 30, 2024 December 31, 2024 June 5, 2023 June 5, 2023 University of Alberta, Edmonton, Alberta, Canada https://ClinicalTrials.gov/show/NCT05889494 43 NCT05889481 Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma MicroGenUM Recruiting No Results Available Uveal Melanoma Genetic: cytogenetic analysis on tumour tissue|Biological: Digital Pathology morpho-phenotypic evaluation of uveal melanoma.|Molecular prognostic factors Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Other 5703 January 2008 May 2025 May 2025 June 5, 2023 June 5, 2023 Monica Maria Pagliara - Oncologia Oculare, Rome, Italy https://ClinicalTrials.gov/show/NCT05889481 44 NCT05889468 Postpartum ASA and NT-proBNP Not yet recruiting No Results Available Blood Pressure Drug: Aspirin 81Mg Ec Tab|Drug: Placebo NT-proBNP levels at 4 weeks postpartum|NT-proBNP levels at 6 weeks postpartum|Average Blood Pressures|Rate of preeclampsia diagnosis postpartum|Rate of eclampsia|Hospital readmission rates for blood pressure monitoring or cardiovascular disease work-up indications|Number of subjects requiring initiation or increase in blood pressure medications|hospital readmission rates for bleeding-related complications|Rate of blood transfusions Duke University Female 18 Years to 60 Years   (Adult) Phase 4 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment Pro00112143 June 30, 2023 October 1, 2024 October 1, 2024 June 5, 2023 June 5, 2023 Duke University, Durham, North Carolina, United States https://ClinicalTrials.gov/show/NCT05889468 45 NCT05889455 Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab COMPETE Recruiting No Results Available Migraine Without Aura Drug: Sildenafil|Other: Placebo Incidence of migraine attack|Incidence of headache|Intensity of headache Danish Headache Center|Novartis All 18 Years and older   (Adult, Older Adult) Not Applicable 16 Other|Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other H-22031717 February 16, 2023 February 2024 February 2024 June 5, 2023 June 5, 2023 Danish Headache Center, Copenhagen, Denmark https://ClinicalTrials.gov/show/NCT05889455 46 NCT05889442 Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab COLLIDE Recruiting No Results Available Migraine Without Aura Drug: Levcromakalim|Other: Placebo Incidence of migraine attack|Incidence of headache|Intensity of headache|Diameter of superficial temporal artery Danish Headache Center|Novartis All 18 Years and older   (Adult, Older Adult) Not Applicable 16 Other|Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other H-22031695 February 15, 2023 February 2024 February 2024 June 5, 2023 June 5, 2023 Danish Headache Center, Copenhagen, Denmark https://ClinicalTrials.gov/show/NCT05889442 47 NCT05889429 Correlation Between Brain Structure and Activity and Spontaneous Recovery of Motor Function Following Brain Ischemic Stroke Recruiting No Results Available Ischemic Stroke Diagnostic Test: MRI scans|Behavioral: clinical assessments Neurochemical concentration levels as revealed by MRS scans. Including GABA, Glu and GSH.|Clinical measures- Arm Research Action Test (ARAT)|Clinical measures- Fugl-Meyer Upper Extremity (FM-UE)|Modified Ashworth Scale (MAS)|Semmes-Weinstein Monofilament Examination (SWME) Technion, Israel Institute of Technology|Sheba Medical Center All 21 Years to 80 Years   (Adult, Older Adult) 60 Other Observational Observational Model: Case-Control|Time Perspective: Prospective MOH_2020-06-24_009069 January 26, 2021 January 2025 January 2025 June 5, 2023 June 5, 2023 Sheba Medical Center, Ramat Gan, Israel https://ClinicalTrials.gov/show/NCT05889429 48 NCT05889416 The Perfect-CR Implementation Study Not yet recruiting No Results Available Myocardial Infarction|Risk Reduction Other: Audit and feedback through a quality registry|Other: Implementation support Adherence score|Blood pressure target attainment|Systolic blood pressure|Low-density lipoprotein cholesterol target attainment|Low-density lipoprotein cholesterol|Self-reported quality of life|Self-reported smoking status|Self-reported dietary habits|Self-reported physical activity|Attendance in an exercise-based CR programme|Major adverse cardiovascular events (MACE)|Total mortality|Acceptability of the implementation support|Adoption of the implementation support|Fidelity of the implementation support|Implementation cost and cost effectiveness Skane University Hospital|Lund University|Uppsala University All 18 Years to 79 Years   (Adult, Older Adult) Not Applicable 75 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research Perfect-CR V2.0 2023 September 2023 December 2026 December 2030 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889416 49 NCT05889403 Evaluation of the Patient's Autonomy Vis-à-vis the Therapeutic Project Proposed in a Chronic Pain Structure DoulEthic Active, not recruiting No Results Available Chronic Pain Measurement of patient autonomy|Good capacity for evaluation by the investigators of the autonomy of their patient Groupe Hospitalier Paris Saint Joseph All 18 Years and older   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective DoulEthic February 15, 2023 May 15, 2023 December 31, 2023 June 5, 2023 June 5, 2023 Fondation Hôpital Saint-Joseph, Paris, France https://ClinicalTrials.gov/show/NCT05889403 50 NCT05889390 Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer NeoHTerMa Recruiting No Results Available HER2-negative Breast Cancer Device: Oncotherm EHY-2030|Drug: Paclitaxel|Drug: Carboplatin|Drug: Cyclophosphamide/Doxorubicin|Procedure: Breast cancer removal surgery Residual size of the primary tumor, determined by imaging techniques (in percentage)|Percentage of complete pathological response|Treatment response patterns|Comparison of surgical procedure ratios|Effect of treatment on white blood cell counts|Effect of treatment on red blood cell counts|Effect of treatment on platelet counts|Effect of treatment on hemoglobin levels|Effect of treatment on hematocrit levels|Number of treatments where the planned power output of the Oncotherm EHY-2030 device could not be reached|Longitudinal analysis of the EORTC QLQ-C30 questionnaire's total scores|Longitudinal analysis of the EORTC QLQ-BR23 questionnaire's total scores|Longitudinal analysis of the EQ-5D-5L questionnaire scores Semmelweis University Female 18 Years and older   (Adult, Older Adult) Phase 2|Phase 3 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NeoHTerMa February 20, 2023 December 31, 2024 April 30, 2025 June 5, 2023 June 5, 2023 Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary https://ClinicalTrials.gov/show/NCT05889390 51 NCT05889377 Socket Preservation Technique Using Bovine Bone, Platelet Rich Fibrin Or A Combination Of Both: A Clinical, Radiographic And Histological Assesment At 4 Months Enrolling by invitation No Results Available Ridge Preservation|Post Extraction Alveolar Bone Resorption Procedure: Socket preservation Hard tissue change by measuring bone profil retraction between 0,4 and 12 months using 3D slicer software|Soft tissue change by measuring gingival retraction between 0,4 and 12 months using 3D slicer sftware Saint-Joseph University All 18 Years to 62 Years   (Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment XFMD218 November 3, 2021 December 20, 2024 December 20, 2024 June 5, 2023 June 5, 2023 Saint Joseph University, Beirut, Lebanon https://ClinicalTrials.gov/show/NCT05889377 52 NCT05889364 AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation Active, not recruiting No Results Available Tuberculosis, Pulmonary Diagnostic Test: AI-based x-ray analysis and triage ("normal/tuberculosis suspected") Diagnostic accuracy metric 1|Diagnostic accuracy metric 2|Diagnostic accuracy metric 3|Diagnostic accuracy metric 4|Diagnostic accuracy metric 5|Diagnostic accuracy metric 6 Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department All 18 Years to 80 Years   (Adult, Older Adult) 308 Other Observational Observational Model: Other|Time Perspective: Retrospective 2018-1 February 1, 2018 March 15, 2018 December 30, 2023 June 5, 2023 June 5, 2023 Research and Practical Center of Medical Radiology, Department of Health Care of Moscow, Moscow, Russian Federation https://ClinicalTrials.gov/show/NCT05889364 53 NCT05889351 Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus Completed No Results Available Nasal Decolonization of Staphylococcus Aureus Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications|Drug: LTX-109 3% gel, 4 + 4 applications|Drug: LTX-109 3% gel, 4 + 2 applications Operating Window Eradication|Number eradicated at specific timepoints|Percentage change in colony forming units (CFUs) in subjects from baseline|Number of subjects on LTX-109 versus placebo with bacterial eradication period lasting for 48 hours|Adverse events|Local tolerability assessed by health care professional|Local tolerability assessed by the subject|Asessment of Vital Signs (Systolic and diastolic blood pressure and pulse)|Safety laboratory assessments Pharma Holdings AS|CTC Clinical Trial Consultants AB All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 27 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment C22-109-08 September 19, 2022 October 28, 2022 October 28, 2022 June 5, 2023 June 5, 2023 ClinSmart Sweden AB, Uppsala, Sweden https://ClinicalTrials.gov/show/NCT05889351 54 NCT05889338 Effect of Adalimumab Therapy on Psoriasis Patient Not yet recruiting No Results Available Psoriasi Drug: adalimumab and methotrexate Psoriasis Area and Severity Index|Dermatology Life Quality Index Sohag University All 18 Years and older   (Adult, Older Adult) Not Applicable 140 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Soh-Med-23-04-26MS_ June 2023 January 2024 January 2024 June 5, 2023 June 5, 2023 Sohag University Hospital, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05889338 55 NCT05889325 To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases Not yet recruiting No Results Available Colorectal Liver Metastases (CRCLM) Procedure: DEB-TACE plus HAIC Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DoR) Peking University Cancer Hospital & Institute All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Retrospective CRCLM-HEPA-HAIC-001 July 1, 2023 September 2023 November 2023 June 5, 2023 June 5, 2023 Beijing Cancer Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05889325 56 NCT05889312 Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET Not yet recruiting No Results Available Cancer|Diagnosis|Resistant Cancer|Response, Acute Phase Diagnostic Test: 18F-FSPG PET/CT in NSCLC|Diagnostic Test: 18F-FSPG PET/CT in HNSCC Changes in tumour cellular redox status|18F-FSPG kinetics|18F-FSPG heterogeneity|Correlation with histopathology and blood biomarkers Guy's and St Thomas' NHS Foundation Trust|King's College London All 16 Years and older   (Child, Adult, Older Adult) 32 Other Observational Observational Model: Cohort|Time Perspective: Prospective 312860 September 2023 September 2025 September 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889312 57 NCT05889299 Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting No Results Available Paroxysmal Nocturnal Hemoglobinuria Drug: OMS906 study drug To assess overall safety and tolerability of repeat-dose OMS906 5 mg/kg SC administration at 4-week intervals in patients with PNH.|To assess preliminary efficacy by the effect on hemolysis and anemia measured by hemoglobin (Hgb).|To assess preliminary efficacy by the effect on hemolysis and anemia measured by Lactate dehydrogenase (LDH).|To assess preliminary efficacy by the effect on hemolysis and anemia measured by red blood cell (RBC) transfusion burden.|To assess preliminary efficacy measured by PK, PD, and ADA. Omeros Corporation All 18 Years and older   (Adult, Older Adult) Phase 1 10 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment OMS906-PNH-002 December 9, 2022 October 30, 2023 June 30, 2024 June 5, 2023 June 5, 2023 Omeros Investigational Site, Kyiv, Ukraine https://ClinicalTrials.gov/show/NCT05889299 58 NCT05889286 F18-MHF: Orthopedic Implants-Associated Infection Detection Not yet recruiting No Results Available Knee Disease|Knee Infection Drug: [F-18]MHF Number of patients who are positive on [F-18]MHF who also have orthopedic implant-associated infections as established by the standard of truth during surgery|Number of patients who are negative on [F-18]MHF who do not have have orthopedic implant-associated infections as established by the standard of truth during surgery or on clinical examination if surgery not performed. Emory University|National Institute of Allergy and Infectious Diseases (NIAID) All 18 Years and older   (Adult, Older Adult) 30 Other|NIH Observational Observational Model: Cohort|Time Perspective: Prospective STUDY00006008|5R42AI157552-03 June 2023 June 2024 June 2024 June 5, 2023 June 5, 2023 Emory University Hospital, Atlanta, Georgia, United States https://ClinicalTrials.gov/show/NCT05889286 59 NCT05889273 ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) Recruiting No Results Available Autism Spectrum Disorder Drug: ML-004 (IR)/(ER) tablet Frequency of occurrence of treatment-emergent adverse events (TEAEs).|Frequency of occurrence of Serious Adverse Events (SAEs)|Frequency of occurrence of TEAEs leading to discontinuation.|Frequency of occurrence of TEAEs arising from clinically important changes in other safety assessments.|Frequency of occurrence of suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale. MapLight Therapeutics All 12 Years to 45 Years   (Child, Adult) Phase 2 120 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ML-004-003 June 2023 August 2025 September 2025 June 5, 2023 June 5, 2023 Richmond Behavioral Associates, Staten Island, New York, United States https://ClinicalTrials.gov/show/NCT05889273 60 NCT05889260 Speech Accessibility Project SAP Recruiting No Results Available Parkinson Disease|Amyotrophic Lateral Sclerosis|Cerebral Palsy|Stroke|Down Syndrome Recorded Speech University of Illinois at Urbana-Champaign|LSVT Global|Amazon.com Services LLC|Apple Inc.|Google LLC.|Meta Platforms, Inc.|Microsoft Corporation All 18 Years and older   (Adult, Older Adult) 2000 Other|Industry Observational Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional 23183 March 15, 2023 May 31, 2024 May 31, 2024 June 5, 2023 June 5, 2023 LSVT Global, Denver, Colorado, United States|University of Illinois at Urbana-Champaign, Urbana, Illinois, United States "Study Protocol, Statistical Analysis Plan, and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/60/NCT05889260/Prot_SAP_ICF_000.pdf https://ClinicalTrials.gov/show/NCT05889260 61 NCT05889247 Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer PRELUCA Not yet recruiting No Results Available Non-small Cell Lung Cancer Metastatic Other: Circulating tumor DNA treatment monitoring Overall Survival|Physicians Global Assessment to measure quality of life|Common Terminology Criteria for Adverse Events Zealand University Hospital All Child, Adult, Older Adult Not Applicable 350 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment SJ-1011 June 2023 June 2027 June 2032 June 5, 2023 June 5, 2023 Department of Clinical Oncology and Palliative Care, Naestved, Zealand, Denmark|Department of Oncology, Aalborg, Denmark|Department of Oncology, Vejle, Denmark https://ClinicalTrials.gov/show/NCT05889247 62 NCT05889234 Prediction of Adolescents With MDD Response to ECT Via MRI Recruiting No Results Available Major Depressive Disorder|Magnetic Resonance Imaging|Electroconvulsive Therapy Device: Modified Electroconvulsive Therapy|Drug: Conventional pharmacotherapy Changes in CDRS-R (Children's Depression Rating Scale, Revised) scores|Changes in BDI (Beck's Depression Inventory) scores|Changes in SCARED (Screen for Child Anxiety Related Disorders) scores|Changes in suicide risk on C-SSRS (Columbia Suicide Severity Rating Scale) scores|Changes in PSQI (Pittsburgh Sleep Quality Index) scores|Changes in PedsQL4.0 (The Pediatric Quality of Life Inventory 4.0) scores|Changes in CGI-S (Clinical Global Impressions-Severity Scales) scores|Changes in CGI-I (Clinical Global Impressions-Improvement Scales) scores|Changes in RSS (Ruminative Responses Scale) scores|Assessment of CTQ（Childhood Trauma Questionnaire）|Assessment of OB/VQ（Olweus Bully/Victim Questionnaire）|Changes in Morisky Medication Adherence Scale|Changes in AE（Adverse Event）Scale|Assessment of SAE（Serious Adverse Event）Scale|Changes in THINC-it|Changes in functional MRI|Changes in structural MRI T1 and T2|Changes in Cerebral Blood Flow|Changes in concentration of Glu and GABA in ACC First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Chongqing Medical University|Second Xiangya Hospital of Central South University All 13 Years to 18 Years   (Child, Adult) 180 Other Observational Observational Model: Cohort|Time Perspective: Prospective 1stChongqingMUZXY May 26, 2023 December 31, 2024 January 1, 2026 June 5, 2023 June 5, 2023 The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China https://ClinicalTrials.gov/show/NCT05889234 63 NCT05889221 Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma Not yet recruiting No Results Available Multiple Myeloma|Myeloma Multiple|Myeloma Other: Drug and medical device VGPR Rate Poitiers University Hospital|Sanofi|Intergroupe Francophone du Myelome All 65 Years and older   (Older Adult) Not Applicable 74 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ISASOCUT - IFM2022-05 July 1, 2023 May 1, 2024 July 1, 2028 June 5, 2023 June 5, 2023 CHU Poitiers, Poitiers, France https://ClinicalTrials.gov/show/NCT05889221 64 NCT05889208 Prophylactic Permanent Pacemaker in Patients With Right Bundle Branch Block Undergoing Transcatheter Aortic Valve Implantation TAVI-PACE Not yet recruiting No Results Available Aortic Stenosis|Right Bundle-Branch Block Device: Prophylactic pacemaker implantation Events in the control arm Aalborg University Hospital All 70 Years and older   (Older Adult) Not Applicable 320 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TAVI-PACE December 1, 2023 December 1, 2026 December 1, 2027 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889208 65 NCT05889195 Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria microDRIVE Not yet recruiting No Results Available Urothelial Carcinoma Diagnostic Test: Cxbladder urine test The alignment of Cxbladder Detect-plus results with the standard of care diagnostic result for the presence or absence of UC, to validate Cxbladder Detect-plus performance in subjects with microscopic hematuria.|To determine the performance characteristics of Cxbladder Triage for subjects with a recent history of microscopic hematuria who are referred to urology and scheduled for cystoscopy for evaluation of microscopic hematuria. Pacific Edge Limited All 18 Years and older   (Adult, Older Adult) 1000 Industry Observational Observational Model: Case-Only|Time Perspective: Prospective CXB/2023/microDRIVE September 2023 April 2024 April 2024 June 5, 2023 June 5, 2023 Durham VA Health Care System, Durham, North Carolina, United States https://ClinicalTrials.gov/show/NCT05889195 66 NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Not yet recruiting No Results Available Hidradenitis Suppurativa Drug: Upadacitinib|Drug: Placebo Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50|Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75|Percentage of Participants Achieving Numeric Rating Scale 30 (NRS30) at Week 4 Among Subjects with NRS ≥ 3 at Baseline|Incidence of Hidradenitis Suppurativa (HS) Flare During Period 1|Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA)|Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)|Change from Baseline in Dermatology Life Quality Index (DLQI) for Adult Subjects and Adolescent Subjects Age 17 Years Old or Children's DLQI (CDLQI) for Adolescent Subjects Ages 12 to 16 Years Old|Change from Baseline in Hidradenitis Suppurativa (HS)-Related Odor, Based on Hidradenitis Suppurativa Symptom Assessment (HSSA) Question 8 AbbVie All 12 Years and older   (Child, Adult, Older Adult) Phase 3 1328 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment M23-698 June 1, 2023 October 24, 2025 August 1, 2027 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889182 67 NCT05889169 Stroke-induced Immunodepression in Neurorehabilitation NeuroLympho Completed No Results Available Stroke|Lymphopenia|Immunosuppression Other: Neurorehabilitation Difference between group 1 and group 2 in FIM score (Functional Independence Measure) after rehabilitation|Difference between group 1 and group 2 in NIHSS score (National Institutes of Health Stroke Scale) after rehabilitation|Difference between group 1 and group 2 in Barthel Index after rehabilitation|Difference between group 1 and group 2 in Tinetti score after rehabilitation|Difference between group 1 and group 2 in Hauser Ambulation Index score after rehabilitation|Difference between group 1 and group 2 in infectious complication during rehabilitation IRCCS National Neurological Institute "C. Mondino" Foundation All 18 Years to 95 Years   (Adult, Older Adult) 90 Other Observational Observational Model: Case-Control|Time Perspective: Prospective NeuroLympho February 1, 2019 May 30, 2022 September 30, 2022 June 5, 2023 June 5, 2023 Headache Science & Neurorehabilitation Center, Pavia, Italy https://ClinicalTrials.gov/show/NCT05889169 68 NCT05889156 Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia Not yet recruiting No Results Available High Triglycerides Drug: NST-1024|Other: Placebo Evaluate the efficacy of NST-1024 by percentage change in TG|Percent Change in Cholesterol Values|Percent change in Apolipoprotein B and Apolipoprotein C3|Percent Change in Lipoprotein a|Percent Change in remnant-like particle cholesterol (RLP-C)|Changes in fasting plasma glucose, fasting plasma insulin, and HbA1c|Change in insulin resistance.|Change in lipoprotein associated phospholipase A2|Change in hsCRP|Safety Assessments NorthSea Therapeutics B.V. All 18 Years to 79 Years   (Adult, Older Adult) Phase 2 50 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment NST-1024-03 June 30, 2023 February 29, 2024 February 29, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889156 69 NCT05889143 A Study to Evaluate the Efficacy and Safety of CREZET Tablet Recruiting No Results Available Dyslipidemias Drug: Ezetimibe/Rosuvastatin The Rate of change Daewoong Pharmaceutical Co. LTD. All 19 Years and older   (Adult, Older Adult) 15000 Industry Observational Observational Model: Other|Time Perspective: Prospective DWCRZ_OS_01 May 24, 2023 December 31, 2023 June 30, 2024 June 5, 2023 June 5, 2023 Kimyounggi Clinic, Busan, Korea, Republic of https://ClinicalTrials.gov/show/NCT05889143 70 NCT05889130 Investigation of the Effectiveness of Intradialytic Resistance Exercise Time Recruiting No Results Available Hemodialysis Other: Resistant Exercise systolic and diastolic blood pressure will be measured|The Short Physical Performance Battery Scale|Kidney Disease Quality of Life-36 Muş Alparlan University All 18 Years to 90 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 2023-86766 May 1, 2023 May 7, 2023 June 30, 2023 June 5, 2023 June 5, 2023 Mus Alparslan University, Muş, Güzeltepe District, Turkey|Marmara University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05889130 71 NCT05889117 Brain Stimulation for Concussion Not yet recruiting No Results Available Transcranial Magnetic Stimulation|Magnetic Resonance Imaging|Neuropsychological Tests|Traumatic Brain Injury|Post-Concussion Syndrome Device: Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure) Post-concussive symptoms|Neurometabolite diffusion related to neuronal function and inflammation|Cognitive functioning|Functional outcome|Brain network functioning The Mind Research Network|University of New Mexico All 18 Years to 64 Years   (Adult) Not Applicable 15 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 23-110 June 2023 December 2024 December 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889117 72 NCT05889104 Effect of Progressive Loading Protocol on Bone Mineral Density Not yet recruiting No Results Available Osteoporosis Other: Randomization Program|Other: Progressive Loading Protocol (PLP): Measuring the result of change by Dual energy x ray absorptiometry (DXA) During the Intervention Imam Abdulrahman Bin Faisal University All 50 Years to 60 Years   (Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other PLP on Bone Mineral in OR Pt. June 21, 2023 August 21, 2023 August 30, 2023 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889104 73 NCT05889091 A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment Recruiting No Results Available Head and Neck Squamous Cell Carcinoma Other: HRQOL instruments|Other: LENT SOMA instrument Proportion of patients that experience a complications|changes in HRQOL scores Memorial Sloan Kettering Cancer Center All 18 Years and older   (Adult, Older Adult) Not Applicable 12 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 23-102 May 16, 2023 May 16, 2026 May 16, 2026 June 5, 2023 June 5, 2023 Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States https://ClinicalTrials.gov/show/NCT05889091 74 NCT05889078 The Effects of Walking in Nature (vs. an Urban Setting) on the Wellbeing of Postsecondary Students. Active, not recruiting No Results Available Affect|Wellness, Psychological|Depressive Symptoms|Anxiety Disorders and Symptoms|Stress|Sleep|Non-suicidal Self-injury Behavioral: A 4-week walking intervention Change in baseline positive affect at 4 weeks|Change in baseline negative affect at 4 weeks|Change in baseline depression symptoms at 5 weeks|Change in baseline anxiety symptoms at 5 weeks|Change in baseline perceived stress levels at 5 weeks|Change in baseline sleep quality at 5 weeks|Change in baseline mindfulness at 5 weeks|Change in baseline levels of wellbeing at 5 weeks|Change in baseline non-suicidal self-injury at 5 weeks McGill University All 18 Years to 25 Years   (Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other IUSMD-18-33 Phase 2 November 9, 2022 May 30, 2023 May 30, 2023 June 5, 2023 June 5, 2023 Douglas Mental Health University Institute, Montreal, Quebec, Canada https://ClinicalTrials.gov/show/NCT05889078 75 NCT05889065 Effects of Scapular Proprioceptive Neuromuscular Facilitation on Pain and Range of Motion in Patients With Adhesive Capsulitis Active, not recruiting No Results Available Adhesive Capsulitis Procedure: Conventional Physical Therapy|Procedure: PNF techniques Shoulder Pain|Shoulder range of motion (ROM)|Scapular mobility Foundation University Islamabad All 40 Years to 80 Years   (Adult, Older Adult) Not Applicable 32 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment FUI/CTR/2023/8 August 1, 2022 June 15, 2023 July 1, 2023 June 5, 2023 June 5, 2023 Foundation University Islamabad, Islamabad, Federal, Pakistan https://ClinicalTrials.gov/show/NCT05889065 76 NCT05889052 Perennial Malaria Chemoprevention (PMC) in Cameroon Not yet recruiting No Results Available Anemia|Malaria Drug: Sulfadoxine pyrimethamine Incidence of malaria infection and clinical malaria|Incidence of severe malaria, malaria deaths, anaemia and severe anaemia|Malaria and anaemia incidence by delivery platform, number of doses and dose schedule|Dose-response effects of SP on malaria and anaemia|Effects of distance to health facility on malaria and anaemia London School of Hygiene and Tropical Medicine|Fobang Institutes Centre for Health Implementation and Translational Research All up to 9 Months   (Child) 2080 Other Observational Observational Model: Cohort|Time Perspective: Prospective PLUS-27988-CAM June 2023 December 2024 July 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889052 77 NCT05889039 Effects of Osteopathic Manipulative Treatment (OMT) and Bio Electro-Magnetic Regulation (BEMER) Therapy on Neck Pain in Adults Completed No Results Available Neck Pain Device: BEMER|Procedure: OMT|Procedure: Sham OMT + Sham BEMER Neck Pain Rating Neck Disability Index (NDI)|Neck Pain Rating Visual Analog Scale (VAS)|Quality of Life Rating Short Form 12-item (SF-12) Health Survey Lake Erie College of Osteopathic Medicine All Child, Adult, Older Adult Not Applicable 44 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment 26-164 September 17, 2019 February 16, 2022 February 16, 2022 June 5, 2023 June 5, 2023 Lake Erie College of Osteopathic Medicine, Bradenton, Florida, United States https://ClinicalTrials.gov/show/NCT05889039 78 NCT05889026 The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Completed No Results Available Stroke|Hemiplegia, Spastic|Muscle Spasticity Device: Extracorporeal shock wave therapy|Procedure: Botulinum toxin treatment Modified ashworth scale of upper extremities spasticity|Modified tardieu scale of upper extremities spasticity|Fugl-Meyer assessment of upper extremity Fugl-Meyer assessment of upper extremity Fugl-Meyer assessment of upper extremity Fugl-Meyer assessment of upper extremity|Fugl-Meyer assessment of upper extremity|Action research arm test|Modified barthel index Korea University Guro Hospital|Daewoong Pharmaceutical Co. LTD. All 19 Years to 80 Years   (Adult, Older Adult) Not Applicable 16 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment ESWT RCT August 6, 2020 September 8, 2021 September 8, 2021 June 5, 2023 June 5, 2023 Korea university guro hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05889026 79 NCT05889013 Utility of PCD Diagnostics to Improve Clinical Care Not yet recruiting No Results Available Primary Ciliary Dyskinesia Device: Nasal Nitric Oxide testing Creation of Nasal NO REDCap registry|Evaluation of utility of PCD diagnostic testing|Refinement and Improvement of PCD Diagnostic Testing Connecticut Children's Medical Center|UConn Health All 2 Years and older   (Child, Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 23-052 June 2023 June 2024 June 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05889013 80 NCT05889000 Quality of Life Questionnaire and Disease Severity Scale Completed No Results Available Pelvic Congestion Syndrome Other: questionnaire responses internal consistency assessment|discriminant validity evaluation internal consistency score|internal consistency score|determination of criterion validity|Sensitivity assessment. Kazan State Medical University|Interregional Clinical Diagnostic Center, Russia Female 18 Years to 70 Years   (Adult, Older Adult) 397 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 10012022 January 10, 2018 December 31, 2020 January 10, 2022 June 5, 2023 June 5, 2023 State Medical University, Kazan, Republic Of Tatarstan, Russian Federation https://ClinicalTrials.gov/show/NCT05889000 81 NCT05888987 Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection ABCORFILM Not yet recruiting No Results Available Severe Infectious Keratitis|Infectious Keratitis|Microbial Keratitis|Corneal Infection Biological: PCR multiplex by FilmArray Time to modification of the first line antimicrobial treatment towards a treatment targeting the detected pathogen.|Duration of hospitalization|Best corrected visual acuity|Modification of the initial antimicrobial treatment after detection of the etiological agent|Descriptive analysis of pathogens responsible for severe infectious keratitis in Champagne-Ardenne|• Costs of diagnostic methods (conventional and FilmArray) and management (cost of the average length of stay in ophthalmology at the Reims University Hospital for severe infectious keratitis) CHU de Reims All 18 Years and older   (Adult, Older Adult) 46 Other Observational Observational Model: Other|Time Perspective: Other PA23064 June 2023 June 2025 January 2026 June 5, 2023 June 5, 2023 Damien JOLLY, Reims, France https://ClinicalTrials.gov/show/NCT05888987 82 NCT05888974 Diagnostic Performance of the Mitral Annulus Velocity Variation Measured by Tissue Doppler to Evaluate the Fluid Responsiveness During the Initial Management of Shock in Patients Admitted to the Emergency Department EVO-E' Not yet recruiting No Results Available Shock Diagnostic Test: Cardiac ultrasonography E' variation (∆E')|Fluid filling responsiveness|∆E'late Centre Hospitalier Universitaire de Nīmes All 18 Years and older   (Adult, Older Adult) 187 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023-A00022-43 July 1, 2023 July 1, 2024 December 31, 2024 June 5, 2023 June 5, 2023 CHU de Nîmes, Nîmes, France https://ClinicalTrials.gov/show/NCT05888974 83 NCT05888961 Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials MAPEG 2 Not yet recruiting No Results Available Cognitive Disorders Biological: Blood samples|Other: Interviewing the subject and scales|Other: Neurocognitive evaluation|Other: Taste tests|Other: Computerized food preference questionnaires|Other: Nutritional status - body composition Amplitude of the gustatory evoked potentials|Gustatory evoked potentials latency Centre Hospitalier Universitaire Dijon All 18 Years and older   (Adult, Older Adult) Not Applicable 125 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other JACQUIN 2023 June 2023 June 2026 June 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888961 84 NCT05888948 Surgical Emergencies Gradation and Postoperative Outcome BUGRADA Recruiting No Results Available Emergency Surgery|Gradation|Complication|Mortality Number Post-operative complications|Mortality at 1 year|Length of stay in intensive care unit Centre Hospitalier Universitaire, Amiens All 18 Years and older   (Adult, Older Adult) 700 Other Observational Observational Model: Cohort|Time Perspective: Retrospective PI2022_843_0056 April 25, 2022 April 2024 April 2024 June 5, 2023 June 5, 2023 CHU Amiens-Picardie, Amiens, France https://ClinicalTrials.gov/show/NCT05888948 85 NCT05888935 Detection of Periapical Lesions on Dental Panoramic Radiographs Based on Artificial Intelligence OPTITOMO Recruiting No Results Available Periapical Diseases Artificial Intelligence software performance|Artificial Intelligence software specificity Centre Hospitalier Régional Metz-Thionville All 18 Years and older   (Adult, Older Adult) 2000 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 2023-04Obs-CHRMT October 1, 2022 December 1, 2024 December 1, 2024 June 5, 2023 June 5, 2023 CHR Metz-Thionville/Hopital de Mercy, Metz, France https://ClinicalTrials.gov/show/NCT05888935 86 NCT05888922 Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia Not yet recruiting No Results Available Androgenetic Alopecia|Female Pattern Baldness Drug: Minoxidil Tablets|Drug: Minoxidil Topical|Drug: Placebo oral tablet|Drug: Vehicle solution Change in Target Area non vellus Hair Counts (TAHC) Industrial Farmacéutica Cantabria, S.A.|Bioskin GmbH|BioClever 2005 S.L. Female 18 Years and older   (Adult, Older Adult) Phase 3 520 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment P22112a October 2023 June 2024 November 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888922 87 NCT05888909 Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy Recruiting No Results Available Diabetic Nephropathy Type 2|Diabetic Kidney Disease|Type 2 Diabetes change in estimated glomerular filtration rate (eGFR) from baseline Chinese PLA General Hospital|Beijing Municipal Science & Technology Commission|China-Japan Friendship Hospital|Beijing Friendship Hospital|Beijing Tongren Hospital|Beijing Hospital|Dongzhimen Hospital, Beijing|Xuanwu Hospital, Beijing All 18 Years and older   (Adult, Older Adult) 2000 Other Observational Observational Model: Cohort|Time Perspective: Prospective S2022-482-01 August 1, 2022 November 1, 2026 December 31, 2026 June 5, 2023 June 5, 2023 Chinese PLA General Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05888909 88 NCT05888896 Effect of Foot Reflexology on Preeclampsia Not yet recruiting No Results Available Mild Pre-eclampsia Other: methyldopa tablets 250mg|Other: methyldopa tablets 250mg + foot reflexology Mean arterial blood pressure|Overall quality of life questionnaire|Serum cortisol|Proteinuria Cairo University Female 20 Years to 36 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment p.t.REC/012/003568 May 25, 2023 July 25, 2023 July 25, 2023 June 5, 2023 June 5, 2023 Abeer Ali Ahmed Mansour, Assiut, Assuit, Egypt https://ClinicalTrials.gov/show/NCT05888896 89 NCT05888883 Microbial Keratitis Sampling for Biomarker Discovery Not yet recruiting No Results Available Microbial Keratitis Proteomic and Metabolomic analysis of ocular tear samples in disease and health|Proteomic and Metabolomic analysis of ocular tear samples during disease course|Differences in microorganisms identified between the affected eyes of microbial keratitis participants and control eyes University of Edinburgh|NHS Lothian All 16 Years and older   (Child, Adult, Older Adult) 70 Other Observational Observational Model: Case-Control|Time Perspective: Prospective 2023/0017 July 2023 December 2024 January 2028 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888883 90 NCT05888870 ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor Not yet recruiting No Results Available Hemophilia A With Inhibitor Drug: SCT800 and Daratumumab success rate of ITI success rate of ITI success rate of ITI success rate of ITI|Success rate and partial sucess rate of ITI after 3-month treatment|ITI success time Institute of Hematology & Blood Diseases Hospital|Sinocelltech Ltd. All 14 Years to 65 Years   (Child, Adult, Older Adult) Phase 4 50 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SCT800-AITI June 1, 2023 December 1, 2026 December 1, 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888870 91 NCT05888857 A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. TAYLOR Not yet recruiting No Results Available Advanced Solid Tumor Drug: MEDI5752 Assessment of the antitumor activity of MEDI5752 (independently for eah cohort)|24-weeks clinical benefit rate (CBR) independently for each cohort|Best overall response (BoR) independently for each cohort|Duration of response (DoR) independently for each cohort|1-year progression-free survival (PFS), independently for each cohort|2-year progression-free survival (PFS), independently for each cohort|1-year overall survival (OS), independently for each cohort|2-year overall survival (OS), independently for each cohort|Safety profile, independently for each cohort: Common Terminology Criteria for Adverse Events version 5|24-weeks clinical benefit rate (iCBR) independently for each cohort as per iRECIST|Duration of response (iDoR) independently for each cohort as per iRECIST|1-year progression-free survival (iPFS), independently for each cohort as per iRECIST|2-year progression-free survival (iPFS), independently for each cohort as per iRECIST|iORR independently for each cohort Institut Bergonié|National Cancer Institute, France|AstraZeneca All 18 Years and older   (Adult, Older Adult) Phase 2 102 Other|Industry Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IB2023-01|2023-503451-94 September 2023 March 2026 September 2027 June 5, 2023 June 5, 2023 Institut Bergonie, Bordeaux, France https://ClinicalTrials.gov/show/NCT05888857 92 NCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Not yet recruiting No Results Available Cutaneous Squamous Cell Carcinoma Drug: INCB099280 Objective response rate (ORR)|Number of participants with Treatment-emergent Adverse Events (TEAEs)|Number of participants with TEAEs leading to dose modification or discontinuation|Disease Control Rate (DCR)|Duration Of Response (DOR)|Time to Response (TTR)|Progression-free survival (PFS)|Overall Survival (OS)|INCB099280 pharmacokinetic (PK) in Plasma Incyte Corporation All 18 Years and older   (Adult, Older Adult) Phase 2 240 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment INCB 99280-212|2022-502476-23-00 June 16, 2023 December 31, 2025 December 31, 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888844 93 NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors Not yet recruiting No Results Available Advanced Solid Tumors Drug: BMS-986449|Drug: Nivolumab Number of participants with Dose-Limiting Toxicities (DLTs)|Number of participants with Adverse Events (AEs)|Number of participants with Serious Adverse Events (SAEs)|Number of participants with AEs leading to discontinuation|Number of deaths|Maximum observed plasma concentration (Cmax)|Time of maximum observed concentration within a dosing interval (Tmax)|Area under the concentration-time curve within a dosing interval (AUC[TAU]) Bristol-Myers Squibb All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 100 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CA120-1001|2023-503484-42|U1111-1287-3575 June 1, 2023 May 21, 2025 July 1, 2027 June 5, 2023 June 5, 2023 The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States|R.J. Zuckerberg Cancer Center, Lake Success, New York, United States|Local Institution - 0016, Brussels, Bruxelles-Capitale, Région De, Belgium|Local Institution - 0017, Gent, Oost-Vlaanderen, Belgium|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, France|Gustave Roussy, Villejuif, Paris, France|Institut Paoli-Calmettes, Marseille, Provence-Alpes-Côte-d'Azur, France|Centre Leon Berard, Lyon CEDEX 08, Rhône-Alpes, France|Local Institution - 0023, Rozzano, Milano, Italy|Local Institution - 0024, Siena, Toscana, Italy|Local Institution - 0026, Bergamo, Italy|Local Institution - 0025, Roma, Italy|Local Institution - 0020, Nijmegen, Gelderland, Netherlands|Local Institution - 0030, Amsterdam, Netherlands|Local Institution - 0018, Groningen, Netherlands|Local Institution - 0015, Málaga, Andalucía, Spain|Local Institution - 0013, Badalona, Barcelona [Barcelona], Spain|Local Institution - 0012, Pamplona, Navarra, Spain|Local Institution - 0014, Madrid, Spain|Local Institution - 0011, Madrid, Spain https://ClinicalTrials.gov/show/NCT05888831 94 NCT05888818 The Effect of Cold Application on Nausea and Vomiting in the Early Postoperative Period Recruiting No Results Available Local Application/Packing Too Cold|Patient Satisfaction|Postoperative Nausea and Vomiting Other: Cold application Determining the mean scores of the experimental and control groups from the nausea numerical scale|Determination of patient satisfaction of the experimental and control groups|Antiemetic use status of the groups Zonguldak Bulent Ecevit University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention 2022/16-08 October 1, 2022 July 30, 2023 October 30, 2024 June 5, 2023 June 5, 2023 Zonguldak Bulent Ecevit University, Zonguldak, Kozlu, Turkey https://ClinicalTrials.gov/show/NCT05888818 95 NCT05888805 Effectiveness of the Defocus Incorporated Spectacle Lenses on Fast Progressing Myope - Auxiliary Group Not yet recruiting No Results Available Myopia Other: DIMS spectacle lens Cycloplegic refraction change in spherical equivalent refraction (SER)|Axial length change The Hong Kong Polytechnic University|HOYA Lens Thailand LTD. All 4 Years to 12 Years   (Child) Not Applicable 59 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment P0043588 June 1, 2023 February 28, 2026 May 31, 2026 June 5, 2023 June 5, 2023 School of Optometry, The Hong Kong Polytechnic University, Hung Hom, Hong Kong https://ClinicalTrials.gov/show/NCT05888805 96 NCT05888792 Effectiveness of the Defocus Incorporated Spectacle Lenses on Fast Progressing Myope Not yet recruiting No Results Available Myopia Other: Variant of Defocus Incorporated Spectacle lens (DG2) Cycloplegic refraction change in spherical equivalent refraction (SER)|Axial length change The Hong Kong Polytechnic University|HOYA Lens Thailand LTD. All 4 Years to 12 Years   (Child) Not Applicable 118 Other|Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment H-ZGET June 1, 2023 February 28, 2026 May 31, 2026 June 5, 2023 June 5, 2023 School of Optometry, The Hong Kong Polytechnic University, Hung Hom, Hong Kong https://ClinicalTrials.gov/show/NCT05888792 97 NCT05888779 Beverages for Thought: Exploring the Relationship Between Blood Glucose and Cognition Recruiting No Results Available Overweight Other: Beverage One (Milk)|Other: Beverage Two (Juice) Written cognitive task results from novel cognitive assessment questionnaire. USDA Grand Forks Human Nutrition Research Center All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 160 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other GFHNRC156 June 2023 June 2024 June 2024 June 5, 2023 June 5, 2023 USDA Grand Forks Human Nutrition Research Center, Grand Forks, North Dakota, United States https://ClinicalTrials.gov/show/NCT05888779 98 NCT05888766 Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg Not yet recruiting No Results Available Migraine Disorders Drug: Rimegepant 75 milligrams Salivary CGRP levels during attacks|Relationship between Rimegepant's response and salivary CGRP levels|Relationship between Rimegepant's response and habituation at baseline|Relationship between Rimegepant's response and sensitization at baseline|Effects of Rimegepant 75 mg on habituation after 1 month of therapy|Changes from Baseline in the sensitization after 1 month of therapy|Changes from Baseline in the pain threshold after 1 month of therapy|Changes from Baseline in the sensory detection threshold after 1 month of therapy University of Roma La Sapienza All 18 Years to 65 Years   (Adult, Older Adult) 20 Other Observational Observational Model: Cohort|Time Perspective: Prospective S-LT-000002620231 July 1, 2023 July 30, 2024 September 30, 2024 June 5, 2023 June 5, 2023 Sapienza University of Rome Polo Pontino - ICOT, Latina, Italy / Latina, Italy https://ClinicalTrials.gov/show/NCT05888766 99 NCT05888753 TEXTBOOK OUTCOME IN ADRENAL NEOPLASMS Completed No Results Available Outcome Assessment|Adrenal Neoplasm Procedure: Adrenalectomy Textbook Outcome Hospital General Universitario de Alicante All 18 Years and older   (Adult, Older Adult) 105 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 05/2023 September 1, 2022 December 31, 2022 April 1, 2023 June 5, 2023 June 5, 2023 Juan Jesús Rubio García, Alicante, Spain https://ClinicalTrials.gov/show/NCT05888753 100 NCT05888740 Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD) Waltz Recruiting No Results Available Peripheral Arterial Disease Device: VibratoSleeve Therapeutic Ultrasound Device Mean acute flow rate difference during TUS treatment sessions|Tissue oxygen saturation (StO2)|Ankle Brachial Index|Safety Endpoint Vibrato Medical, Inc. All 65 Years and older   (Older Adult) Not Applicable 12 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 022-01 February 22, 2023 December 31, 2024 December 31, 2024 June 5, 2023 June 5, 2023 Vascular & Interventional Specialists of Orange County, Orange, California, United States https://ClinicalTrials.gov/show/NCT05888740 101 NCT05888727 Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis Not yet recruiting No Results Available Multiple Sclerosis Behavioral: Seated Physical activity INtervention for persons with MS, "SPIN" program- Intervention Condition|Behavioral: Wellness for MS (WellMS)- Control Condition Study Feasibility: Recruitment|Study Feasibility: Retention|Study Feasibility: Safety|Acceptability: Semi-structured interview|Acceptability: Survey University of North Texas, Denton, TX|University of Illinois at Chicago|Craig Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) All 18 Years and older   (Adult, Older Adult) Not Applicable 24 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care IRB-21-529|R03HD107615 January 1, 2024 October 15, 2024 October 15, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888727 102 NCT05888714 Pilot Study for Peripheral Neuromuscular Electrical Stimulation of the Quadriceps Muscle Not yet recruiting No Results Available Spinal Cord Injuries|Brain Injuries|Muscle Atrophy Device: Experimental FES cycling|Device: Comparator FES cycling|Other: Conventional physical therapy Change in knee joint extensors peak torque (Newton-Meters)|Change in knee joint flexors peak torque (Newton-Meters)|Change in thigh perimeter (centimeters)|Change in rectus femoris thickness (centimeters)|Change in vastus intermedius thickness (centimeters)|System Usability Score|Patients Perception of Treatment Outcomes Score|Adverse effects inventory University of Sao Paulo General Hospital|Agência Brasileira de Desenvolvimento Industrial (Brazilian Agency For Industrial Development) All 18 Years and older   (Adult, Older Adult) Not Applicable 15 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CAAE 64324122.0.0000.0068 June 1, 2023 September 1, 2023 December 31, 2023 June 5, 2023 June 5, 2023 Instituto de Medicina Física e Reabilitação, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil https://ClinicalTrials.gov/show/NCT05888714 103 NCT05888701 "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. Recruiting No Results Available Mantle-cell Lymphoma|B Cell Chronic Lymphocytic Leukemia Primary endopoint|Secondary endopoints University of Milano Bicocca All 18 Years and older   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Retrospective CD24.DEM September 8, 2022 September 2023 December 2024 June 5, 2023 June 5, 2023 Andrea Aroldi, Monza, MB, Italy https://ClinicalTrials.gov/show/NCT05888701 104 NCT05888688 The Sarcopenia Study Not yet recruiting No Results Available Heart Failure|Sarcopenia|Heart Failure With Reduced Ejection Fraction|Heart Failure With Preserved Ejection Fraction|Type 2 Diabetes|Frailty Volumetric quadriceps skeletal muscle mass (cm^3)|HF symptoms and quality of life|Frailty assessment|Comparison of Body composition|The difference in Muscle fat fraction (percent)|quadriceps Skeletal muscle strength (N)|Calf plantar flexor strength (N)|Handgrip strength (N)|A comparison of post-exercise recovery metabolites|A comparison in distance (metres) walked during 6MWT|A comparison of daily physical activity|The Short Physical Performance Battery (SPPB) performance|Sarcopenia assessment University of Leicester All 18 Years and older   (Adult, Older Adult) 80 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 0916 June 1, 2023 September 1, 2026 September 1, 2026 June 5, 2023 June 5, 2023 University of Leicester, Leicester, Leicestershire, United Kingdom https://ClinicalTrials.gov/show/NCT05888688 105 NCT05888675 Clinical Study of Weifuchun Treatment on Gastric Cancer Completed No Results Available Gastric Cancer (Diagnosis) Drug: Weifuchun Overall survival|Progression-free survival|EORTC QLQ-C30|Clinical symptoms|Tumor markers|Immune function ShuGuang Hospital All 18 Years to 70 Years   (Adult, Older Adult) Early Phase 1 72 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 42507214-10 July 1, 2016 October 1, 2020 October 1, 2020 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888675 106 NCT05888662 Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT) EPIC-VT Not yet recruiting No Results Available Ischemic Cardiomyopathy|Catheter Ablation of Ventricular Tachycardia Procedure: Endo-epicardial ablation|Procedure: endocardial ablation only Survival free from ventricular arrhythmia recurrence|Number of ventricular arrhythmias treated|Percentage of patients with recurrent ventricular arrhythmia|Percentage of patients with a electrical storm|Number of serious complications|Number of patients hospitalized for cardiovascular reasons|Number of patients requiring a redo ablation for ventricular arrhythmia|mortality rate|Number of patients in each group who are non-inducible at the end of the procedure Rennes University Hospital All 18 Years and older   (Adult, Older Adult) Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 35RC20_9765_EPIC-VT June 1, 2023 June 1, 2028 June 1, 2028 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888662 107 NCT05888649 Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia Not yet recruiting No Results Available Ebola Virus Disease Behavioral: Community Clusters Measure #1|Measure #2|Measure #3|Measure #4 UL-PIRE Africa Center|West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP) All 18 Years and older   (Adult, Older Adult) 1500 Other Observational Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional MISP 101054 June 2023 April 30, 2025 April 30, 2025 June 5, 2023 June 5, 2023 Montserrado, Margibi and Lofa Counties, Monrovia, Montserrado County, Liberia https://ClinicalTrials.gov/show/NCT05888649 108 NCT05888636 Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma TEDROMM Recruiting No Results Available Multiple Myeloma Other: ChIP-seq, NGS, ATAC-seq Transcriptomics variations in treated and non-treated MGUS, MM smouldering and syntomatic MM samples|Epigenetics variations in treated and non-treated MGUS, MM smouldering and syntomatic MM samples Regina Elena Cancer Institute All Child, Adult, Older Adult 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective RS1237 June 18, 2019 December 12, 2022 December 31, 2023 June 5, 2023 June 5, 2023 Regina elena Cancer Institute, Roma, Italy|"Regina Elena" National Cancer Institute, Rome, Italy https://ClinicalTrials.gov/show/NCT05888636 109 NCT05888623 Computer Assisted Detection of Neoplasia During Colonoscopy Evaluation CADeNCE Enrolling by invitation No Results Available Colorectal Neoplasms Device: Computer Assisted Detection Adenoma Detection Rate|Withdrawal time without interventions|Withdrawal time, including interventions|Adenomas per colonoscopy|Polyp detection rate|Polyps per colonoscopy|Provider satisfaction with computer assisted detection for colonoscopy|Adenocarcinoma detection rate VA Puget Sound Health Care System|VA Salt Lake City Health Care System|San Francisco Veterans Affairs Medical Center All Child, Adult, Older Adult 200000 U.S. Fed Observational Observational Model: Cohort|Time Perspective: Prospective VHA_NGHP_001 October 1, 2022 September 30, 2023 September 30, 2024 June 5, 2023 June 5, 2023 VA Puget Sound Health Care System, Seattle, Washington, United States https://ClinicalTrials.gov/show/NCT05888623 110 NCT05888610 Caregiver Solutions for Dementia Patients Not yet recruiting No Results Available Alzheimer's Disease|Dementia|Caregivers|Remote Monitoring Behavioral: Digital Outpost Number of Days that Participants Use Digital Outpost|Number of Clinical Assessments Completed|Usability as Measured by the System Usability Scale at 2 weeks Prepped Health LLC|Duke University All Child, Adult, Older Adult Not Applicable 10 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 00109123 June 1, 2023 July 2023 July 2023 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888610 111 NCT05888597 Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease Ment-COPD Not yet recruiting No Results Available Chronic Obstructive Pulmonary Disease (COPD) Drug: L-menthol|Other: Placebo Breathlessness intensity|Dyspnea unpleasantness|Total time|Exercise capacity|Work load|Minute ventilation|Tidal volume (VT)|Ventilatory reserve|Cardiac reserve|Inspiratory capacity|Breathing frequency|Peak dyspnea intensity|Leg discomfort|Anaerobic threshold|Ventilatory efficacy|Respiratory exchange ratio|Saturation|Stop reason|Adverse events Region Skane|Lund University All 18 Years and older   (Adult, Older Adult) Phase 2 20 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science Ment-COPD May 24, 2023 June 30, 2024 December 30, 2024 June 5, 2023 June 5, 2023 Lund University, Lund, Sweden https://ClinicalTrials.gov/show/NCT05888597 112 NCT05888584 Improving Access and Recruitment to Clinical Trials for Lung Cancer Patients LungI-ACT Not yet recruiting No Results Available Lung Cancer Other: Research readiness tool self-efficacy|research contacts with lung cancer patients|lung cancer nurses' clinical trials knowledge|lung cancer nurses' clinical trials confidence|lung cancer nurses' clinical trials awareness Oxford Brookes University|De Montfort University All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research IRAS project ID: 325757 July 1, 2023 March 30, 2025 March 30, 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888584 113 NCT05888571 Pre-pectoral Breast Reconstruction With or Without Mesh Not yet recruiting No Results Available Prepectoral Breast Reconstruction|TiLOOP Mesh Procedure: prepectoral breast reconstruction Major Complication Rates|Patient Breast-Q questionnaire|Minor Complication Rates|Rates of capsule contracture|The rate of surgical revision of reconstructed breasts|The rate of implant or tissue expander removal Tianjin Medical University Cancer Institute and Hospital Female 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 164 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment E20230013 July 2023 June 2026 December 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888571 114 NCT05888558 Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis Enrolling by invitation No Results Available Myasthenia Gravis Device: Body fluid diagnosis A specific miRNA maybe miR-340-5p，miR-106b-5p or miR-27a-3p is a biological marker for diagnosis of OMG First Affiliated Hospital of Jinan University All 18 Years to 50 Years   (Adult) 160 Other Observational Observational Model: Case-Crossover|Time Perspective: Cross-Sectional 2021.11JinanU July 4, 2023 March 31, 2024 May 31, 2024 June 5, 2023 June 5, 2023 First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05888558 115 NCT05888545 Clinical Study on a Novel Anti-adhesion Barrier Film Active, not recruiting No Results Available Intrauterine Adhesion Device: anti-adhesion diaphragm Incidence of uterine adhesions in the 3rd postoperative menstrual cycle.|bleeding volume (Normal, decrease, increase)|Postoperative Menstrual time（days）|Abdominal pain|Physician satisfaction checklist|Patient acceptance chaecklist|Patient comfort after placement checklist The Fourth Affiliated Hospital of Zhejiang University School of Medicine Female 18 Years to 40 Years   (Adult) Not Applicable 1176 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention K2023016 April 1, 2023 December 1, 2023 December 31, 2023 June 5, 2023 June 5, 2023 The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China|Lishui Hospital of TCM, Lishui, Zhejiang, China|Lishui People's Hospital, Lishui, Zhejiang, China|Quzhou People's Hospital, Quzhou, Zhejiang, China|The Second People's Hospital Of Quzhou, Zhejiang, Quzhou, Zhejiang, China|Wenzhou Central Hospital, Wenzhou, Zhejiang, China|The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, Zhejiang, China|Yuyao People's Hospital of Zhejiang Province, Yuyao, Zhejiang, China https://ClinicalTrials.gov/show/NCT05888545 116 NCT05888532 64Cu-GRIP B in Patients With Advanced Genitourinary Malignancies Not yet recruiting No Results Available Prostate Cancer|Renal Cancer|Urethral Cancer Drug: Copper-64 labeled Granzyme B (64Cu-GRIP B)|Procedure: Positron Emission Tomography (PET) Frequency of treatment-emergent adverse events (Cohort A)|Percent of injected activity (Cohort A)|Time to maximum observed concentration (Tmax) (Cohort A)|Maximum observed concentration (Cmax) (Cohort A)|Area under the concentration-time curve (AUC) (Cohort A)|AUC extrapolated to infinity (Cohort A)|Median clearance (Cohort A)|Apparent terminal elimination rate constant (Cohort A)|Apparent terminal elimination half-life (Cohort A)|Change in SUVmax (Cohorts B & C)|Change in SUVmax/SUVave (Cohorts B & C)|Frequency of treatment-emergent adverse events (Cohort B & C)|Mean SUVmax in metastatic lesions by disease site|Percent of lesions detected for metastatic participants|Median change in SUVmax from baseline with reported immune-related adverse event (Cohorts B & C)|Median change in SUVmax-ave from baseline with reported immune-related adverse event (Cohorts B & C)|Association of baseline uptake with object response (ORR)|Association of baseline uptake with progression-free survival (PFS)|Association of baseline uptake with reported PSA50 response|Association of baseline 64Cu-GRIP B uptake with reported immune-related adverse events (irAEs) Rahul Aggarwal|National Cancer Institute (NCI)|U.S. Army Medical Research Acquisition Activity|University of California, San Francisco All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 61 Other|NIH|U.S. Fed Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 23921|NCI-2023-04001|5R01CA229354 July 1, 2023 December 31, 2026 January 31, 2027 June 5, 2023 June 5, 2023 University of California, San Francisco, San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05888532 117 NCT05888519 Evaluation of Safety and Tolerability of Investigational Ocular Lubricants Not yet recruiting No Results Available Dry Eye Disease Other: FID123300 ocular lubricant|Other: FID123301 ocular lubricant|Other: FID122505 ocular lubricant Best corrected visual acuity (BCVA) with manifest refraction, at distance Alcon Research All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment DEP918-E001 July 2023 October 2023 October 2023 June 5, 2023 June 5, 2023 George Street Eye Centre, Sydney, New South Wales, Australia|Ophthalmic Trials Australia, Teneriffe, Queensland, Australia|University of Melbourne, Department of Optometry and Vision Science, Carlton, Victoria, Australia https://ClinicalTrials.gov/show/NCT05888519 118 NCT05888506 Ketone Ester Supplementation and Nocturnal Blood Pressure Not yet recruiting No Results Available Cardiovascular Diseases in Old Age|Aging|Cardiovascular Diseases|Sleep Dietary Supplement: Ketone Ester|Dietary Supplement: Placebo Nocturnal blood pressure dipping|Nighttime blood pressure|Nighttime heart rate variability|Objective sleep duration|Objective sleep efficiency|Subjective sleep quality|Pulse wave analysis|Pulse wave velocity Georgia Southern University|Auburn University All 50 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment H23223 June 1, 2023 May 1, 2024 May 1, 2024 June 5, 2023 June 5, 2023 Biodynamics and Human Performance Center, Savannah, Georgia, United States https://ClinicalTrials.gov/show/NCT05888506 119 NCT05888493 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma LEDA Not yet recruiting No Results Available Follicular Lymphoma (FL) Biological: Tisagenlecleucel|Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Drug: Lymphodepleting chemotherapy|Other: Corticosteroids and/or Radiation (Bridging therapy) Progression-free survival (PFS) determined by blinded independent review committee (BIRC)|Complete response rate (CRR) as assessed by BIRC (Key Secondary)|Overall response rate (ORR) by BIRC|Overall survival (OS)|Time to next anti-lymphoma treatment (TTNT)|Duration of Response (DOR)|Pre-existing (prior to treatment) and treatment-induced anti-mCAR antibodies (humoral immunogenicity)|Anti-mCAR, T cell response, as measured by IFNγ expression (cellular immunogenicity)|CAR transgene levels, as measured by quantitative polymerase chain reaction (qPCR), in peripheral blood, bone marrow (and other tissues, if available)|Replication competent lentivirus (RCL) by VSV-g qPCR in participants receiving tisagenlecleucel Novartis Pharmaceuticals|Novartis All 18 Years and older   (Adult, Older Adult) Phase 3 108 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CCTL019E2301|2023-503452-27-00 August 10, 2023 May 31, 2028 December 16, 2028 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888493 120 NCT05888480 A Culturally Specific End-of-life Communication Skills Training Not yet recruiting No Results Available End-Of-Life Other: The end-of-life communication skills training|Other: Routine training activity Change from Baseline Skills at 3 months|Change from Baseline Self-efficacy at 3 months|Change from Baseline Outcome expectancy beliefs 3 months The Hong Kong Polytechnic University All 18 Years and older   (Adult, Older Adult) Not Applicable 148 Other Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other HSEARS20230525002 July 2023 December 2023 December 2023 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888480 121 NCT05888467 Physical Activity and Cardiovascular Profile of Pre-conceptional Women at Risk for GHD SPORTY Recruiting No Results Available Gestational Hypertension|Cardiovascular Pregnancy Complication Other: supervised infrared exercise group|Other: supervised non-infrared exercise group|Other: Control group Change in cardiac output level from Baseline at week 12 visit|Change in arterial parameters from Baseline at week 12 visit|Change in venous parameters from Baseline at week 12 visit|Change in cardiac parameters from Baseline at week 12 visit|Change in body water volumes from Baseline at week 12 visit Hasselt University Female 18 Years to 50 Years   (Adult) Not Applicable 140 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other SPORTY-01 May 8, 2023 May 2024 November 2024 June 5, 2023 June 5, 2023 Hasselt University, Diepenbeek, Limburg, Belgium https://ClinicalTrials.gov/show/NCT05888467 122 NCT05888454 Integrative Group Program for Type 2 Diabetes Mellitus (T2DM) Not yet recruiting No Results Available Diabetes Mellitus, Type 2 Other: Integrative Group Program|Other: Conventional treatment for T2DM HbA1c levels (%)|Fasting insulin (mU/mL)|Fasting glucose (mg/dL)|Homeostatic Model Assessment (HOMA index)|High-sensitivity C-reactive protein (hs-CRP, mg/dL)|Change in lifestyle instrument|Subjective sense of wellbeing instrument|Adherence to pharmacological interventions for T2DM|Change in dose of pharmacological interventions for T2DM Hospital San Jose Tec de Monterrey|TecSalud|Fundación Santos y de la Garza Evia I.B.P All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care Dando pasos juntos June 2023 December 2023 December 2023 June 5, 2023 June 5, 2023 Centro Médico Zambrano Hellion, Fundación Santos y de la Garza Evia I.B.P, TecSalud, San Pedro Garza Garcia, Nuevo León, Mexico|Centro de Salud Integral, Fundación Santos y de la Garza Evia I.B.P, TecSalud, Santa Catarina, Nuevo León, Mexico https://ClinicalTrials.gov/show/NCT05888454 123 NCT05888441 Obstacle Negotiation in Older People With and Without Vision Impairment Recruiting No Results Available Low Vision Other: Obstacle characteristics Vertical foot clearance, lead limb|Foot placement variability|Obstacle crossing speed|Gaze sequencing Indiana University All 18 Years and older   (Adult, Older Adult) Not Applicable 150 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science 16447 April 14, 2023 December 31, 2025 December 31, 2025 June 5, 2023 June 5, 2023 Indiana University, Bloomington, Indiana, United States https://ClinicalTrials.gov/show/NCT05888441 124 NCT05888428 Study of Efficacy of the MyoTrain System in a Population of Individuals With Trans-radial Limb Loss Not yet recruiting No Results Available Amputation|Upper Limb Device: MyoTrain|Behavioral: Motor Imagery Mean Prosthesis Wear Duration|Assessment of Capacity for Myoelectric Control (ACMC)|Clothespin Relocation Test (CRT)|Module 2 of MyoTrain|Patient-Reported Outcomes Measurement Information System (PROMIS)|Daily Mean Number of Movement Bouts Infinite Biomedical Technologies|National Institute of Neurological Disorders and Stroke (NINDS)|Johns Hopkins University|Hanger Clinic: Prosthetics & Orthotics All 18 Years and older   (Adult, Older Adult) Not Applicable 16 Industry|NIH|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care U44NS119842 July 31, 2023 January 31, 2026 January 31, 2026 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888428 125 NCT05888415 WELL-being Improvement Following Sophrology Practice SoWell-Learn Not yet recruiting No Results Available Well-being DHEAS|Cortisol|Leptine|Ghrelin|Leptin|Subjective stress|Sociodemographic|Sophrology practice|Drug treatment|Tobacco consumption|Coffee consumption|Tea consumption|Alcohol consumption|Cannabis consumption|Food consumption|Physical activity|Well-being University Hospital, Clermont-Ferrand All Child, Adult, Older Adult 60 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional RNI 2022 DUTHEIL 2 September 2023 September 2024 September 2025 June 5, 2023 June 5, 2023 CHU Clemront-Ferrand, Clermont-Ferrand, France https://ClinicalTrials.gov/show/NCT05888415 126 NCT05888402 Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC InTRist Not yet recruiting No Results Available Local Advanced Non-small Cell Lung Cancer Drug: Toripalimab|Radiation: Radical thoracic radiotherapy Progression-free survival (PFS)|Overall survival (OS）|Adverse Event|Objective Tumour Response (ORR)|Disease control rate（DCR） Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Shanghai Junshi Bioscience Co., Ltd. All 18 Years to 70 Years   (Adult, Older Adult) Phase 2 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment InTRist June 30, 2023 June 30, 2025 December 31, 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888402 127 NCT05888389 Nerve Block Anesthesia Combined With Sedative Anesthesia Versus General Anesthesia in Surgery for CSDH Not yet recruiting No Results Available Chronic Subdural Hematoma|Anesthesia Procedure: Nerve Block Anesthesia Combined With Sedative Anesthesia|Procedure: General Anesthesia|Procedure: Burr hole craniostomy Incidence of delirium during 1-5 days after surgery|Incidence of intraoperative body movement|Modified Rankin scale at 6 months after operation.|Markwalder Grading Scale at 6 months after operation.|Recurrence rate at 6 months after surgery|Incidence of non-delirium complications within 30 days after surgery|Rate of change to general anesthesia|Pain assessment after surgery|Satisfaction scores of intraoperative analgesia by patients and surgeons|Recovery assessment after surgery|Rate of tension pneumocephalus Beijing Tiantan Hospital All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 496 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment HX-B-2022078 May 30, 2023 June 30, 2025 December 31, 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888389 128 NCT05888376 A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter Enrolling by invitation No Results Available AKI - Acute Kidney Injury|Acute Renal Failure|CKD|ESRD Device: Vascular access catheter to support dialysis or CRRT Catheter Survival|Reason(s) for Catheter Removal|Adverse Events Baxter Healthcare Corporation All 18 Years and older   (Adult, Older Adult) 75 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective BXU565389 June 2023 March 2024 June 2024 June 5, 2023 June 5, 2023 Independent Public Hospital No. 4, Lublin, Lublin, Poland|Independent Public Health Care Unit, Łęczna, Łęczna, Poland https://ClinicalTrials.gov/show/NCT05888376 129 NCT05888363 Management and Removal of Foreign Bodies in the Emergency Department Completed No Results Available Rectal Foreign Body|Rectal Perforation|Colonic Perforation Other: No Intervention Surgical site infections within the first 30 days|Length of Hospital Stay|Hospital Mortality Arrowhead Regional Medical Center All 18 Years to 99 Years   (Adult, Older Adult) 78 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 20-46a December 8, 2020 December 8, 2021 December 8, 2021 June 5, 2023 June 5, 2023 Arrowhead Regional Medical Center, Colton, California, United States https://ClinicalTrials.gov/show/NCT05888363 130 NCT05888350 Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. CC-ICS Not yet recruiting No Results Available Cough Drug: Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Drug: Placebo The AUC of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.|The optimal cut-off value of blood eosinophils in cells/μL-1 in predicting the response to inhaled corticosteroid in patients with chronic cough.|The optimal cut-off value of FeNO in pbb in kU/L in predicting the response to inhaled corticosteroid in patients with chronic cough.|The optimal cut-off value of total IgE in kU/L in predicting the response to inhaled corticosteroid in patients with chronic cough.|The sensitivity and specificity in percentage of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.|Clinical characteristics of responders and non-responders|LCQ change from baseline to the 4th week|Cough VAS change from baseline to the 4th week The First Affiliated Hospital of Guangzhou Medical University|Huizhou Third People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine|Nanfang Hospital of Southern Medical University|Shenzhen People's Hospital|SSL Central Hospital of Dongguan City|China-Japan Friendship Hospital|Beijing Chao Yang Hospital|Zunyi Medical College|Henan Provincial People's Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Second Hospital of Jilin University|Inner Mongolia People's Hospital|The First Affiliated Hospital of Shanxi Medical University|Ruijin Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Tongji Hospital|First Hospital of China Medical University|Chongqing Songshan Hospital|The First People's Hospital of Yunnan All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 520 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other CC-ICS May 27, 2023 December 31, 2023 January 30, 2024 June 5, 2023 June 5, 2023 The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05888350 131 NCT05888337 Comparison of Contoura Vision Outcomes Programmed Using the Manifest Refraction Verses Using Phorcides Planning Software in Patients With Oblique Astigmatism Not yet recruiting No Results Available Myopia|Astigmatism Device: Contoura LASIK with Phorcides planning strategy|Device: Contoura LASIK with manifest refraction planning strategy Percentage of eyes with monocular UDVA of logMAR -0.10 (20/16) in each group|Percentage of eyes with monocular UDVA of logMAR -0.20 (20/12.5) in each group Bismarck Lasik|Sengi All 18 Years and older   (Adult, Older Adult) 53 Other|Industry Observational Observational Model: Cohort|Time Perspective: Prospective SW-23-01 June 15, 2023 December 1, 2024 December 1, 2024 June 5, 2023 June 5, 2023 Bismarck Lasik, Bismarck, North Dakota, United States https://ClinicalTrials.gov/show/NCT05888337 132 NCT05888324 Factors Associated With the Onset of Chronic Headaches in Patients Who Received a Blood Patch in Post Partum CHROBLOOD Not yet recruiting No Results Available Blood Patch|Post-Dural Puncture Headache Other: Questionnaires Description of the conditions of the accidental breach|Time to onset|Positional|Neck pain|Analog visual scale (AVS)|Neurosensory disorders|Completion time after childbirth|Volume injected|Height of puncture compared to the initial breach|Paresthesias|Adverse events|Duration of strict decubitus in the immediate afterglow|Age|Height|Weight|Parity|Mode of delivery|History of headaches or migraines before pregnancy|Initial treatment (before 1st BP)|Imaging|Lumbar punction|Other examinations if performed|Complications during the initial postpartum stay|Number of patients with chronic headaches|Number of patients with chronic low back pain|Modified Headache Impact Questionnaire (HIT)|Number of patients with late recurrence of typical post dural puncture acute headache (PDPH)|Number of patients who have been rehospitalized|Number of patients consulted for headaches|Number of patients who received complementary treatments|Patient data collection Assistance Publique - Hôpitaux de Paris Female 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective APHP220572|022-A00933-40 June 2023 December 2024 January 2025 June 5, 2023 June 5, 2023 Port-Royal Maternity ward - Cochin Hopsital - APHP, Paris, Ile De France, France https://ClinicalTrials.gov/show/NCT05888324 133 NCT05888311 Evaluation of the Protection of a Liquid Bandage Not yet recruiting No Results Available Skin Care Device: Liquid bandage|Other: Activated carbon Evaluate the protective potential in the barrier/film formation formed by the product Eurofarma Laboratorios S.A. All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 35 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening EF 184 effectiveness June 30, 2023 August 30, 2023 October 30, 2023 June 5, 2023 June 5, 2023 Eurofarma Laboratorios S.A, São Paulo, Brazil https://ClinicalTrials.gov/show/NCT05888311 134 NCT05888298 Proximal and Distal Approach GON RFT in Migraine Active, not recruiting No Results Available Migraine Disorders|Headache Migraine Chronic Procedure: Greater occipital nerve radiofrequency The MIDAS (Migraine Disability Assessment) questionnaire|VAS Visual analog scale Diskapi Teaching and Research Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GONRFT September 1, 2022 September 1, 2023 September 28, 2023 June 5, 2023 June 5, 2023 Diskapi Training and Research Hospital, Ankara, Turkey|Dişkapi Reserch and Education Hospital, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05888298 135 NCT05888285 Erector Spina Plane Block and Radiofrequency Treatmen Completed No Results Available Back Pain|Block|Pain, Muscle Procedure: Erector spina plane block|Procedure: Erector spina bale block and pulsed radiofrequency Visual analog scale|Centrality of pain Scale Diskapi Teaching and Research Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment ESP Block VS ESP RF January 1, 2023 May 1, 2023 May 14, 2023 June 5, 2023 June 5, 2023 Gevher Rabia Genç Perdecioğlu, Ankara, Umit Province, Turkey https://ClinicalTrials.gov/show/NCT05888285 136 NCT05888272 Addressing Stress Among Women Entrepreneurs in Ethiopia - Scale up Recruiting No Results Available Mental Stress|Stress|Stress, Job|Emotion Regulation|Violence, Gender-Based|Economic Problems Behavioral: Stress managment Mental Distress using the Kessler Psychological Distress Scale (K-6)|Depression using the Patient Health Questionnaire (PHQ-9)|Stress using the Perceived Stress Scale|Self-Esteem using the Rosenberg Self-esteem Scale|World Health Organisation- Five Well-Being Index (WHO-5)|Functional Impairment using the World Health Organization Disability Assessment Schedule (WHODAS-2.0 -12 item version)|Business Performance 1|Business Performance 2|Business Performance 3|Intimate Partner Violence 1|Intimate Partner Violence 2 World Bank|Ethiopian Medical Association|Policy Studies Institute|Addis Ababa University Female 18 Years and older   (Adult, Older Adult) Not Applicable 1200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention DWMTS-Scaleup April 4, 2023 July 31, 2024 December 31, 2024 June 5, 2023 June 5, 2023 Policy Studies Institute, Addis Ababa, Ethiopia https://ClinicalTrials.gov/show/NCT05888272 137 NCT05888259 Plantar Pressure Distribution in Diabetic Foot Ulcer PPDDFU Enrolling by invitation No Results Available Diabetic Foot Ulcer Other: foot insole peak pressures|pressure-time integrals Cairo University All 50 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment F.P.T2207014 September 17, 2021 July 1, 2023 July 20, 2023 June 5, 2023 June 5, 2023 faculty of physical therapy, Cairo University, Giza, Egypt https://ClinicalTrials.gov/show/NCT05888259 138 NCT05888246 Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram Completed No Results Available Healthy People Diagnostic Test: Magnetocardiogram PR interval|QRS interval|QT interval|Corrected QT interval|The magnetic field intensity parameter (R/T ratio)|Maximum current vector angle (MCV angle)|Maximum current vector amplitude (MCV amplitude)|Total current vector angle (TCV angle)|Total current vector amplitude (TCV amplitude) Hangzhou Nuochi Life Science Co., Ltd. All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 412 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic Hangzhounuochi May 2, 2022 May 14, 2022 May 14, 2022 June 5, 2023 June 5, 2023 The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05888246 139 NCT05888233 Allopurinol Improves Heart Function in African Americans With Resistant Hypertension RESIST Not yet recruiting No Results Available Heart Failure Preserved Ejection Fraction|Resistant Hypertension Drug: Allopurinol Normalized peak early diastolic filling rate (E)|Six minute walk test|Self Reported health survey for Heart Failure|Self reported Health Survey|Left ventricular end-diastolic volume index|LV end-diastolic mass index|LV end-diastolic fractional shortening|LV end-diastolic mid-wall radius to wall thickness ratio|Normalized peak late diastolic filling rate (A), EDV/s|Systolic Blood Pressure|Xanthine Oxidase|mitochondrial DNA damage-associated molecular patterns|Brain Natriuretic Peptide|Diastolic Blood Pressure VA Office of Research and Development All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 50 U.S. Fed Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment F4655-P|I21RX004655-01 June 1, 2023 March 26, 2025 May 30, 2025 June 5, 2023 June 5, 2023 Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States https://ClinicalTrials.gov/show/NCT05888233 140 NCT05888220 Application of Warm Water and Warm Salt Water to Patients With Rheumatoid Arthritis Completed No Results Available Rheumatoid Arthritis - Rheumatism Other: warm salt water bath Pain Visual Analog Scale|Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire|Pittsburgh Sleep Quality Index|Health Assessment Questionnaire Hacettepe University All 18 Years and older   (Adult, Older Adult) Not Applicable 54 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care 2021/56 January 4, 2022 October 31, 2022 January 10, 2023 June 5, 2023 June 5, 2023 S.B.Ü Gülhane Training and Education Hospital, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05888220 141 NCT05888207 A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects Not yet recruiting No Results Available Healthy Male Subjects Drug: Savolitinib|Drug: Fluvoxamine Maximum observed plasma (peak) drug concentration (Cmax) for savolitinib|Area under plasma concentration time curve from zero to infinity (AUCinf) for savolitinib|Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) for savolitinib|AUClast for metabolites M2 and M3|Cmax for metabolites M2 and M3|AUCinf for metabolites M2 and M3|Ratio of metabolite Cmax to parent Cmax (MRCmax)|Ratio of metabolite AUCinf to parent AUCinf (MRAUCinf)|Ratio of metabolite AUClast to parent AUClast (MRAUClast)|Time to reach peak or maximum observed concentration or response following drug administration (tmax) for savolitinib and metabolites (M2 and M3)|Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz) for savolitinib and metabolites (M2 and M3)|Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for savolitinib and metabolites (M2 and M3)|Number of data points used for λz determination (λzN) for savolitinib and metabolites (M2 and M3)|Apparent total body clearance of drug from plasma after extravascular administration (CL/F) for savolitinib|Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F) for savolitinib|Number of subjects with adverse events (AEs) AstraZeneca|Parexel Male 18 Years to 55 Years   (Adult) Phase 1 16 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other D5084C00015 June 15, 2023 August 30, 2023 August 30, 2023 June 5, 2023 June 5, 2023 Research Site, Brooklyn, Maryland, United States https://ClinicalTrials.gov/show/NCT05888207 142 NCT05888194 The Effect of Mucogyne® Gel on Wound Healing ARTHEMIS Not yet recruiting No Results Available Perineal Tear and Episiotomy Device: Mucogyne® gel To assess the effectiveness of topical application of Mucogyne® gel in postpartum perineal wound healing promotion.|To describe wound characteristics|To assess pain relief (related to the vaginal wound)|To assess the need/use of pain relieving drugs|To assess change in clinical status|To assess the patient wound cosmetic appearance|To assess the overall patient's satisfaction|To assess re-appropriation and acceptance of the body by the patient|To assess the patient perception of the Medical Device|To assess compliance with the Medical Device use|To assess the safety of Mucogyne® gel : Number, nature and characteristics of any incident reported: incidence, seriousness, severity, resolution. Biocodex Female 18 Years and older   (Adult, Older Adult) Not Applicable 118 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other MUCG-233 June 2023 May 2024 May 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888194 143 NCT05888181 App-based Education and GOal-setting in Rheumatoid Arthritis AEGORA Recruiting No Results Available Rheumatoid Arthritis Other: Mobile app-based self-management intervention Arthritis Self-Efficacy Scale (ASES)|Pain Catastrophizing Scale (PCS)|Rheumatoid Arthritis Impact of Disease (RAID)|International Physical Activity Questionnaire Short form (IPAQ-S)|Pittsburgh Sleep Quality Index (PSQI) Universitaire Ziekenhuizen KU Leuven|Sidekick Health All 18 Years and older   (Adult, Older Adult) Not Applicable 120 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care S66633 March 3, 2023 December 31, 2023 February 29, 2024 June 5, 2023 June 5, 2023 UZ Leuven, Leuven, Vlaams Brabant, Belgium|AZ Sint-Lucas Brugge, Brugge, West-Vlaanderen, Belgium https://ClinicalTrials.gov/show/NCT05888181 144 NCT05888168 Predictors of Postoperative Atrial Fibrillation After CABG CODA-AF Active, not recruiting No Results Available Coronary Artery Disease|Atrial Fibrillation New Onset Procedure: CABG Incidence of POAF|Hospital length of stay|ICU admission time|Number of participants with Stroke|Mortality Kun Hua|Beijing Anzhen Hospital All 18 Years and older   (Adult, Older Adult) 15000 Other Observational Observational Model: Case-Control|Time Perspective: Retrospective 2023065X January 1, 2018 December 15, 2023 May 1, 2024 June 5, 2023 June 5, 2023 Beijing Anzhen Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05888168 145 NCT05888155 Clinical Presentation of Genetic Disorders in Patients Attending Genetic Outpatient Clinic of Assiut University Children Hospital Not yet recruiting No Results Available Genetic Disease Clinical Presentation in Patients Attending Genetics Outpatient Clinic of Assiut University Children Hospital Clinical presentation of genetic disorders in patients attending genetics outpatient clinic of Assiut university children hospital Assiut University All 1 Day to 18 Years   (Child, Adult) 100 Other Observational Observational Model: Other|Time Perspective: Other Genetic disorders presentation August 2023 August 2024 September 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888155 146 NCT05888142 Using Immersive Virtual Reality to Treat Complex Regional Pain Syndrome in Adults Recruiting No Results Available Pain, Chronic Behavioral: in clinic pain VR reduction exercises|Behavioral: In clinic VRpain reduction exercises + VR homeworks The Patient Global Impression of Change scale (PGIC), regarding CRPS pain.|The Patient Global Impression of Change scale (PGIC), regarding functionality/physical abilities|The Patient Global Impression of Change scale (PGIC), regarding functionality/physical abilities.|The Central Sensitization Inventory (CSI).|CES-D Center for Epidemiologic Studies Depression Scale (CES-D), NIMH.|Mindfulness.|Pain Catastrophizing Scale.|The 8-item PROMIS Sleep Disturbance Short Form.|Quickdash (measure of physical function).|Tampa Scale for Kinesiophobia.|Brief Pain Inventory (BPI) Short form, Pain interference scale. University of Washington|Mayday Fund All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 12 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment STUDY00015202 September 16, 2022 August 29, 2024 August 29, 2024 June 5, 2023 June 5, 2023 University of Washington (only CRPS patients are eligible), Seattle, Washington, United States https://ClinicalTrials.gov/show/NCT05888142 147 NCT05888129 Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer COSNALAP Completed No Results Available Postoperative Complications Procedure: surgery after neoadjuvant chemotherapy oncologic outcome Asan Medical Center All 18 Years to 90 Years   (Adult, Older Adult) 1 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 2016-0902 January 1, 2017 December 31, 2020 December 31, 2022 June 5, 2023 June 5, 2023 Asan medical center, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05888129 148 NCT05888116 Efficacy and Safety of a Hyaluronic Acid-Based Vaginal Moisturizer Medical Device to Ease Symptoms of Vaginal Dryness HYALU-LAUDE Not yet recruiting No Results Available Vaginal Disease Device: Hidrante HA|Device: Cumlaude Hidrante Interno® Vaginal Health Index|Severity of subjective symptoms (investigator record)|Subjective symtomps (patient's notebook)|Objective signs of vulvovaginal atrophy|Vaginal pH|Sexual function|Global Symptom Score (GSS)|Safety and Tolerability|Overall Safety Assessment|Patient satisfaction Dermofarm, S.A.U Female 18 Years and older   (Adult, Older Adult) Not Applicable 60 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment DFARM-HYDRA-HA-2022 June 1, 2023 December 20, 2023 December 20, 2023 June 5, 2023 June 5, 2023 Corofas Menopause, Tomelloso, Ciudad Real, Spain https://ClinicalTrials.gov/show/NCT05888116 149 NCT05888103 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. V-Mono China Not yet recruiting No Results Available Primary Hypercholesterolemia or Mixed Dyslipidemia Drug: Inclisiran|Drug: Matching Placebo for Inclisiran Percentage change in Low-density Lipoprotein Cholesterol(LDL-C) from baseline|Absolute change in low-density lipoprotein cholesterol (LDL-C) from baseline|Percentage change from baseline in protein convertase subtilisin/kexin type 9 (PCSK9)|Absolute change from baseline in protein convertase subtilisin/kexin type 9 (PCSK9)|Percentage change from baseline in total cholesterol|Percentage change from baseline in high-density lipoprotein cholesterol (HDL-C)|Percentage change from baseline in non-HDL-C|Percentage change from baseline in apolipoprotein B (ApoB)|Percentage change from baseline in apolipoprotein A-1 (ApoA-1)|Percentage change from baseline in lipoprotein (a) (Lp(a))|Percentage change from baseline in triglycerides|Absolute change from baseline in total cholesterol|Absolute change from baseline in high-density lipoprotein cholesterol (HDL-C)|Absolute change from baseline in non-HDL-C|Absolute change from baseline in apolipoprotein B (ApoB)|Absolute change from baseline in apolipoprotein A-1 (ApoA-1)|Absolute change from baseline in lipoprotein (a) (Lp(a))|Absolute change from baseline in triglycerides|Percentage change in LDL-C from baseline for inclisiran group|Absolute change in LDL-C from baseline for inclisiran group|Number of participants with Adverse Events (AEs) during core part|Number of participants with Adverse Events (AEs) during extension part Novartis Pharmaceuticals|Novartis All 18 Years to 75 Years   (Adult, Older Adult) Phase 3 200 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment CKJX839D12305 August 25, 2023 August 20, 2024 February 16, 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888103 150 NCT05888090 The Effect of Position Given to Preterms After Feeding on Gastric Residual Volume, Abdominal Oxygenation and Fractional Oxygen Extraction Recruiting No Results Available Determination of the Effect of Position Given to Preterms After Feeding on Gastric Residual Volume, Abdominal Oxygenation and Fractional Oxygen Extraction Other: Positioning (Prone, right lateral and semi-raised supine position) Does position affect gastric residual volume in preterm neonates?|Does position have an effect on abdominal oxygenation and physiological parameters in preterm newborns? Istanbul University - Cerrahpasa (IUC) All 28 Weeks to 33 Weeks   (Child) Not Applicable 48 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 14311537094 July 1, 2023 July 1, 2024 July 1, 2024 June 5, 2023 June 5, 2023 Hande Özgörü, Merkez, Isparta, Turkey https://ClinicalTrials.gov/show/NCT05888090 151 NCT05888077 Extracorporeal Shock Wave Lithotripsy Using Latest Lithotripter and Laser Lithotripsy for Difficult Bile Duct Stones Not yet recruiting No Results Available Bile Duct Stenosis Other: ESWL_LL Efficacy ESWL and Laser lithotripsy Asian Institute of Gastroenterology, India All Child, Adult, Older Adult 450 Other Observational Observational Model: Other|Time Perspective: Retrospective ESWL_LL July 1, 2023 July 1, 2024 July 1, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05888077 152 NCT05888064 Multi-parametric Imaging in Personalized Radiotherapy Recruiting No Results Available Skull Base Chordoma Diagnostic Test: diffusion MRI sequences no clinical outcome is expected CNAO National Center of Oncological Hadrontherapy|Dept. of Electronics, Informatics, Bioengineering, Politecnico di Milano, Italy All 18 Years and older   (Adult, Older Adult) 35 Other Observational Observational Model: Cohort|Time Perspective: Prospective CNAO 43 2021 April 19, 2022 February 18, 2024 April 18, 2025 June 5, 2023 June 5, 2023 CNAO, Pavia, Pv, Italy https://ClinicalTrials.gov/show/NCT05888064 153 NCT05888051 Assessment of Lower Extremity Isokinetic Muscle Strength and Balance in Individuals With Chronic Low Back Pain Not yet recruiting No Results Available Back Pain Visual Analog Scale|Lower Extremity Muscle Strength|Balance|Disability Istanbul Medipol University Hospital All 18 Years to 60 Years   (Adult) 110 Other Observational Observational Model: Family-Based|Time Perspective: Other E-10840098-772.02-2998 June 6, 2023 June 6, 2023 September 6, 2023 June 5, 2023 June 5, 2023 HAZAL genç, Istanbul, None Selected, Turkey https://ClinicalTrials.gov/show/NCT05888051 154 NCT05888038 Virtual Reality's Effect on Decreasing Pain and Subsequent Opioid Use in Pediatric Patients in the Post-Operative Period Following Scoliosis Repair Recruiting No Results Available Scoliosis; Juvenile|Scoliosis; Adolescence|Scoliosis Device: virtual reality Pain Assessment|Stress Assessment Northwell Health All 7 Years to 21 Years   (Child, Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 22-0286 September 3, 2022 September 30, 2024 September 30, 2024 June 5, 2023 June 5, 2023 SIUH Northwell Health, Staten Island, New York, United States https://ClinicalTrials.gov/show/NCT05888038 155 NCT05888025 MBCT-T for Preoperative Pain Catastrophizing and Pain Outcomes After Spine Surgery Recruiting No Results Available Pain Behavioral: Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T) Percentage of Participants who Attend More than Half of Scheduled Sessions|Client Satisfaction Questionnaire (CSQ-8) Score|Change in Pain Catastrophizing Scale (PCS) Score NYU Langone Health All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 19-00339 January 9, 2020 June 2024 June 2024 June 5, 2023 June 5, 2023 NYU Langone Health, New York, New York, United States https://ClinicalTrials.gov/show/NCT05888025 156 NCT05888012 Balloon Catheter vs. Basket Catheter in Pancreatic Duct Stone Clearance Completed No Results Available Chronic Pancreatitis Device: basket catheter|Device: balloon catheter the rate of stone clearance in basket and balloon catheter groups|the rates of ERCP peri-procedural outcomes and the rates of complications of ERCP in basket and balloon catheter groups Changhai Hospital All Child, Adult, Older Adult 6493 Other Observational Observational Model: Cohort|Time Perspective: Retrospective Basket vs. Balloon February 1, 2012 December 31, 2021 April 10, 2023 June 5, 2023 June 5, 2023 Changhai Hospital, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05888012 157 NCT05887999 A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus Not yet recruiting No Results Available Diabetes Mellitus, Type 1 Drug: LY3532226|Drug: Placebo Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia|The amount of exogenous glucose infused to maintain a plasma glucose level of >2.5 millimole per liter (mmol/L), after the insulin infusion is terminated.|Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT)|Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT Eli Lilly and Company All 18 Years to 70 Years   (Adult, Older Adult) Phase 1 30 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science 18064|J2V-MC-GZLC June 12, 2023 January 8, 2024 February 28, 2024 June 5, 2023 June 5, 2023 ProSciento, Inc, Chula Vista, California, United States https://ClinicalTrials.gov/show/NCT05887999 158 NCT05887986 Management of Dyspnea: Use of Hand Held Fan Enrolling by invitation No Results Available Lung Cancer Other: hand-held fan airflow stimulation dyspnea level|comfort level Aysegul Celik|Izmir Bakircay University All 18 Years and older   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care BU December 22, 2022 June 30, 2023 December 30, 2023 June 5, 2023 June 5, 2023 Izmir Provincial Health Directorate Health Sciences University Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey https://ClinicalTrials.gov/show/NCT05887986 159 NCT05887973 Addressing Root Causes for Gun Violence Prevention (ARC-GVP) Recruiting No Results Available Violence|Adolescent|Firearm Injury|Aggression Behavioral: The T.R.I.G.G.E.R Project Change in Civic Efficacy|Change in Pro-Social Involvement|Change in Attitudes towards Violence and Retaliation|Change in Aggressive Behavior|Change in Firearm Carriage Frequency|Change in Firearm Use|Change in Firearm Aggression University of Michigan|Centers for Disease Control and Prevention All 14 Years to 24 Years   (Child, Adult) 250 Other|U.S. Fed Observational Observational Model: Cohort|Time Perspective: Prospective HUM00215637 June 27, 2022 July 2026 July 2026 June 5, 2023 June 5, 2023 University of Michigan, Ann Arbor, Michigan, United States https://ClinicalTrials.gov/show/NCT05887973 160 NCT05887960 Impact of Neutrophil Lymphocyte and Monocyte Lymphocyte Ratio on Chronic Kidney Disease Patients Outcome Not yet recruiting No Results Available Hemodialysis Complication Other: CBC and flow cytometry test for monocyte Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome Assiut University All 18 Years to 60 Years   (Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional CKD patients June 1, 2023 July 2024 October 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887960 161 NCT05887947 Impact of E-cigarette Nicotine Concentration on Compensation Recruiting No Results Available Smoking Cessation Other: Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|Other: Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|Other: Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|Other: Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5% Total inhaled volume University of Kansas Medical Center All 21 Years and older   (Adult, Older Adult) Not Applicable 48 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 147694 February 20, 2023 February 20, 2025 February 20, 2025 June 5, 2023 June 5, 2023 University of Kansas Medical Center, Kansas City, Kansas, United States https://ClinicalTrials.gov/show/NCT05887947 162 NCT05887934 Bone-Lead Level Associations With Brain and Mental Health Not yet recruiting No Results Available Lead Exposure Device: X-Ray Fluorescence Analyzer Neuropsychiatric Diagnoses|Cognitive Function Medical University of South Carolina All 18 Years to 70 Years   (Adult, Older Adult) 500 Other Observational Observational Model: Case-Only|Time Perspective: Prospective Pro00126756 July 1, 2023 May 1, 2027 May 1, 2027 June 5, 2023 June 5, 2023 Medical University of South Carolina, Charleston, South Carolina, United States https://ClinicalTrials.gov/show/NCT05887934 163 NCT05887921 Inguinal Lymphadenectomy for Penile Cancer Completed No Results Available Penile Cancer|Lymph Node Metastasis|Sentinel Lymph Node|Surgical Complication Procedure: Inguinal Lymphadenectomy Surgical outcomes of lymph drainage (ml) Azienda Ospedaliera Città della Salute e della Scienza di Torino Male 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 14 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 00025/2020 April 30, 2019 December 22, 2022 May 24, 2023 June 5, 2023 June 5, 2023 A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT05887921/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/21/NCT05887921/ICF_001.pdf https://ClinicalTrials.gov/show/NCT05887921 164 NCT05887908 Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis Integral-1 Recruiting No Results Available Complicated Urinary Tract Infection|Acute Pyelonephritis Drug: co-administration of cefepime and nacubactam|Drug: co-administration of aztreonam and nacubactam|Drug: imipenem/cilastatin The primary efficacy endpoint is the proportion of patients who achieve composite clinical and microbiological success at TOC in the Microbiological Modified Intent-to-Treat (m-MITT) Population. Meiji Seika Pharma Co., Ltd. All 18 Years and older   (Adult, Older Adult) Phase 3 600 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment OP0595-5 May 23, 2023 August 2024 August 2024 June 5, 2023 June 5, 2023 Meiji Research Site, Meegomäe, Voru, Estonia https://ClinicalTrials.gov/show/NCT05887908 165 NCT05887895 To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects Not yet recruiting No Results Available Diabetes Drug: INS062 injection、INS068 injection、HR20014 injection Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS068）|Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062）|Area under the Glucose Infusion Rate (GIR) - time curve|Maximum concentration of INS068|Maximum concentration of INS062|Incidence and severity of adverse events (AEs) Jiangsu HengRui Medicine Co., Ltd. All 18 Years to 45 Years   (Adult) Phase 1 12 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HR20014-102 May 30, 2023 August 10, 2023 August 30, 2023 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887895 166 NCT05887882 Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors PNOC028 Not yet recruiting No Results Available Pediatric Brain Tumor|Recurrent Pediatric Brain Tumor|Pediatric Supratentorial Neoplasm Biological: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|Procedure: Implantation Proportion of participants with treatment-emergent adverse events|Recommended Phase II dose (RP2D) Sabine Mueller, MD, PhD|Rally Foundation|Washington University School of Medicine|Nationwide Children's Hospital|University of California, San Francisco All 1 Year to 39 Years   (Child, Adult) Phase 1 24 Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 210831|NCI-2023-03216 July 1, 2023 July 31, 2027 July 31, 2027 June 5, 2023 June 5, 2023 University of California, San Francisco, San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05887882 167 NCT05887869 South Carolina WIC Telehealth Solution Recruiting No Results Available Telehealth|Nutrition Education|Breast Feeding|Dietary Intake|WIC Behavioral: Telehealth solution Satisfaction with the telehealth solution|Breastfeeding duration|Attendance at scheduled appointments|Dietary intake|Attitudes to breastfeeding and nutrition education|Barriers encountered in obtaining nutrition education and breastfeeding support Tufts University|U.S. Department of Agriculture|South Carolina Department of Health and Environmental Control (DHEC)|RTI International Female 18 Years and older   (Adult, Older Adult) Not Applicable 5300 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other IRB.22-012 April 4, 2022 August 2023 August 2023 June 5, 2023 June 5, 2023 Tufts University, Boston, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05887869 168 NCT05887856 Reduction of Pre-operative Anxiety Using a Specially Designed Educational Program for Breast Cancer Patients Undergoing Surgery: A Randomized Controlled Trial PAUSDE Not yet recruiting No Results Available Patient Satisfaction|Preoperative Anxiety|Anxiety Other: comprehensive educational program for reduction of Pre-Operative Anxiety Patient Pre-Operative Anxiety|Patient Satisfaction. Shaukat Khanum Memorial Cancer Hospital & Research Centre Female 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 400 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention IRB-22-40 June 1, 2023 December 30, 2023 March 30, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887856 169 NCT05887843 Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Not yet recruiting No Results Available Seasonal Allergic Rhinitis Drug: Mometasone + Azelastine|Drug: Mometasone Furoate|Drug: Azelastine Hydrochloride AUCt|AUCinf|Cmax|Tmax|Kel|Thalf Sandoz All 12 Years to 24 Years   (Child, Adult) Phase 1 60 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SAN-0791|2023-000362-34 May 29, 2023 August 21, 2023 August 21, 2023 June 5, 2023 June 5, 2023 Sandoz Investigational Site, Toronto, Ontario, Canada https://ClinicalTrials.gov/show/NCT05887843 170 NCT05887830 Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial Not yet recruiting No Results Available Acute Anterior ST Segment Elevation Myocardial Infarction Drug: Nivolumab ∆Infarct size/Left Ventricular mass%|The incidence of adverse events|∆Left ventricle ejection fraction%|∆Left ventricle end systolic volume/Body surface area|∆Left ventricle end diastolic volume/Body surface area|∆Troponin T|∆proBNP Second Affiliated Hospital, School of Medicine, Zhejiang University All 18 Years to 80 Years   (Adult, Older Adult) Phase 1|Phase 2 96 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment YAN2023-0193 January 1, 2024 August 31, 2025 December 31, 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887830 171 NCT05887817 Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) FIVE-STAR Not yet recruiting No Results Available Type 2 Diabetes|Chronic Kidney Diseases Drug: Finerenone|Drug: Placebo Change in CAVI|Change in UACR|Change in pentosidine|Change in urinary type IV collagen|Change in urinary alpha1-MG|Change in urinary beta2-MG|Change in urinary NGAL|Change in urinary NAG|Change in urinary L-FABP Saga University All 20 Years and older   (Adult, Older Adult) Phase 4 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 00002 September 1, 2023 February 28, 2025 July 31, 2026 June 5, 2023 June 5, 2023 Saga University Hospital, Saga, Japan https://ClinicalTrials.gov/show/NCT05887817 172 NCT05887804 COMPARISON OF KELOID VOLUME AND SYMPTOMS REDUCTION BETWEEN INTRALESIONAL UMBILICAL-CORD MESENCHYMAL STEM CELLS, ITS CONDITIONED MEDIUM, AND TRIAMCINOLONE ACETONIDE INJECTION AS KELOID THERAPY: A RANDOMISED CONTROLLED TRIAL Completed No Results Available Keloid|Stem Cell Biological: umbilical cord-derived mesenchymal stem cells Keloid volume reduction|Symptoms reduction Rumah Sakit Pusat Angkatan Darat Gatot Soebroto|Indonesia University All 18 Years to 55 Years   (Adult) Phase 4 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment KET-1206 October 1, 2021 June 9, 2022 June 9, 2022 June 5, 2023 June 5, 2023 RSPAD Gatot Soebroto, Jakarta Pusat, DKI Jakarta, Indonesia https://ClinicalTrials.gov/show/NCT05887804 173 NCT05887791 Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects Not yet recruiting No Results Available Healthy|Prediabetic State Dietary Supplement: Collagen hydrolysate|Other: Placebo Glucose iAUC|Glucose Cmax|Delta Cmax|Tmax|T baseline|Matsuda-Index|Glucose dip|Insulin iAUC|GLP-1|Satiety assessment Rousselot BVBA|BioTeSys GmbH All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 15 Industry|Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention BTS1984/23 May 30, 2023 December 23, 2023 December 23, 2023 June 5, 2023 June 5, 2023 BioTeSys GmbH, Esslingen, Germany https://ClinicalTrials.gov/show/NCT05887791 174 NCT05887778 Dexamethasone in Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist Surgery Not yet recruiting No Results Available Wrist Disease|Hand Injuries and Disorders Drug: Sodium Chloride 0.9% Inj|Drug: 0,1mg/kg Dexamethasone|Drug: 0,2mg/kg Dexamethasone first need of opiate|Opioid Consumption|Pain score|Blood glucose|NLR|PLR|Mobilisation Poznan University of Medical Sciences All 3 Months to 18 Years   (Child, Adult) Phase 4 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 9/2023 July 1, 2023 July 1, 2024 August 1, 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887778 175 NCT05887765 Effect of Systematic Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery Not yet recruiting No Results Available Ankle Disease|Foot Deformities|Foot Diseases|Cerebral Palsy Drug: Sodium Chloride 0.9% Inj|Drug: 0,1mg/kg Dexamethasone|Drug: 0,2mg/kg Dexamethasone first need of opiate|Opioid Consumption|Pain score|Blood glucose|NLR|PLR|Mobilisation Poznan University of Medical Sciences All 3 Months to 18 Years   (Child, Adult) Phase 4 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 8/2023 July 1, 2023 July 1, 2024 August 1, 2024 June 5, 2023 June 5, 2023 Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland, Poznań, Wielkopolska, Poland|Poznan Univesity of Medical Sciences, Poznań, Wielkopolska, Poland https://ClinicalTrials.gov/show/NCT05887765 176 NCT05887752 Hunova® Randomized Controlled Trial for Trunk Control Improvement in Spinal Cord Injured Patients Not yet recruiting No Results Available Spinal Cord Injury Other: Standard rehabilitation|Device: Hunova® rehabilitation Change of trunk control after 10 sessions of Hunova® rehabilitation|Change of trunk equilibrium after 10 sessions of Hunova® rehabilitation|Change of trunk control after 20 versus 10 Hunova® rehab sessions|Change of trunk equilibrium after 20 versus 10 Hunova® rehabilitation sessions|Comparison between trunk control measurements obtained by Hunova® and a validated clinical scale|Estimation of correlation between change of trunk control and functional activities - self care|Estimation of correlation between change of trunk control and functional activities - overall mobility|Estimation of correlation between change of trunk control and patients' self-perception of performances in functional activities|Estimation of correlation between change of trunk control and patients' satisfaction with performances in functional activities|Estimation of correlation between change of trunk control and patients' quality of life|Change of the COP area as a function of SCI neurologic categories|Change of activity patterns in muscles involved in trunk control, assessed by electromyography|Tolerability of the Hunova® rehab treatment|Satisfaction of the Hunova® rehab treatment Montecatone Rehabilitation Institute S.p.A. All 18 Years and older   (Adult, Older Adult) Not Applicable 78 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment CE AVEC 286-2023-DISP-AUSLIM|MRI_47-2023 June 2023 April 2025 April 2025 June 5, 2023 June 5, 2023 Montecatone Rehabilitation Institute S.p.A., Imola, BO, Italy https://ClinicalTrials.gov/show/NCT05887752 177 NCT05887739 Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome Recruiting No Results Available GLUT1DS1|Dystonia|Gait Disorders, Neurologic|Gait Ataxia Diagnostic Test: Inertial gait analysis Comparison of Harmonic Ratio between patients and healthy controls at baseline|Comparison of largest Lyapunov exponent between patients and healthy controls at baseline|Comparison of coefficient of variation between patients and healthy controls at baseline|Comparison of normalized jerk score between patients and healthy controls at baseline|Comparison of recurrence quantification analysis between patients and healthy controls at baseline|Comparison of Multiscale entropy between patients and healthy controls at baseline|Comparison of Harmonic Ratio in patients between subsequent visits|Comparison of coefficient of variation in patients between subsequent visits|Comparison of normalized jerk score in patients between subsequent visits|Comparison of largest Lyapunov exponent in patients between subsequent visits|Comparison of recurrence quantification analysis in patients between subsequent visits|Comparison of Multiscale entropy in patients between subsequent visits IRCCS National Neurological Institute "C. Mondino" Foundation|University of Roma La Sapienza All 3 Years to 60 Years   (Child, Adult) 25 Other Observational Observational Model: Case-Control|Time Perspective: Prospective Gait analysis in GLUT1DS January 1, 2023 December 31, 2024 December 31, 2026 June 5, 2023 June 5, 2023 Child and Adolescent Epileptology Center, Pavia, Italy|Headache Science & Neurorehabilitation Center, Pavia, Italy https://ClinicalTrials.gov/show/NCT05887739 178 NCT05887726 Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors Not yet recruiting No Results Available Diffuse Large B Cell Lymphoma Drug: Zanubrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vincristine|Drug: Prednisone Complete response rate（CRR）|Overall response rate （ORR）|Progression-free Survival(PFS)|Overall survival (OS)|Duration of Response|Incidence of adverse event|Assessment of the correlation between MYD88、CD79B、NOTCH1、BCL6、NOTCH2 or other gene abnormality and efficacy. Liaoning Tumor Hospital & Institute All 18 Years and older   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ZR-CHOP HR June 1, 2023 June 1, 2024 June 1, 2025 June 5, 2023 June 5, 2023 Xing Xiaojing, Shenyang, Liaoning, China https://ClinicalTrials.gov/show/NCT05887726 179 NCT05887713 Novel Mental Health Therapies to Improve Military Readiness Not yet recruiting No Results Available Anxiety|Alpha Stim|Cranial Electrotherapy Stimulation|Cognitive Behavioral Therapy|Heart Rate Variability Device: Experimental: Alpha-Stim 100|Device: Sham Comparator Beck Anxiety Inventory (BAI)|Hamilton Anxiety Rating Scale (HAM-A)|Heart Rate Variability (HRV)|Vagal Efficiency (VE) David Moss|Mike O'Callaghan Military Hospital All 18 Years and older   (Adult, Older Adult) Not Applicable 160 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment alpha stim June 2023 June 2025 June 2025 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887713 180 NCT05887700 Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up Not yet recruiting No Results Available Atrial Septal Defect Device: CeraFlex™ Atrial Septal Defect (ASD) Closure System Procedural success|Incidence of moderate or large residual shunt|Incidence of device or procedure related Adverse Events (AEs)|Incidence of device or procedure related Serious Adverse Events (SAEs)|Incidence of Device Deficiencies (DD)|Incidence of death Lifetech Scientific (Shenzhen) Co., Ltd. All Child, Adult, Older Adult 145 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective LT-TS-271-2023-01 December 2023 June 2024 December 2024 June 5, 2023 June 5, 2023 Hospital Pequeno Príncipe, Curitiba, Brazil|Hospital Beneficência Portuguesa, Porto Alegre, Brazil|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Instituto de Cardiologia de Santa Catarina, São José, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Onassis Cardiothorasic Center, Athens, Greece|IRCCS Policlinico San Donato, Milan, Italy|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain https://ClinicalTrials.gov/show/NCT05887700 181 NCT05887687 68Ga-P3 PET/CT Imaging in Malignancy Recruiting No Results Available Neoplasms Drug: [68Ga]P3 The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of malignant tumors|The dosimetry of 68Ga-P3|Quantitative evaluation of 68Ga-P3|Correlation with pathological expression Peking University First Hospital All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 350 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic [68Ga]P3 May 20, 2023 July 31, 2025 July 31, 2025 June 5, 2023 June 5, 2023 Peking University First Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05887687 182 NCT05887674 Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease SIM-2 Recruiting No Results Available Mild Cognitive Impairment|Mild Dementia Behavioral: Diet intervention|Behavioral: Exercise|Behavioral: Cognitive training Change from baseline global cognitive function at one year|Change from baseline memory at one year|Change from baseline visual spatial ability and visual memory at one year|Changes in cognition assessed by Clock drawing test, Symbol-digit test, Trail making test, Boston naming test and Language fluency test|Changes in hippocampus related neural circuit-specific resting-state connectivity (FC)|Changes in structural brain MRI including volume of hippocampus and other specific brain regions|Changes in Inflammatory biomarkers|Changes in gut microbiota|Changes in Metabolic biomarkers Ruijin Hospital|Shanghai Sinopharm Nursing Care Center All 60 Years to 90 Years   (Adult, Older Adult) Not Applicable 180 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention RJNeuroBank-SIM2 May 11, 2023 August 30, 2026 August 30, 2026 June 5, 2023 June 5, 2023 Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05887674 183 NCT05887661 Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy Recruiting No Results Available Hepatocellular Carcinoma Procedure: hypovolemic phlebotomy The proportion of allogeneic red blood cell products transfusion|The volume of Phlebotomy|The volume of Intraoperative blood loss|The volume of Allogeneic transfusion (perioperative)|The volume of Allogeneic transfusion (postoperative)|The volume of Allogeneic transfusion (intraoperative)|The volume of Fresh frozen plasm (FFP) transfusion|The volume of Platelets transfusion|The volume of Albumin transfusion|Perioperative lowest concentration of Hb|Pre-transection central venous pressure (CVP), (basic CVP)|Lowest central venous pressure (CVP)|time of pringle maneuver|number of pringle maneuver|operating time|The proportion of laparoscopic hepatectomy converted to open liver resection|Length of stay|Number of Participants with postoperative complications (overall) The First Affiliated Hospital with Nanjing Medical University All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2022-SR-102 May 1, 2022 October 31, 2023 December 31, 2023 June 5, 2023 June 5, 2023 The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China https://ClinicalTrials.gov/show/NCT05887661 184 NCT05887648 Effect of Singapore-contextualized Dance-based Exergame Among Community-dwelling Older Adults Recruiting No Results Available Community-dwelling Older Adults Behavioral: SinDance Short Fall Efficacy Scale International (short FES-I)|15-item Geriatric Depression Scale (GDS-15)|Frenchay Activities Index (FAI)|Five times sit-to-stand test (FTSTS)|Time Up & Go Test (TUG)|Functional Reach Test|Modified Barthel ADL Index|Attendance (for SinDance group only)|Duration of play (for SinDance group only)|Level of motivation (for SinDance group only)|Level of enjoyment (for SinDance group only) National University of Singapore|National University Hospital, Singapore|Lions Befrienders Service Association (Singapore) All 60 Years and older   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention NUHS Seed Grant Call Sep 2021 April 5, 2023 January 31, 2024 February 29, 2024 June 5, 2023 June 5, 2023 Lb Aac @ Clementi 344, Singapore, Singapore|Lb Aac @ Clementi 366/367, Singapore, Singapore|Lb Aac @ Clementi 420A, Singapore, Singapore https://ClinicalTrials.gov/show/NCT05887648 185 NCT05887635 Pilot Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus STEAM T-2DM Not yet recruiting No Results Available Diabetes Mellitus Type 2 Device: RF Vapor Ablation Safety endpoint|Efficacy endpoint|Tolerability Endpoint:|Change in HbA1c at 84 and 168 days post procedure|Change in HbA1c by visit over time|Change in FPG from baseline to 84 and 168 days post procedure|Change in FPG change by visit over time (168 days post procedure)|Proportion of ablation-treated subjects with an HbA1c improvement from baseline at 168 days|Changes in HOMA-IR by visit over time (168 days post procedure).|Change in UACR from baseline to 24 weeks post procedure|Change in ALT and AST from baseline to 24 weeks post procedure. Aqua Medical, Inc. All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CLD-1021 August 2023 August 2024 August 2024 June 5, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05887635 186 NCT05887622 The Potassium Supplementation Study Recruiting No Results Available Cardiovascular Health|Cardiovascular Risk Factor Dietary Supplement: Potassium chloride supplement|Dietary Supplement: Placebo Conduit artery endothelial dependent dilation|Blood pressure reactivity|Superoxide levels University of Delaware All 18 Years to 45 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention 1465208 January 24, 2022 January 31, 2025 June 30, 2025 June 5, 2023 June 5, 2023 Tower at STAR, Newark, Delaware, United States https://ClinicalTrials.gov/show/NCT05887622 187 NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib Not yet recruiting No Results Available Ovary Cancer|Peritoneal Cancer|Fallopian Tube Cancer Drug: Mirvetuximab Soravtansine|Drug: Olaparib To measure progression free survival (PFS) with the use of MIRV combined with Olaparib in women with recurrent platinum sensitive ovarian, peritoneal, and fallopian tube cancer.|To evaluate safety and tolerability of MIRV combined with Olaparib by Adverse Events as measured by CTCAE v 5.0|Determine Overall Response Rate|Determine Duration of Response|Determine Overall Survival University of Colorado, Denver|ImmunoGen, Inc. Female 18 Years to 99 Years   (Adult, Older Adult) Phase 2 53 Other|Industry Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 22-0384.cc December 2023 April 15, 2026 December 2027 June 5, 2023 June 5, 2023 University of Colorado Hospital, Aurora, Colorado, United States https://ClinicalTrials.gov/show/NCT05887609 188 NCT05887596 The Effect of Patient Education on Pain Completed No Results Available Fear of Pain|Pain|Pain Management|Patient Education Other: Patient education Pain Level|Fear of Pain Trakya University All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 52 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 2021/541 December 15, 2021 March 15, 2022 March 15, 2022 June 2, 2023 June 2, 2023 Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Bakırköy, Turkey https://ClinicalTrials.gov/show/NCT05887596 189 NCT05887583 Supporting Physical Literacy at School and Home SPLASH Not yet recruiting No Results Available Physical Inactivity Behavioral: The Rising New York Road Runners program Baseline physical activity level|End-point physical activity level|Baseline fundamental movement skill in running, locomotion, object control and Balance|End-point fundamental movement skill in running, locomotion, object control and Balance Tufts University|George Washington University All 6 Years to 12 Years   (Child) Not Applicable 400 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention STUDY00003794 June 2023 June 2025 June 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887583 190 NCT05887570 Procedure-Specific Resident Objective Modular Training Evaluation PROMOTE Recruiting No Results Available Resident Education Behavioral: Educational intervention|Other: Control - Regular Instruction Primary Outcome - investigation of whether procedure-specific skills acquired in surgical lab|Secondary Outcome 1 - Improved Knowledge|Secondary Outcome 2 - Less OR Time|Secondary Outcome 3 - Implemention of modular training|Seconday Outcome 4 - remedial training|Secondary Outcome 6 - Resident satisfaction and self confidence University of British Columbia|Royal College of Physicians and Surgeons of Canada|University of Calgary|University of Alberta All 19 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other H11-00779 June 13, 2011 July 2, 2023 July 2, 2023 June 2, 2023 June 2, 2023 St. Paul's Hospital, Vancouver, British Columbia, Canada https://ClinicalTrials.gov/show/NCT05887570 191 NCT05887557 Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation Recruiting No Results Available HIV Other: Active Referral|Other: Drop-In Multidisciplinary HIV Care|Other: Mobile HIV Care|Other: Staged Care|Other: Identify and prepare champions at referral sites|Other: Audit and feedback at referral sites|Other: Build a coalition among referral and clinical sites|Other: Assess for readiness and identify barriers|Other: Promote adaptability|Other: Develop a formal implementation blueprint|Other: Develop educational materials; conduct ongoing training|Other: Create a learning collaborative Reach|Number of participants with HIV viral suppression|Evaluate sustained engagement in HIV care|Participants with durable viral suppression University of California, San Francisco|La Clínica de La Raza Inc.|Lifelong Medical Care|San Francisco AIDS Foundation|National Institute of Allergy and Infectious Diseases (NIAID) All 15 Years and older   (Child, Adult, Older Adult) Not Applicable 400 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other R01AI169667 December 16, 2022 February 28, 2026 February 28, 2026 June 2, 2023 June 2, 2023 La Clinica de la Raza, Inc, Oakland, California, United States|Lifelong Medical Care, Oakland, California, United States|San Francisco AIDS Foundation, San Francisco, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05887557 192 NCT05887544 Towards Objective Dietary Assessment in Large-scale Studies ODA Not yet recruiting No Results Available Diabetes Mellitus, Type 2 Other: Exposure: Plant-based diet pattern|Other: Intervention: Fermented dairy products|Other: Exposure: individual foods and food groups Concentration of Indole-3-lactic acid in blood|Concentration of Indole-3-lactic acid in urine|Concentration of 3-Phenyllactic acid in blood|Concentration of 3-Phenyllactic acid in urine University of Copenhagen|Aarhus University Hospital|University of Aarhus All 18 Years to 75 Years   (Adult, Older Adult) 60 Other Observational Observational Model: Cohort|Time Perspective: Prospective M244 June 1, 2023 October 1, 2023 October 1, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887544 193 NCT05887531 Abdominopelvic Cancer Prehabilitation Not yet recruiting No Results Available Prehabilitation|Cancer of Colon|Cancer of Rectum|Cancer, Ovarian Other: Prehabilitation Post-surgical recovery time|Post-surgical readmisions|Self-care capacity|Anxiety levels|Aerobic capacity|Flexibility|Strength Universitat Jaume I All 18 Years to 100 Years   (Adult, Older Adult) Not Applicable 66 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care malcazar June 1, 2023 December 31, 2023 October 10, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887531 194 NCT05887518 The Effect of Socks Developed wıth Wearable Technology for Patıents Undergoıng Transurethral Resectıon Surgery Not yet recruiting No Results Available Transurethral Resection|Wearable Devices|Venous Thromboembolism|Hypothermia|Nurse Device: Socks Developed with Wearable Technology Body temperature|Shivering level|Comfort perception|Development of venous thromboembolism Tarsus University|Mersin University All Child, Adult, Older Adult Not Applicable 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention MU-BOZKUL-002 July 1, 2023 September 1, 2023 December 31, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887518 195 NCT05887505 Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy Not yet recruiting No Results Available Hepatocellular Carcinoma|Liver Function|Postoperative Complications Other: Vitamin D|Other: Placebo Whether there is an association between 25(OH)D and PTH: positive or negative association , or no association|Ratio of liver failure|25(OH)D status|Prevalence of high PTH|Prevalence of hypercalcemia|Prevalence of hypomagnesemia|30-day mortality|Clinical outcomes|Complications after surgery Taoyuan General Hospital All 20 Years and older   (Adult, Older Adult) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment TYGH111086 May 22, 2023 December 1, 2027 December 31, 2027 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887505 196 NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Not yet recruiting No Results Available Non Small Cell Lung Cancer|Solid Tumors, Adult|Endometrial Cancer|Pancreatic Cancer|Cervical Cancer|Breast Cancer|Carcinoma of Unknown Primary Drug: TNG260|Drug: Pembrolizumab Determine the MTD and RP2D(s) (Phase 1 only)|Measure antitumor activity using RECIST 1.1 (Phase 2 only)|Measure antitumor evidence of TNG260 + pembrolizumab antineoplastic activity by RECIST 1.1 (Phase 1 only)|Characterize Area Under the Curve (AUC) of TNG260|Characterize the time to achieve Time to Maximal Concentration (Tmax) of TNG260|Characterize Maximum Observed Plasma Concentration (Cmax) of TNG260|Characterize Terminal Half-life (T1/2) of TNG260|Characterize pembrolizumab concentrations when administered with TNG260|Safety and tolerability of TNG260 by CTCAE 5.0|To measure changes in histone acetylation when administered with TNG260 Tango Therapeutics, Inc. All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 126 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TNG260-C101 July 2023 January 2025 June 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887492 197 NCT05887479 The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity Not yet recruiting No Results Available Cerebrovascular Disorders|Spasticity, Muscle|Botulinum Toxin Drug: Botulinum toxin type A|Drug: %0,9 NaCl Pain - Visual Analog Scale|Range of Motion|Modified Ashworth Scale|The Fugl-Meyer assessment scale Sisli Hamidiye Etfal Training and Research Hospital All 35 Years to 80 Years   (Adult, Older Adult) Phase 4 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 042023 May 25, 2023 July 15, 2023 August 15, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887479 198 NCT05887466 Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients Recruiting No Results Available Parkinson Disease Drug: A9-DPC Occurrence of treatment-emergent adverse events (TEAEs) after administration of the IP|Failure or rejection of transplantation|Occurrence of bleeding|Occurrence of infection|Occurrence of adverse event of special interest (AESI)* after administration of the IP|Change in the MDS-UPDRS Total Score, part Ⅲ (defined on/off) & part Ⅳ|Change in the K-MMSE|Change in the Seoul Neuropsychological screening battery (SNSB, Screening & Week 96 (24 months))|Change in the K-MoCA|Change in the Parkinson's Questionnaire (PDQ-39)|Change in the Schwab and England ADL scale (SEADL)|Change in the Non-Motor Symptoms Scale for Parkinson's Disease (NMS)|Change in Graft size through MRI|Change in Cerebral FDG uptake and Striatal FDG uptake|Change in density of dopamine transporters as measured by FP-CIT PET|Percentage of subjects who used concomitant medication related to Parkinson-mobility or Parkinson-Non-mobility during the whole clinical trial period and Change in dose of each concomitant medication (per component) S.Biomedics Co., Ltd.|Yonsei University All 50 Years to 75 Years   (Adult, Older Adult) Phase 1|Phase 2 12 Industry|Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SB-PD-001 May 9, 2023 January 2024 January 2026 June 2, 2023 June 2, 2023 Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05887466 199 NCT05887453 An Exploratory Clinical Study to Evaluate the Specificity of Magnetocardiogram in Atrial Fibrillation and the Prediction of Recurrence Recruiting No Results Available Atrial Fibrillation Device: Magnetocardiography sensitivity and specificity|Independent predictors of recurrence of paroxysmal atrial fibrillation Second Affiliated Hospital, School of Medicine, Zhejiang University All 18 Years and older   (Adult, Older Adult) 450 Other Observational Observational Model: Cohort|Time Perspective: Prospective JWang March 22, 2023 August 2023 December 2023 June 2, 2023 June 2, 2023 The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05887453 200 NCT05887440 Isokinetic Strength Training in Hemiparetic Patient With Knee Extension Thrust ISOWALK Not yet recruiting No Results Available Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis)|Gait Disorder Behavioral: isokinetic strength training of knee extensor and flexor muscles spontaneous walking speed|Extensor thrust analysis|Walking speed|Stairs test|Inclined plan|6-minute walk test|Sit to stand test|Extensor thrust during locomotor tasks|Fatigue|Likert Scale|Strength Rennes University Hospital All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 12 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 35RC20_9899_ISOWALK September 1, 2023 March 1, 2026 September 1, 2026 June 2, 2023 June 2, 2023 CHU de Rennes, Rennes, France https://ClinicalTrials.gov/show/NCT05887440 201 NCT05887427 Acute Effect of Neural Mobilization in Cervical Radiculopathy: A Randomized Controlled Study Completed No Results Available Cervical Radiculopathy Other: Neural Mobilisation|Other: Conservative physiotherapy Numerical Pain Rating Scale (NPRS)|Neuropathic Pain Questionnaire (NPQ)|Hand Grip Strength|Pinch Grip Strength Uskudar University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 44 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment Üsküdar Üniversitesi November 10, 2022 January 6, 2023 January 6, 2023 June 2, 2023 June 2, 2023 Üsküdar University, Istanbul, Üsküdar, Turkey https://ClinicalTrials.gov/show/NCT05887427 202 NCT05887414 TRIAD Patient Surveys TRIAD Recruiting No Results Available Appendicitis Other: Baseline|Other: 30 Day Follow Up Ottawa Decisional Conflict Scale University of Washington|Patient-Centered Outcomes Research Institute All 18 Years and older   (Adult, Older Adult) 3000 Other Observational Observational Model: Case-Only|Time Perspective: Prospective STUDY00016171|DI-2021C3-24262 October 1, 2022 October 1, 2024 October 1, 2025 June 2, 2023 June 2, 2023 Kaiser Permanente Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente Los Angeles, Los Angeles, California, United States|Kaiser Permanente Riverside, Riverside, California, United States|Grady Health System / Morehouse School of Medicine, Atlanta, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Boston Medical Center, Boston, Massachusetts, United States|Michigan Medicine- University of Michigan, Ann Arbor, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Atrium Health, Charlotte, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Lyndon B Johnson- Harris Health, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Tech University, Lubbock, Texas, United States|Harborview Medical Center, Seattle, Washington, United States|Northwest Hospital and Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States https://ClinicalTrials.gov/show/NCT05887414 203 NCT05887401 Physical Activity and Healthy Eating Among Young Adult Cancer Survivors Not yet recruiting No Results Available Physical Activity|Neoplasms|Cancer Behavioral: Core|Behavioral: Simplified Nutrition Monitoring (Green)|Behavioral: Behavioral: Simplified Nutrition Monitoring (Red)|Behavioral: Nutrition Goals (Yes)|Behavioral: Nutrition Goals (No)|Behavioral: Supportive Text Messages (Yes)|Behavioral: Supportive Text Messages (No)|Behavioral: Lesson Delivery (Once)|Behavioral: Lesson Delivery (Weekly) Accrual rate|Participation rate|Retention rate at 3 months|Acceptability of the intervention.|Adherence to physical activity monitoring.|Adherence to diet self-monitoring|Moderate-to-vigorous physical activity (objective)|Self-reported physical activity|Dietary intake: Healthy Eating Index (HEI)|Weight|Fried physical frailty phenotype: FRAIL Index|Health-related Quality of Life: AYA PROMIS PRO Core Battery|Competence for Exercise and Nutrition|Self-efficacy for Exercise and Nutrition|Self-regulation for Exercise and Nutrition|Autonomy Support and Relatedness UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) All 18 Years to 39 Years   (Adult) Not Applicable 80 Other|NIH Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care LCCC2233|T32CA057726 June 2023 March 2024 March 2024 June 2, 2023 June 2, 2023 Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States https://ClinicalTrials.gov/show/NCT05887401 204 NCT05887388 Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers Completed No Results Available Pathologic Processes Behavioral: Connect-Home Plus Number of participants for whom the intervention components were feasible|Mean patient intervention satisfaction scores|Mean caregiver intervention satisfaction scores|Care Transitions Measure-15|Preparedness for Caregiving Scale|Life Space Assessment|Dementia Quality of Life Measure (patient)|Dementia Quality of Life-Proxy measure (DEMQOL-Proxy)|Self-Reported Days of ED or Hospital Use 30 Days After Skilled Nursing Facility Discharge|Zarit Caregiver Burden Scale|Distress Thermometer University of North Carolina, Chapel Hill|National Institute of Nursing Research (NINR) All 18 Years and older   (Adult, Older Adult) Not Applicable 38 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 20-2406|R01NR017636-03 September 10, 2021 February 27, 2022 March 18, 2022 June 2, 2023 June 2, 2023 UNC-Chapel Hill, Chapel Hill, North Carolina, United States https://ClinicalTrials.gov/show/NCT05887388 205 NCT05887375 Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery Not yet recruiting No Results Available Spine Surgery|Reversal of Neuromuscular Blockade|Urinary Retention Postoperative Drug: Sugammadex|Drug: Neostigmine|Drug: Glycopyrrolate|Drug: Rocuronium Incidence of urinary retention|Micturition|Bladder urine volume|Urinary retention symptoms|Bladder catheterization|Length of hospital stay University of Missouri-Columbia|Merck Sharp & Dohme LLC All 18 Years and older   (Adult, Older Adult) Phase 4 118 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2096001|MISP Database number 101357 July 2023 July 2024 August 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887375 206 NCT05887362 The Power of Hand Reflexology in Ameliorating Anxiety, Pain, and Fatigue Among Patients Undergoing Coronary Angiography Completed No Results Available Coronary Artery Disease Behavioral: Hand Reflexology Pain intensity|Fatigue|Anxiety Alexandria University All 20 Years to 60 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 2022935 July 1, 2022 November 1, 2022 November 15, 2022 June 2, 2023 June 2, 2023 Faculty of Nursing, Alexandria university, Alexandria, Egypt https://ClinicalTrials.gov/show/NCT05887362 207 NCT05887349 Investigation of the Efficacy of Rocabado Exercises in Individuals With Chronic Neck Pain Not yet recruiting No Results Available Neck Pain Other: Neck Stabilization Exercise|Other: Neck Stabilization Exercise + Rocabado Exercises Pain assessment|Joint Range of Motion assessment|Proprioception assessment Kirsehir Ahi Evran Universitesi All Child, Adult, Older Adult Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment 43834581758 July 1, 2023 September 1, 2023 November 1, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887349 208 NCT05887336 Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment Method for the Relief of Symptoms of Dry Eye Recruiting No Results Available Dry Eye|Dry Eye Syndromes Device: Walther System|Device: Sham Walther System|Drug: Non preserved ocular lubricants|Procedure: Eye lid procedure Change in Ocular Surface Disease Index (OSDI)|Adverse Events|Device Deficiencies|Remission|Non-Invasive Tear Break-Up time (NIBUT)|Schirmer's Test|Tear Meniscus Height (TMH)|Lissamine Green Test|Corneal Staining Test|Lipid Layer Test|Compliance Abilion Medical Systems AB All 18 Years and older   (Adult, Older Adult) Not Applicable 110 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment A-DE-002 June 2023 March 2024 June 2024 June 2, 2023 June 2, 2023 Øjenhospitalet Danmark, Charlottenlund, Copenhagen, Denmark|Kontaktlinse Instituttet, Århus, Denmark|Källmarkskliniken, Solna, Stockholm, Sweden https://ClinicalTrials.gov/show/NCT05887336 209 NCT05887323 LBBAP Data Collection Registry Recruiting No Results Available Bradycardia|Sinus Node Dysfunction|Heart Block|Syncope|Cardiomyopathies|Heart Failure Device: Implantation of the Tendril 2088 lead in the LBBA The primary safety endpoint evaluates freedom from LBBAP lead related serious adverse device effects (SADEs).|The primary effectiveness endpoint evaluates the composite success rate of acceptable capture thresholds and sense amplitudes for LBBAP Abbott Medical Devices All 18 Years and older   (Adult, Older Adult) 220 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective ABT-CIP-10474 April 25, 2023 June 30, 2023 July 31, 2023 June 2, 2023 June 2, 2023 Medanta - The Medicity Hospital, Gurgaon, Nct Dlh, India https://ClinicalTrials.gov/show/NCT05887323 210 NCT05887310 In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells Enrolling by invitation No Results Available Depressive Disorder, Treatment-Resistant Create in vitro human cellular models of some drug-resistant psychiatric disorders.|To study the etiopathogenesis of these drug-resistant psychiatric disorders University of Milano Bicocca|Università degli Studi di Trento|National Research Council All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Cohort|Time Perspective: Prospective FaReStem August 5, 2022 August 5, 2024 August 5, 2024 June 2, 2023 June 2, 2023 Fondazione IRCCS San Gerardo di Monza, Monza, Monza E Brianza, Italy https://ClinicalTrials.gov/show/NCT05887310 211 NCT05887297 Impact of Cognitive Behavioural Therapy for Insomnia on Endocrine Therapy Adherence Recruiting No Results Available Insomnia|Breast Cancer|Adherence, Medication|Quality of Life|Survivorship Behavioral: Cognitive behavioural therapy for insomnia Endocrine therapy adherence|Insomnia symptoms|Depressive symptoms|Anxiety symptoms|Fatigue|Musculoskeletal pain|Vasomotor symptoms|Sleep efficiency|Total sleep time|Sleep onset latency|Wake after sleep onset University of Strathclyde All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care UEC23/09 March 23, 2023 December 23, 2023 December 23, 2023 June 2, 2023 June 2, 2023 University of Strathclyde, Glasgow, County (optional), United Kingdom "Study Protocol, Statistical Analysis Plan, and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/97/NCT05887297/Prot_SAP_ICF_000.pdf https://ClinicalTrials.gov/show/NCT05887297 212 NCT05887284 Investigation of the Clinical Efficacy of Low-dose Ionizing Radiation in the Treatment of Osteoarthritis IMMO-LDRT02 Not yet recruiting No Results Available Arthrosis|Osteoarthritis Radiation: low dose radiotherapy (0.5 Gy)|Radiation: mock radiation treatment|Radiation: low dose radiotherapy (1.0 Gy) Improvement in general pain (determined by visual analog scale (VAS) score) after LDRT compared to the placebo.|Identification of immunological changes, which contribute to the success of therapy and are specifically found in the test group.|Evidence of an objectionable clinical benefit of LDRT for finger/wrist osteoarthritis.|Analysis of the efficacy of LDRT against placebo in modulating patient's well-being.|Analysis of the clinical efficacy of LDRT against placebo in fingers / wrists.|Analysis of the clinical efficacy of LDRT against placebo in shoulders.|Analysis of the clinical efficacy of LDRT against placebo in knees.|Analysis of the clinical efficacy of LDRT against placebo in foot and ankle joints.|Documentation and examination of general medication and pain medication.|Investigation of the drop-out rate in the test and control group.|Comparison of the two series with single doses 0.5 Gy against one series with single dose 1.0 Gy with regard to pain score reduction and immunological changes|Modulation-matrix of immune cell function.|Detection of chromosome aberrations|Investigation of side effect profile of LDRT University of Erlangen-Nürnberg Medical School|Johann Wolfgang Goethe University Hospital All 39 Years and older   (Adult, Older Adult) Not Applicable 132 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment IMMO-LDRT02 July 1, 2023 September 30, 2026 December 31, 2028 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887284 213 NCT05887271 A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction AMEND Recruiting No Results Available Heart Failure With Preserved Ejection Fraction|Heart Failure, Diastolic|Diabetes Mellitus, Type 2|Diabetes Mellitus Type 2 in Obese|Obesity Adult Onset Drug: Low calorie meal replacement plan|Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|Diagnostic Test: Transthoracic echocardiography|Diagnostic Test: Blood test|Diagnostic Test: Electrocardiogram|Diagnostic Test: Accelerometery|Diagnostic Test: 6 minute walk test (6MWT)|Diagnostic Test: Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Other: Assessment of quality of life and heart failure symptoms|Other: Assessment of sarcopenia|Other: Assessment of frailty|Other: Qualitative interview|Diagnostic Test: Skeletal muscle magnetic resonance spectroscopy Change in the distance walked during 6 minute walk test (6MWT)|Beneficial reverse cardiovascular remodelling|Change in physical activity levels|Change in lower limb muscle power|Change in upper limb muscle power|Improvement in exercise tolerance|Improvement in symptoms of heart failure|Change in frailty|Change in sarcopenia|Exploratory outcome: Improving skeletal and cardiac energetics|Exploratory outcome: change in fibroinflammatory biomarker panel University of Leicester|University of Oxford|University of Manchester All 18 Years and older   (Adult, Older Adult) Phase 2|Phase 3 102 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 0861 March 29, 2023 June 1, 2025 January 1, 2026 June 2, 2023 June 2, 2023 University of Leicester, Glenfield Hospital, Groby Road, Leicester, Leicestershire, United Kingdom|University of Manchester, Wythenshawe Hospital, Southmoor Road, Manchester, United Kingdom|University of Oxford, John Radcliffe Hospital, Headley Way, Oxford, United Kingdom https://ClinicalTrials.gov/show/NCT05887271 214 NCT05887258 Opioid-free Vs Traditional Balanced Anesthesia in Laparoscopic Colorrectal Surgery OFA_GAL_21 Recruiting No Results Available Colorectal Surgery Drug: Opioid free anesthesia Pain control|VNS score|morphine rescues Unai Ortega Mera|Osakidetza All 18 Years and older   (Adult, Older Adult) Phase 3 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 2021-003245-38 May 15, 2022 May 15, 2024 June 15, 2024 June 2, 2023 June 2, 2023 Hospital de Galdakao, Galdakao, Vizcaya, Spain https://ClinicalTrials.gov/show/NCT05887258 215 NCT05887245 Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy Recruiting No Results Available Renal Cell Carcinoma|Kidney Neoplasm|Urologic Neoplasms|Urogenital Neoplasms|Kidney Diseases Evaluation of clinical risk factors for the occurrence of adherent perinephric fat in patients undergoing partial nephrectomy.|Evaluation of the impact of adherent perinephric fat on functional, perioperative, and oncological treatment outcomes. Centre of Postgraduate Medical Education All 18 Years and older   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective nr 21/2023 April 17, 2023 April 17, 2025 January 1, 2030 June 2, 2023 June 2, 2023 European Health Centre, Second Department of Urology, Centre of Postgraduate Medical Education, Otwock, Poland https://ClinicalTrials.gov/show/NCT05887245 216 NCT05887232 Comparison of Co2 Laser Versus Co2 Laser With PRP in Scars Completed No Results Available CO2 Laser in Scars Procedure: Fractional CO2 laser|Procedure: Fractional CO2 with Platelet Rich Plasma Quartile grading scale for assessment of scars Combined Military Hospital Abbottabad All 18 Years to 50 Years   (Adult) Phase 1 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CMHAbbottabad1988 November 1, 2022 April 30, 2023 April 30, 2023 June 2, 2023 June 2, 2023 Dr.Zahra Nigar, Abbottabad, KPK, Pakistan https://ClinicalTrials.gov/show/NCT05887232 217 NCT05887219 Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Completed No Results Available Melasma Drug: Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Drug: Group B Azelaic Acid 20 % Cream for 6 months Melasma Area and Severity Index Combined Military Hospital Abbottabad Female 20 Years to 45 Years   (Adult) Phase 1 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CMHAbbottabad1987 November 1, 2022 April 30, 2023 April 30, 2023 June 2, 2023 June 2, 2023 Zahra Nigar, Abbottabad, KPK, Pakistan https://ClinicalTrials.gov/show/NCT05887219 218 NCT05887206 Corneal Toxicity in Patients Treated by Belantamab Mafodotin Completed No Results Available Myeloma Multiple Other: Collection of datas Keratopathy and Visual Acuity (KVA) scale|Refraction (no unit)|Monoyer scale|Parinaud scale|Keratometry (diopter = 1/m)|Epithelial pachymetry (µm) Centre Hospitalier Universitaire de Saint Etienne All 18 Years and older   (Adult, Older Adult) 43 Other Observational Observational Model: Cohort|Time Perspective: Retrospective IRBN292021/CHUSTE May 2, 2022 May 2, 2023 May 2, 2023 June 2, 2023 June 2, 2023 CHU Dijon, Dijon, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|HCL- Croix Rousse, Lyon, France|Clinique Monticelli-Vélodrome, Marseille, France|CHRU de Nancy, Nancy, France|CHU Nice, Nice, France|APHP - Kremlin-Bicêtre, Paris, France|CHU Saint-Etienne, Saint-Étienne, France|CHRU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France https://ClinicalTrials.gov/show/NCT05887206 219 NCT05887193 Comparison of Penile Oxygen Pressure. Completed No Results Available Healthy Device: Biothesiometry|Device: Near Infrared Spectroscopy|Device: Cycling on a home trainer|Device: Bike Fitting Difference in penile oxygen pressure on different types of saddles Charles University, Czech Republic Male 23 Years to 45 Years   (Adult) 30 Other Observational Observational Model: Case-Control|Time Perspective: Prospective Snuparek, peritoneal area April 21, 2023 May 14, 2023 May 14, 2023 June 2, 2023 June 2, 2023 Charles University, Prague, Czechia https://ClinicalTrials.gov/show/NCT05887193 220 NCT05887180 PräVaNet - Structured, Intersectoral, Multiprofessional, Digitized Program to Optimize Cardiovascular Prevention PräVaNet Active, not recruiting No Results Available Type 2 Diabetes|Arteriosclerosis|Arterial Hypertension|Lipid Metabolism Disorders Other: PräVaNet-Intervention Rate of adverse cardiovascular and cerebrovascular events (MACCE "Plus" events)|Cardiovascular risk|Complication rate|Adherence to therapy|Changes in self-reported quality of life|Changes in patient reported quality of care|Changes in patient reported physical, psychological and social health|Changes in diabetes self-care activities|Inpatient health care utilization|Direct medical costs|Relative share of outpatient costs, inpatient costs and pharmaceutical costs in total direct medical costs|Costs of work incapacity / early retirement|Incremental cost-effectiveness ratio (ICER) using the primary outcome measure (MACCE "Plus" events) as the effectiveness criterion (cost-effectiveness analysis)|Incremental cost-utility relation (societal perspective) Charite University, Berlin, Germany|Association of Statutory Health Insurance Physicians (KV Berlin)|Statutory health insurance provider AOK Nordost|German Foundation for the Chronically ill (DScK)|aQua - Institute for Applied Quality Improvement and Research in Health Care GmbH|Scientific Institute for Health Economics and Health System Research (WIG2) All 18 Years and older   (Adult, Older Adult) Not Applicable 209 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 01NVF20001 January 1, 2022 June 30, 2024 June 30, 2025 June 2, 2023 June 2, 2023 Deutsches Herzzentrum der Charité; Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany https://ClinicalTrials.gov/show/NCT05887180 221 NCT05887167 Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Not yet recruiting No Results Available Hematologic Malignancy|Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Mantle Cell Lymphoma|Multiple Myeloma|Diffuse Large B Cell Lymphoma Biological: autologous hematopoietic stem cells added to planned CAR T To assess feasibility of collecting the target HSC cell dose for at least 50% of enrolled patients.|To assess safety of aHSC to planned CAR T therapy in the first 60 days through the incidence, severity, and duration of CRS based on the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system.|To assess safety of aHSC to planned CAR T therapy in the first 60 days through the incidence, severity, and duration of ICANS based on the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system.|Response rate of CAR T at 6 weeks.|Assess rate of recovery of absolute neutrophil count (ANC) by Day 28.|Assess red blood cell (RBC) count and transfusion independence by Day 28.|Assess platelet count and transfusion independence rate by Day 28.|Assess safety and tolerability of combining aHSCs with an FDA-approved CAR T regimen within first 52 weeks of aHSC infusion.|Median progression-free survival (PFS) for the duration of the study|Median overall survival (OS) for the duration of the study Joshua Sasine, MD, PhD|Cedars-Sinai Medical Center All 18 Years to 85 Years   (Adult, Older Adult) Phase 1 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IIT2022-04-Sasine-CAR-T August 15, 2023 July 15, 2024 July 15, 2026 June 2, 2023 June 2, 2023 Cedars-Sinai Medical Center, Los Angeles, California, United States https://ClinicalTrials.gov/show/NCT05887167 222 NCT05887154 Non Surgical Treatment (Microwave Ablation) of Breast Cancer MASTER Not yet recruiting No Results Available Breast Cancer Stage I Device: Microwave ablation MWA followed by MRI in breast tumors|Cosmetic outcome|breast cancer recurrence fear|Quality of life University Medical Center Groningen Female 18 Years and older   (Adult, Older Adult) Not Applicable 15 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NL76030.042.21|4901216 July 1, 2023 June 1, 2024 June 1, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887154 223 NCT05887141 Self-compassion and Self-criticism: a Virtual Reality Intervention VirtuS Recruiting No Results Available Self-Criticism Behavioral: Double Standards|Behavioral: Self-criticism avatar Self-Criticism and Self-Compassion Scales (SCCS) - Change in Self-Criticism scale|Self-Criticism and Self-Compassion Scales (SCCS) - Change in Self-Compassion scale|Change in negative affect|Change in positive affect|Change in self-compassion and self-esteem University Medical Center Groningen|PPO|University of Groningen All 17 Years to 30 Years   (Child, Adult) Not Applicable 136 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 10036 October 12, 2021 June 9, 2023 June 9, 2023 June 2, 2023 June 2, 2023 University Medical Center Groningen, Groningen, Netherlands https://ClinicalTrials.gov/show/NCT05887141 224 NCT05887128 Accuracy of Extra-oral Bite-wing Radiography in Detecting Calculus and Crestal Bone Loss Not yet recruiting No Results Available Periodontitis|Calculus, Dental|Bone Loss, Alveolar Radiographic evidence of calculus|Radiographic measure of alveolar bone loss|Clinical evidence of calculus|Clinical measure of alveolar bone loss University of Colorado, Denver All 18 Years to 100 Years   (Adult, Older Adult) 80 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 22-2079 June 1, 2023 June 1, 2024 June 1, 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887128 225 NCT05887115 Nurse Family Partnership for Women With Previous Live Births Recruiting No Results Available Pregnancy, High Risk|Child Development|Post Partum Depression Behavioral: Nurse Family Partnership Presence of Pregnancy-related hypertension|Change in maternal tobacco use by cotinine|Change in self reported maternal tobacco use|Index child language development measured by the Bayley IV language subscale|Index child language development measured by the MacArthur Bates CDI (Communicative Development Inventories)|Number of participants with infection during pregnancy based on medical record review|Number of infants born with weight less than 2500 grams per medical record review|Number of infants born less than 34 weeks gestation per medical record review|Change in self-reported maternal substance use|Initiation and continuation of any breastfeeding per maternal report|Percentage of well-child visits attended for index child per medical record review|Index child immunization use per medical record review|Index child emergency room visits for serious preventable injuries and sentinel injuries for child abuse.|Index child hospitalization for injuries|Change in quality of home environment measured by the HOME (Home Observation Measurement of the Environment) Inventory short form|Change in quality of home environment measured by the CHAOS (Confusion, Hubbub and Order Scale) Scale|Mother-child interaction measured by the Dyadic Assessment of Naturalistic Caregiver-child Experiences (DANCE)|Child's developmental index measured by Bayley IV developmental assessment|Index child's social and emotional development based on Bayley IV socio-emotional subscale|Index child's social and emotional development measured by the Child Behavior Checklist (CBCL) (maternal report)|Change in maternal perceived stress measured by Perceived Stress Scale (maternal report) University of Colorado, Denver|Nationwide Children's Hospital|University of Rochester Female 16 Years and older   (Child, Adult, Older Adult) Not Applicable 880 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Health Services Research 20-0470 March 31, 2023 February 28, 2026 February 28, 2027 June 2, 2023 June 2, 2023 Nationwide Children's Hospital, Columbus, Ohio, United States "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/15/NCT05887115/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05887115 226 NCT05887102 Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors PACHA Not yet recruiting No Results Available Breast Neoplasms|Breast Cancer Behavioral: PACHA Program Mean change from baseline to the end of 6-month follow-up in intention to adhere to adjuvant endocrine therapy (AET)|Mean change from baseline to the end of 6-month follow-up in adjuvant endocrine therapy (AET) knowledge|Mean change from baseline to the end of 6-month follow-up in attitude towards AET|Mean change from baseline to the end of 6-month follow-up in perceived social support|Mean change from baseline to the end of 6-month follow-up in perceived behavioural control|Mean change from baseline to the end of 6-month follow-up in anticipated regret|Mean change from baseline to the end of 6-month follow-up in coping planning|Mean change from baseline to the end of 6-month follow-up in fear of recurrence|Mean change from baseline to the end of 6-month follow-up in side effects|Mean change from baseline to the end of 6-month follow-up in the cognitive representations of medication|Percentage of pharmacists who used PACHA tools in the intervention group|Percentage of women who used PACHA tools|Mean number of interventions dispensed by the pharmacists to the participating women|Percentage of eligible and enrolled pharmacists|Percentage of eligible and enrolled women|Percentage of pharmacies randomized|Cluster size|Proportion of days covered by an Adjuvant Endocrine Therapy (AET)|Proportion of women having an AET|Mean change from baseline to the end of 6-month follow-up in quality of life|Program Acceptability and Feasibility CHU de Quebec-Universite Laval|Canadian Institutes of Health Research (CIHR)|Fondation Cancer du Sein du Québec All 18 Years and older   (Adult, Older Adult) Not Applicable 66 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care number CIHR 420809 June 2023 June 2024 December 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887102 227 NCT05887089 Analytical Impact of the Transport of Pathological Biological Material by Drone PATH-AIRCHU Recruiting No Results Available Biological Transport|Biological Samples Other: drone transport variation of ASAT concentration between both groups|variation of ALAT concentration between both groups|variation of BNP concentration between both groups|variation of LDH concentration between both groups|variation of Glucose concentration between both groups|variation of Troponin concentration between both groups|variation of Potassium concentration between both groups|variation of HIL concentration between both groups Centre Hospitalier Universitaire, Amiens All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Case-Control|Time Perspective: Prospective PI2023_843_0030 May 22, 2023 September 2023 September 2023 June 2, 2023 June 2, 2023 CHU Amiens Picardie, Amiens, Picardie, France https://ClinicalTrials.gov/show/NCT05887089 228 NCT05887076 Postoperative Delirium After Kidney Transplantation Recruiting No Results Available Post-operative Delirium Incidence of delirium|Duration of delirium|Severity of delirium|Intraoperative parameter|Anesthesia|Anesthesiological parameters|Immunosupressive therapy|Delirium treatment|Pain teatment|Intensive care unit stay|Hospital stay|Mortality Charite University, Berlin, Germany All 18 Years and older   (Adult, Older Adult) 400 Other Observational Observational Model: Cohort|Time Perspective: Retrospective PODNTX May 24, 2023 December 2023 December 2023 June 2, 2023 June 5, 2023 Department of Anaesthesiology and Intensive Care Medicine CCM, Charite - Universitätsmedizin, Berlin, Germany|Medical Clinic with a focus on Nephrology and Internal Intensive Care Medicine, Berlin, Germany https://ClinicalTrials.gov/show/NCT05887076 229 NCT05887063 Trialling an Online UK Dementia Awareness for Caregivers Course DAC-UK Completed No Results Available Dementia|Caregiver Burden Other: Dementia Awareness Course UK Percentage of target sample recruited within 6 months.|Percentage of participants retained at follow-up to measure feasibility of the study design.|Percentage of completion of outcome measures to measure feasibility and acceptability.|Retention and attendance percentages to measure feasibility and acceptability of the intervention.|Qualitative acceptability of the intervention, as measured by qualitative thematic analysis of participant interviews to capture themes regarding participant experience of the course.|Change from baseline in the mean Zarit burden inventory scores at one-month follow up|Change from baseline in the mean Quality caregiver-patient relationship (QCPR) scores at one-month follow up|Change from baseline in the mean GAIN measure scores at one-month follow up|Change from baseline in the mean approaches to dementia (ADQ-19) scores at one-month follow up|Change from baseline in the mean short sense of competence (SSCQ) scores at one-month follow up University College, London All Child, Adult, Older Adult Not Applicable 51 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 22375.001 June 13, 2022 December 6, 2022 December 6, 2022 June 2, 2023 June 2, 2023 University College London, London, United Kingdom "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/63/NCT05887063/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05887063 230 NCT05887050 Effects of a Dietary Supplement Containing Salacia Extract, Citrus Bioflavonoids, and Trivalent Chromium on Markers of Glucose Control Completed No Results Available Glucose Intolerance Dietary Supplement: Active|Dietary Supplement: Placebo Glucose kinetics|Insulin kinetics|Hemoglobin A1c (HgA1c)|C-reactive protein|Adiponectin|Ferritin|Appetite|Satiety|Food cravings|Sweet food cravings|Blood urea nitrogen to creatinine ratio The Center for Applied Health Sciences, LLC All 21 Years to 65 Years   (Adult, Older Adult) Not Applicable 26 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science MEND-2023 December 3, 2020 June 22, 2021 July 20, 2021 June 2, 2023 June 5, 2023 The Center for Applied Health Sciences, Canfield, Ohio, United States https://ClinicalTrials.gov/show/NCT05887050 231 NCT05887037 Economic Impact of mNGS on Diagnosis of Post-neurosurgical Central Nervous System Infection mNGS Not yet recruiting No Results Available Central Nervous System Infections Diagnostic Test: mNGS|Diagnostic Test: The traditional microbiological cultures Incremental cost effectiveness ratio|Cost comparison|Efficacy comparison Jian-Xin Zhou|Capital Medical University All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 204 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic KY2023-018-02 July 1, 2023 June 20, 2025 July 1, 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887037 232 NCT05887024 Effect of Shockwave Therapy on Post-laminectomy Fibrosis Low Back Pain Patients. SWT Not yet recruiting No Results Available Post-laminectomy Syndrome Device: Radial Extracorporeal Shock wave Therapy|Device: Transcutaneous Electrical Nerve Stimulation (TENS)|Procedure: McKenzie Back exercises|Device: electric heating pads Visual Analogue Scale (VAS)|Pain algometry|Lumbar Range Of Motion|The Oswestry Disability Index: (ODI)|Sensory Nerve Conduction Study (NCS) Marwa Mohamed Hany Sedeek Abousenna|Cairo University All 30 Years to 50 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment P.T.REC/012/004382 June 1, 2023 January 1, 2024 May 1, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05887024 233 NCT05887011 CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia PASSAT Recruiting No Results Available Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC) Demographic and clinical characteristics of the population. NSCLC stage by TNM classification (% of patients). Patient status - locoregional recurrence and inoperable. Histology type. % of patients with known PD-L1 status and EGFR mutation status.|Chemoradiotherapy (CRT) details|The short-term effectiveness results of the initial CRT treatment administered to patients with recently first diagnosed LA NSCLC (% of patients with CR, PR, ORR, SD, PD, unevaluable for response) for cCRT and sCRT respectively|Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC|Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC.|Chemoradiotherapy (CRT) details: concurrent CRT vs sequential CRT|Chemoradiotherapy (CRT) details: presence of interruptions|Chemoradiotherapy (CRT) details: number of interruptions|Chemoradiotherapy (CRT) details: durations of interruptions|Chemoradiotherapy (CRT) details:Reasons for RT interruptions and dose reductions/ withdrawals;|Chemoradiotherapy (CRT) details:· RT: doses, fractionation, planning, selective and elective irradiation of lymph nodes|Chemoradiotherapy (CRT) details:· Type of platinum-based chemotherapy used|Chemoradiotherapy (CRT) details: For sCRT: duration between ChT and RT AstraZeneca All 18 Years and older   (Adult, Older Adult) 6000 Industry Observational Observational Model: Cohort|Time Perspective: Prospective D133HR00026 March 31, 2023 December 31, 2025 December 31, 2025 June 2, 2023 June 2, 2023 GBU Republic oncology dispensary, Grozny, Russian Federation|Irkutsk Regional Cancer Center, Irkutsk, Russian Federation|Kostroma Regional Cancer Center, Kostroma, Russian Federation|Sbhi Od №2, Sochi, Russian Federation|GBUZ "SakhOOD", Yuzhno-Sakhalinsk, Russian Federation https://ClinicalTrials.gov/show/NCT05887011 234 NCT05886998 Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury Recruiting No Results Available Smoke Inhalation Injury|Acute Lung Injury Drug: Heparin|Other: Normal Saline Occurrence of acute lung injury|Occurrence of severe acute lung injury|Duration of mechanical ventilation|Mortality|Side effects Ain Shams University All 18 Years and older   (Adult, Older Adult) Phase 3 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention FMASU MD 238/2020 November 1, 2021 June 30, 2023 September 30, 2023 June 2, 2023 June 2, 2023 Ain Shams University Hospitals, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05886998 235 NCT05886985 Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome Not yet recruiting No Results Available Acute Respiratory Distress Syndrome Drug: MatriPlax The incidence of treatment-emergent adverse events (TEAEs) up to 28 days after receiving MatriPlax|The incidence of serious adverse events (SAEs) up to 28 days after receiving MatriPlax|The incidence of suspected unexpected serious adverse reactions (SUSAR) up to 28 days after receiving MatriPlax|Changes in PaO2/FiO2 ratio from baseline|Changes in Lung injury score (LIS) from baseline|Overall survival|All-cause mortality rate|Cumulative ventilator-free hours (VFH)|Time to the first weaning from ventilator|Number of subjects weaned from ventilator|Intensive Care Unit (ICU) free hours|Time to the first ICU discharge|Number of subjects discharged from ICU|ICU/Respiratory Care Center (RCC) free hours|Changes in Sequential Organ Failure Assessment (SOFA) score from baseline|Cumulative vasopressor free days|Cumulative oxygen support free hours|The net change in c-reactive protein (CRP) from baseline|The net change in D-dimer from baseline|The net change in Lactate Dehydrogenase (LDH) from baseline|The domain scores and total score of 12-item Short Form Survey (SF-12) Quality of Life (QoL) health survey questionnaire|Number of subjects who experienced Dose Limiting Toxicity (DLT)|Incidence of TEAEs (treatment-emergent AEs) and SAEs|Number of participants with abnormalities in vital signs|Number of participants with abnormalities in physical examination|Number of participants with abnormalities in laboratory examination parameters|Number of participants with abnormalities in ECG parameters BioSpring Medical Co., Ltd All 20 Years to 80 Years   (Adult, Older Adult) Phase 1 24 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MP-01 December 2023 December 2026 May 2027 June 2, 2023 June 5, 2023 Taipei Medical University Hospital, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05886985 236 NCT05886972 Effect Of Patient Awareness About Possibility Of Occurrence Of Pain During Propofol Injection On The Rate Of Incidence And Severity Of Pain During Injection . No acronym Not yet recruiting No Results Available Effect of Patient Awareness on Incidence and Severity of Propofol Injection Induced Pain Behavioral: Awareness about propofol injection induced pain Pain assessment|Age|Weight Beni-Suef University Female 20 Years to 40 Years   (Adult) 210 Other Observational Observational Model: Cohort|Time Perspective: Prospective FMBSUREC/02052023/sayem June 1, 2023 October 1, 2023 November 1, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886972 237 NCT05886959 The Effect of Mindfulness-Based Compassionate Living Training Given to Caregivers of Inpatients in Palliative Clinic Mindfulness Completed No Results Available Informal Caregiver Other: Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|Other: Session 2: Threat and Self-Compassion|Other: Session 3: Unraveling the Knots of Desire and Patterns|Other: Session 4: Internalizing compassion|Other: Session 5: Me and others - Expanding the circle|Other: Session 6: Growing happiness|Other: Session 7: Weaving Wisdom and Compassion into Daily Life|Other: Session 8: Living with the Heart Introductory Information Form|Maslach Burnout Scale Ataturk University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 54 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care MCENGİZ2 April 17, 2023 May 24, 2023 May 24, 2023 June 2, 2023 June 2, 2023 Ataturk University Faculty of Nursing, Erzurum, Yakutiye, Turkey https://ClinicalTrials.gov/show/NCT05886959 238 NCT05886946 Abg in Blunt Chest Trauma Not yet recruiting No Results Available Blunt Injury of Thorax Other: ABG Arterial blood gas as an early screening tool for predicting lung injury in blunt chest trauma Assiut University All 6 Months and older   (Child, Adult, Older Adult) 150 Other Observational Observational Model: Cohort|Time Perspective: Prospective Abg in blunt chest July 1, 2023 February 1, 2024 August 1, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886946 239 NCT05886933 Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet Recruiting No Results Available Gastroesophageal Reflux Disease Drug: Fexuprazan Hydrochloride Average score change Daewoong Pharmaceutical Co. LTD. All 19 Years to 75 Years   (Adult, Older Adult) 18000 Industry Observational Observational Model: Other|Time Perspective: Prospective DWFE_P407 May 22, 2023 December 31, 2023 June 30, 2024 June 2, 2023 June 2, 2023 Co&Ping Otolaryngology Clinic, Busan, Korea, Republic of https://ClinicalTrials.gov/show/NCT05886933 240 NCT05886920 Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations Not yet recruiting No Results Available Advanced Solid Tumors With MAPK Pathway Mutations Drug: D3S-002 Number of Participants With Adverse Events (AEs)|Number of Participants With Dose-Limiting Toxicities (DLTs)|D3S-002 maximum observed plasma concentration (Cmax)|D3S-002 time to maximum plasma concentration (tmax)|D3S-002 half-life (t1/2)|D3S-002 area under the concentration-time curve (AUC)|Objective response rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)|Disease control rate (DCR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)|Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) D3 Bio (Wuxi) Co., Ltd All 18 Years and older   (Adult, Older Adult) Phase 1 60 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment D3S-002-100 June 30, 2023 November 2025 November 2025 June 2, 2023 June 2, 2023 D3 Bio Investigative Site, Nedlands, Western Australia, Australia https://ClinicalTrials.gov/show/NCT05886920 241 NCT05886907 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] CLR624-M103 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886907 242 NCT05886894 Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses Not yet recruiting No Results Available Refractive Errors Device: Lotrafilcon B multifocal soft contact lenses|Device: Comfilcon A multifocal soft contact lenses Distance visual acuity at 1 year - Daily Wear|Near visual acuity at 1 year - Daily Wear|Distance visual acuity at 3 years - Extended Wear|Near visual acuity at 3 years - Extended Wear|Incidence of corneal infiltrative events - Daily Wear|Incidence of corneal infiltrative events - Extended Wear|Incidence of microbial keratitis - Daily Wear|Incidence of microbial keratitis - Extended Wear Alcon Research All 40 Years and older   (Adult, Older Adult) 340 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective CLJ241-N003 July 2023 January 2024 January 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886894 243 NCT05886881 Air Optix Extended Wear Contact Lenses Not yet recruiting No Results Available Refractive Errors Device: Lotrafilcon B spherical soft contact lenses|Device: Lotrafilcon B spherical soft contact lenses with comfort additive|Device: Lotrafilcon B toric soft contact lenses with comfort additive|Device: Comfilcon A spherical soft contact lenses|Device: Comfilcon A toric soft contact lenses Distance visual acuity (VA) with study lenses at Baseline|Distance visual acuity (VA) with study lenses at Year 3|Incidence of corneal infiltrative events|Incidence of microbial keratitis Alcon Research All 18 Years and older   (Adult, Older Adult) 640 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective CLJ241-N002 July 2023 December 2023 December 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886881 244 NCT05886868 Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors Not yet recruiting No Results Available Advanced Solid Tumor Drug: BL0020 Maximum Tolerated Dose(MTD)|Recommended Phase II Dose(RP2D)|Area under the plasma concentration-time curve (AUC)|Half life (t1/2)|Disease Control Rate(DCR)|Progression-Free Survival (PFS)|Duration of overall response (DOR)|Objective response rate(ORR) Shanghai Best-Link Bioscience, LLC All 18 Years and older   (Adult, Older Adult) Phase 1 66 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BL0020-101 July 2023 July 2024 February 2025 June 2, 2023 June 2, 2023 Sarawak General Hospital, Kuching, Malaysia https://ClinicalTrials.gov/show/NCT05886868 245 NCT05886855 Evaluation of PerioMonitor for Detection of Oral Inflammatory Load (OIL) in Human Subjects. Not yet recruiting No Results Available Oral Inflammation Bleeding on Probing (BOP) Oral Science International Inc.|Advarra All 18 Years and older   (Adult, Older Adult) 400 Industry|Other Observational Observational Model: Cohort|Time Perspective: Prospective 230123-01 May 24, 2023 December 20, 2023 January 31, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886855 246 NCT05886842 Reliability (Test-retest) of 30 Seconds Sit-to-stand and Timed Up and Go in Adults With Long Covid Recruiting No Results Available Long COVID Other: Test-retest Reliability of 30 seconds Sit to stand|Reliability of Timed Up and Go European University Cyprus|Eden Resort Wellness Rehabilitation Center All 18 Years and older   (Adult, Older Adult) 19 Other Observational Observational Model: Cohort|Time Perspective: Prospective Test-Retest December 21, 2022 August 21, 2023 December 21, 2023 June 2, 2023 June 2, 2023 Eden resort wellness rehabilitation, Larnaca, Cyprus https://ClinicalTrials.gov/show/NCT05886842 247 NCT05886829 Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III ACCROS-III Completed No Results Available COVID-19|Symptoms and Signs|COVID-19 Pandemic|Coronavirus Disease 2019|Coronavirus Infections Combination Product: Chlorpheniramine Maleate 0.4% Nasal Spray|Combination Product: Placebo Daily symptoms score (DSS)|Visual Analog Scale (VAS)|Hospitalization|Mortality|The proportion of subjects reporting olfactory function|The proportion of subjects reporting the presence of upper respiratory symptoms Dr. Ferrer BioPharma|Hospital CEMESA Cortés, San Pedro Sula, Honduras All 18 Years to 65 Years   (Adult, Older Adult) Phase 2|Phase 3 157 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment DFB-006 July 27, 2022 January 19, 2023 February 1, 2023 June 2, 2023 June 2, 2023 Hospital CEMESA, Cortés, San Pedro Sula, Honduras https://ClinicalTrials.gov/show/NCT05886829 248 NCT05886816 Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 Not yet recruiting No Results Available SARS-CoV Infection|COVID-19 Drug: Mitoquinone/mitoquinol mesylate|Other: Placebo SARS-CoV-2 infection|Safety of mito-MES|Symptomatic SARS-CoV-2 infection|Severity of symptoms of SARS-CoV-2 infection|Duration of symptoms of SARS-CoV-2 infection University of Texas Southwestern Medical Center All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 112 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment IRB#STU-2023-0524 September 1, 2023 July 31, 2025 July 31, 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886816 249 NCT05886803 Prediction of the Spontaneous Breathing Test Success Using Biosignal and Biomarker in Critical Care Unit by a Machine Learning Approach Recruiting No Results Available Weaning From Mechanical Ventilation in Care Unit Other: Spontaneous ventilation test Prediction of the spontaneous breathing test outcome. Centre Hospitalier Universitaire de Nice All Child, Adult, Older Adult 500 Other Observational Observational Model: Case-Control|Time Perspective: Retrospective 23Rea01 January 1, 2023 December 12, 2024 December 12, 2025 June 2, 2023 June 2, 2023 University Hospital of Nice, Nice, France https://ClinicalTrials.gov/show/NCT05886803 250 NCT05886790 A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes Recruiting No Results Available COVID-19 Biological: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Biological: Bivalent COVID-19 mRNA Vaccine|Biological: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation Anti-XBB-specific neutralizing antibody|The incidence of adverse reactions|The incidence of adverse event|The incidence of SAE and AESI|specific neutralizing antibody against XBB and BA.5 variant on 0 and 28 days|specific neutralizing antibody against XBB and BA.5 variant at 14 days, 3 and 6 months Zhongnan Hospital|Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China All 18 Years and older   (Adult, Older Adult) Not Applicable 450 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention AMMS85-2301 May 30, 2023 December 31, 2023 May 29, 2024 June 2, 2023 June 2, 2023 Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China https://ClinicalTrials.gov/show/NCT05886790 251 NCT05886777 A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV). Not yet recruiting No Results Available Healthy Participants Biological: Combination [RSVpreF+BNTb162b2]|Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: RSVpreF|Biological: QIV|Biological: Normal Saline Placebo Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events|Percentage of participants reporting serious adverse events|Group 1 vs Group 4 noninferiority analysis: Geometric mean ratios (GMRs) of RSV A and RSV B neutralizing titers (NTs)|Group 1 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 Omicron BA.4/BA.5-strain neutralizing titers (NTs)|Group 1 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 reference-strain neutralizing titers (NTs)|Group 1 vs Group 5 noninferiority analysis: Influenza strain-specific geometric mean ratios (GMRs) of hemagglutination inhibition (HAI) titers.|Group 2 vs Group 4 noninferiority analysis: Geometric mean ratios (GMRs) of RSV A and RSV B neutralizing titers (NTs)|Group 2 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 Omicron BA.4/BA.5-strain neutralizing titers (NTs)|Group 2 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 reference-strain neutralizing titers NTs|Group 7 vs Group 4 noninferiority analysis: Geometric mean ratios (GMRs) of RSV A and RSV B neutralizing titers (NTs)|Group 7 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 Omicron BA.4/BA.5-strain neutralizing titers (NTs)|Group 7 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 reference-strain neutralizing titers (NTs)|Group 7 vs Group 5 noninferiority analysis: Influenza strain-specific geometric mean ratio (GMR) of hemagglutination inhibition (HAI) titers.|Group 6 vs Group 4 noninferiority analysis: Geometric mean ratios (GMRs) of RSV A and RSV B neutralizing titers (NTs)|Group 6 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 Omicron BA.4/BA.5-strain neutralizing titers (NTs)|Group 6 vs Group 3 noninferiority analysis: Geometric mean ratios (GMRs) of SARS-CoV-2 reference-strain neutralizing titers (NTs) Pfizer All 65 Years and older   (Older Adult) Phase 2 1050 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention C5481001 June 1, 2023 December 15, 2023 December 15, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886777 252 NCT05886764 Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials Not yet recruiting No Results Available Cancer|Malignancy|Malignant Neoplasm Other: Digital Intervention|Other: Community Outreach Percentage of patients that enroll to early phase cancer treatment clinical trials.|Number of successfully completed outreach efforts|Percentage of patients that enroll to early phase cancer treatment clinical trials post intervention.|Percent change in number of African Americans that enroll to cancer clinical trials University of Chicago|Stand Up To Cancer All 18 Years and older   (Adult, Older Adult) Not Applicable 180 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other IRB23-0221 July 2023 July 2027 July 2027 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886764 253 NCT05886751 Randomized Trial of Trust in Online Videos About Prostate Cancer Completed No Results Available Prostate Cancer Other: Black Doctor Screening Video|Other: White Doctor Screening Video|Other: Black Patient Screening Video|Other: White Patient Screening Video|Other: Black Doctor Clinical Trials Video|Other: White Doctor Clinical Trials Video|Other: Black Patient Clinical Trials Video|Other: White Patient Clinical Trials Video Level of Trust in the Video NYU Langone Health All 40 Years and older   (Adult, Older Adult) Not Applicable 3649 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other 20-00540 August 18, 2021 January 7, 2022 January 7, 2022 June 2, 2023 June 2, 2023 NYU Langone Health, New York, New York, United States https://ClinicalTrials.gov/show/NCT05886751 254 NCT05886738 Investigating the Effect of Short-term Fasting on T Cell Metabolism, Function, and Phenotype in Obesity Not yet recruiting No Results Available Obesity|Fasting|T-Cell Dysfunction Other: Fasting Change from baseline in the rate of T cell fat-supported oxidative mitochondrial respiration assessed by Oroboros O2K after 48 hours of fasting|Change from baseline in the frequency (%) of T cell subsets assessed by multi-colour flow cytometry|Change from baseline in the rate of T cell proliferation assessed by cell number University of British Columbia All 19 Years to 69 Years   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science H22-03605 June 1, 2023 August 30, 2023 August 30, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886738 255 NCT05886725 At-home Walking Cadence Functional Assessment and Recovery Trajectory for Older Adults Undergoing Major Surgery CADENCE Recruiting No Results Available Gait, Unsteady Other: Patients using Step Test Application and Accelerometer Accuracy of gait-cadence measured from at-home and in-clinic walk tests as measured by ActivPAL accelerometers.|Change in disability, as measured by the World Health Organization Disability Assessment Schedule (WHODAS) 2.0: 12-item.|Change in functional status, as measured by an interview in which participants will be asked, "At the present time, do you need help from another person to (complete the task)?"|Change in global health, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 - Global Health.|Change in pain interference, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Short Form v1.1 - Pain Interference 6a.|Change in gait-cadence after surgery University of Chicago All 65 Years and older   (Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective IRB22-0556 January 2, 2023 October 1, 2024 January 1, 2025 June 2, 2023 June 2, 2023 University of Chicago Medical Center, Chicago, Illinois, United States https://ClinicalTrials.gov/show/NCT05886725 256 NCT05886712 Improving Equitable Access to Naloxone to Prevent Opioid Overdose Deaths Within Syringe Service Programs (SAIA-Naloxone) SAIA-N Not yet recruiting No Results Available Overdose|Implementation as Usual Other: Naloxone|Other: Usual intervention Reach (Aim 1)|Fidelity (Aim 1)|Reach (Aim 2)|Fidelity (Aim 2)|Cost (Aim 3) (Substance Abuse Services Cost Analysis Program (SASCAP))|Cost-effectiveness (Incremental Cost-effectiveness Ratio (ICER)) RTI International|University of California, San Diego|Heluna Health All 18 Years and older   (Adult, Older Adult) Not Applicable 32 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 00021706 June 4, 2023 December 31, 2023 December 31, 2025 June 2, 2023 June 5, 2023 RTI International, Berkeley, California, United States https://ClinicalTrials.gov/show/NCT05886712 257 NCT05886699 Comparison of PRP & DFDBA vs. DFDBA in Intrabony Periodontal Defects Completed No Results Available Chronic Periodontitis Other: PRP combined with DFDBA|Other: DFDBA Change in Probing Pocket Depth (PPD) from baseline to 12 months|Change in Periodontal Attachment Level (PAL) from baseline to 12 months|Change in Gingival Recession (GR) from baseline to 12 months|Change in Crestal bone resorption from baseline to 12 months|Change in Defect fill from baseline to 12 months|Change in Defect resolution from baseline to 12 months|Plaque Index|Gingival Index Government Dental College and Hospital, India All 28 Years to 55 Years   (Adult) Not Applicable 13 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment PMeshram January 2012 December 2012 December 2013 June 2, 2023 June 2, 2023 212, Department of Periodontology, Government Dental college and Hospital, Nagpur, Maharashtra, India https://ClinicalTrials.gov/show/NCT05886699 258 NCT05886686 Contactless Vital Signs Measurement Study (CVMS) CVMS Recruiting No Results Available Vital Signs|Inpatients|Hospital-at-home Device: Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device Accuracy validation - heart rate|Accuracy validation - pulse oximetry for peripheral venous blood oxygen saturation|Accuracy validation - temperature Melbourne Health All 18 Years to 110 Years   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective RMH89542 April 5, 2023 July 2023 September 2023 June 2, 2023 June 2, 2023 Royal Melbourne Hospital, Melbourne, Victoria, Australia https://ClinicalTrials.gov/show/NCT05886686 259 NCT05886673 Development of a Protective Cream Against Radiodermatitis Caused by Radiotherapy. RADIOCREMVAL Recruiting No Results Available Radiodermatitis Other: cosmeceutical cream|Other: Placebo Reduction the occurrence of grade 2 radiodermatitis|Incidence of radiodermatitis Antonio J. Conde Moreno|University of Valencia|Instituto de Investigacion Sanitaria La Fe All 18 Years and older   (Adult, Older Adult) Not Applicable 5 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention 2022-963-1 March 29, 2023 June 2023 July 2023 June 2, 2023 June 2, 2023 Medical Reserarch Institute La Fe, Valencia, Spain "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/73/NCT05886673/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/73/NCT05886673/ICF_001.pdf https://ClinicalTrials.gov/show/NCT05886673 260 NCT05886660 Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance Recruiting No Results Available Motion Sickness, Space|Motion Sickness|Sea Sickness Drug: DPI-386 Nasal Gel|Drug: Placebo Nasal Gel Motion sickness (MS) symptom severity using Pensacola Diagnostic Index (PDI) scale|Motion sickness symptom severity using a Subjective Discomfort Rating (SDR)|Time to MS endpoint (based on PDI score of 8 points)|Performance measures: response time|Performance measures: error Repurposed Therapeutics, Inc.|National Aeronautics and Space Administration (NASA) All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 30 Industry|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment NASA 0354 (Aim 1) January 21, 2022 September 2024 September 2024 June 2, 2023 June 2, 2023 NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05886660 261 NCT05886647 Non-invasive Neustimulation and Respiratory Rehabilitation Recruiting No Results Available Lung Diseases Other: Active non-invasive stimulation and inspiratory muscle training|Other: Sham compatorator and inspiratory muscle training Lung function|Maximum inspiratory pressure|functional capacity|dyspnea sensation|health-related quality of life|respiratory muscle resistance Suellen Andrade|Federal University of Paraíba All 18 Years and older   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment HD-tDCS+respiratory disorders January 23, 2023 June 2024 November 2024 June 2, 2023 June 2, 2023 Federal University of Paraiba, João Pessoa, Paraiba, Brazil https://ClinicalTrials.gov/show/NCT05886647 262 NCT05886634 A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Recruiting No Results Available Dedifferentiated Liposarcoma|Soft Tissue Sarcoma|Sarcoma,Soft Tissue|Sarcoma|Recurrent Dedifferentiated Liposarcoma|Unresectable Dedifferentiated Liposarcoma|Metastatic Dedifferentiated Liposarcoma Drug: Etrumadenant|Drug: Zimberelimab Overall Response Rate Memorial Sloan Kettering Cancer Center All 18 Years and older   (Adult, Older Adult) Phase 2 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 22-277 May 23, 2023 May 23, 2027 May 23, 2027 June 2, 2023 June 2, 2023 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States https://ClinicalTrials.gov/show/NCT05886634 263 NCT05886621 Pilot RCT of the Integrated mHealth Intervention "SiS-H" Not yet recruiting No Results Available Smoking Cessation Behavioral: Smiling instead of Smoking - HIV|Behavioral: QuitGuide App usage|Time spent applying content|Expected app usage|Use of smoking cessation strategies|Satisfaction with smoking cessation support|App usability rating, System Usability Scale (SUS)|User mobile application rating (uMARS)|Smoking Self-Efficacy Questionnaire (SEQ-12)|Positive affect - Positive and Negative Affect Schedule (PANAS)|Negative affect - Positive and Negative Affect Schedule (PANAS)|Brief Questionnaire of Smoking Urges (QSU)|Attitudes Towards Smoking Scale (ATS) - adverse effects of smoking sub-scale|Attitudes Towards Smoking Scale (ATS) - psychoactive benefits of smoking sub-scale|Attitudes Towards Smoking Scale (ATS) - pleasure of smoking sub-scale|Decisional Balance Inventory (DBI) for Smoking - negative expectancies sub-scale|Decisional Balance Inventory (DBI) for Smoking - positive expectancies subscale|Modified version of the Twenty Statements Test Massachusetts General Hospital|National Cancer Institute (NCI) All 18 Years and older   (Adult, Older Adult) Not Applicable 64 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other 2023P001360|R21CA261458 June 2023 May 2024 August 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886621 264 NCT05886608 Evaluation of the Effect of the AI500™ SINGLE-DOSE GEL Medical Device in Patients With Reduced Knee Function Completed No Results Available Pain, Acute|Pain, Chronic|Knee Injuries|Knee Osteoarthritis|Knee Arthritis|Knee Pain Swelling Device: AI 500™ SINGLE-DOSE GEL Clinical performance of AI500™ SINGLE DOSE GEL in improving knee function after 1 week|Clinical performance of AI500™ SINGLE DOSE GEL in improving knee function after 48 hours|Clinical performance of AI500™ SINGLE DOSE GEL in alleviating pain after 24h and 48h of treatment.|Safety and Tolerability of AI500™ SINGLE DOSE GEL Contrad Swiss SA All 18 Years and older   (Adult, Older Adult) Not Applicable 35 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CTD-SW AI500 2021 August 30, 2022 March 16, 2023 March 16, 2023 June 2, 2023 June 2, 2023 Humanitas Research Hospital, Rozzano, Milano, Italy https://ClinicalTrials.gov/show/NCT05886608 265 NCT05886595 Being Young : My Mental Health JEMMA Not yet recruiting No Results Available Mental Health Issue|Mental Disorder Strengths and Difficulties Questionnaire (SDQ)|Hospital Anxiety and Depression Scale (HADS)|Suicidal Behaviors Questionnaire (SBQ)|Ask Suicide-Screening Questions (ASQ)|Addictive disorders|Quality of Life, Enjoyment, and Satisfaction Questionnaire- (Q-LES-Q)|Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (P-Q-LES-Q)|Sleep disorders|Patient healthcare trajectory|social relation, social integration and social support|sociodemographic , environmental and psycho social factors Centre Hospitalier St Anne|Groupement Interrégional de Recherche Clinique et d'Innovation All 10 Years to 24 Years   (Child, Adult) 400 Other Observational Observational Model: Cohort|Time Perspective: Prospective D22-EPI031 September 4, 2023 September 30, 2025 August 31, 2026 June 2, 2023 June 2, 2023 Pediatric Emergency Department - Armand Trousseau Hospital, Paris, Île-de-France, France|ATRAP (Acute unit for child outpatients), Paris, Île-de-France, France|C.P.O.A (Psychiatric Emergency Department), Paris, Île-de-France, France|Pediatric Emergency Department - Necker Hospital, Paris, Île-de-France, France|CIAPA (Inpatient unit for Adolescents), Paris, Île-de-France, France|Adult Emergency Department - Bichât Hospital, Paris, Île-de-France, France|Pediatric Emergency Department - Robert Debré Hospital, Paris, Île-de-France, France https://ClinicalTrials.gov/show/NCT05886595 266 NCT05886582 Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder Not yet recruiting No Results Available Substance-Related Disorders Drug: Rotigotine Transdermal System [Neupro]|Drug: Placebo Cocaine-positive urine samples|self-reported cocaine use|executive function (change)|QoLI total score (change)|dorsolateral prefrontal cortex (DLPFC)|stop signal task (SST)|EC from DLPFC to striatum during working memory demands Virginia Commonwealth University|National Institute on Drug Abuse (NIDA) All 18 Years to 55 Years   (Adult) Phase 2 60 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment HM20026910|1U01DA057846-01 June 2023 June 2026 June 2026 June 2, 2023 June 2, 2023 Virginia Commonwealth University, Richmond, Virginia, United States https://ClinicalTrials.gov/show/NCT05886582 267 NCT05886569 DIGIPREDICT-Physio-DE Not yet recruiting No Results Available Biomarkers Device: DIGIPREDICT Physiopatech Short-term kinetics of C-reactive protein|Short-term kinetics of procalcitonin|Short-term kinetics of interleukin-6|Short-term kinetics of ferritin|Short-term kinetics of NT-pro brain natriuretic peptide|Short-term kinetics of high sensitive troponin T|Short-term kinetics of lactate|Short-term kinetics of blood pH|Short-term kinetics of body surface temperature|Short-term kinetics of bioimpedance|Correlation between C-reactive protein and body surface temperature|Correlation between C-reactive protein and bioimpedance|Correlation between procalcitonin and body surface temperature|Correlation between procalcitonin and bioimpedance|Correlation between interleukin-6 and body surface temperature|Correlation between interleukin-6 and bioimpedance|Correlation between ferritin and body surface temperature|Correlation between ferritin and bioimpedance|Correlation between NT-pro brain natriuretic peptide and body surface temperature|Correlation between NT-pro brain natriuretic peptide and bioimpedance|Correlation between high sensitive troponin T and body surface temperature|Correlation between high sensitive troponin T and bioimpedance|Correlation between lactate and body surface temperature|Correlation between lactate and bioimpedance|Correlation between blood pH and body surface temperature|Correlation between blood pH and bioimpedance Charite University, Berlin, Germany All 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic DIGIPREDICT-Physio-DE May 25, 2023 November 24, 2023 November 24, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886569 268 NCT05886556 Validity of Lung Ultrasound in Diagnosis of Acute Respiratory Distress Syndrome Recruiting No Results Available of Lung Ultrasound in Diagnosis of Acute Respiratory Distress Syndrome diagnostic data checklist|success rate|lung ultrasound as a predictor for weaning Zagazig University All 19 Years to 70 Years   (Adult, Older Adult) 57 Other Observational Observational Model: Cohort|Time Perspective: Prospective 8053 June 1, 2022 May 30, 2023 December 30, 2023 June 2, 2023 June 2, 2023 Faculty of Medicine,Zagazig University, Zagazig, El Sharkia, Egypt https://ClinicalTrials.gov/show/NCT05886556 269 NCT05886543 Pilates Exercise and Inhalation Injury Post Burn burn Completed No Results Available Inhalation Injury Behavioral: Conventional chest physical therapy|Behavioral: Pilates exercise Measurement of Pulmonary Function (spirometry)|Measurement of anthropometric parameters. Khadra Mohamed Ali|Cairo University All 25 Years to 45 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 341989 September 30, 2021 November 20, 2021 January 30, 2023 June 2, 2023 June 2, 2023 faculty of physical therapy , Cairo university, Giza, Egypt https://ClinicalTrials.gov/show/NCT05886543 270 NCT05886530 DSD Models at South Africa Sentinel Sites SENTINEL 2 Recruiting No Results Available HIV Other: No intervention Proportion of patient survey participants with HIV viral suppression ≤400 copies/ml at most recent test Boston University|Health Economics and Epidemiology Research Office (HE2RO), University of the Witwatersrand|Clinton Health Access Initiative, Nigeria All 15 Years and older   (Child, Adult, Older Adult) 15520 Other Observational Observational Model: Cohort|Time Perspective: Prospective H-41402|M210241 June 1, 2021 December 2025 June 2026 June 2, 2023 June 2, 2023 Health economics and Epidemiology Research Office, Johannesburg, South Africa https://ClinicalTrials.gov/show/NCT05886530 271 NCT05886517 Transfemoral Transcatheter Aortic Valve Implementation at Hospital Without On-site Cardiac Surgery: Early Clinical Outcome in Patients With Prohibitive Surgical Risk. Recruiting No Results Available Aortic Stenosis Device: Transfemoral transcatheter aortic valve implementation number of all cause death patients in 30 days following TAVI/total TAVI patients AUSL Romagna Rimini All 75 Years to 120 Years   (Older Adult) Not Applicable 200 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TAVI at Home May 1, 2023 May 2024 May 2025 June 2, 2023 June 2, 2023 AUSL Romagna Morgagni - Pierantoni Hospital, Forli, Emilia Romagna, Italy https://ClinicalTrials.gov/show/NCT05886517 272 NCT05886504 Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users DRIVEMINDII Recruiting No Results Available Psychiatric Disorder|Drug Use Other: Community-based psychiatric intervention Viral exposure score|Severity of substance use score|Quality of life score|Percentage of compliant participant :effectiveness of HIV treatment|Percentage of participant facing difficulty to access to care|Ppercentage of Psychiatric disorder associated with methamphetamine (meth) use|HIV/HCV incidence|Incidence of psychiatric disorders in the control groups|Cost of a specialized community-based psychiatric intervention ANRS, Emerging Infectious Diseases|Centre Pierre Nicole Croix-Rouge française|Haiphong University of Medicine and Pharmacy|Université Montpellier|Center for supporting Community Developement Initiatives Hai Phong All 18 Years and older   (Adult, Older Adult) Not Applicable 600 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research ANRS 0041s March 28, 2022 July 28, 2023 July 28, 2023 June 2, 2023 June 2, 2023 Mental Health Department, Haiphong, Hai Phong, Vietnam https://ClinicalTrials.gov/show/NCT05886504 273 NCT05886491 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Not yet recruiting No Results Available Leukemia Drug: GDX012|Drug: Chemotherapy Agents Number of Participants With Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD) of GDX012|Number of Participants With Adverse Events (AEs)|Number of Participants With Disease Response|Number of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow Cytometry|Duration of Response (DOR)|Event-free Survival (EFS)|Overall Survival (OS) Takeda All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 53 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TAK-012-1501 July 7, 2023 April 1, 2026 June 30, 2027 June 2, 2023 June 2, 2023 City of Hope National Medical Center, California City, California, United States|Robert Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05886491 274 NCT05886478 A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin Not yet recruiting No Results Available T-Cell Lymphoma Drug: No intervention Objective Response Rate (ORR) After First BV Administration|ORR After Re-Treatment|Progression Free Survival (PFS) After First BV Administration|PFS After BV Re-Treatment|Time to Next Treatment (TTNT) After First BV Administration (Regardless of Type of Next Treatment, i.e., BV or non-BV)|TTNT After BV Re-Treatment|Number of Participant With Grading of Motor Neuropathy During First BV Treatment|Time to Improvement of Motor Neuropathy During/ Post First BV Treatment|Time to Resolution of Motor Neuropathy During/ Post First BV Treatment|Number of Participants With Grading of Motor Neuropathy During BV Re-Treatment|Time to Improvement of Motor Neuropathy During/ Post BV Re-Treatment|Time to Resolution of Motor Neuropathy During/ Post BV Re-Treatment|Number of Participants With Grading of Sensory Neuropathy During First BV Treatment|Time to Improvement of Sensory Neuropathy During/ Post First BV Treatment|Time to Resolution of Sensory Neuropathy During/ Post First BV Treatment|Number of Participants With Grading of Sensory Neuropathy During BV Re-Treatment|Time to Improvement of Sensory Neuropathy During/ Post BV Re-Treatment|Time to Resolution of Sensory Neuropathy During/ Post BV Re-Treatment|Number of Participants With Grading of Neutropenia During First BV Treatment|Number of Participants With Grading of Neutropenia During BV Re-Treatment|Number of Participants With Grading of Febrile Neutropenia During First BV Treatment|Number of Participants With Grading of Febrile Neutropenia During BV Re-Treatment|Number of Participants With Grading of Serious Infections During First BV Treatment|Number of Participants With Grading of Serious Infections During BV Re-Treatment|Number of Participants With Cutaneous Lymphoma Co-Medications or Strategies Used to Treat CTCL Disease|Amount of BV Dose|Number of Cycles of BV Administered|Time Interval Between BV Administration Takeda All 18 Years and older   (Adult, Older Adult) 50 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective Brentuximab-5020 May 24, 2023 August 10, 2023 August 10, 2023 June 2, 2023 June 2, 2023 Hopital Saint Andre, Bordeaux, France|Hopital Saint Louis, Paris, France|CHU Roeun, Rouen, France|Universitätsmedizin Göttingen, Göttingen, Germany|Klinikum Ludwigshafen, Hautklinik, Ludwigshafen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Ospedale Maggiore Policlinico, Milan, Italy|AZ OSP Citta' Della Salute (Torino), Torino, Italy|Hospital Clinic, Barcelona, Barcelona, Spain|ICO Hospitalet, Barcelona, Barcelona, Spain|Hospital Son Espases, Palma, Spain https://ClinicalTrials.gov/show/NCT05886478 275 NCT05886465 HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial Recruiting No Results Available Hepatocellular Carcinoma Drug: Atezolizumab|Drug: Bevacizumab|Procedure: HAIC with FOLFOX Progression free survival rate at 6 months|Overall survival (OS)|Progression free survival (PFS)|Objective response rate (ORR)|Adverse events Sun Yat-sen University All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 40 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment S-014 May 24, 2023 June 1, 2024 December 1, 2024 June 2, 2023 June 2, 2023 Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05886465 276 NCT05886452 Success of Dailies Total1 for Astigmatism Contact Lenses in Patients That Have Previously Failed With Toric Contact Lenses Not yet recruiting No Results Available Astigmatism Device: DT1fA contact lenses Percentage of patients with positive ratings (>50 out of 100) for satisfaction of comfort and vision. Mann Eye Institute|Sengi All 18 Years to 39 Years   (Adult) 65 Other|Industry Observational Observational Model: Cohort|Time Perspective: Prospective PB-23-02 June 7, 2023 July 1, 2024 July 1, 2024 June 2, 2023 June 2, 2023 Mann Eye Institute, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05886452 277 NCT05886439 LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Recruiting No Results Available Advanced Lung Carcinoma Drug: LK101 injection (personlized neoantigen pulsed DC vaccine )|Drug: Pembrolizumab|Drug: Durvalumab DLT|AE|irAE|SAE|ORR|DoR|DCR|TTR|TTP|PFS|OS|Immune response evaluation Cancer Institute and Hospital, Chinese Academy of Medical Sciences All 18 Years and older   (Adult, Older Adult) Phase 1 40 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment LK101-IIT02 May 11, 2023 July 30, 2025 December 30, 2026 June 2, 2023 June 2, 2023 Cancer hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05886439 278 NCT05886426 4DCT Wrist Reference and DRUJ Not yet recruiting No Results Available Distal Radioulnar Joint Sprain Diagnostic Test: 4DCT wrist and standard CT wrist Primary study parameter Volunteer study|Primary study parameter Reliability study|Primary study parameter prospective Clinical study (DRUJ instability)|Volunteer study secondary outcome|Secondary outcome reliability study|Comparison with atroscopy (DRUJ instability)|Demographic variables Radboud University Medical Center All 18 Years to 50 Years   (Adult) 60 Other Observational Observational Model: Cohort|Time Perspective: Prospective 114440 August 1, 2023 February 1, 2024 February 1, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886426 279 NCT05886413 Potential Impact of the Use of the Application VentilO After Cardiac Surgery Not yet recruiting No Results Available Mechanical Ventilation Complication Other: VentilO application acid-base abnormalities on arterial blood gases|Occurence of optimal arterial blood gases result|Severity of unbalance of arterial blood gases result|hemodynamic instabilities|ICU length of stay|Mechanical Ventilation duration|Acute renal failure|Hospital length of stay|ICU mortality Laval University All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 2023-4030 July 2023 December 2023 June 2024 June 2, 2023 June 2, 2023 Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada https://ClinicalTrials.gov/show/NCT05886413 280 NCT05886400 The Effects of Environmental Distractions on SCAT5 Outcomes Not yet recruiting No Results Available Concussion, Brain|Mild Traumatic Brain Injury Other: SCAT5|Other: Visual/ Auditory Distraction Significant association between visual and auditory distractions and the outcomes of the SCAT5 assessment|Symptom list|Modified Balance Error Scoring System Indiana University All 18 Years to 30 Years   (Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening 18810 June 1, 2023 May 1, 2024 May 2024 June 2, 2023 June 2, 2023 Indiana University School of Public Health, Bloomington, Indiana, United States https://ClinicalTrials.gov/show/NCT05886400 281 NCT05886387 a Bayesian Analysis of Three Randomised Clinical Trials of Intraoperative Ventilation Active, not recruiting No Results Available Mechanical Ventilation Complication|Surgery|Pulmonary Complication|Postoperative Complications Other: High PEEP + Recruitment maneuvers Incidence of postoperative pulmonary complications Instituto de Investigacion Sanitaria La Fe|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Hospital Israelita Albert Einstein|University Hospital Carl Gustav Carus|Hospital Clínico Universitario de Valencia All 18 Years and older   (Adult, Older Adult) 3836 Other Observational Observational Model: Cohort|Time Perspective: Prospective Bayes_Repeat September 22, 2022 September 2023 November 2023 June 2, 2023 June 2, 2023 Hospital Israelita Albert Einstein, Sao Paulo, Brazil|IRCCS San Martino Policlinico Hospital, Genoa, Italy|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Hospital Clinic, Barcelona, Spain https://ClinicalTrials.gov/show/NCT05886387 282 NCT05886374 A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Not yet recruiting No Results Available Advanced Malignant Solid Tumors Drug: HMPL-415S1 To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or RP2D of HMPL-415S1 as a single oral agent in advanced malignant solid tumor|To investigate the pharmacokinetic (PK) profile of oral HMPL-415S1|AUCinf (Cycle 0 ) of HMPL-415S1|AUC(0-tlast) (Cycle 0 ) of HMPL-415S1|Objective Response Rate (ORR)|Disease control rate (DCR)|uration of response (DoR)|Time to response (TTR)|Progression-free survival (PFS)|Overall survival (OS) Hutchmed All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 81 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-415-00CH1 July 1, 2023 May 31, 2025 June 30, 2026 June 2, 2023 June 2, 2023 Zhongshan Hospital Fudan University, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05886374 283 NCT05886361 Somatic Symptoms in Autism Spectrum Disorder: Data Integration Completed No Results Available Autism Spectrum Disorder|Somatic Symptom Disorder Other: No intervention involved Patient health questionnaire-15, PHQ-15|Health assessment questionnairse, HAQ|Beck depression inventory, BDI|Beck anxiety inventory National Taiwan University Hospital All 15 Years to 70 Years   (Child, Adult, Older Adult) 1423 Other Observational Observational Model: Case-Control|Time Perspective: Retrospective 202206027RINA January 1, 2014 May 31, 2022 May 31, 2022 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886361 284 NCT05886348 The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens Not yet recruiting No Results Available Myopia Device: Novel spectacle lens|Device: Single vision spectacle lens Axial length|Spherical equivalent cycloplegic autorefraction HOYA Lens Thailand LTD. All 8 Years to 13 Years   (Child) Not Applicable 285 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment DG2-3A May 25, 2023 December 31, 2025 December 31, 2026 June 2, 2023 June 2, 2023 Guangzhou Aier Eye Hospital, Yuexiu, Guangzhou, China|Tianjin Medical University Eye Hospital, Nankai, Tianjin, China https://ClinicalTrials.gov/show/NCT05886348 285 NCT05886335 Evaluation of the Influence of Timing of Post-transplant Cyclophosphamide in Allogeneic Haematopoietic Stem Cell Transplant Patients. Not yet recruiting No Results Available Cyclophosphamide Toxicity|Allogenic Haematopoetic Transplantation Drug: Cyclophosphamide incidence haemorrhagic cystitis GII-IV|GVHD acute and chronic|Mortality and relapsed Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau All 18 Years and older   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Retrospective IIBSP-CFM-2023-45 June 2023 September 2023 December 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886335 286 NCT05886322 Remote Monitoring of IBD Recruiting No Results Available Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis Diagnostic Test: patient reported outcome measures|Diagnostic Test: fecal calprotectin|Diagnostic Test: colonoscopy Prediction of mucosal inflammation in daily clinical practice with PROMs and FC home test|Recalibration of PROMs|prediction of mucosal inflammation in strict trial setting with PROMs and FC home test|Agreement between FC home test and routine laboratory tests|Association between clinical (abdominal pain) and histologic disease activity|Association between IBD-control and histologic disease activity Maastricht University Medical Center|Maastricht University All 18 Years and older   (Adult, Older Adult) 400 Other Observational Observational Model: Cohort|Time Perspective: Prospective NL75205.068.20|NL9313 June 7, 2022 June 2024 June 2024 June 2, 2023 June 2, 2023 Jeroen Bosch Hospital, Den Bosch, Netherlands|Catharina Hospital Eindhoven, Eindhoven, Netherlands|Maastricht University Medical Centre, Maastricht, Netherlands|Franciscus Gasthuis&Vlietland, Rotterdam, Netherlands|Zuyderland Medical Centre, Sittard, Netherlands https://ClinicalTrials.gov/show/NCT05886322 287 NCT05886309 Measurement of Serum Ferritin With a Cryo Detector Mass Spectrometer (CDMS) Not yet recruiting No Results Available Serum Ferritin Diagnostic Test: Collection of Blood samples Assessment of the mass of serum ferritin molecules (kDa) University Hospital, Basel, Switzerland|Metromol SA All 18 Years to 75 Years   (Adult, Older Adult) 25 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023-00550; th22Infanti June 2023 March 2024 March 2024 June 2, 2023 June 2, 2023 University Hospital Basel, Basel, Switzerland https://ClinicalTrials.gov/show/NCT05886309 288 NCT05886296 Pre-surgical Information Session for People Who Must Undergo Shoulder Rotator Cuff Surgery Recruiting No Results Available Rotator Cuff Injuries|Surgery|Empowerment, Patient Behavioral: Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process. Shoulder Functionality|Shoulder Function|Empowerment|Participants' Quality of Life perception|Participant's satisfaction Consorci Sanitari de Terrassa All 18 Years and older   (Adult, Older Adult) Not Applicable 54 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care 01-23-280-028 May 19, 2023 January 2024 December 2024 June 2, 2023 June 2, 2023 Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain https://ClinicalTrials.gov/show/NCT05886296 289 NCT05886283 Qualitative and Quantitative Endothelium Changes After Cataract Surgery: Ultrasound Phacoemulsification vs Nanolaser Technique Completed No Results Available Effect of Cataract Surgery on Corneal Endothelium; About 2 Techniques Procedure: phacoemulsification|Procedure: utrasound phacoemulsification|Procedure: nanolaser phacoemulsification Endothelial cell density (ECD)|Percentage of endothelial cell loss (ECL)|Mean percentage of hexagonal cells|Mean coefficient of variance (CoV)|Central corneal thickness (CCT)|Uncorrected visual acuity (UVA)|Best corrected visual acuity (BCVA) University Tunis El Manar All 50 Years to 90 Years   (Adult, Older Adult) Not Applicable 74 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment 14-03-2023 March 1, 2017 May 31, 2020 December 30, 2020 June 2, 2023 June 5, 2023 Mohamed Taher Maamouri Hospital, Nabeul, Tunisia https://ClinicalTrials.gov/show/NCT05886283 290 NCT05886270 Implementation of the Child Housing Assessment for a Safe Environment CHASE Enrolling by invitation No Results Available Accident Injury|Home Injury Other: Housing Assessment/Safety Modifications Change in number of Poison Storage hazards|Change in number of Smoke Alarms hazards|Change in number of Fire Escape Safety hazards|Change in number of Sprinkler System hazards|Change in number of Carbon Monoxide Alarm hazards|Change in number of Electrical Fire and Shock hazards|Change in number of Electrical Tripping Risk hazards|Change in number of Hot Water Burn hazards|Change in number of Window Fall hazards|Change in number of Accidental Strangulation hazards|Change in number of Stair Fall hazards|Change in number of Bathroom Fall hazards|Change in number of Protruding Nail hazards|Change in number of Falling Furniture hazards|Change in number of Stair Gate hazards|Cost of installing injury prevention measures|Change in participants' self-reported rates of experienced barriers and facilitators to incorporating injury prevention tools in their home.|Change in qualitative descriptions of participants' confidence to make and maintain injury prevention measures in their home. Johns Hopkins Bloomberg School of Public Health|Green and Healthy Homes Initiative|US Department of Housing and Urban Development All up to 7 Years   (Child) Not Applicable 300 Other|U.S. Fed Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention MDHHU0059-20 June 24, 2022 June 2023 December 2023 June 2, 2023 June 2, 2023 Johns Hopkins Center for Injury Research & Policy, Baltimore, Maryland, United States https://ClinicalTrials.gov/show/NCT05886270 291 NCT05886257 Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T Withdrawn No Results Available Hepatocellular Carcinoma Drug: Candonilimab|Drug: Bevacizumab ORR per RECIST 1.1|Overall survival (OS)|Progression free survival (PFS)|Adverse events|PD-L1 Biomarker Shi Ming|Sun Yat-sen University All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 0 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment S104 December 7, 2022 March 31, 2023 March 31, 2023 June 2, 2023 June 2, 2023 Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05886257 292 NCT05886244 Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China Soliris Not yet recruiting No Results Available Paroxysmal Nocturnal Hemoglobinuria Drug: Eculizumab Percentage change from baseline in Lactate Dehydrogenase (LDH) at Week 12|Number(%) of participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Pharmacokinetics (PK): Serum Eculizumab Concentration|Change from baseline in Serum Free and total Complement 5 (C5) Concentration|Number(%) of participants with Antidrug Antibodies (ADAs) to Eculizumab|Change from baseline in functional assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 64|Number(%) of participants with Breakthrough Hemolysis|Number(%) of participants achieving LDH Normalization|Number(%) of participants needing Blood Transfusion|Number(%) of participants changes from baseline in vital signs and laboratory parameters at all scheduled visits. Alexion|AstraZeneca All 18 Years and older   (Adult, Older Adult) Phase 3 25 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment D7414C00001 July 3, 2023 April 30, 2025 April 30, 2025 June 2, 2023 June 2, 2023 Research Site, Beijing, China|Research Site, Hangzhou, China|Research Site, Nantong, China|Research Site, Shanghai, China|Research Site, Tianjian, China|Research Site, Tianjin, China|Research Site, Wuhan, China https://ClinicalTrials.gov/show/NCT05886244 293 NCT05886231 The Effects of Instrumental Music on Intraoperative Parameters and Postoperative Pain and Side Effects Completed No Results Available Music and Anesthesia Other: music sound therapy heart rate|non invasive blood pressure|Pulse oxymeter|BIS (Bispektral index)|level of opioid|muscle relaxant|Side effects|VAS scores Yuzuncu Yıl University All 20 Years to 60 Years   (Adult) Not Applicable 80 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening 2023/1 March 2, 2020 September 2, 2020 December 2, 2020 June 2, 2023 June 2, 2023 Arzu Esen Tekeli, Van, Turkey|Van Yüzüncü Yil University, Van, Turkey https://ClinicalTrials.gov/show/NCT05886231 294 NCT05886218 Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery Recruiting No Results Available Sugammadex Device: Quantitative Neuromuscular Function Monitoring Oxygen desaturation|The rate of compliance with muscle relaxant monitoring and reversal protocols|Total intraoperative rocuronium use|Total sugammadex dose|Post-operative supplemental oxygen requirement|Post-operative unit length of stay|Hospital Length of stay|Success rate for wearable device University of California, Davis All 18 Years and older   (Adult, Older Adult) 215 Other Observational Observational Model: Other|Time Perspective: Prospective 2004503 February 8, 2023 February 2024 July 2024 June 2, 2023 June 2, 2023 UC Davis Medical Center, Sacramento, California, United States https://ClinicalTrials.gov/show/NCT05886218 295 NCT05886205 Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy Recruiting No Results Available Refractory Focal Epilepsy Drug: iPSC-Exos adverse events as assessed by CTCAE|Number of participants with abnormal vital signs and abnormal Physical examination findings|Number of participants with abnormal Neurological examination|Number of participants with abnormal laboratory tests results|Number of participants with abnormal Urine analysis|Seizures frequency|Scalp electroencephalogram monitoring|Head magnetic resonance imaging (MRI) examination Peking Union Medical College Hospital|Guidon Pharmaceutics Ltd. All 18 Years to 70 Years   (Adult, Older Adult) Early Phase 1 34 Other Interventional Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment K2153-K22C1488 May 23, 2023 June 13, 2025 November 13, 2025 June 2, 2023 June 2, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05886205 296 NCT05886192 The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients Recruiting No Results Available Septic Shock Drug: norepinephrine+vasopressin|Drug: Norepinephrine 28days-Mortality in ICU|ICU duration|RVDEA/LVDEA|right ventricular thickness|Tricuspid Annular Plane Systolic Excursion|resistance index of superior mesenteric artery|venous excess ultrasound grading system(VexUS)|Intestinal ultrasound score|pulsatility index of the middle cerebral artery Peking Union Medical College Hospital All 18 Years and older   (Adult, Older Adult) Phase 4 60 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 2022-PUMCH-B-115 May 1, 2023 January 1, 2025 September 30, 2025 June 2, 2023 June 2, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05886192 297 NCT05886179 COVID-19 IN CHILDREN IN NIGER, 2020 Completed No Results Available to Contribute to a Better Control of COVID-19 in Children in Niger Other: cross-sectional study data base analysis Centre de Recherche Médicale et Sanitaire All 0 Years to 15 Years   (Child) 572 Other Observational Observational Model: Other|Time Perspective: Retrospective CERMES February 25, 2020 August 28, 2020 January 15, 2021 June 2, 2023 June 2, 2023 IDE AMADOU Habibatou, Niamey, Niger https://ClinicalTrials.gov/show/NCT05886179 298 NCT05886166 Clinical Utility of Exoskeleton Robot Training in Patients With Septic Arthritis After a Thermal Injury: A Case Report Not yet recruiting No Results Available Septic Arthritis|Gait Disorder, Sensorimotor Other: robot assisted training Functional ambulatory category (FAC)|6-min walking test (6 MWT) distance|visual analog scale (VAS)|Isometric muscle strength|range of motion (ROM) Hangang Sacred Heart Hospital All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 2 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HangangSHH-16 June 15, 2023 December 25, 2023 December 31, 2023 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886166 299 NCT05886153 Verification Protocol for the Cloud DX Vitaliti Continuous Vital Signs Monitor (VERDICT-2) VERDICT-2 Not yet recruiting No Results Available Blood Pressure|Respiration|Pulse Rate|Oxygen Saturation|Temperature|Heart Rate Device: Vitaliti Continuous Vital Sign Monitor Model CVSM-1A Respiration Rate|Pulse Rate|Oxyhemoglobin Saturation|Temperature|Heart Rate|Blood Pressure Hamilton Health Sciences Corporation|McMaster University|Population Health Research Institute|Cloud DX Inc. All 18 Years to 100 Years   (Adult, Older Adult) Not Applicable 35 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other v2.0_2023-01-05 June 2023 August 2023 August 2023 June 2, 2023 June 2, 2023 McMaster University, Hamilton, Ontario, Canada https://ClinicalTrials.gov/show/NCT05886153 300 NCT05886140 Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin Not yet recruiting No Results Available Squamous Cell Carcinoma of the Skin Drug: Carrilizumab with albumin-binding paclitaxel Objective Response Rate|Progression-Free-Surviva Henan Cancer Hospital All 18 Years to 99 Years   (Adult, Older Adult) Not Applicable 24 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HN-SHR-1210-cSCC-002 May 31, 2023 April 30, 2025 April 30, 2025 June 2, 2023 June 2, 2023 Henan Cancer Hospital, Zhengzhou, Henan, China https://ClinicalTrials.gov/show/NCT05886140 301 NCT05886127 Treatment of Postsphincterotomy Bleeding With a Novel Self-assembling Peptide Hemostatic Gel. ERCPURA Recruiting No Results Available Biliary Obstruction|Complication of Treatment Device: A novel hemostatic agent (Purastat®) Number of bleeding episodes after ERCP sfincterothomy or precut|Number of nonbleeding complications after ERCP sfincterothomy or precut General University Hospital, Prague All 18 Years and older   (Adult, Older Adult) 80 Other Observational Observational Model: Cohort|Time Perspective: Other ERCP-PURA/1 August 1, 2022 July 31, 2023 October 30, 2023 June 2, 2023 June 2, 2023 Petr Hrabak, Prague, Czechia https://ClinicalTrials.gov/show/NCT05886127 302 NCT05886114 A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China HERITAGE Recruiting No Results Available Cognitive Impairment|Alzheimer Disease|Vascular Cognitive Impairment|Dement|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Neurocognitive Disorders|Mental Disorder|Cognition Disorder Behavioral: Structured Multi-domain Intervention|Behavioral: Self-Guided Intervention Global Cognition|Domain-specific Cognition|Neuroimaging: MRA|Neuroimaging: MRI|Neuroimaging: fMRI|Number of participants with Laboratory Values /Blood markers|Incident dementia|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Alzheimer's Disease Cooperative Study Activities of Daily Living Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS MCI-ADL)|Cardiovascular morbidity|Physical Performance: Grip strength|Physical Performance: Gaid speed|Physical Performance: Balance|Physical Performance: Endurance|Physical Performance: Lower limb strength|Quality of Life Questionnaire (15D)|The Geriatric Depression Scale (GDS)|Pittsburgh Sleep Quality Index (PSQI)|Leisure-Time Activities Questionnaire|Resource Use Inventory (RUI)|Hight|Weight|Hip circumference|Waist circumference|Changes in Blood Pressure|Changes in lipid Profile|Changes in Glucose Regulation|Retinal Imaging Markers|Falls Zhejiang University All 60 Years to 80 Years   (Adult, Older Adult) Not Applicable 1200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention 31005808A111272274170 May 28, 2023 April 28, 2025 April 28, 2027 June 2, 2023 June 2, 2023 School of Public Health and The Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05886114 303 NCT05886101 Increase Health Literacy Through Health Education to Improve Menstruation Related Self-care and Work Productivity Recruiting No Results Available Work-Related Condition|Menstrual Discomfort|Occupational Problems Behavioral: Health Education Improvement of health literacy measured by European health literacy scale (12-items short version) (Finbraten et al., 2018) among women in Ready Made Garments (RMG) sector in Bangladesh|Improve reproductive age women specific health literacy by using the Health literacy scale for women of reproductive age, Bangla version (From Japanese to Bangla and standardized in Study Hiroshima University Female 18 Years to 49 Years   (Adult) Not Applicable 400 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention Health literacy & productivity April 1, 2023 December 30, 2023 February 28, 2024 June 2, 2023 June 2, 2023 Rokeya Akter Bristy, Dhaka, Dhamrai, Bangladesh https://ClinicalTrials.gov/show/NCT05886101 304 NCT05886088 Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus DÁLIA Not yet recruiting No Results Available Type 2 Diabetes Mellitus Drug: LID104|Drug: Dapagliflozin|Drug: Linagliptin Glycated hemoglobin (HbA1c)|Fasting blood glucose|HbA1c reduction to < 7%|Treatment failure|Body weight|Blood pressure EMS All 18 Years to 75 Years   (Adult, Older Adult) Phase 3 597 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment LID104-III-0123 February 2024 May 2026 January 2027 June 2, 2023 June 2, 2023 Investigational site, Hortolândia, SP, Brazil https://ClinicalTrials.gov/show/NCT05886088 305 NCT05886075 A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors Recruiting No Results Available Lung Cancer|Bronchial Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Sarcoma|Colorectal Cancer|Gastric Cancer|Liver Cancer|Breast Cancer|Pancreatic Cancer|Head and Neck Cancer|Ovarian Cancer Drug: Recombinant oncolytic herpes simplex virus type 1 (R130) Subject incidence of adverse events|Subject incidence of laboratory abnormalities|Systemic Immune Response|Disease Assessment for Disease Control Rate|Disease Assessment for Duration of Response|Quality of Life Assessment Shanghai Yunying Medical Technology|The PLA Navy Anqing Hospital All 18 Years to 75 Years   (Adult, Older Adult) Early Phase 1 24 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment AQNH-R130-AST March 30, 2023 March 2025 March 2025 June 2, 2023 June 2, 2023 The PLA Navy Anqing Hospital, Anqing, Anhui, China https://ClinicalTrials.gov/show/NCT05886075 306 NCT05886062 Effects of Motor Imagery Training on Performance and Heart Rate Change in Adolescent Basketball Players Recruiting No Results Available Motor Imagery Other: Motor Imagery to Facilitate Sensorimotor Re-Learning Training|Other: Control Group Balance|Muscle Power|Muscle Strength|Shooting Performance|Agility|Heart Rate Change Ege University Male 11 Years to 19 Years   (Child, Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-1251 January 1, 2023 September 1, 2023 December 1, 2023 June 2, 2023 June 2, 2023 Ege University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, İzmir, Turkey https://ClinicalTrials.gov/show/NCT05886062 307 NCT05886049 Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Not yet recruiting No Results Available Acute Myeloid Leukemia With KMT2A Rearrangement|Acute Myeloid Leukemia With NPM1 Mutation Procedure: Biospecimen Collection|Procedure: Bone Marrow Aspiration|Procedure: Bone Marrow Biopsy|Drug: Cytarabine|Drug: Daunorubicin|Procedure: Multigated Acquisition Scan|Drug: Revumenib|Procedure: Transthoracic Echocardiography Maximum tolerated dose (MTD) for Induction|Maximum tolerated dose (MTD) for Consolidation|Recommended phase 2 dose for expansion cohort|Pharmacokinetics (PK) of revumenib (SNDX-5613) National Cancer Institute (NCI) All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 28 NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NCI-2023-04141|10596|UM1CA186712 June 30, 2023 February 29, 2024 February 29, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886049 308 NCT05886036 Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Not yet recruiting No Results Available Nodular Lymphocyte Predominant Hodgkin Lymphoma|Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma|Refractory Nodular Lymphocyte Predominant Hodgkin Lymphoma Procedure: Biopsy|Procedure: Biospecimen Collection|Procedure: Bone Marrow Biopsy|Procedure: Computed Tomography|Other: Fludeoxyglucose F-18|Procedure: Magnetic Resonance Imaging|Biological: Mosunetuzumab|Procedure: Positron Emission Tomography|Biological: Rituximab|Biological: Rituximab and Hyaluronidase Human Progression-free survival (PFS) time|Objective response|Duration of response|Overall survival (OS) National Cancer Institute (NCI) All 18 Years and older   (Adult, Older Adult) Phase 2 70 NIH Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NCI-2023-04108|10590|UM1CA186688 August 31, 2023 March 31, 2026 March 31, 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05886036 309 NCT05886023 Nitrate INFORMER Vegetable Study Not yet recruiting No Results Available Health Risk Behaviors Dietary Supplement: High nitrate vegetables|Dietary Supplement: Low nitrate vegetables N-nitrosamines in urine post intervention (up to 24 hours)|N-nitrosamines in stool samples post intervention (up to 24 hours) Edith Cowan University|The University of Western Australia|Flinders University All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 25 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention 2023-04297-BONDONNO June 26, 2023 October 31, 2023 December 31, 2024 June 2, 2023 June 2, 2023 Royal Perth Hospital Research Foundation, Perth, Western Australia, Australia https://ClinicalTrials.gov/show/NCT05886023 310 NCT05886010 Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins Not yet recruiting No Results Available Solar Lentigo|Senile Lentigo Device: prototypes 1 everyday|Device: prototypes 1 every week|Device: prototypes 1 every two weeks|Device: prototypes 2 every two weeks|Device: prototypes 3 every two weeks Change from baseline skin hyperpigmentation|Change from baseline skin hypopigmentation|Change from baseline skin appearance - expected events|Change from baseline skin sensation|Self-assesment of pain by VAS|Change from baseline spots visibility Cryonove Pharma|CEISO All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 120 Industry Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment CS5_4 September 1, 2023 February 29, 2024 February 29, 2024 June 2, 2023 June 2, 2023 Laboratoire BIO-EC, Longjumeau, France https://ClinicalTrials.gov/show/NCT05886010 311 NCT05885997 Implementing a Home Blood Pressure Monitoring Program in Primary Care MonitorBP Not yet recruiting No Results Available Hypertension Behavioral: Supported HBPM program plus multifaceted implementation strategy|Other: Usual care Change in patient's office systolic blood pressure (SBP)|Office diastolic blood pressure (DBP)|Change in patient's antihypertensive medication regimen intensity|Antihypertensive medication adherence|Uncontrolled hypertension Columbia University|Weill Medical College of Cornell University|New York Presbyterian Hospital All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 16000 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research AAAS5544 August 1, 2023 August 1, 2025 August 1, 2027 June 2, 2023 June 2, 2023 Columbia University Irving Medical Center, New York, New York, United States https://ClinicalTrials.gov/show/NCT05885997 312 NCT05885984 Acceptance and Commitment Therapy on Fatigue Interference in Patients With Advanced Lung Cancer and Caregiver Burden (ACT) Not yet recruiting No Results Available Lung Cancer|Advanced Cancer|Caregiver Burden Behavioral: Acceptance and Commitment Therapy (ACT) plus health education|Other: Health education Eligibility rate|Recruimtment rate|Attrition rate|Adherence rate|Change from baseline in the score of fatigue interference assessed by The Fatigue Symptom Inventory at one week after the intervention|Change from baseline in the score of caregiver burden assessed by The Zarit Caregiver Burden Inventory at one week after the intervention|Change from baseline in the score of health-related quality of life assessed by Functional Assessment of Cancer Therapy - Lung, Version 4 at one week after the intervention|Change from baseline in the score of meanfing of life assessed by The Meaning of Life questionnaire (MLQ) at one week after the intervention|Change from baseline in the score of psychological flexibility assessed by Comprehensive assessment of Acceptance and Commitment Therapy processes at three months after the intervention|Change from baseline in the score of mindful attention assessed by Mindful Attention Awareness Scale at one week after the intervention Chinese University of Hong Kong|Association for contextual behavioral science All 18 Years and older   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care CREC Ref. No. 2023.030 July 2023 November 2023 January 2024 June 2, 2023 June 2, 2023 Xiangya Hospital Central South University, Changsha, Hunan, China https://ClinicalTrials.gov/show/NCT05885984 313 NCT05885971 Detection of Eating Disorders in Pregnant Women PREGN'ED Not yet recruiting No Results Available Eating Disorders|Pregnancy Related Diagnostic Test: Administration of the SCOFF-F and EDE-Q questionnaires Specific Eating Disorders items in pregnant women Centre Hospitalier Henri Laborit Female 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 2023-A00529-36 June 2023 June 2023 June 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885971 314 NCT05885958 Timing of Active Void Trials After Urogynecologic Procedures Not yet recruiting No Results Available Postoperative Care|Urinary Catheters|Urogynecology Other: time Pass Rate|Time in PACU|Pass Rate After Failing|UTI|Type of Surgery University of South Florida Female 18 Years and older   (Adult, Older Adult) Not Applicable 208 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic STUDY005629 July 2023 June 2025 June 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885958 315 NCT05885945 Diaphragmmatic Muscle Strength and Balance in Women With Dysmenorhea Dysmenorhea Recruiting No Results Available Dysmenorrhea Primary Balance|diaphragmatic muscle strength|sociodemographic variables Catholic University of Murcia Female 18 Years to 65 Years   (Adult, Older Adult) 23 Other Observational Observational Model: Case-Control|Time Perspective: Prospective TC-01/23 February 15, 2023 June 14, 2023 July 31, 2023 June 2, 2023 June 2, 2023 University Catholic of Murcia, Guadalupe, Murcia, Spain https://ClinicalTrials.gov/show/NCT05885945 316 NCT05885932 Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis VISTA Not yet recruiting No Results Available Ischemic Stroke|Vertebral Artery Stenosis Procedure: Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|Drug: Aspirin and clopidogrel or ticagrelor|Procedure: mono anti-platelet therapy Any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year.|Fatal or non-fatal stroke within 30 days|Ischemic stroke in the territory of the target artery beyond 30 days to 1 year|Ischemic stroke in the territory of the target artery within 1 year|Crescendo TIA in the territory of the target artery within 1 year|Fatal stroke within 1 year|Disabling stroke (defined by a modified Rankin Scale Score of ≥3) within 1 year|Any stroke within 1 year|Any stroke, myocardial infarction or death within 1 year|All cause mortality within 1 year|Symptomatic cerebral hemorrhage within 1 year|Modified Rankin Scale (mRS) score (0-5, higher score refers to a worse outcome)|In-stent restenosis (Stenosis ≥ 50%) Xuanwu Hospital, Beijing All 18 Years and older   (Adult, Older Adult) Not Applicable 472 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment VISTA September 2023 September 2025 September 2028 June 2, 2023 June 2, 2023 Xuanwu Hospital, Capital Medical University., Beijing, China https://ClinicalTrials.gov/show/NCT05885932 317 NCT05885919 Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke EARLYS Not yet recruiting No Results Available Ischemic Stroke, Acute|Treatment Outcome Drug: Edaravone Dexborneol Concentrated Solution for injection|Drug: Edaravone Dexborneol placebo A 90-day mRS score of 0 to 2 in participants with acute ischaemic stroke|Neurological recovery|Modified Rankin scale|Quality of life score (EQ-5D)|The incidence of serious adverse events|All-cause mortality Xiangya Hospital of Central South University|Jiangsu Simcere Pharmaceutical Co., Ltd. All 18 Years to 80 Years   (Adult, Older Adult) Phase 3 212 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment Shenjingneike June 1, 2023 December 31, 2024 December 31, 2024 June 2, 2023 June 2, 2023 Brain Hospital of Hunan Province, Changsha, Hunan, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|XiangYa School of Medicine, Changsha, Hunan, China https://ClinicalTrials.gov/show/NCT05885919 318 NCT05885906 Aloe Vera Versus Thyme Honey Mouthwash in Management of Xerostomia in Type 2 Diabetics Not yet recruiting No Results Available Xerostomia Drug: Aloevera|Drug: Thyme honey|Drug: Saline Change in unstimulated Salivary flow rate Ain Shams University All Child, Adult, Older Adult Phase 3 45 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care FDASU-RecIM122208 July 2023 October 2023 March 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885906 319 NCT05885893 Smartphone Addiction Level and Neck Muscle Completed No Results Available Smartphone Addiction|Neck Muscle Issue Neck Pain Intensity Assessment|Smartphone Addiction Level Assessment|Functional Level Assessment|Pain Sensitivity Level Assessment|Muscle Activation Level Assessment Suleyman Demirel University Male 15 Years to 25 Years   (Child, Adult) 112 Other Observational Observational Model: Other|Time Perspective: Other MS2022/033 December 10, 2017 June 1, 2019 June 15, 2019 June 2, 2023 June 2, 2023 Menekşe ŞAFAK, Merkez, Isparta, Turkey https://ClinicalTrials.gov/show/NCT05885893 320 NCT05885880 Blue-Button Regional Trial Screening Enrolling by invitation No Results Available Cancer Other: Blue-button screening Rate of clinical trial participation|Participant reports on Blue-button tool usability|Patient reasons for non-enrollment American Cancer Society Cancer Action Network All 18 Years and older   (Adult, Older Adult) Not Applicable 1050 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research 2018254-4 June 2023 June 2024 December 2024 June 2, 2023 June 2, 2023 University of Texas Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States https://ClinicalTrials.gov/show/NCT05885880 321 NCT05885867 The Activation and Walking Speed of the Prefrontal Cortex of the Elderly Mild Cognitive Impairment During Dual Task. Recruiting No Results Available Mild Cognitive Impairment|Dual Task Behavioral: Seniors with mild cognitive impairment over 65 years of age prefrontal cortex activity for single and dual tasks|Walking speed for single and dual tasks Sahmyook University All 65 Years and older   (Older Adult) 30 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional SYU 2023-02-013-002 May 30, 2023 June 5, 2023 June 5, 2023 June 2, 2023 June 2, 2023 Sahmyook university, Seoul, Nowon-gu, Korea, Republic of https://ClinicalTrials.gov/show/NCT05885867 322 NCT05885854 XTR003 PET Radiotracer for the Detection of Viable Myocardium Completed No Results Available Ischemic Heart Disease (IHD) Drug: XTR003 To investigate the sensitivity of combining XTR003/FDG PET imaging|To investigate the specificity of combining XTR003/FDG PET imaging|Number of study participants with treatment-related adverse events as determined by safety parameter changes according to CTCAE v5.0 Sinotau Pharmaceutical Group All 18 Years to 80 Years   (Adult, Older Adult) Phase 2 51 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic STB-XTR003-201 December 15, 2021 March 4, 2023 March 5, 2023 June 2, 2023 June 2, 2023 TEDA International Cardiovascular Hospital, Tianjin, Tianjin, China https://ClinicalTrials.gov/show/NCT05885854 323 NCT05885841 Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD Completed No Results Available Coronary Artery Disease (CAD) Drug: XTR004 Qualitative reading and semi-qualitative MPI analysis (SSS and SDS)|Quantitative index of XTR004 PET myocardial blood flow (Stress MBF, MFR)|Number of study participants with treatment-related adverse events as determined by safety parameter changes according to CTCAE v5.0 Sinotau Pharmaceutical Group All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 83 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic STB-XTR004-201 February 15, 2022 May 9, 2023 May 9, 2023 June 2, 2023 June 2, 2023 Beijing Hospital, Beijing, Beijing, China|Beijing Tongren Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05885841 324 NCT05885828 The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes Not yet recruiting No Results Available Type 2 Diabetes Other: White bread|Other: Whole wheat bread|Behavioral: Plant-based diet|Other: Conventional diabetic diet|Other: Follow-up visit every 1-2 years Changes in gut microbiome profile|Blood glucose profile|Carotid plaque|Carotid intima-media thickness|Number of participants with chronic kidney disease|Cognitive function|Changes in fasting blood glucose|Changes in fasting blood C-peptide|Changes in fasting blood HbA1c|Changes in lipid metabolism Westlake University|Hangzhou Third People's Hospital All 35 Years to 70 Years   (Adult, Older Adult) Not Applicable 1500 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other 20230306ZJS002 May 30, 2023 December 1, 2024 December 1, 2033 June 2, 2023 June 2, 2023 Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05885828 325 NCT05885815 Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy Not yet recruiting No Results Available Lung Cancer OS|PFS|ORR|DOR Shanghai Pulmonary Hospital, Shanghai, China All 19 Years to 75 Years   (Adult, Older Adult) 500 Other Observational Observational Model: Case-Only|Time Perspective: Prospective 2023HY0520 June 2023 June 2024 June 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885815 326 NCT05885802 Sngception and Pain in Spine Enhanced Recovery After Surgery (ERAS) Pathways Recruiting No Results Available Pain Postoperative Other: No specific intervention other than routine anesthesia protocol Postoperative Sngception (Sng)|Postoperative Pain|Morphine consumption Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital All 20 Years and older   (Adult, Older Adult) 40 Other Observational Observational Model: Cohort|Time Perspective: Prospective IRB 2022-09-009BC March 29, 2023 December 31, 2023 December 31, 2024 June 2, 2023 June 2, 2023 Taipei Veterans General Hospital, Taipei City, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05885802 327 NCT05885789 Improvement of Laryngoscopic View by Bed-up-head-elevated Position During Tracheal Intubation in Paediatric Patients Recruiting No Results Available Paediatric Airway Management Procedure: Intubation in Bed-Up-Head-Elevated (BUHE) position Change in Percentage of Glottic Opening (POGO) score after BUHE position|Ease of handling of laryngoscope University of Malaya All 3 Years to 12 Years   (Child) 125 Other Observational Observational Model: Other|Time Perspective: Prospective BUHE in paediatric March 1, 2023 May 31, 2024 May 31, 2024 June 2, 2023 June 5, 2023 University of Malaya Medical Center, Kuala Lumpur, Malaysia https://ClinicalTrials.gov/show/NCT05885789 328 NCT05885776 Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research PYTHON Recruiting No Results Available Breast Cancer Drug: Pyrrolidine、trastuzumab、AI Follow up on postoperative pathological reports for evaluation for Pathological complete response rate (tpCR: ypT0-is/ypN0)|Follow up on postoperative pathological reports for evaluation for Optimal overall response rate (BORR) Tianjin Medical University Cancer Institute and Hospital Female 18 Years to 75 Years   (Adult, Older Adult) Phase 2 48 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Tianjin Cancer Hospital September 13, 2022 March 30, 2024 September 30, 2025 June 2, 2023 June 2, 2023 Tianjin Cancer Hospital, Tianjin, Tianjin, China https://ClinicalTrials.gov/show/NCT05885776 329 NCT05885763 Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis Recruiting No Results Available End Stage Renal Disease on Hemodialysis Drug: Difelikefalin Injection Evaluation of the PK profile of difelikefalin - Cmax|Evaluation of the PK profile of difelikefalin - Tmax|Evaluation of the PK profile of difelikefalin - AUC0-t|AUCinf|AUCextrap(%)|t½|Clearance|Vz Vifor Fresenius Medical Care Renal Pharma|Tigermed Consulting Co., Ltd All 18 Years to 85 Years   (Adult, Older Adult) Phase 1 30 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment KOR-CHINA-101|JXHL2101166 June 1, 2023 June 2024 June 2024 June 2, 2023 June 2, 2023 Investigator Site 1, Beijing, China|Investigator Site 2, Beijing, China|Investigator Site 3, Beijing, China|Investigator Site 4, Shijiazhuang, China https://ClinicalTrials.gov/show/NCT05885763 330 NCT05885750 The Impact of Plant-Based Protein-rich Food Products With Varying Degree of Processing on the Human Gut Microbiome Composition and Human Metabolome Recruiting No Results Available Metabolism|Gut Microbiota|Inflammation Behavioral: Unprocessed|Behavioral: Mildly processed|Behavioral: Heavily refined Metabolomics|Transcriptomics|Metagenomics|Inflammation status|Glucose homeostasis|Lipid homeostasis|Body weight University of Turku All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 38 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other Newplant April 5, 2023 September 30, 2023 December 31, 2024 June 2, 2023 June 2, 2023 Food Sciences Unit, Department of Life Technologies, Faculty of Technology, University of Turku, Turku, Finland https://ClinicalTrials.gov/show/NCT05885750 331 NCT05885737 Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Recruiting No Results Available Uremic Pruritus Drug: Difelikefalin Injection|Drug: Placebo Injection Change from baseline in the weekly mean of the daily 24-hour WI-NRS score at Week 4 of the double-blind period|Proportion of subjects achieving ≥3-point improvement from baseline with respect to the weekly mean of the daily 24-hour WI-NRS|Proportion of subjects achieving ≥4-point improvement from baseline with respect to the weekly mean of the daily 24-hour WI-NRS|Change from baseline in itch-related Quality of Life (QoL) at the end of Week 12 of the double-blind period, as assessed by the 5-D itch scale total score.|Change from baseline in itch-related QoL at the end of Week 12 of the double-blind period, as assessed by the Skindex-10 scale total score.|Patient Global Impression of Change. Vifor Fresenius Medical Care Renal Pharma|Tigermed Consulting Co., Ltd All 18 Years to 85 Years   (Adult, Older Adult) Phase 3 258 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment KOR-CHINA-301|JXHL2101166 May 30, 2023 July 2025 July 2025 June 2, 2023 June 2, 2023 Investigator Site 25, Baotou, China|Investigator Site 01, Beijing, China|Investigator Site 07, Beijing, China|Investigator Site 37, Beijing, China|Investigator Site 26, Changsha, China|Investigator Site 06, Guangzhou, China|Investigator Site 12, Jiaxing, China|Investigator Site 02, Lanzhou, China|Investigator Site 09, Lanzhou, China|Investigator Site 34, Mianyang, China|Investigator Site 03, Nanjing, China|Investigator Site 10, Nanjing, China|Investigator Site 19, Nanjing, China|Investigator Site 36, Nantong, China|Investigator Site 18, Shenyang, China|Investigator Site 21, Shenyang, China|Investigator Site 16, Shenzhen, China|Investigator Site 08, Shihezi, China|Investigator Site 32, Shijiazhuang, China|Investigator Site 20, Taiyuan, China|Investigator Site 24, Taiyuan, China|Investigator Site 39, Tianjin, China|Investigator Site 17, Wuhan, China|Investigator Site 33, Wuxi, China|Investigator Site 13, Xiamen, China|Investigator Site 15, Xianyang, China|Investigator Site 22, Xining, China|Investigator Site 38, Xinxiang, China|Investigator Site 11, Yangzhou, China|Investigator Site 30, Yibin, China|Investigator Site 29, Yinchuan, China|Investigator Site 23, Zhengzhou, China|Investigator Site 31, Zhenjiang, China|Investigator Site 35, Zhuzhou, China|Investigator Site 04, Ürümqi, China https://ClinicalTrials.gov/show/NCT05885737 332 NCT05885724 Novel Targetable BIOmarkers in ANorexia NervosA BIOANNA Recruiting No Results Available Anorexia Nervosa|Anorexia Nervosa Restricting Type Growth Differentiation Factor-15 (GDF-15) (pg/ml) level in the plasma|Growth Differentiation Factor-15 (GDF-15) (pg/ml) level in the cerebrospinal fluids University Hospital, Basel, Switzerland|University of Zurich All 18 Years to 60 Years   (Adult) 32 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023-00513, kt23timper2 May 1, 2023 April 30, 2024 April 30, 2024 June 2, 2023 June 2, 2023 University Hospital Basel, Basel, Switzerland https://ClinicalTrials.gov/show/NCT05885724 333 NCT05885711 Self-management Pessary Project ZPP Recruiting No Results Available Pelvic Organ Prolapse Other: self-management Number of patients that succeed in learning self-management of the pessary Zuyderland Medisch Centrum Female 18 Years and older   (Adult, Older Adult) 288 Other Observational Observational Model: Cohort|Time Perspective: Prospective Z2022098 January 9, 2023 January 1, 2025 March 1, 2025 June 2, 2023 June 2, 2023 Zuyderland Medisch Centrum, Heerlen, Netherlands https://ClinicalTrials.gov/show/NCT05885711 334 NCT05885698 MYLUNG Consortium Part 3: Observational Study MYLUNG Recruiting No Results Available Carcinoma, Non-Small-Cell Lung Proportion of Patients Who Receive Biomarker Test Results Prior to Systemic Therapy or Death|Proportion of Patients Who Receive Single-gene Testing Compared to Those that Receive Comprehensive Biomarker Testing|For Patients without Biomarker Test Results, List Reasons for Not Conducting Testing|Proportion of patients placed on biomarker-directed first treatment regimen vs those who were not|Time span between first systemic therapy as compared to date of initial presentation, date of diagnostic biopsy, date of first visit to a medical oncologist, and date of biomarker test order(s) and result(s).|For Patients who Receive Comprehensive Biomarker Testing, list Types of Test Ordered|For Patients without Biomarker-Directed First Treatment Regimen, Catalog Reasons for Not Prescribing Biomarker-Targeted Therapy|For Patients who Receive Comprehensive Biomarker Testing, list Types of Resulting Treatment Regimen Assigned|Characteristics of Cancer Care Practices: Number of Geographic Clinical Locations Per Practice|Characteristics of Cancer Care Practices: Rural Setting vs Urban Setting at each Practice|Characteristics of Cancer Care Practices: Number of Staff per Practice|Characteristics of Cancer Care Practices: Patient Volume per Practice US Oncology Research All 18 Years and older   (Adult, Older Adult) 7500 Industry Observational Observational Model: Cohort|Time Perspective: Prospective 22285 January 30, 2023 December 2030 December 2030 June 2, 2023 June 2, 2023 Southern Cancer Center, PC, Daphne, Alabama, United States|Arizona Oncology Associates, PC - NAHOA, Prescott Valley, Arizona, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Care Centers of Brevard, Inc., Palm Bay, Florida, United States|Woodlands Medical Specialists, PA, Pensacola, Florida, United States|Affiliated Oncologists, LLC, Chicago Ridge, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Maryland Oncology Hematology, P.A., Silver Spring, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States https://ClinicalTrials.gov/show/NCT05885698 335 NCT05885685 Investigating the Effects of Nabilone on Endocannabinoid Metabolism NABI Not yet recruiting No Results Available Healthy Drug: Nabilone Oral Capsule [11C]CURB binding in the brain|[11C]CURB decreases related to mood related assessments|[11C]CURB decreases related to drug-related effects|[11C]CURB related to blood measurements of endocannabinoids Centre for Addiction and Mental Health All 19 Years to 65 Years   (Adult, Older Adult) Phase 4 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science 098-2017|CAMHPET-CTA-109 June 2023 June 2026 June 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885685 336 NCT05885672 Improving the Early Detection of Cardiometabolic Disease Risk Not yet recruiting No Results Available Metabolic Syndrome Behavioral: Online psychoeducational lifestyle intervention Blood Pressure|Waist Circumference|Fasting blood glucose|Blood lipids|Metabolic syndrome severity score|Insulin|Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)|Tumor necrosis factor-alpha|Body fat percentage|Fat mass|Fat-free mass|Body circumferences|Heart Rate Variability|Cardiac Baroreflex Sensitivity|Flow-mediated changes in vascular diameter|Flow-mediated changes in blood flow|Flow-mediated changes in blood pressure|Flow-mediated changes in vascular conductance|Flow-mediated changes in vascular resistance|Flow-mediated changes in skeletal muscle oxygenation|Passive Limb Movement Mediated Changes in Vascular Diameter|Passive Limb Movement Mediated Changes in Blood Flow|Passive Limb Movement Mediated Changes in Blood Pressure|Passive Limb Movement Mediated Changes in Vascular Conductance|Passive Limb Movement Mediated Changes in Vascular Resistance|Passive Limb Movement Mediated Changes in Skeletal Muscle Oxygenation|Carotid-Femoral Pulse Wave Velocity|Cold Pressor Test Blood Pressure Responses|Cold Pressor Test Heart Rate Responses|Cold Pressor Test Vascular Conductance Responses|Cold Pressor Test Vascular Resistance Responses|Cold Pressor Test stroke volume Responses|Cold Pressor Test Cardiac Output Responses|Metaboreflex Blood Pressure Responses|Metaboreflex Heart Rate Responses|Metaboreflex Vascular Conductance Responses|Metaboreflex Vascular Resistance Responses|Metaboreflex Stroke Volume Responses|Metaboreflex Cardiac Output Responses|Functional Sympatholysis Blood Flow Responses|Functional Sympatholysis Vascular Conductance Responses|Functional Sympatholysis Vascular Resistance Responses|Functional Sympatholysis Blood Pressure Responses|Gait velocity|Stride Length|Stride Width|Gait Cadence|Ankle joint angle|Ankle joint moment|Knee joint angle|Knee joint moment|Hip joint angle|Hip joint moment|Ground reaction forces|Center of pressure - right leg|Center of pressure - left leg|Center of pressure - bilateral|Timed-up and go|Sit-to-stand|Time Up and Down Stairs|Isometric strength|Visceral adipose tissue|Subcutaneous adipose tissue|Motivation and Attitudes Towards Health|Readiness for Behavior Change|Treatment Seeking Behavior|Height|Weight University of Southern Mississippi|University of Mississippi Medical Center All 18 Years to 39 Years   (Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective 23-0446 August 1, 2023 July 31, 2024 July 31, 2024 June 2, 2023 June 2, 2023 University of Southern Mississippi - School of Kinesiology and Nutrition, Hattiesburg, Mississippi, United States https://ClinicalTrials.gov/show/NCT05885672 337 NCT05885659 Smoking Cessation Program for Adults With Type 2 Diabetes Mellitus (DiMe-SALUD2 Project) DiMe-SALUD2 Not yet recruiting No Results Available Tobacco Use Disorder|Diabetes Mellitus, Type 2 Other: Control group (waiting list)|Behavioral: Cognitive Behavioral Treatment (CBT) for smoking cessation|Behavioral: CBT for smoking cessation + DiMeSALUD2 protocol Smoking abstinence|Mean number of days of smoking continuous abstinence|Variability of glycemic levels|Treatment retention|Change in the number of cigarettes smoked per day|Readiness to change smoking behavior|Nicotine dependence|Multidimensional nature of nicotine dependence|Barriers for quitting|Anxiety sensitivity|Anxiety|Depressive symptomatology|Distress tolerance|Diabetes quality of life|Diet|Healthy eating habits|Physical activity|Anthropometric data University of Seville|Andalusian Plan for Research, Development, and Innovation All 18 Years and older   (Adult, Older Adult) Not Applicable 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment ProyExcel_00669 September 1, 2023 December 31, 2025 December 31, 2025 June 2, 2023 June 2, 2023 Carla López Núñez, Sevilla, Spain https://ClinicalTrials.gov/show/NCT05885659 338 NCT05885646 Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes SURF Not yet recruiting No Results Available Importance of Interictal Epileptiform Activity on Sleep EEG Drug: Sulthiame Percentage of patients showing improved sleep EEG at day 14 compared to baseline EEG University Hospital, Angers All 6 Years to 15 Years   (Child) 15 Other Observational Observational Model: Cohort|Time Perspective: Prospective 49RC23_0073 July 2023 July 2024 September 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885646 339 NCT05885633 Endometrial Vitamin D Receptor in PCOS Completed No Results Available Vitamin D Receptor Defect Procedure: endometrial sampling with pipelle The primary aim of the study was to investigate whether there is a difference in VDR expression in the endometrium of PCOS patients compared to controls by qPCR and immunohistochemical methods|To reveal the effects of insulin resistance, HA, OD, and PCOM on endometrial VDR mRNA expression using correlation analyses.|Clinical pregnancy and miscarriage rates Uşak University|Bahçeşehir University|Firat University Female 26 Years to 32 Years   (Adult) Not Applicable 64 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment UsakUn October 21, 2022 January 25, 2023 April 29, 2023 June 2, 2023 June 2, 2023 Usak University Training and Research Hospital, Usak, Turkey https://ClinicalTrials.gov/show/NCT05885633 340 NCT05885620 SAMi Intervention Study to Evakute Smartwatch Interventions Ins Persons With MCI and Dementia SAIN_UMR Completed No Results Available Dementia|Mild Cognitive Impairment|Alzheimer Disease|Dementia With Lewy Bodies|Dementia, Vascular|Dementia, Mixed|Dementia Frontotemporal Device: drinking reminder and cognitive task (smartwatch-based application) Success|Usability|Design|Usefulness|Concerns University of Rostock|German Center for Neurodegenerative Diseases (DZNE)|Fraunhofer Institute All 50 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other A 2020-0071 November 10, 2020 November 10, 2022 November 10, 2022 June 2, 2023 June 2, 2023 Rostock University Medical Center, Rostock, Germany https://ClinicalTrials.gov/show/NCT05885620 341 NCT05885607 Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure EMAS-HF Not yet recruiting No Results Available Heart Failure NYHA Class II|Heart Failure NYHA Class III|Heart Failure Assess the impact of SGLT2i on systemic metabolomic and proteomic profiles|Assess the impact of SGLT21 on ambulation|Assess the impact of SGLT2i on skeletal muscle oxidative phosphorylation capacity (SkM OxPhos)|Assess the impact of SGLT2i on skeletal muscle perfusion during exercise University of Pennsylvania|Amgen All 18 Years and older   (Adult, Older Adult) 40 Other|Industry Observational Observational Model: Cohort|Time Perspective: Prospective 853146 May 30, 2023 May 30, 2024 May 30, 2025 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885607 342 NCT05885594 Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study AUD Not yet recruiting No Results Available Alcohol Use Disorder Drug: [18F]NOS [18F]NOS uptake (distribution volume) in the brain and other organs in body|Amount of c-reactive protein (mg/dl) in blood|Amount of magnetic resonance spectroscopy Glutamate levels (in mM) in the brain University of Pennsylvania All 18 Years to 65 Years   (Adult, Older Adult) Early Phase 1 90 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 851462 July 1, 2023 March 15, 2027 March 15, 2027 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885594 343 NCT05885581 "Grow Well: Addressing Childhood Obesity in Low-income Families" Recruiting No Results Available Diet Habit Other: Arm A Grow Well|Other: Arm B Healthy Steps Efficacy of the adapted intervention on mothers' and caregivers' infant.|Data Collection-Infant Feeding Practices|Data collection-anthropometric data|Data collection-sociodemographic questions University of California, Riverside Female 18 Years and older   (Adult, Older Adult) Not Applicable 90 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention UCRiverside April 5, 2023 February 28, 2024 February 28, 2024 June 2, 2023 June 5, 2023 UC Riverside, Riverside, California, United States "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/81/NCT05885581/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/81/NCT05885581/ICF_001.pdf https://ClinicalTrials.gov/show/NCT05885581 344 NCT05885568 Validation of the Transport of Biological Material by Drone TRANS-AIRGHT Recruiting No Results Available Drone Transport|Biological Samples|Unmanned Aerial System Biological: blood sampling|Other: drone transportation|Other: car transportation Variation of destination arrival between both transportation types|Variation of sample temperature during transportation|Variation of sample allotted time after both transportation types|Variation of sample degradation after both transportation types Centre Hospitalier Universitaire, Amiens|Centre Hospitalier de l'Arrondissement de Montreuil-sur-mer All 18 Years and older   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other PI2023_843_0031 May 1, 2023 August 2023 August 2023 June 2, 2023 June 2, 2023 CHU Amiens Picardie, Amiens, Picardie, France https://ClinicalTrials.gov/show/NCT05885568 345 NCT05885555 A Phase 2 Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Not yet recruiting No Results Available Primary Immune Thrombocytopenia (ITP) Biological: Ianalumab Confirmed response|Time to confirmed response|Duration of confirmed response|Complete Response rate at each timepoint|Response rate at each timepoint|Stable response at 6 months|Stable response at 1 year|Number of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale|Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale|Number of participants who received rescue treatment|Percentage of participants who received rescue treatment|Change from baseline in the frequency of CD19+ B-cell counts|Change from baseline in the absolute number of CD19+ B-cell counts|Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL|Change from baseline in immunoglobulins|Incidence of anti-ianalumab antibodies in serum (ADA assay) over time|Titer of anti-ianalumab antibodies in serum (ADA assay) over time|Ianalumab serum concentrations over time Novartis Pharmaceuticals|Novartis All 18 Years and older   (Adult, Older Adult) Phase 2 40 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CVAY736Q12201|2022-503041-21-00 August 3, 2023 October 15, 2024 October 13, 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885555 346 NCT05885542 SCORE Emerging Adult Cannabis Use & Stress Not yet recruiting No Results Available Cannabis Use Disorder Drug: Cannabidiol oral solution|Drug: Placebo Cannabis withdrawal symptoms|Stress reactivity|Time to resumption of cannabis use Medical University of South Carolina All 18 Years to 25 Years   (Adult) Phase 1|Phase 2 148 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Pro00127995 August 1, 2023 July 31, 2028 July 31, 2028 June 2, 2023 June 2, 2023 Medical University of South Carolina, Charleston, South Carolina, United States https://ClinicalTrials.gov/show/NCT05885542 347 NCT05885529 Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries GUEST Not yet recruiting No Results Available Traumatic Brain Injury Other: UCH-L1 GFAP performance of UCH-L1 and GFAP combined to rule out intracranial complication after MTBI|Performance of UCH-L1 and GFAP combined to rule out intracranial bleeding after MTBI|Comparation of UCH-L1 and GFAP combined or alone, to S100b protein (PS100b)|Predicted impact of using UCH-L1 and GFAP combined|Performance of UCHL-1 and GFAP alone or combined to predict complications Centre Hospitalier Princesse Grace|BioMérieux|Assistance Publique - Hôpitaux de Paris|University Hospital, Clermont-Ferrand|Hospices Civils de Lyon|Poitiers University Hospital|University Hospital, Angers|Centre Hospitalier Universitaire de Nīmes|Centre Hospitalier Universitaire de Nice|CHU de Nantes|University Hospital, Montpellier|Centre Hospitalier Universitaire Dijon|University Hospital, Grenoble|Fondation Hôpital Saint Joseph|CHU de Tours All 18 Years and older   (Adult, Older Adult) 1500 Other|Industry Observational Observational Model: Cohort|Time Perspective: Prospective 22-22 June 30, 2023 December 31, 2023 June 30, 2024 June 2, 2023 June 2, 2023 Centre Hospitalier Universitaire d'Angers, Angers, France|Hôpital Gabriel-Montpied - CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hôpital François Mitterrand - CHU de Dijon, Dijon, France|Hôpital Nord - CHU de Grenoble-Alpes, Grenoble, France|Hospices Civils de Lyon, Lyon, France|Hôpital Lapeyronie - CHU de Montpellier, Montpellier, France|Hôtel Dieu - CHU de Nantes, Nantes, France|Hôpital Pasteur CHU de Nice, Nice, France|Hôpital Carémeau - CHU de Nîmes, Nîmes, France|AP-HP Nord Lariboisière, Paris, France|AP-HP Sorbonne Université, site Pitié-Salpêtrière, Paris, France|Hôpital Saint-Joseph, Paris, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Trousseau - CHRU Tours, Tours, France|Centre Hospitalier Princesse Grace, Monaco, Monaco https://ClinicalTrials.gov/show/NCT05885529 348 NCT05885516 Double vs Single Intrauterine Insemination in Male Factor Infertility Not yet recruiting No Results Available Male Factor Infertility Procedure: intrauterine insemination Rate of clinical pregnancy|Rate of biochemical, ectopic pregnancies and rate of miscarriages Umraniye Education and Research Hospital Female 18 Years to 40 Years   (Adult) Not Applicable 264 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment B.10.1.TKH.4.34.H.GP.0.01/384 June 5, 2023 May 22, 2024 June 15, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885516 349 NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema Not yet recruiting No Results Available Diabetic Macular Edema Biological: RC-28E|Biological: Aflibercept Change from baseline in BCVA at Week 52|Average change in BCVA from baseline over the period week 40 through week 52|Change from baseline in BCVA over time|Proportion of patients gaining >15, >10, >5, or >0 letters in BCVA from baseline at Week 52|Proportion of patients avoiding a loss of >15, >10, >5, or >0 letters in BCVA from baseline at Week 52|Change from baseline in CST at Week 52|Mean change from baseline in CST over a period of week 40 through week 52|Change from baseline in CST over time|Proportion of patients with absence of intraretinal fluid at Week 52|Proportion of patients with absence of subretinal fluid at Week 52|Proportion of patients with absence of intraretinal fluid and subretinal fluid at Week 52|Proportion of patients with a >2-step or>3-step DRS worsening from baseline on ETDRS DRSS at Week 52|Proportion of patients who develop new PDR or high risk PDR at Week 52|Incidence and severity of ocular adverse events and non-ocular adverse events|Plasma concentration of RC28-E over time|Presence of ADAs during the study relative to the presence of ADAs at baseline RemeGen Co., Ltd. All 18 Years and older   (Adult, Older Adult) Phase 3 316 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 28C005 June 2023 June 2026 June 2026 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885503 350 NCT05885490 IReC-Bio Protocol for The International Centre for Recurrent Head and Neck Cancer (IReC) Clinical and Biological Tissue Bank IReC-Bio Not yet recruiting No Results Available Head Cancer Neck Development of a national research tissue bank Royal Marsden NHS Foundation Trust All Child, Adult, Older Adult 10000000 Other Observational Observational Model: Other|Time Perspective: Prospective 5604 July 2023 December 2050 December 2050 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885490 351 NCT05885477 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] 2000-UEP-0001 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885477 352 NCT05885464 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) Recruiting No Results Available Lymphoblastic Lymphoma|T-Cell Lymphoblastic Leukemia/Lymphoma|Lymphoblastic Leukemia Biological: BEAM-201 Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)|Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion|Proportion of patients who achieve MRD negative response (defined as < 0.1%) by flow cytometry or next generation sequencing (NGS) in patients achieving morphologic response|Proportion of patients treated with BEAM-201 deemed appropriate for HSCT based on investigator assessment of clinical response|Duration of Response (DOR)|Relapse-free survival (RFS)|Overall survival|Relapse-related mortality Beam Therapeutics Inc. All 18 Years to 50 Years   (Adult) Phase 1|Phase 2 102 Industry Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BTX-ALO-001 May 25, 2023 December 2031 December 2031 June 2, 2023 June 5, 2023 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05885464 353 NCT05885451 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants Completed No Results Available Chronic Graft-versus-Host Disease (cGVHD) Drug: AMG 592|Other: Placebo Maximum Observed Serum Concentration (Cmax) of AMG 592|Time of Maximum Observed Concentration (tmax) of AMG 592|Area Under the Serum Concentration-time Curve to the Last Measurable Point (AUClast) of AMG 592|Area Under the Concentration-time Curve (AUC) from Time Zero to Infinity (AUCinf)|Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)|Number of Participants who Experience Anti-AMG 592 Antibodies Formation Amgen All 18 Years to 55 Years   (Adult) Phase 1 18 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science 20180132 January 29, 2019 April 11, 2019 April 11, 2019 June 2, 2023 June 2, 2023 Research Site, Randwick, New South Wales, Australia https://ClinicalTrials.gov/show/NCT05885451 354 NCT05885438 ACT for Healthy Living: a Brief Acceptance and Commitment Therapy Intervention for Women With Obesity Not yet recruiting No Results Available Obesity Behavioral: ACT workshop Change from baseline in psychological flexibility at Week 1|Change from baseline in distress tolerance at Week 1|Change from baseline in valued living at Week 1|Change from baseline in psychological flexibility at 1 month|Change from baseline in distress tolerance at 1 month|Change from baseline in valued living at 1 month|Change from baseline in weight self-stigma at Week 1|Change from baseline in weight self-stigma at 1 month|Change from baseline in body image at Week 1|Change from baseline in body image at Month 1|Change from baseline in emotional eating at Week 1|Change from baseline in emotional eating at 1 month|Change from baseline in physical activity at Week 1|Change from baseline in physical activity at 1 month|Change from baseline in diet quality at Week 1|Change from baseline in diet quality at 1 month|Change from baseline in body weight at 1 week|Change from baseline in body weight at 1 month University of Alabama at Birmingham Female 40 Years to 70 Years   (Adult, Older Adult) Not Applicable 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IRB-300010404 June 2023 April 2024 December 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885438 355 NCT05885425 Management of Telemedicine Monitoring of Patients With Chronic Heart Failure Not yet recruiting No Results Available Congestive Heart Failure Chronic Behavioral: Telemedicine correction of medical treatment|Behavioral: Education for proper lifestyle Hospitalization for cardiac reasons|Visit to the emergency room (urgent)|Unplanned visit to cardiology / internist|Calling Quick Medical Assistance home|Fundamental change of treatment (new type of drug, change of drug group, increased dose)|Fundamental changes in the quality of life according to questionnaires Trnava University in Trnava All 45 Years to 75 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Case-Control|Time Perspective: Prospective OPII-VA/DP/2021/9.3-01 September 1, 2023 May 1, 2024 September 1, 2024 June 2, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05885425 356 NCT05885412 A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) Not yet recruiting No Results Available PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) Genetic: RP-A601 Incidence of treatment emergent adverse events (TEAEs)|Incidence of Serious Adverse Events (SAEs)|Identification of Dose Limiting Toxicities (DLTs)|Change in PKP2 myocardial tissue expression|Change in the frequency of clinical markers of life threatening arrhythmias Rocket Pharmaceuticals Inc. All 18 Years and older   (Adult, Older Adult) Phase 1 9 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RP-A601-0323 June 2023 May 2025 May 2026 June 2, 2023 June 2, 2023 University of California, San Diego, La Jolla, California, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05885412 357 NCT05885399 The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment Recruiting No Results Available Pheochromocytoma, Metastatic|Pheochromocytoma Malignant|Paraganglioma, Malignant Drug: Penpulimab The objective response rate (ORR)|The disease control rate (DCR)|progression-free survival (PFS)|biochemical response|Incidence of adverse events Peking Union Medical College Hospital All 15 Years to 75 Years   (Child, Adult, Older Adult) Phase 2 5 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 06086-06 April 1, 2023 March 1, 2025 March 1, 2025 June 2, 2023 June 2, 2023 Peking Union Medical College Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05885399 358 NCT05885386 A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL Recruiting No Results Available Pheochromocytoma|Paraganglioma Drug: Temozolomide The proportion of patients whose tumor change from unresectable to resectable tumor|the objective response rate (ORR)|The ratio of tumor shrinkage.|The biochemical response.|R0 resection rate|Major pathological response rate (MPR)|Pathologic complete remission (pCR)|Safety of temozolomide treatment Peking Union Medical College Hospital All 10 Years to 70 Years   (Child, Adult, Older Adult) Phase 2 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 06086-05 April 1, 2023 October 1, 2025 October 1, 2025 June 1, 2023 June 1, 2023 Peking Union Medical College Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05885386 359 NCT05885373 A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD Recruiting No Results Available Non-Alcoholic Fatty Liver Disease Dietary Supplement: SIM01 Change in CAP score by fibroscan after taking SIM01 for 3 months|Change in liver enzymes (alanine aminotransferase (ALT) and aspartate transaminase (AST)) across the study period.|Change in fasting lipid and HbA1c across the study period.|Change of body mass index (BMI) across the study period.|Change of body waist circumference across the study period.|Change in interleukin-6 (IL-6) across the study period. GenieBiome Limited Female 55 Years and older   (Adult, Older Adult) Not Applicable 40 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other GB-NAFLD March 1, 2023 October 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 GenieBiome Limited, Hong Kong, Hong Kong https://ClinicalTrials.gov/show/NCT05885373 360 NCT05885360 Istradefylline Effect Protocol on Parkinson's Disease Tremor Recruiting No Results Available Parkinson Disease|Tremor Drug: Istradefylline Pill To observe the effect of Istradefylline on tremor in PD patients.|To evaluate the changes in MDS-UPDRS part I (non-motor) in PD patients with tremor.|To evaluate the changes in MDS-UPDRS II motor symptoms in PD patients with tremor.|To evaluate the changes in cognition, mood and behavior in Parkinson's disease patients treated with Istradefylline.|To evaluate the the Geriatric depression scale (GDS) in PD patients with tremor.|To evaluate the effect of Istradefylline on activities of daily living in PD patients with tremor.|To assess the utility of a tremor capturing application such as Mindsquare app.|To assess changes in motor impairment using the Right Eye eye- tracking technology. Georgetown University|Kyowa Kirin, Inc. All 18 Years and older   (Adult, Older Adult) Phase 4 25 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment STUDY00005472 January 20, 2023 September 2023 December 2023 June 1, 2023 June 1, 2023 Georgetown University Hospital, McLean, Virginia, United States https://ClinicalTrials.gov/show/NCT05885360 361 NCT05885347 Innovative Teaching Solutions to Improve the Outcomes of Home Caregivers Enrolling by invitation No Results Available Medication Errors and Other Product Use Errors and Issues Other: 360 videos|Other: VR|Other: AR|Other: Control group Reduction in errors by caregivers at home|IEXPAC Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 227 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention PI00868 February 1, 2023 February 28, 2023 December 31, 2025 June 1, 2023 June 1, 2023 Fundación Fisabio, San Juan De Alicante, Alicante, Spain "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/47/NCT05885347/Prot_SAP_000.pdf https://ClinicalTrials.gov/show/NCT05885347 362 NCT05885334 Caregivers Training Using Artificial Intelligence and Virtual Reality RealityCare Recruiting No Results Available Medication Errors and Other Product Use Errors and Issues|Caring Other: control|Other: Virtual Reality|Other: Augmented reality|Other: 360 videos Reduction in number of caring errors and medication errors Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 333 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention TED2021-130383B-I00 February 1, 2023 December 31, 2023 December 31, 2024 June 1, 2023 June 1, 2023 Fundación Fisabio, San Juan De Alicante, Alicante, Spain https://ClinicalTrials.gov/show/NCT05885334 363 NCT05885321 Exploring the Correlation Between Post Traumatic Stress Disorder, Perceived Stress and Scar Pruritus in Burn Patients Recruiting No Results Available Burns|Scar Pruritus|Post Traumatic Stress Disorder|Perceived Stress the Chinese version of the 5D itch scale|Chinese version of Perceived Stress Scale|Chinese version of the post traumatic diagnostic scale for DSM-5|garmin_Vivosmart 3 National Taiwan University Hospital All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Other|Time Perspective: Prospective 202212108RINC March 6, 2023 December 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 National Taiwan University Hospital, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05885321 364 NCT05885308 Intervening for Increased Quality of Life Among Older People in Sweden Completed No Results Available Physical Inactivity|Mental Health Issue Behavioral: Otago Change in physical activity|Change in leg strength and endurance|Change in depression|Change in Quality Of Life Karlstad University All 65 Years and older   (Older Adult) Not Applicable 45 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention 20210102 April 1, 2022 November 30, 2022 December 1, 2022 June 1, 2023 June 1, 2023 Karlstad University, Karlstad, Varmland, Sweden https://ClinicalTrials.gov/show/NCT05885308 365 NCT05885295 The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3) IC3 Recruiting No Results Available Stroke|Stroke (CVA) or TIA|Dementia, Vascular|Cerebrovascular Disorders|Small Vessel Cerebrovascular Disease|Cognitive Impairment Diagnostic Test: MRI brain, Blood tests, cognitive assessments cognition|MOCA|NIHSS|Lawton and Brody Instrumental activities of daily living (IADL)|MRS Imperial College London All 18 Years and older   (Adult, Older Adult) 700 Other Observational Observational Model: Cohort|Time Perspective: Prospective RGIT / R&D REF: 21HH7075|MRC|299333|CPMS 50479 December 1, 2021 May 15, 2028 May 15, 2028 June 1, 2023 June 1, 2023 Imperial College London, London, United Kingdom https://ClinicalTrials.gov/show/NCT05885295 366 NCT05885282 Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises Enrolling by invitation No Results Available Multiple Sclerosis|Ataxia Device: paraspinal vibration|Device: gastrosoleus muscle complex vibration|Other: Control Exercise Expanded Disability Status Scale|International Cooperative Ataxia Rating Scale|Berg Balance Scale|Trunk Impairment Scale|Limits of Stability and Postural Sways|Gait Analysis|Prone Bridge Test|Lateral Bridge Test|Sorensen Test (Trunk Extensor Test)|Trunk Flexors Test Hacettepe University All 18 Years to 50 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment Local Vibration Application August 1, 2023 June 1, 2024 August 1, 2024 June 1, 2023 June 1, 2023 Hacettepe University Faculty of Health Sciences Department of Physical Therapy and Rehabilitation, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05885282 367 NCT05885269 Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata Completed No Results Available Alopecia Areata Drug: Group A applied topical Clobetasol Propionate|Drug: Group B applied topical Tacrolimus The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight. Combined Military Hospital Abbottabad All 20 Years to 50 Years   (Adult) Phase 1 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CMHAbbottabad2021 November 1, 2022 April 30, 2023 April 30, 2023 June 1, 2023 June 1, 2023 Danyal Sajjad, Abbottabad, Khyber Pakhtunkhwa, Pakistan https://ClinicalTrials.gov/show/NCT05885269 368 NCT05885256 Clinical Assessment of Low Calcium In traUMa (CALCIUM) CALCIUM Recruiting No Results Available Hypocalcemia Diagnostic Test: Amending current standard trauma order set Additional Lab blood Draw Sample Brooke Army Medical Center|University of Colorado, Denver|The University of Texas Health Science Center at San Antonio All 18 Years and older   (Adult, Older Adult) 391 U.S. Fed|Other Observational Observational Model: Cohort|Time Perspective: Prospective H-21-034 September 1, 2022 January 30, 2024 January 30, 2024 June 1, 2023 June 1, 2023 Brooke Army Medical Center, San Antonio, Texas, United States "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/56/NCT05885256/Prot_SAP_000.pdf https://ClinicalTrials.gov/show/NCT05885256 369 NCT05885243 Evaluation of the Efficiency of ESWT and Custom İnsoles Produced With Podometric Measurement in the Treatment of Painful Heel Spurs (ESWT: Extracorporeal Shock Wave Therapy) eswt Recruiting No Results Available Heel Spur|Heel Spur Syndrome|Heel Pain Syndrome Device: ESWT|Device: customized insoles|Combination Product: combined ESWT and custtomized insoles Visual Analog Scale|American Orthopaedic Foot and Ankle Society (AOFAS) Pain Subscale|Foot Function Index Pain Subscale|Roles and Maudsley Score|American Orthopaedic Foot and Ankle Society (AOFAS) Score|Foot Function Index Bezmialem Vakif University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 48 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 4.2019/10 March 1, 2023 June 15, 2023 June 15, 2023 June 1, 2023 June 1, 2023 Bezmialem Vakif University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05885243 370 NCT05885230 Efficacy of Ultrasound Guided PIFB Versus Lidocaine Infusion on Postoperative Pain After Thoracotomy Recruiting No Results Available Cardiac Surgery Procedure: pecto intercostal fascial block using bupivacaine 0.25%|Drug: lidocaine infusion Total dose of morphine in the first 24 h postoperatively.|NRS numerical rating scale.|chronic postoperative pain in 3 and/or 6 months after operation according to numerical rating scale|Time to rescue analgesic|time to extubation|length of intensive care stay Beni-Suef University All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 138 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention FMBSUREC/09042023/Mikhael May 1, 2023 May 2023 May 2024 June 1, 2023 June 1, 2023 Benisuef University Hospital, Banī Suwayf, e\EYGPT, Egypt https://ClinicalTrials.gov/show/NCT05885230 371 NCT05885217 Measurement of Serum microRNA in Acne Vulgaris Patient Not yet recruiting No Results Available Acne Vulgaris Other: measure serum MicroRNA in acne vulgaris Evaluate serum levels of microRNA in acne vulgaris patients South Valley University All 10 Years to 50 Years   (Child, Adult) 120 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional serum microRNA June 2023 April 2024 July 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05885217 372 NCT05885204 RARC vs LRC in A Multicenter Cohort Study Not yet recruiting No Results Available Bladder Cancer Procedure: Robot-assisted radical cystectomy|Procedure: Conventional laparoscopic radical cystectomy Overall Survival|Recurrence-free Survival|Cancer-specific Survival Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University All 18 Years and older   (Adult, Older Adult) 3815 Other Observational Observational Model: Cohort|Time Perspective: Retrospective SYSKY-2023-353-01 June 1, 2023 December 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05885204 373 NCT05885191 True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae in Women Not yet recruiting No Results Available Malnutrition; Protein Other: 2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture True ileal amino acid digestibility|Hemoglobin (Hb)|C-Reactive Protein (CRP)|Appearance of 13CO2 enrichment in breath Diego Moretti|Swiss Distance University of Applied Sciences|Swiss Federal Institute of Technology|St. John's Research Institute|Wageningen University and Research Female 18 Years to 45 Years   (Adult) Not Applicable 5 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other TmD01 July 2023 August 2023 September 2023 June 1, 2023 June 1, 2023 ETH Zurich, Laboratory of Human Nutrition, Zürich, Switzerland https://ClinicalTrials.gov/show/NCT05885191 374 NCT05885178 Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-1 (TRACK-LVO-1) TRACK-LVO-1 Completed No Results Available Stroke, Acute Ischemic|Endovascular Procedures|Large Vessel Occlusion Procedure: Endovascular Therapy Modified ranking scale (mRS) at 90 days|Mortality within 90 days|National Institutes of Health Stroke Scale (NIHSS) scores at 90 days|Occurrence of periprocedural complications|ASPECT score (Alberta Stroke Program Early CT score) Tianjin Huanhu Hospital All 18 Years and older   (Adult, Older Adult) 2910 Other Observational Observational Model: Cohort|Time Perspective: Retrospective TJHH-2023-WeiMing January 1, 2018 November 1, 2021 November 1, 2021 June 1, 2023 June 1, 2023 Tianjin Huanhu Hospital, Tianjin, Tianjin, China https://ClinicalTrials.gov/show/NCT05885178 375 NCT05885165 Supervised Online Resistance Training vs Unsupervised Self-administered Resistance Training for Elders ONTRAEL Recruiting No Results Available Healthy Aging Behavioral: Exercise training Change in 5 times sit-to-stand|Change in 1 repetition maximum (RM) leg press|Change in Fat mass|Change in Fat-free mass|Change in Resting blood pressure|Change in Quality of life (QoL)|Change in Aerobic fitness|Change in Balance|Adherence to exercise|Food records University of Copenhagen|Studnitz Consulting|Aktiv Hele Livet v. Rasmus Stagsted|Aktiv Hele Livet v. Manuel Thomasen|Moustgaard Consulting All 65 Years and older   (Older Adult) Not Applicable 75 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care 514-0396/23-5000 February 20, 2023 November 15, 2023 November 15, 2023 June 1, 2023 June 1, 2023 University of Copenhagen, Copenhagen, Denmark https://ClinicalTrials.gov/show/NCT05885165 376 NCT05885152 Acute Effect of Whole-body Electrical Stimulation in COPD Patients Not yet recruiting No Results Available Chronic Obstructive Pulmonary Disease Other: Whole-body electrical stimulation Peripheral oxygen saturation|Respiratory rate|Heart rate|Systolic blood pressure|Diastolic blood pressure|Dyspnea and Fatigue|Autonomic control|Adverse events|Muscle damage|Muscle fatigue|Delayed onset muscle pain|Peripheral muscle strength Federal University of Health Science of Porto Alegre All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 8 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment WBES_COPD July 1, 2023 August 1, 2023 September 1, 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05885152 377 NCT05885139 Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy EXOCEP2GER Recruiting No Results Available Cerebral Palsy|Spasticity|Muscle|Pain Syndrome|Hemiplegia|Diplegia|Tetraplegia|Balance Device: Exopulse Mollii Suit|Device: Sham Exopulse Mollii Suit Changes in Pediatric Balance Scale (PBS)|Changes in Modified Ashworth Scale (MAS)|Changes in Timed Up and Go (TUG) Exoneural Network AB|Ottobock SE & Co. KGaA|Hannover Medical School|Pohlig GmbH All 5 Years to 12 Years   (Child) Not Applicable 34 Industry|Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment PS00011278C-001 April 17, 2023 December 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 Pohlig GmbH, Traunstein, Bavaria, Germany|Medizinische Hochschule Hannover (MHH), Hanover, Germany https://ClinicalTrials.gov/show/NCT05885139 378 NCT05885126 The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients Enrolling by invitation No Results Available Chemotherapy-induced Nausea and Vomiting|Nursing Caries Other: MANDALA TECHNIQUE Acute Nausea-Vomiting|Genel Comfort Level Ege University All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 38 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention 123456123456 December 1, 2022 June 15, 2023 August 30, 2023 June 1, 2023 June 1, 2023 Gaziantep Islamic and Technology University, Pazarcık, Kahramanmaraş, Turkey|Gaziantep İslamic and Technology University, Gaziantep, Turkey https://ClinicalTrials.gov/show/NCT05885126 379 NCT05885113 Developmental Intervention for Hospitalized Newborns With Congenital Heart Disease Not yet recruiting No Results Available Cardiology|Infant Development|Development Delay Behavioral: NIDCAP Developmental Care NIDCAP Organizational Structures Assessment (OSA))|Neonatal Network Neurobehavioral Scale II (NNNS) of Young Children-Second Edition (DAYC-2)|Developmental Assessment of Young Children-Second Edition (DAYC-2) Boston Children's Hospital All up to 4 Months   (Child) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research IRB-P00044306 July 1, 2023 May 1, 2025 May 1, 2025 June 1, 2023 June 2, 2023 Boston Children's Hospital, Boston, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05885113 380 NCT05885100 Prospective Validation Of The Eleveld TCI Model For Propofol In The Malaysian Obese Population Not yet recruiting No Results Available Total Intravenous Anaesthesia, Eleveld Model, Obes Drug: Eleveld Model evaluate and validate the performance index of the Eleveld TCI model for use in the obese population in Malaysia National University of Malaysia All 18 Years and older   (Adult, Older Adult) Not Applicable 32 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment NN22-140 June 1, 2023 November 30, 2025 December 31, 2025 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05885100 381 NCT05885087 'Extended Balloon Catheter' Labour Induction; a Single Arm Pilot Trial' Completed No Results Available Labor, Induced Device: Foley or balloon catheter Successful labor induction|Adverse event|Acceptability University of Botswana Female 18 Years to 45 Years   (Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment UBR/RES/IRB/BIO/GRAD/145 February 1, 2022 August 1, 2022 September 1, 2022 June 1, 2023 June 1, 2023 Princess Marina Hospital, Gaborone, South East, Botswana https://ClinicalTrials.gov/show/NCT05885087 382 NCT05885074 Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors Not yet recruiting No Results Available Obesity|Weight Loss Drug: Empagliflozin Arm|Other: Control Arm|Other: Exercise capacity VO2 maximum determination|Other: Exercise Challenge Change in Resting Energy Expenditure|Change in Body Weight|Change in Body Mass Index|Change in Waist Circumference|Change in HbA1C levels|Change in lipid profile|Change in HOMA-IR|Change in ESR|Change in CRP|Change in IL-6|Change in TNF-α|Change in glucagon-like peptide-1 (GLP-1)|Change in peptide YY (PYY)|Change in ghrelin|Change in glucose-dependent insulinotropic polypeptide (GIP)|Change in glucagon University of Alabama at Birmingham All 18 Years to 80 Years   (Adult, Older Adult) Phase 2 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science 300011125 June 30, 2023 January 30, 2026 June 30, 2027 June 1, 2023 June 1, 2023 University of Alabama at Birmingham, Birmingham, Alabama, United States https://ClinicalTrials.gov/show/NCT05885074 383 NCT05885061 Effects of Spinal Cord Stimulation Recruiting No Results Available Chronic Pain Device: Spinal cord stimulation Pain intensity University of Aarhus|Aarhus University Hospital All 18 Years to 99 Years   (Adult, Older Adult) Not Applicable 25 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment UAarhus_SCS May 1, 2023 December 31, 2028 December 31, 2028 June 1, 2023 June 1, 2023 Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark https://ClinicalTrials.gov/show/NCT05885061 384 NCT05885048 Impact of Gonadotoxic Therapies on Fertility FertiTOX Not yet recruiting No Results Available Cancer|Fertility Issues|Fertility Preservation|Toxicity Due to Chemotherapy|Toxicity Due to Radiotherapy|Effects of Immunotherapy Diagnostic Test: Blood samples for analysis|Diagnostic Test: Sperm samples for analysis|Other: Satisfaction evaluation|Other: Quality of Life questionnaire Anti-Müllerian hormone (AMH) concentration in females|Sperm concentration in males|Fertility preservation measures performed|Satisfaction with the fertility preservation counselling before the gonadotoxic treatment|Satisfaction with the decision to have undergone fertility preservation measures or not|Number of spontaneous pregnancies and children born|Number of pregnancies and children born with the help of fertility preservation measures|Quality of life assessment Michael von Wolff|University of Bern|Universitätsklinik fur Frauenheilkunde, Inselspital Bern All 14 Years to 50 Years   (Child, Adult) 7000 Other Observational Observational Model: Cohort|Time Perspective: Prospective KEK Bern 2022-02284|KLS 5650-08-2022 June 1, 2023 December 31, 2028 December 31, 2038 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05885048 385 NCT05885035 Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks Active, not recruiting No Results Available Cellulite Drug: Calcium Hydroxyapatite Global Aesthetic Improvement Scale (GAIS) Rating|Cellulite Severity Scale (CSS) Rating|Patient Satisfaction of Aesthetic Appearance|Patient Treatment Satisfaction|Telephone Assessment Kalpna Kay Durairaj, MD, FACS|Merz North America, Inc.|K. Kay Durairaj, MD, FACS, A Medical Corporation Female 21 Years to 50 Years   (Adult) Phase 1 25 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment KD2019 January 1, 2023 September 2023 September 2023 June 1, 2023 June 1, 2023 K. Kay Durairaj, MD, FACS, A Medical Corporation, Pasadena, California, United States https://ClinicalTrials.gov/show/NCT05885035 386 NCT05885022 Feasibility Clinical Evaluation of the Calibreye System Recruiting No Results Available Glaucoma, Open-Angle Device: Calibreye Glaucoma Device Intraocular Pressure|Adverse Events|Glaucoma Medication Usage Myra Vision Inc. All 18 Years and older   (Adult, Older Adult) Not Applicable 30 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CFP-101, CFP-102, CFP-103 May 2023 December 2024 April 2025 June 1, 2023 June 1, 2023 Lions Eye Diabet Clinic, Tbilisi, Georgia|Dr. Agarwal's Eye Hospital Ltd., Chennai, India|Oftalmología Láser de Puebla S.C., Puebla, Mexico https://ClinicalTrials.gov/show/NCT05885022 387 NCT05885009 Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) HOPE-PROSTATE Recruiting No Results Available Metastatic Prostate Cancer Genetic: Liquid Biopsy|Genetic: Archival Tumor DNA sequencing To evaluate the feasibility of a liquid-biopsy based Comprehensive Genomic Panel (CGP) test in the management of mPC patients, following a patient-centric approach|To evaluate the impact of a liquid-biopsy based CGP test in the management of mPC patients, following a patient-centric approach|To describe the genomic landscape of mPC in a real-world population beyond clinical trials using validated targeted sequencing assays in tissue and ctDNA.|To study the feasibility of liquid-biopsy based genomic testing in patient subsets: metastatic hormone-naïve and castration-resistant mPC|To study the concordance rate for key genomic alterations between ctDNA and tumor targeted sequencing (in a subset of patients who have both samples available).|To study the clinical impact of genomic testing in terms of matched therapies prescribed from treating physicians.|Description Overall Survival (OS) among the included patients|Description Progression Free Survival (PFS) of treatments aimed at identified alterations SOLTI Breast Cancer Research Group|Pfizer|AstraZeneca|Merck Sharp & Dohme LLC|Advanced Accelerator Applications|Astellas Pharma Inc|Guardant Health, Inc. Male 18 Years and older   (Adult, Older Adult) 240 Other|Industry Observational Observational Model: Other|Time Perspective: Prospective SOLTI-2102 March 28, 2023 March 28, 2026 March 28, 2028 June 1, 2023 June 1, 2023 SOLTI Cancer Research Group, Barcelona, Spain https://ClinicalTrials.gov/show/NCT05885009 388 NCT05884996 Kabat Training Program With Elastic Bands for Shoulder in Amateur Swimmers Not yet recruiting No Results Available Healthy Other: PNF training change in ROM external rotation of the shoulder in degrees|change in ROM internal rotation of the shoulder in degrees|change in external rotation isometric strength of the shoulder in newton|change in internal rotation isometric strength of the shoulder in newton|change in scapular displacement in maximum flexion in centimeters Universidad Europea de Madrid Male 18 Years to 40 Years   (Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention THERA2020 May 2023 July 2023 October 2023 June 1, 2023 June 1, 2023 Universidad Europea de Madrid, Villaviciosa De Odón, Madrid, Spain "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/96/NCT05884996/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/96/NCT05884996/ICF_001.pdf https://ClinicalTrials.gov/show/NCT05884996 389 NCT05884983 Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma Recruiting No Results Available Nasopharyngeal Carcinoma Procedure: participants will undergo dual-energy CT and endoscopy Sensitivity and specificity of dual-energy CT and endoscopy in the diagnosis of nasopharyngeal carcinoma|Positive and negative predictive values of dual-energy CT and endoscopy in the diagnosis of nasopharyngeal carcinoma Zhongshan People's Hospital, Guangdong, China All 30 Years to 69 Years   (Adult, Older Adult) 12000 Other Observational Observational Model: Cohort|Time Perspective: Prospective NPC-PRO-004 February 1, 2023 December 31, 2023 December 31, 2024 June 1, 2023 June 1, 2023 Zhongshan People's Hospital, Zhongshan, Guangdong, China https://ClinicalTrials.gov/show/NCT05884983 390 NCT05884970 In Vivo Efficacy of Salbutamol (Sandoz) Versus Salbutamol Ventolin (GSK) in Children With Asthma Salsa Recruiting No Results Available Agents, Anti Asthmatic|Asthma in Children Drug: "100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Sandoz"|Drug: "100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Ventolin GSK"|Drug: "100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Sandoz"|Drug: "100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Ventolin GSK" FEV1 (%) 100ug salbutamol|VAS 100ug salbutamol|FEV1 (%) 400ug salbutamol|VAS 400ug salbutamol Canisius-Wilhelmina Hospital All 4 Years to 14 Years   (Child) Phase 3 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment NL67238.091.19 March 30, 2023 March 2024 September 2024 June 1, 2023 June 1, 2023 Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands https://ClinicalTrials.gov/show/NCT05884970 391 NCT05884957 Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction Not yet recruiting No Results Available Erectile Dysfunction|Diabetes Mellitus Procedure: Nitric oxide synthase gene ِAssessments of endothelial nitric oxide synthase In diabetes mellitus|Tadalafil 5milligram (tablets) therapy in diabetic patients Egymedicalpedia Male 40 Years to 70 Years   (Adult, Older Adult) Not Applicable 40 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment Mona Hamza June 1, 2023 December 15, 2023 January 1, 2024 June 1, 2023 June 1, 2023 Qena Hospital, Qinā, Egypt https://ClinicalTrials.gov/show/NCT05884957 392 NCT05884944 Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients Recruiting No Results Available Parkinson Disease|Osteopathy in Diseases Classified Elsewhere Procedure: Sham- Light touch, not reaching restrictive barrier|Procedure: Experimental: Interventional Group- OMM- Muscle energy Mechanical stress via the MyotonPro|Dynamic Stiffness via the MyotonPro|Step Cycle time via the Biodex Gait Trainer 3|Average step length via the Biodex Gait Trainer 3|Step Symmetry- time on each foot via the Biodex Gait Trainer 3|Goniometer- Hip ROM (Flexion and Extension)|Goniometer- Hip ROM Flexion|Goniometer- Hip ROM Extension|Goniometer- Knee ROM - Flexion|Goniometer- Knee ROM - Extension|Goniometer- Ankle ROM- Dorsiflexion|Goniometer- Ankle ROM- Plantarflexion|The Timed Up & Go- 3 Meter walk|Lower Extremity Functional Scale (LEFS) New York Institute of Technology All 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment BHS-1850 June 2023 March 2024 August 2024 June 1, 2023 June 1, 2023 NYIT College of Osteopathic Medicine, Old Westbury, New York, United States https://ClinicalTrials.gov/show/NCT05884944 393 NCT05884931 Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment Recruiting No Results Available GastroIntestinal Bleeding Device: Nexpowder|Procedure: Conventional Treatment Rate of rebleeding within 7 days of successful endoscopic hemostasis|Rate of rebleeding within 30 days of successful endoscopic hemostasis Except for cases of rebleeding within 7 days of successful endoscopic hemostasis)|Check for haemostasis within 5 minutes from the moment of application of Nexpowder Analysis of patients with bleeding during the initial hemostasis experimental group|Perforation incidence|Death rate|Blood transfusion case rate|Number of Nexpowder applications (experimental group)|Number of usage of Nexpowder (experimental group)|Incidence of device malfunction (experimental group)|Rate of ease of use (experimental group) Next Biomedical Co., Ltd. All 19 Years and older   (Adult, Older Adult) Not Applicable 66 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Nexpowder_02 October 18, 2022 August 12, 2023 October 18, 2023 June 1, 2023 June 1, 2023 Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chungnam National University Sejong Hospital, Sejong, Korea, Republic of https://ClinicalTrials.gov/show/NCT05884931 394 NCT05884918 Intraoperative Hypotension in High-risk Patients Undergoing Surgery IRIoHYP Recruiting No Results Available Anesthesia|Hypotension on Induction|Perioperative Injury|Perioperative Hypotension Incidence of intraoperative hypotension (IOH)|Risk factors of IOH.|Development of a risk scale for IOH (MAP < 65mmHg) based on the identified risk factors in the study.|Determination of indications for intraoperative extended hemodynamic monitoring.|Assessment of the incidence, duration, and depth of hypotension as a complication of general anesthesia at each stage of anesthesia.|Evaluation of the relationship between the depth and duration of hypotensive episodes and the occurrence of postoperative complications within 30 days of the surgical procedure.|Analysis of the anesthesiologist's management approach in the event of hypotensive episodes or hypotension risks and an attempt to establish an optimal management strategy for its occurrence. Mazovia Regional Hospital in Siedlce All 18 Years and older   (Adult, Older Adult) 2000 Other Observational Observational Model: Case-Control|Time Perspective: Prospective 1/2023 March 2, 2023 January 1, 2025 January 31, 2025 June 1, 2023 June 1, 2023 Mazovian Regional Hospital, Siedlce, Mazovian, Poland https://ClinicalTrials.gov/show/NCT05884918 395 NCT05884905 Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration Recruiting No Results Available Renal Insufficiency|Cis-Platinum Nephropathy Procedure: short hydration|Procedure: conventional hydration renal dysfunction at least grade 1 following cisplatin treatment in short hydration group|renal dysfunction >= grade 2 following cisplatin treatment in short hydration group|rate of cisplatin modification due to adverse effects in short hydration group Mahidol University|Siriraj Hospital All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment si186/2023 March 7, 2023 January 7, 2025 March 7, 2025 June 1, 2023 June 1, 2023 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand https://ClinicalTrials.gov/show/NCT05884905 396 NCT05884892 Egyptian Hypertrophic Cardiomyopathy Program Recruiting No Results Available Hypertrophic Cardiomyopathy Incidence of HCM in Egypt|Determinants of clinical severity of HCM in Egypt|Determinants of cardiac phenotype severity of HCM in Egypt|Determinant of genotype severity of HCM in Egypt|Study the basic mechanisms responsible for the HCM in Egypt Magdi Yacoub Heart Foundation All Child, Adult, Older Adult 2000 Other Observational Observational Model: Cohort|Time Perspective: Prospective AHC-HCM January 1, 2014 January 1, 2030 January 1, 2030 June 1, 2023 June 1, 2023 Aswan Heart Centre - Magdi Yacoub Heart Foundation, Aswan, Egypt https://ClinicalTrials.gov/show/NCT05884892 397 NCT05884879 Listening Effort in Tinnitus Patients ALERT Recruiting No Results Available Listening Effort|Tinnitus Behavioral: Tinnitus simulation Listening effort|Listening effort predictability of tinnitus related questionnaire: TQ|Listening effort predictability of tinnitus related questionnaire: TFI|Listening effort predictability of tinnitus related questionnaire: HADS Maastricht University Medical Center All 18 Years to 39 Years   (Adult) 80 Other Observational Observational Model: Cohort|Time Perspective: Prospective 301849 April 6, 2023 October 31, 2023 July 31, 2024 June 1, 2023 June 1, 2023 Maastricht UMC+, Maastricht, Limburg, Netherlands https://ClinicalTrials.gov/show/NCT05884879 398 NCT05884866 A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. DapaBalci-Leap Recruiting No Results Available Chronic Renal Failure|Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis Drug: Dapagliflozin 10mg Tab|Drug: Balcinrenone 50mg Capsule|Drug: Balcinrenone 100mg Capsule|Drug: Dapagliflozin matching Placebo|Drug: Balcinrenone 50mg matching Placebo|Drug: Balcinrenone 100mg matching Placebo To show that treatment with balcinrenone preserves the beneficial dapagliflozin-driven increase in 24h renal glucose excretion|To demonstrate that the dapagliflozin induced increase in urine solute concentration is not altered by balcinrenone|To demonstrate that treatment with dapagliflozin, with or without balcinrenone reduces free-water clearance within 48h, and further urine concentration is observed after 4 weeks|To demonstrate that treatment with dapagliflozin, with or without balcinrenone, increases the contribution of glucose to osmoticdiuretic volume formation within 48h, and that this effect persists after 4 weeks|To demonstrate that treatment with dapagliflozin, with or without balcinrenone, decreases the contribution of sodium and urea to osmotic-diuretic volume formation within 48h, and that this effect persists after 4 weeks|To demonstrate that treatment with dapagliflozin, with or without balcinrenone, does not change the contribution of potassium to osmotic-diuretic volume formation within 48h, and that this effect persists after 4 weeks|To demonstrate that treatment with dapagliflozin with or without balcinrenone does not change body water content after 4 weeks|To demonstrate that patients treated with dapagliflozin alone or in combination with balcinrenone show increased plasma copeptin levels within 48h and/or after 4 weeks|To demonstrate that patients treated with dapagliflozin alone or in combination balcinrenone show increased plasma glucagon and reduced plasma insulin levels within 48h and/or after 4 weeks Klinikum Nürnberg All 50 Years and older   (Adult, Older Adult) Phase 2 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment CT114-2022-01|2022-002721-99 May 8, 2023 January 31, 2025 January 31, 2025 June 1, 2023 June 1, 2023 Assistance Publique-Hopitaux de Marseille (AP-HM), Marseille, France|Klinikum Nuernberg, Nuremberg, Bavaria, Germany https://ClinicalTrials.gov/show/NCT05884866 399 NCT05884853 The Plasticity of Social Brain Network in Adults With Autism Spectrum Disorder Recruiting No Results Available Autism Spectrum Disorder Behavioral: PEERS Autism Diagnostic Interview Revised, ADIR|The Autism Diagnostic Observation Schedule, ADOS|Autism Spectrum Quotient|Social responsiveness scale|Quality of socialization questionnaire|Empathy quotient National Taiwan University Hospital All 18 Years to 50 Years   (Adult) Not Applicable 120 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 202012163RIND January 1, 2021 July 31, 2024 July 31, 2024 June 1, 2023 June 1, 2023 National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan https://ClinicalTrials.gov/show/NCT05884853 400 NCT05884840 New Cardiovascular Risk Screening Strategy. HELENA Not yet recruiting No Results Available Cardiovascular Prevention|Screening|Peripheral Artery Disease|Arteriosclerosis|Asymptomatic Diagnostic Test: HELENA Hard coronary heart disease (CHD)|Major adverse cardiovascular event (MACE)|All-cause mortality|Tabaco consumption (CVD risk factors improvement assessment)|Lipid profile (CVD risk factors improvement assessment)|Systolic and diastolic pressure (CVD risk factors improvement assessment)|Weight (CVD risk factors improvement assessment)|Height (CVD risk factors improvement assessment)|BMI (CVD risk factors improvement assessment)|Glycaemia (CVD risk factors improvement assessment)|Glycated haemoglobin (CVD risk factors improvement assessment)|Creatinine (CVD risk factors improvement assessment)|Proteinuria (CVD risk factors improvement assessment)|Albumin-to-creatinine ratio (ACR) (CVD risk factors improvement assessment)|Glomerular filtrate rate (CVD risk factors improvement assessment)|Coronary heart disease|Cerebrovascular disease|Cardiovascular disease|Lipid lowering medication Adverse effects Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina|Hospital del Mar Research Institute (IMIM)|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|Institut Català de la Salut|Biocruces Bizkaia Health Research Institute All 50 Years to 74 Years   (Adult, Older Adult) Not Applicable 54000 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention SLT/21/000015 June 2023 June 2026 June 2026 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884840 401 NCT05884827 Peroneal Nerve Dysfunction in Epiphyseal Transfer Not yet recruiting No Results Available Epiphyseal Arrest Device: EMG Assessment of peroneal nerve dysfunction after proximal fibular epiphyseal harvesting Assiut University All 18 Months to 14 Years   (Child) 15 Other Observational Observational Model: Case-Only|Time Perspective: Prospective EMG in Epiphyseal transfer June 1, 2023 August 2024 September 2024 June 1, 2023 June 1, 2023 Omar, Assiut, Egypt https://ClinicalTrials.gov/show/NCT05884827 402 NCT05884814 Timing of Resistance Exercise in Type 1 Diabetes T-REX Not yet recruiting No Results Available Type 1 Diabetes Behavioral: Morning exercise|Behavioral: Afternoon exercise|Behavioral: Habitual physical activity levels Change in muscle strength|Change in interstitial glucose time in range|Change in appendicular skeletal muscle mass|Change in whole body fat mass|Change in physical function|Change in HbA1c|Change in interstitial glucose average|Change in interstitial glucose variability|Change in interstitial glucose time in hypoglycaemia|Change in interstitial glucose time in hyperglycaemia Dasman Diabetes Institute All 21 Years to 60 Years   (Adult) Not Applicable 54 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RA HM-2023-009 July 1, 2023 December 31, 2024 December 31, 2024 June 1, 2023 June 1, 2023 Dasman Diabetes Institute, Kuwait City, Kuwait https://ClinicalTrials.gov/show/NCT05884814 403 NCT05884801 Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors Not yet recruiting No Results Available Advanced Solid Tumor Drug: QLS1103 Maximum tolerated dose (MTD)|Recommended dose for phase II (RP2D)|Adverse events(AEs) / Serious adverse events(SAEs)|Maximum observed plasma concentration (Cmax) of QLS1103|Time of maximum observed plasma concentration (Tmax) of QLS1103|Area under the plasma concentration-time curve (AUC) of QLS1103|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Progression free survival (PFS) Qilu Pharmaceutical Co., Ltd. All 18 Years and older   (Adult, Older Adult) Phase 1 148 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment QLS1103-101 June 30, 2023 January 30, 2025 July 30, 2025 June 1, 2023 June 1, 2023 Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05884801 404 NCT05884788 Study of the Life Stories of Patients Making a Request for Euthanasia, in the Context of Advanced Cancer. RECIFE Not yet recruiting No Results Available Advanced Cancer Other: free interview, and questionnaires in a second time Description of the life stories of patients requesting euthanasia to explore which life experiences are brought forward when making this request, in a context of advanced oncological pathology.|Calculation of the Bartholomew score|Calculation of the distress thermometer's score Centre Leon Berard All 18 Years and older   (Adult, Older Adult) 15 Other Observational Observational Model: Case-Only|Time Perspective: Prospective ET22000324 June 2023 March 2024 March 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884788 405 NCT05884775 Novel Digital Patient-Reported Outcomes Tool for Diabetes Management Not yet recruiting No Results Available Type 2 Diabetes Other: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool Change in Hemoglobin A1C (HbA1c)|Percentage of Patients Eligible for Participation in Trial who Enroll|Percentage of PCP Practices Eligible for Participation in Trial that Enroll|Percentage of Providers who View PRO Reports|Percentage of Patients who Respond to PRO Text Messages|Percentage of Patients who View PRO Interactive Dashboard|Mean Number of EHR Reports Viewed by Providers|Total Number of EHR Reports Viewed by Providers|Percentage of PRO Messages Responded To by Patients|Mean Number of PRO Messages Responded To by Patients|Total Number of PRO Messages Responded To by Patients|Mean Number of Reports Viewed by Patients via PRO Interactive Dashboard|Total Number of Reports Viewed by Patients via PRO Interactive Dashboard NYU Langone Health|Agency for Healthcare Research and Quality (AHRQ) All 18 Years and older   (Adult, Older Adult) Not Applicable 353 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research 23-00608 November 2023 January 1, 2028 May 1, 2028 June 1, 2023 June 1, 2023 NYU Langone Health, New York, New York, United States https://ClinicalTrials.gov/show/NCT05884775 406 NCT05884762 earlY Upper Limb Rehabilitation WIth EEG-Neurofeedback After Stroke YUWIN-Stroke Not yet recruiting No Results Available Stroke|Stroke Hemorrhagic|Stroke, Ischemic|Stroke Rehabilitation|Brain Infarction Other: electroencephalographic neurofeedback|Other: SHAM electroencephalographic neurofeedback Measurement of motor impairment by the Fugl-Meyer Assesment - Upper Extremity Rennes University Hospital|Fondation de l'Avenir All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 35RC22_9743_YUWIN-Stroke|2023-A01150-45 September 1, 2023 February 1, 2025 February 1, 2025 June 1, 2023 June 1, 2023 Rennes Chu, Rennes, France https://ClinicalTrials.gov/show/NCT05884762 407 NCT05884749 Peer to Community (P2C) Model: A Pilot Randomized Controlled Trial Active, not recruiting No Results Available Social Inclusion|Mental Illness|Substance Use Disorders Behavioral: Peer to Community (P2C) Model|Behavioral: Care as Usual (UC) Change in Community Integration|Change in meaningful activity engagement|Change in mental well-being|Change in substance use Western University, Canada|Providence Care Hospital, Kingston, ON, Canada|Trellis HIV and Community Care, Kingston, ON, Canada All 16 Years and older   (Child, Adult, Older Adult) Not Applicable 28 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research P2CPilot May 15, 2023 May 19, 2024 September 1, 2025 June 1, 2023 June 1, 2023 Western University, London, Ontario, Canada https://ClinicalTrials.gov/show/NCT05884749 408 NCT05884736 Confirming Permanent Lack of Blood Flow to the Brain During A-NRP DCC Organ Transplant CONCLUDE Not yet recruiting No Results Available Organ Transplant Other: Neuromonitoring Donor resumption of brain blood flow and/or activity|Donor accrual rate|Consent rate|Neuromonitoring modalities|Duration and proportion of neuromonitoring signal|Neuromonitoring failure Western University, Canada|University Health Network, Toronto All 18 Years to 75 Years   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective 4436 September 2023 September 2024 March 2025 June 1, 2023 June 1, 2023 Toronto Western Hospital, Toronto, Ontario, Canada https://ClinicalTrials.gov/show/NCT05884736 409 NCT05884723 Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis Not yet recruiting No Results Available Liver Steatoses|Liver Metastasis Colon Cancer|NAFLD Dietary Supplement: Ketogenic Diet Perioperative blood transfusion|Amount of perioperative blood transfusion|Intraoperative blood loss|Steatosis|Change in steatosis|Operative time|Postoperative complications|Postoperative length of hospital stay|Postoperative hospital readmission|Postoperative rates of reoperation|Postoperative liver failure|Postoperative mortality|Adherence to ketogenic diet|Disease recurrence|Measurement of circulating cell-free tumor DNA|Cancer-related mortality Western University, Canada All 18 Years and older   (Adult, Older Adult) Not Applicable 124 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment 122435 July 2023 July 2025 July 2030 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884723 410 NCT05884710 Effectıveness of Foot Core Exercises on paın and functıonal Performance ın patıents wıth Patellofemoral paın Syndrome Recruiting No Results Available Patellofemoral Pain Syndrome Other: Foot core exercises|Other: Conventional Physiotherapy Visual Analog Scale|10 meter walk test|Timed up and go test|Stair climb test|International Physical Activity Questionnaire|SF-36 short form|Knee and ankle ROM Yeditepe University All 20 Years to 59 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 777 June 1, 2023 July 15, 2023 July 30, 2023 June 1, 2023 June 1, 2023 Yeditepe University, Istanbul, İnönü Mah. Kayışdağı Cad. 326a. 26 Ağustos Yerleşimi, Turkey https://ClinicalTrials.gov/show/NCT05884710 411 NCT05884697 Let's K-Talk - HPV Study for Ethnic Koreans Recruiting No Results Available Human Papillomavirus Viruses|Papillomavirus Vaccines Other: K-Talk Intervention (Storytelling and K-Bot)|Other: Storytelling Intervention|Other: K-Bot Intervention|Other: Written Information Number of participants who completed 3 doses of HPV vaccines at 12-months|Number of participants who completed 3 doses of HPV vaccines at 6-months|Number of participants who received at least one dose of HPV vaccine at 3-month|Number of participants who received at least one dose of HPV vaccine at 6-month|Number of participants who received at least one dose of HPV vaccine at 12-month|Assessment of Knowledge about HPV and HPV Vaccines: A 34-Item Survey (True/False/I don't know)|Assessing Perceived Risk of HPV and Other STIs: A 17-Item Survey (on a 1-5 Likert scale)|Assessment of Intention to Receive HPV Vaccine: Two Items Self-Report University of Cincinnati All 18 Years to 26 Years   (Adult) Not Applicable 160 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention HPV Study for Ethnic Koreans May 10, 2023 December 31, 2024 July 31, 2025 June 1, 2023 June 1, 2023 Minjin Kim, Cincinnati, Ohio, United States https://ClinicalTrials.gov/show/NCT05884697 412 NCT05884684 What is the Potential Impact of Reviewing Post-procedure Images With Patients Following Interventional Spine Procedures. Not yet recruiting No Results Available Patient Satisfaction Other: Reviewing Imaging with Participant Modified Press Gainey Satisfaction (PGS) Questionnaire|Patient Global Impression of Change (PGIC) University of Michigan All Child, Adult, Older Adult Not Applicable 200 Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care HUM00216837 June 2023 December 2023 December 2023 June 1, 2023 June 1, 2023 University of Michigan - Burlington Building, Ann Arbor, Michigan, United States https://ClinicalTrials.gov/show/NCT05884684 413 NCT05884671 Dopamine and Cognition Completed No Results Available Effect of Sulpiride on Working Memory Gating and Associated BOLD Signal in the Striatum|Effect of Sulpiride on the Influence of the Average Reward Rate on Perceptual Evidence Accumulation|Effect of Sulpiride on the Influence of the Average Reward Rate on Cognitive Effort Allocation Drug: Sulpiride 400 MG|Drug: Placebo Working memory gating task: Reaction time|Working memory gating task: Accuracy|Working memory gating task: BOLD-response|Simon task: Accuracy|Simon task: Reaction time|Perceptual decision-making task: Accuracy|Perceptual decision-making task: Reaction time|Eye-blink rate|Operation Span test|Digit Span test|Beck Depression Inventory|Barratt Impulsiveness Scale|Behavioural Inhibition Scale/Behavioural Activation Scale|State and Trait Anxiety Inventory|Utrechtse Burnout Schaal/Maslach Burnout Inventory|Covid-19 Stress Scales Donders Centre for Cognitive Neuroimaging|Dr. Hanneke den Ouden, Donders Centre for Cognition, Radboud University|Dr. Rebecca Calcott, Donders Centre for Cognitive Neuroimaging, Radboud University|Prof. Dr. Robbert-Jan Verkes, Radboud University Medical Centre Department of Psychiatry|Floortje Spronkers, Donders Centre for Cognition, Radboud University|Funding: NWO + KNAW All 18 Years to 45 Years   (Adult) Not Applicable 47 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science 3017048.09 September 23, 2021 July 12, 2022 July 12, 2022 June 1, 2023 June 1, 2023 Donders Centre for Cognition, Radboud University, Nijmegen, Gelderland, Netherlands https://ClinicalTrials.gov/show/NCT05884671 414 NCT05884658 Hysterectomy by Transvaginal Natural Orifice Transluminal Endoscopic Surgery Versus or Laparoscopic Hysterectomy vNOTESHC Not yet recruiting No Results Available Hysteromyoma Procedure: vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|Procedure: laparoscopic hysterectomy Proportion of patient with complications|Conversion Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France Female 18 Years and older   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 21PH265 June 1, 2023 June 1, 2026 August 31, 2026 June 1, 2023 June 1, 2023 HFME - Hospices Civils de Lyon, Bron, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|Ch Issoire, Issoire, France|CHU Saint-Etienne, Saint-Étienne, France|Clinique Mutualiste de Saint-Etienne, Saint-Étienne, France https://ClinicalTrials.gov/show/NCT05884658 415 NCT05884645 Artificial Intelligence in Paediatric Video IntubaTION (VITION-AI) VITION-AI Active, not recruiting No Results Available Pediatric ALL|Intubation Complication|Intubation; Difficult or Failed Procedure: Video-directed endotracheal intubation Anatomical landmarks.|Time consumption of the course.|Number of attempts.|Successful endotracheal intubation.|Overall course success.|Severe oxygen desaturations|Non-severe TIAEs|Severe TIAEs Lise Aunsholt|Copenhagen Academy for Medical Education and Simulation|Rigshospitalet, Denmark All up to 5 Years   (Child) 250 Other Observational Observational Model: Cohort|Time Perspective: Prospective VITION-AI May 1, 2023 June 1, 2024 June 1, 2025 June 1, 2023 June 1, 2023 Rigshospitalet, København, Denmark https://ClinicalTrials.gov/show/NCT05884645 416 NCT05884632 Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients DART-PHASER Recruiting No Results Available Prostate Cancer Radiation: Daily Adaptive RadioTherapy Acute gastrointestinal toxicity|Acute genitourinary toxicity|Late toxicity|QLQ-C30|Biochemical failure|Time to biochemical failure|Local in-field relapse|Metastases-free survival IRCCS Sacro Cuore Don Calabria di Negrar Male 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 184 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-51 April 3, 2023 April 30, 2030 April 30, 2030 June 1, 2023 June 1, 2023 IRCCS Sacro Cuore Don Calabria di Negrar, Negrar, Verona, Italy https://ClinicalTrials.gov/show/NCT05884632 417 NCT05884619 Efficacy and Safety of Dual-target DBS for Treatment-resistant Alcohol Use Disorder Not yet recruiting No Results Available Alcohol Use Disorder|Deep Brain Stimulation Device: Dual-target deep brain stimulation Heavy drinking rate|Cumulated uncontrolled alcohol use days|Maximum consecutive alcohol abstinent days|Alcohol use volume|Cumulated alcohol abstinent days|Subjective alcohol craving|Alcohol withdrawal scores|Sleep status|affect status|Social functionings Second Xiangya Hospital of Central South University|Shanghai Mental Health Center|Huashan Hospital|Shanghai 6th People's Hospital|SceneRay Corporation, Limited All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 12 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SR1182-AUD-I June 15, 2023 December 30, 2024 December 30, 2024 June 1, 2023 June 1, 2023 Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Huashan Hospital, Shanghai, Shanghai, China|Shanghai 6th People's Hospital, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05884619 418 NCT05884606 The Allurion Digital Behaviour Change Intervention Completed No Results Available Obesity Device: Allurion Digital Behaviour Change Intervention Change in percent total body weight loss (percent TBWL)|Change in mental wellbeing|Change in anxiety|Change in quality of life|Change in loss of control over eating|Change in self-efficacy|Change in barriers to exercise|Time spent in physical activity steps (daily number of steps)|Engagement with Health Coaching|Engagement with the mobile and web app|Patient satisfaction Allurion Technologies All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 107 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TRL-1000-0005 June 19, 2021 May 6, 2022 November 6, 2022 June 1, 2023 June 1, 2023 Allurion Kliniek, Nederland, AB Hilversum, Netherlands|Nederlandse Obesitas Kliniek (NOK), Amsterdam, Netherlands|Medizen Aesthetic Clinic, Sutton Coldfield, Birmingham, United Kingdom|Monkhouse Surgical, Bromley, Kent, United Kingdom https://ClinicalTrials.gov/show/NCT05884606 419 NCT05884593 Analysis of Pedicle Screw Accuracy to Plan Using Medtronic Mazor Robotic System Active, not recruiting No Results Available Spinal Deformity|Spinal Infection|Trauma|Neoplastic Processes|Degenerative Spinal Conditions Device: Pedicle screw instrumentation using Mazor X robotic system Total deviation (mm) from the pre-planned screw entry point|Accuracy assessment for degree of pedicle breach Ohio State University|Medtronic All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2020H0434 March 5, 2021 July 31, 2022 December 31, 2023 June 1, 2023 June 1, 2023 The Ohio State University Wexner Medical Center Neurological Surgery, Columbus, Ohio, United States https://ClinicalTrials.gov/show/NCT05884593 420 NCT05884580 Neuflo System for the Treatment of BPH Not yet recruiting No Results Available Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms Device: Neuflo BPH Treatment System Effectiveness: Relief of BPH symptoms as measured by international prostate symptom score (IPSS)|Improvement in urinary function, sexual function, and quality of life|Treatment tolerability & procedural medication requirements|Secondary intervention and medication use for Lower Urinary Tract Symptoms (LUTS)|Neuflo System performance|Change in prostate volume|Maintenance of improvement of LUTS|Participant satisfaction ProstaCare Pty Ltd Male 45 Years and older   (Adult, Older Adult) Not Applicable 25 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Neuflo-CIP-ANZ-202303 June 2023 September 2024 December 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884580 421 NCT05884567 Effectiveness of Neck Isometric Exercises and Cervical Mobilization on Cervical Radiculopathy Completed No Results Available Cervical Radiculopathy Other: Isometric exercises|Other: Mobilization Numeric Pain Rating Scale|Range of motion Neuro Counsel Hospital, Pakistan|Al Nafees Medical Hospital, Islamabad|National Institute of Rehabilitation Medicine, Islamabad, Pakistan All 25 Years to 50 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other 342 January 10, 2023 May 9, 2023 May 9, 2023 June 1, 2023 June 1, 2023 Al Nafees Medical Hospital, Islamabd, Islamabad, Federal, Pakistan https://ClinicalTrials.gov/show/NCT05884567 422 NCT05884554 A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883. Not yet recruiting No Results Available COVID-19 Drug: PF-07817883 Maximum Observed Plasma Concentration (Cmax) of PF-07817883|Area Under the Plasma Concentration-time Profile from Time Zero to Extrapolated Infinite Time (AUCinf)|Area Under the Plasma Concentration-time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)|Number of Participants with Non-Serious Adverse Events|Number of Participants with Treatment Emergent Adverse Events|Number of Participants with Clinically Significant ECG Abnormalities|Number of Participants with Clinically Significant Abnormal Vital Signs|Number of Participants with Clinically Significant Abnormal Laboratory Values|Number of Participants with Serious Adverse Events Pfizer All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 40 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science C5091014 May 27, 2023 December 1, 2023 December 1, 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884554 423 NCT05884541 Promoting Math in Young Children: Leveraging Pediatric Clinics to Reach Underrepresented Children in Rural Communities MATH Not yet recruiting No Results Available Early Math Learning Other: TipsbyText Messages Change in child early math skills measured by the Research-based Early Math Assessment (REMA-Brief)|Change in child literacy measured by the Phonological Awareness Literacy Screening Tools (PALS-PreK) Score|Change in parent confidence teaching math and literacy by the Development and Research in Early Math Education (DREME) Oregon Health and Science University|Stanford University All 36 Months to 59 Months   (Child) Not Applicable 1000 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other 1021594 May 2023 September 30, 2024 August 31, 2025 June 1, 2023 June 1, 2023 Oregon Rural Practice Research Network, Portland, Oregon, United States https://ClinicalTrials.gov/show/NCT05884541 424 NCT05884528 Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia RELY-CD Not yet recruiting No Results Available Cervical Dystonia Biological: CC BoNT/A|Biological: CF BoNT/A|Biological: CF to CC BoNT/A|Biological: CC to CF BoNT/A Percentage of patients with a clinically meaningful change in dose-effect at year 7 compared to reference year 2 between complex-free and complex-containing BoNT/A monotherapy|Clinical meaningfulness of change in efficacy from baseline (first visit on record) at each visit in years 2, 5, 7, 10 in all treatment groups Merz Therapeutics GmbH|Heinrich-Heine University, Duesseldorf|Merz Pharmaceuticals GmbH All 18 Years to 64 Years   (Adult) 981 Industry|Other Observational Observational Model: Case-Control|Time Perspective: Retrospective M602011073 May 2023 December 2023 June 2024 June 1, 2023 June 1, 2023 Düsseldorf University Hospital, Düsseldorf, North Rhine-Westphalia, Germany https://ClinicalTrials.gov/show/NCT05884528 425 NCT05884515 Evaluation of Home Use COVID-19 Frequent Antigen Testing and Data Reporting Chelsea_MA Recruiting No Results Available COVID-19 Respiratory Infection Diagnostic Test: SARS CoV-2 antigen tests Diagnostic tests results positive or negative IDX20 Inc|National Institute on Minority Health and Health Disparities (NIMHD) All 12 Years and older   (Child, Adult, Older Adult) Phase 1 1000 Industry|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic COVID-19 frequent testing|4U24MD016258-02 December 13, 2021 November 21, 2023 November 21, 2023 June 1, 2023 June 5, 2023 Chelsea Housing Authority, Chelsea, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05884515 426 NCT05884502 A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke Recruiting No Results Available Dyslipidemias|Stroke, Acute Ischemic Drug: combination of high-dose rosuvastatin and ezetimibe|Drug: high-dose rosuvastatin single administration Absolute value of LDL-C (low-density lipoprotein cholesterol) reduction Korea University Anam Hospital All 19 Years and older   (Adult, Older Adult) Phase 4 330 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2021AN0073 September 1, 2022 December 31, 2023 December 31, 2024 June 1, 2023 June 1, 2023 Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Koera University Guro Hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05884502 427 NCT05884489 Usability and Feasibility of the NutriQuest Application Completed No Results Available Gamification|Nutrition|Behavior Change Behavioral: A gamified smartphone app-based eating behaviour intervention Usability|Motivation|Application visits|Acceptance|Change from baseline Adherence to Mediterranean diet at 6 weeks|Change from Self-efficacy at 6 weeks|Change from Knowledge at 6 weeks|Digital health literacy Jessa Hospital|Hasselt University All 18 Years and older   (Adult, Older Adult) Not Applicable 21 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 2022/058 June 1, 2022 October 12, 2022 October 12, 2022 June 1, 2023 June 1, 2023 Cardiology Department, Jessa Hospital, Hasselt, Limburg, Belgium https://ClinicalTrials.gov/show/NCT05884489 428 NCT05884476 Randomized Clinical Trial of Re-Evaluating Suicidal Thoughts in Veterans REST-V Not yet recruiting No Results Available Suicidal Ideation|Suicide, Attempted Other: Treatment-as-usual|Behavioral: Re-Evaluating Suicidal Thoughts Suicidal ideation severity change|Psychological inflexibility of suicidal ideation change|Suicidal behaviors change VA Office of Research and Development All 18 Years and older   (Adult, Older Adult) Phase 2 180 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment MHBC-006-22S September 1, 2023 June 30, 2027 June 30, 2027 June 1, 2023 June 1, 2023 Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana, United States https://ClinicalTrials.gov/show/NCT05884476 429 NCT05884463 18F-FAPI PET Imaging in Pancreatic Adenocarcinoma Completed No Results Available 18F-FAPI|18F-FDG|Pancreas Adenocarcinoma|Diagnosis|Staging Drug: 18F-FAPI|Drug: 18F-FDG Diagnostic value|Maximum standardized uptake value|Diagnostic efficacy for primary lesions|SUVmax for primary lesions|SUVmax for lymph node|SUVmax for distant metastasis|Correlation between the SUVmax of 18F-FAPI and 18F-FDG uptake in patients with different treatment response Zhejiang University All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 62 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic FAPIPDAC01 April 1, 2021 February 28, 2023 February 28, 2023 June 1, 2023 June 1, 2023 the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05884463 430 NCT05884450 The Effect of Acupressure on the Management of Dyspnea Not yet recruiting No Results Available Palliative Care|Dyspnea Other: Acupressure Patient Descriptive Information Form:|Modified Borg Scale (MBS)|Change Modified Borg Scale (MBS)|Functional Assessment of Chronic Illness Therapy- Palliative Care (FACIT - Pal)|Change Functional Assessment of Chronic Illness Therapy- Palliative Care (FACIT - Pal) Istanbul Aydın University All 18 Years and older   (Adult, Older Adult) Not Applicable 140 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care ACUPRESSURE DYSPNEA May 22, 2023 August 30, 2023 October 30, 2023 June 1, 2023 June 1, 2023 Dilek Yildirim, Istanbul, Küçükçekmece, Turkey https://ClinicalTrials.gov/show/NCT05884450 431 NCT05884437 The Effects of Chiropractic in Adults With Metabolic Syndrome Not yet recruiting No Results Available Metabolic Syndrome Procedure: Chiropractic adjustment Recruitment rate|Participant adherence rate|Participant tolerability rate|Participant retention rate|Acceptability of treatment regimen for participants|EEG resting state broadband power|EEG resting state functional connectivity|EEG evoked latency|EEG evoked amplitude|skin conductance level (SCL)|Impedance cardiogram (ICG) pre-ejection period (PEP)|ECG mean interbeat interval|ECG respiratory sinus arrhythmia (RSA)|ECG de-trended fluctuation analysis|Impedance cardiogram (ICG) initial systolic time interval (ISTI)|Electrodermal activity (EDA) non-specific skin conductance responses (SCR)|Electrodermal activity (EDA) power spectral density (PSD)|Composite Autonomic Symptom Score (COMPASS-31)|Composite Autonomic Symptom Score COMPASS-31)|Patient-Reported Outcomes Measurement Information System (PROMIS-29)|Patient-Reported Outcomes Measurement Information System Cognitive Abilities and Cognitive Concerns Scale (PROMIS-Cog)|Perceived Stress Scale (PSS) Life University All 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other I-0023 June 1, 2023 March 1, 2024 March 1, 2024 June 1, 2023 June 2, 2023 Dr. Sid E. Williams Center for Chiropractic Research, Atlanta, Georgia, United States https://ClinicalTrials.gov/show/NCT05884437 432 NCT05884424 Effectiveness and Cost-Effectiveness of Robot Therapy With the Paro Robot in People Living With Dementia Enrolling by invitation No Results Available Dementia|Neurocognitive Disorders|Mild Cognitive Impairment Behavioral: PARO Therapy Robot Quality of life evaluated through Quality of Life - Alzheimer's Disease (QoL-AD)|Change in quality of life evaluated through Quality of Life - Alzheimer's Disease (QoL-AD)|Quality of life evaluated through EQ-5D-5L|Change in quality of life evaluated through EQ-5D-5L|Mood assessed through the Geriatric Depression Scale-15 (GDS-15)|Change in mood assessed through the Geriatric Depression Scale-15 (GDS-15)|Apathy assessed through the Apathy in Dementia-Nursing Home (APADEM-NH)|Change in apathy assessed through the Apathy in Dementia-Nursing Home (APADEM-NH)|Agitation assessed through the Cohen-Mansfield Agitation Inventory (CMAI)|Change in agitation assessed through the Cohen-Mansfield Agitation Inventory (CMAI) Instituto de Mayores y Servicios Sociales (IMSERSO)|Asturhealth SL|Servicio de Evaluación y Planificación del Servicio Canario de la Salud (SESCS) All 60 Years and older   (Adult, Older Adult) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment 04/22 April 10, 2023 October 6, 2023 October 6, 2023 June 1, 2023 June 1, 2023 ATENDO Calidade S.L, Vigo, Pontevedra, Spain|Residencia DomusVi Alcoi, Alicante, Spain|Residencia DomusVi Alicante Babel, Alicante, Spain|Residencia CleceVitam San Pedro Poveda, Burgos, Spain|Residencia DomusVi Vila-Real, Castelló, Spain|Centro Residencial CleceVitam Bastiagueiro, La Coruña, Spain|Residencia CleceVitam Ponent, Lérida, Spain|Residencia de Mayores Albertia Moratalaz, Madrid, Spain|Residencia ORPEA Madrid Buenavista, Madrid, Spain|Residencia ORPEA Pinto, Madrid, Spain|Centro Residencial CleceVitam Carmen Conde, Murcia, Spain|Residencia Bañosalud, Palencia, Spain|Residencia CleceVitam San Antonio, Salamanca, Spain|CleceVitam Gerohotel, Valladolid, Spain|Residencia León Trucíos, Vizcaya, Spain https://ClinicalTrials.gov/show/NCT05884424 433 NCT05884411 Evaluation of Left Bundle Branch Area Pacing As A Rescue Strategy for Cardiac Resynchronization Therapy Non-Response Recruiting No Results Available Systolic Heart Failure|Heart Failure With Reduced Ejection Fraction|CRT Non-Response|Left Bundle Branch Area Pacing Device: Left bundle branch area pacing|Diagnostic Test: Cardiac MRI Left ventricular ejection fraction by echocardiography|Left ventricular ejection fraction by cardiac MRI|Interventricular mechanical delay measurement by 2D speckle-tracking echocardiography VA Office of Research and Development All Child, Adult, Older Adult Not Applicable 24 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CARA-001-22F|CX002525 April 30, 2023 March 31, 2028 March 31, 2028 June 1, 2023 June 1, 2023 Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States https://ClinicalTrials.gov/show/NCT05884411 434 NCT05884398 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC LIBERTAS Not yet recruiting No Results Available Metastatic Castrate-sensitive Prostate Cancer Drug: Apalutamide|Drug: Androgen-deprivation Therapy (ADT) Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)|Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months|Mean Percentage Changes From Randomization in Severity Adjusted Hot Flash Score and Hot Flash Frequency|Second Progression-free Survival (PFS2)|Overall Survival (OS)|Prostate Cancer-specific Survival|Serum Prostate Specific Antigen (PSA) Evaluations|Duration of Time on Androgen-deprivation Therapy (ADT)|Time to First ADT Restart|Duration of Time with Testosterone Level Less than (<) 50 nanograms per millilitre (ng/mL)|Time to Recovery of Testosterone >50 nanogram per decilitre (ng/dL)|Time to Recovery of Testosterone Greater Than or Equal (>=) Screening Testosterone Level|Time to Testosterone Recovery to Normal Range (>270 ng/dL)|Time to Metastatic Castration-resistant Prostate Cancer (mCRPC)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Abnormal Clinical Laboratory Parameters|Number of Participants with Abnormal Vital Sign Parameters|Number of Participants with Abnormal Physical Examination Parameters|Hot Flash Related Daily Interference Score (HFRDIS)|Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score|Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire -Prostate Cancer Module (EORTC-PR25) Questionnaire|Change From Baseline in European Organization for the Research and Treatment of Cancer (EORTC) Customized Study Form|Change From Baseline in Patient-Reported Outcomes Measurement Information System Cognitive Function (PROMIS-Cog) Questionnaire|Change From Baseline in Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Questionnaire|Change From Baseline in Patient Health Questionnaire (PHQ-9) Questionnaire|Change From Baseline in Patient Global Impression of Severity scale (PGIS) Questionnaire|Change From Baseline in Patient Global Impression of Change (PGIC) Questionnaire|Time to Recovery From Baseline as Assessed by EORTC-QLQ-C30|Time to Recovery From Baseline as Assessed by EORTC-PR25|Time to Recovery From Baseline as Assessed by EORTC Customized Study Form|Time to Recovery From Baseline as Assessed by MAX-PC|Time to Recovery From Baseline as Assessed by PHQ-9|Time to Recovery From Baseline as Assessed by PGIS|Time to Recovery From Baseline as Assessed by PGIC|Time to Recovery From Baseline as Assessed by PROMIS-Cog|Time to Deterioration in EORTC-QLQ-C30 Over Time|Time to Deterioration in EORTC-PR25 Over Time|Time to Deterioration in EORTC Customized Study Form Over Time|Time to Deterioration as per PROMIS-Cog Questionnaire Over Time|Time to Deterioration in MAX-PC Questionnaire Over Time|Time to Deterioration as per PHQ-9 Questionnaire Over Time|Time to Deterioration in PGIS Questionnaire Over Time|Time to Deterioration as per PGIC Questionnaire Over Time Janssen Research & Development, LLC Male 18 Years and older   (Adult, Older Adult) Phase 3 333 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CR109327|56021927PCR3020|2022-502686-24-00 August 31, 2023 May 31, 2027 May 31, 2027 June 1, 2023 June 1, 2023 Colorado Clinical Research, Lakewood, Colorado, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Asklepios Klinik Altona, Hamburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany https://ClinicalTrials.gov/show/NCT05884398 435 NCT05884385 Effect of Surgeon Warm-up and Mental Visualisation During Robot-assisted Laparoscopic Surgery MURALS2 Not yet recruiting No Results Available Cognitive Deficit in Attention|Musculoskeletal Strain|Fatigue|Surgery Other: Simulated exercises|Other: Mental Visualisation Muscle demands|Cognitive demands Lancaster University|East Lancashire Hospitals NHS Trust All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 10 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention DEV046 May 30, 2023 October 25, 2023 October 25, 2023 June 1, 2023 June 1, 2023 East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom https://ClinicalTrials.gov/show/NCT05884385 436 NCT05884372 Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis. Not yet recruiting No Results Available Osteoporosis in Postmenopausal Women Drug: Eldecalcitol|Drug: Native Vitamin D|Drug: Denosumab|Drug: Calcium the percent change from baseline at month 12 in BMD at the lumbar spine L1-4.|the percent change from baseline at month 6 in BMD at the lumbar spine L1-4.|the percent change from baseline at each visit in BMD at the femoral neck and total hip.|the percent change from baseline at each visit in serum CTX,P1NP,PTH.|the percent change from baseline at month 6 and month 12 in limb skeletal muscle content by DXA.|the percent change from baseline at month 6 and month 12 in body balance ability by measuring One Leg Standing (OLS).|the score change from baseline at month 6 and month 12 in quality of life by 16-item Assessment of Health-Related Quality of Life in Osteoporosis,(ECOS-16).|Incidence rate of new vertebral fracture and new non-vertebral fracture in 1 year.|1.the percent change from baseline at month 6 and month 12 in physical function by measuring 5 times chair stand.|the percent change from baseline at month 6 and month 12 in muscle strength by measuring grip strength.|the percent change from baseline at month 6 and month 12 in body balance ability by measuring Timed Up and Go (TUG).|the percent change from baseline at month 6 and month 12 in body balance ability by measuring 10 Meter Walk (10MW). Xi'an Honghui Hospital|Chugai Pharma China Co., Ltd. Female Child, Adult, Older Adult Phase 4 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ELD-IIS00X June 2023 December 2024 June 2025 June 1, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05884372 437 NCT05884359 Left Bundle Branch Area Mapping for Conduction System Pacing Not yet recruiting No Results Available Left Bundle-Branch Block|Pacemaker DDD Diagnostic Test: 3D Electroanatomical Mapping (NavX) Electroanatomical characteristics of the target area for Left Bundle lead implantation Steward St. Elizabeth's Medical Center of Boston, Inc. All 18 Years to 88 Years   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective SEMC June 1, 2023 June 1, 2024 December 31, 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884359 438 NCT05884346 Association Between Coronary and Peripheral Vascular Injury in Heart Failure Patients With Preserved Ejection Fraction. COROVASC Not yet recruiting No Results Available Heart Failure With Preserved Ejection Fraction Other: Ultrahigh-frequency ultrasound Digital vascular remodeling by ultrahigh-frequency ultrasound|Radial vascular remodeling by echo-tracking|Carotid vascular remodeling by echo-tracking|Endothelial dysfunction|Pulse wave velocity|Retinal microvascularization|Calcium score Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France All 18 Years and older   (Adult, Older Adult) Not Applicable 84 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic APHP230214|2022-A02455-38|23.00664.000175 June 2023 May 2024 May 2024 June 1, 2023 June 2, 2023 Hôpital européen Georges Pompidou - AP-HP, Paris, France https://ClinicalTrials.gov/show/NCT05884346 439 NCT05884333 Cord Blood Transplant in Adults With Blood Cancers Recruiting No Results Available Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Chronic Myelogenous Leukemia (CML)|Myelodysplastic Syndromes (MDS)|Myeloproliferative Disorder|Non-Hodgkin's Lymphoma Drug: Conditioning Chemotherapy|Biological: Cord blood graft Overall survival (OS)|Time to neutrophil engraftment Memorial Sloan Kettering Cancer Center All 21 Years to 65 Years   (Adult, Older Adult) Phase 2 54 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 23-143 May 22, 2023 May 22, 2028 May 22, 2028 June 1, 2023 June 1, 2023 Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States|Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States https://ClinicalTrials.gov/show/NCT05884333 440 NCT05884320 Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers Not yet recruiting No Results Available Gland|Salivary Gland Cancers Drug: Sacituzumab Govitecan Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 M.D. Anderson Cancer Center|Gilead Sciences All 18 Years and older   (Adult, Older Adult) Phase 2 30 Other|Industry Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-0813|NCI-2023-04260 November 30, 2023 December 31, 2024 December 31, 2026 June 1, 2023 June 1, 2023 M D Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05884320 441 NCT05884307 Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria Not yet recruiting No Results Available Gender Dysphoria Other: Trans Care Web App Acceptability of Intervention Measure (AIM) Score|Intervention Appropriateness Measure (IAM) Score|Feasibility of Intervention Measure (FIM) Score|Summary of Qualitative Prompts University of Wisconsin, Madison All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 2023-0644: FAA|UW Baldwin Endowment April 2024 May 2024 May 2024 June 1, 2023 June 2, 2023 University of Wisconsin, Madison, Wisconsin, United States https://ClinicalTrials.gov/show/NCT05884307 442 NCT05884294 Midline Catheter Versus Long Peripheral Intravenous Catheter in Hospitalized Adult Patients Not yet recruiting No Results Available Vascular Access Devices Device: PowerGlide Pro Midline catheter. Lenght of time of vascular access without isolated or combined complications.|End of the proposed therapy with the same vascular access; Hospital de Clinicas de Porto Alegre All 18 Years and older   (Adult, Older Adult) Not Applicable 102 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other 2022-0363 June 1, 2023 December 1, 2023 December 1, 2024 June 1, 2023 June 1, 2023 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil https://ClinicalTrials.gov/show/NCT05884294 443 NCT05884281 Efficacy of Roflumilast in Prevention of Peripheral Neuropathy Not yet recruiting No Results Available Peripheral Neuropathy Drug: Roflumilast|Drug: Placebo Incidence of chemotherapy induced-peripheral neuropathy using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria Mansoura University All 18 Years to 75 Years   (Adult, Older Adult) Phase 1|Phase 2 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention 8/2023 July 2023 December 2023 December 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884281 444 NCT05884268 Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy Not yet recruiting No Results Available Laparoscopic Cholecystectomy Drug: Venlafaxine|Drug: Placebo Change in postoperative pain between the two groups using visual analogue score (VAS)|Postoperative nausea and vomiting (PONV) Mansoura University All 18 Years to 75 Years   (Adult, Older Adult) Phase 1|Phase 2 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 6-2023 May 30, 2023 January 30, 2024 January 30, 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884268 445 NCT05884255 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Not yet recruiting No Results Available Advanced Gastroenteropancreatic Neuroendocrine Tumor Drug: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Drug: long-acting Octreotide. Progression-free survival (PFS) assessed by BICR|Overall Survival(OS)|Objective Response Rate(ORR)|Duration of Overall Response(DoR)|Disease Control Rate|Incidence and severity of AE and SAE Jiangsu HengRui Medicine Co., Ltd. All 18 Years to 75 Years   (Adult, Older Adult) Phase 3 220 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HRFS-Q-2011-301 June 2023 December 2026 October 2030 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884255 446 NCT05884242 A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge Recruiting No Results Available Healthy Drug: Adalimumab|Drug: Lipopolysaccharide (LPS) Change From Baseline in C-reactive Protein (CRP)|Change From Baseline Tumour Necrosis Factor-alpha (TNF-alpha)|Longitudinal Change From Baseline in Temperature|Longitudinal Change From Baseline in Heart Rate|Longitudinal Change From Baseline in Blood Pressure|Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)|Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) Janssen Research & Development, LLC All 18 Years to 55 Years   (Adult) Phase 1 20 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science CR109299|2022-002896-13|NOPRODPBNAP1001|PLATFORMPBNAP1001 May 22, 2023 July 10, 2023 August 7, 2023 June 1, 2023 June 1, 2023 Clinical Pharmacology Unit, Merksem, Belgium https://ClinicalTrials.gov/show/NCT05884242 447 NCT05884229 The Effect of SPI (Surgical Pleth Index) - Guided Anaesthesia on Opioid Consumption in Gastric Sleeve Surgery Recruiting No Results Available Intraoperative Monitoring Other: Intra-operative analgesia guided by SPI Pain scores on the visual analog scale during the first 90 minutes post-operatively|Opioid consumption|Sevoflurane concentration|Time from neuromuscular reversal to extubation|Hemodinamic events|Rescue analgesia Iuliu Hatieganu University of Medicine and Pharmacy All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other 1 January 1, 2023 January 1, 2024 January 1, 2024 June 1, 2023 June 1, 2023 First Surgical Clinic, County Hospital, Cluj-Napoca, Romania https://ClinicalTrials.gov/show/NCT05884229 448 NCT05884216 Entarik Feeding Tube System Placement in Adult ICU Recruiting No Results Available Nasogastric Tube Device: Entarik Feeding Tube System|Device: Entarik Feeding Tube System without monitoring Percentage of accurate verifications of anatomical locations of the tip of the Entarik feeding tube. The position of the feeding tube tip as processed by the Entarik placement algorithm will be compared to x-ray. Gravitas Medical, Inc. All 18 Years and older   (Adult, Older Adult) Not Applicable 110 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other CRD-04-1642-01 May 30, 2023 September 2023 December 2023 June 1, 2023 June 2, 2023 Nova Clinical Research at HCA Florida Blake Hospital, Bradenton, Florida, United States|HCA Chippenham and Johnston-Willis Medical Center, Richmond, Virginia, United States https://ClinicalTrials.gov/show/NCT05884216 449 NCT05884203 Improving Prosthetic Provision in Rural Communities: Limb Scanning With Caregiver Assistance Not yet recruiting No Results Available Lower Extremity Amputation Device: Caregiver socket|Device: Prosthetist socket Socket Comfort Score (SCS)|Comprehensive Lower-limb Amputee Socket Survey (CLASS) Stability Score|Comprehensive Lower-limb Amputee Socket Survey (CLASS) Suspension Score|Comprehensive Lower-limb Amputee Socket Survey (CLASS) Comfort Score|Standing distal end residual pressure|Walking distal end residual limb pressure VA Office of Research and Development All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 25 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment F4276-R|I01 RX004276|1676634 July 1, 2023 April 1, 2026 September 30, 2026 June 1, 2023 June 1, 2023 VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States https://ClinicalTrials.gov/show/NCT05884203 450 NCT05884190 Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension Not yet recruiting No Results Available Postpartum Hypertension Other: Remote Medical Model (RMM)|Other: Community Health Model (CHM)|Other: SoC Change in mean postpartum systolic blood pressure (SBP) at 6 weeks|Depression severity at 3 months postpartum assessed using the Edinburgh Postnatal Depression Scale (EPDS).|Participant engagement Yale University|Patient-Centered Outcomes Research Institute Female 18 Years and older   (Adult, Older Adult) Not Applicable 6030 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 2000033779|MMM-2021C2-23671 June 2023 October 2027 October 2027 June 1, 2023 June 1, 2023 Yale New Haven Hospital, New Haven, Connecticut, United States|University of Massachusetts Memorial Health, Worcester, Massachusetts, United States|Oishei Children's Hospital University at Buffalo, Buffalo, New York, United States https://ClinicalTrials.gov/show/NCT05884190 451 NCT05884177 Inuit and Cold Exposure ICE Recruiting No Results Available Healthy Other: Short-term cold exposure BAT detection|Temperature of the core and at the skin on multiple sites|Changes in thyroid function|Changes in metabolites|Insulin sensitivity|Adipose tissue composition Stig Andersen|University of Copenhagen|Greenland University|Aalborg University Hospital All 18 Years to 50 Years   (Adult) 25 Other Observational Observational Model: Case-Control|Time Perspective: Cross-Sectional F2023-040 May 2023 December 2024 December 2025 June 1, 2023 June 1, 2023 Aalborg University Hospital, Aalborg, Denmark https://ClinicalTrials.gov/show/NCT05884177 452 NCT05884164 ESPB Versus PVPB Regarding Their Effect on Peri-operative Opioid Consumption in Patients Undergoing Minimally Invasive Mitral Valve Replacement Active, not recruiting No Results Available ERAS|Post Operative Pain Procedure: Thoracic erector spinae plane block|Procedure: Thoracic paravertebral plane block intraoperative opioid consumption|Postoperative opioid consumption|Time for extubation|Time for ambulation|Postoperative respiratory depression|Length of ICU stay Ain Shams University All 18 Years and older   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other FMASU MD89 / 2022 March 24, 2022 August 2023 October 2023 June 1, 2023 June 1, 2023 Ain Shams University, Cairo, Abbasya, Egypt https://ClinicalTrials.gov/show/NCT05884164 453 NCT05884151 Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Completed No Results Available Melasma Drug: Tranexamic acid|Drug: Platelets rich plasma Melasma severity index Combined Military Hospital Abbottabad All 20 Years to 40 Years   (Adult) Phase 1 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Cmh abbottabad321 November 1, 2022 April 30, 2023 April 30, 2023 June 1, 2023 June 1, 2023 Dr sana aslam, Abbottabad, Khyber Pakhtun Khwaa, Pakistan|Sana aslam, Abbottabad, Khyber Pakhtun Khwa, Pakistan|Sana aslam, Abbottābād, Khyber Pakhtun Khwa, Pakistan https://ClinicalTrials.gov/show/NCT05884151 454 NCT05884138 Effect of Essential Aminoacid Supplementation and Exercise on Skeletal Muscle Function in Hemodialysis Patients Not yet recruiting No Results Available Sarcopenia Other: exercise and nutritional support Handgrip strength in Kg using a portable dyanometer|Body composition using dual energy x-ray absorptiometry (DXA)|Body composition using body composition monitor (BCM)|The total score of Short Physical Performance Battery(SPPB)|The second of 5 times Chair Stand Test|skeletal muscle mass index(SMI) in cm2/m2|Glucose pattern using continuous glucose monitoring system(freestyle libre) Chungnam National University Hospital All 20 Years to 80 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CNUH-ED-2023-001 July 1, 2023 November 30, 2023 February 29, 2024 June 1, 2023 June 1, 2023 Chungnam National University Hospital, Daejeon, Korea, Republic of https://ClinicalTrials.gov/show/NCT05884138 455 NCT05884125 Promoting Healing of Injured Nerves With Electrical Stimulation Therapy PHINEST Not yet recruiting No Results Available Nerve Injury|Peripheral Nerve Injuries|Peripheral Nerve Injury Upper Limb|Nerve Palsy Device: Checkpoint BEST System Change in Motor Recovery assessed using the Medical Research Council (MRC) motor grading|Grip Strength|Lateral Pinch Strength|2-point discrimination|Semmes-Weinstein Monofilament Testing|Patient Reported Outcome Measurement System (PROMIS) Upper Extremity Function|Patient Reported Outcome Measurement System (PROMIS) Pain Interference|quick Disabilities of thee Arm, Shoulder, and Hand (DASH) questionnaire|Electromyography (EMG)|Motor Unit Number Estimation (MUNE) Checkpoint Surgical Inc.|Congressionally Directed Medical Research Programs All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 60 Industry|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 0153-CSP-002|W81XWH1920065 June 2023 June 2027 June 2027 June 1, 2023 June 1, 2023 Northwestern Feinberg School of Medicine - Department of Orthopaedic Surgery, Chicago, Illinois, United States|The Ohio State Univeristy - Department of Plastic and Reconstructive Surgery, Columbus, Ohio, United States https://ClinicalTrials.gov/show/NCT05884125 456 NCT05884112 Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation Recruiting No Results Available Narcolepsy Device: "MAGSTIM" reprtitive Transcranial Magnetic Stimulator (rTMS) System|Device: sham control Beck Depression Inventory|The Beck Anxiety Inventory|Polysomnography -SE|Polysomnography -TST|Polysomnography -WASO|Polysomnography -REM|Polysomnography -SL|Polysomnography -SWS|Multiple sleep latency test|Conners' Continuous Performance Test|Wisconsin Card Sorting Test|Epworth Sleepoiness Scale|Short Form-36|PET/MRI|Actigraphy-WASO|Actigraphy-SE|Actigraphy-TST|Pittsburgh Sleep Quality Index|Visual Analogue Scale Chang Gung Memorial Hospital All 18 Years to 60 Years   (Adult) Not Applicable 105 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 202102036A3 February 22, 2023 June 2025 June 2025 June 1, 2023 June 1, 2023 Chang-Gung Memorial Hospital, Taoyuan, Taiwan https://ClinicalTrials.gov/show/NCT05884112 457 NCT05884099 Intercostal Cryoanalgesia for Chronic Pain After VATS Lung Resection CRYO-VATS-2 Not yet recruiting No Results Available Cryotherapy Effect|Chronic Pain|Lung Cancer|Surgery Procedure: Cryoanalgesia AND single-injection paravertebral block|Procedure: Single-injection paravertebral block Incidence of persistent thoracic pain|Severity of persistent thoracic pain|Incidence of persistent opioid consumption|Incidence of postoperative neuropathic pain|Incidence of new prescription for neuropathic pain medication|Persistent hypoesthesia over the ipsilateral thorax Centre hospitalier de l'Université de Montréal (CHUM) All 18 Years and older   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2024-11564 September 1, 2023 September 1, 2024 March 1, 2025 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884099 458 NCT05884086 Ataxia GAA-FGF14 - Descriptive Genetic and Clinical Study GAA-FGF14 Active, not recruiting No Results Available Ataxia, Gait description of clinical symptoms|description of genotype Central Hospital, Nancy, France All Child, Adult, Older Adult 20 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023PI013-372 May 1, 2023 June 2026 June 2026 June 1, 2023 June 1, 2023 Centre hospitalier régional universitaire, Nancy, France https://ClinicalTrials.gov/show/NCT05884086 459 NCT05884073 Exercise for Oncology Care Professionals C4C+ Not yet recruiting No Results Available Burnout, Caregiver|Compassion Fatigue Behavioral: Circuit-based Resistance Training|Behavioral: Circuit-based Resistance Training + Home-based Walking|Behavioral: Home-based Walking Feasibility - Recruitment|Feasibility - Participant Fidelity (Intervention Adherence)|Feasibility - Safety|Feasibility - Retention/Attrition|Feasibility - Participant Experience|Feasibility - Attendance|Maslach Burnout Inventory (MBI) for Medical Personnel (MP)|Professional Quality of Life Scale (ProQOL)|Depression, Anxiety, and Stress Scale - Short Version (DASS21)|Physical Activity Behavior - Daily step count|Physical Activity Behavior - Self-reported|Resting heart rate|Resting Blood Pressure|Aerobic fitness|Upper Body Strength|Muscular Endurance|Body Mass Index Melanie Keats|Nova Scotia Health Authority All 18 Years and older   (Adult, Older Adult) Not Applicable 36 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care C4C+ September 1, 2023 August 31, 2024 August 31, 2024 June 1, 2023 June 1, 2023 Physical Activity and Cancer (PAC) Lab, Halifax, Nova Scotia, Canada https://ClinicalTrials.gov/show/NCT05884073 460 NCT05884060 Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones Completed No Results Available PNH|Thrombosis Other: No intervention PNH risk factors translation into query codes that can be interpreted by a computer system for analysis|Number of patients identified with high risk for PNH clone and per type of screening criteria by developing a computational screening algorithm|The number of patients at high risk for PNH, categorized by risk factor, across each medical department AZ Delta|Alexion All 14 Years and older   (Child, Adult, Older Adult) 568 Other|Industry Observational Observational Model: Cohort|Time Perspective: Retrospective B1172022000017 April 20, 2018 March 1, 2022 March 1, 2022 June 1, 2023 June 2, 2023 AZ Delta, Roeselare, West-Vlaanderen, Belgium https://ClinicalTrials.gov/show/NCT05884060 461 NCT05884047 The Effect Of Virtual Reality Glasses On Vital Signs And State Anxiety Level In Cancer Patients Completed No Results Available Cancer Patients Device: Virtual Glasses Vital signs- Blood pressure|Vital signs-pulse Bahar İNKAYA|Ankara Yildirim Beyazıt University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care Ankara Yilidirim Beyazit Un. January 27, 2020 April 1, 2020 June 1, 2020 June 1, 2023 June 1, 2023 Bahar İnkaya, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05884047 462 NCT05884034 Effects of a Self-care Educational Program Via Telerehabilitation in Caregivers Not yet recruiting No Results Available Quality of Life Other: Telerehabilitation|Other: Education Change in caregiver burden score measured through Zarit scale|Change in quality of life score measured through World Health Organization Quality of Life-100 (WHOQOL-BREF)|Change in pain score measured through McGill Pain Questionnaire|Change in stress score measured through Perceived Stress Scale (PSS)|Change in depressive symptoms evaluated through Beck Depression Inventory|Change in night awakenings measured through Sênior Saúde Móvel platform|Change in sleep patterns measured through Sênior Saúde Móvel platform|Change in level of physical activity measured through Sênior Saúde Móvel platform|Change in heart rate variability measured through Sênior Saúde Móvel platform Universidade Federal do Rio Grande do Norte All 18 Years and older   (Adult, Older Adult) Not Applicable 22 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care CEP/UFRN 4.076.825/20 June 2023 October 2023 December 2023 June 1, 2023 June 1, 2023 Federal University of Rio Grande do Norte, Natal, Rio Grande Do Norte, Brazil https://ClinicalTrials.gov/show/NCT05884034 463 NCT05884021 Effectiveness of Pain Control and Adverse Reactions After Intravenous PCA in Chinese Population Completed No Results Available Postoperative Pain, Acute Other: Postoperative analgesia Poor postoperative analgesia|Incidence of adverse effects of postoperative analgesia Huazhong University of Science and Technology All Child, Adult, Older Adult 40000 Other Observational Observational Model: Cohort|Time Perspective: Retrospective postoperative pain January 1, 2016 December 31, 2021 December 31, 2022 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05884021 464 NCT05884008 Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I RECOGNIZE-I Recruiting No Results Available Coronary Artery Disease Coronary artery plaque risk level Ruijin Hospital All 18 Years to 80 Years   (Adult, Older Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 2022YFC2533502-1 May 1, 2023 June 30, 2025 December 31, 2025 June 1, 2023 June 1, 2023 Cangzhou Center Hospital, Cangzhou, Hebei, China|First affiliated hospital of Harbin Medical University, Harbin, Heilongjiang, China|First affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Techonology, Wuhan, Hubei, China|First Hospital of Nanjing, Nanjing, Jiangsu, China|First affiliated hospital of Dalian Medical College, Dalian, Liaoning, China|General Hospital of Northern Theater Command, Shenyang, Liaoning, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05884008 465 NCT05883995 Avis-PHAGEinLYON Clinic Recruiting No Results Available Bone Infection Other: Phage therapy requests Number of phage therapy requests Hospices Civils de Lyon All Child, Adult, Older Adult 1500 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional 23-5092 February 1, 2023 February 1, 2028 February 1, 2029 June 1, 2023 June 1, 2023 Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc) - Hôpital de la Croix-Rousse, Lyon, France https://ClinicalTrials.gov/show/NCT05883995 466 NCT05883982 Intra-articular I-PRF Injections in Patients With Temporomandibular Joint Dysfunction Not yet recruiting No Results Available Temporomandibular Joint Disorders|Temporomandibular Joint Pain Procedure: I-PRF injection Articular pain|Mandibular mobility Hospital of the Ministry of Interior, Kielce, Poland All 18 Years and older   (Adult, Older Adult) Phase 4 40 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CT/2022/1 June 1, 2023 January 1, 2024 June 1, 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883982 467 NCT05883969 GO-PLAY - Early Family-Centered Intervention for Infants With High-Risk of Cerebral Palsy GO-PLAY Recruiting No Results Available Cerebral Palsy Behavioral: GO-PLAY|Behavioral: Usual care Peabody Developmental Motor Scales - Second edition (PDMS-2)|Alberta Infant Motor Scale (AIMS)|Gross Motor Function Measure (GMFM-66)|Hand Assessment in Infants (HAI)|The Parental Stress scale (PSS)|The Depression Anxiety Stress Scales (DASS-21)|The Measure of Processes of Care 20 (MPOC-20) Rigshospitalet, Denmark|Aalborg University Hospital|Aarhus University Hospital All 3 Months to 12 Months   (Child) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment H-22041835 April 1, 2023 September 30, 2025 March 31, 2028 June 1, 2023 June 1, 2023 Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark https://ClinicalTrials.gov/show/NCT05883969 468 NCT05883956 A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia PREFER Not yet recruiting No Results Available Myelodysplastic Syndromes|Leukemia, Myeloid, Acute|Leukemia, Myelomonocytic, Chronic|Patient Preference Drug: Subcutaneous azacitidine|Drug: Oral decitabine/cedazuridine Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the patient treatment preference in myelodysplasia questionnaire (pTPMQ)|Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the pTPMQ|Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the carer treatment preference in myelodysplasia questionnaire (cTPMQ)|Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the cTPMQ|Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the medical treatment preference in myelodysplasia questionnaire (mTPMQ)|Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the mTPMQ|Proportion of clinicians choosing oral decitabine/cedazuridine vs subcutaneous azacitidine for continuation of treatment and reasons for the treatment choice based on the mTPMQ|Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients|Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients|Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients|Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients|The difference in the incidence of treatment discontinuation and reasons for treatment discontinuation|Incidence and severity of adverse events upon study physician discretion. Otsuka Australia Pharmaceutical Pty Ltd All 18 Years and older   (Adult, Older Adult) Phase 3 42 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 393-419-00041 July 2023 August 2024 April 2025 June 1, 2023 June 1, 2023 Calvary Mater Newcastle, Newcastle, New South Wales, Australia https://ClinicalTrials.gov/show/NCT05883956 469 NCT05883943 Cook Venous Valve System for Treatment of Chronic Venous Insufficiency Recruiting No Results Available Venous Insufficiency of Leg Device: Cook® Venous Valve System Freedom from major adverse events in the first 30 days|Freedom from MAE at three months, six months, and 12 months MED Institute Inc. All 18 Years and older   (Adult, Older Adult) Not Applicable 15 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 21-4344 April 24, 2023 August 2024 January 2029 June 1, 2023 June 1, 2023 Angiosur S.A.S., Antioquia, Colombia|Clínica de La Costa S.A.S., Barranquilla, Colombia|Fundacion Oftalmologica De Santander, Santander, Colombia https://ClinicalTrials.gov/show/NCT05883943 470 NCT05883930 The Effect of the Mobile Software Let's Move Program on Changing Sedentary Behaviors of University Students Enrolling by invitation No Results Available Public Health Nursing Other: 'Let's Move' program|Other: no intervention International Physical Activity Questionnaire (IPAQ)|Transtheoretical Model Sedentary Life Stages of Change Survey|Transtheoretical Model Sedentary Life Self-efficacy Scale|Transtheoretical Model Sedentary Life Decision Balance Scale|Step counter|Body Mass Index (BMI)|Body fat to muscle ratio Marmara University|Marmara University Scientific Research Projects Unit|THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TÜRKİYE (TUBITAK) All 18 Years to 25 Years   (Adult) Not Applicable 194 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention MARMARA ÜNİVERSİTESİ June 15, 2023 September 15, 2023 December 15, 2023 June 1, 2023 June 1, 2023 Marmara University/ Maltepe, Maltepe, İstanbul, Turkey|Marmara University/ Maltepe, İstanbul, Turkey "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/30/NCT05883930/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/30/NCT05883930/ICF_001.pdf https://ClinicalTrials.gov/show/NCT05883930 471 NCT05883917 Clinical Utility of Robot-Assisted Gait Training in Patients With Spinal Cord Injury Caused by Electrical Burns: A Case Report Not yet recruiting No Results Available Gait Disorder, Sensorimotor|Burns|Spinal Cord Injuries Procedure: robot assisted gait training American Spinal Injury Association|lower extremity motor subscale score (LEMS; range 0-50)|passive range of motions|The ambulatory motor index (AMI; range 0-30) Hangang Sacred Heart Hospital All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 2 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HangangSHH-15 June 15, 2023 December 15, 2023 December 31, 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883917 472 NCT05883904 Real World Evidence of Fedratinib Effectiveness in MF REALFed Not yet recruiting No Results Available Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis Drug: Fedratinib Splenic response Gruppo Italiano Malattie EMatologiche dell'Adulto All 18 Years and older   (Adult, Older Adult) 93 Other Observational Observational Model: Case-Only|Time Perspective: Prospective MPN0223 September 2023 September 2025 September 2025 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883904 473 NCT05883891 Prothrombin Time Predicts Steroid Response in Severe Alcoholic Hepatitis. AH2023 Completed No Results Available Alcoholic Hepatitis Diagnostic Test: prothrombin time response to steroid treatment|death|early liver transplantation|infection Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years to 70 Years   (Adult, Older Adult) 52 Other Observational Observational Model: Case-Only|Time Perspective: Retrospective 5840 June 1, 2017 September 30, 2022 November 30, 2022 June 1, 2023 June 1, 2023 Agostino Gemelli Polyclinic, Rome, Roma (provincia), Italy https://ClinicalTrials.gov/show/NCT05883891 474 NCT05883878 Innovative Approaches for Personalised Cardiovascular Prevention INNOPREV Not yet recruiting No Results Available Cardiovascular Diseases Genetic: PRS|Device: Digital app and wearable device Change in the Lifestyle Category|Modification of the Lipid Profile Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Università degli Studi di Perugia|Policlinic Hospital "G. Rodolico"|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo All 40 Years to 69 Years   (Adult, Older Adult) Not Applicable 1020 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 5506 July 2023 October 2024 May 2025 June 1, 2023 June 1, 2023 Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Roma, Italia, Italy https://ClinicalTrials.gov/show/NCT05883878 475 NCT05883865 Safety Study of Fenofibrate During Pregnancy Recruiting No Results Available Severe Hypertriglyceridemia During Pregnancy Drug: Fenofibrate rate of preterm birth of infants|Apger score of infants|body weight of infants|length of infants|head circumference of infants|placental transfer|milk penetration First People's Hospital of Hangzhou Female 20 Years to 45 Years   (Adult) 250 Other Observational Observational Model: Cohort|Time Perspective: Other IIT-20221208-0197-01 June 1, 2022 June 1, 2024 December 1, 2025 June 1, 2023 June 1, 2023 Hangzhou First People's Hospital, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05883865 476 NCT05883852 EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer Not yet recruiting No Results Available HER2 Positive Early Breast Cancer Drug: Docetaxel|Drug: carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Epirubicin|Drug: cyclophosphamide iDFS|DRFS|OS|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Fudan University Female 18 Years to 70 Years   (Adult, Older Adult) Phase 3 1406 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SCHBCC-N055 July 1, 2023 July 1, 2031 July 1, 2031 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883852 477 NCT05883839 Turkish Validity and Reliability Study of the "Sexual Health Care Questionnaire" Recruiting No Results Available Nursing Education|Nursing Students|Sexuality|Sexual Health|Validation Study Other: Student Group Knowledge of Sexual Healthcare Scale|Attitude to Sexual Healthcare Scale|Self-Efficacy for Sexual Healthcare Scale Marmara University All 18 Years and older   (Adult, Older Adult) 310 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional marmaraceydasugunduzistanbul April 28, 2023 May 2023 May 2023 June 1, 2023 June 1, 2023 Marmara University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05883839 478 NCT05883826 The Effect of Sexual Health Assessment Training Given to Nursing Students Knowledge, Attitude and Self-Efficacy Enrolling by invitation No Results Available Nursing Education|Nursing Students|Nursing Model Behavioral: sexual health assessment training Knowledge of Sexual Healthcare Scale|Attitude to Sexual Healthcare Scale|Self-Efficacy for Sexual Healthcare Scale|Sexual Myths Scale|Student Opinion Form on Sexual Health Assessment Education (part 1)|Student Opinion Form on Sexual Health Assessment Education (part 2) Marmara University All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention marmaraceydasugunduzistanbul34 May 2023 September 2023 September 2023 June 1, 2023 June 1, 2023 Marmara University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05883826 479 NCT05883813 Immediate Effects of Suboccipital Muscle Release Combined With Sustained Natural Apophyseal Glides in Patients With Chronic Tension Type Headache Active, not recruiting No Results Available Tension-Type Headache Procedure: sustained natural apophyseal glides (SNAGS)|Procedure: suboccipital muscle release|Procedure: Supplemental therapy cervical range of motion|Pain intensity|Blood pressure Foundation University Islamabad All 18 Years to 64 Years   (Adult) Not Applicable 48 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment FUI/CTR/2023/11 January 1, 2023 June 15, 2023 July 1, 2023 June 1, 2023 June 1, 2023 Fauji Foundation Hospital, Rawalpindi, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05883813 480 NCT05883800 Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer TNT-RECORD Not yet recruiting No Results Available Rectal Cancer Radiation: On-couch adaptive radiotherapy Incidence of acute gastro-intestinal toxicity equal or higher than grade 2|Number of participants that require alteration of chemotherapy due to toxicity|Number of patients with disease related treatment failure|Number of patients with pathological complete response (pCR)|Tumour regression grade|Overall survival|Incidence of late gastro-intestinal toxicity equal or higher than grade 2 Haukeland University Hospital All 18 Years and older   (Adult, Older Adult) Not Applicable 61 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TNT-RECORD May 30, 2023 December 31, 2026 December 31, 2031 June 1, 2023 June 1, 2023 Haukeland University Hospital, Bergen, Norway https://ClinicalTrials.gov/show/NCT05883800 481 NCT05883787 Development of a Technical Solution to Digitalize the Analysis of Failure and Effects. e-AMFE Enrolling by invitation No Results Available Notification, Spousal Other: Exploration of a database FMEA José Joaquín Mira Solves|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana All 0 Years to 99 Years   (Child, Adult, Older Adult) 1 Other Observational Observational Model: Ecologic or Community|Time Perspective: Retrospective UGP-22-379 January 1, 2023 December 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 FISABIO, Alicante, Spain https://ClinicalTrials.gov/show/NCT05883787 482 NCT05883774 Effects of rTMS on the Anxiety State of Older Patients With GAD Not yet recruiting No Results Available Generalized Anxiety Disorder Device: Repetitive Transcranial Magnetic Stimulation|Device: Sham Repetitive Transcranial Magnetic Stimulation Differences in HAMA scores after 10 sessions of rTMS/sham-rTMS between two groups. Yi Yang|The First Hospital of Jilin University All 60 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment TMS-GAD June 1, 2023 May 1, 2024 June 1, 2024 June 1, 2023 June 5, 2023 First Hospital of Jilin University, Changchun, Jilin, China https://ClinicalTrials.gov/show/NCT05883774 483 NCT05883761 Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment Recruiting No Results Available Neural Tube Defects|Congenital Abnormalities|Teratogens Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on DTG at conception.|Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-negative women|Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on non-DTG ARV at conception|Prevalence of major external birth defects among all live and stillborn infants regardless of maternal HIV or ART status.|Proportion of other pregnancy outcomes Elizabeth Glaser Pediatric AIDS Foundation|Ministry of Health Eswatini|George Washington University Female Child, Adult, Older Adult 50000 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional EG0259 September 7, 2021 September 30, 2023 June 30, 2024 June 1, 2023 June 1, 2023 Good Shepherd Hospital, Lubombo, Swaziland|Mankayane Government Hospital, Manzini, Swaziland|Raleigh Fitkin Memorial Hospital, Manzini, Swaziland|Mbabane Government Hospital, Mbabane, Swaziland|Hlathikhulu Hospital, Shiselweni, Swaziland "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/61/NCT05883761/Prot_SAP_000.pdf https://ClinicalTrials.gov/show/NCT05883761 484 NCT05883748 Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP Not yet recruiting No Results Available Erythropoietic Protoporphyria Drug: DISC-1459 Incidence of treatment-emergent adverse events|Incidence of clinically abnormal vital signs|Incidence of clinically abnormal physical exam|Incidence of abnormal laboratory test results|Assessment of PHQ-8|Assessment of C-SSRS|Change from baseline in daily daylight tolerance, as assessed by total hours spent in the sunlight without pain and average time to first prodromal syndrome in sunlight|Change from baseline in whole blood metal-free PPIX levels|Plasma Bitopertin Concentrations Disc Medicine, Inc All 12 Years and older   (Child, Adult, Older Adult) Phase 2|Phase 3 200 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment DISC-1459-501 June 2023 June 2028 June 2028 June 1, 2023 June 2, 2023 University of Alabama Hospital, Birmingham, Alabama, United States|University of California San Francisco, San Francisco, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Hospital, New York, New York, United States|Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Pavilion, Pittsburgh, Pennsylvania, United States|University of Texas, Galveston, Texas, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia https://ClinicalTrials.gov/show/NCT05883748 485 NCT05883735 Retrospective Study of Radio-induced Toxicities in the Treatment of Lung Cancer With Tomotherapy ETRICAPT Not yet recruiting No Results Available Lung Cancer late toxicity of radiotherapy|acute toxicity of radiotherapy Centre Hospitalier Régional Metz-Thionville All 18 Years and older   (Adult, Older Adult) 396 Other Observational Observational Model: Cohort|Time Perspective: Retrospective 2023-05Obs-CHRMT May 2023 December 2023 December 2023 June 1, 2023 June 1, 2023 CHR Metz-Thionville/Hopital de Mercy, Metz, France https://ClinicalTrials.gov/show/NCT05883735 486 NCT05883722 Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation Not yet recruiting No Results Available Atrial Fibrillation, Persistent Procedure: Catheter ablation Atrial fibrillation recurrence|Atrial fibrillation/atrial tachycardia recurrence Xu Liu|The Third Xiangya Hospital of Central South University|Yangpu District Central Hospital Affiliated to Tongji University|Shanghai Chest Hospital All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment KS(Y)23218 June 30, 2023 December 30, 2024 December 30, 2024 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883722 487 NCT05883709 A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL Not yet recruiting No Results Available Diffuse Large B-cell Lymphoma Drug: Tafasitamab Injection objective remission rate|Progression-free survival (PFS) Zhao Weili|Ruijin Hospital All 18 Years and older   (Adult, Older Adult) 15 Other Observational Observational Model: Cohort|Time Perspective: Retrospective KY2023-006 July 1, 2023 December 30, 2023 December 30, 2024 June 1, 2023 June 1, 2023 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China https://ClinicalTrials.gov/show/NCT05883709 488 NCT05883696 Palliative Care Needs Among Elderly People at Emergency Department Recruiting No Results Available Palliative Medicine|Palliative Care|Elderly Person Other: Swedish Palliative Care Guide (S-PCG) Palliative care needs|Palliative care needs documented in medical records. Region Skane All 75 Years and older   (Older Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 2020-05905 March 31, 2023 June 30, 2023 October 31, 2023 June 1, 2023 June 1, 2023 Region Skane, Helsingborg, Skane, Sweden https://ClinicalTrials.gov/show/NCT05883696 489 NCT05883683 Molecular Study and Precision Medicine for Colorectal Cancer MSPM Not yet recruiting No Results Available Advanced Colorectal Carcinoma|Recurrent Colorectal Carcinoma Other: Molecular Profiling & drug testing in tumor organoids and PDXs Identification of effective drugs or drug combinations|Comparison of clinical actionable alterations identified in native tumor and organoids.|Correlation between organoid and PDX drug sensitivities Wuhan Union Hospital, China All 18 Years to 75 Years   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective CIT-CoPT-R01 July 1, 2023 July 1, 2026 July 1, 2026 June 1, 2023 June 1, 2023 Wuhan Union Hospital, China, Wuhan, Hubei, China https://ClinicalTrials.gov/show/NCT05883683 490 NCT05883670 Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer Recruiting No Results Available Cervical Cancer Drug: Serplulimab Objective Response Rate (ORR)|Progression free survival (PFS)|Overall Survival (OS)|Duration of response (DOR)|Time to the first disease progression|1-year and 2-year Progression free survival Rate|1-year and 2-year Overall Survival Rate|1-year and 2-year Disease Control Rate Shandong University Female 18 Years and older   (Adult, Older Adult) 118 Other Observational Observational Model: Other|Time Perspective: Prospective ASTRUM-CC02 March 9, 2023 March 31, 2024 December 31, 2025 June 1, 2023 June 1, 2023 Qilu Hospital of Shandong University, Jinan, Shandong, China https://ClinicalTrials.gov/show/NCT05883670 491 NCT05883657 Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) Not yet recruiting No Results Available Solar Lentigo|Senile Lentigo|Post Inflammatory Hyperpigmentation Device: Condition 1 : Prototypes (816-v1) every weeks|Device: Condition 2 : Prototypes (816-v1) every two weeks Change from baseline skin hyperpigmentation|Change from baseline skin hypopigmentation|Change from baseline skin appearance|Change from baseline skin sensation|Self-assesment of pain by VAS|Change from baseline spots visibility|Incidence of unexpected events|Self assessment of skin appearance Cryonove Pharma|Dermatech|CEISO|Sefako Makgatho Health Sciences University All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 80 Industry|Other Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment CS5_7 June 10, 2023 December 12, 2023 December 12, 2023 June 1, 2023 June 1, 2023 Photobiology Laboratory, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa https://ClinicalTrials.gov/show/NCT05883657 492 NCT05883644 Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) SIERRA Not yet recruiting No Results Available Advanced Hepatocellular Carcinoma Drug: Durvalumab|Drug: Tremelimumab Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs)|Objective response rate (ORR)|Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event of special interest (AESIs), immune-mediated AEs (imAEs)|Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate at Week 16 (DCR-16w)|Disease Control Rate at Week 24 (DCR-24w)|Duration of Response (DOR)|Duration of Treatment (DOT)|Time to deterioration in Health-Related Quality of Life (HRQoL), assessed using the EORTC QLQ C-30.|Clinically meaningful change from baseline in HRQoL as assessed by EORTC QLQ C-30|Best overall response for HRQoL as assessed by EORTC QLQ C-30|Change from baseline in HRQoL as assessed by EORTC QLQ C-30|Time to deterioration in HRQoL as assessed by EORTC QLQ-HCC18|Clinically meaningful change from baseline in HRQoL as assessed by EORTC QLQ-HCC18|Best overall response for HRQoL as assessed by EORTC QLQ-HCC18|Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18 AstraZeneca All 18 Years to 130 Years   (Adult, Older Adult) Phase 3 140 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment D419CR00030 July 14, 2023 April 10, 2026 April 13, 2026 June 1, 2023 June 1, 2023 Research Site, La Jolla, California, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bobigny, France|Research Site, Clichy, France|Research Site, Creteil, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Rennes, France|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Kiel, Germany|Research Site, Köln, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Pisa, Italy|Research Site, Rozzano, Italy|Research Site, Turin, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Matsuyama-city, Japan|Research Site, Musashino-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam https://ClinicalTrials.gov/show/NCT05883644 493 NCT05883631 Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Atrial Fibrillation Sources and Guide Ablation Therapy. RESOLVE-AF Not yet recruiting No Results Available Atrial Fibrillation|Atrial Fibrillation, Persistent|Atrial Fibrillation Paroxysmal|Arrhythmia|Arrhythmias, Cardiac|Atrial Flutter|Atrial Fibrillation, Paroxysmal or Persistent|Atrial Arrhythmia|Atrial Tachycardia Device: Ablacath™ Mapping Catheter, Ablacath™ Mapping Catheter Accessory Cables, Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software Freedom from documented AF episodes lasting > 30 seconds (with or without AAD) following the index procedure through 12-months|Freedom from a composite of serious adverse events (SAEs) occurring within 7 days from the index procedure|Demonstrate the predictive value of EGF phenotype for ablation outcome|Freedom from a composite of SAE occurring within 30 days from post-index ablation procedure|Overall reduction in burden of AF for subset of patients with implantable loop recorder|Overall procedure time, fluoro time, total EGF-guided mapping time, total EGF-guided ablation time Ablacon, Inc. All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 500 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CP006 September 1, 2023 February 1, 2025 September 1, 2025 June 1, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05883631 494 NCT05883618 Global Neurotrauma Outcomes Study: Spine GNOS Spine Recruiting No Results Available Spine Injury|Trauma Other: Exposure Frankel Grade|Mortality|Length of Stay|Peri-operative Complications|Independence with activities of daily living (ADLs)|Mobility University of Cambridge|NIHR Global Health Research Group on Neurotrauma All 18 Years and older   (Adult, Older Adult) 1000 Other Observational Observational Model: Cohort|Time Perspective: Prospective GNOSSpine July 12, 2021 May 30, 2023 May 30, 2023 June 1, 2023 June 1, 2023 University of Cambridge, Cambridge, County, United Kingdom "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/18/NCT05883618/Prot_SAP_000.pdf https://ClinicalTrials.gov/show/NCT05883618 495 NCT05883605 Clinical Validation of The Combei BP 880 W Completed No Results Available Hypertension Device: Measuring blood pressure Accuracy of blood pressure measurement|differences between the tested device and the gold standard (mercury sphygmomanometer according to the baseline blood pressure and to the wrist circumference International Society for Vascular Health All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 85 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other VALCOMBW22 January 10, 2023 May 23, 2023 May 27, 2023 June 1, 2023 June 1, 2023 Roland Asmar, Paris, France https://ClinicalTrials.gov/show/NCT05883605 496 NCT05883592 A Real-World Study on Distal Aortic Remodeling for Stanford Type B Aortic Dissection With Fabulous Thoracic Aortic Stent System Not yet recruiting No Results Available Aortic Dissection Device: Fabulous Thoracic Aortic Stent System Change of diameter|Changes of cross-sectional area|Volumetric change|Splanchnic arteries perfusion|Incidence of distal new entry|Tortuosity of the descending thoracic aorta|Immediate technical success|Incidence of type I and III endoleak|Major adverse events occurring within 30 days after surgery|Incidence of severe adverse events Hangzhou Endonom Medtech Co., Ltd. All 18 Years and older   (Adult, Older Adult) 50 Industry Observational Observational Model: Case-Only|Time Perspective: Prospective Fabulous WQ-F01 May 2023 May 2024 May 2024 June 1, 2023 June 1, 2023 Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China https://ClinicalTrials.gov/show/NCT05883592 497 NCT05883579 Application of Coronary Artery Chronic Total Occlusion Scoring Systems CTO-PCI Recruiting No Results Available Chronic Total Occlusion of Coronary Artery Procedure: percutaneous coronary intervention comparison of the effecacy of using CTO scoring systems (J-CTO scoring, Castle Score and progress scoring along with the CC scoring in prediction of technical success. Assiut University|National Taiwan University Hospital All Child, Adult, Older Adult 650 Other Observational Observational Model: Cohort|Time Perspective: Retrospective CTO-PCI scores application April 1, 2023 July 1, 2023 August 1, 2023 June 1, 2023 June 1, 2023 National Taiwan University Hospital, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05883579 498 NCT05883566 Comparison of Dental Pain Response in Children Recruiting No Results Available Dental Anxiety Behavioral: experimental Post operative pain Altamash Institute of Dental Medicine All 6 Years to 12 Years   (Child) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care Dental Pain in children May 1, 2023 June 30, 2023 June 30, 2023 June 1, 2023 June 2, 2023 Hira, Karachi, Sindh, Pakistan|Hira Danish, Karachi, Sindh, Pakistan https://ClinicalTrials.gov/show/NCT05883566 499 NCT05883553 Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients. EROS Recruiting No Results Available Transgenderism|Erectile Dysfunction|Prosthesis Durability|Gender Dysphoria|Sexual Dysfunction Device: Usability and added value of device within sexual activity Percentage of patients choosing either for the prosthesis or the epithesis at the start of study|Difference in capability rate of vaginal and/or anal penetration of the participant's partner|Interest in continued use of epithesis by both patient and partner|Difference in quality of sexual experience|Difference in treatment satisfaction|Difference in relationship satisfaction|Difference in lower urinary tract symptoms|Difference in maximum flow rate|Postoperative complication rate|Overall complication rate University Hospital, Ghent|ELATOR/EREKTOR Female 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment B6702023000188 May 17, 2023 June 30, 2024 December 31, 2024 June 1, 2023 June 1, 2023 Department of Urology, University Hospital Ghent, Ghent, East-Flanders, Belgium|Department of Urology, Amsterdam University Medical Center, Amsterdam, Noord-Holland, Netherlands https://ClinicalTrials.gov/show/NCT05883553 500 NCT05883540 Lysergic Acid Diethylamide (LSD) in Palliative Care LPC Not yet recruiting No Results Available Palliative Care|Pain|Anxiety|Depression|Demoralization|Psychological Distress|Quality of Life|Caregiver Burden|Fear of Death|Existential Distress Drug: Lysergic Acid Diethylamide Tartrate Changes in state anxiety assessed by questionnaire (state anxiety inventory, STAI-S) compared with active placebo|Changes in pain levels assessed by questionnaire compared with active placebo|Changes in opioid use (dosages of opioids unified according to equivalent dosages of oral morphine) compared with active placebo|Changes in spiritual well-being assessed by questionnaires (Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being; The 12-item Spiritual Well-Being Scale (FACIT-Sp-12)) compared with active placebo|Changes in demoralization assessed by questionnaires (Demoralization Scale II (DS-II)) compared with active placebo|Changes in quality of life assessed with a single-item question compared with active placebo|Changes in anxiety, pain levels, quality of life, demoralization, and spiritual well-being shortly after first intervention compared with scores shortly after second intervention|Changes in patient's depression, isolation, anxiety, fear and denial of imminence of death, and pre-occupation with pain using investigator-ratings compared with active placebo|Changes in patient's behaviour and attitudes rated by community observers compared with active placebo|Changes in caregiver burden assessed by questionnaire compared with active placebo|Associations between acute LSD effects assessed with questionnaires and long-lasting therapeutic effects assessed with questionnaires|Changes in burden of suffering assessed with the Pictorial Representation of Illness and Self-Measure (PRISM) compared with active placebo|Qualitative description of subjective changes after intervention assessed with semistructured interviews|Expectancy as a mediator for treatment effects assessed with questionnaire|Assessment of adverse events (AE)|Physical and general discomfort during drug sessions using standardized questions (adapted list of complaints)|Changes in vital signs during drug sessions University Hospital, Basel, Switzerland|University Hospital, Zürich All 25 Years and older   (Adult, Older Adult) Phase 2 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care BASEC 2022-01818 September 2023 September 2027 September 2027 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883540 501 NCT05883527 Partnership in Safeguarding People With Dementia From Primary and Social Care Perspectives Recruiting No Results Available Dementia|Abuse Client|Neglect; Care, Malnutrition Other: Not applicable as not an intervention - PLwD and family/carers|Other: Not applicable as not an intervention - HCP's Trends in reporting of routinely collected safeguarding datasets - NHS digital|Trends in reporting of routinely collected safeguarding datasets - ELSA data|Quality Outcomes Framework (QOF) Recorded Dementia Diagnoses University of Manchester All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Other|Time Perspective: Retrospective IRAS ID: 319897 May 2023 August 2023 March 31, 2024 June 1, 2023 June 1, 2023 CRN, Leeds, United Kingdom|Leeds Local Authority, Leeds, United Kingdom|CRN, Manchester, United Kingdom|Greater Manchester Local Authority, Manchester, United Kingdom|CRN, Southport, United Kingdom https://ClinicalTrials.gov/show/NCT05883527 502 NCT05883514 The Feasibility of Motivational Interviewing on Emotional Intelligence, Dispositional Optimism, and Adherence to Care Practices Among Patients With Permanent Pacemaker Recruiting No Results Available Pacemaker DDD Behavioral: Motivational interviewing Adherence with Pacemaker Care Practices|Emotional Intelligence|Dispositional optimism Alexandria University All 20 Years to 65 Years   (Adult, Older Adult) Not Applicable 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 0001 April 15, 2023 August 15, 2023 September 15, 2023 June 1, 2023 June 1, 2023 Faculty of Nursing, Alexandria university, Alexandria, Egypt https://ClinicalTrials.gov/show/NCT05883514 503 NCT05883501 Effect of Self-affirmation Versus Back Massage on Psychological Distress and Fear of Birth Among Primigravid Women in Third Trimester Recruiting No Results Available Self-affirmation, Back Massage Behavioral: Self-affirmation versus back massage Psychological Distress|Fear of childbirth Alexandria University Female 20 Years to 35 Years   (Adult) Not Applicable 80 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 2252023 April 1, 2023 October 1, 2023 October 20, 2023 June 1, 2023 June 1, 2023 Faculty of Nursing, Alexandria, Egypt https://ClinicalTrials.gov/show/NCT05883501 504 NCT05883488 Effectiveness of Robot-Assisted Upper Extremity Rehabilitation in Children With Cerebral Palsy Not yet recruiting No Results Available Cerebral Palsy|Upper Extremity Problem Other: Robot-assisted upper extremity rehabilitation|Other: Conventional rehabilitation QUEST (Quality of Upper Extremity Skills Test)|ABILHAND-Kids|Box and Block Test|KINDL (Questionnaire to assess Health-Related Quality of Life in children and adolescents)|Modified Ashworth Scala (MAS) Ankara City Hospital Bilkent All 5 Years to 15 Years   (Child) Not Applicable 42 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment AnkaraCHBilkent-BT June 15, 2023 November 15, 2023 November 15, 2023 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883488 505 NCT05883475 Effects of Hemiplegic Shoulder Pain Completed No Results Available Stroke|Shoulder Pain Other: Disabilities of the Arm, Shoulder, and Hand Questionnaire|Other: Arm Motor Ability Test|Other: Nine Hole Peg Test|Other: Pittsburg Sleep Quality Index|Other: Functional Independence Measure DASH|AMAT|Nine Hole Peg Test|Sleep Qaulity|Functional Independence Ankara Yildirim Beyazıt University All 18 Years to 90 Years   (Adult, Older Adult) 63 Other Observational Observational Model: Case-Control|Time Perspective: Cross-Sectional 963 June 1, 2022 October 15, 2022 October 30, 2022 June 1, 2023 June 1, 2023 Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Esenboğa, Turkey https://ClinicalTrials.gov/show/NCT05883475 506 NCT05883462 Paclitaxel-Coated Nasal Balloon for the Treatment of Recurrent Chronic Rhinosinusitis With or Without Nasal Polyps (FIH) Not yet recruiting No Results Available Chronic Rhinosinusitis Combination Product: Airiver Nasal Drug Coated Balloon (DCB) Catheter. Primary safety: Freedom from major device related adverse events (MADE) post index procedure assessed by the proportion of subjects free from the primary safety event through 30 days.|Primary efficacy: Freedom from target lesion reintervention due to recurrence of CRS without nasal polyposis or CRS with nasal polyposis (retuning to baseline symptoms or worse) through 6 months.|Incidence of, and time to symptom-driven reintervention|Change in patient reported 22-item Sino-Nasal Outcome Test (SNOT-22) from the baseline|Change in Lund-Kennedy Endoscopic Scores from the baseline|Change in Lund-Mackay computed tomography (LMK-CT) score from the baseline|Change of Health-related quality -of- life (HRQL) from the baseline (Euro-QOL-5D questionnaire)|Change in sense of smell using the University of Pennsylvania Smell Identification Test (UPSIT) from the baseline|Clinical pharmacokinetics of paclitaxel in 15 subjects|Change in Asthma Control Questionnaire-6 (ACQ-5) Scores from baseline for subjects with comorbid asthma|Nasal DCB performance evaluation in index procedures Airiver Medical, Inc. All 18 Years and older   (Adult, Older Adult) Early Phase 1 45 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RESTORE-1 June 2023 December 2024 December 2029 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883462 507 NCT05883449 Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL LuminICE-203 Not yet recruiting No Results Available Relapsed or Refractory Hodgkin Lymphoma|Peripheral T Cell Lymphoma Drug: AFM13|Drug: AB-101|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Interleukin-2 Objective Response Rate by Independent Radiology Committee|Duration of Response by Investigator and Independent Radiology Committee|Complete response rate (CRR) by Investigator and Independent Radiology Committee|ORR by Investigator based on PET-CT as assessed by the Lugano classification|Incidence of subjects receiving subsequent transplant|Incidence of TEAEs and SAEs|Immunogenicity assessment of AFM13 in combination with AB-101|Progression-free survival (PFS) by Independent Radiology Committee|Overall survival (OS) Affimed GmbH|Artiva Biotherapeutics, Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 154 Industry Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment AFM13-203 July 31, 2023 April 30, 2026 November 30, 2027 June 1, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05883449 508 NCT05883436 Investigation of DEXA-C Anterior Cervical Interbody System DEXA-C Recruiting No Results Available Degenerative Disc Disease Device: DEXA-C Cervical Interbody System Fusion Assesment|Subsidence Aurora Spine and Pain All 18 Years and older   (Adult, Older Adult) Not Applicable 80 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 01-AUR-DEXA-23 February 22, 2023 February 22, 2025 December 31, 2025 June 1, 2023 June 1, 2023 UCI Center for Clinical Research, Orange, California, United States|Orthopaedic Institute of Western KY, Metropolis, Illinois, United States https://ClinicalTrials.gov/show/NCT05883436 509 NCT05883423 Application of Frailty Prevention Care Management Program of Community Elderly Adults Not yet recruiting No Results Available Frailty Other: FPCMP-Old Age The Taiwanese version of Tilburg frailty indicator(TFI-T)|Chronic Disease and Health Problems Scale|Health Function|Nutritional Assessment Chang Gung Memorial Hospital All 60 Years to 99 Years   (Adult, Older Adult) Not Applicable 70 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research 202202269B0 June 1, 2023 December 31, 2023 December 31, 2023 June 1, 2023 June 1, 2023 Taiwan, Chiayi City, Taiwan https://ClinicalTrials.gov/show/NCT05883423 510 NCT05883410 The Effect of Two Different Protocol in Wrist Joint Limitation After Distal Radius End Fractures Not yet recruiting No Results Available Distal Radius Fracture|Wrist Fracture Other: Exercise|Other: PNF Technique|Other: Mulligan Mobilization Pain Threshold Assessment|Visual Analog Scale|Muscle Strength Assessment|Range of Motion Assessment (ROM)|Proprioception Assessment|Tampa Kinesiophobia Scale|Patient Rated Wrist Evaluation (PRWE) Biruni University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 34 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment Biruni Uni May 30, 2023 July 15, 2023 October 1, 2023 June 1, 2023 June 1, 2023 Biruni University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05883410 511 NCT05883397 Enhanced Hippocampal Neuroplasticity for Surfacing of Inaccessible Traumatic Memories in Veterans With PTSD Recruiting No Results Available PTSD|Peritraumatic Amnesia Other: HBOT|Other: Hippocampal training Changes in memory gaps (as assessed by the traumatic scene form)|Time to inaccessible memory surfacing|Change in brain activity as assessed by fMRI (functional magnetic resonance imaging)|cognitive performance as assessed using "Neurotrax"|RAVLT memory test|ROCFT memory test|Verbal Pairs memory test Assaf-Harofeh Medical Center|Weizmann Institute of Science|Office of Naval Research (ONR) Male 25 Years to 60 Years   (Adult) Not Applicable 60 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 90-22 May 25, 2023 May 1, 2025 August 1, 2025 June 1, 2023 June 1, 2023 Assaf-Harofeh Medical Center, Ramla, Israel https://ClinicalTrials.gov/show/NCT05883397 512 NCT05883384 Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy Recruiting No Results Available Cow's Milk Allergy Other: stool analysis , CBC, specific IgE FOR Cow milk protein allergy patient who are diagnosed as cow milk protein allergy by CoMiss|interpretation of the Cow's milk-related symptoms score|Food Challenge Test Sohag University All 1 Minute to 5 Years   (Child) 100 Other Observational Observational Model: Other|Time Perspective: Prospective Soh-Med-23-01-01 January 1, 2023 June 2023 August 2023 May 31, 2023 May 31, 2023 Sohag University Hospital, sOHAG, Egypt https://ClinicalTrials.gov/show/NCT05883384 513 NCT05883371 IMPACT - AndHealth Autoimmune Research Registry Not yet recruiting No Results Available Arthritis, Rheumatoid|Arthritis, Psoriatic|Psoriasis|Ankylosing Spondylitis|Autoimmune Diseases Other: Root-cause autoimmune treatment program PROMIS - Global Health|Routine Assessment of Patient Index Data 3 (RAPID 3)|Dermatology Life Quality Index (DLQI)|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|Patient Health Questionnaire for Anxiety and Depression (PHQ4)|Disease Activity Score 28 (DAS28)|Psoriasis Area and Severity Index (PASI) AndHealth All 18 Years to 70 Years   (Adult, Older Adult) 2500 Industry Observational Observational Model: Other|Time Perspective: Prospective 044-AND May 22, 2023 November 22, 2023 May 22, 2028 May 31, 2023 May 31, 2023 AndHealth, Columbus, Ohio, United States https://ClinicalTrials.gov/show/NCT05883371 514 NCT05883358 Kratom Use Disorder Management Using Clonidine and/or Buprenorphine Recruiting No Results Available Withdrawal Syndrome Drug: Clonidine, Buprenorphine Clinical Opiate Withdrawal Score Salem Anaesthesia Pain Clinic All 20 Years to 99 Years   (Adult, Older Adult) 50 Other Observational Observational Model: Case-Crossover|Time Perspective: Prospective SalemAnes2022 Kratom Addiction July 2, 2020 August 31, 2023 August 31, 2023 May 31, 2023 May 31, 2023 Salem Anaesthesia Pain Clinic, Surrey, British Columbia, Canada https://ClinicalTrials.gov/show/NCT05883358 515 NCT05883345 Validation of Serum Assays for the Diagnosis of Gastritis Recruiting No Results Available Cancer Screening Tests Diagnostic Test: Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels Validity of blood tests for gastric cancer screening and gastritis type Konkuk University Medical Center All 18 Years to 99 Years   (Adult, Older Adult) 1400 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023-04-056 April 24, 2023 April 23, 2025 December 31, 2025 May 31, 2023 May 31, 2023 Konkuk University Medical Center, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05883345 516 NCT05883332 A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters Completed No Results Available Lower Urinary Tract Symptoms Drug: Self-Administered Nitrous Oxide|Other: Oxygen Bladder capacity|Intra-Urodynamic Study (UDS) pain|Intra-Urodynamic Study (UDS) anxiety|Post void residual|Max flow rate|Detrusor overactivity|Detrusor pressure at maximum flow Beth Israel Deaconess Medical Center|Boston Children's Hospital All 21 Years to 85 Years   (Adult, Older Adult) Phase 4 19 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care 2022P-000826 January 10, 2023 March 2, 2023 March 9, 2023 May 31, 2023 May 31, 2023 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/32/NCT05883332/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05883332 517 NCT05883319 The Effect Of Cervical Mobilization And Clinical Pilates in Cervicogenic Headache Recruiting No Results Available Headache, Cervicogenic|Exercise|Therapeutics Other: manuel therapy|Other: exercises Change of muscle stiffness degree|Change of blood flow degree|Change intensity of pain|neck functional status|deep neck flexor muscle strength|headache life quality Meltem Uzun|Sanko University All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 45 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment SankoMU August 1, 2020 August 1, 2023 September 1, 2023 May 31, 2023 May 31, 2023 SANKO University, Gaziantep, Please Select, Turkey https://ClinicalTrials.gov/show/NCT05883319 518 NCT05883306 Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans Completed No Results Available Healthy Subjects|Pharmacokinetics of 14C-labeled of LXI-15028 Drug: [14C]LXI-15028 Mass balance|Metabolite Profiling|Total radioactivity in plasma PK:Tmax|Total radioactivity in plasma PK:AUC0-t|Total radioactivity in plasma PK:t1/2|Total radioactivity in plasma PK:CL/F|Total radioactivity in plasma PK:Vd/F|LXI-15028 and metabolite PK:Cmax|LXI-15028 and metabolite PK:Tmax|LXI-15028 and metabolite PK:AUC0-t|LXI-15028 and metabolite PK:AUC0-inf|LXI-15028 and metabolite PK:t1/2|LXI-15028 and metabolite PK:CL/F|LXI-15028 and metabolite PK:Vd/F|Adverse events Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Male 18 Years to 45 Years   (Adult) Phase 1 6 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research NE822201 June 30, 2022 July 21, 2022 December 23, 2022 May 31, 2023 May 31, 2023 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China https://ClinicalTrials.gov/show/NCT05883306 519 NCT05883293 Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis CEFFE-IPF Recruiting No Results Available Idiopathic Pulmonary Fibrosis Drug: Cell Free Fat Extract(CEFFE) Modified UK Medical Research Council Respiratory Questionnaire (mMRC)|Borg grading scale|SGRQ Quality of Life Questionnaire|Vital capacity (VC)|Forced vital capacity (FVC)|Forced expiratory volume in the first second (FEV1)|The ratio of the measured carbon monoxide dispersion to the expected value (DLCO%)|Adverse reactions Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University All 18 Years to 80 Years   (Adult, Older Adult) Early Phase 1 7 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CEFFE-IPF-2023 June 1, 2023 December 31, 2024 December 31, 2024 May 31, 2023 May 31, 2023 The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05883293 520 NCT05883280 The Effect of Binaural Sound on the Occurrence of Emergence Delirium in Children Undergoing Strabismus Surgery Not yet recruiting No Results Available Emergence Delirium Other: Binaural beats Incidence of emergence delirium in postanesthetic care unit (PACU)|Paediatric Assessment of Emergence Delirium (PAED) score|Pain score (The Face, Legs, Activity, Cry and Consolability score)|EEG analysis during emergence period Seoul National University Hospital All up to 7 Years   (Child) Not Applicable 74 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention pediatric ED_binaural beat May 20, 2023 May 20, 2025 June 20, 2025 May 31, 2023 May 31, 2023 Seoul National University Hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05883280 521 NCT05883267 Virtual Reality and Children With Type 1 Diabetes Not yet recruiting No Results Available Virtual Reality Device: Virtual reality glasses|Device: Vocal-guided affective imagery Pain assessment|Anxiety assessment - state anxiety|Anxiety assessment - trait anxiety|Regimen adherence|Glycemic control measures - percentage of time in range 70-180 mg/dL|Glycemic control measures - percentage of time below range <70 mg/dL|Glycemic control measures - percentage of time below range <54 mg/dL|Glycemic control measures - percentage of time above range I >180 mg/dL|Glycemic control measures - percentage of time above range >250 mg/dL|Glycemic control measures - estimated HbA1c as measured by glucose management indicator (GMI)|Glycemic control measures - mean glucose|Glycemic control measures - standard deviation|Glycemic control measures - coefficient of variation (CV)|VR Satisfaction and effectiveness assessment Sheba Medical Center All 8 Years to 15 Years   (Child) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care SHEBA-21-816421-NG-CTIL May 2023 August 2023 September 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883267 522 NCT05883254 Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia Intermedia Not yet recruiting No Results Available Sickle Cell Disease, Beta Thalassemia Intermedia Diagnostic Test: RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR Expression pattern of PUM1 gene in patients with sickle cell anemia and β-thalassemia intermedia. Assiut University All Child, Adult, Older Adult 80 Other Observational Observational Model: Case-Control|Time Perspective: Cross-Sectional PUM1 Sickle cell Thalassemia August 2023 December 2026 December 2027 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883254 523 NCT05883241 Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture Not yet recruiting No Results Available Bone Fracture|Fresh Fracture Device: Sustained Acoustic Device with 2.5% Diclofenac Patch|Drug: 2.5% Diclofenac Patches Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain from Baseline ZetrOZ, Inc. All 18 Years to 80 Years   (Adult, Older Adult) Phase 1 90 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BF-01-2023 June 1, 2023 June 30, 2024 December 31, 2024 May 31, 2023 May 31, 2023 ZetrOZ Systems LLC, Trumbull, Connecticut, United States|National Sports Medicine Institute, Lansdowne Town Center, Virginia, United States https://ClinicalTrials.gov/show/NCT05883241 524 NCT05883228 Anesthesiologist Perspectives/Opinions/Ethics on Intraoperative/Intraprocedural Code Status and Intraoperative/Intraprocedural Code Status Management Plans AnesOpIntraDNR Not yet recruiting No Results Available Physician's Role|Opinions Aggregate Responses to Questions on Survey of ASA Members and Anesthesiologists Joseph Hendrix|University of Texas Southwestern Medical Center All Child, Adult, Older Adult 3000 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional STU-2023-0329 September 2023 December 2024 March 2025 May 31, 2023 June 1, 2023 University of Texas Southwestern Medical Center, Dallas, Texas, United States https://ClinicalTrials.gov/show/NCT05883228 525 NCT05883215 Effects of Social Media Usage on Pain Catastrophizing and Disease Impact in Female Patients With Fibromyalgia Syndrome Not yet recruiting No Results Available Fibromyalgia Other: Pain catastrophizing scale|Other: Beck Anxiety Inventory|Other: Social Media Use Integration Scale|Other: Fibromyalgia Impact Questionnaire Correlation between social media use and pain catastrophizing|Correlation between social media use and disease impact|Correlation between social media use and anxiety Uskudar State Hospital|Basaksehir Cam & Sakura Şehir Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey Female 18 Years to 65 Years   (Adult, Older Adult) 73 Other Observational Observational Model: Case-Only|Time Perspective: Prospective FMS1 October 1, 2023 June 1, 2024 December 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883215 526 NCT05883202 Effect of the Abutment-Prosthesis Connection on Marginal Bone Loss and Gingival Sealing Around Dental Implants Recruiting No Results Available Jaw, Edentulous, Partially Device: Connect®|Device: Multi-unit Marginal bone level|Peri-implant microbiome|Peri-implant inflammation Universidad de Granada All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 2622CEIH2022 May 22, 2023 May 31, 2025 July 31, 2025 May 31, 2023 May 31, 2023 Universidad de Granada, Granada, Spain https://ClinicalTrials.gov/show/NCT05883202 527 NCT05883189 Establish the Referenc Range of Antiphospholipid Antibody in Healthy Preganany Women Not yet recruiting No Results Available Focus Health Pregancy Women Diagnostic Test: Draw blood 95th and 99th pencentile data of pregancy and non-pregancy women Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Female 18 Years to 45 Years   (Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Prospective SYSKY-2022-412-01 May 20, 2023 October 7, 2023 February 28, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883189 528 NCT05883176 TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria B-TACE Not yet recruiting No Results Available Hepatocellular Carcinoma by BCLC Stage Drug: Bevacizumab Biosimilar QL 1101 Objective response rate (ORR) by RECIST 1.1 and mRECIST|Disease control rate (DCR)|Duration of response (DOR) by RECIST 1.1 and mRECIST|Progression-free survival (PFS) by RECIST 1.1 and mRECIST|Overall survival rate (OSR)|Progression-free survival time (mPFS)|Median overall survival time (mOS) Sun Yat-sen University All 18 Years to 70 Years   (Adult, Older Adult) Phase 2 35 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment B-TACE June 1, 2023 May 31, 2025 July 1, 2025 May 31, 2023 May 31, 2023 Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05883176 529 NCT05883163 STIMIT Activator 1 Pivotal Study Not yet recruiting No Results Available Diaphragm Issues Device: Stimit Activator 1 Preservation of Diaphragm Thickness|the rate of device or treatment related serious adverse events Stimit AG All 21 Years and older   (Adult, Older Adult) Not Applicable 40 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment D26606 July 5, 2023 February 5, 2024 February 5, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883163 530 NCT05883150 Intranasal Versus Nebulized Midazolam in Behaviuor Modification of Preschool Children Undergoing Dental Treatment Recruiting No Results Available Dental Sedation Drug: Nebulized Midazolam|Drug: Intranasal Midazolam Behavior rating|Onset of sedation|Level of sedation Nourhan M.Aly|University of Alexandria All 3 Years to 6 Years   (Child) Phase 2|Phase 3 68 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 210 November 10, 2022 August 2023 August 2023 May 31, 2023 May 31, 2023 Faculty of Oral and Dental Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt, Kafr Ash Shaykh, Egypt https://ClinicalTrials.gov/show/NCT05883150 531 NCT05883137 High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill HiPOXIC Not yet recruiting No Results Available Critical Illness|Respiratory Failure|Multi Organ Failure|Hypoxia Device: Optiflow Switch Desaturation up until 5 minutes after intubation|Frequency of complications|Change of intubation method|Intensive care length of stay|ETCO2 in the first breath after intubation|Duration of intubation|Arterial oxygen and carbon dioxide levels after intubation|Perceived intubation difficulties|Number of intubation attempts|Number of oesophageal intubations|30-day mortality|Perceived operator stress Region Stockholm|Karolinska Institutet All 18 Years to 100 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2023-0063201 May 20, 2023 May 31, 2025 June 30, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883137 532 NCT05883124 Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h) Active, not recruiting No Results Available Bioequivalence Drug: Rivastigmine twice-weekly 9,5 mg/24 h|Drug: Exelon® 9.5 mg/24 h AUC96-264|Cmax,96-264|CTau264|Patch adhesion properties|Adverse events SocraTec R&D GmbH Male 18 Years to 55 Years   (Adult) Phase 1 38 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other 1429riv22ct|2023-000074-10 April 17, 2023 June 2023 July 2023 May 31, 2023 May 31, 2023 SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thuringia, Germany https://ClinicalTrials.gov/show/NCT05883124 533 NCT05883111 HPV Self-testing in Transgender Individuals Self-TI Not yet recruiting No Results Available HPV Infection Diagnostic Test: HPV DNA methylation assay Feasibility of self-sampling in clinic|Acceptability of self-sampling in clinic|Feasibility of self-sampling at home|Acceptability of self-sampling at home|HPV concordance between vaginal self-sample and clinician-collected cervical swab|HPV correlation between self-samples taken at clinic and in home among trans women and non-binary people. Queen Mary University of London|National Cancer Institute (NCI) All 21 Years to 65 Years   (Adult, Older Adult) Not Applicable 100 Other|NIH Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 319364 October 1, 2023 October 1, 2024 October 2028 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05883111 534 NCT05883098 SDRM® vs. Collagen for Diabetic Foot Ulcers Active, not recruiting No Results Available Diabetic Foot|Ulcer Foot|Wound Heal Procedure: Wound debridement|Device: Wound closure matrix application Time to heal|Healing by 12 weeks|Direct costs|Infection rate Polymedics Innovations Inc.|McGill University All 18 Years and older   (Adult, Older Adult) Not Applicable 30 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment PMI-SUPRASDRM®-01 July 1, 2022 January 31, 2023 June 1, 2023 May 31, 2023 May 31, 2023 WAFL Inc, Circleville, Ohio, United States https://ClinicalTrials.gov/show/NCT05883098 535 NCT05883085 A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL Recruiting No Results Available Pheochromocytoma|Paraganglioma Drug: Anlotinib hydrochloride The proportion of PPGL patients whose tumor change from unresectable to resectable tumor.|The objective response rate (ORR)|The ratio of tumor shrinkage|The biochemical response.|R0 resection rate.|Major pathological response rate (MPR).|Pathologic complete remission (pCR).|Safety of anlotinib treatment. Peking Union Medical College Hospital All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 10 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 06086-02 May 1, 2022 December 1, 2023 May 1, 2024 May 31, 2023 May 31, 2023 Peking Union Medical College Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05883085 536 NCT05883072 Exploring the Effectiveness of AI Generative Models for Diabetic Patients Recruiting No Results Available Diabetes Mellitus, Type 2|Diabetic Retinopathy|Diabetes Behavioral: Exploring AI-Chatbot Usability of the Chatbot for diabetic patient|Internet Speed|Analyzing Chat response generated by AI Chatbot Pakistan Council of Scientific and Industrial Research All 18 Years to 100 Years   (Adult, Older Adult) 300 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional AI Chatbot Evaluation January 5, 2023 December 30, 2024 December 31, 2026 May 31, 2023 June 5, 2023 CDLE, PCSIR Lbas Complex, Karachi, Sindh, Pakistan https://ClinicalTrials.gov/show/NCT05883072 537 NCT05883059 Clinical Study On Lower Limb Robot For Lower Limb Dysfunction After Stroke Recruiting No Results Available Stroke Device: Lower limb robot assisted walking training|Other: routine rehabilitation Change from Baseline Berg Balance Scale at 4 weeks|Change from Baseline functional ambulation category scale at 4 weeks|Change from Baseline fugl-meyer assessment-lower extremity at 4 weeks|Change from Baseline modified barthel index at 4 weeks|Change from Baseline Gait parameters at 4 weeks|Change from Baseline Minimum Mental State Examination at 4 weeks liuyong|The First Affiliated Hospital of Dalian Medical University All 18 Years and older   (Adult, Older Adult) Not Applicable 18 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment PJ-KS-KY-2023-63(X) April 1, 2023 January 1, 2024 May 1, 2024 May 31, 2023 May 31, 2023 The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China https://ClinicalTrials.gov/show/NCT05883059 538 NCT05883046 The Acute Effects of Combined Caffeine and Sodium Bicarbonate Consumption on Isometric Mid-thigh Pull Completed No Results Available Athletes Other: Performance-Enhancing Substances|Other: Placebo|Other: Baseline (Control) Isometric Mid-Thigh Pull (IMTP) Bozok University All 18 Years to 24 Years   (Adult) Not Applicable 19 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other BozokU-SBF-IK-01 March 7, 2022 March 8, 2022 March 12, 2022 May 31, 2023 May 31, 2023 Faculty of Sport Sciences Eskisehir Technical University, Eskişehir, Tepebasi, Turkey https://ClinicalTrials.gov/show/NCT05883046 539 NCT05883033 VAC and Conventional Dressing in the Healing Process of Necrotizing Fasciitis Not yet recruiting No Results Available Necrotizing Fascitis Device: VAC Hospital staying length|Required other stages of debridement|Expected closure of the wound by secondary intention Assiut University All 1 Year and older   (Child, Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment Necrotizing fasciitis June 1, 2023 April 1, 2024 April 30, 2024 May 31, 2023 May 31, 2023 Assiut University, Assiut, Egypt https://ClinicalTrials.gov/show/NCT05883033 540 NCT05883020 Effect of Radial Shockwave on Calf Muscle Spasticity in Patients With Cerebral Palsy Recruiting No Results Available Cerebral Palsy Other: Experimental Interventions|Other: Standard physical therapy program calf muscle tone|ankle joint ROM|plantar surface area|gross-motor function|cerebral palsy quality of life questionnaire University of Hail All 8 Years to 14 Years   (Child) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research H-2023-150 March 13, 2023 March 13, 2024 March 13, 2024 May 31, 2023 May 31, 2023 King Salman Hospital, Hail, Saudi Arabia https://ClinicalTrials.gov/show/NCT05883020 541 NCT05883007 Dose Optimized BNCT for Head and Neck Cancer ST-BNCT2001 Active, not recruiting No Results Available Head and Neck Cancer|Squamous Cell Carcinoma Radiation: Accelerator-based BNCT with borofalan(10B) Adverse events (Absence and presence of serious adverse events)|Objective response rate: ORR|Duration of Response|Disease control rate (DCR)|Overall survival (OS)|Progression-Free Survival (PFS)|Late Adverse Events|Quality of life (QOL) Score Based on EORTC QLQ C30 and H&N35.|Quality-Adjusted Life Year (QALY) Southern Tohoku BNCT Research Center All 20 Years and older   (Adult, Older Adult) Phase 1 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ST-BNCT2001 June 1, 2020 May 31, 2022 May 31, 2024 May 31, 2023 June 5, 2023 Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan https://ClinicalTrials.gov/show/NCT05883007 542 NCT05882994 The Effect of Range of Motion Exercises on Fatigue and Sleep Quality in Hemodialysis Not yet recruiting No Results Available Renal Failure Behavioral: rom exercise Piper Fatigue Scale|Pittsburgh Sleep Quality Index (PUKI) Necmettin Erbakan University All 18 Years and older   (Adult, Older Adult) Not Applicable 44 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care Necmettin Erbakan Üniversty June 15, 2023 October 15, 2023 June 15, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882994 543 NCT05882981 Increased Femoral Anteversion and Physical Performance Not yet recruiting No Results Available High Femoral Anteversion|Muscle Strength|Flexibility|Functional Performance|Functional Capacity Other: Sit and reach test|Other: Hand grip strength measurement|Other: Back-leg-chest muscle strength measurement|Other: Functional performance|Other: Functional capacity Functional performance tests|Functional capacity measurement|Sit and reach test|Back-leg-chest muscle strength measurement|Hand grip strength measurement Bezmialem Vakif University All 17 Years to 26 Years   (Child, Adult) 44 Other Observational Observational Model: Case-Control|Time Perspective: Cross-Sectional DT-04 June 20, 2023 September 1, 2023 November 1, 2023 May 31, 2023 May 31, 2023 Bezmialem Vakif University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05882981 544 NCT05882968 Prevalence of H.Pylori in CKD Patients Not yet recruiting No Results Available H.Pylori Infection Diagnostic Test: kidney function tests Relationship between H.pylori and CKD patients according to Glomural filtration rate (GFR )according to kdigo guide lines Assiut University All 18 Years to 65 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective H.pylori in CKD patients July 1, 2023 July 2025 September 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882968 545 NCT05882955 Designing a Mixed-initiative Recipe Recommender App for Vegan and Vegetarian Sub-groups PERNUG Enrolling by invitation No Results Available Mobile Applications Behavioral: Recipes consumption|Behavioral: Hydroponic unit Change in serum ferritin after the dietary app intervention|Change of serum B12 after the hydroponic unit intervention|App usability rating|Score on the Unified Theory of Acceptance and Use of Technology questionnaire|Recipe recommendation performance Universitaire Ziekenhuizen KU Leuven Female 18 Years to 50 Years   (Adult) Not Applicable 52 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science G-2021-4203-R5(AMD) December 1, 2022 December 31, 2024 December 31, 2024 May 31, 2023 May 31, 2023 Departement Computerwetenschappen, Leuven, Vlaams-Brabant, Belgium https://ClinicalTrials.gov/show/NCT05882955 546 NCT05882942 Matcha Green Tea Effects at Rest and During Moderate-intensity Exercise in Females Recruiting No Results Available No Condition Dietary Supplement: Matcha green tea|Dietary Supplement: Placebo Heart rate variability|Carbohydrate oxidation|Fat oxidation|Cardiac output|Stroke volume|Total peripheral resistance University of Chichester Female 18 Years to 30 Years   (Adult) Not Applicable 14 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science 22231905455 March 3, 2023 July 26, 2023 August 15, 2023 May 31, 2023 May 31, 2023 Mark Willems, Chichester, West Sussex, United Kingdom|University of Chichester, Chichester, United Kingdom https://ClinicalTrials.gov/show/NCT05882942 547 NCT05882929 The Effect of Distraction in the Postoperative Period of Pediatric Patients Undergoing Outpatient Surgery Recruiting No Results Available Pain, Postoperative|Surgery|Child, Only Other: Watching Cartoons|Other: ball spin pain level of children|physiological parametres of the child: body temperature level|physiological parametres of the child: peak heart rate|physiological parametres of the child: respiratory rate|physiological parametres of the child: oxygen saturation (SpO2) Selcuk University All 6 Years to 12 Years   (Child) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other 2021/45 March 1, 2023 June 1, 2023 August 1, 2023 May 31, 2023 May 31, 2023 Selcuk University, Konya, Selcuklu, Turkey https://ClinicalTrials.gov/show/NCT05882929 548 NCT05882916 Reaching the Last 20% (the Pamoja Kwa Afya Study) Not yet recruiting No Results Available HIV Device: HIV self-testing|Behavioral: Behavioral economic 'nudges' HIV testing|HIV case diagnoses|ART and PrEP initiation Sue Napierala|Impact Research & Development Organization|University of Pennsylvania|University of North Carolina, Chapel Hill|RTI International Female 18 Years and older   (Adult, Older Adult) Not Applicable 5000 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 0218622 May 29, 2023 January 1, 2026 May 30, 2026 May 31, 2023 May 31, 2023 Impact Research and Development Organization (IRDO), Kisumu, Kenya https://ClinicalTrials.gov/show/NCT05882916 549 NCT05882903 The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients With Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS) Not yet recruiting No Results Available Chronic Rhinosinusitis (Diagnosis) Drug: Betamethasone Dipropionate Nasal Cream 0.0644%|Device: Pre-filled syringe and applicator device Change in 4-Cardinal Symptom score (4CSS) Baseline to Week 3.|Change in SNOT-22 Baseline to Week 3.|Safety of one application of BMDP Cream onto the sinus mucosa. Oticara Australia PTY LTD All 18 Years to 80 Years   (Adult, Older Adult) Phase 2 12 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment OT-007B June 1, 2023 December 1, 2023 December 1, 2023 May 31, 2023 May 31, 2023 Oticara Investigational Site, Brisbane, Queensland, Australia https://ClinicalTrials.gov/show/NCT05882903 550 NCT05882890 Does Craniosacraltherapy Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat? Active, not recruiting No Results Available Xerostomia Following Radiotherapy|Xerostomia Following in Neck Ore Head After Cancersurgery Other: cranio sacral therapy Xerostomia questionnaire after minimun 3 months|Xerostomia questionnaire after 3 months|side effect diary Cathrine Rahbek|Danish Cancer Society|DLHM - Danish Society for Mouth and Throat Cancer|Danish Network for Mouth and Throat Cancer|Rahbek Kraniosakralterapi All 18 Years to 81 Years   (Adult, Older Adult) Not Applicable 11 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RahbekKST-PILOT March 18, 2022 January 20, 2023 August 1, 2023 May 31, 2023 May 31, 2023 Center for Kræft og Sundhed, København, Denmark|- Rahbek kraniosakralterapi -FysioDanmark Skødstrup, Skødstrup, Århus, Denmark https://ClinicalTrials.gov/show/NCT05882890 551 NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) ROCKET-ASCEND Not yet recruiting No Results Available Atopic Dermatitis Drug: Rocatinlimab|Other: Placebo Number of Participants With Treatment-emergent Adverse Events|Maintaining Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1 Response Among Participants Achieving vIGA-AD 0/1 Response at Day 1|Maintaining vIGA-AD 0/1 and Presence of Barely Perceptible Erythema or No Erythema Response Among Participants Achieving vIGA-AD 0/1 With Additional Assessments of Morphology Response at Day 1|Maintaining EASI 75 Response Among Participants Achieving EASI 75 Response at Day 1|Maintaining vIGA-AD 0/1 Response and EASI 75 Response Among Participants Achieving vIGA-AD 0/1 Response and EASI 75 Response at Day 1|Percent Change From Parent Study Baseline in EASI Score Among Participants Achieving EASI 75 Response at Day 1|Maintaining ≥ 4-point Reduction From Parent Study Baseline in Weekly Average of Daily Worst Pruritus Numerical Rating Scale (NRS) Score Amgen All 12 Years to 100 Years   (Child, Adult, Older Adult) Phase 3 2200 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 20210146|2022-501587-17|EMEA-002886-PIP01-20-M02 May 31, 2023 February 7, 2027 February 7, 2027 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882877 552 NCT05882864 Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus With Immunohistochemical Analysis Not yet recruiting No Results Available Oral Lichen Planus Drug: 6-Gingerol|Drug: Triamcinolone Acetonide 0.1% Oromucosal Paste Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus Ain Shams University All 40 Years to 60 Years   (Adult) Phase 4 28 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment Herbs in oral medicine August 1, 2023 June 1, 2025 August 1, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882864 553 NCT05882851 Effect of Nutrition in the Treatment of Vaginitis Completed No Results Available Vaginitis Behavioral: determination of the current nutritional status of patients determination of the current nutritional status of patients|comparison of vaginitis treatment results and nutritional analysis results, determination of the effect of nutrition on treatment Osmaniye Korkut Ata University Female 18 Years and older   (Adult, Older Adult) 106 Other Observational Observational Model: Case-Only|Time Perspective: Prospective OsmaniyeKAUnad January 1, 2022 March 1, 2022 April 30, 2022 May 31, 2023 May 31, 2023 Aybala Tazeoğlu, Merkez, Osmaniye, Turkey https://ClinicalTrials.gov/show/NCT05882851 554 NCT05882838 The Level of Knowledge and Awareness of Myofascial Pain Syndrome in the Turkish Population Not yet recruiting No Results Available Myofascial Pain Syndrome Other: Myofascial Pain Syndrome Knowledge and Awareness Questionnaire Level of Knowledge and Awareness of Myofascial Pain Syndrome in the Turkish Population Uskudar State Hospital|Basaksehir Cam & Sakura Şehir Hospital All 18 Years to 65 Years   (Adult, Older Adult) 85 Other Observational Observational Model: Ecologic or Community|Time Perspective: Prospective MPSK1 November 1, 2023 July 1, 2024 November 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882838 555 NCT05882825 The Level of Knowledge and Awareness of Dry Needling Treatment in the Turkish Population Not yet recruiting No Results Available Dry Needling Other: Dry Needling Therapy Knowledge and Awareness Questionnaire Level of Knowledge and Awareness of Dry Needling Therapy in the Turkish Population Uskudar State Hospital|Basaksehir Cam & Sakura Şehir Hospital All 18 Years to 65 Years   (Adult, Older Adult) 400 Other Observational Observational Model: Ecologic or Community|Time Perspective: Prospective DNK1 August 1, 2023 December 1, 2023 July 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882825 556 NCT05882812 Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis Recruiting No Results Available Osteo Arthritis Knee|Arthritis Device: Sustained Acoustic Device with 2.5% Diclofenac Patch|Device: Sustained Acoustic Device with 0% Diclofenac Patch|Drug: 2.5% Diclofenac Patches Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline|Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) ZetrOZ, Inc. All 35 Years to 80 Years   (Adult, Older Adult) Phase 2 120 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment KP-01-2022 June 3, 2022 December 31, 2023 December 31, 2023 May 31, 2023 May 31, 2023 Orthopaedic Foundation, Stamford, Connecticut, United States|ZetrOZ Systems, Trumbull, Connecticut, United States|Cayuga Medical Center - Medical Pain Consultants, Dryden, New York, United States https://ClinicalTrials.gov/show/NCT05882812 557 NCT05882799 Ultrasound-guided vs. Blinded Dry Needling for Piriformis Syndrome Not yet recruiting No Results Available Piriformis Syndrome Procedure: Ultrasound-guided dry needling|Procedure: Blinded dry needling Change in Visual Analog Scale for Pain|Change in Oswestry Disability Index (ODI) Uskudar State Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment Priformis1 July 1, 2023 December 1, 2023 February 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882799 558 NCT05882786 Corticosteroid Injection Versus Tendon Dry Needling for Subacromial Impingement Syndrome Not yet recruiting No Results Available Shoulder Pain|Shoulder Impingement Syndrome|Shoulder Impingement|Subacromial Impingement Syndrome|Subacromial Impingement Procedure: Corticosteroid injection|Procedure: Dry Needling Change in Visual Analog Scale for Pain|Change in The Shoulder Pain and Disability Index (SPADI)|Change in Range Of Motion (ROM) Measurements Uskudar State Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment ImpDn1 July 1, 2023 December 1, 2023 January 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882786 559 NCT05882773 Asian Myeloproliferative Neoplasm (MPN) Registry Recruiting No Results Available Myeloproliferative Neoplasm|Polycythemia Vera|Essential Thrombocythemia|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis|Primary Myelofibrosis|Primary Myelofibrosis, Prefibrotic Stage|Primary Myelofibrosis, Fibrotic Stage Time to progression to secondary myelofibrosis (for PV and ET)|Progression-free survival (PFS)|Overall survival (OS) The University of Hong Kong|Novartis All 18 Years and older   (Adult, Older Adult) 1000 Other|Industry Observational Observational Model: Cohort|Time Perspective: Other AMWG002 May 2023 May 2026 December 2026 May 31, 2023 May 31, 2023 Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong https://ClinicalTrials.gov/show/NCT05882773 560 NCT05882760 Postoperative Sensitivity Following Placement With Different Restorative Materials In Vital Posterior Teeth GCP Not yet recruiting No Results Available Sensitivity, Tooth Drug: Tetric N Bond Universal®|Drug: Self Etch Tetric N Bond Universal®|Drug: GC Fuji IX, GC, Japan®|Drug: Activa TM Bioactive Restorative ® Post Operative Sensitivity Liaquat University of Medical & Health Sciences All 18 Years to 40 Years   (Adult) Phase 4 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment LUMHS/REC/-29 June 1, 2023 September 30, 2023 December 31, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882760 561 NCT05882747 Renal Cell Carcinoma Metastases to Pancreas Completed No Results Available Surgery overall survival|disease free survival|complications Rigshospitalet, Denmark All 18 Years and older   (Adult, Older Adult) 25 Other Observational Observational Model: Cohort|Time Perspective: Retrospective RH-2023-3 January 1, 2011 December 31, 2021 December 31, 2022 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882747 562 NCT05882734 M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Not yet recruiting No Results Available Non-Small Cell Lung Cancer Drug: M1774|Drug: Cemiplimab Phase 1b/Phase 2a: Confirmed Overall response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 As assessed by Investigator|Phase 1b: Number of Participants With Adverse Events (AEs) and Treatment-related AEs|Phase 1b/Phase 2a: Duration of Response (DoR) According to RECIST 1.1 as Assessed by the Investigator|Phase 1b/Phase 2a: Progression Free Survival (PFS) According to RECIST 1.1 as Assessed by the Investigator|Phase 1b/Phase 2a: Overall survival (OS)|Phase 2a: Number of Participants With AEs and Treatment-related AEs EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 180 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MS201924_0022|2022-502010-85-00 July 11, 2023 August 25, 2026 September 3, 2026 May 31, 2023 May 31, 2023 UPMC Cancer Center, Pittsburgh, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05882734 563 NCT05882721 Treatment for Improvement of Cellulite Appearance Using Form Applicator Recruiting No Results Available Cellulite Device: Sofwave Primary Outcome Measure: Sofwave Medical LTD Female 18 Years to 60 Years   (Adult) Not Applicable 60 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Sofwave19 February 20, 2023 February 20, 2024 February 20, 2024 May 31, 2023 May 31, 2023 Laser & Skin Surgery Center of Northern California, Sacramento, California, United States|Schweiger Dermatology GP Research, Hackensack, New Jersey, United States|UnionDerm, New York, New York, United States|Main Line Center for Laser Surgery, Ardmore, Pennsylvania, United States|Tennessee Clinical Research Center, Nashville, Tennessee, United States https://ClinicalTrials.gov/show/NCT05882721 564 NCT05882708 Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis Not yet recruiting No Results Available Sepsis|Ivabradine|Hemodynamics|Heart Rate Control Drug: Ivabradine The difference in heart rate|The difference in MAP|The difference in CI|The difference in LVEF|The difference in SVI|Overall mortality|difference of the Sequential Organ Failure Assessment score|length of ICU stay|The percentage of need for organ support|length of in-hospital stay Second Affiliated Hospital of Guangzhou Medical University All 18 Years and older   (Adult, Older Adult) Phase 4 172 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-LCYJ-YYDZX-02 July 1, 2023 December 31, 2024 March 31, 2025 May 31, 2023 May 31, 2023 the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05882708 565 NCT05882695 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants Not yet recruiting No Results Available Amyotrophic Lateral Sclerosis Drug: SPG302|Drug: Placebo Safety and tolerability in healthy volunteers (SAD cohort)|Safety and tolerability in healthy volunteers (SAD food effect cohort)|Safety and tolerability in healthy volunteers (MAD cohort)|Safety and tolerability in participants with ALS|Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD cohort)|Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD food effect cohort)|Plasma pharmacokinetics of SPG302 in healthy volunteers (MAD cohort)|Plasma pharmacokinetics of SPG302 in participants with ALS|Clinical outcomes of multiple oral doses of SPG302 in participants with ALS Spinogenix All 18 Years to 55 Years   (Adult) Phase 1 112 Industry Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment SPG302-ALS-001 July 2023 May 2024 December 2024 May 31, 2023 May 31, 2023 Nucleus Melbourne, Melbourne, Victoria, Australia https://ClinicalTrials.gov/show/NCT05882695 566 NCT05882682 Impact of Food-to-Food Fortified Cereal Products on Diet Quality in Eldoret, Kenya KenyaMPS Completed No Results Available Vitamin A Deficiency|Iron-deficiency Assessment of staple intake in urban Kenyan households and children|Assessment of the nutritional adequacy of urban Kenyan households and children Purdue University All 18 Months and older   (Child, Adult, Older Adult) 1800 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional IRB-2022-695 October 20, 2022 December 12, 2022 December 30, 2022 May 31, 2023 May 31, 2023 University of Eldoret, Eldoret, Uasin Gishu, Kenya https://ClinicalTrials.gov/show/NCT05882682 567 NCT05882669 Quality of Life, Functional Outcomes and Costs in Knee Arthroplasty Recruiting No Results Available Knee Arthropathy Other: Questionnaire administration Change in cost-utility of the primary total knee arthroplasty|Change in functional outcomes measured by total scores of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire|Change in quality of life indicators measured by the 5-level version of the EuroQol-5 Dimension questionnaire (EQ-5D-5L) health profile (state), index and the visual analogue scale score (EQ VAS)|Level of patients' satisfaction with the primary total knee arthroplasty procedure and overall treatment at the facility I.M. Sechenov First Moscow State Medical University All 18 Years and older   (Adult, Older Adult) 200 Other Observational Observational Model: Cohort|Time Perspective: Prospective 03.006.P.35.2 June 1, 2023 December 2024 June 2025 May 31, 2023 June 2, 2023 Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation https://ClinicalTrials.gov/show/NCT05882669 568 NCT05882656 Quality of Life, Functional Outcomes and Costs in Hip Arthroplasty Recruiting No Results Available Hip Arthropathy Other: Questionnaire administration Change in cost-utility of the primary total hip arthroplasty|Change in functional outcomes measured by total scores of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire|Change in quality of life indicators measured by the 5-level version of the EuroQol-5 Dimension questionnaire (EQ-5D-5L) health profile (state), index and the visual analogue scale score (EQ VAS)|Level of patients' satisfaction with the primary total hip arthroplasty procedure and overall treatment at the facility I.M. Sechenov First Moscow State Medical University All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective 03.006.P.35.1 June 1, 2023 December 2024 June 2025 May 31, 2023 June 2, 2023 Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation https://ClinicalTrials.gov/show/NCT05882656 569 NCT05882643 Deep Neuromuscular Blockade in Strabismus Surgery Not yet recruiting No Results Available Strabismus Other: moderate to deep neuromuscular blockade|Other: shallow to minimal neuromuscular blockade The incidence of grade 2 or greater oculocardiac reflex (induced)|The incidence of grade 1 oculocardiac reflex (induced)|The incidence of grade 2 or greater oculocardiac reflex (during strabismus surgery)|The incidence of grade 1 greater oculocardiac reflex (during strabismus surgery)|Number of times Rescue IV Atropine has been used for oculocardiac reflex|The incidence of hypotension|Postoperative nausea/vomiting Seoul National University Hospital All 3 Years to 18 Years   (Child, Adult) Not Applicable 204 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention H-2303-079-1412 June 1, 2023 June 1, 2026 June 1, 2026 May 31, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05882643 570 NCT05882630 Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer Not yet recruiting No Results Available Small Cell Lung Cancer Drug: Surufatinib,Serplulimab,Etoposide,Carboplatin Progress Free Survival(PFS)|Objective response rate(ORR)|Overall Survival(OS)|Disease control rate(DCR) Fujian Cancer Hospital|Hunan Cancer Hospital|Wuhan TongJi Hospital All 18 Years to 75 Years   (Adult, Older Adult) Phase 1|Phase 2 39 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HMPL-012-SPRING-L110 June 1, 2023 June 1, 2025 June 1, 2026 May 31, 2023 May 31, 2023 Fujian Cancer Hospital, Fuzhou, Fujian, China https://ClinicalTrials.gov/show/NCT05882630 571 NCT05882617 Patient Satisfaction With Different Numbers of Implants Completed No Results Available Patient Satisfaction Other: implants supported overdentures patient satisfaction for masticatory ability, mental life comfortability with dentures Cairo University All 55 Years to 75 Years   (Adult, Older Adult) Not Applicable 48 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other 33922 January 12, 2021 January 10, 2023 January 10, 2023 May 31, 2023 June 5, 2023 Doaa Mahmoud Elkady, Cairo, Egypt|Nesma Mohamed Awaad, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05882617 572 NCT05882604 MESNA Injection for TMJ Internal Derangement Not yet recruiting No Results Available TMJ Disorder Drug: Mesna Injection|Drug: Arthrocentesis with ringer solution maximal interincisal opening (MIO)|Joint pain|clicking sound Tanta University All Child, Adult, Older Adult Not Applicable 12 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment #R-OS-4-23-3 May 2023 November 2023 December 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882604 573 NCT05882591 Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment Recruiting No Results Available Meniscus Disorder|Meniscus; Degeneration|Meniscus Tear|Meniscus Lesion Procedure: Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1). Presence of pain in full knee flexion|The functional assessment with the The International Knee Documentation Committee Questionnaire (IKDC)|The functional assessment with the Knee injury and Osteoarthritis Outcome Score (KOOS) Artromedical Konrad Malinowski Clinic All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 10 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 4-pro-ar-2023 October 9, 2020 December 31, 2026 December 31, 2027 May 31, 2023 May 31, 2023 Artromedical Orthopaedic Clinic, Bełchatów, Łódzkie, Poland https://ClinicalTrials.gov/show/NCT05882591 574 NCT05882578 Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals WIM_22 Active, not recruiting No Results Available Breast Cancer|Exercise Oncology|Cancer Survivors|Fitness Capacity Other: Oncological physical exercise intervention|Other: Active Physical Activities intervention Cardiovascular fitness improvement|Effects in Body composition|Physical functionality|Exercise adherence|Exercise Level|Fatigue levels|Quality of life and health|Anxiety and depression levels Tigers Running Club Female 18 Years and older   (Adult, Older Adult) Not Applicable 76 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care WIM_SURVIVALS_22 January 12, 2023 April 9, 2023 July 31, 2023 May 31, 2023 May 31, 2023 Tigers Running Club, Madrid, Spain https://ClinicalTrials.gov/show/NCT05882578 575 NCT05882565 A Brief Online Mindfulness Intervention: An RCT Protocol Recruiting No Results Available Stress|Anxiety|Depression Behavioral: A brief (14-day) online mindfulness intervention|Behavioral: Psychoeducation online Depression Anxiety Stress Scale-21 (DASS-21; Lovibond & Lovibond, 1995)|Five Facet Mindfulness Questionnaire (FFMQ: Baer et al., 2006)|Perseverative Thinking Questionnaire (PTQ)|Momentary repetitive negative thinking|Mood questions|Daily Journal Ka Yan|Radboud University Medical Center|Maranatha Christian University All 17 Years and older   (Child, Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 7/KEP/II/2021 March 3, 2023 January 2024 January 2024 May 31, 2023 June 1, 2023 Universitas Kristen Maranatha, Bandung, West Java, Indonesia https://ClinicalTrials.gov/show/NCT05882565 576 NCT05882552 Tilted Gaze Target Test in the Examination of Children With Superior Oblique Muscle Palsy Not yet recruiting No Results Available Children With Torticollis Diagnostic Test: Tilted Gaze Target Tast|Diagnostic Test: Conventional Examination Methods The accuracy of test in predicting the degree of improvement in head position after surgery|Comparison with the traditional combined diagnosis of monocular masking, eye movement and Bielschowsky head-tilting test，the positive predictive value of tilt test in the diagnosis and treatment of oculomotor-derived torticollis|Comparison with the traditional combined diagnosis of monocular masking, eye movement and Bielschowsky head-tilting test，the negative predictive value of tilt test in the diagnosis and treatment of oculomotor-derived torticollis Tianjin Eye Hospital All 1 Year to 8 Years   (Child) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic 2023018 May 22, 2023 April 30, 2024 December 31, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882552 577 NCT05882539 Oral Mucosal Pressure Injury in ICU Patients With Oral Tracheal Intubation Recruiting No Results Available Oral Mucosal Pressure Injury Device: endotracheal tube material,Bite block Material oral mucosal pressure injury Second Affiliated Hospital, School of Medicine, Zhejiang University All 18 Years and older   (Adult, Older Adult) 471 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2022-0586 January 1, 2023 December 30, 2023 December 30, 2024 May 31, 2023 May 31, 2023 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05882539 578 NCT05882526 Compartive Evalution of the Efficiency of Maxillary Canine Retraction Using Power Chain Versus Burstone T-loop Active, not recruiting No Results Available Class I Malocclusion Device: BURSTONE T-LOOP rate of canine retraction|Canine rotation|canine tipping Mansoura University All 14 Years to 25 Years   (Child, Adult) Not Applicable 12 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment canine retraction in tooth May 15, 2023 October 2024 December 2024 May 31, 2023 May 31, 2023 Mansoura University, Mansoura, Egypt https://ClinicalTrials.gov/show/NCT05882526 579 NCT05882513 Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer Recruiting No Results Available NSCLC|Neoadjuvant Therapy Drug: Serplulimab and neoadjuvant therapy|Procedure: surgical resection of lung cancer Pathological Complete Response (PCR)|Major Pathological Response (MPR)|Objective Response Rate (ORR)|2-year and 5-year overall survival|Incidence of Treatment-related Adverse Events|R0 resection rate Second Affiliated Hospital, School of Medicine, Zhejiang University All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 55 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2023-0485 May 16, 2023 May 31, 2025 May 31, 2030 May 31, 2023 May 31, 2023 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China https://ClinicalTrials.gov/show/NCT05882513 580 NCT05882500 Osteopontin as a Biomarker in Pancreatitis PtitStudien Completed No Results Available Pancreatitis Other: No intervention, observation Se-osteopontin Linkoeping University All 18 Years and older   (Adult, Older Adult) 103 Other Observational Observational Model: Cohort|Time Perspective: Prospective PtitStudien March 3, 2011 October 19, 2016 January 31, 2023 May 31, 2023 May 31, 2023 Linkoping University Hospital, Linköping, Sweden https://ClinicalTrials.gov/show/NCT05882500 581 NCT05882487 Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD Not yet recruiting No Results Available Parkinson Disease Genetic: KL002 injection solution Incidence of Treatment Emergent Adverse Events|Parkinson's Symptoms|PET Scan Imaging Second Affiliated Hospital, School of Medicine, Zhejiang University|R&D Kanglin Biotech All 40 Years to 70 Years   (Adult, Older Adult) Early Phase 1 9 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2023-0013 June 1, 2023 April 30, 2026 June 30, 2026 May 31, 2023 May 31, 2023 Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05882487 582 NCT05882474 Correlation Between PaCO2 and Respiratory Effort in Patients With COVID-19 With Extracorporeal Membrane Oxygenation Completed No Results Available COVID-19 Acute Respiratory Distress Syndrome|Extracorporeal Membrane Oxygenation Complication|Respiratory Effort-Related Arousal Device: PaCO2 Pressure muscle index|airway pressure swing during occlusion Peking Union Medical College Hospital All 18 Years and older   (Adult, Older Adult) 10 Other Observational Observational Model: Case-Control|Time Perspective: Prospective 2023-PUMCH-A-216-2 December 1, 2022 March 30, 2023 March 30, 2023 May 31, 2023 May 31, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05882474 583 NCT05882461 An E-health Letter Intervention for Caregivers 90Second Recruiting No Results Available Caregivers|Acquired Brain Injury Behavioral: 90Second Caregiver health letter Caregiving self-efficacy|Psychological strain|Caregiver burden|Savouring|Overall quality of life and general health IWK Health Centre All 18 Years and older   (Adult, Older Adult) Not Applicable 330 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment 1025834 February 17, 2021 March 2024 March 2024 May 31, 2023 May 31, 2023 IWK Health Centre, Halifax, Nova Scotia, Canada https://ClinicalTrials.gov/show/NCT05882461 584 NCT05882448 Study of the Influence of Intraperitoneal Insufflation of CO2 by Laparoscopy on the Short-term Evolution of Premature Infants With Ulcerative Necrotizing Enterocolitis NECO2 Not yet recruiting No Results Available Preterm Birth|Enterocolitis, Necrotizing Procedure: laparotomy|Procedure: Laparoscopy C reactive protein blood level|Postoperative biological inflammatory reaction|Specific post-operative biological inflammatory reaction|Postoperative mortality|Postoperative intestinal morbidity: stoma rate|Postoperative intestinal morbidity: Duration of parenteral nutrition|Postoperative intestinal morbidity: Duration of hemodynamic support|Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)|Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN|Postoperative reoperation rate|Length of hospitalization|Medium-term postoperative neurological morbidity|Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))|Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))|Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))|Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))|Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy) Assistance Publique - Hôpitaux de Paris All Child, Adult, Older Adult Not Applicable 54 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment APHP221170 September 2023 June 2025 September 2025 May 31, 2023 May 31, 2023 Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale, Paris, France|Hôpital Robert Debré Service de Chirurgie Pédiatrique, Paris, France https://ClinicalTrials.gov/show/NCT05882448 585 NCT05882435 Use of Augmented Intelligence for the Interpretation of Bone Standard X-rays Prescribed by the Emergency Department (IMMEDIAT Urgences) IMMEDIAT Recruiting No Results Available Bone Fracture Other: Organization with AI Diagnostic error rate|Time between x-ray and first diagnostic|Time between x-ray and first diagnostic by the emergency physician|Time between x-ray and final diagnostic by the emergency physician|Rate of X-rays interpretation by radiologist without delay|Number of all radiological exam per patient prescribed by the ED|Number of X-rays with a report by a radiologist at 30 days|Time spent in the ED by the patient|Number of patients invited to come back in the ED|30 days morbidity|Total cost from the hospital viewpoint Assistance Publique - Hôpitaux de Paris All 18 Years and older   (Adult, Older Adult) Not Applicable 8400 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research 21OLE May 31, 2023 December 15, 2023 December 15, 2023 May 31, 2023 May 31, 2023 Hopital Saint Antoine, Paris, France|Hôpital Salpétrière, Paris, France|Hôpital Tenon, Paris, France https://ClinicalTrials.gov/show/NCT05882435 586 NCT05882422 Evaluation of the Effect of Dietary PI and TAC on the Outcome of Pregnancy in In Vitro Fertilization Treatment Enrolling by invitation No Results Available Ongoing Pregnancy|In-vitro Fertilization Ongoing pregnancy|Clinical pregnancy Hacettepe University All 18 Years to 51 Years   (Adult) 280 Other Observational Observational Model: Cohort|Time Perspective: Prospective 222S315 February 15, 2023 February 15, 2024 April 15, 2024 May 31, 2023 May 31, 2023 Hacettepe, Ankara, Altındag, Turkey https://ClinicalTrials.gov/show/NCT05882422 587 NCT05882409 Education Given on Their Attitudes Towards Violence Against Women and Their Conflict violence Completed No Results Available University Students|Attitudes|Conflict|Education|Women|Violence|Awareness Behavioral: Education Attitudes towards Violence Scale among University Students|Conflict and Violent Awareness Scale Cumhuriyet University Female 18 Years to 21 Years   (Adult) Not Applicable 87 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care TR SIVAS 03 October 1, 2019 March 1, 2020 March 1, 2020 May 31, 2023 May 31, 2023 Sukran Ertekin Pinar, Sivas, Turkey https://ClinicalTrials.gov/show/NCT05882409 588 NCT05882396 Rood's Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients Not yet recruiting No Results Available Colorectal Cancer|Peripheral Neuropathy Other: Rood's approach|Other: Traditional physical therapy program NCT-CTCAE peripheral neuropathy grading|The Ntx-12 questionnaire|Brief Pain Inventory Short Form (BPI-SF) Bworst pain|Total Neuropathy Score|The 4-Stage Balance Test Cairo University All 18 Years to 60 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment P.T.REC/012/004322 June 1, 2023 December 28, 2023 January 11, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882396 589 NCT05882383 Changes of Optical Quality During the Peak of the Covid-19 Pandemic Completed No Results Available Corneal Wavefront Aberration|SARS-CoV-2 The value of cornea aberration|The value of cornea backscatter|The value of cornea thickness Tianjin Eye Hospital All 18 Years to 32 Years   (Adult) 110 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional KY-2023019 November 25, 2022 January 20, 2023 January 20, 2023 May 31, 2023 May 31, 2023 Tianjin Eye Hospital, Tianjin, Tianjin, China https://ClinicalTrials.gov/show/NCT05882383 590 NCT05882370 TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study Not yet recruiting No Results Available Hepatocellular Carcinoma Drug: Cadonilimab|Procedure: transjugular intrahepatic portosystemic shunt (TIPS) Objective response rate (ORR) by RECIST 1.1 and mRECIST|Disease control rate (DCR)|Duration of response (DOR)|Overall survival rate (OSR)|Progression-free survival time (mPFS)|Median overall survival time (mOS) Fei Gao|Sun Yat-sen University All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SCALE July 1, 2023 June 30, 2025 August 31, 2025 May 31, 2023 May 31, 2023 Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05882370 591 NCT05882357 Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age Not yet recruiting No Results Available Cystic Fibrosis Drug: ELX/TEZ/IVA|Drug: IVA Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and their Relevant Metabolites|Part A: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part B: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and their Relevant Metabolites|Part B: Absolute Change in Sweat Chloride (SwCl) Vertex Pharmaceuticals Incorporated All 12 Months to 24 Months   (Child) Phase 3 64 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment VX22-445-122|2023-503230-49-00 September 2023 October 2025 October 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882357 592 NCT05882344 Deep Brain Stimulation for Alzheimer's Not yet recruiting No Results Available Alzheimer Disease, Early Onset|Dementia|Alzheimer Disease Procedure: Device Implantation- Boston Scientific, VERCISE GENUS™ system|Device: DBS Stimulation - Boston Scientific, VERCISE GENUS™ system Clinical Dementia Rating score change Vanderbilt University Medical Center|Boston Scientific Corporation All 60 Years to 80 Years   (Adult, Older Adult) Not Applicable 8 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 221713 October 2023 October 2028 October 2028 May 31, 2023 May 31, 2023 Vanderbilt Medical Center, Nashville, Tennessee, United States https://ClinicalTrials.gov/show/NCT05882344 593 NCT05882331 Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 COVID-ECP Recruiting No Results Available COVID-19 Procedure: Extracorporeal photopheresis Clinical outcomes|Virological outcomes|Radiological outcomes Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases All 18 Years to 100 Years   (Adult, Older Adult) Not Applicable 15 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment COVID-ECP January 1, 2021 December 31, 2023 December 31, 2024 May 31, 2023 May 31, 2023 South Pest Central Hospital, National Institute of Haematology and Infectious Diseases, Budapest, Hungary https://ClinicalTrials.gov/show/NCT05882331 594 NCT05882318 Effectiveness of eCoin at Sensory and Subsensory Amplitudes ESSENCE Not yet recruiting No Results Available Urge Incontinence Device: eCoin Peripheral Neurostimulator System Reduction in UUI Episodes|Quality of Life with OABq|Patient Satisfaction Valencia Technologies Corporation All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 111-6133 June 1, 2023 May 1, 2024 July 1, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882318 595 NCT05882305 KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial Not yet recruiting No Results Available EBV-associated Lymphomas Biological: (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate Incidence of dose-limiting toxicity(DLT) by dose group|Incidence of Effective dose range by dose grouphaematologic neoplasms|Type and incidence of adverse events(AEs) and serious adverse events(SAEs) by dose group|EBV-DNA load|Objective response rate(ORR)|Disease control rate(DCR)|Duration of response(DoR)|Progression-free survival(PFS)|Overall survival(OS)|Levels of EBV-specific CD8+ T cells|Levels of B cells|Levels of NK cells Kousai Bio Co., Ltd. All 18 Years to 70 Years   (Adult, Older Adult) Early Phase 1 9 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment KSD-101-CR002 June 10, 2023 December 31, 2024 December 31, 2025 May 31, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05882305 596 NCT05882292 A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration Not yet recruiting No Results Available Neoplasms Drug: ABN401 Disease control rate (DCR) at 16 weeks|Overall survival (OS)|Progression-free survival (PFS)|Objective response rate (ORR)|Duration of response (DoR) Yonsei University All 19 Years and older   (Adult, Older Adult) Phase 2 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 4-2023-0093 July 1, 2023 December 31, 2024 December 31, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882292 597 NCT05882279 A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan Not yet recruiting No Results Available Multiple Myeloma Other: No Intervention Number of Pharmacists who Have Provided Patients With the Contents of the RMP Material|Number of Pharmacists who Have Received the RMP Material for Patients|Number of Pharmacist With Understanding of the Proper NINLARO Dosing Schedule|Number of Pharmacist With Understanding of the Importance of Providing NINLARO Dosing Schedule Takeda All 18 Years and older   (Adult, Older Adult) 300 Industry Observational Observational Model: Other|Time Perspective: Prospective C16065 June 1, 2023 June 12, 2023 June 12, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882279 598 NCT05882266 The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk Not yet recruiting No Results Available Cardiovascular Risk Dietary Supplement: Plant Omega|Other: Dietary therapy only Changes in lipid profile after 12 weeks intervention of plant based omega 3|Changes in the blood pressure after 12 weeks intervention of plant based omega 3|Changes in microarray gene expression profile in blood from individual with CVD risk|Changes in anti-inflammatory effect of plant-based omega-3 after 12 weeks|Changes in fasting blood glucose after 12 weeks intervention of plant based omega-3|Changes in glycated hemoglobin after 12 weeks intervention of plant based omega-3|Changes in quality of life of individuals with CVD risk, before and after the consumption of plant-based omega 3 for 12 weeks Universiti Putra Malaysia|Beacon Hospital Sdn Bhd All 18 Years to 60 Years   (Adult) Not Applicable 72 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment RSCH ID-23-00839-PGP June 30, 2023 June 29, 2025 July 15, 2025 May 31, 2023 May 31, 2023 Beacon Hospital Sdn Bhd, Petaling Jaya, Selangor, Malaysia https://ClinicalTrials.gov/show/NCT05882266 599 NCT05882253 Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial) IMAGINED Not yet recruiting No Results Available Prostate Cancer Other: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) RSM mapping value The University of Texas Health Science Center at San Antonio Male Child, Adult, Older Adult Not Applicable 225 Other Interventional Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research HSC20220897H June 30, 2023 March 31, 2026 March 31, 2028 May 31, 2023 June 5, 2023 Audie Murphie VA, San Antonio, Texas, United States|The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center, San Antonio, Texas, United States|University Health System, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05882253 600 NCT05882240 Performance of PLR as Predicting Preload Responsiveness PLR Completed No Results Available Stroke Volume Other: choice of initial position We aimed to establish current practice of correct application and interpretation of the PLR in critical care patients|Profession|Measurement of cardiac output Johannes Gutenberg University Mainz All Child, Adult, Older Adult 292 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional JohannesGUVT December 1, 2021 January 31, 2022 February 28, 2022 May 31, 2023 May 31, 2023 Department of Anesthesiology,Prof. C. Werner, Universitätsmedizin of the JG University, Mainz, Rhineland-Palatinate, Germany https://ClinicalTrials.gov/show/NCT05882240 601 NCT05882227 Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program. NIRARATC Recruiting No Results Available Osteoarthrosis|ERAS|Anxiety|Nurse Behavioral: video|Behavioral: Traditional information Hospital Anxiety and Depression Scale (HADS)|EuroQol-5D|Sociodemographic variables University of Barcelona All 18 Years to 100 Years   (Adult, Older Adult) Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment HCB/2023/0015|Jordi Galimany Masclans|Zaida Palmira Agüera Imbernón|Montserrat Puig Llobet June 20, 2023 December 20, 2023 May 20, 2024 May 31, 2023 May 31, 2023 Elisabet Ripoll Romero, Barcelona, Spain https://ClinicalTrials.gov/show/NCT05882227 602 NCT05882214 Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink NMN-MeABD Not yet recruiting No Results Available Binge Drinking|Liver Injury|Nutritional Supplementation|Hepatic Steatosis Dietary Supplement: β-nicotinamide Mononucleotide|Dietary Supplement: Maltodextrin Ethanol concentration|Acetaldehyde concentration|Hepatic fibrosis change|hepatic function change|hepatic injury change|Lipid metabolism change|hangover cognition assessment tools after drinking|Laboratory markers of inflammation|nicotinamide adenine dinucleotide metabolism change|Fecal metabolites|Metabolomics profiling Zhejiang Chinese Medical University Male 18 Years to 30 Years   (Adult) Not Applicable 20 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research Alleviate a hangover with NMN June 5, 2023 July 19, 2024 July 18, 2026 May 31, 2023 May 31, 2023 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05882214 603 NCT05882201 Comparison of Femoral Nerve Block Versus Fascia Iliaca Compartment Block for Pain Control in Traumatic Femur Fracture Repair in Pediatric Population Recruiting No Results Available Regional Anesthesia Morbidity Procedure: Fascia Iliaca compartment block group|Procedure: Femoral nerve block group|Procedure: General care Postoperative pain|Postoperative need for analgesia Menoufia University All 5 Years to 12 Years   (Child) Not Applicable 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2/2023ANESTH58 June 1, 2023 October 1, 2023 October 1, 2023 May 31, 2023 May 31, 2023 Menoufia university hospitails, Shibīn Al Kawm, Menoufya, Egypt https://ClinicalTrials.gov/show/NCT05882201 604 NCT05882188 The Cost-effectiveness of Hysterosalpingography Versus Hysterosalpingo-foam Sonography During Fertility Work-up FOil Not yet recruiting No Results Available Infertility Procedure: Oil-based contrast|Procedure: ExEm Foam Number of pregnancies leading to live birth.|Time to pregnancy leading to live birth|Number of clinical pregnancies|Number of miscarriages|Number of multiple pregnancies|Number of ectopic pregnancies|Number of adverse events|Procedural pain scores|Number of fertility treatment cycles|Number of pregnancy complications|Cost-effectiveness Amsterdam UMC, location VUmc|ZonMw: The Netherlands Organisation for Health Research and Development Female 18 Years to 42 Years   (Adult) Not Applicable 1102 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NL83352.018.22 July 1, 2023 December 1, 2026 June 1, 2027 May 31, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05882188 605 NCT05882175 Prospective Validation of the OHI Index HLH Recruiting No Results Available HLH|Hemophagocytic Lymphohistiocytoses|Hemophagocytic Syndrome|Hematologic Malignancy|Hematologic Neoplasms To assess 365 days mortality of OHI+ and OHI- patients|To determine the incidence of OHI+ patients in our cohort Meir Medical Center|Children's Hospital Medical Center, Cincinnati|Rabin Medical Center|Sheba Medical Center|Schneider Children's Medical Center, Israel All 18 Years and older   (Adult, Older Adult) 300 Other Observational Observational Model: Cohort|Time Perspective: Prospective 0321-19-MMC March 3, 2021 March 3, 2025 March 3, 2026 May 31, 2023 May 31, 2023 Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel https://ClinicalTrials.gov/show/NCT05882175 606 NCT05882162 Conventional Coronectomy vs Coronectomy in Combination Vital Pulp Treatment Using Calcium Silicate Completed No Results Available Impacted Third Molar Tooth Procedure: Coronectomy|Procedure: Pulp Capping with calcium silicate Presence of inferior alveolar nerve injury (yes/no)|Root exposure (yes/no)|Periapical lesion (yes/no)|Dentin bridge formation (yes/no)|Pain (1-10)|Root migration (yes/no)|Maintenance of periodontal status of the adjacent tooth (yes/no) zeynep cukurova yilmaz|Istanbul Medipol University Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 66291034-604.01.01-E.46464-17 March 20, 2018 February 20, 2022 April 20, 2022 May 31, 2023 May 31, 2023 İstanbul Medipol University, İstanbul, Esenler, Turkey https://ClinicalTrials.gov/show/NCT05882162 607 NCT05882149 Single Strain Probiotic CHOICE Not yet recruiting No Results Available Abdominal Obesity Dietary Supplement: Single strain probiotic|Dietary Supplement: Placebo Change in waist circumference|Change in hip circumference|Change in waist-hip-ratio|Change in Body weight|Change in Body mass index|Change in Total fat mass|Change in Free fat mass|Change in Lean body mass|Change in Visceral fat index|Change in Conicity index|Change in Visceral adipose tissue|Change in Subcutaneous fat|Changes in Fasting blood glucose|Changes in Fasting insulin|Changes in HOMA index|Changes in glycosylated hemoglobin (HbA1c)|Changes in Total cholesterol|Changes in HDLc|Changes in LDLc|Changes in Total Triglycerides|Changes in Systolic blood pressure|Changes in Diastolic blood pressure|Changes in Pulse Pressure|Changes in Three Factor Eating Questionnaire (TFEQ; Spanish edition)|Changes in Bing Eating Scale (BES; Spanish edition)|Changes in dietary intake|Changes in Satiety|Changes in bowel habit|Changes in flatulences|Changes in nausea|Changes in reflux|Changes in abdominal distension|Changes in diarrhea|Changes in gut microbiota|Changes in oral microbiota Rosa Sola|Biopolis S.L.|Chic-kles Gum, S.L.|University Rovira i Virgili All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 180 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 074/2023 July 15, 2023 April 2024 September 2024 May 31, 2023 June 5, 2023 Universitat Rovira i Virgili, Reus, Tarragona, Spain https://ClinicalTrials.gov/show/NCT05882149 608 NCT05882136 Acute Intermittent Porphyria Related Abnormalities in Cardiovascular System AIPRACUS Recruiting No Results Available Porphyrias, Hepatic Number of participants with heart failure and left ventricular dysfunction.|Number of participants with hypertension.|Rate of cardiac arrhythmias.|Number of participants with increased concentrations of markers of heart failure.|Number of participants with increased concentrations of markers of myocardial injury.|Number of participants with chronic kidney disease.|Number of participants with dyslipidemia.|Number of participants with diabetes.|Level of quality of life. National Institute of Cardiology, Warsaw, Poland|Institute of Hematology and Transfusion Medicine, Warsaw All 18 Years to 65 Years   (Adult, Older Adult) 160 Other Observational Observational Model: Case-Control|Time Perspective: Prospective 2.39/VII/18 April 5, 2019 December 31, 2023 December 31, 2023 May 31, 2023 May 31, 2023 Institute of Hematology and Transfusion Medicine, Warsaw, Poland|National Institute of Cardiology, Warsaw, Poland https://ClinicalTrials.gov/show/NCT05882136 609 NCT05882123 Gender Heterogeneity in the Influencing Factors for Cerebral Microbleeds in Acute Ischemic Stroke Patients Completed No Results Available Acute Ischemic Stroke Other: cerebral microbleeds Comparison of clinical data between AIS patients in CMB and non-CMB groups|Comparison of clinical data between male and female AIS patients|Comparison of CMB-related characteristics between the male and female AIS patients|Predictive factor analysis for CMBs in male AIS patients|Predictive factor analysis for CMBs in female AIS patients Xin Guo|The First Hospital of Hebei Medical University All 18 Years and older   (Adult, Older Adult) 482 Other Observational Observational Model: Other|Time Perspective: Retrospective 20220642 January 2014 December 2015 December 2015 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882123 610 NCT05882110 Amplification of Autologous Epidermal Cells to Repair Large Area Deep Wounds Not yet recruiting No Results Available Autologous Epidermal Cell Transplantation Procedure: Cultured autologous epidermal cell membrane Take rate of cultured epidermal autograft|The incidence of serious adverse events Yicheng Ma|First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University All Child, Adult, Older Adult Not Applicable 100 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment AOAECTRLADW August 1, 2023 August 31, 2025 October 31, 2025 May 31, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05882110 611 NCT05882097 Transform Randomised Control Trial in Uganda Not yet recruiting No Results Available Health Behavior|Economic Problems|Values, Social Other: Transform program Change from baseline in EuroQol-5 Dimension - 5 levels (EQ-5D-5L) at 6 and 12 months|Change from baseline in poverty probability index at 6 and 12 months|Change from baseline in duckworth index at 6 and 12 months International Care Ministries, Philippines All 18 Years to 90 Years   (Adult, Older Adult) Not Applicable 4800 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other icmugrct May 30, 2023 September 30, 2024 September 30, 2024 May 31, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05882097 612 NCT05882084 Oral Supplementation of Astaxanthin on Skin Photoaging, Hydration and Elasticity Not yet recruiting No Results Available Photoaging Dietary Supplement: Astaxanthin 6 mg daily|Dietary Supplement: Placebo Skin Hydration|Skin elasticity|Facial pigmentation|Facial redness Integrative Skin Science and Research|AstaReal Female 30 Years to 55 Years   (Adult) Not Applicable 24 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Asta_Skin_01 May 2023 September 30, 2023 December 31, 2023 May 31, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05882084 613 NCT05882071 Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France Not yet recruiting No Results Available Diabetes Mellitus, Type 2 Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i) Baseline characteristic: Age|Baseline characteristic: Gender|Baseline characteristic: Region of residence|Baseline characteristic: History of diabetes (date of first Long Term Disease (LTD) status related to diabetes)|Baseline characteristic: Type of diabetes|Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)|Incidence rate of acute cardiovascular atheromatous events during the exposure period following initiation of the SGLT2i|Time from drug initiation to first event of acute cardiovascular atheromatous events|Incidence rate of heart failure hospitalization during the exposure period following initiation of the SGLT2i|Time from drug initiation to first event of heart failure hospitalization|Incidence rate of deaths all cause during the exposure period following initiation of the SGLT2i|Time from drug initiation to death all cause Boehringer Ingelheim All 18 Years and older   (Adult, Older Adult) 50000 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective 1245-0287 June 15, 2023 December 31, 2025 December 31, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882071 614 NCT05882058 DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Not yet recruiting No Results Available Small Cell Lung Carcinoma|Neuroendocrine Neoplasms Drug: BI 764532 Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR)|Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment period|Duration of objective response (DOR) based on investigator assessment|Progression-free survival (PFS) based on investigator assessment|Disease control (DC), defined as best overall response of CR or PR or stable disease (SD) based on investigator assessment|Overall survival (OS), defined as the time from treatment start until death from any cause|Change from baseline in EORTC QLQ-C30 physical functioning domain score|Change from baseline in EORTC QLQ-C30 role functioning domain score|Occurrence of treatment-emergent AEs leading to study drug discontinuation during the on-treatment period Boehringer Ingelheim All 18 Years and older   (Adult, Older Adult) Phase 2 120 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 1438-0005|2023-504247-13-00 August 7, 2023 September 25, 2024 July 3, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882058 615 NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease TRIUMPH-3 Not yet recruiting No Results Available Obesity|Cardiovascular Diseases Drug: Retatrutide|Drug: Placebo Percent Change from Baseline in Body Weight|Change from Baseline in Body Mass Index (BMI)|Change from Baseline in Waist Circumference|Percent Change from Baseline in Total Cholesterol|Percent Change from Baseline in Triglycerides|Change from Baseline in Systolic Blood Pressure (SBP)|Change from Baseline in Diastolic Blood Pressure (DBP)|Change from Baseline in Hemoglobin A1c (HbA1c)|Percent Change from Baseline in Fasting Insulin|Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC) Eli Lilly and Company All 18 Years and older   (Adult, Older Adult) Phase 3 1800 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 18582|J1I-MC-GZBM|2023-503659-88-00 June 30, 2023 January 20, 2026 February 17, 2026 May 31, 2023 May 31, 2023 Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Valley Clinical Trials, Inc., Covina, California, United States|Valley Research, Fresno, California, United States|Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States|Velocity Clinical Research, Westlake, Los Angeles, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Velocity Clinical Research, Panorama City, Panorama City, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Charter Research - Winter Park, Winter Park, Florida, United States|Pacific Diabetes & Endocrine Center, Honolulu, Hawaii, United States|Elite Clinical Trials, Blackfoot, Idaho, United States|Humphreys Diabetes Center, Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Great Lakes Clinical Trials - Gurnee, Gurnee, Illinois, United States|Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative, Springfield, Illinois, United States|Brengle Family Medicine, Indianapolis, Indiana, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|MedVadis Research Corporation, Waltham, Massachusetts, United States|StudyMetrix Research, Saint Peters, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Palm Research Center Tenaya, Las Vegas, Nevada, United States|Amici Clinical Research LLC, Warren, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC Montefiore University Hospital, Pittsburgh, Pennsylvania, United States|Tribe Clinical Research, LLC, Greenville, South Carolina, United States|Trial Management Associates, Myrtle Beach, South Carolina, United States|Tribe Clinical Research - Spartanburg, Spartanburg, South Carolina, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Pinnacle Clinical Research, Austin, Texas, United States|Southern Endocrinology Associates, Mesquite, Texas, United States|Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States|Sleep Therapy Research Center, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Rainier Clinical Research Center, Renton, Washington, United States|CEDIC, Caba, Buenos Aires, Argentina|Consultorio de Investigación Clínica EMO SRL, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina|IDIM - Instituto de Investigaciones Metabólicas, Ciudad de Buenos Aires, Buenos Aires, Argentina|MICA - Medicina e Investigación Cardiometabólica, Del Viso, Buenos Aires, Argentina|Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|DIM Clínica Privada, Ramos Mejía, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Zarate, Zárate, Buenos Aires, Argentina|Stat Research S.A., Buenos Aires, Ciudad Aut, Argentina|Centro Médico Viamonte, Buenos Aires, Ciudad Aut, Argentina|Investigaciones Medicas Imoba Srl, Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina|Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aire, Argentina|Centro Medico Privado CEMAIC, Capital, Córdoba, Argentina|Centro Medico Privado San Vicente Diabetes, Cordoba, Córdoba, Argentina|Centro de Salud e Investigaciones Médicas, Santa Rosa, La Pampa, Argentina|CIPADI - Centro Integral de Prevencion y Atencion en Diabetes, Godoy Cruz, Mendoza, Argentina|Centro de Investigaciones Clínicas Baigorria, Granadero Baigorria, Santa Fe, Argentina|INECO Neurociencias Oroño, Rosario, Santa Fe, Argentina|Instituto de Investigaciones Clinicas Rosario, Rosario, Santa Fe, Argentina|Sanatorio San Martin, Venado Tuerto, Santa Fe, Argentina|Sanatorio Norte, Santiago del Estero, Santiago D, Argentina|Centro de Investigaciones Médicas Tucuman, San Miguel De Tucumán, Tucumán, Argentina|Fundación Respirar, Buenos Aires, Argentina|Instituto Médico DAMIC, Córdoba, Argentina|Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina|Emeritus Research, Botany, New South Wales, Australia|The AIM Centre / Hunter Diabetes Centre, Merewether, New South Wales, Australia|University of Sydney - Charles Perkins Centre, Sydney, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Core Research Group, Brisbane, Queensland, Australia|CDH Research Institute, Maroochydore, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Fusion Clinical Research, Adelaide, South Australia, Australia|Nightingale Research, Adelaide, South Australia, Australia|Southern Adelaide Diabetes & Endocrine Services, Oaklands Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Emeritus Research, Camberwell, Victoria, Australia|Barwon Health, Geelong, Victoria, Australia|Austin Health - Repatriation Hospital, Heidelberg West, Victoria, Australia|Advara HeartCare Joondalup, Joondalup, Western Au, Australia|BC Diabetes Office, Vancouver, British Columbia, Canada|Discovery Clinical Services, Victoria, British Columbia, Canada|Centricity Research - New Minas, New Minas, Nova Scotia, Canada|Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Concord, Ontario, Canada|Dr. Steven V. Zizzo Medicine Professional Corporation, Hamilton, Ontario, Canada|Milestone Research Inc., London, Ontario, Canada|Centricity Research Oshawa, Oshawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Private Practice - Dr. Pierre Bonin, Sudbury, Ontario, Canada|Manna Research Toronto, Toronto, Ontario, Canada|Ecogene-21 - Cmas, Chicoutimi, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Clinique de médecine Urbaine du Quartier Latin, Montreal, Quebec, Canada|Centre de Medecine Metabolique de Lanaudiere (CMML), Terrebonne, Quebec, Canada|Syneos Health, Quebec, Canada|Arina Trial Research, Orosháza, Békés, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, Csongrád, Hungary|Regia Med Kft, Szekesfehervar, Fejér, Hungary|Medifarma 98 Kft, Nyiregyhaza, Nyíregyháza, Hungary|Szent Lázár Megyei Kórház, Salgótarján, Nógrád, Hungary|Óbudai Egészségügyi Centrum - Kaposvár Site, Kaposvár, Somogy, Hungary|DRC Gyógyszervizsgáló Központ, Balatonfüred, Veszprém, Hungary|Zala Megyei Szent Rafael Kórház, Zalaegerszeg, Zala, Hungary|Óbudai Egészségügyi Centrum, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|TRANTOR'99 Bt. Anyagcsere Centrum, Budapest, Hungary|Debreceni Egyetem - Kenézy Gyula Egyetemi Oktatókórház, Debrecen, Hungary|Óbudai Egészségügyi Centrum - Zalaegerszeg, Zalaegerszeg, Hungary|Centro de Investigacion Cardiovascular y Metabólica, Tijuana, Baja California, Mexico|RM Pharma Specialists, Mexico City, Distrito Federal, Mexico|Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares, Mexico City, Distrito Federal, Mexico|Centro Multidisciplinario de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigación Clínica y Atención Médica HEPA, Guadalajara, Jalisco, Mexico|Centro de Investigacion Medica de Occidente, S.C., Zapopan, Jalisco, Mexico|IMED Internal Medicine Clin Trials, Monterrey, Nuevo León, Mexico|Clínica García Flores SC, Monterrey, Nuevo León, Mexico|Eukarya PharmaSite, Monterrey, Nuevo León, Mexico|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, Mexico|Medical Care and Research SA de CV, Merida, Yucatán, Mexico|EME RED Hospitalaria, Mérida, Yucatán, Mexico|Investigacion En Salud Y Metabolismo Sc, Chihuahua, Mexico|Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia, Durango, Mexico|Centro de Atención e Investigación Cardiovascular del Potosí, San Luis Potosí, Mexico|FAICIC S. de R.L. de C.V., Veracruz, Mexico|NBR Polska, Warszawa, Mazowieckie, Poland|RST Rehabilitacja, Bialy Kosciol, Małopolskie, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET, Krakow, Małopolskie, Poland|KLIMED Marek Klimkiewicz, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland|Ambulatorium Sp. z o.o., Elbląg, Warmińsko-mazurskie, Poland|Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Łódzkie, Poland|Centrum Medyczne Pratia Katowice, Katowice, Śląskie, Poland|NZOZ Salvia CM, Katowice, Śląskie, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 SUM, Zabrze, Śląskie, Poland|Clinical Research Management Group Inc. - Hospital San Cristobal, Ponce, Puerto Rico|Ponce Medical School Foundation Inc., Ponce, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|Nemocnica s poliklinikou Lucenec, Lucenec, Banskobystrický Kraj, Slovakia|Metabol KLINIK, Bratislava, Bratislavský Kraj, Slovakia|MediVet s.r.o., Malacky, Bratislavský Kraj, Slovakia|Human Care s.r.o., Kosice, Košický Kraj, Slovakia|Tatratrial s.r.o., Rožňava, Košický Kraj, Slovakia|Areteus s.r.o., Trebisov, Košický Kraj, Slovakia|MEDI-DIA s.r.o., Sabinov, Prešovský Kraj, Slovakia|ProDia s.r.o., Povazska Bystrica, Trenčiansky Kraj, Slovakia|MediTask, Bratislava, Slovakia|Diab - Int, Bytca, Žilinský Kraj, Slovakia|Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval, Ferrol, A Coruña [La Coruña], Spain|Hu Reina Sofia, Cordoba, Andalucía, Spain|'Hospital Virgen de la Victoria, Malaga, Andalucía, Spain|Hospital Quiron Infanta Luisa, Sevilla, Andalucía, Spain|Hospital Universitari Son Espases, Palma, Balears [Baleares], Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Virgen del Camino, Sanlúcar de Barrameda, Cádiz, Spain|Hospital Virgen de las Montañas, Villamartin, Cádiz, Spain|Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Lleida [Lérida], Spain|Vithas Hospital Sevilla, Seville, Sevilla, Spain|Hospital Universitario de La Ribera, Alzira, Valenciana, Comunitat, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain https://ClinicalTrials.gov/show/NCT05882045 616 NCT05882032 A Study of LY3502970 in Participants With Impaired and Normal Liver Function Not yet recruiting No Results Available Healthy|Hepatic Insufficiency Drug: LY3502970 Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3502970|PK: Area under the concentration versus time curve from time zero to last time point (AUC0-tlast) of LY3502970|PK: Maximum observed concentration (Cmax) of LY3502970 Eli Lilly and Company All 18 Years to 80 Years   (Adult, Older Adult) Phase 1 30 Industry Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science 18624|J2A-MC-GZPB June 16, 2023 July 1, 2024 July 1, 2024 May 31, 2023 May 31, 2023 Clinical Pharmacology of Miami, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05882032 617 NCT05882019 Evaluation of the Bexa™ Breast Examination (BBE) Not yet recruiting No Results Available Breast Cancer Device: Breast Exam with Bexa Bexa sensitivity of mass detection|False Negative Comparison between Bexa and Mammography|Bexa Detected Breast Cancers Sure, Inc.|MaineHealth Female 30 Years to 80 Years   (Adult, Older Adult) Not Applicable 700 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening Pro00067814 May 2023 September 2023 December 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05882019 618 NCT05882006 Gallstones and Risk of Inflammatory Bowel Disease Not yet recruiting No Results Available Inflammatory Bowel Diseases Other: gallstones The prevalence of gallstone disease among patients with or without IBD|The odds ratio of the association between the presence of gallstone disease and risk of inflammatory bowel disease Hepatopancreatobiliary Surgery Institute of Gansu Province All 18 Years to 90 Years   (Adult, Older Adult) 5000 Other Observational Observational Model: Case-Control|Time Perspective: Retrospective IBD Risk of Gallstones May 21, 2023 January 1, 2024 January 1, 2024 May 31, 2023 May 31, 2023 Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou, Gansu, China|Lanzhou University Second Hospital, Lanzhou, Gansu, China|Wuwei Tumor Hospital, Wuwei, Gansu, China|The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China https://ClinicalTrials.gov/show/NCT05882006 619 NCT05881993 Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects Recruiting No Results Available Healthy Volunteer Study Drug: CBP-4888|Other: Placebo Adverse Events|Pain at Site of Injection|Tenderness at Site of Injection|Erythema at Site of Injection|Swelling at Site of Injection|Cmax of CBP-4888|AUC of CBP-4888|Tmax of CBP-4888 Comanche Biopharma Female 18 Years to 50 Years   (Adult) Early Phase 1 15 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment CBP-4888-100 May 22, 2023 July 2023 August 2023 May 31, 2023 June 2, 2023 Comanche Biopharma Clinical Research Site #1, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05881993 620 NCT05881980 Efficacy and Safety of Terbinafine and Itraconazole Not yet recruiting No Results Available Tinea Corporis|Tinea Cruris|Tinea Faciei|Dermatophytoses Drug: Terbinafine Tablets|Drug: Itraconazole Assessment of clinical parameters (itching, erythema, and scaling)|Achievement of mycological cure at 2 weeks|Achievement of mycological cure at 4 weeks|Achievement of mycological cure at 6 weeks|Achievement of mycological cure at 8 weeks|Assessment of overall clinical symptoms with PGA|Assessment of treatment failure|Patient's Satisfaction with treatment Dhaka Medical College All 18 Years to 60 Years   (Adult) Phase 2|Phase 3 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ERC-DMC/ECC/2023/81 May 2023 October 2023 November 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881980 621 NCT05881967 Molecular Mechanism Study of Uterine Sarcoma Recruiting No Results Available Uterine Sarcoma Diagnostic Test: Diagnostic biomarker Susceptible gene in women with uterine sarcoma Shixuan Wang|Tongji Hospital Female 18 Years to 99 Years   (Adult, Older Adult) 300 Other Observational Observational Model: Case-Control|Time Perspective: Retrospective IRB20221166 March 1, 2023 November 30, 2025 November 30, 2025 May 31, 2023 May 31, 2023 Yan Li, Wuhan, Hubei, China https://ClinicalTrials.gov/show/NCT05881967 622 NCT05881954 Outcomes of Natives and Graft-related Femoral Reconstruction With Tubulized Pericardial Patchs Recruiting No Results Available Vascular Complications Procedure: Groin infection Patency|Absence of reinfection|Reintervention|Late patency University Paul Sabatier of Toulouse All 18 Years and older   (Adult, Older Adult) 20 Other Observational Observational Model: Cohort|Time Perspective: Prospective FEMORALROLLED January 1, 2020 January 10, 2020 September 1, 2023 May 31, 2023 May 31, 2023 Aurélien Hostalrich [ahostalrich], Toulouse, France https://ClinicalTrials.gov/show/NCT05881954 623 NCT05881941 The Effect of Sound-Insulated Music Playing and Fıgured Mask Nebulızer Application on the Processing Anxiety of Children Completed No Results Available Anxiety|Child, Only Device: using a soundproof nebulizer with a music and a funny mask added|Device: using a silent nebulizer with no extra attachments|Device: using a routinely employed nebulizer The Wong-Baker Faces Pain Scale|The Children's Emotional Indicators Scale (CIAS)|The Child Fear Scale (CFS) Eda SORKUN|Eskisehir Osmangazi University All 3 Years to 6 Years   (Child) Not Applicable 120 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care EskisehirOU2643 May 1, 2022 June 1, 2022 August 8, 2022 May 31, 2023 May 31, 2023 Osmangazi University, Eskişehir, Centre, Turkey https://ClinicalTrials.gov/show/NCT05881941 624 NCT05881928 Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study Not yet recruiting No Results Available Epilepsy|Lamotrigine|Sodium Valproate Adverse Reaction Drug: Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|Drug: Lamotrigine|Device: E.E.G Weight|liver function tests|serum ammonia.|complete blood count|E.E.G|Serum concentration of LTG Assiut University All 2 Years to 12 Years   (Child) Phase 4 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other lamotrigine , sodium valproate June 1, 2023 June 1, 2024 April 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881928 625 NCT05881915 Epinephrine Infusion for Prophylaxis Against Maternal Hypotension After Spinal Anesthesia for Cesarean Delivery Not yet recruiting No Results Available Hypotension During Surgery Drug: Phenylephrine|Drug: Epinephrine incidence of post spinal hypotension|incidence post spinal reactive hypertension|fetal outcome Cairo University Female 18 Years to 40 Years   (Adult) Not Applicable 196 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention MD-245-2022 June 1, 2023 December 1, 2023 December 1, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881915 626 NCT05881902 THE EFFECT OF CANCER EDUCATION ON WOMEN'S AWARENESS LEVELS AND THEIR BEHAVIORS ON SCREENINGS Recruiting No Results Available Cancer Behavioral: HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|Behavioral: STANDART CANCER EDUCATİON The Gynecological Cancers Awareness Scale|Champion's Health Belief Model Scale for Breast Cancer and Screening Yeşim KAYAPA|Ankara Yildirim Beyazıt University Female 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening AYBÜ-HMS-YK-01 January 1, 2023 July 1, 2023 July 1, 2023 May 31, 2023 May 31, 2023 Ankara Yildirim Beyazit University, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05881902 627 NCT05881889 Effects of Repetitive Transcranial Magnetic Stimulation on Fear of Cancer Recurrence: mPFC-amygdala-hippocampus Not yet recruiting No Results Available Psychology Device: low-frequency repetitive transcranial magnetic stimulation|Device: sham low-frequency repetitive transcranial magnetic stimulation Fear of Cancer Recurrence Questionnaire (FCRQ7)|Patient Health Questionnaire (PHQ9)|Generalized Anxiety Disorder (GAD7)|Numeric Rating Scale (NRS)|Insomnia Severity Index (ISI) Guangdong Provincial People's Hospital Female 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 8220053738 July 1, 2023 December 1, 2024 December 30, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881889 628 NCT05881876 Determining the Reliability and Validity of a New Method for Measuring Upper Extremity Joint Range of Motion in Burn Patients Using a Tracking System Not yet recruiting No Results Available Contracture Joint range of motion of joint|AMA evaluation Hangang Sacred Heart Hospital All 18 Years to 75 Years   (Adult, Older Adult) 50 Other Observational Observational Model: Other|Time Perspective: Prospective HangangSHH-14 June 15, 2023 December 25, 2023 December 31, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881876 629 NCT05881863 To Investigate Airway Oxygen Concentrations During Rigid Bronchoscopy Procedures Performed With High Frequency Jet Ventilation Not yet recruiting No Results Available Central Airway Obstruction Other: No intervention Time in seconds to AiO2 from 90 to 40%|Differences in time to laser mode AiO2 University of Minnesota All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Cohort|Time Perspective: Prospective Setty_Airway June 1, 2023 June 1, 2024 June 1, 2024 May 31, 2023 May 31, 2023 University of Minnesota, Minneapolis, Minnesota, United States https://ClinicalTrials.gov/show/NCT05881863 630 NCT05881850 Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49 Enrolling by invitation No Results Available Osteoporosis Risk Other: Education Program to Raise Osteoporosis Awareness Pre-test data: An introductory information form, Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale|Post-test data: Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale Ankara University Female 18 Years to 49 Years   (Adult) Not Applicable 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 861123-11/658 May 2023 July 2023 December 2023 May 31, 2023 May 31, 2023 Altındağ Municipality; Karapürçek 1, Mimar Başak Cengiz, Yıldıztepe, Beşikkaya Women's Culture and Education Centers, Ankara, Turkey https://ClinicalTrials.gov/show/NCT05881850 631 NCT05881837 Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes Not yet recruiting No Results Available Overweight or Obesity Drug: HRS9531 injection|Drug: HRS9531 injection Placebo Percentage change in body weight|Proportion of subjects with weight loss of ≥5% from baseline in body weight after 24 weeks of treatment|Proportion of subjects with weight loss of ≥10% from baseline in body weight after 24 weeks of treatment|Change from baseline in body weight after 24 weeks of treatment|Change from baseline in waist circumference after 24 weeks of treatment|Change from baseline in BMI after 24 weeks of treatment|Change from baseline in blood pressure after 24 weeks of treatment|Change from baseline in total cholesterol after 24 weeks of treatment|Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment|Change from baseline in glycosylated haemoglobin (HbA1c) after 24 weeks of treatment|Number of AEs During the Trial Fujian Shengdi Pharmaceutical Co., Ltd. All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 240 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment HRS9531-201 June 15, 2023 April 30, 2024 April 30, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881837 632 NCT05881824 PAP Adherence After Diet/Lifestyle Intervention in OSA Patients Completed No Results Available Obstructive Sleep Apnea Behavioral: MDG intervention Difference in PAP adherence|Difference in Body mass index|Difference in Blood pressure measurements|Difference in daytime sleepiness University of Crete All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 74 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment OSADIET1 December 1, 2021 March 30, 2022 June 30, 2022 May 31, 2023 May 31, 2023 University of Crete, Heraklion, Crete, Greece https://ClinicalTrials.gov/show/NCT05881824 633 NCT05881811 An Open-label Phase I Study to Evaluate the Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects Recruiting No Results Available PHN - Post-Herpetic Neuritis Drug: HSK16149，probenecid, cimetidine Cmax|AUC0-t|AUC0-inf|Tmax|t1/2|Vz|CL|Ae|Fe|CLr Haisco Pharmaceutical Group Co., Ltd. All 18 Years to 50 Years   (Adult) Phase 1 48 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other HSK16149-105 March 20, 2023 May 31, 2023 July 30, 2023 May 31, 2023 May 31, 2023 Beijing Jishuitan Hoispital, Beijing, China https://ClinicalTrials.gov/show/NCT05881811 634 NCT05881798 Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study Not yet recruiting No Results Available Deep Vein Thrombosis|Venous Thromboembolism|Pulmonary Embolism Device: Celect Platinum Vena Cava Filter Filter-related primary endpoint (safety)|Filter-related primary endpoint (performance)|Filter Retrieval-related primary endpoint Cook Research Incorporated|Cook Group Incorporated All 18 Years and older   (Adult, Older Adult) 82 Industry Observational Observational Model: Cohort|Time Perspective: Prospective MDR-2126 October 2023 January 2024 January 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881798 635 NCT05881785 Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis Active, not recruiting No Results Available Axial Spondyloarthritis Biological: GR1501 low dose|Biological: GR1501 high dose|Biological: placebo The Proportion of Participants Who Achieve an ASAS 20 Response|The Proportion of Participants Who Achieve an ASAS 40 Response|The Proportion of Participants Who Achieve an ASAS 5/6 Response|Change From Baseline in Mobility on the BASMI|Change From Baseline in BASDAI Response|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)|Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)|Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) Genrix (Shanghai) Biopharmaceutical Co., Ltd. All 18 Years and older   (Adult, Older Adult) Phase 3 465 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment GR1501-007 June 13, 2022 November 10, 2024 April 2, 2025 May 31, 2023 May 31, 2023 Peking union Medical Hosipital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05881785 636 NCT05881772 Acute Effect of Photobiomodulation on Quadriceps Muscle Strength in Patients With Chronic Kidney Failure on Hemodialysis Not yet recruiting No Results Available Renal Insufficiency, Chronic|Renal Dialysis Other: Photobiomodulation Maximal isometric muscle strength of the quadriceps|Muscle pain of lower limbs|Fatigue Federal University of Health Science of Porto Alegre All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 10 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment Laser_HD June 1, 2023 July 1, 2023 August 1, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881772 637 NCT05881759 Integrating Food Rx With Best Feeding Practices With EFNEP Not yet recruiting No Results Available Dietary Habits|Childhood Obesity|Food Selection|Feeding Behavior Behavioral: Revised ESBA Change in feeding practices at 3-months will be assessed using the Food Parenting Inventory Baylor College of Medicine|Prairie View A&M University|University of Houston All 18 Years to 64 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention H-50824 September 16, 2023 March 31, 2024 March 31, 2026 May 31, 2023 May 31, 2023 Baylor College of Medicine, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05881759 638 NCT05881746 Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness Not yet recruiting No Results Available Colorectal Carcinoma|Liver Metastases Procedure: anatomical liver resection|Procedure: nonanatomical liver resection relapse-free survival|overall survival|postoperative hospital stay|postoperative complication|postoperative mortality Fudan University All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 176 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment ARCLAMP July 1, 2023 July 1, 2026 July 1, 2028 May 31, 2023 May 31, 2023 Zhongshan hospital, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05881746 639 NCT05881733 Effect of a Bigger Cryoballoon on the Total Antral Lesion Size: Evaluation of POLARx FIT BETTER-FIT Not yet recruiting No Results Available Atrial Fibrillation Device: POLARx FIT cryoballoon Extent of antral lesion size after cryoablation with a 31 mm balloon size POLARx FIT|Rate of grade 4 occlusion with a 31 mm balloon size POLARx FIT (on PV level)|Single shot success rate with a 31 mm balloon size POLARx FIT cryoablation catheter (on PV level). Erasmus Medical Center|Boston Scientific Corporation All 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MEC-2023-0325|NL84423.078.23 August 2023 April 2025 July 2025 May 31, 2023 May 31, 2023 Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands https://ClinicalTrials.gov/show/NCT05881733 640 NCT05881720 Sacubitril/Valsartan Versus Valsartan in Heart Failure Recruiting No Results Available Heart Failure Drug: Sacubitril / Valsartan Oral Tablet|Drug: Valsartan 160mg LVEF %|Lipo A (pg/ml)|Troponin.I (ng/ml)|NT-Pro BNP|Neopterin (nmol/l) Damanhour University|Tanta University All 35 Years to 80 Years   (Adult, Older Adult) Phase 4 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment sacubitril/valsartan in HF April 10, 2023 December 1, 2023 December 30, 2023 May 31, 2023 June 1, 2023 Tanta University Hospital, Tanta, Elgarbia, Egypt https://ClinicalTrials.gov/show/NCT05881720 641 NCT05881707 A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg Not yet recruiting No Results Available Hypertension Drug: CKD-828, D064, D702 AUCt of CKD-828|Cmax of CKD-828 Chong Kun Dang Pharmaceutical All 19 Years to 54 Years   (Adult) Phase 1 42 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment A30_18BE2304 June 7, 2023 August 19, 2023 August 26, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881707 642 NCT05881694 Accuracy of Upper Lip Bite Test and Measurement of Skin-to-epiglottis Distance in Predicting Difficult Laryngoscopy: a Prospective Observational Study Not yet recruiting No Results Available Difficult Laryngoscopy|Upper Lip Bite Test The accuracy of combined class 3 ULBT and DSE >2 cm in predicting difficult laryngoscopy Cairo University All 40 Years to 60 Years   (Adult) 210 Other Observational Observational Model: Cohort|Time Perspective: Prospective MS-122-2022 May 30, 2023 October 1, 2023 October 5, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881694 643 NCT05881681 A Mindfulness Approach to UA for Afro-descendants Recruiting No Results Available Anxiety|Stress Behavioral: App-Delivered Mindfulness Training (MT) Focused interviews|Change in anxiety|Change in worry|Change in non-reactivity Brown University|Richard King Mellon Foundation|University of Pittsburgh Medical Center All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2112003165 September 6, 2022 October 31, 2023 October 31, 2023 May 31, 2023 May 31, 2023 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05881681 644 NCT05881668 MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation Not yet recruiting No Results Available Liver Failure, Acute on Chronic Biological: MSC-EV Number of participants with MSC-EV infusion-related toxicity as assessed by CTCAE v4.0.|Aspartate aminotransferase (AST)|Alanine aminotransferase (ALT)|Bilirubin level|International normalized ratio (INR)|carbohydrate Compound antigen (GGT) level|Adverse events|Number of survived patients at 1 year after liver transplantation, according to the follow-up results.|Number of survived grafts at 1 year after liver transplantation, according to the follow-up results.|Recipient's immune function, as assessed by analysis of immune cell subsets from biopsy or blood samples ,at months 1-6 after liver transplantation. Third Affiliated Hospital, Sun Yat-Sen University All 18 Years to 60 Years   (Adult) Phase 1 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MSC-EV of ThirdSunYatSen September 30, 2023 September 30, 2024 April 30, 2025 May 31, 2023 May 31, 2023 Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05881668 645 NCT05881655 Slow Myopia Progression With Different Irradiance Light Recruiting No Results Available Myopia, Progressive Device: Airdoc Red Lighting Device|Device: Special Spectacles to Control Myopia Mean Change of Ocular Axial length elongation at follow-up from Baseline (mm)|Mean Change of Refractive Error at follow-up from Baseline (mm)|Mean Change of Choroidal Thickness (um)|Change of Fundus Beijing Airdoc Technology Co., Ltd.|Shanghai Children's Medical Center All 6 Years to 12 Years   (Child) Not Applicable 75 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Airdoc MPC May 20, 2023 May 30, 2024 December 30, 2025 May 31, 2023 May 31, 2023 Shanghai Children Medical Center, Shanghai, China https://ClinicalTrials.gov/show/NCT05881655 646 NCT05881642 Robot-assisted Function-sparing Cystectomy Followed by Modified Orthotopic Ileal Neobladder Not yet recruiting No Results Available Negative Surgical Margins Procedure: Prostate and seminal-sparing Cystectomy|Procedure: Conventional Radical Cystoprostatectomy Post-operative urinary function|bladder cancer specific survival rate|Sexual function Wuhan Union Hospital, China Male 20 Years to 70 Years   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 0857-01 October 1, 2023 November 1, 2025 January 1, 2026 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881642 647 NCT05881629 Early Diagnosis and Intervention for Fetal Malposition in Active Labor and Its Impact on Mode of Delivery Not yet recruiting No Results Available Cesarean Delivery Affecting Fetus|Labor Dystocia|Labor Complication Behavioral: Maternal position change to side-lying lateral with peanut ball|Behavioral: Free maternal position Operative Delivery Rate|Rotation at Complete Dilation|Rotation at Delivery|Duration of Active Second Stage|Estimated Blood Loss|Degree of Laceration following Delivery|Score on Labor Agentry Scale|Apgar Scores|Neonatal Intensive Care Unit (NICU) Admission Women and Infants Hospital of Rhode Island Female 18 Years and older   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2015598-1 December 1, 2023 June 1, 2025 June 1, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881629 648 NCT05881616 Study on Serum Metabolomics of GDM Not yet recruiting No Results Available GDM|Pathogenesis|Diagnosis Other: Specimen samples and baseline data collection Content of serum metabolomics Zhejiang University|Women's Hospital School Of Medicine Zhejiang University Female 20 Years to 40 Years   (Adult) 480 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional IRB-20230193-R May 2023 May 2023 May 2023 May 31, 2023 May 31, 2023 Women's Hospital School Of Medicine Zhejiang University, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05881616 649 NCT05881603 Prevalence of Venous conGestion and Its Association With Renal Injuries Evaluated by the VExUS Score On Admission With UltraSound in Patients With Cardiogenic Pulmonary Edema GRIEVOUS Not yet recruiting No Results Available Cardiogenic Acute Pulmonary Edema Other: " VExUS score " (Venous Excess Ultrasound Score) Estimate the prevalence of the different grades of venous congestion assessed by the VExUS score in ultrasound|Evaluate the association between the different ultrasound grades of venous congestion described by the ultrasound VExUS score and the occurrence of renal complications during hospitalization defined by the MAKE-Discharge|Assess the association between the grade of the VExUS ultrasound score on admission and the total and daily dose of furosemide administered to the patient|Evaluate the kinetics of evolution of the VExUS ultrasound score performed at the patient's bedside in comparison with the values found on admission|Evaluate the association between the presence of venous congestion (VExUS score ≥ 1) or not and vital and functional status : Gerontological autonomy iso-resource groups|Evaluate the association between the presence of venous congestion (VExUS score ≥ 1) or not and vital and functional status : Activities of daily living|Evaluate the association between the presence of venous congestion (VExUS score ≥ 1) or not and vital and functional status : Barthel Index Centre Hospitalier Universitaire de la Réunion All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2022/CHU/22|2022-A02815-38 May 2023 May 2025 August 2025 May 31, 2023 May 31, 2023 CHU de la Réunion, Saint-Denis, France https://ClinicalTrials.gov/show/NCT05881603 650 NCT05881590 Hybrid Pulmonary Rehabilitation Study Recruiting No Results Available Respiratory Disease Other: Hybrid pulmonary rehabilitation Feasibility - patient recruitment rates|Feasibility - recruitment|Feasibility - participant retention rates|Feasibility - Availability of data for primary and secondary outcomes of a larger definitive trial|Feasibility - success of propensity matching of control group|Feasibility - Success of integrating hybrid pulmonary rehabilitation into routine practice|Feasibility - patient/staff acceptability of the hybrid pulmonary rehabilitation programme|Feasibility - safety of the hybrid pulmonary rehabilitation programme|Patient uptake of the hybrid pulmonary rehabilitation programme|Pulmonary rehabilitation class sessions completed|Drop out rate from pulmonary rehabilitation|Changes in exercise capacity measures|Adherence to the hybrid pulmonary rehabilitation programme (activity adherence)|Adherence to the hybrid pulmonary rehabilitation programme (educational adherence)|Adherence to the hybrid pulmonary rehabilitation programme (medication adherence)|Changes in symptoms|Changes in knowledge, skills, and confidence to manage health and wellbeing|Number of reported symptoms during the hybrid pulmonary rehabilitation programme|Changes in disease knowledge|Changes in lower limb function|Changes in health-related quality of life|Changes in anxiety measures|Changes in depression measures|Patient costs|Health care resources - service capacity|Health care resources - waiting times|Health care resources - health care professionals time Anglia Ruskin University|Royal Brompton & Harefield NHS Foundation Trust|Aseptika Ltd.|So What? Consultancy Ltd. All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care HEMS_2223001 May 4, 2023 December 31, 2023 December 31, 2023 May 31, 2023 May 31, 2023 Guy's and St Thomas' NHS Foundation Trust - Harefield Hospital, Harefield, Uxbridge, United Kingdom https://ClinicalTrials.gov/show/NCT05881590 651 NCT05881577 The Effect of Allergic Rhinitis on Educational Outcomes Recruiting No Results Available Allergic Rhinitis Other: Observational Primary school final examination test grades (oral and written) in: Language (Danish, English), Mathematics Obtained high school degree Obtained university degree|Cost of inpatient and outpatient hospitalisation|Cost of prescription medicine|Number of inpatient and outpatient visits ALK-Abelló A/S|Ernst & Young All 5 Years to 12 Years   (Child) 150000 Industry|Other Observational Observational Model: Case-Control|Time Perspective: Other NI-X-06 February 15, 2023 July 31, 2023 July 31, 2023 May 31, 2023 May 31, 2023 ALK Abello, Hørsholm, Hovedstaden, Denmark https://ClinicalTrials.gov/show/NCT05881577 652 NCT05881564 Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery Recruiting No Results Available Congenital Heart Disease Other: blood use for priming cardiopulmonary bypass circuit|Other: clear prime for cardiopulmonary bypass Age of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Weight of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Gender of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Demographics of bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Diagnosis of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Surgery performed in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Previous surgery prior to bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Blood received during bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Volume transfused during bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with unplanned reoperation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with unplanned cardiac catheterization in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with a neurologic complication in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with chylothorax in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with vocal cord injury in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with diaphragm paralysis in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with pacemaker implantation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with postoperative pneumothorax in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with wound infection in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with bleeding requiring reoperation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients with pericardial effusion in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)|Number of patients who died following bloodless cardiac surgery in patients 3.5-12kg (categorical variable) Augusta University All Child, Adult, Older Adult Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 2000190-3 May 10, 2023 May 11, 2025 May 12, 2026 May 31, 2023 June 1, 2023 Children's Hospital of Georgia, Augusta, Georgia, United States https://ClinicalTrials.gov/show/NCT05881564 653 NCT05881551 Pain Assessment Via Force Measurement Using eEgg After Blockade of the Lumbar Facet Joints SMeEgg Recruiting No Results Available Pain Measurement Device: eEgg|Other: NRS Comparison of the expressions of pain ratings in eEgg-Arm and in NRS-Arm|Comparison of the expressions of the pain ratings within eEgg-Arm|Comparison of pain rating by NRS from eEgg-Arm with pain rating by NRS from NRS-Arm|Number of measurements with the eEgg during the night|Comparison of the standardization values in the eEgg group at the beginning of the study|Comparison of the standardization values in the eEgg group at the end of the study|Difference in pain sensation (NRS) due to the different local anesthetics|Questionnaire evaluation on the handling of the eEgg University of Witten/Herdecke All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic SMeEgg May 25, 2023 August 31, 2023 October 31, 2023 May 31, 2023 May 31, 2023 Helios Universitätsklinikum Wuppertal, Wuppertal, Germany https://ClinicalTrials.gov/show/NCT05881551 654 NCT05881538 High Intensity Intervallic Training in Children With Bronchiolitis Obliterans PIBOHIIT Not yet recruiting No Results Available Bronchiolitis Obliterans Other: Exercise group Change in peak oxygen consumption|Change in time to ventilatory threshold|Change in percent oxygen consumption at ventilatory threshold|Change in ventilatory efficiency|Change in forced expiratory volume in the first second|Change in forced vital capacity|Change in forced expiratory flow between 25 and 75% of forced vital capacity|Change in muscle strength|Change in lower body strength|Change in free fat mass|Change in lean mass|Change in hip-waist ratio|Change in body mass index|Change in quality of life|Change in dyspnea Universitat Internacional de Catalunya|Consejo Superior de Deportes All 6 Years to 20 Years   (Child, Adult) Not Applicable 62 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment PIBOHIIT-UIC May 31, 2023 July 2024 September 2024 May 31, 2023 May 31, 2023 "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/38/NCT05881538/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05881538 655 NCT05881525 NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors Recruiting No Results Available Advanced Solid Tumors Biological: TC-N201 cells|Drug: IL-2|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Nab-paclitaxel Dose Limiting Toxicity or Maximum Tolerated Dose (MTD)|Overall response rate|Treatment-related adverse events as assessed by National Cancer Institute general terminology standard for adverse events (NCI CTCAE) v5.0|Duration of response|Progression free survival|Overall survival|Maximum Persistence (Cmax) of TC-N201|Time to Maximum Persistence|Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC [0-28])|Anti-PD-1 single chain antibody concentration TCRCure Biopharma Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences All 18 Years to 70 Years   (Adult, Older Adult) Phase 1 18 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TC-N201-ST June 1, 2023 October 2023 March 2025 May 31, 2023 May 31, 2023 TCRCure Biopharma Ltd., Chongqing, China https://ClinicalTrials.gov/show/NCT05881525 656 NCT05881512 Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea Completed No Results Available Obstructive Sleep Apnea|OSA Device: Transcutaneous Upper Airway Stimulation Device Apnea Hypopnea Index|Arterial Oxygen Saturation (SaO2) Somnial Inc All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 12 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility SOMN-001 September 12, 2022 September 18, 2022 February 22, 2023 May 31, 2023 May 31, 2023 United Diagnostics, Commack, New York, United States https://ClinicalTrials.gov/show/NCT05881512 657 NCT05881499 The Effects of Earthquake on Fear of Movement and Fear of Falling Not yet recruiting No Results Available Fear of Movement|Fear of Falling Fear of movement|Fear of falling|Level of physical activity|Intensity of pain|Psychological Resilience Status Atılım University All 18 Years to 60 Years   (Adult) 185 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional Atılım University June 1, 2023 July 1, 2023 August 1, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881499 658 NCT05881486 Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery Not yet recruiting No Results Available Postoperative Nausea and Vomiting|Anesthesia Complication|Thoracic Diseases Drug: Ondansetron 8mg|Drug: Fosaprepitant 150 mg Incidence of PONV within 24 hours|Incidence of PONV within 48 hours|occurrence of Drug-related adverse effects|Postoperative pain score|The dosage of opioids used after surgery|the length of hospital stay|postoperative pulmonary complications Qilu Hospital of Shandong University All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 234 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment KYLL-202210-072-1 May 2023 May 2023 June 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881486 659 NCT05881473 Clavipectoral Fascial Plane Block Versus Superficial Cervical Block in Fracture Clavicle Recruiting No Results Available Fracture Clavicle Diagnostic Test: pain assessment after clavicular fracture repair visual analogue score (VAS score) post operative|hemodynamics Ain Shams University All 21 Years to 60 Years   (Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment fracture clavicle June 1, 2023 July 1, 2023 August 1, 2023 May 31, 2023 May 31, 2023 Ain Shams University, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05881473 660 NCT05881460 Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2 Recruiting No Results Available Parkinson Disease Device: Active vibrotactile coordinated reset|Device: Sham vibrotactile coordinated reset Change in Movement Disorders Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3|Change in gait speed as measured by Ambulatory Parkinson's Disease Monitoring (APDM) Mobility Lab|Quality of life improvements|Change in freezing severity index Synergic Medical Technologies, Inc. All 45 Years to 85 Years   (Adult, Older Adult) Not Applicable 30 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 25412 May 22, 2023 September 21, 2024 January 21, 2025 May 31, 2023 June 1, 2023 Oregon Health & Science Institution, Portland, Oregon, United States https://ClinicalTrials.gov/show/NCT05881460 661 NCT05881447 Longitudinal Assessment of Chronic Kidney Disease Prevalence Rate and Risk Signature in Semirural Sub-Saharan Africa RenalTWO Not yet recruiting No Results Available Chronic Kidney Diseases|Type 2 Diabetes Mellitus|Arterial Hypertension|Obesity|Cardiovascular Diseases|HIV Infections|Anemia ≥ 90 days confirmed chronic kidney disease (CKD) prevalence rate assessed according to KDIGO guidelines.|Longitudinally assessed and confirmed CKD risk signature in a primary care population from semirural sub-Saharan Africa|Concordance and usefulness of glycated hemoglobin A1c (HbA1c) in patients with anemia for diabetes diagnostics Swiss Tropical & Public Health Institute|University Hospital, Basel, Switzerland|Ifakara Health Institute All 18 Years to 99 Years   (Adult, Older Adult) 1200 Other Observational Observational Model: Cohort|Time Perspective: Prospective HSR-2022-27 June 1, 2023 April 1, 2024 December 30, 2024 May 31, 2023 May 31, 2023 Bagamoyo District Hospital, Bagamoyo, Pwani, Tanzania https://ClinicalTrials.gov/show/NCT05881447 662 NCT05881434 Influence of a Questionnaire on Patients' Emergency Room Expectations Completed No Results Available Emergencies|Satisfaction, Patient|Expectations|Physician-Patient Relations Other: Emergency Department Visit Expectations Questionnaire Patient reported provider understanding of patient's visit expectations|Patient reported degree to which visit expectations were met|Patient reported provider courtesy|Patient reported provider listening|Patient reported inclusion in treatment decisions Orange Park Medical Center All 18 Years and older   (Adult, Older Adult) Not Applicable 308 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research Expectations January 31, 2022 October 17, 2022 October 17, 2022 May 31, 2023 May 31, 2023 Orange Park Medical Center, Orange Park, Florida, United States https://ClinicalTrials.gov/show/NCT05881434 663 NCT05881421 DISRUPT PAD III Observational Study PAD III OS Completed No Results Available Peripheral Arterial Disease Procedural Success - Primary Effectiveness Endpoint|Procedural Success - Secondary Effectiveness Endpoint Shockwave Medical, Inc. All 18 Years and older   (Adult, Older Adult) 1373 Industry Observational Observational Model: Cohort|Time Perspective: Prospective CP 60892 OS November 16, 2017 June 10, 2021 June 10, 2021 May 31, 2023 May 31, 2023 Stanford Hospital, Palo Alto, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|UCHealth Northern Colorado, Loveland, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Tallahassee Research Institute Inc., Tallahassee, Florida, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Steward St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|North Mississippi Medical Center, Tupelo, Mississippi, United States|St. Luke's Cardiovascular Consultants, Kansas City, Missouri, United States|Mount Sinai West, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|NC Heart & Vascular Research, LLC, Raleigh, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|St. John Clinic, Bartlesville, Oklahoma, United States|Providence Heart & Vascular Institute, Portland, Oregon, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Pinnacle Health Cardiovascular Institute, Harrisburg, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Baptist Medical Center, Memphis, Tennessee, United States|St. David's Heart and Vascular (Austin Heart), Austin, Texas, United States|Baylor Clinic McNair Campus, Houston, Texas, United States|Charleston Area Medical Center, Charleston, West Virginia, United States|Evangelisches Krankenhaus Mulheim an der Ruhr, Mülheim, Germany|St. Franziskus Hospital, Münster, Germany|RoMed Klinikum Rosenheim, Rosenheim, Germany|Auckland City Hospital, Auckland, New Zealand https://ClinicalTrials.gov/show/NCT05881421 664 NCT05881408 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) ENVISION Not yet recruiting No Results Available Duchenne Muscular Dystrophy Genetic: SRP-9001|Genetic: Placebo Part 1: Change From Baseline in the Total Score of Performance of Upper Limb (PUL) (Version 2.0) at Week 72|Part 1: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 72|Part 1: Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 72|Part 1: Quantity of SRP-9001 Protein Expression at Week 12 as Measured by Western Blot|Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information (PROMIS) Score in Upper Extremity Function to Week 72|Number of Participants with a Treatment Emergent Adverse Event (TEAE), Adverse Event of Special Interest (AESI), and Serious Adverse Event (SAE)|Part 1 (For Cohort 2 Only): Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 72|Part 1: Change From Baseline in Global Circumferential Strain as Measured by Cardiac MRI at Week 72 Sarepta Therapeutics, Inc.|Hoffmann-La Roche Male Child, Adult, Older Adult Phase 3 148 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment SRP-9001-303|2020-002372-13 June 30, 2023 January 31, 2026 January 31, 2027 May 31, 2023 May 31, 2023 Arkansas Children's, Little Rock, Arkansas, United States|Rady Children's Hospital-San Diego, San Diego, California, United States|University of Florida, UF Health Center for Pediatric Neuromuscular and Rare Diseases, Gainesville, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Dept of Pediatrics, Iowa City, Iowa, United States|The Johns Hopkins Hospital, Charlotte R. Bloomberg Children's Center, Pediatric Clinical Research Unit, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Washington University of St. Louis, St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Rochester, Dept of Neurology, Rochester, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|VUMC- Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Children's Wisconsin, Milwaukee, Wisconsin, United States https://ClinicalTrials.gov/show/NCT05881408 665 NCT05881395 Assessment of Sensory Block During Labour Epidural Analgesia in Patients Experiencing Pain During First Stage of Labour. Not yet recruiting No Results Available Labor Pain Lower sensory block level: ice test when the patient is experiencing pain|Upper sensory block level: ice test when the patient is experiencing pain|Lower sensory block level: pinprick test when the patient is experiencing pain|Upper sensory block level: pinprick test when the patient is experiencing pain|Verbal Numeric Rating Score (VNRS) at the time of request of assessment by anesthesiologist|Verbal Numeric Rating Score (VNRS) at 10 minutes after each epidural top-up administered.|Lower sensory block level: ice test following epidural top-up|Upper sensory block level: ice test following epidural top-up|Lower sensory block level: pinprick test following epidural top-up|Upper sensory block level: pinprick test following epidural top-up|Motor block score using Bromage score at the time of request of assessment by anesthesiologist|Motor block score using Bromage score following epidural top-up|Number of epidural top-ups required|Type of pain: questionnaire|Location of pain: questionnaire Samuel Lunenfeld Research Institute, Mount Sinai Hospital Female 18 Years to 60 Years   (Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective 23-01 May 2023 December 2023 December 2023 May 31, 2023 May 31, 2023 Mount Sinai Hospital, Toronto, Ontario, Canada https://ClinicalTrials.gov/show/NCT05881395 666 NCT05881382 Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction HEAL-MI Not yet recruiting No Results Available ST Elevation Myocardial Infarction Drug: Dutogliptin + Filgrastim|Drug: Placebo Time of first occurence of the following composite endpoint of cardiovascular (CV) death and worsening of heart failure (HF)|Time to cardiovascular death|Worsening heart failure|Total symptom score of the Kansas City Cardiomyopathy Questionnaire Recardio, Inc. All 18 Years to 85 Years   (Adult, Older Adult) Phase 3 4100 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment REC-DUT-003 September 2023 September 2025 September 2025 May 31, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05881382 667 NCT05881369 Examining Clinical Research Participation for Substance Abuse Disorder Patient Not yet recruiting No Results Available Substance Abuse Disorder Rate of patients who decide to enroll in a substance abuse disorder clinical study.|Number of substance abuse disorder patients who remain in clinical trial until completion. Power Life Sciences Inc. All 18 Years and older   (Adult, Older Adult) 500 Industry Observational Observational Model: Case-Crossover|Time Perspective: Prospective 91257336 June 2024 June 2025 June 2026 May 31, 2023 May 31, 2023 Power Life Sciences, San Francisco, California, United States "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/69/NCT05881369/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05881369 668 NCT05881356 Discovering Factors in the Clinical Study Journey of Patients With OCD Recruiting No Results Available OCD|Obsessive-Compulsive Disorder Rate of participants who decide to enroll in a OCD clinical study.|Number of OCD patients who remain in clinical trial until completion. Power Life Sciences Inc. All 18 Years and older   (Adult, Older Adult) 500 Industry Observational Observational Model: Case-Crossover|Time Perspective: Prospective 91191727 June 2024 June 2025 June 2026 May 31, 2023 May 31, 2023 Power Life Sciences, San Francisco, California, United States "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/56/NCT05881356/ICF_000.pdf https://ClinicalTrials.gov/show/NCT05881356 669 NCT05881343 Retrospective Case Series of COVID19+ Patients Undergoing Orthopedic Surgery COVID19&SURG Completed No Results Available Coronavirus Infection|Orthopedic Disorder|Bone Fracture|Bone Metastases|Bone Neoplasm SARS-CoV-2 infection|SARS-CoV-2 mortality|Population|Known SARS-CoV2 infection and type of anesthesia|Known SARS-CoV2 mortality|Known SARS-CoV2 infection|SARS-CoV2 infection and DVT/PE|SARS-CoV2 and surgical site infection|SARS-CoV2 and postoperative oxygen therapy|SARS-CoV2 infection and TEG|Mortality in SARS-CoV2 patients vs historical population|Surgical site infection in SARS-CoV2 patients vs historical population Istituto Ortopedico Rizzoli All Child, Adult, Older Adult 40 Other Observational Observational Model: Cohort|Time Perspective: Retrospective CORONAVIRUS&SURGERY July 18, 2020 September 30, 2020 March 1, 2021 May 31, 2023 May 31, 2023 IORizzoli, Bologna, BO, Italy https://ClinicalTrials.gov/show/NCT05881343 670 NCT05881330 ArtiAid® for Knee Osteoarthritis: A Post-market Study Completed No Results Available Hyaluronic Acid Device: ArtiAid Intra-articular Injection Incidence of Treatment-related Adverse Events|Resting knee pain: VAS (visual analog scale)|Satisfaction of treatment: VAS (visual analog scale) Maxigen Biotech Inc. All 40 Years and older   (Adult, Older Adult) Not Applicable 59 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other MCQ-AA2105 July 1, 2021 September 22, 2022 November 25, 2022 May 31, 2023 May 31, 2023 Tri-Service General Hospital, Taoyuan City, Taiwan (r.o.c.), Taiwan https://ClinicalTrials.gov/show/NCT05881330 671 NCT05881317 ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study Completed No Results Available Hyaluronic Acid Device: ArtiAid® Plus Intra-articular Injection Incidence of Treatment-related Adverse Events|Resting knee pain: VAS (visual analog scale)|Satisfaction of treatment: VAS (visual analog scale) Maxigen Biotech Inc. All 40 Years and older   (Adult, Older Adult) Not Applicable 59 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other MCQ-200305 August 2, 2021 June 6, 2022 November 21, 2022 May 31, 2023 May 31, 2023 Maxigen Biotech Inc., Taoyuan City, Taiwan (r.o.c.), Taiwan https://ClinicalTrials.gov/show/NCT05881317 672 NCT05881304 Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC SWITCHED Not yet recruiting No Results Available Electronic Cigarette Use Device: Standardized research e-cigarette (SREC) Cigarettes smoked per day|Study enrollment|E-cigarette use during e-cigarette provision|Breath carbon monoxide|Anabasine|Study completion Massachusetts General Hospital All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2023p001364 August 2023 December 2024 December 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881304 673 NCT05881291 Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement Not yet recruiting No Results Available Hemodynamics|Transcatheter Aortic Valve Replacement|General Anesthesia|Post-induction Hypotension Drug: ciprofol|Drug: propofol primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 15 min after induction|Incidence of hypotension|Incidence of bradycardia|dose of vasopressor used within 15 minutes after induction of anesthesia and vasopressor drugs used during surgery|Incidence of injection pain|Incidence of postoperative nausea and vomiting|Quality of life and disease recovery (QoR-15) score on postoperative day 1|changes of IL-6 and TNF-α before and one first day after surgery|changes of CK-MB and cTnT before and one first day after surgery Second Affiliated Hospital, School of Medicine, Zhejiang University All 60 Years to 85 Years   (Adult, Older Adult) Not Applicable 124 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 2023-0135 May 25, 2023 May 25, 2024 June 25, 2024 May 31, 2023 June 5, 2023 The Second Affiliated Hospital of Zhejiang University anesthesiology department, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05881291 674 NCT05881278 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] NIHP - 001 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881278 675 NCT05881265 Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia Active, not recruiting No Results Available APL Drug: Chidamide+venetoclax complete remission and complete remission with incomplete recovery of peripheral blood count|Overall survival|Leukemia-free survival|Non-relapse mortality|relapse|Early death Shanghai Jiao Tong University School of Medicine|Shanghai Clinical Research Center All 16 Years to 70 Years   (Child, Adult, Older Adult) Phase 2 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment R/R-APL-2023 May 15, 2023 January 1, 2025 January 1, 2026 May 31, 2023 May 31, 2023 Jiong HU, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05881265 676 NCT05881252 An Observational Study of Perinatal Outcomes Following Change in Clinical Criteria in for Treatment of Maternal Hypertension Not yet recruiting No Results Available Maternal Hypertension Procedure: Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Procedure: Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension Number of patients with Congestive Heart Failure/Pulmonary Edema, hemorrhagic or ischemic Stroke, Acute Kidney Injury (creatinine > 1.5mg/dL), and/or or Myocardial Ischemia.|Number of patients with non-reassuring fetal heart rate tracing (NR-FHRT) requiring caesarean delivery|Number of patients with Apgar score < 7 at 5 min|Number of patients with eclampsia|Number of patients with placental abruption|Number of patients with posterior reversible encephalopathy syndrome (PRES)|Number of patients with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome The University of Texas Health Science Center, Houston Female Child, Adult, Older Adult 540 Other Observational Observational Model: Case-Control|Time Perspective: Prospective HSC-MS-23-0241 June 1, 2023 June 1, 2025 June 1, 2025 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881252 677 NCT05881239 Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD Recruiting No Results Available Subjective Cognitive Concerns|Mild Cognitive Impairment|Mild Behavioral Impairment|Healthy Aging Device: AROMHA Brain Health Test AROMHA Brain Health Test Massachusetts General Hospital All 18 Years to 100 Years   (Adult, Older Adult) 250 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 2022P002451 May 9, 2023 October 2023 June 2024 May 31, 2023 May 31, 2023 Massachusetts General Hospital, Boston, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05881239 678 NCT05881226 Application of Biomarkers in Neurological Diseases Not yet recruiting No Results Available Biomarkers mRS score in 90 days Yi Yang|The First Hospital of Jilin University All Child, Adult, Older Adult 3000 Other Observational Observational Model: Cohort|Time Perspective: Prospective Bio-Neuro June 1, 2023 December 1, 2030 December 1, 2031 May 31, 2023 May 31, 2023 First Hospital of Jilin University, Changchun, Jilin, China https://ClinicalTrials.gov/show/NCT05881226 679 NCT05881213 Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults CKD-378 Not yet recruiting No Results Available Type II Diabetes Drug: CKD-378 (low-dose) area under the curve (AUC)t of CKD-378|Cmax of CKD-378 Chong Kun Dang Pharmaceutical All 19 Years to 55 Years   (Adult) Phase 1 24 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment A129_02BE2227 May 24, 2023 June 14, 2023 July 2, 2023 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881213 680 NCT05881200 Magnetic Mitohormesis: Effect of Magnetic Signals on Metabolic Adaptions in Type 2 Diabetes (MENSA-T2D) MENSA-T2D Not yet recruiting No Results Available Diabetes Mellitus, Type 2 Device: Magnetic mitohormesis Change in HbA1C|Change in insulin resistance Singapore General Hospital|QuantumTX Pte Ltd All 40 Years to 75 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MENSA-T2D June 1, 2023 March 31, 2024 September 30, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881200 681 NCT05881187 Pack Cross Linking for Infectious Keratitis Not yet recruiting No Results Available Infectoius Keratitis Drug: Riboflavin|Drug: Antibotice.g vigamox ED Antifungal e.g Dflucan|Device: pack cross linking corneal THICKNESS Sohag University All 16 Years and older   (Child, Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Pack cross linking June 15, 2023 April 2024 June 2024 May 31, 2023 May 31, 2023 Sohag University Hospital, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05881187 682 NCT05881174 Rapid Acupuncture Treatment for Post-Traumatic Stress Disorder Recruiting No Results Available PTSD Procedure: acupuncture The Post Traumatic Stress Disorder Checklist (PCL-5) for the Diagnosis and Statistical Manual of Mental Disorders (DMS-5) Analysis Malcolm Grow Medical Clinics and Surgery Center|Uniformed Services University of the Health Sciences All 18 Years and older   (Adult, Older Adult) Not Applicable 204 U.S. Fed Interventional Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 20190055H November 24, 2020 November 24, 2026 November 24, 2026 May 31, 2023 June 1, 2023 Malcom Grow Medical Clinics and Surgery Center, Morningside, Maryland, United States https://ClinicalTrials.gov/show/NCT05881174 683 NCT05881161 Bridging the Adherence Gap in Internet Interventions: A Randomized Controlled Trial Protocol Not yet recruiting No Results Available Adherence, Treatment|Job Stress Behavioral: Adherence self-efficacy-enhancing exercise|Behavioral: Med-Stress Student Adherence|Job Stress (Perceived Stress Scale; PSS-4)|Work Engagement (Utrecht Work Engagement Scale; UWES-9) University of Social Sciences and Humanities, Warsaw|Stockholm University All 18 Years and older   (Adult, Older Adult) Not Applicable 720 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention Adherence January 8, 2024 January 31, 2025 January 31, 2025 May 31, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05881161 684 NCT05881148 Carbon Sprinting Spiked-Shoes Trial CS3T Not yet recruiting No Results Available Sprint Performance|Carbon Spiked-shoe|Force-velocity Profile|N of 1 Study Design Other: Carbon sprinting spiked-shoes|Other: Standard carbon-free sprinting spiked-shoes 30m-sprint Time Hôpital Léon Bérard All 16 Years and older   (Child, Adult, Older Adult) Not Applicable 21 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other 2023-CS3T-Multiple N-of-1Trial June 3, 2023 July 3, 2023 July 3, 2023 May 31, 2023 May 31, 2023 Hopital Leon Berard, Hyeres, Var, France https://ClinicalTrials.gov/show/NCT05881148 685 NCT05881135 Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) SCARLET Not yet recruiting No Results Available COVID-19 Drug: Citicoline|Drug: Saline/Placebo Safety of citicoline over a range of doses in COVID-19 patients presenting with acute hypoxemic respiratory failure.|Citicoline's effect on acute hypoxemic respiratory failure in COVID-19 patients.|Effect of citicoline on COVID specific disease severity scale in patients with acute COVID associated hypoxemic respiratory failure.|Effect of citicoline on Sequential Organ Failure Score (SOFA) in patients with COVID associated acute respiratory failure. Ohio State University All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2022H0451 May 2023 May 2025 May 2026 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881135 686 NCT05881122 Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability Completed No Results Available Inflammation|Spinal Cord Injuries|Multiple Sclerosis|Muscular Dystrophies|Diet Habit Behavioral: Mad Dog Dietary Consultation Custom-designed task self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Adherence to the anti-inflammatory diet|Neuropathic pain questionnaire (NPQ)|Depression as determined by the Centre for Epidemiological Studies depression (CES-D) questionnaire Brock University All 18 Years and older   (Adult, Older Adult) Not Applicable 11 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 21-054 - Ditor November 1, 2021 April 30, 2022 May 30, 2022 May 31, 2023 May 31, 2023 Brock University, St. Catharines, Ontario, Canada https://ClinicalTrials.gov/show/NCT05881122 687 NCT05881109 Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents Completed No Results Available Invasive Fungal Infections Drug: Caspogunfin The PTAs of AUC24/MIC90 for C. albicans , C. glabrata , and C. parapsilosis|The PTAs of AUC24/MIC for various species of Candida spp isolates|The PTAs of trough concentration Shandong University All 12 Years to 17 Years   (Child) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective caspofungin-001 January 1, 2018 March 3, 2019 March 3, 2019 May 31, 2023 May 31, 2023 Wuhan Children's Hospital, Wuhan, China https://ClinicalTrials.gov/show/NCT05881109 688 NCT05881096 Effectiveness of START (Startle Adjuvant Rehabilitation Therapy) in Enhancing Arm Function Post-Stroke Recruiting No Results Available Stroke Other: START - Startle Adjuvant Rehabilitation Therapy|Other: Sham Control Change in EMG (electromyography) onset (in ms) during functional reaching task|Change in EMG (electromyography) amplitude (in mV) during the functional reaching task|Change in movement onset (in ms) on functional reaching task|Change in movement linearity (in mm) on functional reaching task|Change in functional reaching task scores during training|Change in functional reaching task scores|Change in sorting task scores|Change in dressing task scores|Retention in functional reaching task scores|Retention in skill transfer 1 : sorting task scores|Retention in skill transfer 2: dressing task Arizona State University All 18 Years to 99 Years   (Adult, Older Adult) Early Phase 1 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment STUDY00002440b June 7, 2022 July 2023 December 2023 May 31, 2023 June 1, 2023 Arizona State University, Tempe, Arizona, United States https://ClinicalTrials.gov/show/NCT05881096 689 NCT05881083 Nicotine Replacement Therapy Sampling for Smokers in the Community QTW2023 Not yet recruiting No Results Available Tobacco Smoking Behavioral: 1-week nicotine replacement therapy sampling|Behavioral: Brief cessation advice Biochemically validated tobacco abstinence|Self-reported 7-day point-prevalence tobacco abstinence|Self-reported 24-hour quit attempt|Self-reported use of nicotine replacement therapy product|Self-reported use of smoking cessation service The University of Hong Kong|Hong Kong Council on Smoking and Health All 18 Years and older   (Adult, Older Adult) Not Applicable 1014 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment QTW2023 June 17, 2023 May 31, 2024 June 30, 2024 May 31, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881083 690 NCT05881070 Effectiveness of Mobile-health Self Management on Quality of Life of Patients Undergoing Chemotherapy MANNER Not yet recruiting No Results Available Cancer|Chemotherapy Effect|Quality of Life|Self Efficacy Behavioral: Mobile-health self management Patient's Quality of life|Patient's Self-efficacy Universitas Muhammadiyah Yogyakarta All 20 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Manner and QOL June 15, 2023 August 31, 2023 September 30, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05881070 691 NCT05881057 Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer Not yet recruiting No Results Available Lung Cancer Overall Survival(OS)|Recurrence free survival(RFS) Shanghai Pulmonary Hospital, Shanghai, China All 19 Years to 75 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Case-Only|Time Perspective: Prospective 2022HY0519 June 2023 June 2027 June 2028 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05881057 692 NCT05881044 Psychiatric and Social Impacts of IVF Not yet recruiting No Results Available In Vitro Fertilization Other: Psychiatric interview Measurement of depression in couples with IVF . Assiut University All 18 Years to 40 Years   (Adult) 52 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional Impacts of IVF June 1, 2023 September 1, 2023 January 1, 2024 May 30, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05881044 693 NCT05881031 Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity Recruiting No Results Available Sleep-Disordered Breathing Other: Home Initiation of NiPPV Recruitment and retention rate|Proportion of eligible patients randomized|Proportion of patients that crossover based on safety criteria|Mean minutes of nightly NiPPV usage|Proxy-reported Psychological Scale (percentage rank)|Proxy-reported Psychological Scale (T-value)|Self-Reported Psychological Scale (percentage rank)|Self-Reported Psychological Scale (T-value)|Caregiver reported Sense of Mastery|Patient and family study experience, preference of intervention and barriers|Difference in expiratory positive airway pressure based on home NiPPV titration and PSG titration in the intervention arm|Difference in inspiratory positive airway pressure based on home NiPPV titration and PSG titration in the intervention arm The Hospital for Sick Children All 60 Months to 215 Months   (Child) Not Applicable 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 1000080480 May 25, 2023 May 1, 2025 May 1, 2025 May 30, 2023 May 30, 2023 The Hospital for Sick Children, Toronto, Ontario, Canada https://ClinicalTrials.gov/show/NCT05881031 694 NCT05881018 Investigating the Effects of Diet and Physical Activity on Esport Performance Not yet recruiting No Results Available Sports Physical Therapy|Dietary Habits|Diet, Healthy Dietary Supplement: Low glycaemic index|Dietary Supplement: High glycaemic index|Behavioral: Physical activity Change in esport performance (test battery)|Glucose response (continuous glucose monitor): 3h iAUC|Glycaemic variability (continuous glucose monitor): 24h MAGE Beneo-Institute|German Sport University, Cologne All 18 Years to 45 Years   (Adult) Not Applicable 48 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other ES01 July 1, 2023 December 1, 2023 December 1, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05881018 695 NCT05881005 Fatty Liver in Cushing FLIC Not yet recruiting No Results Available Cushing Syndrome|Fatty Liver Disease Diagnostic Test: hepatic MRI Frequency of resolution of hepatic steatosis|Prevalence of steatosis at diagnosis of Cushing|Fatty Liver Index (non-invasive biomarkers of hepatic steatosis )|FIB-4 (non-invasive biomarkers advanced hepatic fibrosis)|e-LIFT (non-invasive biomarkers advanced hepatic fibrosis)|NAFLD Fibrosis Score (non-invasive biomarkers advanced hepatic fibrosis) University Hospital, Angers All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 2023-A00727-38 July 2023 May 2028 May 2028 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05881005 696 NCT05880992 Trimodal Prehabilitation in Colorectal Cancer Patients: a Feasibility Pilot PrehabCRC Not yet recruiting No Results Available Colorectal Cancer Behavioral: Exercise|Dietary Supplement: Nutrition|Behavioral: Mindfulness Retention rate|Recruitment rate|Exercise completion rate|Nutrition compliance rate|Mindfulness compliance rate|Adherence rate|All-cause Mortality|Readmission to hospital|Presentation to emergency department|Non-home discharge|Major complications Jordan Leitch|Queen's University All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention PrehabCRC June 1, 2023 September 30, 2023 June 30, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880992 697 NCT05880979 Engaging Together for Healthy Relationships Pilot Trial ETHR Not yet recruiting No Results Available Violence in Adolescence|Domestic Violence Behavioral: Engaging Together for Healthy Relationships|Behavioral: Regular well child care Percentage of participants who are eligible out of the total who are approached|Percentage of participants who are consented out of the total who are eligible|Percentage of participants who complete the baseline survey out of the total who consented|Percentage of participants who complete the well-visit out of the total who consented|Percentage of participants who complete the immediate post-intervention survey out of the total who consented|Percentage of participants who complete the 1-month post-intervention survey out of the total who consented|Percentage of participants who complete the 3-month post-intervention survey out of the total who consented|Percentage of participants who strongly agree or agree that the intervention is acceptable using a 4-item validated measure (Acceptability of Intervention Measure)|Self-efficacy in preventing adolescent relationship abuse (ARA), change in outcome between baseline and 3 months|Percentage of participants who utilize ARA resources at each measurement point, change in outcome over time|Attitudes about ARA, change in outcome between baseline and 3 months|Parent-adolescent communication around dating and ARA, change in outcome over time|Parental monitoring around dating and ARA, change in outcome over time|Percentage of adolescents reporting ARA victimization and perpetration University of Pittsburgh All 11 Years and older   (Child, Adult, Older Adult) Not Applicable 168 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention STUDY22060047 June 1, 2023 May 1, 2024 July 1, 2024 May 30, 2023 May 30, 2023 Primary Care Center Oakland, Pittsburgh, Pennsylvania, United States|Primary Care Center Turtle Creek, Pittsburgh, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05880979 698 NCT05880966 Functional Fitness for Overweight or Obese Adults With Mobility Disabilities COBRE Pilot Recruiting No Results Available Mobility Limitation|Overweight or Obesity|Physical Disability Behavioral: Functional Fitness Weight|Body Composition|Waist Circumference|Blood Pressure|Glucose|Cholesterol|Triglycerides|Body Mass Index|Quality of Life (QOL)|Life Satisfaction|Flexibility|Balance|Strength|Mobility|Sense of Community|Shoulder Pain - manual wheelchair users only|Exercise self-efficacy|Sleep|Barriers to Health|Psychological Need Satisfaction|Self-determination|Perceived Functional Performance University of Kansas All 18 Years to 64 Years   (Adult) Not Applicable 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 00043722 April 17, 2023 March 1, 2024 March 1, 2024 May 30, 2023 May 30, 2023 University of Kansas, Lawrence, Kansas, United States https://ClinicalTrials.gov/show/NCT05880966 699 NCT05880953 Parent-to-parent Coaching While Awaiting Hospital Discharge With a Child With a Ventilator Not yet recruiting No Results Available Invasive Mechanical Ventilation|Children With Medical Complexity|Home Nursing|Empowerment Behavioral: Parent-to-parent coaching Change in parent empowerment as measured by the family empowerment scale (FES)|Change in nursing coverage|Satisfaction with coaching program University of Chicago|National Institute on Minority Health and Health Disparities (NIMHD) All 18 Years and older   (Adult, Older Adult) Not Applicable 30 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other IRB23-0348|P50MD017349 June 2023 May 2024 May 2024 May 30, 2023 June 2, 2023 University of Chicago, Chicago, Illinois, United States https://ClinicalTrials.gov/show/NCT05880953 700 NCT05880940 Comparing Different Rehabilitation Exercise Strategies for Improving Arm Recovery After Stroke Boost Not yet recruiting No Results Available Stroke Device: Boost - Moveable Wheelchair Armrest|Behavioral: Electronic Arm and Hand Exercise Program Fugl-Meyer Arm Motor Assessment Score (FMAMA)|Modified Ashworth Spasticity Scale|Box and Blocks Test|Shoulder subluxation Distance University of California, Irvine|Flint Rehabilitation Devices, LLC|Rancho Research Institute, Inc.|Casa Colina Hospital and Centers for Healthcare All 18 Years to 84 Years   (Adult, Older Adult) Not Applicable 60 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 5R44HD106850-02 July 1, 2023 August 31, 2024 August 31, 2025 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880940 701 NCT05880927 Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer Recruiting No Results Available Breast Cancer Drug: Pyrotinib iDFS|OS|Adverse events Taizhou Hospital Female 18 Years to 75 Years   (Adult, Older Adult) Phase 2 150 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment PERSIST January 1, 2019 December 31, 2024 December 31, 2025 May 30, 2023 May 30, 2023 Taizhou Hospital, Taizhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05880927 702 NCT05880914 Precision Medicine Approaches to Renal Osteodystrophy PMaROD Recruiting No Results Available Renal Osteodystrophy|Chronic Kidney Diseases|CKD-MBD|Bone Turnover Rate Disorder|Secondary Hyperparathyroidism To determine the utility of a miRNA panel to discriminate changes in bone turnover|To determine whether of a miRNA panel that identifies bone turnover type is able to also identify with bone quality|To confirm that miRNAs in circulation reflect miRNAs in bone-tissue|To confirm that miRNAs in circulation reflect changes in bone based on bone imaging Thomas Nickolas, MD MS|Indiana University School of Medicine|Columbia University All 18 Years and older   (Adult, Older Adult) 40 Other Observational Observational Model: Other|Time Perspective: Prospective AAAU1119 December 21, 2022 August 17, 2026 June 30, 2027 May 30, 2023 May 31, 2023 Columbia University Irving Medical Center, New York, New York, United States https://ClinicalTrials.gov/show/NCT05880914 703 NCT05880901 Healthy Kids Beyond the Bell: Investigating the Impact of After-School and Summer Programs Not yet recruiting No Results Available Health Status Disparities|Pediatric Obesity|Ethnic Group|Socioeconomic Factors Behavioral: After school program|Behavioral: Summer day camp Change in Body Mass Index University of South Carolina All 5 Years to 12 Years   (Child) Phase 2 480 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention Pro00125471 January 1, 2024 August 31, 2027 August 31, 2028 May 30, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05880901 704 NCT05880888 Investigating the Clinical Impact of a Novel Adipose Allograft Matrix on Knee Fat Pad Impingement Treatment Recruiting No Results Available Fat Pad Syndrome Biological: Renuva Knee MRI measurements of fat pad thickness (mm)|Knee MRI measurements of fat pad surface area (mm2)|Knee MRI measurements of fat pad volume (mm3)|Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome questionnaire|Knee injury and Osteoarthritis Outcome Score (KOOS) Symptoms patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Function in daily living (ADL) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Function in Sport and Recreation (Sport/Rec) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) knee related quality of life (QOL) patient reported outcome|Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome Ohio State University All 18 Years to 85 Years   (Adult, Older Adult) Phase 1 5 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2023H0043 April 22, 2023 November 30, 2023 April 30, 2024 May 30, 2023 May 30, 2023 Jameson Crane Sports Medicine Institute, Columbus, Ohio, United States|Ohio State Outpatient Lewis Center, Lewis Center, Ohio, United States https://ClinicalTrials.gov/show/NCT05880888 705 NCT05880875 Enhancing Early Care and Education Through Reflective Supervision Enrolling by invitation No Results Available Emotion Regulation Behavioral: Reflective Supervision Enhancement Change from Baseline Teaching Progress Assessment at 9 months|Change from Baseline Teaching Progress Assessment at 12 months|Change from 9-month Teaching Progress Assessment at 12 months|Change from Baseline Observed Classroom Quality at 9 months|Change from Baseline Observed Classroom Quality at 12 months|Change from 9-month Observed Classroom Quality at 12 months|Change from Baseline Child Social-Emotional Functioning as assessed by Cognitive Toybox at 9 months|Change from Baseline Child Emotion Regulation at 9 months|Change from Baseline Child Prosocial/Communication Skills at 9 months|Change from Baseline Child Social Competence at 9 months|Change from Baseline Child-Teacher Relationship Quality at 9 months|Change from Baseline Supervisor Reflective Capacity at 9 months|Change from Baseline Supervisory Competence at 9 months|Change from Baseline Supervisor Reflective Functioning at 9 months|Change from Baseline Supervisor Well-Being at 9 months|Change from Baseline Quality of Reflective Supervision Relationship at 9 months|Program Climate assessed by Early Childhood Environment Rating Scale-Revised|Change from Baseline Supervisor Reflective Capacity at 9 months assessed by teacher-report|Change from Baseline Teacher Reflective Functioning at 9 months|Change from Baseline Teacher Well-Being at 9 months|Change from Baseline Child Academic Functioning as assessed by Cognitive Toybox at 9 months|Change from Baseline Child Academic Skills at 9 months Bradley Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) All 18 Years and older   (Adult, Older Adult) Not Applicable 32 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention K23HD107243 May 18, 2023 October 1, 2026 February 28, 2027 May 30, 2023 May 30, 2023 Bradley Hospital, Riverside, Rhode Island, United States https://ClinicalTrials.gov/show/NCT05880875 706 NCT05880862 Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Not yet recruiting No Results Available Urinary Bladder, Overactive|Urinary Incontinence|Accidental Falls Behavioral: Pelvic Floor Muscle Training|Drug: Mirabegron|Drug: Trospium Chloride Evaluability|Clinical-Based Adherence|Home-Based Adherence|Medication Adherence|International Consultation on Incontinence Modular Questionnaire - Overactive Bladder (ICIQ-OAB)|International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)|Falls Efficacy Scale International (FES-I)|Number of Participants with Incident falls|PROMIS Satisfaction with Participation in Social Roles|Short Physical Performance Battery (SPPB)|Physical activity|PROMIS physical functioning 8b|Absorbent pad use The University of Texas Medical Branch, Galveston Female 60 Years to 99 Years   (Adult, Older Adult) Early Phase 1 48 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 22-0262 August 2023 December 2024 July 2025 May 30, 2023 June 2, 2023 University of Texas Medical Branch at Galveston, Galveston, Texas, United States https://ClinicalTrials.gov/show/NCT05880862 707 NCT05880849 Choline Effects - Pre-symptomatic AD Recruiting No Results Available Alzheimer Disease Drug: Choline Changes in the fatty acid desaturation index (FADI) in the CSF following choline supplementation|Changes in phosphatidylcholine (PC) in the CSF following choline supplementation|Number of participants with treatment-related adverse events|Changes in phospholipids in CSF following choline supplementation|Changes in phosphatidylcholine in blood following choline supplementation|Changes in choline in blood following choline supplementation|Changes in proinflammatory cytokines in blood plasma following choline supplementation|Changes in neurofilament light chain (Nf-L) in CSF following choline supplementation|Changes in amyloid-β 42/40 ratio CSF following choline supplementation|Changes in p-Tau/Total Tau ratio in CSF following choline supplementation Paul E Schulz|M.D. Anderson Cancer Center|Massachusetts Institute of Technology|Balchem Corporation|The University of Texas Health Science Center, Houston All 55 Years to 80 Years   (Adult, Older Adult) Phase 1 14 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HSC-MS-22-0637 May 2023 May 2025 May 2026 May 30, 2023 May 30, 2023 The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05880849 708 NCT05880836 In Line Aerosol Nebulization With High Flow ILAN Not yet recruiting No Results Available Hypoxemic Respiratory Failure|Airway Obstruction Device: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|Device: standard jet nebulization (SJN) with face mask Maximal decrease in SpO2 during nebulization with jet nebulizer vs. inline via HFNC compared to the baseline SpO2 values prior to the nebulization therapy|Proportion of patients with documented hypoxemia (<88%) during the nebulization|Duration of hypoxemic episodes with SpO2<88% during the nebulization delivery|Lowest absolute desaturation from the beginning until completion of nebulizer treatment compared to the baseline SpO2 values defined as the lowest adequately measured SpO2 within two minutes prior to the nebulization|Increase in respiratory rate from the baseline during the nebulization by >10%|Change in respiratory rate during nebulization compared to the baseline rate|Requirement for additional interventions to maintain patient's safety during the nebulization|Need to increase O2 support after the nebulization therapy to maintain SpO2>88%|Nosebleed within 2 hours of nebulizer delivery|ROX score University of California, Los Angeles|Aerogen All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other|Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 21-001966 July 1, 2023 December 1, 2023 July 1, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880836 709 NCT05880823 Post Market Data Collection Protocol to Evaluate the Performance of the Synergy Disc Not yet recruiting No Results Available Cervical Degenerative Disc Disease Device: Synergy cervical disc system Neck Disability Index (NDI)|Device Related or Device Procedure Related Adverse Events|Neck and Arm Pain Measurement|Patient Satisfaction|Motor and Sensory Function in the Arm|Nurick's Criteria|Odom's criteria Synergy Spine Solutions|MCRA All 21 Years and older   (Adult, Older Adult) 50 Industry Observational Observational Model: Cohort|Time Perspective: Prospective CP 21-001-GER01 May 2023 May 2028 May 2033 May 30, 2023 May 30, 2023 Neurochirurgie am Gasteig, Munich, Bavaria, Germany https://ClinicalTrials.gov/show/NCT05880823 710 NCT05880810 Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients Not yet recruiting No Results Available Diabetes Mellitus Device: Continuous Glucose Monitor Dexcom G6 PRO Time in Range|Mean daily glucose|Frequency of hypoglycemia episodes|MARD variation with Oxygen saturation|MARD variation with Daily hemoglobin|MARD variation with Glomerular filtration rate (GFR)|MARD variation with Arterial blood pressure|Percentage of subjects to continue use of continuous glucose monitor Mayo Clinic All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 23-000733 August 2023 August 2024 August 2024 May 30, 2023 May 30, 2023 Mayo Clinic in Florida, Jacksonville, Florida, United States https://ClinicalTrials.gov/show/NCT05880810 711 NCT05880797 Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma Not yet recruiting No Results Available Oropharyngeal Carcinoma|Human Papilloma Virus Sample collection|tumor sample Stanford University All 18 Years and older   (Adult, Older Adult) 1000 Other Observational Observational Model: Cohort|Time Perspective: Prospective IRB-69452 August 2023 August 2026 August 2026 May 30, 2023 May 30, 2023 Stanford University, Palo Alto, California, United States https://ClinicalTrials.gov/show/NCT05880797 712 NCT05880784 PEN Implementation Study Recruiting No Results Available Package of Essential Non-Communicable Diseases (PEN)|Peer Coaching|Clinical Audit|Mixed Method Implementation Study Other: Reinforcement of Peer coaching and clinical audit|Other: Continuation of usual practice without intervention Acceptability of Intervention Measure 4-item questionnaire|Acceptability of the intervention by peer coaches and other health facility staff|Completion of peer coaching activities/ orientation|Clinical audits performed|Completeness of clinical audit form|Proportion of health facility staff involved in implementation of PEN protocol and routine clinical audits|Time taken to perform a clinical audit activities|Health facility staff re-oriented and trained for PEN protocol implementation|Additional cost-incurred for peer coaching activities|Additional cost for clinical auditing|Willingness to continue peer-coaching and clinical audit activities for PEN program implementation and adherence to PEN after intervention duration Shahid Gangalal National Heart Centre|Kathmandu University School of Medical Sciences All Child, Adult, Older Adult Not Applicable 17 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research PEN Study February 1, 2022 June 2023 June 2023 May 30, 2023 May 30, 2023 Shahid Gangalal National Heart Centre, Kathmandu, Bagmati, Nepal https://ClinicalTrials.gov/show/NCT05880784 713 NCT05880771 Immediate Implant Placement: a Clinical and Radiographic Study on Hard and Soft Tissues Retraction at One Year. Enrolling by invitation No Results Available Immediate Implant Placement|Guided Surgery|Immediate Tamporization Other: Immediate Implant Placement Hard tissue change by superimposing CBCT scans between 0 and 12 months using 3d slicer software|Soft tissue change by superimposing surface intraoral scans between 0 and 12 months using 3d slicer software Saint-Joseph University All 35 Years to 74 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment XFMD203 January 1, 2021 November 30, 2024 November 30, 2024 May 30, 2023 May 30, 2023 Saint Joseph University, Beirut, Lebanon https://ClinicalTrials.gov/show/NCT05880771 714 NCT05880758 Impact of Yo-Yo Sleep on Cardiometabolic Health Recruiting No Results Available Cardiometabolic Syndrome|Obesity Behavioral: Intermittent Short Sleep (ISS)|Behavioral: Social Jetlag (SJL)|Behavioral: Sustained Adequate Sleep (SAS) Fasting Plasma Glucose|Insulin Level|Morning Systolic and Diastolic Blood Pressure|Evening Systolic and Diastolic Blood Pressure|Fat mass|Low-density Lipoprotein (LDL) Level|High-density Lipoprotein (HDL) Level|Total Cholesterol Level|Triglyceride Level|C-reactive protein (CRP) Level|Interleukin 6 (IL-6)|Tumor necrosis factor alpha (TNF-alpha)|Total daily energy expenditure|Energy Intake|Total Ghrelin|Serum Leptin|Adiponectin Level|Glucagon-like peptide 1 (GLP-1) Level|Change in Nuclear factor kappa B (NFkB) Level Columbia University|Icahn School of Medicine at Mount Sinai|University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI) All 18 Years to 49 Years   (Adult) Not Applicable 72 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science AAAU3694|R35HL155670 June 1, 2023 December 2027 June 2028 May 30, 2023 June 2, 2023 Columbia University Irving Medical Center, New York, New York, United States https://ClinicalTrials.gov/show/NCT05880758 715 NCT05880745 The Effect of the Level of Hand Fatigability on Multiple Sclerosis on General Fatigue and Functionality Completed No Results Available Fatigue|Functionality|Multiple Sclerosis|Dexterity Diagnostic Test: Nine-Hole Peg Test (NHPT) Expanded Disability Status Scale (EDSS)|Modified Ashworth Scale (MAS)|Ataxia Rating and Rating Scale (SARA)|Nine-Hole Peg Test (NHPT), and the Dexterity Questionnaire-24 (DextQ-24)|Beck Depression Scale|Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS)|Dynamic and Static Fatigue Index Pamukkale University All 18 Years to 60 Years   (Adult) Not Applicable 2 Other Interventional Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other PamukkaleU-sımsek-MS-Tez-002 December 8, 2018 June 10, 2019 December 9, 2019 May 30, 2023 May 30, 2023 Pamukkale Unıversity, Denizli, Turkey "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/45/NCT05880745/Prot_000.pdf https://ClinicalTrials.gov/show/NCT05880745 716 NCT05880732 Magnesium Sulfate on Postoperative Pain Completed No Results Available Postoperative Pain Drug: Magnesium Sulfate|Drug: normal saline isotonic solution Postoperative pain was measured and recorded with the Verbal Numeric Rating Scale Pamukkale University Female 18 Years and older   (Adult, Older Adult) Not Applicable 68 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention PAU123 January 1, 2021 January 1, 2022 March 1, 2022 May 30, 2023 May 30, 2023 Pamukkale Univercity Medical School, Denizli, Turkey https://ClinicalTrials.gov/show/NCT05880732 717 NCT05880719 Pilot and Descriptive Study of the Effects of Setting up Computer-assisted Music (CAM) Remediation Groups on the Cognitive Functioning of Young Patients With a First Episode Psychosis (PEP) MAOPEP Recruiting No Results Available Psychotic Episode Other: Computer-assisted Music remediation A statistical significant change in episodic memory functionning from Baseline 1 to Baseline 2 (Week 14).|A statistical significant change in working memory functionning from Baseline 1 to Baseline 2.|A statistical significant change in mental flexibility from Baseline 1 to Baseline 2.|A statistical significant change in inhibition ability from Baseline 1 to Baseline 2.|A statistical significant change in sustained attention ability from Baseline 1 to Baseline 2.|A statistical significant change in processing speed from Baseline 1 to Baseline 2.|A statistical significant change in humor from Baseline 1 to Baseline 2.|A statistical significant change in self-esteem from Baseline 1 to Baseline 2.|A symptomatology statistical significant change from Baseline 1 to Baseline 2. University Hospital, Caen All 18 Years to 30 Years   (Adult) Not Applicable 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 21-0179 May 25, 2023 June 30, 2025 June 30, 2025 May 30, 2023 May 30, 2023 CAEN University Hospital, Caen, France https://ClinicalTrials.gov/show/NCT05880719 718 NCT05880706 A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer Not yet recruiting No Results Available Non-small Cell Lung Cancer Drug: BL-B01D1|Drug: Osimertinib Mesylate Tablets Recommended Phase II Dose (RP2D)|Objective response rate (ORR)|Progression-free survival (PFS)|Disease control rate (DCR)|Duration of response (DOR)|Treatment-Emergent Adverse Event (TEAE) Sichuan Baili Pharmaceutical Co., Ltd. All 18 Years and older   (Adult, Older Adult) Phase 2 42 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BL-B01D1-203 July 2023 July 2025 July 2025 May 30, 2023 May 30, 2023 Shanghai Pulmonary Hospital, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05880706 719 NCT05880693 Comparisons Between Dexmedetomidine and Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries Completed No Results Available Hypotension Drug: Dexmedetomidine|Drug: Magnesium sulfate The primary outcome was to determine the bleeding score mohamed|Azhar University All 18 Years to 60 Years   (Adult) Phase 1 56 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention Sameh January 1, 2022 April 1, 2023 May 1, 2023 May 30, 2023 May 31, 2023 Mohamed gawad Abdel aboelsuod, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05880693 720 NCT05880680 SEAL™ ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry SEAL™ ME Not yet recruiting No Results Available Aneurysm|Aneurysm, Ruptured Device: SEAL Device Proportion of subjects with successful aneurysm occlusion at 12 months without parent artery stenosis or retreatment, as determined by independent core lab. Galaxy Therapeutics INC All 18 Years to 80 Years   (Adult, Older Adult) 200 Industry Observational Observational Model: Cohort|Time Perspective: Prospective TP0050 June 15, 2023 June 15, 2025 June 15, 2030 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880680 721 NCT05880667 Adaptive Radiation for Abdominopelvic Metastases Not yet recruiting No Results Available Neoplasm - Soft Tissue Pelvis Malignant Secondary|Malignant Neoplasm of Stomach Radiation: Adaptive Stereotactic Body Radiation To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity. Fox Chase Cancer Center All 18 Years and older   (Adult, Older Adult) Phase 1 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RT-218 July 1, 2023 June 1, 2028 June 1, 2029 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880667 722 NCT05880654 IL-39 & IL-35 Gingival Crevicular Fluid Levels in Diabetic Patients With Generalized Periodontitis Completed No Results Available Generalized Periodontal Disease, AVDC Stage 3 Procedure: Scaling & root planning GCF levels of IL-39 & IL35|Effect of SRP on GCF levels of IL-39 & IL35 Fayoum University All 35 Years to 50 Years   (Adult) Not Applicable 57 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment #REC-FDBSU/06102022-02/HS January 1, 2023 April 30, 2023 May 15, 2023 May 30, 2023 May 30, 2023 Sandy hassan, Cairo, Virginia, Egypt|Sandy hassan shaaban, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05880654 723 NCT05880641 Use of Shockwave M5+ IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access SHOCK-ACCESS Not yet recruiting No Results Available Aortic Diseases|Aorto-Iliac Atherosclerosis|Peripheral Arterial Disease Minimum Lumen Diameter (MLD) Gain|Technical success of Shockwave™ M5+ IVL|Composite of Freedom from iliac complications|Freedom from vessel flow-limiting dissections|Freedom from vessel distal embolization|Freedom from vessel trauma|Freedom from vessel rupture|Freedom from bailout manoeuvres|Freedom from iliac secondary procedures|Freedom from access-site adjunctive/secondary procedures;|Primary patency of the target lesion for each iliac axis treated with IVL|Freedom from SAE|All-cause mortality|Freedom from Clinically-driven TLR|Rutherford shift|Device Success|Procedural Success|Clinical Success|Freedom from procedure related complications|CASS score (exploratory endpoint) EndoCore Lab s.r.l.|Fondazione Italiana Vascolare All 18 Years and older   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective IVL 022022 June 2023 June 2024 June 2025 May 30, 2023 May 30, 2023 Sant'Orsola Hospital, Bologna, Emilia-Romagna, Italy|Fondazione PTV - Policlinico Tor Vergata, Rome, Lazio, Italy|Ospedale San Giovanni di Dio, Firenze, Toscana, Italy|Ospedale Santa Maria della Misericordia di Perugia, Perugia, Umbria, Italy|Azienda Ospedaliero-Universitaria di Padova, Padova, Veneto, Italy https://ClinicalTrials.gov/show/NCT05880641 724 NCT05880628 Evaluation of Faisability, Safety and Effectiveness and of Discogel in Patients With Aneurysmal and Simple Bone Cysts Recruiting No Results Available Bone Cysts Other: datas of medical record. Feasibility of the technique|Safety of the technique by number of adverse event|efficacity of the technique by sclerose of the lesion Centre Hospitalier Universitaire de Saint Etienne All Child, Adult, Older Adult 30 Other Observational Observational Model: Cohort|Time Perspective: Retrospective IRBN552022/CHUSTE April 14, 2022 December 2023 December 2023 May 30, 2023 May 30, 2023 CHU Saint-Etienne, Saint-Étienne, France https://ClinicalTrials.gov/show/NCT05880628 725 NCT05880615 Opioid Reduced Anesthesia With Parasternal CATheters on Postoperative Delirium After Cardiac Surgery ORACAT Completed No Results Available Cardiac Disease Other: collection of datas Number of Postoperative delirium (POD) assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) in the first 48 hours after surgery|Number of hypoxemia postoperative in the first 48 hours after extubation|Number of Ileus postoperative in the first 48 hours after extubation|Total morphine consumption within 48h after extubation|Pain at 24 hours and 48 hours postoperative|postoperative nausea and vomiting|major complications (neurological, respiratory, cardiac, infectious)|mortality at 30 days after surgery Centre Hospitalier Universitaire de Saint Etienne All 18 Years to 85 Years   (Adult, Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Retrospective IRBN452022/CHUSTE May 2, 2022 August 1, 2022 August 1, 2022 May 30, 2023 May 30, 2023 CHU Saint-Etienne, Saint-Étienne, France https://ClinicalTrials.gov/show/NCT05880615 726 NCT05880602 Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection Not yet recruiting No Results Available Urinary Tract Infection Dietary Supplement: Nettle and Cranberry complex capsules|Dietary Supplement: Placebo(starch) UTI-free duration in 8 weeks|UTI recurrent incidence in 8 weeks|International Prostate Symptom Score (IPSS) Change from Baseline|Overactive Bladder Symptom Score (OABSS) Change from Baseline|International Consultation on Incontinence Questionnaire Overactive Bladder Score (ICIQ-OAB) Change from Baseline|Bladder diary Chung Shan Medical University|Glory Kingdom Corporation All 30 Years to 75 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment CS2-23025 June 1, 2023 September 30, 2023 September 30, 2023 May 30, 2023 May 30, 2023 Chung Shan Medical University Hospital, Taichung, Taiwan https://ClinicalTrials.gov/show/NCT05880602 727 NCT05880589 Efficacy and Safety of Milk Secretory Supplement in Breast-feeding Volunteers Recruiting No Results Available Lactation Dietary Supplement: Milk secretory supplement group|Dietary Supplement: Placebo group Amount of breast milk|Calcium in milk|Iron in milk|Docosahexaenoic acid in milk|Quality of life of volunteers|Skin reaction after taking supplement|Gastrointestinal reaction after taking supplement|Respiratory tract reaction after taking supplement|Satisfaction after taking supplement Chulalongkorn University All Child, Adult, Older Adult Not Applicable 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care SIRB710/2565 December 8, 2022 October 31, 2023 November 10, 2023 May 30, 2023 May 30, 2023 Pornanong Aramwit, Bangkok, Thailand https://ClinicalTrials.gov/show/NCT05880589 728 NCT05880576 The Arch Watch Study: An Integrated Evaluation of Hemodynamics in Infants With Suspected Coarctation of the Aorta Not yet recruiting No Results Available Coarctation of the Aorta|Aortic Arch Obstruction Device: Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy Number of participants with arch or CoA repair|Number of participants with echocardiographic finding of aortic arch obstruction|Number of participants with end organ damage as evidence by necrotizing enterocolitis, or acute kidney injury in the first three postnatal months Boston Children's Hospital All 0 Days to 60 Days   (Child) 60 Other Observational Observational Model: Cohort|Time Perspective: Prospective P00044159 June 1, 2023 June 1, 2025 June 30, 2025 May 30, 2023 June 1, 2023 Boston Children's Hospital, Boston, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05880576 729 NCT05880563 Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) 18F-RoSMALS Not yet recruiting No Results Available Amyotrophic Lateral Sclerosis Drug: [18F]-RoSMA-18-d6 Difference of [18F]RoSMA-18-d6 uptake in the brain and spinal cord between ALS patients (at baseline and day 360) and healthy, age- and gender-matched subjects, as assessed by PET and MRI to allow morphological mapping|[18F]RoSMA-18-d6 uptake at month twelve (360 days) compared with uptake at baseline as assessed by PET/CT of the brain and spinal cord.|Correlation of [18F]RoSMA-18-d6 uptake with corresponding ALSFRS-Score from baseline to day 360.|Correlation of [18F]RoSMA-18-d6 uptake with corresponding respiratory function measurements (FVC, SNIP) from baseline to day 360.|Correlation of the change of [18F]RoSMA-18-d6 endpoints (Δ-CB2R; baseline to day 360) with corresponding changes of the-ECAS score Markus Weber|ETH Zurich|University Hospital Inselspital, Berne|Cantonal Hospital of St. Gallen All 18 Years and older   (Adult, Older Adult) Phase 1 30 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science 18F-RoSMALS August 2023 September 2026 September 2026 May 30, 2023 May 30, 2023 Muskelzentrum/ALS-Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland https://ClinicalTrials.gov/show/NCT05880563 730 NCT05880550 PCOS and US Cavitation Not yet recruiting No Results Available PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries Other: ultrasound cavitation in addition to aerobic ex|Other: aerobic exercises. Infertily related Stress level|cortisol level|Anthrometric measurement (BMI And waist hip ratio)|Hormonal profile (LH- FSH - LH /FSH ratio). Cairo University Female 20 Years to 35 Years   (Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment US cavitation and PCOS May 25, 2023 August 25, 2023 September 25, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880550 731 NCT05880537 Safety, Efficacy, & Use of Decellularized Femoral Artery Allograft NexeonAVX Not yet recruiting No Results Available End Stage Renal Disease Biological: Nexeon AVX Establishing vascular access for patients needing hemodialysis and evaluating the outcome of aneurysm formation, anastomotic bleeding, graft infection, and irritation and inflammation at the implant site.|Secondary Endpoint: LifeNet Health All 18 Years and older   (Adult, Older Adult) Early Phase 1 100 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care CR-21-005 May 22, 2023 December 15, 2024 December 15, 2025 May 30, 2023 May 30, 2023 Olive View - UCLA Medical Center, Sylmar, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States https://ClinicalTrials.gov/show/NCT05880537 732 NCT05880524 Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) ReSCInD Not yet recruiting No Results Available Ischemic Stroke|Inflammatory Response Drug: Dornase Alfa|Drug: Isotonic Saline Solution Concentration of interleukin-1 beta in blood of patients with acute ischemic stroke receiving Dornase alfa compared to placebo treatment with Isotonic Saline Solution.|cfDNA concentration in blood.|DNase 1 activity in blood.|Concentration of DNase 1 in blood.|Analysis of the composition of the leukocyte population in blood.|Interleukin-6 concentration in blood after treatment.|Caspase 1 concentration in blood after treatment.|Assessment of patient safety after Dornase alfa treatment.|Comparison of the incidence of infections and antibiotic treatment in both treatment arms.|Functional neurological outcome scores (National Institute of Health Stroke Scale [NIHSS, 0-42] and Modified Rankin Scale [mRS, 0-6]) at both treatment arms. Ludwig-Maximilians - University of Munich|University Hospital Erlangen|University Hospital Regensburg All 18 Years and older   (Adult, Older Adult) Phase 2 36 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment RESCIND-1-2023|2022-003410-37 June 2023 December 2024 January 2025 May 30, 2023 June 2, 2023 Institute for Stroke and Dementia Research, Ludwig Maximilian University Munich, University Hospital, Munich, Bavaria, Germany https://ClinicalTrials.gov/show/NCT05880524 733 NCT05880511 Augmented Reality Sensorimotor Training to Treat Chronic Neck Not yet recruiting No Results Available Chronic Neck Pain Device: Repetitive transcranial magnetic stimulation|Device: Augmented Reality Sensorimotor Training|Device: Sham Repetitive transcranial magnetic stimulation Ability to recruit 20 patients in each group over a 6-month period|Compliance of treatment sessions for the two groups|PROMIS-29 v2.0 Profile|Visual analog scale|Pressure pain threshold (PPT)|Patient Perceived Global Index of Change (PGIC)|The neck disability index|Tampa Scale of Kinesiophobia|Non-Likert type enjoyment scale|Active cervical range of movement (CROM)|Augmented Reality Time to Target|Motor evoked potential recruitment curve McMaster University|St. Joseph's Healthcare Hamilton All 40 Years to 80 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 16310 July 1, 2023 July 1, 2024 December 1, 2024 May 30, 2023 May 30, 2023 St. Joseph's Healthcare Hamilton King Campus, Hamilton, Ontario, Canada|McMaster Unviersity, Hamilton, Ontario, Canada https://ClinicalTrials.gov/show/NCT05880511 734 NCT05880498 Smartphone Mindfulness Autism Research Study SMART Completed No Results Available Anxiety|Stress Behavioral: Mindfulness Intervention State-Trait Anxiety Inventory for Adults|Patient-Reported Outcomes Measurement Information System [PROMIS] Anxiety Short Form|Perceived Stress Scale|Positive and Negative Affect Schedule, Short Form Massachusetts Institute of Technology All 18 Years and older   (Adult, Older Adult) Not Applicable 89 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2105000376 January 30, 2022 April 17, 2023 April 17, 2023 May 30, 2023 May 30, 2023 Massachusetts Institute of Technology, Cambridge, Massachusetts, United States https://ClinicalTrials.gov/show/NCT05880498 735 NCT05880485 Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer Recruiting No Results Available Uterine Cervical Neoplasm Radiation: online adaptive radiotherapy Patient-reported acute toxicity|Physician-reported acute toxicity|Late toxicity evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme|The irradiated doses of organs at risk|The dose coverage of target volume as assessed by planing tumor volume V100%|Target volume contouring accuracy|Response evaluation evaluated with RECIST 1.1|Movement of the uterus during per radiotherapy fractions|Movement of the cervix during per radiotherapy fractions|Progression-free survival Peking Union Medical College Hospital Female 18 Years to 75 Years   (Adult, Older Adult) Phase 1|Phase 2 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment pumch-ART2 February 2, 2023 October 2023 December 2023 May 30, 2023 May 30, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05880485 736 NCT05880472 Percutaneous Holmium Injection in Pancreatic Cancer SLOTH-2a Recruiting No Results Available Pancreas Cancer Device: Intratumoral Average tumour dose (Gy) by SPECT/CT|Number of adverse event per patient per grade by CTCAE v5.0|Average tumour dose (Gy) by MRI quantification|Average tumour dose (Gy)by CT quantification|Microsphere distribution (percentage covered) of 3D target area|Injection percentage (%)|Needle tip position off-target (mm)|Operator hand and total body dose (mSv) Radboud University Medical Center|Quirem Medical B.V.|Terumo Medical Corporation All 18 Years and older   (Adult, Older Adult) Not Applicable 6 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NL.82292.091.22 May 2023 January 2024 May 2024 May 30, 2023 May 30, 2023 Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands https://ClinicalTrials.gov/show/NCT05880472 737 NCT05880459 Sedation in Patients Undergoing GIT Endoscopy Not yet recruiting No Results Available Sedation for Patients Undergoing GIT Endoscopy Drug: propofol and magnesium sulphate ,propofol and nalbuphine The level of patient sedation Assiut University All 18 Years to 60 Years   (Adult) Early Phase 1 60 Other Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening ERCP June 2023 November 2024 December 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880459 738 NCT05880446 PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) PROCAR-BQ Not yet recruiting No Results Available Prostate Cancer|Radiotherapy Side Effect|Bowel Dysfunction|Quality of Life Other: Bowel symptoms & QoL assessment Mean Delta of EORTC Proctitis Module (PRT20) score|Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score Jules Bordet Institute Male Child, Adult, Older Adult Not Applicable 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic IJB-PROCAR-BQ-2023|CE3650 June 2023 September 2023 October 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880446 739 NCT05880433 The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations Completed No Results Available Retinopathy of Prematurity|Mydriasis|Neonatal Disease|Analgesic Adverse Reaction Device: NIRS(INVOS 5100; Covidien Somanetics, Troy, MI NIRS|Doppler US measurements|Changes in heart rate (beats per minute)|Changes in blood pressure|Changes in oxygen saturation. Istanbul Training and Research Hospital All 28 Days to 31 Days   (Child) 62 Other Observational Observational Model: Cohort|Time Perspective: Prospective IstanbulTRH-DArman-001 May 1, 2021 November 30, 2022 November 30, 2022 May 30, 2023 May 30, 2023 IstanbulTRH, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05880433 740 NCT05880420 EXPERIMENTAL STUDY A.R.C.O. (CANCER CAREGIVER REMOTE ASSISTANCE)TELEHEALTH HOME MEDICATION VS/OUTPATIENT MEDICATION OF CENTRAL VENOUS CATHETER PICC (PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER) ARCO Completed No Results Available Infections Device: Caregiver operations with medication accessories|Device: Nurse operations with medication accessories PICC management|Compliance of the cancer patients Regina Elena Cancer Institute|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale All 18 Years and older   (Adult, Older Adult) Not Applicable 27 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care RS1518/21 July 7, 2021 August 16, 2021 August 16, 2021 May 30, 2023 May 30, 2023 "Regina Elena" National Cancer Institute, Rome, Italy https://ClinicalTrials.gov/show/NCT05880420 741 NCT05880407 Pilot Study of Percutaneous Correction of Hallux Valgus hallux valgus Recruiting No Results Available Hallux Valgus Procedure: SERI osteotomy|Procedure: percutaneous osteotomy according to Chevron Visual Analog Score|American Orhtopaedic Foot and Ankle Society forefoot score Istituto Ortopedico Rizzoli All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment hallux valgus February 22, 2022 December 31, 2024 December 31, 2024 May 30, 2023 May 30, 2023 Istituto Ortopedico Rizzoli, Bologna, Italy https://ClinicalTrials.gov/show/NCT05880407 742 NCT05880394 Rayzebio IIT Study of Dotatate in Breast Cancer Recruiting No Results Available Breast Cancer Stage IV Drug: Gallium-68 Uptake of Ga-68-DOTATATE using Krenning Score and standardized uptake value (SUV)|Relationship between biomarkers and concomitant endocrine therapy Hoag Memorial Hospital Presbyterian|RayzeBio, Inc. Female 18 Years and older   (Adult, Older Adult) Phase 2 30 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 163-22-CA January 10, 2023 July 31, 2023 July 31, 2023 May 30, 2023 May 30, 2023 Hoag Memorial Hospital Presbyterian, Irvine, California, United States https://ClinicalTrials.gov/show/NCT05880394 743 NCT05880381 Virtual Reality for Coping With Involuntary Early Pregnancy Loss AViR Recruiting No Results Available Early Pregnancy Loss Device: Virtual Reality Group|Other: Control Group Perinatal Grief Scale (PGS)|Posttraumatic Stress Disorder Checklist (PCL-5)|Hospital Anxiety and Depression Scale (HADS)|System Usability Scale (SUS)|Sense of Presence Inventory (ITC)|User Experience questionnaire Universidade da Madeira|Fundação para a Ciência e a Tecnologia|Serviço de Saúde da Região Autónoma da Madeira- SESARAM Female 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 07/2023 May 1, 2023 October 31, 2023 December 31, 2023 May 30, 2023 May 30, 2023 Universidade da Madeira, Funchal, Portugal "Study Protocol and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/81/NCT05880381/Prot_ICF_000.pdf https://ClinicalTrials.gov/show/NCT05880381 744 NCT05880368 Partnership in Resilience for Medication Safety (PROMIS) PROMIS Not yet recruiting No Results Available Patient Engagement|Patient Empowerment|Patient Activation Other: Patient partnership tools Medication use and self-efficacy|Medication regimen problems The University of Texas at Arlington|Agency for Healthcare Research and Quality (AHRQ) All 50 Years and older   (Adult, Older Adult) Not Applicable 500 Other|U.S. Fed Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research 2019-0439 June 26, 2023 September 29, 2024 September 29, 2025 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880368 745 NCT05880355 Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation Not yet recruiting No Results Available Myocardial Infarction Drug: Dapansutrile|Other: Placebo Remote plaque volume|Plaque inflammation|Coronary microvascular function University of Virginia All 18 Years to 90 Years   (Adult, Older Adult) Early Phase 1 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment HSR230183 January 1, 2024 December 31, 2027 October 30, 2028 May 30, 2023 May 30, 2023 University of Virginia, Charlottesville, Virginia, United States https://ClinicalTrials.gov/show/NCT05880355 746 NCT05880342 The Role of the Brain in Mental and Physical Fatigue Recruiting No Results Available Fatigue Drug: Reboxetine Pill|Drug: Methylphenidate Oral Product Number of repetitions|Electroencephalography (spectral analysis)|Electroencephalography (event related potentials)|Electromyography|Accuracy|Reaction time|Perceived stress scale questionnaire (PSS-10)|the international physical activity questionnaire short form (IPAQ-SF)|The Brunel Mood Scale (BRUMS)|Motivation with visual analog score (Moti-VAS)|The National Aeronautics and Space Administration Task Load Index (NASA-TLX)|Subjective feeling of Mental Fatigue with visual analog score (M-VAS)|Subjective feeling of physical fatigue with visual analog score (P-VAS)|Karolinska Sleepiness Scale (KSS)|Internal load of the physical performance (CR100 RPE)|Heart Rate|Lactate concentration Vrije Universiteit Brussel|Science and Research Centre Koper All 18 Years to 35 Years   (Adult) Phase 3 62 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science G095422N May 3, 2023 March 2025 March 2025 May 30, 2023 May 30, 2023 Brussels Labo voor Inspanning & Topsport U-residence, Brussels, Belgium https://ClinicalTrials.gov/show/NCT05880342 747 NCT05880329 DIagnoSing Care hOme UTI Study DISCO UTI Not yet recruiting No Results Available Urinary Tract Infections Diagnostic Test: Candidate POCTs for detecting UTI As a feasibility study, there is no primary outcome measure.|Proportion of care homes agreeing to participate when recruiting care homes as research sites.|Proportion of residents screened that are eligible and proportion of eligible that are recruited.|Proportion of baseline urine samples obtained from participants recruited (consented)|Proportion of repeated urine samples obtained of those participating in Stage 2|Quality of urine samples obtained|Adherence to urine transport protocols|Proportion of residents that experience a possible UTI during the follow-up period that are reported to the research team.|Proportion of residents with possible UTI that are not reported to the research team.|Proportion of residents with possible UTI in whom the following is obtained:|Using semi-structured interviews with qualitative analysis to describe the views of care home staff, participants and family members on:|Participant baseline demographic characteristics predictive of subsequent possible UTI/clinical outcomes|Participant clinical characteristics at point of possible UTI and association with clinical outcomes|Changes in weekly sample microbiology|Predictors of weekly sample microbiology and changes in microbiology|Association between asymptomatic bacteriuria at baseline or in weekly sampling and onset of possible UTI during follow up period|Association of each urinary biomarker with asymptomatic bacteriuria|Urinary biomarker concentrations in urine samples from asymptomatic participants without bacteriuria|Urinary biomarker concentrations in urine samples from possible UTI episodes|Failure rate of the POCT in residents with possible UTI (no result or invalid result)|Agreement between POCT result and laboratory enhanced culture result at symptom onset for each possible UTI episode, and at 28 days post symptom on set University of Southampton|University of Oxford|University of Bristol|Public Health Wales All 65 Years and older   (Older Adult) 100 Other Observational Observational Model: Cohort|Time Perspective: Prospective 79003 July 1, 2023 January 31, 2024 January 31, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880329 748 NCT05880316 Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting Recruiting No Results Available Fatty Liver Disease Behavioral: Intermittent Fasting Mean change of controlled attenuated parameter (CAP) (dB/m)|Mean change of hepatic fibrosis score (kPa)|Mean change of steatotest, actitest, and fibrotest scores|mean change of Body Mass Index Universiti Kebangsaan Malaysia Medical Centre All 18 Years to 60 Years   (Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment UKM/PPI/111/8/JEP-2023-276 May 28, 2023 June 30, 2023 August 31, 2023 May 30, 2023 May 30, 2023 Hospital Canselor Tuanku Muhriz, Cheras, Kuala Lumpur, Malaysia https://ClinicalTrials.gov/show/NCT05880316 749 NCT05880303 Effect of Nonsurgical Periodontal Therapy (NSPT) on Rheumatoid Arthritis Subjects With Periodontitis Recruiting No Results Available Periodontitis|Rheumatoid Arthritis Procedure: Nonsurgical periodontal therapy Reduction in DAS28-ESR score|Reduction in probing pocket depth (PPD)|Reduction in ACPA levels|Reduction in clinical attachment levels (CAL) University of Malaya All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2019813-7736 January 3, 2023 December 31, 2023 June 30, 2025 May 30, 2023 May 30, 2023 Universiti Malaya, Kuala Lumpur, Federal Territory, Malaysia https://ClinicalTrials.gov/show/NCT05880303 750 NCT05880290 Performance of the Gynaecological Examination in the Lateral Decubitus Position EXADELA Not yet recruiting No Results Available Medical Care Procedure: gynaecological examination in lateral decubitus Gynaecological speculum examination in the lateral decubitus position will be perform during the visit to assess if the performance is sufficient to be offered as an alternative to the examination in the conventional position.|Clinicians' satisfaction with lateral decubitus positioning for pelvic speculum examination will be evaluate with a questionnaire|patients' satisfaction with lateral decubitus positioning for pelvic speculum examination will be evaluate with a questionnaire|The performance (success rate) of early examination (6 first examinations) will be evaluated for each practicioner.|The occurrence of complications at 3 months during IUD insertion in the lateral position will be quantified|The predictive factors for failure of the lateral decubitus examination will be determined University Hospital, Rouen Female 18 Years and older   (Adult, Older Adult) Not Applicable 564 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other 2021/0375/HP June 2023 April 2025 November 2025 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880290 751 NCT05880277 Diagnostic POCUS of Patellar Tendinopathy in Female Athletes POCUS Recruiting No Results Available Patellofemoral Disorder Diagnostic Test: POCUS Changes of patellar tendons in jumping athletes|KOOS Youngstown State University Female 18 Years to 25 Years   (Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic YoungstownSU February 17, 2023 May 15, 2024 May 15, 2025 May 30, 2023 May 30, 2023 Youngstown State University, Youngstown, Ohio, United States https://ClinicalTrials.gov/show/NCT05880277 752 NCT05880264 Development of Standard References of Maximal Inspiratory Pressure and Maximal Expiratory Pressure in Healthy Adults Not yet recruiting No Results Available Healthy Adults Measure MIP for healthy Koreans and obtain the reference value|Measure MEP for healthy Koreans and obtain the reference value.|Measure MVV for healthy Koreans and obtain the reference value.|Check the predictive equation (forced vital capacity)|Check the predictive equation (forced expiratory volume 1)|Check the predictive equation (FEV1/FVC)|Check the predictive equation (PEF) Yonsei University All 19 Years to 65 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Case-Only|Time Perspective: Prospective 4-2022-0745 June 2023 July 2023 July 2023 May 30, 2023 May 30, 2023 Severance hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05880264 753 NCT05880251 Operant Conditioning of Sensory Brain Responses to Reduce Phantom Limb Pain in People With Limb Amputation OCS-PLP Not yet recruiting No Results Available Phantom Limb Pain After Amputation|Lower Limb Amputation|Upper Limb Amputation|Phantom Pain|Chronic Pain Behavioral: Operant Conditioning with Peripheral Stimulation|Behavioral: Control Group with Peripheral Stimulation Only Change in Pain as Measured by the Short form-McGill Pain Questionnaire (SF-MPQ)|Change in Somatosensory Evoked Potential (SSEP) Amplitude as Measured by a Tactile Event Related Potential Test|Change in Somatosensory Evoked Potential (SSEP) Latency as Measured by a Tactile Event Related Potential Test|Change in Impact of Pain on Quality of Life as Measured by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) VA Office of Research and Development All 18 Years and older   (Adult, Older Adult) Not Applicable 20 U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment F4410-P|1I21 RX004410-01A1 August 1, 2023 July 1, 2025 July 1, 2025 May 30, 2023 May 30, 2023 Albany VA Medical Center Samuel S. Stratton, Albany, NY, Albany, New York, United States https://ClinicalTrials.gov/show/NCT05880251 754 NCT05880238 The Effect of Sensory Motor Training in Preschool Children Active, not recruiting No Results Available Pre-school Children Behavioral: Intervention group|Other: Control group The Metropolitan School Readiness Test|Kansas Reflection-Impulsivity for Preschool-KRISP|Childhood Executive Functioning Invantery-CHEXI|Preschool Self-Regulation Scale|Sensory Profile|Bruininks-Oseretsky Test 2 Short Form Biruni University All 5 Years to 6 Years   (Child) Not Applicable 38 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment pre-school intervention May 17, 2023 August 18, 2023 September 1, 2023 May 30, 2023 May 30, 2023 Remziye Akarsu, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05880238 755 NCT05880225 Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers Not yet recruiting No Results Available Autism|Autism Spectrum Disorder Behavioral: Reciprocal Imitation Training|Behavioral: music-enhanced Reciprocal Imitation Training Change in rhythmically entrained eye-looking (eye-tracking)|Change in overall fixation to eyes (eye-tracking)|Change in child elicited motor imitation|Change in child spontaneous motor imitation Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)|National Center for Complementary and Integrative Health (NCCIH) All 18 Months to 36 Months   (Child) Not Applicable 40 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other MH123029 January 3, 2024 April 30, 2026 April 30, 2026 May 30, 2023 May 30, 2023 Vanderbilt University Medical Center, Nashville, Tennessee, United States https://ClinicalTrials.gov/show/NCT05880225 756 NCT05880212 Implementation of the Specific Treatment Of Problems of the Spine Approach in Bangladesh STOPS-Bangla Not yet recruiting No Results Available Chronic Low-back Pain Other: Usual physiotherapy care|Other: Individualized (STOPS) physiotherapy Activity limitation|Back Pain Intensity|Leg Pain Intensity|Work hours missed|Work productivity|Short-Form Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ-SF)|Health-related quality of life (EQ-5D-5L)|Depression, Anxiety and Stress Scales - DASS-21|Pain Self Efficacy|Pain Catastrophizing|Sleep quality|Central Sensitisation symptoms|Inflammatory symptoms|Treatment Credibility|Healthcare utilization|Participant adherence with treatment|Global rating of change|Satisfaction with treatment|Adverse events|Qualitative interviews|Pain severity|Pain interference Mohammad Ali|Hasna Hena Pain, Physiotherapy and Public Health Research Center (HPRC)|La Trobe University|Uttara Adhunik Medical College All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 154 Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment HEC22334 June 2023 December 2024 June 2026 May 30, 2023 May 30, 2023 Uttara Adhunik Medical College Hospital, Dhaka, Uttara, Bangladesh https://ClinicalTrials.gov/show/NCT05880212 757 NCT05880199 BSGM to Evaluate Patients With GI Symptoms Recruiting No Results Available Gastrointestinal Motility Disorders in Children|Functional Gastrointestinal Disorders|Gastroparesis|Dyspepsia and Other Specified Disorders of Function of Stomach Device: Body surface gastric mapping device BSGM pediatric reference ranges in healthy controls.|Abnormal BSGM patterns in participants with functional GI disorders.|Functional disability: Functional disability will be measured by child-reported responses to questions on the Functional Disability Inventory (FDI).|Nausea Severity|Abdominal Pain Severity|Quality of Life - PROMIS-25 Instrument|Quality of Life - PAGI-QoL|Quality of life - Pediatric Quality of Life Modules|Compare pediatric BSGM patterns with gastric scintigraphy, a reference diagnostic test.|Compare BSGM metrics with the antroduodenal manometry (ADM) metrics.|Changes in BSGM patterns after heart rate variability biofeedback (HRVB) sessions.|Changes in BSGM patterns after percutaneous electrical nerve field stimulation (PENFS).|Changes in BSGM patterns after pyloric Botulinum toxin (Botox) injection.|Changes in BSGM patterns after placement of a gastric electrical stimulator (GES). Children's Hospital of Philadelphia|University of Auckland, New Zealand All 8 Years to 25 Years   (Child, Adult) 660 Other Observational Observational Model: Cohort|Time Perspective: Prospective 21-018520 October 1, 2021 December 31, 2024 December 31, 2025 May 30, 2023 May 30, 2023 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05880199 758 NCT05880186 Influence of the Time of Day in the Effect of Caffeine on Maximal Fat Oxidation During Exercise in Women CIRCAF_WOM Completed No Results Available Dietary Supplement Dietary Supplement: Acute caffeine supplementation MFO|FATmax|RPE|FAT AND CHO oxidation Universidad Francisco de Vitoria|Universidad de Granada|Universidad Rey Juan Carlos|Camilo Jose Cela University Female 18 Years to 40 Years   (Adult) Not Applicable 14 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment UFVitoria_2 February 9, 2021 April 9, 2021 April 9, 2021 May 30, 2023 May 30, 2023 Universidad Francisco de Vitoria, Pozuelo De Alarcón, Madrid, Spain https://ClinicalTrials.gov/show/NCT05880186 759 NCT05880173 SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population SCREANIT Not yet recruiting No Results Available Screening|Advanced Liver Fibrosis Diagnostic Test: FIB4 Proportion of advanced hepatic fibrosis.|Determine the rate of patients requiring second-line evaluation by elastometry|Determine the rate of patients requiring management by a liver disease specialist.|Determine the average cost spent on a patient diagnosed with advanced liver fibrosis|Determine patient adherence to the screening procedure|Determine risk factors associated with advanced liver fibrosis, and consequently the subgroup of patients for whom screening should be a priority|Determine the rate of patients with a significant liver complication in the population of patients with risk factors University Hospital, Angers All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 502 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening 49RC22_0399 June 2023 June 2024 September 2024 May 30, 2023 May 30, 2023 Chu Angers, Angers, France|Chu Bordeaux, Angers, France|Chu Grenoble Alpes, Grenoble, France|Centre Hospitalier de Lens, Lens, France|Hopital Saint Joseph, Marseille, France|Chu Nancy, Nancy, France https://ClinicalTrials.gov/show/NCT05880173 760 NCT05880160 Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction HER-SAFE Not yet recruiting No Results Available Cardiotoxicity|HER2-positive Breast Cancer|Heart Failure|Cancer, Therapy-Related Other: Phased withdrawal of heart failure medications Relapse in Cardiotoxicity|Cardiac Biomarkers (N-terminal pro B-type natriuretic peptide [NT-proBNP])|Cardiac Biomarkers (Troponin T)|Quality of life (Kansas City Cardiomyopathy Questionnaire)|Quality of life (Minnesota Living with Heart Failure Questionnaire)|Heart rate|Blood Pressure|Left Ventricular Volumes (By Cardiac MRI)|Left Ventricular Ejection Fraction (By Cardiac MRI)|Left Ventricular Strain (By Cardiac MRI)|T1 mapping (By Cardiac MRI)|Medication Disutility University College, London|British Heart Foundation|Barts & The London NHS Trust|University College London Hospitals All 18 Years and older   (Adult, Older Adult) Not Applicable 90 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 147133|FS/CRTF/22/24395|312432 June 2023 September 2025 September 2025 May 30, 2023 May 30, 2023 St Bartholemew's Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom https://ClinicalTrials.gov/show/NCT05880160 761 NCT05880147 App-based Consent for Pediatric Clinical Research ConsentApp Not yet recruiting No Results Available Consent Device: Consent App|Other: Traditional paper-based consent Effectiveness of app-based consent versus paper-based consent|Trust in the research consent process when using app-based consent versus paper-based consent University of British Columbia|BC Children's Hospital Research Institute All 2 Years to 5 Years   (Child) Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research H22-01928b May 2023 December 2024 December 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880147 762 NCT05880134 Graft Reinforcement for Posterior Nasal Nerve Neurectomy in Allergic Rhinitis Surgeries Recruiting No Results Available Neurectomy Procedure: conventional posterior nerve neurectomy|Procedure: cartilage graft reinforcement after posterior nerve neurectomy 22-item Sino-Nasal Outcome Test (SNOT-22) Kafrelsheikh University All Child, Adult, Older Adult Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment MKSU 51-2-13 March 12, 2022 May 30, 2023 May 30, 2023 May 30, 2023 May 30, 2023 Kafrelsheikh university, Kafr Ash Shaykh, Egypt https://ClinicalTrials.gov/show/NCT05880134 763 NCT05880121 Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus INLES Recruiting No Results Available Systemic Lupus Erythematosus Diagnostic Test: MRI To detect regional brain functional abnormalities in patients with SLE through advanced magnetic resonance imaging (MRI).|To identify autoantigen-specific circulating antibodies associated with neuropsychiatric morbidity and imaging features in patients with SLE.|To correlate antigen-specific CD4+ T-cell dynamics over time with the spectrum of SLE, NPSLE and associated MRI findings. IRCCS San Raffaele|Istituto Giannina Gaslini All 15 Years and older   (Child, Adult, Older Adult) 200 Other Observational Observational Model: Case-Control|Time Perspective: Prospective GR-2021-12372172 April 30, 2023 October 30, 2024 April 29, 2026 May 30, 2023 May 30, 2023 IRCCS Ospedale San Raffaele, Milano, Italy https://ClinicalTrials.gov/show/NCT05880121 764 NCT05880108 Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation MARVEL Not yet recruiting No Results Available Post-COVID Conditions|Obesity Behavioral: 12-weeks of Weight Loss|Behavioral: 12-weeks of Weight Stability Cardiorespiratory Fitness (VO2max)|Change in Cardiorespiratory Fitness (VO2max)|Change in adipose tissue cellular senescence VA Office of Research and Development|South Texas Veterans Health Care System|Baltimore Veterans Affairs Medical Center All 55 Years to 80 Years   (Adult, Older Adult) Not Applicable 150 U.S. Fed|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment F4572-R|1 I01 RX004572-01A1 January 1, 2024 September 30, 2028 September 30, 2028 May 30, 2023 May 30, 2023 Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05880108 765 NCT05880095 Healthy Aging Through Time- Restricted Eating in Adults With Overweight/Obesity and Incipient Liver Disease: the ENSATI Study ENSATI Recruiting No Results Available Biological Aging Other: Unrestricted Mediterranean diet|Other: Energy-reduced Mediterranean diet|Other: Mediterranean diet with time-restricted eating Change from baseline in participant's meal timing measured by questionnaires.|Change from baseline in participant's postprandial glucose levels|Change from baseline in fat mass measured by bioimpedance|Change from baseline in muscle mass measured by bioimpedance|Change from baseline in the blood concentration of metabolites as measured by MNR|Change from baseline in chronotype assessed by the morningness/eveningness (MEQ)questionnaire|Change from baseline in sleep quality as measured with the Pittsburg's questionnaire|Changes form baseline in cognitive function scores measured by the Rey Auditory Verbal Learning Test (RAVLT).|Changes form baseline in cognitive function scores measured by STROOP color and Word test.|Changes from baseline in the Emotional Eating Questionnaire.|Changes from baseline in anxiety scores measured by the Hamilton Anxiety Rating Scale|Changes from baseline in mood scores measured by the EVEA Scale for Mood Assessment.|Changes from baseline in health-related quality of life measured by the SF-36 questionnaire|Changes from baseline in well-being measured by the W-BQ12 questionnaire.|Changes from baseline in the accumulation of autophagy vacuoles|Changes from baseline in biological age measured by the Horvath's DNAmPhenoage algorithm|Changes from baseline in the percentage of senescent T cells IMDEA Food|Ministerio de Ciencia e Innovación, Spain|CIBER Fisiopatología de la Obesidad y la Nutrición All 55 Years to 70 Years   (Adult, Older Adult) Not Applicable 177 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention IMD: PI-057 June 2023 December 2024 December 2024 May 30, 2023 May 31, 2023 IMDEA Food, Madrid, Spain https://ClinicalTrials.gov/show/NCT05880095 766 NCT05880082 PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer PPIO-004-EC001 Not yet recruiting No Results Available Esophageal Squamous Cell Carcinoma Drug: Tislelizumab Objective response rate|Major pathological response rate|Pathological complete response rate|Overall survival|Progression-free survival Daping Hospital and the Research Institute of Surgery of the Third Military Medical University All 18 Years and older   (Adult, Older Adult) Phase 2 62 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment WGUO May 31, 2023 December 1, 2023 December 31, 2024 May 30, 2023 May 30, 2023 Army Medical Center of the People's Liberation Army, Chongqing, Chongqing, China https://ClinicalTrials.gov/show/NCT05880082 767 NCT05880069 Clinical Outcomes in Patients With Infection by Resistant Microorganism Enrolling by invitation No Results Available Pneumonia|Bloodstream Infection|Urinary Tract Infections|Skin Infection|Surgical Site Infection|Staphylococcus Aureus|Klebsiella Pneumonia|Escherichia Coli|Enterococcus Faecium Infection|Acinetobacter Infections|Pseudomonas Aeruginosa Other: Pathogen resistant phenotype Mortality|Number of participants with ICU admission|Number of participants with clinical cure|Number of participants with microbiological cure|Number of participants with recurrence of infection|Number of participants with superinfection|Number of participants with cognitive impairment / disability Hospital Universitario Virgen Macarena|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla All Child, Adult, Older Adult 5000 Other Observational Observational Model: Other|Time Perspective: Other PRIMAVERA October 1, 2022 June 2023 October 2023 May 30, 2023 May 30, 2023 Hospital Universitario Virgen Macarena, Sevilla, Spain https://ClinicalTrials.gov/show/NCT05880069 768 NCT05880056 This Study Will Assess the Response, Efficacy Compliance, and Inset of Action of Heart Rate Reduction of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment In Egyptian Patients With Essential Hypertension. BETTER Not yet recruiting No Results Available Essential Hypertension Drug: Nerkardou 5 mg & Nerkardou 10 mg Investigation of the response to bisoprolol (Nerkardou) in treating patients with hypertension|Measuring patients' compliance to this dosage form, especially being easy to carry and easy to use|Identifying the onset of action of heart rate reduction. Genuine Research Center, Egypt|Nerhadou International for pharmaceutical & Nutraceutical, Egypt All 18 Years and older   (Adult, Older Adult) Phase 4 827 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GRC/NE-CV/EG/39/IV July 15, 2023 July 15, 2024 July 15, 2024 May 30, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05880056 769 NCT05880043 A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma Recruiting No Results Available Advanced Solid Tumors|Relapsed/Refractory Non-Hodgkin Lymphoma|Relapsed/Refractory Multiple Myeloma Biological: GIC-102 (Allogeneic NK cells) Dose-limiting toxicity assessment|Adverse event / Immune related adverse event|Objective response rate and duration of response|Progression free survival|Overall survival GI Cell, Inc. All 19 Years and older   (Adult, Older Adult) Phase 1 9 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GIC-102101 April 28, 2023 December 30, 2025 June 30, 2026 May 30, 2023 May 30, 2023 GI-CELL, Gyeonggi-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul Asan Medical center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05880043 770 NCT05880030 The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis Completed No Results Available Inflammation; Muscle|Iron Metabolism|Ineffective Erythropoiesis|Healthy Drug: Cholecalciferol|Other: placebo The change in vitamin 25(OH)D level after two-week supplementation.|The change in parathyroid hormone level after two-week supplementation.|Observation of changes in inflammatory parameters:interleukin-6 induced by a 100 km run|Observation of changes in inflammatory parameters: C reactive protein - CRP induced by 100 km running.|Observation of changes in creatine kinase level induced by 100 km running.|Observation of changes in leucocytes induced by 100 km running.|Observation of changes in hepcidin level induced by 100 km running.|Observation of changes in serum iron level induced by 100 km running.|Observation of changes in ferritin induced by 100 km running.|Observation of changes in erythrocytes level induced by a 100 km run.|Observation of changes in reticulocytes induced by a 100 km run.|Observation of changes in hematocrit induced by a 100 km run.|Observation of changes in erythropoietin level induced by a 100 km run.|Observation of changes in erythroferrone level induced by a 100 km run. Gdansk University of Physical Education and Sport Male 28 Years to 64 Years   (Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science AWFiS/2022_2_MK October 19, 2016 November 1, 2022 December 31, 2022 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05880030 771 NCT05880017 Thoracolumbar Interfascial Plane Block in Lumber Spine Surgery Recruiting No Results Available Post Operative Pain Management Procedure: Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Procedure: Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Drug: Morphine for peritoperative analgesia (control group).|Drug: Bupivacain postoperative pain intensity expressed as A numerical rating scale (NRS) score at time zero (time of extubation).|Pain intensity expressed as A numerical rating scale (NRS) score at time 1 (time of delivery to Post Anesthesia Care Unit PACU).|Pain intensity expressed as A numerical rating scale (NRS) score at time 6 (6 hours postoperative).|Pain intensity expressed as A numerical rating scale (NRS) score at time 24 (24 hours postoperative).|Early ambulation.|Time of first rescue analgesic.|Total dose of Postoperative morphine consumption during first 24 hours. Ain Shams University All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment FMASU R 167/2022 December 1, 2022 June 1, 2023 June 1, 2023 May 30, 2023 May 30, 2023 Ain Shams university hospitals, Cairo, Al Abbassia, Egypt https://ClinicalTrials.gov/show/NCT05880017 772 NCT05880004 Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness SAFPAS Not yet recruiting No Results Available Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations Behavioral: Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications Change in Client FAST Scores as assessed by the Food Assessment Scoring Tool (FAST) Johns Hopkins Bloomberg School of Public Health|National Heart, Lung, and Blood Institute (NHLBI)|Oakland University All 18 Years and older   (Adult, Older Adult) Not Applicable 537 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 1R34HL161566-01A1 July 1, 2023 April 30, 2025 July 31, 2025 May 30, 2023 May 30, 2023 Johns Hopkins University, Baltimore, Maryland, United States https://ClinicalTrials.gov/show/NCT05880004 773 NCT05879991 A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body Not yet recruiting No Results Available Healthy Drug: BI 1810631 (C-14) formulation 1|Drug: BI 1810631|Drug: BI 1810631 (C-14) formulation 2 Part A - Mass balance and total recovery of [14C]-radioactivity in urine: feurine, 0-tz (fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)|Part A - Mass balance and total recovery of [14C]-radioactivity in faeces: fefaeces, 0-tz (fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)|Part B - For [14C]BI 1810631 after intravenous administration and for BI 1810631 after oral administration in plasma: AUC0-∞ (area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity)|Part A - For BI 1810631 and for [14C]-radioactivity in plasma: Cmax (maximum measured concentration of the analyte)|Part A - For BI 1810631 and for [14C]-radioactivity in plasma: AUC0-tz (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point)|Part B - For [14C]BI 1810631 after intravenous administration and for BI 1810631 after oral administration in plasma: Cmax (maximum measured concentration of the analyte)|Part B - For [14C]BI 1810631 after intravenous administration and for BI 1810631 after oral administration in plasma: AUC0-tz (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point) Boehringer Ingelheim Male 18 Years to 55 Years   (Adult) Phase 1 15 Industry Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 1479-0006 August 16, 2023 October 20, 2023 October 20, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879991 774 NCT05879978 A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 Not yet recruiting No Results Available Small Cell Lung Carcinoma (SCLC)|Neuroendocrine Neoplasms Drug: BI 764532|Drug: Ezabenlimab Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period|Occurrence of DLTs during the on-treatment period|Objective response, defined as best overall response of complete response (CR) or partial response (PR)|Cmax (maximum measured concentration of BI 764532)|Cmax (maximum measured concentration of ezabenlimab)|AUCτ (area under the concentration-time curve of BI 764532 over a uniform dosing interval τ)|AUCτ (area under the concentration-time curve of ezabenlimab) over a uniform dosing interval τ) Boehringer Ingelheim All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 30 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 1438-0002|2022-502728-30-00 May 30, 2023 October 30, 2024 October 30, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879978 775 NCT05879965 Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk POQS-FU PLUS Recruiting No Results Available Monkeypox Proportion of individuals with a positive mpox serology in both groups|Proportion of long-term problems or sequelae in mpox patients|longevity of humoral and/or cellular immune response to mpox or vaccinia virus Institute of Tropical Medicine, Belgium All 18 Years and older   (Adult, Older Adult) 345 Other Observational Observational Model: Cohort|Time Perspective: Prospective 1628/22 October 6, 2022 October 2024 October 2024 May 30, 2023 May 30, 2023 Institute of Tropical Medicine, Antwerp, Belgium https://ClinicalTrials.gov/show/NCT05879965 776 NCT05879952 Virtual Reality and Neuropsychiatric Rehabilitation in Patients With Global Developmental Delay. Recruiting No Results Available Global Developmental Delay Behavioral: TAU + BTsN session|Behavioral: TAU Griffiths-III Mental Development Scale (GMDS-III)|Clinical Global Impressions (CGI)|Protocol adherence|The Child Behavior Checklist (CBCL 1½-5) IRCCS Centro Neurolesi "Bonino-Pulejo" All 12 Months to 66 Months   (Child) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment Nir01 December 1, 2020 September 30, 2025 September 30, 2025 May 30, 2023 May 30, 2023 IRCCS Neurolesi Bonino Pulejo, Messina, Italy https://ClinicalTrials.gov/show/NCT05879952 777 NCT05879939 Percutaneous Repetitive Phrenic Nerve Stimulation in Healthy Adults Recruiting No Results Available Electrical Stimulation|Phrenic Nerve Procedure: Percutaneous, repetitive phrenic nerve electrical stimulation Phrenic nerve compound muscle action potential (CMAP) amplitude (mV)|∙ Phrenic nerve compound muscle action potential (CMAP) duration (ms)|∙ Phrenic nerve compound muscle action potential (CMAP) area (mV∙ms)|Respiratory function|Diaphragmatic function|Pain during phrenic stimulation Seoul National University Hospital|National Research Foundation of Korea All 19 Years to 39 Years   (Adult) 14 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2022R1F1A1071488 April 17, 2023 June 30, 2023 June 30, 2023 May 30, 2023 May 30, 2023 Seoul National University Hospital, Seoul, Korea, Republic of https://ClinicalTrials.gov/show/NCT05879939 778 NCT05879926 Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 OFSET Not yet recruiting No Results Available Breast Cancer Drug: Ovarian Function Suppression + Aromatase Inhibitor|Drug: Adjuvant Chemotherapy + Ovarian Function Suppression Invasive breast cancer-free survival (IBCFS)|Invasive disease-free survival (IDFS)|Overall survival|Distant recurrence-free interval (DRFI)|Breast cancer-free interval (BCFI)|Menopausal symptoms measured by the FACT ESS-19 score|Pain during aromatase inhibitor (AI) therapy NRG Oncology|National Cancer Institute (NCI) Female 18 Years to 60 Years   (Adult) Phase 3 3960 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NRG-BR009|5U10CA180868-07 July 2023 February 2030 July 2034 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879926 779 NCT05879913 Coronary CT Angiography Scan in Prostate Cancer Not yet recruiting No Results Available Prostate Cancer Device: Coronary CT Angiography (CCTA) Proportion of Atherosclerosis in CCTA Arm|Proportion of Subjects Eligible for Treatment Based on Automated Plaque Assessment from CCTA|Reduction in atherosclerotic cardiovascular disease (ASCVD) risk score Indiana University|National Comprehensive Cancer Network|Pfizer|Myovant Sciences GmbH Male 40 Years and older   (Adult, Older Adult) Not Applicable 100 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic CTO-IUSCCC-0807 June 1, 2023 December 31, 2025 December 31, 2026 May 30, 2023 May 30, 2023 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States https://ClinicalTrials.gov/show/NCT05879913 780 NCT05879900 Effects of a Fifteen-minute Functional Exercise Intervention on Levels of Physical Fitness of Schoolchildren Active, not recruiting No Results Available Physical Fitness Other: Functional physical exercises|Other: Physical Education classes Change in Cardiorespiratory Fitness|Change in Muscular Strength/Endurance|Change in Handgrip Strength|Change in Lower Limb Power|Change in Speed|Change in Agility|Change in Flexibility|Change in Body Mass Index|Change in Waist Circunference|Change in Sum of Triceps and Subscapular Skinfolds|Changes in Physical Activity Level|Changes in Recreational Screen Time|Changes in Sleep Time|Changes in Physical Self-Concept|Changes in Motivation to Participate in Physical Education Classes|Changes in Symptoms of anxiety, depression and stress Federal University of Pelotas All 10 Years to 17 Years   (Child) Not Applicable 230 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment ESEF-UFPel March 20, 2023 July 30, 2023 December 31, 2023 May 30, 2023 May 30, 2023 Higher School of Physical Education - Federal University of Pelotas, Pelotas, Rio Grande Do Sul, Brazil https://ClinicalTrials.gov/show/NCT05879900 781 NCT05879887 An Optimization Pilot to Optimize An Early Palliative Care Intervention for Advanced Heart Failure UPHOLDS Not yet recruiting No Results Available Heart Failure NYHA Class III|Heart Failure NYHA Class IV|Chronic Illness Behavioral: UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering) Feasibility of Intervention Delivery and Data Collection|Acceptability of Intervention and Study Procedures|Quality of Life using the Kansas City Cardiomyopathy Questionnaire- 12|Financial toxicity using the Comprehensive score for financial Toxicity|Mood using the Hospital Anxiety and Depression Scale University of Alabama at Birmingham|National Institute of Nursing Research (NINR) All 50 Years and older   (Adult, Older Adult) Not Applicable 64 Other|NIH Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care IRB-300011233 August 1, 2023 October 1, 2025 January 1, 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879887 782 NCT05879874 Prospective Evaluation of NfL as a Biomarker in ATTRv NfLInATTRv Not yet recruiting No Results Available Amyloidosis, Hereditary Change in NfL values|NfL levels correlation Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years to 100 Years   (Adult, Older Adult) 40 Other Observational Observational Model: Cohort|Time Perspective: Prospective ID5545 June 2023 September 2024 June 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879874 783 NCT05879861 Development and Validation of a Risk Prediction Model for Preoperative Frailty in Elderly Patients With Colorectal Cancer Recruiting No Results Available Colorectal Cancer Status of frailty Zunyi Medical College All 60 Years and older   (Adult, Older Adult) 364 Other Observational Observational Model: Cohort|Time Perspective: Retrospective ZSKHZ Zi (2022) no. 337 August 1, 2022 July 31, 2025 July 31, 2025 May 30, 2023 May 30, 2023 Yongmei Zhang, Zunyi, Guizhou, China https://ClinicalTrials.gov/show/NCT05879861 784 NCT05879848 VR Scenario for Labor Pain Control Completed No Results Available Labor Pain Other: VR Subjective pain|NAUSEA|Objective pain via wristband|incidence of episiotomy and lacerations|epidural anesthesia|incidence of operative delivery|neonatal outcome Federico II University Female 18 Years to 45 Years   (Adult) Not Applicable 106 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care FEDIIU485/20 November 1, 2021 June 30, 2022 July 31, 2022 May 30, 2023 May 30, 2023 University Federico II, Naples, Italy https://ClinicalTrials.gov/show/NCT05879848 785 NCT05879835 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] CT23-001-SC001 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879835 786 NCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Not yet recruiting No Results Available Advanced Solid Tumor Drug: INCB099280 Objective response rate (ORR)|Number of participants with Treatment-emergent Adverse Events (TEAEs)|Number of participants with TEAEs leading to dose modification or discontinuation|Disease Control Rate (DCR)|Duration Of Response (DOR)|INCB099280 pharmacokinetic (PK) in Plasma Incyte Corporation All 18 Years and older   (Adult, Older Adult) Phase 2 314 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment INCB 99280-211|2022-502716-37-00 June 30, 2023 April 20, 2027 April 20, 2027 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879822 787 NCT05879809 Effect of Music Therapy in Depressive Symptoms of Mood Disorder（EMTDSMD） Not yet recruiting No Results Available Mood Disorder (Depressive Episodes) Device: The mini apps named "SOUL GYM" on the Wechat Change from baseline in depressive symptoms assessed by the Patient Health Questionnaire-9 (PHQ-9; range: 0-27) at week 4.|Change from baseline in depressive symptoms assessed by Hamilton depression rating scale 17 items (HAMD-17) at week 4|Change from baseline in the Clinical Global Impression-Severity scale (CGI-S) at week 4.|Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) at week 4|Change from baseline in anxiety symptoms assessed by the Generalized Anxiety Disorder-7 (GAD-7, range: 0-21) at week 4.|Change from baseline in insomnia symptoms assessed by the Insomnia Severity Index (ISI; range: 0-28) at week 4.|Change from baseline in perceived stress assessed by the Perceived Stress Scale-14 (PSS-14; range: 0-56) at week 4|Change from baseline in the amplitude of low-frequency fluctuation (ALFF) values measured by resting-state functional magnetic resonance imaging (fMRI) at week 4 Jiangsu Province Nanjing Brain Hospital All 13 Years to 35 Years   (Child, Adult) Not Applicable 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 81725005-5 June 1, 2023 January 1, 2024 May 1, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879809 788 NCT05879796 Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer Not yet recruiting No Results Available Cervical Cancer Drug: cis-platinum|Radiation: radiation|Drug: Envafolimab Injection|Drug: Recombinant Human Endostatin Injection Objective response rate|Disease control rate|progression-free survival|overall survival|The adverse events according to NCI-CTCAE v5.0 Peking University Third Hospital Female 18 Years to 75 Years   (Adult, Older Adult) 30 Other Observational Observational Model: Cohort|Time Perspective: Prospective M2023108 May 16, 2023 May 16, 2024 May 16, 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879796 789 NCT05879783 Optical Biopsy for Peritoneal Nodules in Colorectal Patients Recruiting No Results Available Colorectal Cancer Diagnostic Test: Confocal laser endomicroscopy Accuracy of pCLE optical biopsy|Sensitivity, specificity of pCLE optical biopsy|The positive predictive value and negative predictive value of pCLE optical biopsy Nanfang Hospital of Southern Medical University All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 278 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic NFEC-2023-088 September 15, 2022 September 15, 2023 December 15, 2023 May 30, 2023 May 30, 2023 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05879783 790 NCT05879770 Is the Use of Prolene as Sufficient as the Use of Wire in Shouldice Surgery to Keep the Recurrence Rate Low After One Year? Wire vs Prolen Recruiting No Results Available Inguinal Hernia Other: suture material Recurrence rate|Reoperation rate due to a recurrence Shouldice Hospital All 16 Years and older   (Child, Adult, Older Adult) 1400 Other Observational Observational Model: Cohort|Time Perspective: Retrospective #2023-02 September 1, 2023 January 1, 2024 March 1, 2024 May 30, 2023 May 30, 2023 Shouldice Hospital, Thornhill, Ontario, Canada https://ClinicalTrials.gov/show/NCT05879770 791 NCT05879757 Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency Not yet recruiting No Results Available Multiple Myeloma|Secondary Immunodeficiency (SID) Other: No Intervention Dose of HyQvia per Kilogram of Body Weight|Absolute Dose of HyQvia per Infusion|Treatment Interval|Infusion Volume per Site|Total Infusion Volume|Infusion Rate|Duration of Infusion|Location of Infusion Sites|Number of Infusion Sites|Number of Participants Characterized by Site of Care|Length and Diameter of Infusion Needles|Number of Participants per Type of Pump|Number of Participants With Availability of Caregiver Support|Number of Training Visits|Number of Participants With Infusions That are Discontinued, Slowed, or Interrupted|Number of Participants With Reasons of infusions Discontinued, Slowed, or Interrupted|Number of Participants With Reasons for Discontinued, or Interrupted HyQvia Treatment or Switches to Other Treatment|Time of Multiple Myeloma (MM) Diagnosis|Number of Participants Characterized by Clinical Characteristics|Number of Participants Characterized With Type of Hemato-oncological Treatment|Duration of Hemato-oncological Treatment|Number of Participants With Multiple Myeloma (MM) Disease Status and Outcome at 12 Months|Overall Survival (OS)|Number of Participants With Healthcare Resource Utilization (HCRU)|Duration of Hospitalizations|Number of Participants With Related and Not Related Serious Adverse Events (SAEs)|Number of Participants With Non-serious Adverse Events (AEs) Causally or Temporally Related to HyQvia Treatment|Number of Participants With Premedication use for HyQvia Infusions, any Technical Problems With the Infusion, and the Planned Versus Actual Dosing Takeda All 18 Years and older   (Adult, Older Adult) 100 Industry Observational Observational Model: Cohort|Time Perspective: Prospective TAK-771-5006 June 30, 2023 July 1, 2025 March 1, 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879757 792 NCT05879744 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Recruiting No Results Available NHL|NHL, Relapsed, Adult Drug: CLN-978 Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs|Define dose regimen for CLN-978|Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL|Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL|Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL|Select PK parameters of CLN-978: AUC|Select PK parameters of CLN-978: Cmax|Select PK parameters of CLN-978: Half-life|Immunogenicity of CLN-978 and potential impact on drug exposure Cullinan Oncology, LLC All 18 Years and older   (Adult, Older Adult) Phase 1 90 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CLN-978-001 May 31, 2023 November 2026 April 2027 May 30, 2023 June 1, 2023 University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States https://ClinicalTrials.gov/show/NCT05879744 793 NCT05879731 Consciousness and Nociception During Anesthesia NOCICON Not yet recruiting No Results Available Nociceptive Pain|Anesthesia Other: EEG-hd (high density electroencephalogram) Awake|Pre-Stimulation|Stimulation|Post-Stimulation|Baseline value of the nocicpetion level index (NOL) - Awake|Baseline value of the bispectral index (BIS) - Awake|Baseline value of the mean arterial pressure (MAP) - Awake|Baseline value of the heart rate (HR) - Awake|Basal value of the nocicpetion level index (NOL) - Pre-stimulation|Basal value of the bispectral index (BIS) - Pre-stimulation|Basal value of the mean arterial pressure (MAP) - Pre-stimulation|Basal value of the heart rate (HR) - Pre-stimulation|Value of nociception level index (NOL) - Stimulation|Value of bispectral index (BIS) - Stimulation|Value of the mean arterial pressure (MAP) - Stimulation|Value of the heart rate (HR) - Stimulation|Value of nociception level index (NOL) - Post-stimulation|Value of bispectral index (BIS) - Post-stimulation|Value of the mean arterial pressure (MAP) - Post-stimulation|Value of the heart rate (HR) - Post-stimulation Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal All 18 Years to 60 Years   (Adult) 30 Other Observational Observational Model: Case-Only|Time Perspective: Prospective MP-12-2022-2984 May 29, 2023 November 22, 2023 May 22, 2024 May 30, 2023 May 30, 2023 Hopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montréal, Montréal, Quebec, Canada https://ClinicalTrials.gov/show/NCT05879731 794 NCT05879718 A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. Not yet recruiting No Results Available Lupus Erythematosus, Systemic|Lupus Erythematosus, Cutaneous Drug: Placebo|Drug: PF-06823859 Change from baseline in type 1 IFN GS score in lesional skin at Week 12|Percent change from baseline in CLASI-A score at Week 12|Percent change from baseline in CLASI-A (over time in addition to Week 12)|Change from baseline in CLASI-A score at Week 12|Achieving ≥50%, 4 or 7 points reduction in CLASI-A (over time)|Change from baseline in Physician global assessment (PhGA) (over time)|Incidence and severity of laboratory, vital signs, 12-lead ECG abnormalities, AEs, SAEs and withdrawals due to AEs over time Pfizer All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 48 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment C0251013|2023-503343-33-00 June 12, 2023 December 17, 2025 November 18, 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879718 795 NCT05879705 The Effectiveness of OT-ParentShip on Parental Resilience and Functioning of Adolescents With High Functioning Autism Recruiting No Results Available Autism Spectrum Disorder Other: Parent intervention Autism: Parenting Questionnaire (APQ) (Kim, Anderson, Birkin, Seymour, & Moore, 2004).|Basic Psychological Need Satisfaction in Relationships (La Guardia, Ryan, Couchman, & Deci 2000).|Canadian Occupational Performance Measure (COPM)- Parent (Law, Baptiste, Carswell, McColl, Polatajko, & Pollock, 1998)|Canadian Occupational Performance Measure (COPM)- Parent (Law, Baptiste, Carswell, McColl, Polatajko, & Pollock, 1998)- Transfer goal|Canadian Occupational Performance Measure (COPM)-Adolescent (Law, Baptiste, Carswell, McColl, Polatajko, & Pollock, 1998)|Canadian Occupational Performance Measure (COPM)-Adolescent (Law, Baptiste, Carswell, McColl, Polatajko, & Pollock, 1998)- Transfer goal Meir Medical Center|Hebrew University of Jerusalem All 30 Years to 80 Years   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 0119-20-COM March 3, 2021 May 2023 September 2023 May 30, 2023 May 30, 2023 The Hebrew University of Jerusalem, Jerusalem, Israel https://ClinicalTrials.gov/show/NCT05879705 796 NCT05879692 Response of Irritable Bowel Syndrome to Abdominal Fat Reduction Not yet recruiting No Results Available Irritable Bowel Syndrome|Obesity|Abdominal Obesity Procedure: focused ultrasound|Behavioral: Low Caloric Diet (LCD) and a low (FODMAPs) diet|Other: aerobic exercise change in total body fat percentage|change in abdominal subcutaneous fat percentage|change in abdominal visceral fat percentage|change in Irritable bowel syndrome Severity Scoring system (IBS-SSS)|change in Irritable bowel syndrome-quality of life (IBS-QOL)|change in body weight|change in body mass index|change in waist circumference measurement Cairo University All 20 Years to 45 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment P.T.REC/012/004475 May 2023 October 2023 December 2023 May 30, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05879692 797 NCT05879679 Pilot Study on the Validity of the Metacognitive Hub Model of Craving in Bulimia Nervosa (BN) and Binge Eating Disorders (BED) MetaBou Not yet recruiting No Results Available Bulimia Nervosa|Binge-Eating Disorder Behavioral: Food craving induction Attention Network Test (ANT)|Dot Probe Task|Water load task|Live metacognition|Avoidance/Approach task adapted for food craving|Beck Depression Inventory II (BDI-II)|State-Trait Anxiety Inventory (STAI)|Eating Disorder Examination Questionnaire (EDE-Q)|Food Craving Questionnaire State (FCQ-S)|Food Craving Questionnaire Trait (FCQ-T)|Visual Analogic Scale of craving|Schedule for the Assessment of Insight in Eating Disorders (SAI-ED)|Difficulties in Emotional Regulation Scale (DERS- 18)|Attentional Control Scale (ACS)|Body Awareness Questionnaire (BAQ) Laval University|Université de Nantes|Centre d'expertise Poids, Image et Alimentation (CEPIA)|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec Female 18 Years to 65 Years   (Adult, Older Adult) 60 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional 2024-4019, 22336 September 1, 2023 September 2025 October 2025 May 30, 2023 May 30, 2023 Centre d'expertise Poids, Image et Alimentation (CEPIA), Québec, Canada|IUCPQ, Québec, Canada https://ClinicalTrials.gov/show/NCT05879679 798 NCT05879666 Improving Health and Environmental Health Literacy of Professionals IHEHLP Not yet recruiting No Results Available Health Knowledge, Attitudes, Practice Behavioral: Online educational phthalate course Baseline phthalate environmental health literacy|Change from baseline phthalate environmental health literacy|Sustained change from baseline phthalate environmental health literacy|Baseline Urinary biomarkers of phthalate exposure|Change in urinary biomarkers of phthalate exposure Harvard School of Public Health (HSPH) All Child, Adult, Older Adult Not Applicable 100 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other IRB22-1510 May 30, 2023 July 2023 December 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879666 799 NCT05879653 Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) Not yet recruiting No Results Available Bladder Cancer Drug: MK-3475|Drug: ASG-22CE|Procedure: maximal TURBT|Radiation: Radiation therapy Bladder Intact Event-Free Survival (BI-EFS) rate|Pathologic Complete Response (pCR) Rate at 38 weeks|Overall Survival (OS)|Metastasis-Free Survival (MFS)|Number of participants who experienced an adverse event (AE)|Number of participants who discontinued study intervention due to an AE|Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30|Change from Baseline in Urinary, Bowel, and Sexual Domains of the Bladder Cancer Index (BCI)|Change from Baseline in the Visual Analog Score (VAS) of the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L)|Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30|TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30|TTD in Urinary, Bowel, and Sexual Domains of the BCI|TTD in the VAS of the EQ-5D-5L Kyoto University Hospital|University of Tsukuba|Osaka Metropolitan University|Kobe City Medical Center General Hospital|Merck Sharp & Dohme LLC|Astellas Pharma Inc All 18 Years and older   (Adult, Older Adult) Phase 2 30 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IACT21079 October 1, 2023 September 30, 2025 September 30, 2027 May 30, 2023 May 30, 2023 Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kyoto University Hospital, Kyoto, Japan|Osaka Metropolitan University Hospital, Osaka, Japan https://ClinicalTrials.gov/show/NCT05879653 800 NCT05879640 Sleep After Pediatric Critical Illness Recruiting No Results Available Pediatric|Critical Illness|Sleep Disturbance Behavioral: Sleep education Sleep Disturbances Scale for Children|Pediatric Quality of Life Inventory Scale (PedsQL) Oregon Health and Science University All 6 Years to 18 Years   (Child, Adult) Not Applicable 40 Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 23234 April 18, 2022 August 30, 2023 October 31, 2023 May 30, 2023 May 30, 2023 Oregon Health & Science University, Portland, Oregon, United States https://ClinicalTrials.gov/show/NCT05879640 801 NCT05879627 To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors Recruiting No Results Available Advanced Solid Tumors Drug: BAT8007 for injection Dose limiting toxicity (DLT)|Adverse Events (AEs)|Anti-drug antibodies (ADA) and neutralizing antibodies (NAb)|Cmax|Tmax (Time to reach maximum serum concentration)|t1/2 (terminal half-life)|Systemic Clearance (CL) Bio-Thera Solutions|Zhejiang Tumor Hospital All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 42 Industry|Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment BAT-8007-001-CR January 17, 2023 December 31, 2024 July 1, 2025 May 30, 2023 May 30, 2023 Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05879627 802 NCT05879614 An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) PWS-001 Not yet recruiting No Results Available Prader-Willi Syndrome Drug: NNZ-2591 Safety and Tolerability|Pharmacokinetic - Measurement of Cmax|Pharmacokinetic - Measurement of AUC|Pharmacokinetic - Measurement of time to Cmax|Pharmacokinetic - Measurement of t1/2|Exploratory efficacy measurement Neuren Pharmaceuticals Limited All 4 Years to 12 Years   (Child) Phase 2 20 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NEU-2591-PWS-001 June 30, 2023 June 30, 2024 June 30, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879614 803 NCT05879601 "Comparative Evaluation of 3 Dimensional Changes of Dentition in Post Orthodontic Patients With Immediate vs Delayed (Post 24 Hours) Retainer Delivery Recruiting No Results Available Relapse Other: immediate orthodontic retainer delivery|Other: delayed orthodontic retainer delivery. Overjet|contact point displacement|overbite|intermolar width|intercanine width Postgraduate Institute of Dental Sciences Rohtak All 18 Years to 45 Years   (Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention PGIDS/BHRC/22/33 Sidhant Goyal May 25, 2022 December 25, 2023 April 25, 2024 May 30, 2023 May 30, 2023 Post Graduate Institute of Dental Sciences, Rohtak, Haryana, India https://ClinicalTrials.gov/show/NCT05879601 804 NCT05879588 : "Comparative Evaluation of 3 Dimensional Changes of Dentition in Post Orthodontic Patients With Immediate vs Delayed (Post 3 Days) Retainer Delivery Recruiting No Results Available Relapse Other: immediate orthodontic retainer delivery|Other: delayed orthodontic retainer delivery overjet|contact point displacement|Overbite|Intermolar width|Intercanine width Postgraduate Institute of Dental Sciences Rohtak All 18 Years to 45 Years   (Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention PGIDS/BHRC/22/32 May 25, 2022 December 25, 2023 April 25, 2024 May 30, 2023 May 30, 2023 Post Graduate Institute of Dental Sciences, Rohtak, Haryana, India https://ClinicalTrials.gov/show/NCT05879588 805 NCT05879575 Effects and Pathophysiology of Weight Training on Pregnancy-related Pelvic Girdle Pain (PPGP) Not yet recruiting No Results Available Pelvic Girdle Pain Behavioral: weight training PGQ score|Cervical length|Duration of the first stage of labor|Duration of the second stage of labor National Taiwan University Hospital Hsin-Chu Branch|National Taiwan University Hospital|National Taiwan University Female 20 Years to 50 Years   (Adult) Not Applicable 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 111-152-F May 31, 2023 March 31, 2024 October 1, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879575 806 NCT05879562 Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO MoCA Active, not recruiting No Results Available Cognitive Impairment|Cognitive Change|Cognitive Deficit|Assessment, Self Diagnostic Test: MoCA-Xpresso Correlation between the MoCA XpressO and the Digital MoCA|Correlation between scores of sub-tests on MoCA-XpressO and the Digital MoCA MoCA Clinic and Institute All 50 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Screening MoCA Xpresso 01 October 1, 2022 June 30, 2023 June 30, 2023 May 30, 2023 May 30, 2023 MoCA Clinic and Institute, Greenfield Park, Quebec, Canada https://ClinicalTrials.gov/show/NCT05879562 807 NCT05879549 Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia Not yet recruiting No Results Available Hemophilia A|Hemophilia B Other: Closed Chain Exercise Group|Other: Proprioceptive Exercise Group Medio-lateral and Anterior-posterior stability index|walking speed|Hemophilia joint health score|Single leg stance test|Proprioception|2-dimensional video-based gait kinematic analysis Bahçeşehir University Male 13 Years to 25 Years   (Child, Adult) Not Applicable 63 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment E-74555795-050.01.04-689576 July 1, 2023 September 30, 2023 January 1, 2024 May 30, 2023 May 30, 2023 İstanbul University-Cerrahpaşa, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05879549 808 NCT05879536 The Effect of Intravenous Infusion of Tramadol-ondansetron on Recovery After Caesarean Section. TRON Recruiting No Results Available Post Operative Pain|Cesarean Section|Tramadol|Postoperative Recovery|Quality of Recovery|Ondansetron|QoR-15|ObsQor-10|Postcesarean Recovery Drug: Tramadol-ondansetron continuous infusion|Drug: Ropivacaine via epidural catheter Post-surgical recovery|Analgesia for acute pain|Adverse effects|External validity of ObsQoR10 - Spanish version|Chronic Pain Hospital Universitario La Fe Female 18 Years to 50 Years   (Adult) 312 Other Observational Observational Model: Cohort|Time Perspective: Prospective TRON May 23, 2023 February 28, 2024 February 28, 2024 May 30, 2023 May 30, 2023 Hospital Universitario La Fe, Valencia, Spain https://ClinicalTrials.gov/show/NCT05879536 809 NCT05879523 A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy Not yet recruiting No Results Available Obstructive Hypertrophic Cardiomyopathy Drug: HRS-1893|Drug: Placebo incidence of adverse event (AE), serious adverse event (SAE) Shandong Suncadia Medicine Co., Ltd. All 18 Years to 85 Years   (Adult, Older Adult) Phase 1 98 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment HRS-1893-101 May 2023 June 2024 June 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879523 810 NCT05879510 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses Not yet recruiting No Results Available Clear Cell Renal Cell Carcinoma Diagnostic Test: 68Ga-NY104 PET/CT Binary reading of renal lesions identified on 68Ga-NY104 PET/CT|Histological classification of operated renal lesions|SUVmax of renal lesions identified on 68Ga-NY104 PET/CT|SUVmax of liver uptake on 68Ga-NY104 PET/CT|Tumor grade of operated renal lesions|Intensity of CAIX staining of operated renal lesions|Extent of CAIX staining of operated renal lesions|Binary reading of renal lesions identified on diagnostic CT|Size of renal lesions identified on diagnostic CT|Number of metastatic lesions identified on 68Ga-NY104 PET/CT|Location of metastatic lesions identified on 68Ga-NY104 PET/CT|Szie of metastatic lesions identified on 68Ga-NY104 PET/CT|Number of metastatic lesions on diagnostic CT|Location of metastatic lesions on diagnostic CT|Size of metastatic lesions on diagnostic CT Peking Union Medical College Hospital All 18 Years and older   (Adult, Older Adult) Phase 2 63 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic NYCRPS July 1, 2023 July 1, 2025 July 1, 2025 May 30, 2023 May 31, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05879510 811 NCT05879497 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion Not yet recruiting No Results Available Clear Cell Renal Cell Carcinoma Diagnostic Test: 68Ga-NY104 PET/CT Binary reading of lesions identified on 68Ga-NY104 PET/CT Peking Union Medical College Hospital All 18 Years and older   (Adult, Older Adult) Phase 2 40 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic NYCRMS July 1, 2023 July 1, 2025 July 1, 2025 May 30, 2023 May 30, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05879497 812 NCT05879484 Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS Not yet recruiting No Results Available Sinonasal Cancer|Squamous Non-small Cell Lung Cancer|Lung Cancer|Head and Neck Squamous Cell Carcinoma|Head and Neck Carcnimona|Head and Neck Cancer Drug: pembrolizumab|Drug: valemetostat Phase II: Disease control rate (DCR)|Phase Ib: Safety of valemetostat in combination with pembrolizumab|Phase Ib: Recommended phase II dose (RP2D) of valemetostat in combination with pembrolizumab|Pharmacokinetics of valemetostat in combination with pembrolizumab|Overall survival (OS) in participants treated with valemetostat and pembrolizumab compared to historical controls with pembrolizumab alone|6-month progression free survival (PFS) rate in participants treated with valemetostat and pembrolizumab compared to historical controls treated with pembrolizumab alone|Progression free survival (PFS) in participants treated with valemetostat and pembrolizumab compared to historical controls with pembrolizumab alone|Clinical benefit rate (CBR) in participants treated with valemetostat and pembrolizumab compared to historical controls with pembrolizumab alone|Objective response rate (ORR) in participants treated with valemetostat and pembrolizumab compared to historical controls with pembrolizumab alone|Safety of the valemetostat and pembrolizumab combination (Phase II) National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) All 18 Years to 120 Years   (Adult, Older Adult) Phase 1|Phase 2 47 NIH Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 10001545|001545-C June 8, 2023 July 1, 2025 July 1, 2027 May 30, 2023 June 5, 2023 National Institutes of Health Clinical Center, Bethesda, Maryland, United States https://ClinicalTrials.gov/show/NCT05879484 813 NCT05879471 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma Not yet recruiting No Results Available Metastatic Clear Cell Renal Cell Carcinoma Diagnostic Test: 68Ga-NY104 PET/CT Positivity of lesions detected by 68Ga-NY104 PET|Positivity of lesions detected by 18F-FDG PET|SUVmax of lesions detected by 68Ga-NY104 PET|SUVmax of lesions detected by 18F-FDG PET Peking Union Medical College Hospital All 18 Years and older   (Adult, Older Adult) Phase 2 39 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic NYCRM July 1, 2023 July 1, 2025 July 1, 2025 May 30, 2023 May 30, 2023 Peking Union Medical College Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05879471 814 NCT05879458 Ritlecitinib in CTCL Recruiting No Results Available CTCL|Mycosis Fungoides|Sezary Syndrome Drug: Ritlecitinib Modified Severity Weighted Assessment Tool (mSWAT)|Change in Modified Severity Weighted Assessment Tool (mSWAT)|Treatment Emergent Adverse Events|Number of Serious Adverse Events|Number of Adverse Events|Number of significant events of hypertension or hypotension measured per CTCAE 5.0|Number of significant events of bradycardia or tachycardia measured per CTCAE 5.0|Hematocrit|Hemoglobin count|Platelet count|Red Blood Cells (RBC) count|White blood cell (WBC) count|Basophils count|Eosinophils count|B Lymphocytes count|T cells count|Natural Killer count|Monocytes count|Neutrophils count|Albumin|Alkaline phosphatase|ALT (alanine aminotransferase)|AST (aspartate aminotransferase)|BUN (blood urea nitrogen)|Calcium|Chloride|CO2 (carbon dioxide)|Creatinine|Glucose|Potassium|Sodium|Total bilirubin|Total protein|Change in Percentage of patients achieving 50% or greater improvement mSWAT score|Global Response Score Icahn School of Medicine at Mount Sinai|Pfizer All 18 Years and older   (Adult, Older Adult) Phase 2 20 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GCO 23-0107 May 2023 April 2026 April 2026 May 30, 2023 May 30, 2023 Icahn School of Medicine at Mount Sinai, New York, New York, United States https://ClinicalTrials.gov/show/NCT05879458 815 NCT05879445 Causes, Complications and Outcomes of Severe Acute Liver Disease Cases Admitted to Intensive Care Units Not yet recruiting No Results Available Acute Liver Disease Assessment of Liver function in individuals with ALF admitted to intensive care unit.|Assessment of kidney function in individuals with ALF admitted to intensive care unit.|Assessment of fluid overload in individuals with ALF admitted to intensive care unit.|Mortality rates|Morbidity rates Assiut University All 18 Years to 75 Years   (Adult, Older Adult) 200 Other Observational Observational Model: Other|Time Perspective: Other Severe ALD in intensive care June 20, 2023 August 1, 2024 September 1, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879445 816 NCT05879432 LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery Not yet recruiting No Results Available Acute Kidney Injury|Cardiac Surgery Drug: LSALT Peptide|Drug: Placebo To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria|Maximum severity of AKI per patient between treatment groups|Time to mild, moderate, and severe AKI per patient between treatment groups|Need for RRT within the first 7 days following surgery|Need for RRT at any time during the 28-day study|Duration of AKI at 28 days (End of study - EOS) OR up to hospital discharge after surgery|Kidney function (SCr, eGFR) at 28 days (EOS) OR up to hospital discharge after surgery|28-day all-cause mortality|Composite of death, need for RRT, and/or persistent impaired renal function from baseline (MAKE [major adverse kidney event] criteria) at Day 28 (EOS)|ICU length of stay (in days)|Hospitalization length of stay (in days)|Incidence of new-onset lung or liver disorders following surgery|Change in baseline serum cystatin C, serum NGAL, serum IP-10, serum IL-1beta, serum IL-6, and serum IL-18 biomarker levels|Changes in urinary TIMP-2 and IGFBP7 biomarker and serum NGAL, AGT, and IL-18 biomarker levels Arch Biopartners Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 240 Industry Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention AB003 July 2023 July 2024 September 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879432 817 NCT05879419 Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases RZVRheum Recruiting No Results Available Rheumatoid Arthritis|Spondylitis, Ankylosing|Spondyloarthritis|Systemic Lupus Erythematosus|Sjogren's Syndrome|Systemic Sclerosis|Idiopathic Inflammatory Myopathies|Vasculitis, Systemic|Juvenile Idiopathic Arthritis|Dermatomyositis, Juvenile Biological: Recombinant Herpes Zoster Vaccine (RZV)|Other: MTX Discontinuation|Other: MMF Discontinuation|Other: Placebo|Other: MTX maintain|Other: MMF maintain Subproject A: Disease safety (flare) in ARD patients immunized with RZV in comparison to non-vaccinated ARD patients (placebo group)|Subproject B: Effect of MTX discontinuation on immunogenicity in comparison to MTX maintenance|Subproject B: Effect of MMF discontinuation on immunogenicity in comparison to MMF maintenance|Subproject A: Incidence of vaccine adverse events [safety and tolerability] in ARD patients immunized with RZV in comparison to non-vaccinated ARD patients (placebo group) and non-immunosupressed controls (control group)|Subproject A: Humoral immunogenicity of the RZV in ARD patients in comparison to non-immunosupressed control group University of Sao Paulo General Hospital|GlaxoSmithKline All 18 Years to 75 Years   (Adult, Older Adult) Phase 4 2005 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention 67374823.0.0000.0068 May 23, 2023 May 22, 2025 May 22, 2027 May 30, 2023 May 30, 2023 Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil https://ClinicalTrials.gov/show/NCT05879419 818 NCT05879406 A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne Recruiting No Results Available Non-Cystic Acne Dietary Supplement: VitaMedica® Clear Skin Formula capsules|Other: Placebo Capsules Change in inflammatory lesion counts|Change in non-inflammatory lesion counts|Percentage/Proportion of subjects who achieve at least a one-grade reduction in the Modified IGA Score|Change in Non-Cystic Acne Quality of Life questionnaire scores|Change in Non-Cystic Acne Self Assessment questionnaire scores|Change in Analysis of the Clear Skin Formula Supplement Subject Satisfaction questionnaire Ablon Skin Institute Research Center|Grove Acquisition Subsidiary dba VitaMedica All 18 Years to 40 Years   (Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment VM-CSF-01[ May 22, 2023 May 2024 May 2024 May 30, 2023 May 30, 2023 Ablon Skin Institute & Research Center, Manhattan Beach, California, United States https://ClinicalTrials.gov/show/NCT05879406 819 NCT05879393 The Multistrain Probiotic OMNi-BiOTiC® Active for Upper Respiratory Tract Infections in Older People ProURTI Completed No Results Available Acute Upper Respiratory Tract Infection Dietary Supplement: OMNi-BiOTiC® Active|Other: Placebo Incidence of URTI|Duration of URTI|Changes in concentration of leukocytes, neutrophils segm., lymphocytes, monocytes, eosinophils, basophils in serum|Changes in concentration of Immunoglobulin A (IgA) in serum University Maribor All 65 Years and older   (Older Adult) Not Applicable 95 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention UMaribor October 7, 2020 February 13, 2022 July 13, 2022 May 30, 2023 June 5, 2023 University of Maribor, Faculty of Health Sciences, Maribor, Slovenia https://ClinicalTrials.gov/show/NCT05879393 820 NCT05879380 MR Pulmonary Angiography to Replace CT Pulmonary Angiography for Patients With a Suspicion of a Pulmonary Embolism MIRACLE Not yet recruiting No Results Available Pulmonary Embolism|Radiation Exposure Diagnostic Test: MRPA|Diagnostic Test: CPTA Sensitivity|Specificity|To determine the negative predictive value of MRPA|To determine the positive predictive value of MRPA|To determine the accuracy of MRPA|To determine the inter-observer agreement / variability of MRPA|To determine the feasibility in daily clinical practice of MRPA Noordwest Ziekenhuisgroep|Leiden University Medical Center All 18 Years and older   (Adult, Older Adult) 272 Other Observational Observational Model: Cohort|Time Perspective: Prospective NL90098.029.22 June 2, 2023 March 20, 2024 March 20, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879380 821 NCT05879367 Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting No Results Available Glioblastoma, IDH-wildtype|Glioblastoma|Glioblastoma Multiforme|Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype|GBM Drug: Eflornithine (Dose Level 1)|Drug: Eflornithine (Dose Level 2)|Drug: Eflornithine (Dose Level -1)|Drug: Temozolomide Assessment of Dose Limiting Toxicities|Incidence of TEAEs|Vital Signs (Heart and Respiratory Rate)|Vital Signs (Blood Pressure)|Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests|Progression Free Survival|Overall Response Rate|Pharmacokinetics Cmax|Pharmacokinetics Cmin|Pharmacokinetics Tmax|Pharmacokinetics AUCt|Pharmacokinetics lambdaz|Pharmacokinetics t 1/2 Orbus Therapeutics, Inc. All 18 Years and older   (Adult, Older Adult) Phase 1 60 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment OT-21-101 May 26, 2023 December 15, 2024 December 15, 2024 May 30, 2023 May 30, 2023 The Cleveland Clinic, Cleveland, Ohio, United States https://ClinicalTrials.gov/show/NCT05879367 822 NCT05879354 Active Cycle of Breathing Techniques on Respiratory Distress Symptom Cluster Not yet recruiting No Results Available Lung Neoplasms Other: Active Cycle of Breathing Techniques Dyspnea Level|Fatigue Level|Health-related quality of life in chronic cough Maltepe University|Saglik Bilimleri Universitesi All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 78 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care MAU_DogaUlcay_001 June 10, 2023 May 30, 2024 May 30, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879354 823 NCT05879341 Effect of Gene Polymorphism on Cognitive Function Recruiting No Results Available Polymorphosis|Cognitive Function Other: High intensitiy interval training Change in Serum BDNF levels|Change in Serum Irisin Levels|Change in Stroop Reaction time|Change in Fitlight reaction time|Monitor the Heart rate|Change in Fitlight simple reaction time Kaohsiung Medical University Chung-Ho Memorial Hospital|Ministry of Science and Technology, Taiwan All 20 Years to 40 Years   (Adult) 200 Other Observational Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional KMUHIRB-G(I)-20220005 June 10, 2022 July 2024 July 2024 May 30, 2023 May 30, 2023 Kaohsiung Medical University, Kaohsiung, Taiwan https://ClinicalTrials.gov/show/NCT05879341 824 NCT05879328 The ImmunoXXL Study ImmunoXXL Recruiting No Results Available Hepatocellular Carcinoma Procedure: Liver Transplantation Recurrence-free survival (RFS)|Tumor response|Complication rate|Overall survival (OS)|Patients' reported outcomes (PROs)|Comparison with historical series Fondazione IRCCS Istituto Nazionale dei Tumori, Milano All 18 Years to 75 Years   (Adult, Older Adult) 12 Other Observational Observational Model: Cohort|Time Perspective: Prospective INT 30/23 December 23, 2022 December 31, 2024 December 31, 2024 May 30, 2023 May 30, 2023 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy https://ClinicalTrials.gov/show/NCT05879328 825 NCT05879315 Evaluation of Balance and Movement in Order to Prevent the Risk of Falling in the Post-operative Period NOCADINRIAB Recruiting No Results Available Patient Fall Other: Fall risk prevention in hospital Test UP and GO. The time of performance is measured in seconds and lower values indicate better balance control and lower fall risk.|Four Square Step Test. The time of performance is measured in seconds|Barthel Index. It is a questionnaire|Cumulative Illness Rating Scale. The scale has a cumulative score, which can range from 0 to 56|Stabilometric Test|Morse Scale. It is a questionnaire.|International classification of functioning, disability and health Istituto Ortopedico Rizzoli All 50 Years to 85 Years   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention CE AVEC: 888/2022/Sper/IOR March 20, 2023 March 2024 December 2024 May 30, 2023 May 30, 2023 Rizzoli Orthopedic Institute, Bagheria, Palermo, Italy https://ClinicalTrials.gov/show/NCT05879315 826 NCT05879302 Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision Not yet recruiting No Results Available End Stage Renal Disease|End-Stage Kidney Disease|Kidney Transplantation|Esrd Behavioral: Kidney Offer Shared Decision Making Willingness to accept donor organs at risk of discard|Knowledge|Decisional Conflict|Distress|Shared Decision Making Hennepin Healthcare Research Institute|Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other|NIH Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research Pro00067603|1R01DK134482 August 1, 2023 November 30, 2025 November 30, 2025 May 30, 2023 May 30, 2023 Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT05879302 827 NCT05879289 Evaluation of the Effectiveness of the Anti-aging Effect of a Supplement in Improving Skin Conditions Completed No Results Available Aging Well Dietary Supplement: A power supplement Acceptability in real conditions of use by questionnaire|Evaluation of skin firmness and elasticity using instrumental evaluation - Cutometer|Increase of skin hydration using instrumental evaluation - Corneometer|Detection and accuracy of fine lines and wrinkles- Visia|Increase in dermal thickness and density in the thigh region|Subjective efficacy from the participants|Acceptability in real conditions of use through dermatological questionnaire Farmoquimica S.A.|Medcin Instituto da Pele Ltda Female 35 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Industry|Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention EN20-1103 January 25, 2022 May 17, 2022 May 17, 2022 May 30, 2023 May 30, 2023 Medcin Instituto da Pele, Osasco, São Paulo, Brazil https://ClinicalTrials.gov/show/NCT05879289 828 NCT05879276 Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. EMPASHOCK Not yet recruiting No Results Available Cardiogenic Shock Drug: Empagliflozin 10 MG Time to all-cause death|Time to cardiac transplantation|Time to mechanical ventricular assist|Time to rehospitalization for heart failure.|Left ventricular ejection fraction assessed by cardiac ultrasound.|Death|Heart transplantation or long-term ventricular assistance|Rehospitalization for heart failure|E' wave assessed by cardiac ultrasound|E/e' ratio assessed by cardiac ultrasound|TAPSE assessed by cardiac ultrasound|S wave at the annular tricuspid level assessed by cardiac ultrasound|Renal replacement therapy|Renal function|Bilirubin|Prothrombin Ratio (PT)|SGOT|SGPT|NT-Pro-BNP|Weight Central Hospital, Nancy, France All 18 Years and older   (Adult, Older Adult) Phase 3 164 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2023-503602-37-00 October 2023 January 2026 January 2026 May 30, 2023 May 30, 2023 CHR Metz - Thionville, Ars-Laquenexy, France|CHU de Besançon, Besançon, France|CHU de Dijon Bourgogne, Dijon, France|CHU Lille, Lille, France|CHU Reims, Reims, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|CHRU de NANCY, Vandœuvre-lès-Nancy, France https://ClinicalTrials.gov/show/NCT05879276 829 NCT05879263 "Efficacy of Intermittent Enteral Nutrition Versus Continuous Administration in Intensive Care" ENINCO Recruiting No Results Available Enteral Nutrition|Critical Care|Feeding Methods|Gastric Feeding Tube Other: INTERMITTENT ENTERAL NUTRITITION (IEN)|Other: CONTINUOS ENTERAL NUTRITITION (CEN) Respiratory Complications|Gastrointestinal Complications|Achievement of the caloric objective|Nutritional status: MNA|Changes in blood glucose|ICU Stay|Mortality|Change of type of EN administration|Nutritional status:Glim Criteria|Nutritional status: Biochemical values Complejo Hospitalario Universitario de Albacete|University of Castilla-La Mancha All 18 Years and older   (Adult, Older Adult) Not Applicable 190 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care CHUA_59_07_2021 February 10, 2022 February 29, 2024 April 30, 2024 May 30, 2023 May 30, 2023 Maria Dolores Saiz Vinuesa, Albacete, Spain https://ClinicalTrials.gov/show/NCT05879263 830 NCT05879250 WP1066 and Radiation Therapy in Newly Diagnosed Glioblastoma Patients Not yet recruiting No Results Available Glioblastoma Multiforme Drug: WP1066 Progression Free Survival|Tumor microenvironment analysis Moleculin Biotech, Inc.|Northwestern University All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 39 Industry|Other Interventional Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MB-402 May 31, 2023 March 31, 2025 March 31, 2026 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879250 831 NCT05879237 Role of Vitamin D Supplementation as an Adjuvant Therapy inTreatment of Helicobacter Pylori in Children Not yet recruiting No Results Available Helicobacter Pylori Infection Drug: Vitamin D3|Drug: Helicobacter pylori triple therapy Role of Vitamin D Supplementation as an Adjuvant Therapy inTreatment of Helicobacter Pylori in Children Minia University|Ain Shams University All 4 Years to 18 Years   (Child, Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2021:42 June 1, 2023 December 1, 2023 December 10, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879237 832 NCT05879224 Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia SCOPE Not yet recruiting No Results Available Vivax Malaria|G6PD Deficiency Combination Product: Revised case management package Proportion of patients experiencing at least one Serious Adverse Event (SAE) during treatment|Proportion of patients experiencing at least one Adverse Event of Special Interest(AESI) during treatment|Proportion of patients with P. vivax malaria who correctly receive all components of the revised case management package|The proportion of patients with any AESI during treatment|The proportion of patients with a gastrointestinal (GI) AESI during treatment|The proportion of patients with an AESI related to haemolysis during treatment|The proportion of patients an AESI related to methaemoglobinaemia|Proportion of patients permanently stopping PQ before end of treatment|The proportion of patients receiving correct treatment based on G6PD activity|Proportion of patients who were reviewed on Day 3 and Day 7|Perception of and experience with new radical cure tools among health care providers and community members|Proportion of health care practitioners who comply with the revised radical cure treatment algorithm|Proportion of patients receiving a SD Biosensor G6PD test|Proportion of eligible P. vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test|Proportion of P. vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients|Proportion of P. vivax malaria patients that are reviewed on Day 3|Proportion of P. vivax malaria patients that adhere to their prescribed primaquine regimen|Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified|Barriers and enablers of uptake and implementation at the sub-national levels are identified|Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified|Required knowledge, skills, and training to administer the revised case management and patient-counselling identified|Factors influencing the barriers and facilitators to patient adherence to primaquine after the rollout of the revised case management identified|Factors influencing the acceptability and feasibility of community-based clinical review at Day 3 of primaquine treatment identified|Perceptions of the new radical cure tools and serious adverse events at the community level identified|Local acceptability of the revised case management algorithms among patients, their families, and healthcare workers established|The monthly incidence of confirmed symptomatic P. vivax malaria episodes (mono-infection or mixed) before implementation versus after implementation|The prevalence of P. vivax parasitaemia in patients presenting with fever before implementation versus after implementation|Cumulative risk of representation to the same clinic with symptomatic P. vivax malaria within 6 months|Costs of implementing policy from a healthcare provider perspective, including health systems strengthening processes|Household costs per P. vivax episode|Overall cost-effectiveness of changing policy if revised case management is effective|Cost per episode of P. vivax malaria from the healthcare provider and societal perspectives|Cost per component of the revised case management package|If revised case management package is effective (significantly reduces the incidence of malaria), then the cost-effectiveness of implementing the revised case management as compared with usual care|Proportion of CHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct patient to discontinue treatment)|Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management|The proportion of patients eligible to receive PQ who had a SAE during treatment|Prevalence of severe anaemia in patients presenting with fever before and after implementation Menzies School of Health Research|Gadjah Mada University|Universitas Sumatera Utara|Indonesia University|Yayasan Pengembangan Kesehatan dan Masyarakat|Indonesian National Malaria Control Program, Ministry of Health|National Research and Innovation Agency of Indonesia|Burnet Institute|University of Melbourne|Medicines for Malaria Venture|PATH|UNITAID|Institute of Tropical Medicine, Belgium All 6 Months and older   (Child, Adult, Older Adult) Not Applicable 11250 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other MMV_PQ_21_02 U1111-1291-3218 July 1, 2023 May 31, 2025 July 31, 2025 May 30, 2023 May 30, 2023 Puskesmas Hanura, Hanura, Lampung, Indonesia|Puskesmas Tanjung Leidong, Labuhanbatu, North Sumatra, Indonesia|Puskesmas Bhintuka, Mimika, Papua, Indonesia|Puskesmas Pasar Sentral, Mimika, Papua, Indonesia|Puskesmas Timika, Mimika, Papua, Indonesia|Puskesmas Wania, Mimika, Papua, Indonesia https://ClinicalTrials.gov/show/NCT05879224 833 NCT05879211 Goal Concordant Care Learning Laboratory Not yet recruiting No Results Available Cancer|Heart Failure|Copd|Dementia Behavioral: Feedback Frequency of goals of care communication|Timing of goals of care communication Duke University All 18 Years and older   (Adult, Older Adult) Not Applicable 5000 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care Pro00106230 June 2023 July 2024 July 2025 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879211 834 NCT05879198 Train Your Brain: Improving Memory and Decision Making Not yet recruiting No Results Available Behavior, Health Behavioral: Computer-based Intervention Change in Delay Discounting 5 Trial Adjusted Measure|Change in Consideration of Future Consequences Scale|Change in Tower of Hanoi|Change in Letter Number Sequencing|Change in Iowa Gambling Task|Change in Youth Risk Behavior Survey|Change in Alcohol/Marijuana Effect Expectancies Henry Ford Health System|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) All 12 Years and older   (Child, Adult, Older Adult) Not Applicable 60 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 15549-31|R34DA056732-01 June 26, 2023 September 10, 2023 September 10, 2023 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879198 835 NCT05879185 A Study of XmAb23104 in People With Sarcoma Recruiting No Results Available Sarcoma Biological: XmAb23104 best objective response rate Memorial Sloan Kettering Cancer Center|Xencor, Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 30 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 22-195 April 6, 2023 April 6, 2028 April 6, 2028 May 30, 2023 May 30, 2023 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States https://ClinicalTrials.gov/show/NCT05879185 836 NCT05879172 Electric Tubular Anastomosis in Rectal Cancer Completed No Results Available Anastomosis|Rectal Cancer Device: electric tubular anastomotic device|Device: traditional anastomotic device success rate of anastomosis|time period of anastomosis|time period of recovery LI XIN-XIANG|Fudan University All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 400 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment FDCRC71-LXX July 1, 2021 July 31, 2022 March 31, 2023 May 30, 2023 May 30, 2023 Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05879172 837 NCT05879159 Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection Not yet recruiting No Results Available Liver Behavioral: Questionnaires Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 M.D. Anderson Cancer Center|Intuitive Surgical Inc All 18 Years and older   (Adult, Older Adult) Not Applicable 36 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 2022-0917|NCI-2023-04169 October 30, 2023 February 1, 2025 February 1, 2027 May 30, 2023 May 31, 2023 M D Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05879159 838 NCT05879146 Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study Not yet recruiting No Results Available Tumor Drug: Nirogacestat Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 M.D. Anderson Cancer Center|SpringWorks Therapeutics, Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 40 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022-0610|NCI-2023-04177 October 30, 2023 January 31, 2027 January 31, 2028 May 30, 2023 May 30, 2023 M D Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05879146 839 NCT05879133 HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia Recruiting No Results Available Chronic Lymphocytic Leukemia Behavioral: Questionnaires|Other: Fit Bit Functional Assessment of Cancer Therapy (FACT) questionnaires. M.D. Anderson Cancer Center|CLL Global Research Foundation All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 2022-0411|NCI-2023-04161 May 17, 2023 July 3, 2025 July 3, 2025 May 30, 2023 May 30, 2023 M D Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05879133 840 NCT05879120 Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma Not yet recruiting No Results Available Recurrent Glioblastoma Drug: Pembrolizumab|Device: Exablate MRgFUS + neoadjuvant pembolizumab Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 M.D. Anderson Cancer Center|InSightec|Merck Sharp & Dohme LLC All 18 Years and older   (Adult, Older Adult) Phase 2 10 Other|Industry Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2021-0812|NCI-2023-04164 July 30, 2023 July 19, 2024 July 19, 2026 May 30, 2023 May 30, 2023 M D Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05879120 841 NCT05879107 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults Not yet recruiting No Results Available Respiratory Syncytial Virus Infections Biological: RSVPreF3 OA investigational vaccine|Biological: PCV20 Opsonophagocytic (OP) antibody (Ab) titers for each of the pneumococcal vaccine serotype (ST)|RSV-A neutralizing Ab titers|RSV-B neutralizing Ab titers|RSV-A neutralizing Ab titers expressed as mean geometric increase (MGI) over baseline at 1 month after the RSVPreF3 OA investigational vaccine dose|RSV-B neutralizing Ab titers expressed as MGI over baseline at 1 month after the RSVPreF3 OA investigational vaccine dose|Percentage of participants reporting each solicited administration site adverse event (AE)|Percentage of participants reporting each solicited systemic AE|Percentage of participants reporting unsolicited AE|Percentage of participants reporting serious adverse events (SAEs) after vaccine administration|Percentage of participants reporting potential immune mediated diseased (pIMDs) GlaxoSmithKline All 60 Years and older   (Adult, Older Adult) Phase 3 1090 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 219276|2022-501988-40-00 May 29, 2023 January 15, 2024 June 27, 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879107 842 NCT05879094 Orthopaedic Simulation of Morton's Extension to Test the Effect on Plantar Pressures of Each Metatarsal Head in Patients Without Deformity: A Pre-post-test Study. Completed No Results Available Healthy Subjects Other: Morton extension Before Morton Extension Medium pressure|Before Morton Extension Maximum pressure|After Morton Extension Medium pressure|After Morton Extension Maximum pressure Mayuben Private Clinic All 18 Years to 60 Years   (Adult) Not Applicable 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 20/235-E May 29, 2023 May 31, 2023 June 2, 2023 May 30, 2023 June 5, 2023 Eva María Martínez-Jimenez, Madrid, Spain https://ClinicalTrials.gov/show/NCT05879094 843 NCT05879081 [Trial of device that is not approved or cleared by the U.S. FDA] Withheld No Results Available [Redacted] KOEI0003 May 30, 2023 June 1, 2023 https://ClinicalTrials.gov/show/NCT05879081 844 NCT05879068 A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC Recruiting No Results Available SCLC Drug: PM8002|Drug: Paclitaxel Objective Response Rate|Treatment related adverse events (TRAEs)|Disease control rate (DCR)|Duration of response (DoR)|Progression free survival (PFS)|Overall survival (OS) Biotheus Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 99 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment PM8002-B002C-SCLC-R May 27, 2022 April 30, 2024 April 30, 2026 May 30, 2023 May 30, 2023 Jilin Provincial Tumor Hospital, Changchun, China https://ClinicalTrials.gov/show/NCT05879068 845 NCT05879055 A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN Recruiting No Results Available Neuroendocrine Neoplasm Drug: PM8002|Drug: FOLFIRI Objective Response Rate|Treatment related adverse events (TRAEs)|Disease control rate (DCR)|Duration of response (DoR)|Progression free survival (PFS)|Overall survival (OS) Biotheus Inc. All 18 Years and older   (Adult, Older Adult) Phase 2 60 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment PM8002-B009C-NEN-R May 17, 2023 January 1, 2027 January 1, 2028 May 30, 2023 May 30, 2023 Chinese PLA General Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05879055 846 NCT05879042 Effects of Stretching Types on Gastrocnemius Recruiting No Results Available Stretch Other: Static Stretching|Other: Dynamic Stretching|Other: PNF Stretching|Other: Sham stretching Muscle Tone and Stiffness|Forward Jumping Test on One Leg|Joint Range of Motion:|Isolated Gastrocnemius Shortness Evaluation Kubra Koce|Istinye University All 18 Years to 45 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 22-143 May 30, 2023 June 30, 2023 July 15, 2023 May 30, 2023 May 30, 2023 Istinye University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05879042 847 NCT05879029 Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD Not yet recruiting No Results Available Laryngopharyngeal Reflux Drug: Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Drug: Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets. total effective rate|RFS(reflux finding score) Tongji Hospital|Xi'an Beilin Pharmaceutical Co. Ltd All 18 Years to 65 Years   (Adult, Older Adult) Phase 4 72 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment TJ-IRB20230353 June 2023 December 2024 December 2024 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05879029 848 NCT05879016 Different Taping Methods in Myofascial Pain Syndrome Recruiting No Results Available Myofascial Pain Syndrome|Trigger Point Pain, Myofascial Other: Functional Correction Technique|Other: Fascia Correction Technique|Other: Star Taping Technique|Other: Sham Comparator Visual Analogue Scale|Muscle Strength|Joint Range of Motion|Hand Grip Strength|Pressure Pain Threshold|Number of Active Trigger Points|Nottingham Health Profile|Neck Disability Index Kubra Koce|Istinye University All 18 Years to 30 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment 21-38 May 30, 2023 June 30, 2023 July 15, 2023 May 30, 2023 June 1, 2023 Istinye University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05879016 849 NCT05879003 Neuromuscular Electrical Stimulation on Humeral Adductors in Subjects With Rotator Cuff Tear: an Observational Study Recruiting No Results Available Rotator Cuff Tears Behavioral: neuromuscular electrical stimulation acromiohumeral distance|scapular kinematics National Taiwan University Hospital All 20 Years to 65 Years   (Adult, Older Adult) 60 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional 202012082RINB May 15, 2023 July 2023 July 2023 May 30, 2023 May 30, 2023 School of Physical Therapy, National Taiwan University, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05879003 850 NCT05878990 Quit & Fit 2.0: Feasibility and Usability Testing Recruiting No Results Available Smoking Cessation Behavioral: Culturally-tailored Tobacco Treatment|Behavioral: Culturally-tailored Content Newsletters|Behavioral: Control Preference Scale|Behavioral: Active Content Newsletter or Passive Content Newsletter Feasibility of the 6-week tobacco treatment intervention|Accessibility and Satisfaction of the 6-week tobacco treatment intervention|Effectiveness of the intervention Hackensack Meridian Health Female 18 Years to 69 Years   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care Pro2022-0894 April 25, 2023 May 24, 2024 May 24, 2024 May 30, 2023 May 30, 2023 Hackensack Meridian Health - Center for Discovery and Innovation, Nutley, New Jersey, United States https://ClinicalTrials.gov/show/NCT05878990 851 NCT05878977 Biomarkers in Immunotherapy of Melanoma Recruiting No Results Available Metastatic Melanoma|Immune Checkpoints Inhibitors|Gastrointestinal Microbiome (Bacterial and Viral)|Exosomal mRNA Expression of PD-L1 and IFNγ Drug: Immune checkpoint inhibitor response prediction in first line immune checkpoint inhibitors treatment in metastatic melanoma assessed by human gastrointestinal microbiome (bacterial and viral) and exosomal mRNA expression of PD-L1 and IFNγ Institute of Oncology Ljubljana|University of Ljubljana|Military Medical Academy, Belgrade, Serbia All 18 Years and older   (Adult, Older Adult) Not Applicable 150 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ERIDNPVO-0034/2021 October 5, 2022 December 31, 2026 December 31, 2027 May 30, 2023 May 30, 2023 Institute of Oncology Ljubljana, Ljubljana, Slovenia https://ClinicalTrials.gov/show/NCT05878977 852 NCT05878964 Evaluation of Skin Health and Quality of Life in Patients Receiving Anti-PD1/PDL1/CTLA4 or Cyclin-dependent Kinase (CDK) Inhibitors. SkinHealthOnco Not yet recruiting No Results Available Lung Cancer|Breast Cancer|Kidney Cancer|Bladder Cancer|Gastric Cancer|Skin Cancer|Melanoma|Head Neck Cancer Other: EQ-5D-5L questionnaire|Other: FACT-G (Functional Assessment of Cancer Therapy - General)|Other: FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item) Quality of life in patients undergoing anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors.|Quality of life during therapy with anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors.|Role of gender|Role of therapy Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years and older   (Adult, Older Adult) 420 Other Observational Observational Model: Cohort|Time Perspective: Prospective 5455 May 22, 2023 May 22, 2024 September 22, 2024 May 30, 2023 May 30, 2023 Roberto Iacovelli, Roma, Italy https://ClinicalTrials.gov/show/NCT05878964 853 NCT05878951 Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms Recruiting No Results Available Urinary Incontinence|Overactive Bladder Syndrome|Overactive Bladder|Urologic Diseases Drug: OnabotulinumtoxinA Improve Overactive Bladder Symptoms (OAB) utilizing botox injections into the bladder.|Difference in safety/ adverse effects|Difference in patient REDCap surveys (gross hematuria dysuria, incontinence)|Difference in efficacy endpoints (3-month clinic/telephone follow-up) Northwestern University|University of Calgary|Ohio State University|University of Alberta Male 18 Years to 89 Years   (Adult, Older Adult) Phase 2|Phase 3 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment STU00218130 June 1, 2023 June 1, 2024 August 24, 2024 May 30, 2023 May 30, 2023 Northwestern Medicine, Chicago, Illinois, United States https://ClinicalTrials.gov/show/NCT05878951 854 NCT05878938 A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) FRONTIER 5 Not yet recruiting No Results Available Haemophilia A|Haemophilia A With Inhibitors Drug: NNC0365-3769 (Mim8) PPX Number of treatment-emergent adverse events|Device handling experience using the Hemophilia Device Handling and Preference Assessment (HDHPA) questionnaire|Change in participants' treatment burden using the Hemophilia treatment experience measure (Hemo-TEM) total score Novo Nordisk A/S All 12 Years and older   (Child, Adult, Older Adult) Phase 3 48 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NN7769-4728|U1111-1281-9323|2022-003053-66 June 26, 2023 September 9, 2024 February 24, 2025 May 30, 2023 May 30, 2023 Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, East Lansing, Michigan, United States|Novo Nordisk Investigational Site, Mount Pleasant, Michigan, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Bron Cedex, France|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Nara, Japan|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Parktown, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom https://ClinicalTrials.gov/show/NCT05878938 855 NCT05878925 Nasal Olfactory Stimulation and Its Effect on Respiratory Drive in Preterm Infants NOSE Not yet recruiting No Results Available Apnea of Prematurity|Prematurity|Infant, Premature, Diseases Other: Aroma|Other: Placebo Paired difference in the combined number of desaturations and bradycardia|Paired difference in fraction of inspired oxygen (FiO2)|Paired difference in mean peripheral oxygen saturation|Paired difference in time spent with peripheral oxygen saturations <80%|Paired difference in time spent with heart rate <80 bpm|Paired difference in mean respiratory rate (as counted by nurses and manually) documented according to clinical routine) and heart rate|Paired difference in the apnea score documented by nurses|Paired difference in desaturations requiring stimulation or increase in FiO2|Paired difference in tolerance of enteral nutrition as assessed by gastric residuals (the amount of stomach liquid detected prior to the next meal, in mL) University of Zurich|Bangerter-Rhyner Foundation All 72 Hours and older   (Child, Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment NOSE-Trial June 5, 2023 May 1, 2025 May 1, 2025 May 30, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05878925 856 NCT05878912 The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction OWL-HFPEF Recruiting No Results Available Heart Failure With Preserved Ejection Fraction|Obesity Other: Diet intervention Left atrial volume|Body weight|Exercise capacity|Left ventricular mass|N-terminal pro brain natriuretic peptide (NTproBNP) University of Oxford|British Heart Foundation All 18 Years to 85 Years   (Adult, Older Adult) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 161729 (C)|15/SC/0004|FS/CRTF/22/24293 January 20, 2023 October 2025 December 2026 May 30, 2023 May 30, 2023 Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford, United Kingdom https://ClinicalTrials.gov/show/NCT05878912 857 NCT05878899 Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial PP-HEP Completed No Results Available Venous Thromboembolism Drug: Enoxaparin Recruitement rate|Study participation|Venous thromboembolism|Bleeding|Surgical site complication|Heparin-induced thrombocytopenia|Septic pelvic thrombophlebitis|All-cause mortality|Satisfaction with study intervention University Hospital, Geneva Female 18 Years and older   (Adult, Older Adult) Phase 3 77 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention UGeneva 2021-02350 May 3, 2022 March 13, 2023 March 13, 2023 May 26, 2023 May 26, 2023 Geneva University Hospitals, Geneve, Switzerland https://ClinicalTrials.gov/show/NCT05878899 858 NCT05878886 Mangrove-sword Bean-food Bar on the Weight and Weight for Age Z Score of Under-five Children MFB Completed No Results Available Nutrition Poor Dietary Supplement: Emergency Food Product Effect of mangrove-sword bean-food bar on the weight and Weight-for-Age Z score (WAZ) of under-five children affected by landslide disaster|Change of mothers' balanced nutrition knowledge Indonesia University All 12 Months to 49 Months   (Child) Not Applicable 34 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention Universitas Indonesia (UI)|PUTI Q1 Grants 2023 August 1, 2022 August 15, 2022 October 30, 2022 May 26, 2023 May 31, 2023 Cihanjuang Village, Sumedang, West Java, Indonesia https://ClinicalTrials.gov/show/NCT05878886 859 NCT05878873 The Neural Mechanisms of Split-belt Treadmill Adaptation in People With Multiple Sclerosis Not yet recruiting No Results Available Multiple Sclerosis Behavioral: Split-belt Treadmill|Device: Transcutaneous Electrical Nerve Stimulation (TENS) Change in Cortical Hemodynamics|Change in Step Length Asymmetry|Change in Phase Coordination Index|Change in Limb Excursion Asymmetry|Change in Double Support Percent Colorado State University|National Multiple Sclerosis Society All 18 Years to 86 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 1664 September 2023 December 2024 August 2025 May 26, 2023 May 26, 2023 The Sensorimotor Neuroimaging Laboratory, Fort Collins, Colorado, United States https://ClinicalTrials.gov/show/NCT05878873 860 NCT05878860 ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis LIGHTHOUSE Not yet recruiting No Results Available X-linked Retinoschisis Biological: ATSN-201 Safety and tolerability as assessed by dose-limiting toxicities and treatment-emergent adverse events|Visual acuity as assessed by best-corrected visual acuity|Visual acuity as assessed by low-luminance visual acuity|Visual function as assessed by contrast sensitivity|Visual function as assessed by full-field electroretinogram parameters|Visual function as assessed by microperimetry|Visual function as assessed by static perimetry|Macular structure as assessed by spectral domain optical coherence tomography|Macular structure as assessed by fundus autofluorescence|Subject-reported visual function as assessed by the NEI VFQ-25 in adult subjects|Subject-reported visual function as assessed by the CVAQC in pediatric subjects Atsena Therapeutics Inc. Male 6 Years to 64 Years   (Child, Adult) Phase 1|Phase 2 18 Industry Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ATSN-201-1 July 2023 October 2025 October 2029 May 26, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05878860 861 NCT05878847 Oral Supplement in Older Adults to Support Physical Fitness and Mental Well-being PQQA Recruiting No Results Available Osteo-arthritis Dietary Supplement: Q-actin|Dietary Supplement: Placebo Physical strength|Finger dexterity measurements|EuroQol 5 Dimension 5L (combined score)|Diet choices|Record sleeping habits Aberystwyth University|Phytoquest Ltd|Gateway Health Alliances, Inc|Welsh Government All 50 Years and older   (Adult, Older Adult) Phase 1 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care 23767|PQQA April 22, 2023 December 22, 2023 December 22, 2023 May 26, 2023 May 26, 2023 Well-being and Health Assessment Research Unit (WARU), Aberystwyth, Ceredigion, United Kingdom "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/47/NCT05878847/Prot_000.pdf https://ClinicalTrials.gov/show/NCT05878847 862 NCT05878834 Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients Not yet recruiting No Results Available Chronic Obstructive Pulmonary Disease Patients Dietary Supplement: Beta-glucan supplement group|Dietary Supplement: Placebo group Forced expiratory volume in 1 second/Forced vital capacity|Modified Medical Research Council Dyspnea Score|Breathlessness, Cough, and Sputum Scale|6-minute walk test|Chronic obstructive pulmonary disease assessment test|Tumor necrosis factor alpha|Interleukin-6|C-reactive protein|Aspartate transaminase|Alanine transaminase|Alkaline phosphatase|Creatinine|Blood urea nitrogen Chulalongkorn University All 18 Years and older   (Adult, Older Adult) Not Applicable 72 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care Oh87/65 May 25, 2023 November 30, 2023 December 20, 2023 May 26, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05878834 863 NCT05878821 Effect of Shockwave Therapy on Cervical Myofascial Syndrome in Lactating Women Recruiting No Results Available Cervical Myofascial Pain Syndrome Device: Shockwave Visual analogue scale|Pressure Algometer Cairo University Female 25 Years to 35 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment P.T.REC/012/1004409 May 2023 June 2023 July 2023 May 26, 2023 May 26, 2023 Faculty of physical therapy, Giza, Egypt https://ClinicalTrials.gov/show/NCT05878821 864 NCT05878808 Obsessions and Suicidality in Youth With Bipolar 1 Disorder Completed No Results Available Obsessions|Suicide|Bipolar I Disorder|Obsessive-Compulsive Disorder Diagnostic Test: Psychometric assessment Association of OCD with bipolar I disorder Cairo University All 15 Years to 24 Years   (Child, Adult) 80 Other Observational Observational Model: Case-Control|Time Perspective: Cross-Sectional MS-545- 2021 February 1, 2022 September 15, 2022 January 5, 2023 May 26, 2023 May 26, 2023 Cairo University, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05878808 865 NCT05878795 Written Exposure Therapy for Suicide Prevention Not yet recruiting No Results Available Suicide, Attempted|Suicide Threat Behavioral: WET-SP|Behavioral: TAU Change in Suicidal ideation (SI)|SI at 20 weeks|SI at 30 weeks|Most severe SI Boston University|United States Department of Defense|The University of Texas Health Science Center at San Antonio|School of Medicine, Anschutz Medical Campus, Colorado University All 18 Years and older   (Adult, Older Adult) Not Applicable 160 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention H-43849|W81XWH-22-1-1059 July 2023 June 2024 June 2024 May 26, 2023 May 30, 2023 University of Texas Health Center San Antonio, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT05878795 866 NCT05878782 the Impact of Occupational Therapy : a Multicenter Randomized Controlled Trial OCEAN-OT Not yet recruiting No Results Available Elderly Patient|Cancer|Quality of Life Other: MCRO+Occupational therapy|Other: MCRO without intervention Quality of life (QLQ-C30 questionnaire) Assistance Publique - Hôpitaux de Paris All 70 Years and older   (Older Adult) Not Applicable 232 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research APHP230405 September 1, 2023 May 1, 2026 May 1, 2026 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878782 867 NCT05878769 A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Not yet recruiting No Results Available Chronic Obstructive Pulmonary Disease Drug: Astegolimab Incidence of all adverse events (AEs) Hoffmann-La Roche All 40 Years to 90 Years   (Adult, Older Adult) Phase 3 2000 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GB43374 June 7, 2023 June 30, 2027 June 30, 2027 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878769 868 NCT05878756 Effects of Additional Functional Strength Training on Mobility in Children With Hemiplegic Cerebral Palsy Completed No Results Available Hemiplegic Cerebral Palsy|Mobility Other: Functional Strength Training Gross Motor Function Measure (GMFM)|Gross Motor Function Classification System (GMFCS)|Five time sit to stand (FTSST). Health Education Research Foundation (HERF) All 4 Years to 12 Years   (Child) Not Applicable 32 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment YIRS/1666 January 1, 2020 October 1, 2020 December 1, 2020 May 26, 2023 May 30, 2023 Yusra Institute of Rehablitation Science, Islamabad, Pakistan https://ClinicalTrials.gov/show/NCT05878756 869 NCT05878743 A Qualitative Mixed Methods Realist Evaluation of Safety Planning Not yet recruiting No Results Available Risk Behavior, Health Behavioral: Safety Planning a recovery-orientated mental health risk management intervention Formal theory described which explains how, why, for whom and in what circumstances safety planning works. King's College London All 16 Years and older   (Child, Adult, Older Adult) 30 Other Observational Observational Model: Case-Only|Time Perspective: Retrospective 293012 April 1, 2024 April 30, 2026 May 16, 2027 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878743 870 NCT05878730 Melatonin and Response to Lithium MeLiR Not yet recruiting No Results Available Bipolar Disorder I Diagnostic Test: urine collection|Diagnostic Test: Level of Protein 14.3.3|Diagnostic Test: Level of miR-451 Ratio between 6-sulfatoxy-melatonin (6-SMT) concentration and creatinin concentration on a 12-hours nocturnal urine collection|Level of Protein 14.3.3|Level of miR-451|Level of plasmatic lithium|Level of intraerythrocytic lithium Assistance Publique - Hôpitaux de Paris All 18 Years to 60 Years   (Adult) 60 Other Observational Observational Model: Case-Control|Time Perspective: Prospective APHP221168|2022-A02550-43 July 2023 July 2025 July 2025 May 26, 2023 May 26, 2023 Hôpital Fernand-Widal, Paris, Ile De France, France https://ClinicalTrials.gov/show/NCT05878730 871 NCT05878717 A Study of the Efficiency And Safety Study of Belimumab Compared To Placebo In Adults With Systemic Sclerosis Associated Interstitial Lung Disease BLISSc-ILD Not yet recruiting No Results Available Systemic Sclerosis Associated Interstitial Lung Disease Biological: Belimumab|Other: Placebo Absolute change from baseline in Forced Vital Capacity (FVC) millilitre (mL) at Week 52|Absolute change from baseline in modified Rodnan Skin Score (mRSS) at Week 52|Absolute change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score at Week 52|Time to Systemic sclerosis (SSc) progression or death|Absolute change from baseline in FVC percentage (%) predicted at Week 52|Relative decline from baseline in FVC (mL) greater than or equal to (≥)5% at Week 52|Relative decline from baseline in FVC (mL) ≥10% at Week 52|Absolute change from baseline in mRSS at Week 26|Proportion of participants achieving ≥20% increase in mRSS at Week 26 & 52|Absolute change from baseline in Quantitative interstitial lung disease - whole lung (QILD-WL) at Week 52|Absolute change from baseline in Quantitative lung fibrosis - whole lung (QLF-WL) at Week 52|Proportion of participants achieving ≥2% increase in QILD at Week 52|Absolute change from baseline in Carbon monoxide diffusing capacity (DLco) % predicted at Week 52|Relative decline from baseline in DLco % predicted ≥15% at Week 52|Absolute change from baseline in Cough Numeric Rating Scale (NRS) at Week 52|Absolute change from baseline in Scleroderma Skin Patient-Reported Outcome (SSPRO) at Week 52|Absolute change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52|Absolute change from baseline in Short Form-36 Health Survey Questionnaire (SF-36) at Week 52|Absolute change from baseline in Patient Global Assessment of SSc Disease Activity (PtGA) at Week 52.|Absolute change from baseline in Physician global assessment (PhGA) at Week 52|Absolute change from baseline in Transition Dyspnea Index (TDI) at Week 52|Number of participants with Adverse Events (AEs), Adverse Events of special interest (AESIs) and Serious AEs (SAEs) up to Week 52 GlaxoSmithKline All 18 Years and older   (Adult, Older Adult) Phase 2|Phase 3 300 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 218224|EU CT Number|2023-503219-14-00 May 17, 2023 October 28, 2026 February 3, 2027 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878717 872 NCT05878704 Study of GBT021601 in Participants With Renal Impairment Not yet recruiting No Results Available Renal Impairment Drug: GBT021601 Concentration of GBT021601 in whole blood and plasma|Single-dose PK parameters|Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs Global Blood Therapeutics|Pfizer All 18 Years to 99 Years   (Adult, Older Adult) Phase 1 56 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GBT021601-014|C5351007 June 15, 2023 May 28, 2024 July 15, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878704 873 NCT05878691 A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. Recruiting No Results Available Advanced Solid Tumor|Lymphoma Drug: GRC 54276|Drug: GRC 54276 + Pembrolizumab|Drug: GRC 54276 + Atezolizumab Dose limiting toxicities to establish the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D)|Incidence of treatment-emergent adverse events and serious adverse events|Changes in the laboratory safety values from baseline to end of safety follow-up|Pharmacokinetic profile of GRC54276- Maximum plasma concentration (Cmax)|Pharmacokinetic profile of GRC54276- Time to Cmax (Tmax)|Pharmacokinetic profile of GRC54276- Area under the curve (AUC)|Objective response rate (ORR)|Best overall response rate|Disease control rate|Duration of response Glenmark Specialty S.A. All 18 Years and older   (Adult, Older Adult) Phase 1 320 Industry Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GRC 54276-101|CTRI/2022/05/042484 June 28, 2022 July 30, 2027 July 30, 2027 May 26, 2023 May 30, 2023 Froedtert & Medical College of Wisconsin - Froedtert Hospital - Clinical Cancer Center, Milwaukee, Wisconsin, United States|Artemis Hospital, Gurgaon, Haryana, India|Health Care Global Enterprises Ltd (HCG), Bangalore, Karnataka, India|Vydehi Hospital, Bangalore, Karnataka, India|Malabar Cancer Centre, Kannur, Kerala, India|Krupamayi Hospitals, Aurangabad, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Sankalp Hospital, Nashik, Maharashtra, India https://ClinicalTrials.gov/show/NCT05878691 874 NCT05878678 Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position Recruiting No Results Available Breast Cancer Device: Fixed positions of arm down and arm up The accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different immobilization position|Acute toxicities|Late toxicities|Tumor local control rate|Overall survival rate|Progression free survival rate Shanghai Proton and Heavy Ion Center Female 18 Years to 80 Years   (Adult, Older Adult) Phase 2 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SPHIC-TR-Bca2022-03 May 15, 2023 May 30, 2024 July 30, 2024 May 26, 2023 May 26, 2023 Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05878678 875 NCT05878665 Low-dose Contrast Media for Low-kVp Abdomen CT Not yet recruiting No Results Available Appendicitis Acute Diagnostic Test: Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT Diagnostic accuracy for acute appendicitis Seoul St. Mary's Hospital|GE Healthcare All 19 Years to 44 Years   (Adult) Not Applicable 292 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic DLD-001 June 15, 2023 April 15, 2024 December 31, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878665 876 NCT05878652 Playmaker 3D Printed Knee Extender Recruiting No Results Available ACL|ACL Injury Device: 3D printed knee extender device|Other: Standard Prehabilitation Education Knee Extension Range of Motion|Time to Achieve Full Knee Extension|Knee Swelling|Average Daily Pain Level|Water Bottles Used with Knee Sling|Minutes Spent Using Knee Sling Sanford Health All 14 Years to 60 Years   (Child, Adult) Not Applicable 36 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Playmaker June 15, 2022 December 31, 2023 December 31, 2024 May 26, 2023 May 26, 2023 Sanford Orthopedics and Sports Medicine, Fargo, North Dakota, United States|Sanford Orthopedics and Sports Medicine, Sioux Falls, South Dakota, United States https://ClinicalTrials.gov/show/NCT05878652 877 NCT05878639 Efficacy and Safety of Lactulose for Bowel Preparation in Patients With Inflammatory Bowel Disease Recruiting No Results Available IBD Drug: 3 bottles of Lactulose oral solution|Drug: 3L-polyethylene glycol effective preparation rate|incidence of adverse events|taste score evaluated by patients|effects of bowel preparation drugs on liver function|effects of bowel preparation drugs on serum electrolyte Second Affiliated Hospital of Wenzhou Medical University All 16 Years to 75 Years   (Child, Adult, Older Adult) Not Applicable 140 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment SAHoWMU-CR2023-01-104 March 28, 2023 May 20, 2023 June 20, 2023 May 26, 2023 May 26, 2023 The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05878639 878 NCT05878626 Anodal Transcranial Direct Current Stimulation on Strength in Subacute Stroke Not yet recruiting No Results Available Stroke Other: Transcranial Direct Current Stimulation Manual muscle testing|Berg Balance Scale Riphah International University All 45 Years to 60 Years   (Adult) Not Applicable 73 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment REC01355 Hamad May 2023 November 2023 December 2023 May 26, 2023 May 26, 2023 Rafsan Rehabilitation Center, Peshawar, KPK, Pakistan https://ClinicalTrials.gov/show/NCT05878626 879 NCT05878613 Treadmill Training With Kinesiotaping Affects Balance and Gait in Chronic Stroke Patients Recruiting No Results Available Stroke Device: treadmill training with KT group (TTKT group)|Device: treadmill training without KT group (TT group) Berg Balance Scale (BBS):|Dynamic gait index(DGI): Riphah International University All 30 Years to 50 Years   (Adult) Not Applicable 22 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment REC/RCR & AHS/23/0206 April 1, 2023 July 30, 2023 August 30, 2023 May 26, 2023 May 26, 2023 Pakistan society of rehabilitation for disabled (PSRD), Lahore, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05878613 880 NCT05878600 Cervical Spine Strengthening Exercises Versus Kendall Exercises in Patients With Forward Head Posture. Recruiting No Results Available Forward Head Posture Other: kendall's exercise|Other: cervical spine strengthening Change in NPRS|Range of motion Riphah International University All 20 Years to 40 Years   (Adult) Not Applicable 38 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment REC/RCR & AHS/23/0120 November 16, 2022 July 16, 2023 August 16, 2023 May 26, 2023 May 26, 2023 The Bank of Punjab, Lahore, Lahore, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05878600 881 NCT05878587 Burger Allen Exercises in Knee OA With Type II Diabetes Recruiting No Results Available Knee Osteoarthritis|Type II Diabetes Other: thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Other: thermotherapy+ TENS+ low intensity high repetition exercises KOOS|Numeric Pain Rating Scale|Ankle Brachial Index Riphah International University All 45 Years to 65 Years   (Adult, Older Adult) Not Applicable 36 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment REC/23/0109/Ayesha iftikhar March 31, 2023 August 1, 2023 August 7, 2023 May 26, 2023 May 26, 2023 Tehsil headquarter hospital, Barnala, Azad Kashmir, Pakistan https://ClinicalTrials.gov/show/NCT05878587 882 NCT05878574 Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control Recruiting No Results Available Recurrent Spontaneous Abortion Drug: Low molecular weight heparin ultrasound BMD before medication during pregnancy preparation|ultrasound BMD after medication during pregnancy preparation|ultrasound BMD at 10th weeks of pregnancy|ultrasound BMD at 24th weeks of pregnancy|ultrasound BMD at 32nd weeks of pregnancy|ultrasound BMD at postpartum|osteocalcin before medication during pregnancy preparation|osteocalcin after medication during pregnancy preparation|osteocalcin at 10th weeks of pregnancy|osteocalcin at 24th weeks of pregnancy|osteocalcin at 32nd weeks of pregnancy|osteocalcin at postpartum|calcium before medication during pregnancy preparation|calcium after medication during pregnancy preparation|calcium at 10th weeks of pregnancy|calcium at 24th weeks of pregnancy|calcium at 32nd weeks of pregnancy|calcium at postpartum|PTH before medication during pregnancy preparation|PTH after medication during pregnancy preparation|PTH at 10th weeks of pregnancy|PTH at 24th weeks of pregnancy|PTH at 32nd weeks of pregnancy|PTH at postpartum|live bitrh Aimin Zhao|RenJi Hospital Female 18 Years to 45 Years   (Adult) 344 Other Observational Observational Model: Cohort|Time Perspective: Prospective IIT-2023-0010 November 1, 2022 December 2023 March 2024 May 26, 2023 May 26, 2023 Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China https://ClinicalTrials.gov/show/NCT05878574 883 NCT05878561 A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy Recruiting No Results Available Essential Hypertension Drug: Fimasartan + Indapamide|Drug: Fimasartan + Indapamide placebo Sitting systolic blood pressure Boryung Pharmaceutical Co., Ltd All 19 Years and older   (Adult, Older Adult) Phase 3 244 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment BR-FIC-CT-301 November 9, 2022 October 2024 October 2024 May 26, 2023 May 26, 2023 The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon-si, Kyunggi-do, Korea, Republic of https://ClinicalTrials.gov/show/NCT05878561 884 NCT05878548 Management of Combined Fracture Neck of Femur and Femoral Deformity in Osteogenesis Imperfecta Patient OI Not yet recruiting No Results Available Osteogenesis Imperfecta Procedure: corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture modified McKay's criteria Assiut University All 2 Years to 14 Years   (Child) Not Applicable 1 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NOFOI June 1, 2023 April 1, 2024 April 1, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878548 885 NCT05878535 METFORMIN FOR ATRIAL FIBRILLATION MAFT Not yet recruiting No Results Available Atrial Fibrillation Drug: Metformin|Drug: Placebo Primary Endpoint|Secondary Endpoint Arab Contractors Medical Centre All 20 Years to 65 Years   (Adult, Older Adult) Phase 4 770 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment #18101829 June 1, 2023 January 2025 April 2025 May 26, 2023 May 30, 2023 Arab Contractors Medical Centre, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05878535 886 NCT05878522 A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants. Recruiting No Results Available Healthy Drug: sisunatovir|Drug: placebo|Drug: moxifloxacin Evaluate sisunatovir's effect on the QTc interval (msec) by assessing concentration-QT (C-QT) relationship using exposure-response modeling|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)|Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Time matched mean differences in QTc between moxifloxacin and placebo Pfizer All 18 Years to 65 Years   (Adult, Older Adult) Phase 1 42 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science C5241015 May 15, 2023 November 13, 2023 November 13, 2023 May 26, 2023 May 26, 2023 New Haven Clinical Research Unit, New Haven, Connecticut, United States https://ClinicalTrials.gov/show/NCT05878522 887 NCT05878509 Reliability and Validity of the Tampa Scale for Kinesiophobia Completed No Results Available Hand Injuries|Forearm Injuries|Trauma Other: conducting questionnaires|Other: assesment of the severity and pain Tampa Scale for Kinesiophobia (change)|Pain Catastrophizing Scale|Beck Anxiety Inventory|Modified Hand Injury Scoring System|Visual Analogue Scale Pamukkale University All 18 Years to 65 Years   (Adult, Older Adult) 170 Other Observational Observational Model: Cohort|Time Perspective: Prospective 60116787-020/81396 November 29, 2018 March 1, 2020 March 1, 2023 May 26, 2023 May 26, 2023 Pamukkale University, Denizli, Kınıklı, Turkey https://ClinicalTrials.gov/show/NCT05878509 888 NCT05878496 Short Term Outcome of Pediatric Fracture of Neck Femur Fixation by Plate and Screws Recruiting No Results Available Fracture of Pediatric Neck Femur Procedure: fixation by plate and screws avascular necrosis by degree of bone necrosis in head and neck femur|coxa vara degree by angle of shaft and head femur Sohag University All 1 Year to 16 Years   (Child) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment Soh-Med-23-04-22MS April 1, 2023 October 1, 2023 October 1, 2023 May 26, 2023 May 26, 2023 Sohag University Hospital, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05878496 889 NCT05878483 Autonomous Blood Drawing Optimization and Performance Testing ADOPT Not yet recruiting No Results Available Venipuncture|Phlebotomy Device: Venipuncture Device (VD) First-time venipuncture success rate|Rate of punctured participants|Rate of hemolyzed samples|Adverse Events Vitestro B.V. All 16 Years and older   (Child, Adult, Older Adult) Not Applicable 13618 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other NL80965.000.22 July 2023 July 2025 July 2025 May 26, 2023 May 26, 2023 OLVG Lab, Amsterdam, Noord-Holland, Netherlands|Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands|St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands|Result Laboratorium, location Albert Schweitzer Hospital, Dordrecht, Zuid-Holland, Netherlands|Vitestro, Utrecht, Netherlands https://ClinicalTrials.gov/show/NCT05878483 890 NCT05878470 Reducing Self-stigma Using Brief Video Intervention Completed No Results Available Stigma, Social|Mental Health Disorder Behavioral: video Self-stigma New York State Psychiatric Institute All 18 Years to 35 Years   (Adult) Not Applicable 1214 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 8432 January 25, 2023 March 7, 2023 March 7, 2023 May 26, 2023 May 26, 2023 New York State Psychiatric Institute, New York, New York, United States https://ClinicalTrials.gov/show/NCT05878470 891 NCT05878457 Accelerated rTMS for Post-Stroke Apathy Not yet recruiting No Results Available Apathy|Stroke Sequelae|Stroke (CVA) or TIA|Stroke/Brain Attack|Motivation|Abulia Device: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System Change in apathy symptoms, as measured by the Lille Apathy Rating Scale (LARS)|Incidence of Treatment-Emergent Adverse Events and Side Effects as assessed by iTBS Review of Systems|Change in caregiver burden, as measured by the Zarit Burden Interview|Change in global cognition, as measured by the Montreal Cognitive Assessment (MoCA)|Change in quality of life, as measured by the Stroke Specific Quality of Life Scale (SS-QOL)|Change in apathy symptoms, as measured by the Apathy Evaluation Scale (AES) Medical University of South Carolina All 40 Years and older   (Adult, Older Adult) Phase 1 16 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility Pro00126436 June 15, 2023 May 30, 2024 May 30, 2024 May 26, 2023 May 26, 2023 Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina, United States https://ClinicalTrials.gov/show/NCT05878457 892 NCT05878444 Evaluation of the Colonization Capacity of a Probiotic Bacterium. BIOPRED Not yet recruiting No Results Available Obese|Weight, Body Dietary Supplement: Probiotic Presence of our bacteria in feces|Adverse effect Valencian Innovation Agency All 18 Years to 65 Years   (Adult, Older Adult) Phase 1 15 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment INNVA1/2021/32 June 1, 2023 September 30, 2023 January 31, 2024 May 26, 2023 May 26, 2023 Institute of Agrochemistry and Food Technology, Paterna, Valencia, Spain https://ClinicalTrials.gov/show/NCT05878444 893 NCT05878431 Foot Reflexology in Diabetic Patients With Neuropathic Pain Completed No Results Available Diabetes Mellitus|Patient Engagement|Reflexology Other: Foot Reflexology Vizüel Analog Scale (VAS)|Herth Hope Scale|Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL) Muş Alparlan University All 18 Years and older   (Adult, Older Adult) Not Applicable 102 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care Reflexology January 1, 2022 May 1, 2022 December 1, 2022 May 26, 2023 May 26, 2023 Mus State Hospital, Muş, Turkey https://ClinicalTrials.gov/show/NCT05878431 894 NCT05878418 The Effect of Spinal Orthosis on the Development of Scoliosis and Chest Deformity in Type I Spinal Muscular Atrophy Not yet recruiting No Results Available Spinal Muscular Atrophy Type I|Scoliosis|Chest Deformities|Spinal Orthosis|Pulmonary Rehabilitation Device: Thoracolumbosacral Spinal Orthosis (TLSO)|Other: Pulmonary Rehabilitation(PR) and Pulmonary Care (PC) Radiological Evaluation (Cobb Angle)|Basal Chest Wall Upper-Lower Ratio Measurement|Philadelphia Children's Hospital Infant Test of Neuromuscular Disorders (CHOP-INTEND)|Hammersmith Extended Functional Motor Scale (HFMSE)|World Health Organization Motor Development Scale (WHO Developmental Milestones)|Supine Trunk Rotation Angle Test|Pelvic Tilt Test|Quebec Assistive Technology User Satisfaction Assessment Questionnaire (QUEST) Medipol University All 0 Years to 7 Years   (Child) Not Applicable 22 Other Interventional Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment E-10840098-772.02-200 June 24, 2023 August 24, 2023 January 24, 2024 May 26, 2023 May 26, 2023 Istanbul Medipol University, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05878418 895 NCT05878405 Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer Recruiting No Results Available Hematopoietic and Lymphoid System Neoplasm|Malignant Solid Neoplasm|Stomatitis Other: Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Other: Methylene Blue Oral Rinse Change in oral pain|Change in the amount of oral intake|Change in the amount of daily requirements of oral morphine equivalents Mayo Clinic All 18 Years and older   (Adult, Older Adult) Phase 3 100 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 22-007588|NCI-2023-03542 June 2023 December 30, 2024 June 2025 May 26, 2023 June 2, 2023 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT05878405 896 NCT05878392 Immediate Implant With Different Filling Materials Completed No Results Available Immediate Implant Other: bone filling materials marginal bone loss|Implant Stability:|Peri-implant Pocket depth Mansoura University All 18 Years to 45 Years   (Adult) Not Applicable 36 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment A0103023OS January 1, 2022 June 1, 2022 January 1, 2023 May 26, 2023 May 26, 2023 Heba Elsheikh, Mansoura, Egypt, Egypt https://ClinicalTrials.gov/show/NCT05878392 897 NCT05878379 Effect of a Dietary Iron Program on Iron Status and IQ in Children in Phatthalung Province, Thailand Completed No Results Available Iron Deficiency, Anaemia in Children Behavioral: Dietary Iron Program Iron Status|Intelligence quotient (IQ) score Mahidol University All 9 Years to 11 Years   (Child) Not Applicable 34 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MUPH 2018-048 May 2, 2018 October 30, 2018 October 30, 2018 May 26, 2023 May 26, 2023 Ms Witchada Simla, Phattalung, Phattalung Province, Thailand https://ClinicalTrials.gov/show/NCT05878379 898 NCT05878366 Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) INDIE-SMC Not yet recruiting No Results Available Malaria|Malaria,Falciparum Other: Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Other: Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|Other: Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT Parasite prevalence by quantitative PCR (qPCR) at the end of the transmission season in age groups targeted by seasonal malaria chemoprevention.|Parasite prevalence by qPCR at the end of the transmission season in all age groups|Parasite prevalence by microscopy prior to SMC rounds 2, 3 and 4 in SMC-targeted age groups|Rate of re-infection with P. falciparum at weeks 3, 4 and 5 after the last round of SMC, assessed in SMC-targeted age groups|Gametocyte prevalence by qRT-PCR at weeks 3, 4 and 5 after the last round of SMC, assessed in SMC-targeted age groups|Gametocyte prevalence by qRT-PCR at the end of the transmission season in all age groups|Plasma levels of AQ and DESAQ after the 4th round of SMC in children aged 3 months-9 years London School of Hygiene and Tropical Medicine|Groupe de Recherche Action en Sante|Radboud University Medical Center All 3 Months and older   (Child, Adult, Older Adult) Not Applicable 2160 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other 29193|INV-053846 June 2023 February 2024 October 2024 May 26, 2023 May 26, 2023 Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso https://ClinicalTrials.gov/show/NCT05878366 899 NCT05878353 Influence of Local Doxycycline on the Outcomes of Periodontal Regeneration Recruiting No Results Available Periodontal Diseases Procedure: Decontamination of the pocket with local doxycycline|Procedure: Decontamination of the pocket with mechanical instrumentation Clinical attachment level change|Radiographic bone level change|Probing pocket depth change|Bleeding on probing reduction University of Turin, Italy All 18 Years and older   (Adult, Older Adult) Not Applicable 44 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment DoxyTurin March 1, 2023 June 1, 2023 June 1, 2024 May 26, 2023 May 26, 2023 CIR Dental School, Turin, Italy https://ClinicalTrials.gov/show/NCT05878353 900 NCT05878340 Miffy Eats the Rainbow Miffy Recruiting No Results Available Healthy Behavioral: Miffy|Behavioral: Reward Change in Willingness to try between Wageningen University All 3 Years to 7 Years   (Child) Not Applicable 210 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science Miffy Study October 1, 2022 May 31, 2023 May 31, 2023 May 26, 2023 May 26, 2023 Wageningen University and Research, Wageningen, Gelderland, Netherlands https://ClinicalTrials.gov/show/NCT05878340 901 NCT05878327 Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia Completed No Results Available Livedoid Vasculitis Other: Thrombophilia screening Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.|Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans University of Zurich All 10 Years to 85 Years   (Child, Adult, Older Adult) 15 Other Observational Observational Model: Cohort|Time Perspective: Retrospective KEK-ZH-Nr. 2013-0301 August 2013 June 2015 June 2015 May 26, 2023 May 26, 2023 University hospital of Basel, Basel, Switzerland|University hospital of Bern, Bern, Switzerland|University hospital Zurich, Zurich, Switzerland https://ClinicalTrials.gov/show/NCT05878327 902 NCT05878314 Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer Recruiting No Results Available Hormone Receptor Positive HER-2 Negative Breast Cancer Influence of the menstrual cycle on initial Ki67 in premenopausal women|Influence of preoperative anti-hormonal therapy, dynamics of the growth marker Ki67 (evaluation of positive cell nuclei by pathologist), and individual genetic risk (PAM50 gene test) on recommendations for adjuvant therapy. University Hospital Tuebingen|University Hospital Ulm|University Hospital Freiburg Female 18 Years and older   (Adult, Older Adult) 504 Other Observational Observational Model: Cohort|Time Perspective: Prospective BZ_PEAK April 25, 2023 April 2025 April 2035 May 26, 2023 June 5, 2023 Department of Women's Health, Tuebingen, Germany https://ClinicalTrials.gov/show/NCT05878314 903 NCT05878301 Postprandial Glucose, Insulin Response to Meal Sequence Among Healthy UAE Adults Not yet recruiting No Results Available Postprandial Hyperglycemia Other: vegetable and protein first followed by carbohydrates (VPF) meal sequence To compare the effects of meal sequences VPF meal vs. SMM on the incremental area under the curve of postprandial glucose response among healthy adults in the UAE.|To compare the effects of the VPF meal sequence vs. SMM sequence on the incremental area under the curve of postprandial insulin response.|To compare the postprandial hunger response of the VPF meal sequence vs SMM sequence on the area under the curve using a validated visual analog scale for hunger and fullness (VAS) University of Sharjah All 18 Years to 59 Years   (Adult) Not Applicable 18 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other REC-22-10-18-S May 29, 2023 July 17, 2023 July 28, 2023 May 26, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05878301 904 NCT05878288 Deep sequencIng in Cutaneous Squamous CEll caRciNomas DISCERN Not yet recruiting No Results Available Cutaneous Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Neoplasms|Non-melanoma Skin Cancer Drug: Cemiplimab Rate of successful execution and generation of data from single-cell RNA sequencing and genomic profiling (including whole exome sequencing, RNA sequencing and immunohistochemistry) of CSCC from patients treated with immunotherapy|To evaluate pathological response rates (cPR, mPR defined as <10% viable tumour, and other).|To evaluate ORR using computed tomography (CT) scan imaging assessed by RECIST 1.1|To evaluate ORR using computed tomography (CT) scan imaging assessed by imRECIST|To summarise immune-related adverse events (AE) > grade 2, AESI, AEs > grade 3 and SAEs, according to CTCAE v5.0.|To evaluate DFS rates.|To evaluate OS rates. Peter MacCallum Cancer Centre, Australia|University of Melbourne|University of Adelaide|Monash University|Regeneron Pharmaceuticals|Sanofi All 18 Years and older   (Adult, Older Adult) Phase 2 10 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other HREC/88736/PMCC-2022-326880 May 2023 May 2029 May 2029 May 26, 2023 May 26, 2023 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia https://ClinicalTrials.gov/show/NCT05878288 905 NCT05878275 Supporting Infant Development Not yet recruiting No Results Available Prone Position|Child Development Behavioral: Parent Informational Session Change in motor scale score on the Bailey Scales of Infant & Toddler Development|Change in fine motor scale score on the Ages & Stages Questionnaire-3 University of Tennessee All 1 Day to 4 Weeks   (Child) Not Applicable 50 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment 23-09209-XP June 1, 2023 December 31, 2027 December 31, 2028 May 26, 2023 June 2, 2023 University of Tennessee Health Science Center, Memphis, Tennessee, United States https://ClinicalTrials.gov/show/NCT05878275 906 NCT05878262 The Effect of Pre-emptive Analgesia on the Postoperative Pain in Children Undergoing Pediatric Stomatology Day Surgeries Completed No Results Available Ankyloglossia|Oral Mucoceles|Supernumerary Teeth Drug: ibuprofen suppository The VAS scores for postoperative 1 hour pain|The WBS scores for postoperative 1 hour pain|The FLACC scores for postoperative 1 hour pain|The PPPM scores for postoperative 1 hour pain|The VAS scores for postoperative 4 hours pain|The WBS scores for postoperative 4 hours pain|The FLACC scores for postoperative 4 hours pain|The PPPM scores for postoperative 4 hours pain|The VAS scores for postoperative 24 hours pain|The WBS scores for postoperative 24 hours pain|The FLACC scores for postoperative 24 hours pain|The PPPM scores for postoperative 24 hours pain The Children's Hospital of Zhejiang University School of Medicine All 3 Years to 8 Years   (Child) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention 2022-IRB-183 September 1, 2022 March 15, 2023 May 1, 2023 May 26, 2023 May 26, 2023 Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China https://ClinicalTrials.gov/show/NCT05878262 907 NCT05878249 Role Of Wound Lavage in Direct Pulp Capping Of Permanent Teeth With Carious Exposure Active, not recruiting No Results Available Reversible Pulpitis Procedure: wound lavage with normal saline|Procedure: wound lavage with sodium hypochlorite|Procedure: wound lavage with Ethylenediaminetetraacetic acid(EDTA)|Procedure: wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid clinical and radiographic success at 6 and 12 months.|To assess postoperative pain . Postgraduate Institute of Dental Sciences Rohtak All 18 Years to 50 Years   (Adult) Not Applicable 140 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment ANSHU SINGH November 1, 2022 May 31, 2023 May 31, 2024 May 26, 2023 May 26, 2023 PGIDS, Rohtak, Haryana, India https://ClinicalTrials.gov/show/NCT05878249 908 NCT05878236 iMmune SignAtures and Clinical outComes in AP MoSAIC Recruiting No Results Available Acute Pancreatitis Diagnostic Test: CyTOF Analysis Multi-Cytokine Panel Validation|Cytokine Signature Correlation|Circulating Immune Cells|Immune Pathways Ohio State University|University of Pittsburgh|University of Illinois at Chicago|University of Southern California|Benaroya Research Institute All 18 Years to 75 Years   (Adult, Older Adult) 198 Other Observational Observational Model: Cohort|Time Perspective: Prospective 2022H0394 March 6, 2023 December 31, 2026 December 31, 2027 May 26, 2023 May 26, 2023 University of Southern California, Los Angeles, California, United States|University of Illinois Chicago, Chicago, Illinois, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Benaroya Research Institute, Seattle, Washington, United States https://ClinicalTrials.gov/show/NCT05878236 909 NCT05878223 Comparison of Extracorporeal Shock Wave to Different Muscle Targets in Post-Stroke Spasticity of Ankle Plantar Flexor Recruiting No Results Available Stroke Device: Extracorporeal shock waves Change in Modified Ashworth Scale (MAS)|Change in modified Tardieu scale (mTS)|Change in Passive ROM of the ankle in dorsiflexion|Change in Level of mobility and balance|Ultrasound evaluations National Taiwan University Hospital Hsin-Chu Branch All 20 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 111-044-F January 1, 2023 December 31, 2023 December 31, 2024 May 26, 2023 May 26, 2023 National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan https://ClinicalTrials.gov/show/NCT05878223 910 NCT05878210 Evaluating the SUBLOCADE Treatment Exit Strategy Not yet recruiting No Results Available Opioid Use Disorder Rate of successful taper by the end of 6-month follow-up.|Key secondary - At each given month, for participants not restarting MOUD and not consistently using illicit/nonmedical opioid up to the start of that month:|Participants restarting MOUD (yes/no) during study follow-up|Participants who reported withdrawal symptoms (yes/no) during the past month|Participants who used ancillary medications to treat opioid withdrawal symptoms (yes/no) during the past month|Participants who used rescue MOUD (yes/no) to treat opioid withdrawal symptoms during the past month|Participants who had self-reported illicit/nonmedical opioid use (yes/no) during the past month Indivior Inc. All 18 Years and older   (Adult, Older Adult) 50 Industry Observational Observational Model: Cohort|Time Perspective: Prospective INDV-6000-407 June 2023 September 2024 September 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878210 911 NCT05878197 Effect of Semi-occluded Vocal Tract Therapy on the Phonation of Children With Vocal Fold Nodules Completed No Results Available Voice Disorders in Children|Vocal Nodules in Children|Hoarseness|Dysphonia Behavioral: Straw phonation|Behavioral: Resonant voice therapy|Behavioral: Vocal Hygiene Change in dysphonia severity index|Change in acoustic voice quality index|change in pediatric voice handicap index (pVHI)|Change in Grade of GRBASI-scale|Change in grading scale for pediatric vocal fold nodules University Hospital, Ghent All 6 Years to 12 Years   (Child) Not Applicable 28 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment B670201936069 July 29, 2019 April 3, 2023 April 3, 2023 May 26, 2023 May 26, 2023 Ghent University Hospital, Ghent, East-Flanders, Belgium https://ClinicalTrials.gov/show/NCT05878197 912 NCT05878184 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting No Results Available Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia Drug: SC291 Evaluate safety and tolerability of SC291|Evaluate preliminary anti-tumor activity of SC291|Evaluate cellular kinetics and persistence of SC291|Evaluate host immunogenicity to SC291 Sana Biotechnology All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 54 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SC291-101 May 2, 2023 December 2026 December 2027 May 26, 2023 June 1, 2023 University of Kansas Medical Center, Fairway, Kansas, United States|MD Anderson Cancer Center, Houston, Texas, United States https://ClinicalTrials.gov/show/NCT05878184 913 NCT05878171 Preference of Life-Sustaining Treatment Among Patients With End Stage Renal Disease Not yet recruiting No Results Available End Stage Renal Disease Preference for end-of-life life-sustaining treatment for patients with end-stage renal disease|The influencing factors of life-sustaining treatment preference in patients with end-stage renal disease National Taiwan University Hospital|National Taipei University of Nursing and Health Sciences All 20 Years and older   (Adult, Older Adult) 200 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional 202303044RINC May 31, 2023 April 30, 2024 April 30, 2024 May 26, 2023 May 26, 2023 National Taiwan University Hospital, Taipei, Taiwan|National Taipei University of Nursing and Health Sciences, Taipei, Taiwan https://ClinicalTrials.gov/show/NCT05878171 914 NCT05878158 Simvastatin Versus MTA in Pulpotomy of Immature Permanent Molars Recruiting No Results Available Pulp Exposure, Dental Drug: Simvastatin Presence or absence of pain|Dentin wall thickness Ahmad Elheeny|Minia University All 6 Years to 8 Years   (Child) Early Phase 1 128 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 300 April 1, 2023 January 1, 2024 September 1, 2024 May 26, 2023 May 26, 2023 Faculty of Dentistry, Minya, Egypt https://ClinicalTrials.gov/show/NCT05878158 915 NCT05878145 Study on Rehabilitation Exercise Program for Community-based Spinal Cord Injury Patients Not yet recruiting No Results Available Spinal Cord Injuries|Rehabilitation|Exercise Program Behavioral: Structured rehabilitation exercise program EuroQol 5 Dimension 5 Level|6 minute walk distance|Berg balance scale|Timed up and go test|Grip strength|Sit to stand test|Sit and reach test|Fat-free mass from bioelectrical impedance analysis Pusan National University Yangsan Hospital All 19 Years and older   (Adult, Older Adult) Not Applicable 115 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment SCI REHAB EXERCISE RCT June 1, 2023 October 30, 2023 December 31, 2023 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878145 916 NCT05878132 'Smart Reminder': a Feasibility Pilot Study on the Effects of a Wearable Device Treatment Completed No Results Available Stroke Device: Wearable device -'Smart Reminder'|Other: Conventional therapy Change from baseline Fugl Meyer Upper Extremity assessment|Change from preintervention at 7-week (after crossover) Fugl Meyer Upper Extremity assessment|Change from baseline Motor Activity Log (MAL)|Change from preintervention at 7-week (after crossover) Motor Activity Log (MAL)|Change from baseline Action Research Arm Test|Change from preintervention at 7-week (after crossover) Action Research Arm Test|Change from baseline Active range of motion (AROM) of shoulder and elbow|Change from preintervention at 7-week (after crossover) Active range of motion (AROM) of shoulder and elbow The Hong Kong Polytechnic University All 18 Years and older   (Adult, Older Adult) Not Applicable 12 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment HSEARS20220704001 August 24, 2022 December 30, 2022 December 30, 2022 May 26, 2023 May 26, 2023 Kenneth FONG, Hong Kong, Hong Kong https://ClinicalTrials.gov/show/NCT05878132 917 NCT05878119 Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program Not yet recruiting No Results Available Healthy Drug: Investigational Product - MIB 626|Drug: Placebo|Other: Standardized, progressive, high intensity, multidimensional exercise|Other: Usual Physical Activity Change in Aerobic capacity from baseline to week 11, identified as VO2 max measured during a standardized increasing work rate treadmill protocol|Change in endurance time from baseline to week 11, measured during a constant work rate test|Change from baseline to week 11 in anaerobic threshold during CPXT|Change in upper body muscle performance, assessed as change from baseline to week 10|Change in lower body muscle performance, assessed as change from baseline to week 10|Change over the 10 weeks in performance scores on sustained-attention, reaction-timed task|Change over 10 weeks in working memory and working memory capacity|Change over 10 weeks in selective attention, target identification and response|Change over 10 weeks in total sleep time|Change from baseline in insulin sensitivity|Changes from baseline in blood lipid profile|Change from baseline in sleep latency Metro International Biotech, LLC All 19 Years to 40 Years   (Adult) Phase 2 120 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment MIB-626-206 July 2023 April 2025 June 2025 May 26, 2023 June 5, 2023 https://ClinicalTrials.gov/show/NCT05878119 918 NCT05878106 Creatine Supplementation and Resistance Training in Patients With Breast Cancer CaRTiC Not yet recruiting No Results Available Breast Cancer|Supplementation|Resistance Training|Physical Performance|Quality of Life Dietary Supplement: Creatine supplementation|Other: Resistance training Change in maximal resistance (upper and lower body)|Genetic study|Change in Micro RNA (mRNA)|Change in Physical function (walking)|Change in Physical function (sitting)|Change in Body composition|Change in dietary pattern|Change in Gastrointestinal discomfort|Change in Quality of life (general)|Change in Quality of life (cancer specific)|Change in fatigue level University of Deusto|Hospital de Cruces|Hospital de Basurto|Poznan University of Medical Sciences|Hospital Universitario de Burgos|University of Americas|University of Calabria All 18 Years to 60 Years   (Adult) Not Applicable 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care CaRTiC January 8, 2024 April 20, 2025 December 8, 2025 May 26, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05878106 919 NCT05878093 Dupilumab in Chinese Adult Participants With CRSwNP Recruiting No Results Available Chronic Rhinosinusitis With Nasal Polyps Drug: Dupilumab|Drug: Placebo|Drug: Budesonide Change from baseline in nasal polyps score(NPS)|Change from baseline in NC score (NCS) based on the participant daily morning assessment|Change from baseline in total symptom score(TSS)|Change from baseline in the severity of decreased/loss of smell assessed daily by participants|Change from baseline in total score of 22-item sinonasal outcome test (SNOT-22)|Proportion of participants receiving systemic corticosteroids(SCS) for any reason or undergo surgery for nasal polyps during the study treatment|Number of participants with treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), and TEAEs leading to treatment discontinuation Sanofi All 18 Years and older   (Adult, Older Adult) Phase 3 62 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment EFC17026|U1111-1256-9711 May 16, 2023 October 2, 2024 December 25, 2024 May 26, 2023 June 1, 2023 Investigational Site Number :1560001, Beijing, China|Investigational Site Number :1560022, Fuzhou, China|Investigational Site Number :1560006, Hefei, China|Investigational Site Number :1560025, Jingzhou, China|Investigational Site Number :1560013, Qingdao, China|Investigational Site Number :1560017, Shanghai, China|Investigational Site Number :1560018, Taiyuan, China|Investigational Site Number :1560007, Wuhan, China|Investigational Site Number :1560009, Yantai, China|Investigational Site Number :1560020, Zibo, China https://ClinicalTrials.gov/show/NCT05878093 920 NCT05878080 iTBS/fMRI Study of Hierarchical Control in the PFC Recruiting No Results Available Transcranial Magnetic Stimulation Device: transcranial magnetic stimulation Change in PFC-PPC effective connectivity|Change in PFC-PPC activation|Change in temporal control speed|Change in temporal control accuracy|Change in contextual control speed|Change in contextual control accuracy Florida State University|National Institute of Mental Health (NIMH) All 18 Years to 30 Years   (Adult) Not Applicable 40 Other|NIH Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science STUDY00000533|R01MH121509 May 15, 2023 June 30, 2024 July 14, 2024 May 26, 2023 May 26, 2023 Florida State University Psychology Department Building, Tallahassee, Florida, United States|FSU MRI Facility, Tallahassee, Florida, United States https://ClinicalTrials.gov/show/NCT05878080 921 NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants Recruiting No Results Available Dry Eye Syndrome Drug: ABBV-444 Change from Baseline in Ocular Surface Disease Index (OSDI) Score|Change from Baseline in Patient Eye Drop Experiences (Visual Analog Scale)|Change from Baseline in Symptom Scores (Visual Analog Scale) within 5 Minutes Post Administration of ABBV-444 AbbVie All 18 Years and older   (Adult, Older Adult) Phase 3 40 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment P24-203 May 31, 2023 October 11, 2023 October 11, 2023 May 26, 2023 May 26, 2023 Canyon City Eyecare /ID# 253652, Azusa, California, United States https://ClinicalTrials.gov/show/NCT05878067 922 NCT05878054 Pursuing the Triple Aim in Hotspotters: Identification and Integrated Care Enrolling by invitation No Results Available Complex Patient|Multimorbidity|Psychosocial Problem|Chronic Disease Other: Proactive, integrated and personalised care Costs of care|Quality adjusted life years|Patients' experience of care|Self-efficacy|Proactive coping|Health related quality of life|Level of shared decision making|Level of care integration|Acceptability of Intervention Measure (AIM)|Intervention Appropriateness Measure (IAM)|Feasibility of Intervention Measure (FIM) Leiden University Medical Center All 18 Years and older   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other HTSPT September 6, 2022 December 31, 2025 December 31, 2025 May 26, 2023 May 26, 2023 Leiden University Medical centre, department of Public Healht and Primary care (PHEG), location Health Campus The Hague, Leiden, Netherlands "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05878054/Prot_000.pdf https://ClinicalTrials.gov/show/NCT05878054 923 NCT05878041 Creation of a Multicenter National Registry for Peripartum Cardiomyopathy. PPCMREGISTRY Not yet recruiting No Results Available Peripartum Cardiomyopathy Diagnostic Test: Molecular and genetic screening Death or hospitalization due to heart failure|Development of significant cardiac arrhythmias|Left ventricular dysfunction Federico II University|San Raffaele University Hospital, Italy|San Giuseppe Moscati Hospital Female 18 Years and older   (Adult, Older Adult) 40 Other Observational Observational Model: Case-Only|Time Perspective: Prospective PNRR-MR1-2022-12376858 May 20, 2023 May 19, 2024 May 19, 2025 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05878041 924 NCT05878028 L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC Recruiting No Results Available Non-small Cell Lung Cancer Combination Product: L-TIL, Tislelizumab, Docetaxel ORR|PFS|DCR|DOR Quanli Gao|Henan Cancer Hospital All 18 Years to 75 Years   (Adult, Older Adult) Phase 2 33 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HenanCH L-TIL aNSCLC September 16, 2022 September 15, 2023 September 15, 2024 May 26, 2023 May 26, 2023 No.127 Dongming Road, Zhengzhou, Henan, China https://ClinicalTrials.gov/show/NCT05878028 925 NCT05878015 A Study of Intravenous Acetaminophen for Small Bowel Obstruction Not yet recruiting No Results Available Small Bowel Obstruction Drug: Acetaminophen Resolution of small bowel obstruction|Pain Scores|Length of hospital stay|Death|Bowel Perforation|Surgery|Allergic reaction to acetaminophen Mayo Clinic All 18 Years and older   (Adult, Older Adult) Phase 4 12 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 23-000547 July 2023 December 2023 December 2023 May 26, 2023 May 26, 2023 Mayo Clinic Florida, Jacksonville, Florida, United States https://ClinicalTrials.gov/show/NCT05878015 926 NCT05878002 "Cognitive, Motor and Sleep Evaluation in Patients With Ischemic Stroke of Basal Ganglia After Thrombectomy" CMS - SBGT Recruiting No Results Available Post-stroke Disorders Device: polysomnography Post-stroke cognitive dysfunction Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years and older   (Adult, Older Adult) Not Applicable 300 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic 5137 April 12, 2023 April 12, 2033 April 2034 May 26, 2023 May 26, 2023 Flavia Torlizzi, Rome, Italy https://ClinicalTrials.gov/show/NCT05878002 927 NCT05877989 Evaluation of Effectiveness of Combining High Protein Intake With Early Physical Exercise During Critical Illness Completed No Results Available Muscle Weakness Drug: Amino Acid|Procedure: Physical exercise Quantitative changes (cross-section diameter) of rectus femoris muscle|Functional capacity.|Duration of mechanical ventilation.|Length of Surgical Intensive Care Unit stay.|Mortality rate in Surgical Intensive Care Unit|Rate of hospital acquired infection. Tanta University All 18 Years to 60 Years   (Adult) Phase 4 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 34750/6/21 July 1, 2021 June 30, 2022 June 30, 2022 May 26, 2023 May 26, 2023 Tanta University, Tanta, Egypt https://ClinicalTrials.gov/show/NCT05877989 928 NCT05877976 Impact of Visual Arts Immersion Not yet recruiting No Results Available Cultural Competency|Personal Reflection Behavioral: Visual Arts Immersion Change in Cultural Awareness Scale (CAS) Score from Baseline to Month 6|Change in Clinical Interpersonal Reactivity Index (CIRI) Score from Baseline to Month 6 NYU Langone Health|National Library of Medicine (NLM) All 18 Years and older   (Adult, Older Adult) Not Applicable 60 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other 23-00530 June 9, 2023 November 2023 December 2023 May 26, 2023 May 26, 2023 NYU Langone Health, New York, New York, United States https://ClinicalTrials.gov/show/NCT05877976 929 NCT05877963 Study to Evaluate the Maintenance of Efficacy When Transitioning From Anti-CD20 Therapy to Ublituximab (ENHANCE) Recruiting No Results Available Relapsing Multiple Sclerosis Biological: Ublituximab Percentage of Participants With No Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48|Percentage of Participants Free of T1 Gd-Enhancing Lesions|Percentage of Participants Experiencing Infusion Related Reactions (IRRs)|Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores TG Therapeutics, Inc. All 18 Years to 65 Years   (Adult, Older Adult) Phase 3 300 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TG1101-RMS401 May 2023 June 2025 June 2025 May 26, 2023 May 31, 2023 TG Investigational Site, Fort Collins, Colorado, United States|TG Investigational Site, Farmington, Michigan, United States https://ClinicalTrials.gov/show/NCT05877963 930 NCT05877950 The Effectiveness of Smartphone-Based Speech Therapy for People With Post-Stroke Dysarthria Not yet recruiting No Results Available Dysarthria as Late Effect of Stroke Device: Smartphone-based speech therapy|Other: Home-based speech therapy Speech intelligibility|Maximum phonation Time (MPT)|Oral-diadochokinesis (DDK)|Percentage of Consonants Correct (PCC, %) Ewha Womans University Seoul Hospital|Ewha Womans University Mokdong Hospital|National Rehabilitation Center, Seoul, Korea All 18 Years and older   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment SEUMC 2023-02-003 May 2023 April 2024 May 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877950 931 NCT05877937 Humor Therapy and Rheumatoid Arthritis Completed No Results Available Pain|Anxiety|Rheumatoid Arthritis|Nursing Caries Other: Supportive care (Watching a comedy movie) Visual Analog Scale (VAS)|State-Trait Anxiety Inventory (STAI) Eskisehir Osmangazi University All 18 Years and older   (Adult, Older Adult) Not Applicable 36 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care 202042005 September 1, 2020 November 30, 2021 November 30, 2021 May 26, 2023 May 26, 2023 Eskisehir Osmangazi University, Eskisehir, Turkey https://ClinicalTrials.gov/show/NCT05877937 932 NCT05877924 A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. Not yet recruiting No Results Available Advanced Malignant Tumors Drug: NBL-020 for Injection The occurrence of all adverse events (AEs) and severe adverse events (SAEs).|Cmax|AUC0-t|AUC0-inf|Tmax|t1/2|Vz|ORR|DCR|PFS|DOR|OS|Anti NBL-020 antibody (ADA) and neutralizing antibody (Nab).|NBL-020 receptor occupancy rate for tumor necrosis factor type Ⅱ receptor (TNFR2).|Concentration of free tumor necrosis factor type Ⅱ receptor (TNFR2). NovaRock Biotherapeutics, Ltd All 18 Years and older   (Adult, Older Adult) Phase 1 200 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NBL-020-001 May 2023 April 2025 August 2026 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877924 933 NCT05877911 Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy Not yet recruiting No Results Available Epithelial Ovarian Cancer|Acute Kidney Injury Due to Circulatory Failure Drug: Sodium Sulfate|Other: Hydration|Drug: Cisplatin Calculate the incidence of acute kidney injury after HIPEC based on creatinine levels and 24-hour urine output according to KDIGO criteria.|Calculate the incidence of chronic kidney injury after HIPEC based on creatinine levels according to KDIGO criteria.|Number of patients with sodium sulfate-related adverse events assessed by CTCAE v5.0.|Time from randomization to relapse or death（DFS）. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yunnan Cancer Hospital|Qilu Hospital of Shandong University Female Child, Adult, Older Adult Phase 2 110 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SYSKY-2022-549-02 May 2023 January 2025 April 2025 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877911 934 NCT05877898 Improving Blood Pressure Control Among Food Insecure Hypertensive Adults Not yet recruiting No Results Available Hypertension Behavioral: CHW Education|Behavioral: CHW Education and Navigation Blood pressure|carotenoid levels University of Florida|National Center for Advancing Translational Sciences (NCATS) All 18 Years to 69 Years   (Adult, Older Adult) Not Applicable 75 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IRB202300592|UL1TR001427 July 2023 June 30, 2024 June 30, 2024 May 26, 2023 May 26, 2023 University of Florida, Gainesville, Florida, United States https://ClinicalTrials.gov/show/NCT05877898 935 NCT05877885 Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics Not yet recruiting No Results Available Major Depressive Disorder|Apathy Behavioral: Targeted Cognitive Training Intervention|Behavioral: General Cognitive Training Intervention Change in Resting State Functional Connectivity among the Salience, Executive Control, and Reward Networks|Change in Apathy Evaluation Scale (AES) score|Change in Stroop Interference score Weill Medical College of Cornell University|National Institute of Mental Health (NIMH) All 60 Years and older   (Adult, Older Adult) Not Applicable 84 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 22-09025304|K23MH129882 August 2023 February 2028 March 2028 May 26, 2023 May 26, 2023 Lauren Elizabeth Oberlin, New York, New York, United States|Weill Cornell Medicine Institute of Geriatric Psychiatry, White Plains, New York, United States https://ClinicalTrials.gov/show/NCT05877885 936 NCT05877872 Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma Recruiting No Results Available Nasopharyngeal Carcinoma|De-escaltion Therapy Procedure: Reduced-target resection|Procedure: Full-target resection|Drug: Adjuvant immunotherapy Overall Survival (OS)|The incidence of Severe Adverse events|Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) overall|In-field recurrence rate|Progression-free survival (PFS)|Loco-regional relapse-free survival (LRRFS)|Distant metastasis-free survival (DMFS)|The proportion of Internal carotid artery pretreatment|Surgery-related adverse event|Operative resection time|Estimated blood loss|Progression-free survival after salvage treatment as assessed by the investigator (PFS2) Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Nanfang Hospital of Southern Medical University|First People's Hospital of Foshan|Zhongshan People's Hospital, Guangdong, China|Fifth Affiliated Hospital of Guangzhou Medical University All 18 Years to 75 Years   (Adult, Older Adult) Phase 3 424 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SYSUCC-CMY-2023-04-03 May 20, 2023 March 30, 2029 March 30, 2029 May 26, 2023 May 26, 2023 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05877872 937 NCT05877859 Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab Not yet recruiting No Results Available Breast Cancer Triple Negative|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Invasive Change in the cytokine milieu in the blood|Change in the transcriptomic signatures in the tissue Emory University|National Cancer Institute (NCI) Female 18 Years and older   (Adult, Older Adult) 10 Other|NIH Observational Observational Model: Cohort|Time Perspective: Prospective STUDY00005452|NCI-2023-02943|WINSHIP5818-22|P30CA138292 June 12, 2023 April 10, 2024 April 10, 2025 May 26, 2023 May 26, 2023 Emory University/Winship Cancer Institute, Atlanta, Georgia, United States https://ClinicalTrials.gov/show/NCT05877859 938 NCT05877846 Precision Medicine and Physical Function HMB Not yet recruiting No Results Available Frailty|Weakness, Muscle|Multiple Chronic Conditions Dietary Supplement: Beta-hydroxymethyl butyrate supplement|Dietary Supplement: Vitamin D supplement|Dietary Supplement: Matching Beta-hydroxymethyl butyrate supplement without Vitamin D Percentage of Participants Enrolled|Number of Participants Screened|Percentage of participants consented|Percent attendance|Percent of Interviews completed|Percentage of study measures collected|Percent of participants conducted MRI measure|Percent of participants conducted ultrasound measure|Acceptability of study intervention|Percent of Participants Rating the Intervention as Acceptable|Percent of participants rating the intervention as appropriate|Percent of participants rating the intervention as feasible|Change in weight from baseline|Change in waist circumference from baseline|Change in hip circumference from baseline|Change in arm circumference from baseline|Change in calf circumference from baseline|Change in Language using the Picture Vocabulary Test|Change in Executive function using the Dimensional Change Card Sort Test|Change in Episodic memory using the Picture sequence memory test|Change in Working memory using the List Sorting Test|Change in Processing speed using the Pattern Comparison Test|Change in caloric intake|Changes in total cholesterol blood levels from baseline|Changes in low density lipoprotein blood levels from baseline|Changes in triglycerides blood levels from baseline|Change in high density lipoprotein blood levels from baseline|Change in C-reactive protein blood levels from baseline|Change in Tumor Necrosis Factor- alpha (TNF-a) blood levels from baseline|Change in Interleukin 1 beta (IL-1-beta) blood levels from baseline|Change in Interleukin 6 (IL6) blood levels from baseline|Change in stool alpha-diversity levels from baseline|Change in serum sample from baseline|Change in 30-second sit-to-stand from baseline|Change in grip strength from baseline|Change in gait speed from baseline|Change in 400-meter walk time from baseline|Change in Fat Mass|Change in Fractional Percentage of Fat Mass|Change in Fractional Percentage of Lean Mass|Change in Lean Mass Volume|Change in Fractional Percentage Visceral Mass|Change in Ultrasound Imaging Intensity|Change in Pittsburgh Fatigability Scale|Change in Patient reported outcomes measurement information systems (PROMIS) General Health|Change in Rates of Physical Activity Type|Change in Metabolic equivalents|Change in Caloric Expenditure with Exercise|Change in Social Support for Diet|Change in Social support for exercise|Compliance Rate of b-hydroxymethylbutyrate University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute All 65 Years to 85 Years   (Older Adult) Not Applicable 25 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other 23-0141 July 1, 2023 June 1, 2024 June 1, 2024 May 26, 2023 May 26, 2023 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States https://ClinicalTrials.gov/show/NCT05877846 939 NCT05877833 Evaluating the Safety and Performance Characteristics of Ephemeral® Tattoo Ink in Healthy Subjects Completed No Results Available Tattoo; Pigmentation Other: Vibrancy Assessment Number of participants with tattoo vibrancy of 50% or greater|To evaluate the degree of healing of EPHEMERAL® TATTOO Ink Ephemeral Solutions Inc. All 18 Years to 60 Years   (Adult) 45 Industry Observational Observational Model: Case-Only|Time Perspective: Prospective EPHEM-001 August 10, 2020 February 1, 2023 February 1, 2023 May 26, 2023 May 30, 2023 Brennal Pierre, Milford, Connecticut, United States https://ClinicalTrials.gov/show/NCT05877833 940 NCT05877820 A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC Not yet recruiting No Results Available Fumarate Hydratase Deficient Renal Cell Carcinoma Biological: Tislelizumab|Drug: Lenvatinib Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Overall Survival (OS)|Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Overall Survival (OS) Rate at Month 12 in All Participants|Overall Survival (OS) Rate at Month 24 in All Participants|Number of Participants Who Experienced an Adverse Event (AE) RenJi Hospital All 18 Years to 80 Years   (Adult, Older Adult) Phase 2 10 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment LENTIS July 1, 2023 June 30, 2025 December 31, 2025 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877820 941 NCT05877807 Effect of Baclofen to Prevent Post-Traumatic Stress Disorder BACLO-PTSD Not yet recruiting No Results Available Alcoholism|Post Traumatic Stress Disorder Drug: Baclofen|Other: Placebo Post-traumatic Stress Disorder|Evaluation of the quality of life using the questionnaire European Quality of Life-5 Dimensions (EQ-5D)|Health assessement with the Short Form (SF-36 Quiz)|Screen for anxiety and depressive disorders with Hospital Anxiety and Depression scale (HAD Quiz)|Evaluation of the Posttraumatic stress disorder (PCL-S Quiz)|Assessment of patient Habits Nantes University Hospital All 18 Years to 80 Years   (Adult, Older Adult) 314 Other Observational Observational Model: Case-Control|Time Perspective: Prospective RC21_0251 June 1, 2023 June 1, 2025 June 1, 2025 May 26, 2023 May 26, 2023 Nantes University Hospital, Nantes, Loire-Atlantique, France https://ClinicalTrials.gov/show/NCT05877807 942 NCT05877794 Does the Central Venous Puncture Needle Need to be 7 cm? Not yet recruiting No Results Available Central Venous Catheters Device: central venous catheter insertion The difficulty of catheterization Ajou University School of Medicine All 19 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other AJIRB-MED-INT-22-188 May 27, 2023 June 30, 2023 July 31, 2023 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877794 943 NCT05877781 PEA in Functional Dyspepsia Recruiting No Results Available Dyspepsia and Other Specified Disorders of Function of Stomach Dietary Supplement: Palmitoylethanolamide Effect (change) on the Leuven-postprandial distress scale (LPDS) (0-15), higher score indicating more symptoms)|Effect of PEA supplementation on duodenal permeability|Effect of PEA supplementation on duodenal inflammation|Effect of PEA on gastric emptying Universitaire Ziekenhuizen KU Leuven All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment S65406 November 29, 2021 January 1, 2024 March 1, 2024 May 26, 2023 May 26, 2023 KU Leuven, Leuven, Vlaams-Brabant, Belgium https://ClinicalTrials.gov/show/NCT05877781 944 NCT05877768 Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease EPIPHANY Not yet recruiting No Results Available Coronary Artery Disease Diagnostic Test: Photon Counting Detector Coronary Computed Tomography Angiography Major Adverse Cardiac Events|Objective Image Noise of Photon-Counting Detector Coronary Computed Tomography Angiography (PCD-CCTA)|Objective Assessment of Noise-Power Spectra of PCD-CCTA|Subjective Image Noise of PCD-CCTA|Objective Vessel sharpness in PCD-CCTA|Subjective Vessel sharpness in PCD-CCTA|Objective Image Quality in PCD-CCTA|Subjective Image Quality in PCD-CCTA|Influence of BMI on image quality of the PCD-CCTA|Influence of biological sex on image quality of the PCD-CCTA|Influence of monoenergetic energy levels on image quality of the PCD-CCTA|Influence of slice thickness of reconstruction on image quality of the PCD-CCTA|Influence of reconstruction kernel on image quality of the PCD-CCTA|Influence of kernel sharpness level on image quality of the PCD-CCTA|Influence of radiation dose on image quality of the PCD-CCTA|Influence of the patients heart rate on image quality of the PCD-CCTA|Influence of the acquisition type on image quality of the PCD-CCTA|Quantitative analysis of Coronary Calcium Scoring from PCD-CCTA|Analysis of Stenosis Classification from PCD-CCTA|Quantitative analysis of Coronary Diameter Stenoses from PCD-CCTA|Quantitative analysis of Coronary Area Stenoses from PCD-CCTA|Quantitative analysis of computed Fractional Flow Reserve from PCD-CCTA|Quantitative analysis of myocardial density from PCD-CCTA|Quantitative analysis of myocardial iodine content from PCD-CCTA|Quantitative analysis of extracellular volume fraction from PCD-CCTA|Influence of BMI on quantitative parameters of the PCD-CCTA|Influence of biological sex on quantitative parameters of the PCD-CCTA|Influence of monoenergetic energy levels on quantitative parameters of the PCD-CCTA|Influence of slice thickness of reconstruction on quantitative parameters of the PCD-CCTA|Influence of reconstruction kernel on quantitative parameters of the PCD-CCTA|Influence of kernel sharpness level on quantitative parameters of the PCD-CCTA|Influence of radiation dose on quantitative parameters of the PCD-CCTA|Influence of the patients heart rate on quantitative parameters of the PCD-CCTA|Influence of the acquisition type on quantitative parameters of the PCD-CCTA|Rates of patients undergoing further cardiac diagnostics|Rates of patients undergoing cardiac interventions|Correlation and agreement of quantitative measurements from PCD-CCTA with ICA|Correlation and agreement of non-invasive Fractional Flow Reserve from PCD-CCTA with invasive Fractional Flow Reserve from ICA|Correlation and agreement of Percent diameter stenosis measurement from PCD-CCTA with Fractional Flow Reserve from ICA|Correlation and agreement of Plaque composition assessment from PCD-CCTA with intracoronary techniques|Correlation of quantitative PCD-CCTA parameters with the results of additional imaging ischemia tests|Correlation of quantitative PCD-CCTA parameters with the results of additional other imaging tests|Patient management|Analysis of occurrence in Major Adverse Cardiac Events in subgroups University Medical Center Mainz All 18 Years and older   (Adult, Older Adult) 3000 Other Observational Observational Model: Cohort|Time Perspective: Prospective PCD-CT Registry June 30, 2023 June 30, 2033 June 30, 2033 May 26, 2023 May 26, 2023 University Medical Center Mainz, Mainz, Rhineland-Palatinate, Germany https://ClinicalTrials.gov/show/NCT05877768 945 NCT05877755 Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging CARDIO-IRM Not yet recruiting No Results Available Cardiac Disease Device: Cardiac MRI acquisition Imaging integration success|Integration of the collected images in an internal database to develop new reconstruction and image processing algorithms specific to this application (e.g. using artificial intelligence)|Cardiac MRI feature: location and size of myocardial scars/fibrosis|Cardiac MRI feature native parameter values (T1, T2, T1-rho, T2*)|CMR feature extracellular volume fraction (ECV)|CMR feature ejection fraction University Hospital, Bordeaux|Grant Agreement ERC SMHEART All 18 Years and older   (Adult, Older Adult) Not Applicable 200 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic CHUBX 2023/13 September 1, 2023 August 31, 2028 August 31, 2028 May 26, 2023 May 26, 2023 Chu de Bordeaux, Pessac, France https://ClinicalTrials.gov/show/NCT05877755 946 NCT05877742 AA on Drug Abusers by Nursing Students Recruiting No Results Available Drug Abuse Other: AA group|Other: Control group Screening rate|Eligibility rate|Consent rate|Randomization rate|Attendance rate|Retention rate|Adherence to intervention protocol|Complete rate|Missing data|Adverse events|Self-reported abstinence|Abstinence with urine testing|Self-reported levels of craving|Anxiety|Quality of life measures by short-Form Six-Dimension The Hong Kong Polytechnic University All 18 Years and older   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment AA-drug abusers March 20, 2023 May 20, 2024 May 20, 2024 May 26, 2023 May 26, 2023 Katherine Lam, Hong Kong, Hong Kong,China, Hong Kong https://ClinicalTrials.gov/show/NCT05877742 947 NCT05877729 Intervention for Virologic Suppression in Youth iVY Not yet recruiting No Results Available HIV/AIDS|Young Adult|Mobile Health|Mental Health Issue|Substance Use Other: Standard of Care|Behavioral: Video-counseling+app HIV Viral Load Suppression Comparison Evaluated Using Home-collected Hemaspot Device|Clinical Impact: Frequency of Substance Use Comparison|Severity of Substance Use Comparison|Clinical Impact: Alcohol Use Comparison|Clinical Impact: Depression Comparison|Clinical Impact: PTSD (Post Traumatic Stress Disorder) Comparison|Clinical Impact: Anxiety Comparison University of California, San Francisco|National Institute of Mental Health (NIMH)|AIDS Healthcare Foundation|RTI International All 18 Years to 29 Years   (Adult) Not Applicable 200 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research 22-37017|R01MH131415 May 2023 March 2026 March 2026 May 26, 2023 May 26, 2023 Division of Prevention Science, Center for AIDS Prevention Studies (CAPS), San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05877729 948 NCT05877716 EPI-MINN: Targeting Cognition and Motivation - National Recruiting No Results Available Psychosis|Psychosis Nos/Other|Schizophrenia|Schizo Affective Disorder|Schizoaffective Disorder|Prodromal Schizophrenia|Schizophrenia Spectrum and Other Psychotic Disorders|Schizophreniform Disorders|Major Depression With Psychotic Features|Unspecified Psychosis|Bipolar Disorder Device: Cognitive and Social Cognitive Training|Behavioral: Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|Other: Early Psychosis Coordinated Specialty Care Change in Test My Brain Scores|Change in Dysfunctional Attitudes Scale - Defeatist Beliefs Subscale (DAS-DB) Score|Quality of Life Scale - Abbreviated|Change in Behavioral Inhibition and Activation Scale (BIS/BAS) - BIS Score|Change in Behavioral Inhibition and Activation Scale (BIS/BAS) - BAS Reward Responsiveness Score|Change in Behavioral Inhibition and Activation Scale (BIS/BAS) - BAS Drive Score|Change in Behavioral Inhibition and Activation Scale (BIS/BAS) - BAS Fun Seeking Score|Change in Motivation and Pleasure Scale - Self Report (MAPS-SR) - Social Pleasure Score|Change in Motivation and Pleasure Scale - Self Report (MAPS-SR) - Recreational or Work Pleasure Score|Change in Motivation and Pleasure Scale - Self Report (MAPS-SR) - Feelings and Motivations About Close, Caring Relationships Score|Change in Motivation and Pleasure Scale - Self Report (MAPS-SR) - Motivation and Effort to Engage in Activities Score|COMPASS-10 University of Minnesota|National Institute of Mental Health (NIMH) All 15 Years to 40 Years   (Child, Adult) Not Applicable 200 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment STUDY00018733 May 2023 July 2025 July 2025 May 26, 2023 May 26, 2023 University of Minnesota Department of Psychiatry & Behavioral Sciences, Minneapolis, Minnesota, United States https://ClinicalTrials.gov/show/NCT05877716 949 NCT05877703 Open Versus Close Chain Exercise Effects With Lifestyle Modification and Education in Knee Osteoarthritis Recruiting No Results Available Knee Osteoarthritis Other: close kinetic chain exercises|Other: open kinetic chain exercises Numeric Pain Rating Scale:|Western Ontario and McMaster Universities Arthritis Index|Osteoarthritis Knee and Hip Quality of Life Score Riphah International University All 50 Years to 70 Years   (Adult, Older Adult) Not Applicable 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment REC/RCR & AHS/23/0103 April 15, 2023 September 1, 2023 September 15, 2023 May 26, 2023 May 26, 2023 Al-Raee Trust Hospital, Gujrānwāla, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05877703 950 NCT05877690 Selective Spinal Anaesthesia With Hyperbaric Prilocain With 2%Provides Better Perioperative Hemodynamic Stability for Patients With Peripheral Vascular Disease and Cardiac Dysfunction in Lower Limb Surgery Recruiting No Results Available Hemodynamic Stability Drug: Bupivacaine 0.5% Injectable Solution|Drug: Prilocaine Hydrochloride 2% Injection Monitoring blood pressure both systole and diastole Assiut University All 18 Years to 90 Years   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other Selective spinal anaesthesia October 2023 October 2024 December 2024 May 26, 2023 May 26, 2023 Assuit university, Assiut, Assuit, Egypt https://ClinicalTrials.gov/show/NCT05877690 951 NCT05877677 The Effects Assessment of the Polygonatum Kingianum Extract on Endurance Performance and Anti-fatigue Recruiting No Results Available Fatigue Dietary Supplement: Placebo drink|Dietary Supplement: Polygonatum kingianum extract drink The change of aerobic endurance|The change of continuous attention performance|The change of blood testosterone|The change of blood PDE5 gene expression|The change of blood nitric oxide (NO)|The change of self-assessment fatigue condition TCI Co., Ltd. Male 30 Years to 60 Years   (Adult) Not Applicable 50 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other 23-027-A May 18, 2023 June 30, 2023 December 31, 2023 May 26, 2023 May 26, 2023 National Pingtung University of Science and Technology, Pingtung, Taiwan https://ClinicalTrials.gov/show/NCT05877677 952 NCT05877664 Study of ZG0895.HCl in Patients With Advanced Solid Tumors Not yet recruiting No Results Available Advanced Solid Tumor Drug: ZG0895 Hydrochloride for Injection The incidence of dose-limiting toxicity (DLT)|The maximum tolerated dose (MTD) of ZG0895.HCl|Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Experiencing Serious Adverse Events (SAEs)|Overall Response Rate (ORR) as assessed by the investigator Suzhou Zelgen Biopharmaceuticals Co.,Ltd All 18 Years to 75 Years   (Adult, Older Adult) Phase 1 60 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ZG0895-001 July 2023 June 2026 June 2026 May 26, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05877664 953 NCT05877651 MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. Completed No Results Available Solid Tumors Biological: MASCT-I injection Adverse events and serious adverse events related to MASCT-I|Immune response to tumor-associated antigens|Concentration of Cytokines (IFNγ、IL2、IL4、IL6、IL10 and TNF) SYZ Cell Therapy Co.. All 18 Years to 70 Years   (Adult, Older Adult) Phase 1 22 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MASCT-I-2001 April 21, 2020 October 15, 2021 October 15, 2021 May 26, 2023 May 30, 2023 Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05877651 954 NCT05877638 SWC for Treatment of Superficial Partial-Thickness Burns Recruiting No Results Available Burn Wounds Device: SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|Drug: SILVADENE Cream 1% (silver sulfadiazine) Healing wound progress|New infection rates Synedgen, Inc.|Louisiana State University Health Sciences Center in New Orleans All 18 Years and older   (Adult, Older Adult) Not Applicable 115 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SWC March 27, 2023 March 2024 April 2024 May 26, 2023 May 26, 2023 Louisiana State University Health Science Center at New Orleans, New Orleans, Louisiana, United States https://ClinicalTrials.gov/show/NCT05877638 955 NCT05877625 Study on Dynamic Enviromental Exposome of ICU and the Establishment of Microbial Transmission Model Between Environment and Host Active, not recruiting No Results Available Hospital Acquired Infection|Ventilator-associated Pneumonia Procedure: Expectoration care Community of microbiome in ICU Peking University Third Hospital|Zhejiang University|Central South University All 18 Years and older   (Adult, Older Adult) 180 Other Observational Observational Model: Cohort|Time Perspective: Prospective M2022419 August 1, 2022 July 31, 2023 August 31, 2023 May 26, 2023 May 26, 2023 Peking University Third Hospital, Beijing, Beijing, China https://ClinicalTrials.gov/show/NCT05877625 956 NCT05877612 Efficacy of Spinal Cord Stimulation in Burst Mode in the Treatment of Complex Regional Pain Syndromes Type 1 of the Upper Limbs STIMBURST Not yet recruiting No Results Available Complex Regional Pain Syndrome Type I Device: Implantable spinal cord stimulator Pain assessment at 3 months after implant|procedure assesment|Assessing attention and working memory|qualitatively evaluate the effectiveness of the procedure|Medication use Elsan|Abbott All 18 Years to 75 Years   (Adult, Older Adult) 30 Other|Industry Observational Observational Model: Case-Only|Time Perspective: Prospective 2023-A00638-37 June 1, 2023 October 1, 2024 June 1, 2025 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877612 957 NCT05877599 A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Not yet recruiting No Results Available Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Colorectal Carcinoma|Pancreatic Adenocarcinoma|Breast Cancer|Other Solid Tumors Biological: Autologous, engineered T Cells targeting TP53 R175H Safety of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors|Adverse events and serious adverse events|Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors Neogene Therapeutics, Inc. All 18 Years and older   (Adult, Older Adult) Phase 1 24 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NT-175-201 August 2023 August 2026 August 2039 May 26, 2023 May 26, 2023 City of Hope, Duarte, California, United States https://ClinicalTrials.gov/show/NCT05877599 958 NCT05877586 CLARE Mobile App for Caregiver Training and Support Not yet recruiting No Results Available Caregivers|Technology Other: CLARE app Participation rate|Use of CLARE app|Use of CLARE chat|Intent and Use of CLARE Duke University All 65 Years and older   (Older Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other PRO00111735 July 1, 2023 May 1, 2024 June 30, 2024 May 26, 2023 May 26, 2023 Duke University Hospital, Durham, North Carolina, United States https://ClinicalTrials.gov/show/NCT05877586 959 NCT05877573 Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer Not yet recruiting No Results Available Locally Advanced|High-Risk|Rectal Cancer|MSS Drug: Toripalimab|Radiation: short-term radiotherapy|Drug: Oxaliplatin|Drug: Capecitabine pCR rate|3-year ORR|3-year DCR|3-year OS|AE|SAE Nanfang Hospital of Southern Medical University|Shanghai Junshi Bioscience Co., Ltd. All 18 Years to 75 Years   (Adult, Older Adult) Not Applicable 53 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment NFEC-2023-062 June 1, 2023 January 1, 2025 August 1, 2026 May 26, 2023 May 26, 2023 Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China https://ClinicalTrials.gov/show/NCT05877573 960 NCT05877560 Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency NIBSCI Not yet recruiting No Results Available Convergence Insufficiency Device: Anodal-Transcranial Direct Current Stimulation|Behavioral: Office-Based Vergence/Accommodative Therapy|Device: Sham Transcranial Direct Current Stimulation Near Point of Convergence (NPC)|Positive Fusional Vergence (PFV)|Convergence Insufficiency Symptoms Survey (CISS) Midwestern University|Pennsylvania College of Optometry|Southern California College of Optometry at Marshall B. Ketchum University|New Jersey Institute of Technology|University of Waterloo School of Optometry and Vision Science All 18 Years to 40 Years   (Adult) Not Applicable 150 Other|Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment CIRB-IL 22013 June 1, 2023 December 31, 2028 December 31, 2028 May 26, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05877560 961 NCT05877547 A Clinical Study of Efinopegdutide in in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Not yet recruiting No Results Available Non-alcoholic Fatty Liver Disease|Fatty Liver, Nonalcoholic|NAFLD|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis Drug: Efinopegdutide|Drug: Semaglutide|Drug: Placebo Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52|Percentage of Participants Who Experienced an Adverse Event (AE)|Percentage of Participants Discontinuing Study Medication Due to an AE|Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52|Change from Baseline in Body Weight At Week 52 Merck Sharp & Dohme LLC All 18 Years to 80 Years   (Adult, Older Adult) Phase 2 300 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 6024-013|2022-502647-35-00|MK-6024-013 June 23, 2023 December 5, 2025 December 5, 2025 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877547 962 NCT05877534 Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study Enrolling by invitation No Results Available Postural Orthostatic Tachycardia Syndrome|COVID-19|Post COVID-19 Condition|Post-Acute COVID-19 Syndrome Other: Individual tailored exercise Change in time in upright position and steps per day|Change in Health-Related Quality of Life (HRQoL)|Change in walking distance during 6 minute walk test|Change in oxygen saturation during 6 minute walk test|Change in dyspnea during 6 minute walk test|Change in leg fatigue during 6 minute walk test|Change in exertion during 6 minute walk test|Change in heart rate during 6 minute walk test|Change in Self-reported POTS-symptoms|Change in Anxiety - Generalised Anxiety Disorder 7-item scale|Change in Depression - Patient Health Questionnaire-9|Change in Fatigue|Change in Self-reported outcome measure of physical function|Change in blood pressure during Active standing test|Change in heart rate response during Active standing test|Change in oxygen saturation during Active standing test|Change in respiratory rate during Active Standing Test|Change in dyspnea during Active standing test|Change in leg fatigue during Active Standing Test|Change in exertion during Active standing test|Change in Physical activity|Change in orthostatic symptoms|Change in insomnia|Change in Workability|Change in muscle strength|Change in post-exertional-Malaise (PEM)|Change in pharmacological treatment of POTS|Compliance to intervention Karolinska Institutet|Karolinska University Hospital All 18 Years and older   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment RCT-POTS-ReCov May 25, 2023 June 1, 2024 June 1, 2025 May 26, 2023 May 30, 2023 Karolinska University Hospital, Stockholm, Sweden https://ClinicalTrials.gov/show/NCT05877534 963 NCT05877521 Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief Recruiting No Results Available Chronic Pain|Cancer Pain Behavioral: MORE treatments|Other: Standard of Care for Pain Management Rate of participant enrollment to the study Memorial Sloan Kettering Cancer Center All 18 Years and older   (Adult, Older Adult) Phase 2 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 23-082 May 16, 2023 May 16, 2027 May 16, 2027 May 26, 2023 May 26, 2023 Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States https://ClinicalTrials.gov/show/NCT05877521 964 NCT05877508 Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) outSMART-LC Not yet recruiting No Results Available Long COVID|Post-Acute Sequela of COVID-19|Post-Acute COVID-19 Drug: AER002|Other: Placebo Change in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Score from Baseline. Michael Peluso, MD|Aerium Therapeutics|University of California, San Francisco All 18 Years and older   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 23-38629 July 23, 2023 July 31, 2025 July 31, 2025 May 26, 2023 June 5, 2023 UCSF/Zuckerberg San Francisco General Hospital, San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05877508 965 NCT05877495 Food Safety, Security and Waste Prevention Intervention on the KAB-P Approach of University Students Enrolling by invitation No Results Available Educational Problems Behavioral: Nutritional Education Intervention Knowledge level Selcuk University All 19 Years to 24 Years   (Adult) Not Applicable 110 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other 22408003 November 21, 2022 May 15, 2023 December 29, 2023 May 26, 2023 May 26, 2023 Selcuk University, Konya, Turkey https://ClinicalTrials.gov/show/NCT05877495 966 NCT05877482 Pediatric Pes Planus: Effect of Insoles With and Without SFE Recruiting No Results Available Flexible Flatfoot Other: Short foot exercises|Other: Insoles Navicular Drop (ND) test for inclusion criteria|Six item Foot Posture Index (FPI)|Pain and disability were assessed by pain and disability subscales (both include 9 items) of the Foot Function Index (FFI) Riphah International University All 8 Years to 16 Years   (Child) Not Applicable 26 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment REC/RCR & AHS/22/0719 March 1, 2023 August 1, 2023 September 1, 2023 May 26, 2023 May 26, 2023 Children Hospital Lahore, Lahore, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05877482 967 NCT05877469 Effects of MAT Pilates Versus Functional Training on Mechanical Low Back Pain Recruiting No Results Available Mechanical Low Back Pain Other: Mat pilates Training|Other: Functional Training Modified Oswestry LBP disability index|Numeric Pain Rating Scale|Inclinometer Riphah International University All 25 Years to 40 Years   (Adult) Not Applicable 44 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment REC//23/0107/Wasifa Haider February 1, 2023 August 1, 2023 August 1, 2023 May 26, 2023 May 26, 2023 District Headquarter Hospital Sahiwal, Sahiwal, Punjab, Pakistan https://ClinicalTrials.gov/show/NCT05877469 968 NCT05877456 Validation of the Global Polypectomy Assessment Tool (GPAT) GPAT Enrolling by invitation No Results Available Colorectal Adenoma|Colorectal Polyp|Colo-rectal Cancer To validate the GPAT (global polypectomy assesment tool) scoring tool for polypectomy using key performance indicators. University Hospital, Ghent All 18 Years to 100 Years   (Adult, Older Adult) 100 Other Observational Observational Model: Case-Only|Time Perspective: Prospective ONZ-2022-0597 March 1, 2023 March 1, 2027 March 2, 2027 May 26, 2023 May 26, 2023 uz Gent, Ghent, Gent, Belgium https://ClinicalTrials.gov/show/NCT05877456 969 NCT05877443 Barotrauma in Adults With Critical COVID-19 Completed No Results Available COVID-19|Barotrauma Procedure: Open system|Procedure: Non-invasive mechanical ventilation|Procedure: Invasive mechanical ventilation Barotrauma Karolinska Institutet All 18 Years and older   (Adult, Older Adult) 669 Other Observational Observational Model: Cohort|Time Perspective: Retrospective Barotrauma COVID-19 March 1, 2020 May 31, 2021 August 29, 2021 May 26, 2023 May 30, 2023 Södersjukhuset, Stockholm, Sweden https://ClinicalTrials.gov/show/NCT05877443 970 NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer Not yet recruiting No Results Available NSCLC|HNSCC|Melanoma|Metastatic Cancer|Advanced Solid Tumor|Advanced Cancer Drug: CJRB-101|Drug: Pembrolizumab injection [Phase 1&2] Tolerability and Safety: Incidence of Adverse Events|[Phase 2] Efficacy|[Phase 1&2] Effects of therapy on the microbiome biomarkers - Stool|[Phase 1&2] Effects of therapy on the pharmacodynamic biomarkers - Blood|[Phase 1&2] Effects of therapy on the pharmacodynamic biomarkers - Tumor|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration Of Response (DOR)|Progression Free Survival (PFS)|Overall survival (OS) CJ Bioscience, Inc. All 18 Years and older   (Adult, Older Adult) Phase 1|Phase 2 160 Industry Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CJB-101-01 September 2023 July 2026 October 2027 May 26, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05877430 971 NCT05877417 Blood Flow Restriction and Creatine Supplementation in Women Recruiting No Results Available Physical Inactivity Dietary Supplement: Creatine Monohydrate|Device: Blood Flow Restriction|Other: Exercise Strength|Body Composition|Neuromuscular Function|Endothelial Function|Mood States University of Central Florida Female 18 Years to 35 Years   (Adult) Not Applicable 75 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science STUDY00005471 May 17, 2023 February 1, 2024 February 1, 2024 May 26, 2023 May 26, 2023 University of Central Florida, Orlando, Florida, United States https://ClinicalTrials.gov/show/NCT05877417 972 NCT05877404 Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer Not yet recruiting No Results Available Endometrial Cancer Other: Surveys Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients|Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer|Number of providers reporting confidence in utilizing tumor genetic testing to guide treatment decisions|Number of providers who change their counseling or testing strategies for endometrial cancer Wake Forest University Health Sciences All Child, Adult, Older Adult 360 Other Observational Observational Model: Other|Time Perspective: Prospective IRB00097221|WFBCCC 99323 August 2023 December 2023 December 2023 May 26, 2023 May 30, 2023 Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States https://ClinicalTrials.gov/show/NCT05877404 973 NCT05877391 Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice Recruiting No Results Available Sexual and Gender Minorities|Hospice|Alzheimer's Disease and Related Dementias Barriers and facilitators to communicating with SGM older adults and perceptions and preferences for asking/disclosing SOGI|Content of training|Delivery of content|Feasibility|Sources of bias and stigma|Ongoing engagement around SOGI-informed care|Accessibility University of Colorado, Denver All 18 Years and older   (Adult, Older Adult) 80 Other Observational Observational Model: Other|Time Perspective: Prospective 212337 March 13, 2023 September 2027 September 2027 May 26, 2023 May 26, 2023 University of Colorado, Aurora, Colorado, United States https://ClinicalTrials.gov/show/NCT05877391 974 NCT05877378 Efficacy of PICO Single-use System in Chronic Ulcers Not yet recruiting No Results Available Chronic Ulcer|Venous Ulcer|Diabetic Foot Ulcer|Pressure Injury Device: Single-use negative pressure therapy (PICO) Change in the size of wounds|Healing time|Cure rate|Number of participants with adverse effects|Health-related effects on quality of life. University of Castilla-La Mancha All 18 Years and older   (Adult, Older Adult) Not Applicable 42 Other Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment IMCU001 September 15, 2023 December 15, 2023 April 1, 2024 May 26, 2023 May 26, 2023 Celia Villalba Aguilar, Toledo, Spain https://ClinicalTrials.gov/show/NCT05877378 975 NCT05877365 Effects of 21-day Purification Program on Healthy Adults Not yet recruiting No Results Available Healthy Dietary Supplement: Standard Process 21-Day Purification Program Porphyrins in Urine|Changes in GGT|Changes in GST|Questionnaire|Changes in Weight Standard Process Inc.|Keiser University College of Chiropractic Medicine All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 40 Industry|Other Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care SP-019-2 June 15, 2023 December 31, 2023 January 15, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877365 976 NCT05877352 Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial ELECTRA Recruiting No Results Available Locally Advanced Rectal Cancer|Locally Recurrent Rectal Cancer Radiation: Intraoperative Electron Radiotherapy (IOERT)|Procedure: Extended Margin Surgery Patients meeting eligibility criteria|Patients accepting randomisation|Successful delivery of IOERT|Blind maintained for patients and clinicians|Questionnaire analysis|Availability of potential primary outcome data|Morbidity|Mortality|IOERT Field Recurrence|Overall local recurrence|Overall survival|Treatment related toxicity|Time to local or systemic recurrence|R1 Rate|EQ-5D-5L|LRRC QoL|QLQ-C30|SF-36|Resource use and cost University Hospital Southampton NHS Foundation Trust|IntraOp Medical Corporation|PLANETS Cancer Charity|Cancer Research UK All 16 Years and older   (Child, Adult, Older Adult) Not Applicable 42 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment RHMCAN1600|ISRCTN48105173 May 18, 2022 April 24, 2024 April 24, 2025 May 26, 2023 May 26, 2023 University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom https://ClinicalTrials.gov/show/NCT05877352 977 NCT05877339 The Effect of Exercise on Fatigue in White-collar Workers Not yet recruiting No Results Available Exercise|Fatigue Diagnostic Test: Survey Survey Sisli Hamidiye Etfal Training and Research Hospital All 20 Years to 75 Years   (Adult, Older Adult) 300 Other Observational Observational Model: Case-Crossover|Time Perspective: Cross-Sectional 2023 May 25, 2023 June 25, 2023 June 30, 2023 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877339 978 NCT05877326 Anaesthetic Depth and Short Term Delirium Post Cardiac Surgery Intervention BISCAR Not yet recruiting No Results Available Post-operative Delirium|Anaesthetic Depth Drug: General anesthesia with propofol or sevoflurane|Behavioral: CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative To demonstrate the benefit of reduced depth of anesthesia Centre Cardiologique du Nord All 75 Years to 85 Years   (Older Adult) Not Applicable 200 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention 2022-A02200-43 May 2023 May 10, 2025 May 10, 2025 May 26, 2023 June 1, 2023 Centre cardiologique du nord, Saint-Denis, France https://ClinicalTrials.gov/show/NCT05877326 979 NCT05877313 Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) Not yet recruiting No Results Available Verruca Plantaris Other: Sterile water foot bath|Drug: Nitric Oxide To evaluate the efficacy of NORS as a treatment for verrucae plantaris as measured by lesion clearance (Day 35).|To assess the mean reduction in lesion dimensions as measured by the change in size from baseline observed at Day 7, 14, 21, 28 and 35.|To assess by mean changes in size of lesion as measured by area at Days 7, 14, 21, 28 and 35 and lesion clearance (Day 35).|To evaluate (median) time to pain reduction of lesion(s).|To assess the safety and tolerability of NORS. Sanotize Research and Development corp. All 12 Years and older   (Child, Adult, Older Adult) Phase 2 30 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment HPV-Warts-01 June 2023 October 2023 December 2023 May 26, 2023 May 31, 2023 Achilles Foot Health Centre, Surrey, British Columbia, Canada https://ClinicalTrials.gov/show/NCT05877313 980 NCT05877300 Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement Not yet recruiting No Results Available Esophageal Diseases Combination Product: Cellspan™ Esophageal Implant-Adult (CEI) The number of patients who develops continuous biologic neo-conduit within the esophagus based on CT/MRI imaging and visual endoscopic evaluation.|The number of patients who does not develop anastomotic leak or fistula that requires non-endoscopic therapy.|The number of patients within the first 42 days that do not require a fall back emergency esophagectomy procedure|Number of participants experiencing death within 30 days of index procedure Biostage, Inc. All 18 Years and older   (Adult, Older Adult) Phase 1 10 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BSTG-CEI-101 June 2023 January 2025 December 2026 May 26, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05877300 981 NCT05877287 Effect of Awareness-Based Stress Reducatıon Program Applıed to Parents Wıth A Chıld Wıth Autısm Not yet recruiting No Results Available DEPRESSION|ANXIETY|STRESS|HOPELESSNESS Other: mindfulness-based stress reduction program Depression, Anxiety and Stress Scale (DASS-21)|Beck Hopelessness Scale (BUS) Necmettin Erbakan University All 18 Years and older   (Adult, Older Adult) Not Applicable 94 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care 2023/410:13610 June 1, 2023 September 25, 2023 December 25, 2023 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877287 982 NCT05877274 Sodium Channel Mutations in Patient With the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES) Nav-ACNES Not yet recruiting No Results Available Anterior Cutaneous Nerve Entrapment Syndrome|Nerve Entrapment Syndrome|Chronic Pain Syndrome Other: Sodium channel mutation Sodium Channel 1.7 and 1.8 mutation.|Correlation between mutations and known cause of ACNES.|Correlation between mutations and pain score at start of treatment.|Correlation between mutations and treatment response. Maxima Medical Center All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional NL84021.015.23 July 2023 December 2023 January 2024 May 26, 2023 May 31, 2023 Maxima Medical Center, Veldhoven, Netherlands https://ClinicalTrials.gov/show/NCT05877274 983 NCT05877261 Cementless Triathlon 5YR Follow-Up Not yet recruiting No Results Available Knee Arthroplasty, Total|Knee Osteoarthritis|Radiostereometric Analysis Device: Cementless Total Knee Replacement Implant Migration (tibial component)|Implant Migration (femoral component)|Inducible Displacement (RSA-based)|Inducible Displacement (CT-based)|Bone Density|Texture Features|Microbial Diversity Lawson Health Research Institute|Schulich School of Medicine and Dentistry All 21 Years to 90 Years   (Adult, Older Adult) 33 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 12925 June 2023 October 2023 December 2023 May 26, 2023 May 26, 2023 University Hospital, London, Ontario, Canada https://ClinicalTrials.gov/show/NCT05877261 984 NCT05877248 Preoperative Clear Liquid Diet Fasting; Survey Among Medical School Physician Not yet recruiting No Results Available Fasting Before Operation Score of multiple-choice question test about fasting before operation in physician of medical school. Mahidol University All 20 Years and older   (Adult, Older Adult) 440 Other Observational Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional SI 325/2566 July 1, 2023 January 1, 2024 July 1, 2024 May 26, 2023 May 30, 2023 faculty of medicine Siriraj hospital, Bangkok, Thailand https://ClinicalTrials.gov/show/NCT05877248 985 NCT05877235 Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin: Recruiting No Results Available Coronary Artery Disease|Menopause Dietary Supplement: Quercetin|Dietary Supplement: Placebo Estradiol|Estrone|Sirtuin-1|Cardiometabolic risk factors InCor Heart Institute Female 55 Years to 70 Years   (Adult, Older Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment 64417922.0.0000.0068 October 3, 2021 December 23, 2023 June 23, 2024 May 26, 2023 May 26, 2023 INCOR- Heart Institute, Sao Paulo, São Paulo, Brazil https://ClinicalTrials.gov/show/NCT05877235 986 NCT05877222 A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants Not yet recruiting No Results Available Healthy Drug: Daridorexant 10 mg|Drug: Daridorexant 25 mg Cmax|AUC0-t Idorsia Pharmaceuticals Ltd. All 18 Years to 65 Years   (Adult, Older Adult) Phase 1 38 Industry Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other ID-078-127 June 7, 2023 June 30, 2023 June 30, 2023 May 26, 2023 June 2, 2023 https://ClinicalTrials.gov/show/NCT05877222 987 NCT05877209 Screening of Nutritional Status and Sarcopenia Among Patients With IBD Not yet recruiting No Results Available Inflammatory Bowel Diseases Screening of malnutrition in patients with IBD using and its relation to severity of the disease. Assiut University All 18 Years to 60 Years   (Adult) 100 Other Observational Observational Model: Case-Crossover|Time Perspective: Cross-Sectional NRS score in IBD June 15, 2023 November 1, 2023 December 1, 2023 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877209 988 NCT05877196 A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses SMART Not yet recruiting No Results Available Mild Cognitive Impairment|Alzheimer Disease|Cognitive Impairment|Cognitive Decline|Memory Loss|Memory Impairment Behavioral: Moderate Intensity Continuous Training (MICT)|Behavioral: Chair-based Stretch|Behavioral: High-Intensity Interval Training (HIIT)|Behavioral: Combined Aerobic Resistance Exercise (CARE) Peak oxygen consumption|White Matter Hyperintensity volume|Memory|Physical function|Behavioral and psychiatric symptoms of dementia (BPSD)|Caregiver burden|Quality of Life (QoL)|Blood amyloid-beta 42 and 40|Blood phosphorylated tau 181|Blood total tau, neurofilament light chain Arizona State University|Banner Alzheimer's Institute All 65 Years and older   (Older Adult) Not Applicable 216 Other Interventional Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment STUDY00017678 May 15, 2023 April 1, 2027 June 30, 2028 May 26, 2023 May 26, 2023 Arizona State University, Phoenix, Arizona, United States https://ClinicalTrials.gov/show/NCT05877196 989 NCT05877183 'Smart Reminder': a Randomized Controlled Trial on the Effect of a Wearable Device Not yet recruiting No Results Available Stroke|Wearable Device Device: Wearable device -'Smart Reminder'|Device: Sham device Change from baseline: Fugl Meyer Upper Extremity assessment|Change from baseline: Action Research Arm Test (ARAT)|Change from baseline: Motor Activity Log (MAL)|Change from baseline: Muscle strength of the affected elbow and shoulder|Change from baseline: Active Range of motion of the affected shoulder (flexion/extension), elbow (flexion/ extension), and forearm pronation/supination.|Kinematic data of arm movement The Hong Kong Polytechnic University All 18 Years and older   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment Smart reminder May 22, 2023 March 31, 2024 March 31, 2024 May 26, 2023 May 26, 2023 Kenneth FONG, Hong Kong, Hong Kong https://ClinicalTrials.gov/show/NCT05877183 990 NCT05877170 Impact of Palmitoylethanolamide (PEA) in the Management of Oro-facial Pain Recruiting No Results Available Oral-facial Pain Dietary Supplement: Palmitoyletinolamide|Drug: Placebo Reduction of oral-facial pain University of Catania All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 121-25 February 18, 2020 August 12, 2023 August 17, 2023 May 26, 2023 May 26, 2023 AOU Policlinico G. Rodolico, Catania, Italy https://ClinicalTrials.gov/show/NCT05877170 991 NCT05877157 Pain AND Opioids After Surgery PANDOS Not yet recruiting No Results Available Opioid Use|Pain, Chronic|Pain, Postoperative|Quality of Life Patient reported Opioid use post surgery|Opioid use|Patient reported incidence of pain|Surgical complications|Participant reported quality of life University of Aberdeen|European Society of Anaesthesiology and Intensive Care All 18 Years and older   (Adult, Older Adult) 10000 Other Observational Observational Model: Ecologic or Community|Time Perspective: Prospective 2-082-21 June 2023 April 30, 2024 July 31, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877157 992 NCT05877144 Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery Not yet recruiting No Results Available Erectile Dysfunction|Localized Prostate Carcinoma|Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8 Procedure: Nerve-Sparing Prostatectomy|Other: Medical Device Usage and Evaluation|Procedure: Duplex Ultrasound|Other: Survey Administration|Procedure: Sham Intervention Patient reported sexual function|Change in duplex doppler ultrasound measurement|Erectile function Thomas Jefferson University Male 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment iRISID-2022-0980 June 2023 October 12, 2024 April 2025 May 26, 2023 May 26, 2023 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States https://ClinicalTrials.gov/show/NCT05877144 993 NCT05877131 Evaluate Efficacy Levobupivacaine 0.125% Versuss Ropivacaine 0.2% in Hemodynamic Alterations in Labor and Fetal Repercussions Not yet recruiting No Results Available Hemodynamic Instability|Epidural|Pregnancy|Fetal Cardiac Disorder Drug: Levobupivacaine|Drug: Ropivacaine Systemic vascular resistance ( units of measure:dyn*s/cm5)|Systemic vascular resistance ( units of measure :dyn*s/cm5)|Systolic Blood Pressure (units of measure :mmHg)|Diastolic Blood Pressure (units of measure :mmHg)|Mean Arterial Pressure (units of measure :mmHg)|Pulse Pressure (units of measure :mmHg)|Cardiac Output (units of measure :L/min)|Cardiac Index ( units of measure :L/min/m2)|Pulse Pressure Variation ( units of measure :% Percent)|(Maternal) Heart Rate (units of measure: beats per minute)|Stroke Volume (units of measure :ml)|Systolic Variation Volume ( units of measure :% Percent)|Arterial Oxigen Saturation ( units of measure :% Percent)|Fetal heart rate (units of measure: beats per minute)|Variability (units of measure: beats per minute)|Accelerations (units of measure: beats per minute)|Decelerations (units of measure: beats per minute) Althaia Xarxa Assistencial Universitària de Manresa Female 18 Years to 40 Years   (Adult) Phase 4 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment CEI-pendiente June 1, 2023 December 1, 2023 December 1, 2023 May 26, 2023 May 26, 2023 Althaia Xarxa Assitensial i Universitaria Manresa, Manresa, Barcelona, Spain https://ClinicalTrials.gov/show/NCT05877131 994 NCT05877118 Improving Availability of Intranasal Naloxone Not yet recruiting No Results Available Opioid Overdose Behavioral: Enhanced Overdose Education (EOE)|Behavioral: Standard education Prescription fill rate|Education content survey Hartford Hospital|Hartford HealthCare All 21 Years to 65 Years   (Adult, Older Adult) Not Applicable 84 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research HHC-2023-0079 July 3, 2023 July 31, 2024 December 31, 2024 May 26, 2023 May 26, 2023 Hartford Hospital Emergency Department, Hartford, Connecticut, United States|Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States https://ClinicalTrials.gov/show/NCT05877118 995 NCT05877105 Effect of Selected Evidence-based Practices and Related Nurses' Education on the Incidence and Severity of Ventilator-associated Pneumonia Enrolling by invitation No Results Available Evidence-based Practices|Nursing Education|Incidence|Ventilator-associated Pneumonia Other: Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle Evaluate the effect of the selected EPB and related nurses' education on the incidence VAP|Evaluate the effect of the selected EPB and related nurses' education on the severity of VAP|Assess the compliance of ICU staff with implementing VAP prevention bundel as an EBP Cairo University All 20 Years and older   (Adult, Older Adult) Not Applicable 80 Other Interventional Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention NHTMRI-13/23 May 17, 2023 July 31, 2023 July 31, 2023 May 26, 2023 May 30, 2023 Cairo University, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05877105 996 NCT05877092 Comparative Evaluation of Masticatory Efficiency of Implant Supported Overdenture Completed No Results Available Mastication Disorder|Mandibular Dysfunction Device: implants with overdentures Test of Masticatory Efficiency by using three different food categories|The Number of chewing cycle strokes up to the first sallow|The Number of chewing cycle strokes until the mouth is free of food|The number of swallows until the mouth is free of food|Time (in seconds) until the mouth is free of food Al-Azhar University Male 50 Years to 70 Years   (Adult, Older Adult) Not Applicable 24 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment 903/2935 March 1, 2022 December 20, 2022 January 1, 2023 May 26, 2023 May 26, 2023 Al-Azhar univeristy, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05877092 997 NCT05877079 TRPM8 in Acute Ischemic Stroke by Topical Menthol Not yet recruiting No Results Available Ischemic Stroke Drug: Menthol|Drug: Placebo NIHSS|BI Taipei Medical University Hospital|China Medical University, Taiwan|Chung Shan Medical University All 20 Years and older   (Adult, Older Adult) Phase 4 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care N202302006 May 20, 2023 May 31, 2024 May 31, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877079 998 NCT05877066 Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture GRASP-DC Not yet recruiting No Results Available Dupuytren's Contracture Number of Participants Receiving Each Treatment Type for DC|Change from Baseline in Michigan Hand Questionnaire (MHQ) Scale Score|Change from Baseline in European Quality of Life Five Dimension (EQ-5D) Questionnaire Score|Change from Baseline in Unité Rhumatologique des Affections de la Main (URAM) Scale Score|Participant Satisfaction Questionnaire|Number of Participants Receiving Post-Procedural Care by the Treating Physician Endo Pharmaceuticals|Pulse InfoFrame All 18 Years and older   (Adult, Older Adult) 1000 Industry|Other Observational Observational Model: Cohort|Time Perspective: Other EP01REG May 2023 December 2027 December 2027 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05877066 999 NCT05877053 A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants Recruiting No Results Available Healthy Participants Drug: CK-4021586|Drug: Placebo for CK-4021586 Incidence and severity of AEs|Primary PK parameters of CK-4021586 including AUC|Changes over time from baseline in echocardiographic parameters including, but not limited to, LVEF Cytokinetics All 18 Years to 55 Years   (Adult) Phase 1 132 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science CY 9011 May 9, 2023 January 2024 March 2024 May 26, 2023 May 26, 2023 Celerion, Tempe, Arizona, United States https://ClinicalTrials.gov/show/NCT05877053 1000 NCT05877040 A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy Active, not recruiting No Results Available Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Drug: Rituximab Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale|Medical Research Council sum score|Inflammatory Rasch-built Overall Disability Scale (I-RODS)|Treatment discontinuation|Duration of clinical improvement after therapy with rituximab|Proportion of patients that improve 6 and 12 months after therapy with rituximab in subgroups defined according to the presence or absence of antibody reactivities|Proportion of patients that improve 6 and 12 months after therapy with rituximab in subgroups defined according to the CIDP clinical form (typical or atypical) Istituto Clinico Humanitas All 18 Years and older   (Adult, Older Adult) Phase 2 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment RF-2016-02361887 June 1, 2019 March 30, 2023 September 30, 2023 May 26, 2023 May 26, 2023 Istituto Clinico Humanitas, Rozzano, Milano, Italy https://ClinicalTrials.gov/show/NCT05877040 1001 NCT05877027 Exercise vs. Topical Diclofenac vs. PRP Not yet recruiting No Results Available Gonarthrosis Other: Exercise|Other: Topical Diclofenac|Other: Platelet-Rich-Plasma (PRP) Change of Pain via Numeric Pain Rating Scale|WOMAC|40 meters fast walking test|Stepping Test|Joint Range of Motion Evaluation|Health-Related Quality of Life SF-12 Scale|Global Rating of Change Scale-GRC Istanbul University - Cerrahpasa (IUC) All 40 Years to 65 Years   (Adult, Older Adult) Not Applicable 84 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment 4370438302 July 2023 July 2024 December 2024 May 26, 2023 May 26, 2023 Istanbul University-Cerrahpasa, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05877027 1002 NCT05877014 Unipolar Versus Bipolar Interlocking in Humeral Shaft Fractures in Adults UNILOCH Not yet recruiting No Results Available Humeral Shaft Fracture Other: questionnaires|Other: scanner The proportion of patients with radiologically assessed bone healing at 12 months Centre Hospitalier Universitaire Dijon All 18 Years and older   (Adult, Older Adult) Phase 3 390 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment MARTZ PHRCN 2021 September 2023 October 2027 October 2027 May 26, 2023 May 26, 2023 Chu Dijon Bourgogne, Dijon, France https://ClinicalTrials.gov/show/NCT05877014 1003 NCT05877001 The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases Recruiting No Results Available Colorectal Liver Metastases Drug: Tislelizumab|Drug: Regorafenib|Other: HAIC Safety profiles by NCI-CTCAE version 5 .0|Overall response rate(ORR)|Disease control rate(DCR)|Duration of Response (DoR)|Response rate of intrahepatic lesions|Response rate of extrahepatic lesions|Quality of Life (QoL)|Overall survival (OS)|Progression free survival (PFS) Peking University Cancer Hospital & Institute All 18 Years and older   (Adult, Older Adult) Phase 2 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 2022KT98 May 30, 2023 July 30, 2024 March 1, 2025 May 26, 2023 May 26, 2023 Beijing Cancer Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, China https://ClinicalTrials.gov/show/NCT05877001 1004 NCT05876988 Chinese Acupuncture for Chemobrain in Elderly Cancer Patients Recruiting No Results Available Chinese Acupuncture Device: Chinese acupuncture Changes in score on MoCA|The incidences of adverse events Nanjing First Hospital, Nanjing Medical University|Jiangsu Health Vocational College All 60 Years and older   (Adult, Older Adult) Not Applicable 168 Other Interventional Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention Nanjing First May 30, 2023 December 31, 2025 December 31, 2025 May 26, 2023 May 26, 2023 Nanjing First Hospital, Nanjing, Jiangsu, China https://ClinicalTrials.gov/show/NCT05876988 1005 NCT05876975 Vaginal Axis on Magnetic Resonance Imaging After Laparoscopic Pectopexy Surgery: a Controlled Study Recruiting No Results Available Pelvic Organ Prolapse Procedure: laparoscopic pectopexy Anatomic Success|Urge Symptoms stres incontinence|Sexual functions Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization Female 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 21 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 77 January 4, 2023 June 4, 2023 July 1, 2023 May 26, 2023 May 26, 2023 Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey https://ClinicalTrials.gov/show/NCT05876975 1006 NCT05876962 The Impact of Rapid Diagnostic Methods in the Diagnosis of Fungal Infections in Intensive Care Units of Assiut University Hospital Not yet recruiting No Results Available Fungal Infection Phenotypically identify percentage of different fungal infections isolated from various clinical specimens in intensive care units. and Assess their antifungal susceptibility pattern. Assiut University All Child, Adult, Older Adult 100 Other Observational Observational Model: Other|Time Perspective: Prospective Diagnosis of fungal infection May 2023 May 2024 December 2024 May 26, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05876962 1007 NCT05876949 AVT03 With Xgeva in Healthy Male Subjects Not yet recruiting No Results Available This is a Phase Study Conducted in Healthy Volunteers|Osteoporosis Biological: Denosumab Co-primary PK endpoint_Cmax: maximum serum concentration|Co-primary PK endpoint_AUC0-t: area under the serum concentration-time curve up to time t, where t is the last time point with a concentration above the lower limit of quantitation Alvotech Swiss AG Male 28 Years to 55 Years   (Adult) Phase 1 206 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science AVT03-GL-P03 July 10, 2023 April 3, 2024 April 3, 2024 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05876949 1008 NCT05876936 Prospective, Open Label Study to Assess 24hs IOP Recorded With Triggerfish® in Patients With OAG Before and After DSCI Terminated No Results Available Open Angle Glaucoma Device: contact lens sensor (CLS) SENSIMED Triggerfish® Changes between the nycthemeral IOP patterns recorded with TF during two 24-hour periods in patients with OAG|Changes in diurnal and nocturnal IOP patterns|Changes in visual field|Number of Adverse Events University Hospital, Geneva All 18 Years and older   (Adult, Older Adult) Not Applicable 5 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention TF-1307 December 2013 July 2015 July 2015 May 26, 2023 May 26, 2023 University Hospital Geneva, Geneva, Switzerland https://ClinicalTrials.gov/show/NCT05876936 1009 NCT05876923 The Effects of Acute and Chronic Exercise on the Immune Phenotype of Chronic Lymphocytic Leukemia Patients Recruiting No Results Available Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Procedure: Biospecimen Collection|Other: Cardiopulmonary Exercise Testing|Procedure: Dual X-ray Absorptiometry|Other: Electronic Health Record Review|Other: Exercise Intervention|Procedure: Physical Examination|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Spirometry Assess circulating immune cell abundance and function pre-intervention|Assess circulating immune cell mobilization and function post-intervention Mayo Clinic All 18 Years to 80 Years   (Adult, Older Adult) Not Applicable 100 Other Interventional Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 22-012246|NCI-2023-03210 March 13, 2023 March 13, 2028 April 2028 May 26, 2023 May 26, 2023 Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT05876923 1010 NCT05876910 Neural Mechanisms for Stopping Ongoing Speech Production Enrolling by invitation No Results Available Epilepsy|Speech Behavioral: Speech Production Tasks Mean Change in Neural Activity|Number of sites with stimulation induced speech termination University of California, San Francisco|National Institute on Deafness and Other Communication Disorders (NIDCD) All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science K99DC020235 December 1, 2022 November 30, 2027 November 30, 2027 May 26, 2023 May 26, 2023 University of California, San Francisco, San Francisco, California, United States https://ClinicalTrials.gov/show/NCT05876910 1011 NCT05876897 US vs MRI for Stress Injuries Recruiting No Results Available Stress Fracture US correlation to MRI Ryan Kruse|University of Iowa All 18 Years to 50 Years   (Adult) 25 Other Observational Observational Model: Cohort|Time Perspective: Cross-Sectional 202010068 February 3, 2021 February 1, 2024 February 1, 2024 May 26, 2023 May 26, 2023 University of Iowa Sports Medicine, Iowa City, Iowa, United States https://ClinicalTrials.gov/show/NCT05876897 1012 NCT05876884 Efficacy of a Low-cost Warming Mattress Celsi Warmer for the Management of Hypothermic Newborns at Muhimbili National Hospital, Dar es Salaam, Tanzania Recruiting No Results Available Neonatal Hypothermia Device: Celsi Warmer Mattress Broad Objective|Efficacy of the Device|Safety of Device William Marsh Rice University|Muhimbili University of Health and Allied Sciences|Ifakara Health Institute|Ministry of Health, Community Development, Gender, Elderly, and Children (MOHCDGEC) All 0 Days to 28 Days   (Child) Not Applicable 90 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment TZ Celsi Warmer August 1, 2022 August 20, 2024 August 20, 2024 May 26, 2023 June 1, 2023 Muhimbili National Hospital, Dar Es Salaam, Tanzania https://ClinicalTrials.gov/show/NCT05876884 1013 NCT05876871 Stress Radiography for Pelvic Ring Injuries Recruiting No Results Available Pelvic Fracture Diagnostic Test: Pelvic Binder Radiography Pelvic fracture displacement at 5 kg of stress|Pelvic fracture displacement at 10 kg of stress University of Southern California All 18 Years and older   (Adult, Older Adult) Not Applicable 50 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic HS-22-00217 February 1, 2023 November 30, 2024 December 31, 2025 May 26, 2023 May 26, 2023 Keck Medical Center of USC, Los Angeles, California, United States https://ClinicalTrials.gov/show/NCT05876871 1014 NCT05876858 EXPLORER Total Body PET/CT Imaging for Myofascial Pain Not yet recruiting No Results Available Myofascial Pain Drug: 18F-FDG|Drug: 11C-butanol HEAL outcome measure|Differentiate Myofascial tissues University of California, Davis|National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH) All 18 Years and older   (Adult, Older Adult) Early Phase 1 53 Other|NIH Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science 1834390|1R61AT012187-01 May 2023 September 2025 September 2026 May 26, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05876858 1015 NCT05876845 A Clinical Trial to Assess the Effect of a Combined Pre-, Pro-, and Post-biotic Supplement on Gut and Metabolic Health Completed No Results Available Gut Health Other: Combined pre-, pro-, and post-biotic supplement Change in participant-reported gastrointestinal symptoms [Time Frame: Baseline to 4 weeks]|Change in scores on the Gastrointestinal Symptom Rating Scale (GSRS) [Time Frame: Baseline to 4 Beekeeper's Naturals Inc All 18 Years and older   (Adult, Older Adult) Not Applicable 38 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other 20291 February 9, 2023 March 29, 2023 March 29, 2023 May 26, 2023 May 26, 2023 Citruslabs, Santa Monica, California, United States https://ClinicalTrials.gov/show/NCT05876845 1016 NCT05876832 A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Not yet recruiting No Results Available Acute Myeloid Leukemia With FLT3/ITD Mutation Drug: XY0206|Drug: Salvage Chemotherapy Interim analysis: Complete remission(CR)/CR with partial hematologic recovery(CRh) rate in the experimental group.|The final analysis: Overall Survival(OS).|Key secondary end point: Event-Free Survival (EFS).|Key secondary end point: CR/CRh rate .|CR rate.|Duration of remission (DOR).|Composite complete remission rate.|minimal residual disease(MRD) negative rate|Time to remission(TTR).|Transplantation rate.|Safety assessed by adverse events.|Population pharmacokinetic of XY0206. Shijiazhuang Yiling Pharmaceutical Co. Ltd All 18 Years and older   (Adult, Older Adult) Phase 3 312 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment XY0206AML3001 June 15, 2023 July 1, 2027 July 1, 2027 May 25, 2023 May 26, 2023 https://ClinicalTrials.gov/show/NCT05876832 1017 NCT05876819 Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon ServQual Enrolling by invitation No Results Available Quality of Life|Health Care Acceptability|Disabilities Mental ServQual Shiraz University of Medical Sciences All 50 Years and older   (Adult, Older Adult) 86 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional IR.SUMS.SCHEANUT.REC.1402.03 May 10, 2023 December 1, 2023 January 1, 2024 May 25, 2023 May 25, 2023 Welfare Services Affairs, Shiraz, Dars, Iran, Islamic Republic of https://ClinicalTrials.gov/show/NCT05876819 1018 NCT05876806 Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations Not yet recruiting No Results Available Cancer Drug: Dabrafenib|Drug: Trametinib Disease Control Rate (DCR)|Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR) Seoul St. Mary's Hospital All 19 Years and older   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment BROAD June 2023 March 2026 March 2026 May 25, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05876806 1019 NCT05876793 Effective Dose of Remimazolam Combined With Propofol in Painless Gastroscopy Not yet recruiting No Results Available Effect of Drug Drug: Remimazolam tosilate Incidence of body movements or coughing|Sedation success time|Inspection time|full alert time|incidence of adverse events Sichuan Provincial People's Hospital All 18 Years to 65 Years   (Adult, Older Adult) Not Applicable 30 Other Interventional Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HR7056+propofol June 1, 2023 June 10, 2023 June 30, 2023 May 25, 2023 May 25, 2023 https://ClinicalTrials.gov/show/NCT05876793 1020 NCT05876780 A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) Enrolling by invitation No Results Available Limb Girdle Muscular Dystrophy Genetic: SRP-9003 Number of Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)|Change from Baseline in β-SG Protein Expression Quantity Assessed by Immunofluorescence (IF) Fiber Intensity at Day 60|Change from Baseline in β-SG Protein Expression Quantity Assessed by IF Percent Protein Fibers (PPF) at Day 60|Change from Baseline in β-SG Protein Expression Quantity Assessed by Western Blot at Day 60|Change from Baseline in β-SG Protein Expression Quantity Assessed by IF Fiber Intensity at Month 24|Change from Baseline in β-SG Protein Expression Quantity Assessed by IF Percent Protein Fibers (PPF) at Month 24|Change from Baseline in β-SG Protein Expression Quantity Assessed by Western Blot at Month 24|Change from Baseline in North Star Assessment for Dysferlinopathy (NSAD) at Month 60|Change From Baseline in Time to Rise From the Floor, Time to Complete 100 and 10 meter Walk/Run, and the Timed Stair Ascend 4 Steps Test|Change from Baseline in Performance of Upper Limb Version 2.0 (PUL 2.0) Score at Month 60|Change from Baseline in Ability Captured Through Interactive Video Evaluation (ACTIVE) - Seated Workspace Volume Task at Month 60|Cohort 1 (Ambulatory): Change from Baseline in Stride Velocity (95%) and Stair-climbing Velocity (95%) as Assessed by a Wearable Device at Month 60|Cohort 1 (Ambulatory): Change from Baseline in Number of Stairs Climbed per Hour as Assessed by a Wearable Device at Month 60|Cohort 1 (Ambulatory): Change from Baseline Distance Walked per Hour as Assessed by a Wearable Device at Month 60|Cohort 1 (Ambulatory): Change from Baseline in Stride Length (95%) as Assessed by a Wearable Device at Month 60|Change from Baseline in Upper Extremity Activity at Month 60|Change from Baseline in Angular Wrist Velocity at Month 60|Change from Baseline in Vector Genome Copies Using Droplet Digital Polymerase Chain Reaction (ddPCR) in the Target Muscle Tissue Sarepta Therapeutics, Inc. All 4 Years to 50 Years   (Child, Adult) Phase 1 5 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SRP-9003-102 December 19, 2022 January 31, 2026 January 31, 2027 May 25, 2023 May 25, 2023 Nationwide Children's Hospital, Columbus, Ohio, United States https://ClinicalTrials.gov/show/NCT05876780 1021 NCT05876767 Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants Recruiting No Results Available Healthy Volunteer Drug: SAR444336|Drug: Placebo Part 1: Number of subjects with treatment-emergent adverse events (TEAEs)|Part 2: Number of subjects with treatment-emergent adverse events (TEAEs)|Plasma PK parameters: Cmax|Plasma PK parameters: tmax|Plasma PK parameters: AUClast|Plasma PK parameters: AUC|Plasma PK parameters: t1/2z|Plasma PK parameters: CL/F|Anti-SAR444336 antibodies Sanofi All 18 Years to 55 Years   (Adult) Phase 1 104 Industry Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science TDU17072-TDR17161 October 15, 2021 September 27, 2023 September 27, 2023 May 25, 2023 May 25, 2023 Investigational Site Number :5280002, Groningen, Netherlands|Investigational Site Number :5280001, Leiden, Netherlands https://ClinicalTrials.gov/show/NCT05876767 1022 NCT05876754 Phase 3b Study of Ivosidenib for Patients With Pretreated Locally Advanced or Metastatic Cholangiocarcinoma ProvIDHe Recruiting No Results Available Cholangiocarcinoma Drug: Ivosidenib Oral Tablet Number of Adverse Events (AEs) from Day 1 of Cycle 1 through 28 days after last treatment|Number of Serious Adverse Events (SAEs) from Day 1 of Cycle 1 through study termination or withdrawal of consent, whichever comes first|Number of QT prolongation events during electrocardiogram (ECG) assessed as Grade 2 or worse occurring from Day 1 of Cycle 1 through 28 days after last treatment|Change in Eastern Cooperative Oncology Group (ECOG) performance status (PS) score from baseline to worst value out of the post-baseline assessments.|Number of Adverse Events (AEs) leading to discontinuation or death from day 1 through 28 days after the last treatment|Total laboratory abnormalities using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 grading scale or the low/normal/high classifications based on laboratory normal ranges.|Change from baseline to the worst on-treatment value of laboratory abnormalities.|Number of patients with vital sign values outside limits of the normal range at each time point.|Mean change from baseline values to the worst on-treatment value of patients with vital signs outside limits of the normal range|Progression-free survival (PFS) time beginning at screening|Overall survival (OS)|Duration of response (DOR)|Time to response (TTR)|Change from baseline of Quality of life scores|Proportion of days at home or hospital for all patients|Change from baseline of health economic measures, as assessed by the 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5). Servier All 18 Years and older   (Adult, Older Adult) Phase 3 220 Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment DIM-95031-002|2022-501463-40 May 3, 2023 June 1, 2025 June 1, 2025 May 25, 2023 May 25, 2023 Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Düsseldorf, Düsseldorf, Germany https://ClinicalTrials.gov/show/NCT05876754 1023 NCT05876741 Validation of Prognostic Accuracy of ABC ( Age, Blood Urea Nitrogen , Co-morbidities ) and Horibe Pre-endoscopy Scoring Systems in Patients With Upper Gastrointestinal Bleeding in Sohag University Hospital . Recruiting No Results Available Upper GI Bleeding Diagnostic Test: history taking , vital signs and labaratory investigations comparison between old and new upper git bleeding scoring systems regarding accuracy and prognostic value . Sohag University All 18 Years and older   (Adult, Older Adult) 100 Other Observational Observational Model: Case-Only|Time Perspective: Prospective Soh-Med-23-04-09MS February 15, 2023 February 15, 2024 March 15, 2024 May 25, 2023 May 25, 2023 Sohag University hospitals, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05876741 1024 NCT05876728 Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer Not yet recruiting No Results Available Breast Cancer Genetic: Genotyping find a possible association between irisin gene single nucleotide polymorphism with breast cancer Sohag University All 20 Years to 70 Years   (Adult, Older Adult) 100 Other Observational Observational Model: Case-Control|Time Perspective: Prospective Soh-Med-23-04-10PD June 1, 2023 June 1, 2024 June 1, 2024 May 25, 2023 May 25, 2023 Sohag university Hospital, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05876728 1025 NCT05876715 LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma LINNOVATE Not yet recruiting No Results Available Advanced Soft-tissue Sarcoma Drug: Lurbinectedin Maximum tolerated dose|Objective response rate|Progression free survival at 6 months|Overall survival|Correlation of response with circulating tumor DNA ERLINDA M GORDON|Sarcoma Oncology Research Center, LLC All 18 Years to 90 Years   (Adult, Older Adult) Phase 1|Phase 2 40 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment SOC-2310 July 1, 2023 June 30, 2026 September 30, 2026 May 25, 2023 May 31, 2023 https://ClinicalTrials.gov/show/NCT05876715 1026 NCT05876702 Endoscopic I-scan Versus Histopathological Evaluation Of Esophageal Lesions Recruiting No Results Available Esophageal Lesions Device: endoscopy detection of esophageal lesions Sohag University All Child, Adult, Older Adult Not Applicable 30 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic Soh-Med-23-05-05MS May 1, 2023 May 1, 2024 May 1, 2024 May 25, 2023 May 25, 2023 Sohag university Hospital, Sohag, Egypt https://ClinicalTrials.gov/show/NCT05876702 1027 NCT05876689 Swept Source OCT Imaging With the DREAM VG-OCT Not yet recruiting No Results Available Eye Diseases|Myopia|Glaucoma Device: DREAM OCT Assessing difference in intraocular structures|Assessing difference in intraocular vascular structures|Assessing repeatability of scans Robert T. Chang, MD|Stanford University All 18 Years and older   (Adult, Older Adult) 50 Other Observational Observational Model: Cohort|Time Perspective: Prospective 70411 July 2023 December 2023 December 2023 May 25, 2023 May 25, 2023 Byers Eye Institute, Palo Alto, California, United States https://ClinicalTrials.gov/show/NCT05876689 1028 NCT05876676 RDC Biomarker Study Not yet recruiting No Results Available Cancer Accuracy of Clinical Data Analysis|Accuracy of Polygenic Risk Scores|Number of patients with accurate Imaging Radiomics and Composite Analysis|Number of Participants with Multiparametric and ML Analyse outcome measures Royal Marsden NHS Foundation Trust All 18 Years and older   (Adult, Older Adult) 1000 Other Observational Observational Model: Case-Only|Time Perspective: Cross-Sectional 5557|53826|306766 July 1, 2023 April 1, 2025 April 1, 2026 May 25, 2023 May 30, 2023 https://ClinicalTrials.gov/show/NCT05876676 1029 NCT05876663 Effect of Kinesio Taping on Pulmonary Function and Forward Shoulder Posture FSP of Young Adults FSP Not yet recruiting No Results Available Healthy Young Adults Other: Kinesio Taping|Other: Conventional physiotherapy protocol Peak expiratory flow rate (PEFR)|Forced vital capacity (FVC)|Forced expiratory volume in 1sec (FEV1)|Chest Expansion|Forward Shoulder Posture|Pectoralis Minor Index Riphah International University All 18 Years to 25 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other Saba Khan June 1, 2023 November 1, 2023 December 1, 2023 May 25, 2023 May 25, 2023 Suman Sheraz, Islamabad, AL, Pakistan https://ClinicalTrials.gov/show/NCT05876663 1030 NCT05876650 Pilates Exercises v/s Yoga on Rounded Shoulders Recruiting No Results Available Weakness, Muscle|Muscle Tightness|Range of Motion|Pain|Heart Rate|SpO2|Sleep Quality Other: Pilates exercises|Other: Yoga Rigid transparent plastic protractor|Neck diability Index|Goniometer|The Shoulder Pain and Disability Index|Honor Band 5 Smart Wristband Fitness Tracker Riphah International University Female 18 Years to 24 Years   (Adult) Not Applicable 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment RIPHAH/FR&AHS/Letter-014121 December 1, 2022 May 30, 2023 July 1, 2023 May 25, 2023 May 25, 2023 Riphah International University, Islamabad, Pakistan https://ClinicalTrials.gov/show/NCT05876650 1031 NCT05876637 Effects of Left Nostril Breathing in Young Females Having Cardiovascular Hyper Reactivity to Cold Pressor Test. Not yet recruiting No Results Available Healthy Other: Left Nostril Breathing|Other: Conventional Cold pressor test|Blood pressure|Heart Rate|Oxygen saturation Riphah International University Female 18 Years to 25 Years   (Adult) Not Applicable 60 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other Muqaddas Bibi June 1, 2023 November 15, 2023 December 15, 2023 May 25, 2023 May 31, 2023 Women Instritute of Rehabilitation Sciences, Jinnah College of Nursing, Abbottābād, KPK, Pakistan https://ClinicalTrials.gov/show/NCT05876637 1032 NCT05876624 The Connection Between Personality, Burnout, and Hypertension in Nigerian Bank Employees Enrolling by invitation No Results Available Hypertension Other: Blood Pressure measurement Blood Pressure Renaissance University Ugbawka, Enugu All Child, Adult, Older Adult 600 Other Observational Observational Model: Other|Time Perspective: Cross-Sectional RenaissanceU May 22, 2023 June 19, 2023 July 10, 2023 May 25, 2023 May 25, 2023 Renaissance University, Enugu, Nigeria https://ClinicalTrials.gov/show/NCT05876624 1033 NCT05876611 Clinical Application of a Self Stabilizing Atlantoaxial Fusion Cage Not yet recruiting No Results Available Atlantoaxial Dislocation Device: New type of self stabilizing atlantoaxial fusion cage fusion rate|neural functions|complications Peking University Third Hospital All Child, Adult, Older Adult 400 Other Observational Observational Model: Cohort|Time Perspective: Prospective ZL 2022 1 0362717.5 June 1, 2023 June 1, 2025 December 31, 2025 May 25, 2023 May 25, 2023 https://ClinicalTrials.gov/show/NCT05876611 1034 NCT05876598 BACTERIUM: Study for a Machine-learning-based Model to Predict Bloodstream Infections BACTERIUM Recruiting No Results Available Infection, Bloodstream Drug: antibiotic treatments Rate of appropriate antibiotic therapy in patients with bloodstream infections|Blood cultures Fondazione Policlinico Universitario Agostino Gemelli IRCCS All 18 Years and older   (Adult, Older Adult) 5000 Other Observational Observational Model: Cohort|Time Perspective: Prospective BACTERIUM-4407 November 3, 2021 June 15, 2025 December 30, 2025 May 25, 2023 May 25, 2023 Fondazione Policlinico Agostino Gemelli Irccs, Rome, Italy https://ClinicalTrials.gov/show/NCT05876598 1035 NCT05876585 This Study Will Assess the Efficacy and Safety of Ondansetron Compared to Metoclopramide in the Management of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis. Not yet recruiting No Results Available Gastroenteritis Drug: Ondansetron 8 mg ampoule|Drug: Metoclopramide 10 mg ampoule The proportion of patients experiencing complete control of nausea and vomiting|The proportions of patients who experienced nausea, vomiting, or retching.|The proportion of patients who needed intravenous rehydration|The proportion of patients who needed a rescue anti-emetic medication|The duration of stay at the emergency room before discharge|Overall patient's and physician's satisfaction with the efficacy of the study medication|The number of adverse events and serious adverse events|Overall patient's satisfaction with the tolerability of the study medication Genuine Research Center, Egypt|Adwia Pharma, Egypt All 18 Years to 65 Years   (Adult, Older Adult) Phase 3 126 Industry|Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment GRC/ADGE/EG/38/III June 2023 October 2023 October 2023 May 25, 2023 May 25, 2023 https://ClinicalTrials.gov/show/NCT05876585 1036 NCT05876572 Blood Naloxone Levels Following Intradermal Injection in Humans Not yet recruiting No Results Available Opioid Overdose Drug: intradermal naloxone|Device: microneedle injection Detection of Plasma Naloxone Concentration (ng/mL) using High Performance Liquid Chromatography/Tandem Mass Spectrometry (HPLC-MS/MS).|Measurement of the maximum plasma concentration (Cmax; ng/mL) of Naloxone using HPLC-MS/MS following a single 8mg dose of intradermally delivered Naloxone.|Assessment of the time (minutes) at which the maximum Naloxone concentration (ng/mL) is detected in plasma (Tmax) by HPLC-MS/MS after a single 8mg dose of intradermally delivered Naloxone.|Assessment of Naloxone exposure (mg*h/L) over 60 minutes (AUC 0-60) as measured by HPLC-MS/MS of plasma samples collected after a single 8mg dose of intradermally delivered Naloxone. Johns Hopkins University|DEKA S.r.l. All 18 Years to 65 Years   (Adult, Older Adult) Phase 4 3 Other|Industry Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other IRB00380585 July 2023 December 2023 June 2024 May 25, 2023 May 25, 2023 https://ClinicalTrials.gov/show/NCT05876572 1037 NCT05876559 Joyuus - A Web-based Tool for Postpartum Care Self-care for Underserved Women Not yet recruiting No Results Available Maternal Health Other: Joyuus Self-care Mobile App|Other: Standard Care Barkin Index of Maternal Functioning (BIMF)|Edinburgh Postnatal Depression Scale (EPDS)|State-Trait Anxiety Inventory (STAI)|Connor-Davidson Resilience Scale (CDRS) Joyuus, LLC|National Institutes of Health (NIH)|National Institute on Minority Health and Health Disparities (NIMHD) Female 18 Years to 99 Years   (Adult, Older Adult) Not Applicable 132 Industry|NIH Interventional Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research p-20167|R44MD014923 October 1, 2023 January 31, 2024 February 28, 2024 May 25, 2023 May 25, 2023 Lisa Marceau, Westerly, Rhode Island, United States https://ClinicalTrials.gov/show/NCT05876559 1038 NCT05876546 Evaluation of Skin Irritancy and Sensitization of a Liquid Dressing Not yet recruiting No Results Available Skin Care Device: Liquid bandage|Device: Saline Solution Evaluation of skin irritation and sensitization in 6 weeks Eurofarma Laboratorios S.A. All 18 Years to 70 Years   (Adult, Older Adult) Not Applicable 150 Industry Interventional Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening EF184 May 30, 2023 July 30, 2023 September 30, 2023 May 25, 2023 May 25, 2023 Eurofarma Laboratorios S.A, São Paulo, Brazil https://ClinicalTrials.gov/show/NCT05876546 1039 NCT05876533 R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances Recruiting No Results Available Chronic Heart Failure Device: Cordio HearO Patient Usability success defined as: 1.Total and individual usability score of ≥3 in the usability questionnaire in ≥80% of the users.|Patient Usability success defined as: 2. Total Compliance Cordio Medical All 22 Years and older   (Adult, Older Adult) 250 Industry Observational Observational Model: Cohort|Time Perspective: Retrospective CLN0016 March 18, 2022 September 30, 2023 September 30, 2024 May 25, 2023 May 25, 2023 Kurker Family Medicine, South Windsor, Connecticut, United States|Lake County Med Grp, Athens, Georgia, United States|Barzilai Medical Center- Cardiology, Ashkelon, Israel|Heart Failure Clinic - Clallit Be'er Sheva, Be'er Sheva, Israel|Rabin Medical Center - Cardiology- CHF, Petah tikva, Israel https://ClinicalTrials.gov/show/NCT05876533 1040 NCT05876520 Clinical and Radiographic Assessment of Nano-Bioactive Glass Combined With I-PRF Scaffold in Vital Pulp Treatments in Mandibular Molars With Closed Apices I-PRF Recruiting No Results Available Vital Pulp Treatment in Mature Permanent Teeth With Irreversible Pulpitis Procedure: Total pulpotomy with I-prf mixed with Nano-bioactive glass Clinical , Radiographic and Success rate|Pain intensity Cairo University All 14 Years to 32 Years   (Child, Adult) Not Applicable 28 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment ENDO-3-7-2 January 25, 2023 March 2024 April 2024 May 25, 2023 May 25, 2023 Noor Mohammed Kamal Eldeen, Cairo, Egypt https://ClinicalTrials.gov/show/NCT05876520 1041 NCT05876507 Effect of Progressive Exercise on Renal Transplant Patients Recruiting No Results Available Renal Transplant|Fatigue|Vital Signs|Progressive Relaxation Exercise|Nursing Behavioral: Progressive relaxation exercise Systolic and diastolic blood pressure|fatigue level|Heart rate|Respiratory rate|Body temperature|Oxygen saturation Baskent University All 18 Years and older   (Adult, Older Adult) Not Applicable 52 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care KA22/239 February 13, 2023 May 15, 2023 June 15, 2023 May 25, 2023 May 25, 2023 Baskent University Hospital, Ankara, Çankaya, Turkey https://ClinicalTrials.gov/show/NCT05876507 1042 NCT05876494 Serum Lactate and Ulcerative Colitis Recruiting No Results Available Ulcerative Colitis Diagnostic Test: serum lactate Accuracy (%) of serum lactate in prediction the acute flare of ulcerative colitis Assiut University All 18 Years and older   (Adult, Older Adult) 137 Other Observational Observational Model: Cohort|Time Perspective: Prospective Alaa Esam June 1, 2023 December 31, 2023 December 31, 2023 May 25, 2023 May 25, 2023 Ahmed Mohammed Abu-Elfatth, Assiut, Egypt https://ClinicalTrials.gov/show/NCT05876494 1043 NCT05876481 Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans Not yet recruiting No Results Available PTSD Drug: Psilocybin Symptoms of PTSD measured using the Posttraumatic Stress Disorder Checklist For DSM-5 (PCL- PTSD symptoms|Core features of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ)|Difficulties with anger measured using the Dimensions of Anger Reactions (DAR-5)|Depression symptoms measured using the Patient Health Questionnaire (PHQ-9)|General anxiety symptoms measured using the Generalised Anxiety Disorder (GAD-7)|Mental wellbeing measured using the Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS)|Perceived social support measured using the Oslo Social Support Scale|Challenging aspects of experiences with psilocybin measured using the Challenging Experience Questionnaire Combat Stress|The Watson Trust All 18 Years to 65 Years   (Adult, Older Adult) Phase 2 8 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment CS-2023-002 June 2023 July 2025 August 2025 May 25, 2023 May 25, 2023 Combat Stress, Leatherhead, Surrey, United Kingdom https://ClinicalTrials.gov/show/NCT05876481 1044 NCT05876468 Effects of Continuous Anterior Chest Compression StrapVent Recruiting No Results Available Evaluable Device: Continuous anterior chest compression The end inspiratory transpulmonary pressure (PL-insp) in centimetre of water|Regional pulmonary compliances in centimetre of water|Lung mechanics : Airways pressure, Flow curves and Esophageal pressure|Pulmonary ventilation distribution in percentage|Recruitment-to-inflation (R/I) ratio|Hemodynamics|Arterial blood gazes (ABG|Incidence of CACC adverse events|End expiratory lung impedance (EELZ) expressed in arbitrary units Assistance Publique - Hôpitaux de Paris All 18 Years and older   (Adult, Older Adult) Not Applicable 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science APHP 211357 April 1, 2022